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Wound healing is characterized by the excessive deposition of extracellular matrix 
(ECM) components. Fibrosis is a devastating result of the improper regulation of the wound 
healing process, and it contributes to ~45% of deaths in the developed world. A major hallmark 
of fibrosis is the fibroblast-to-myofibroblast transition. Myofibroblasts have an increased 
production of ECM components and impart contractile forces that cause architectural distortion 
to the surrounding tissue. These forces recruit signal transduction by various extracellular 
signaling pathways, including transforming growth factor β (TGF-β), lysophosphatidic acid 
(LPA), endothelin, and connective tissue growth factor (CTGF), ultimately activating the Rho 
family of GTPases and their downstream kinase, Rho-associated coiled-coil containing protein 
kinase (ROCK). This signaling leads to myocardin-related transcription factor (MRTF)/serum 
response factor (SRF)-mediate gene transcription of SRF-associated cytoskeletal genes, 
ultimately causing fibroblast differentiation into myofibroblast cells. Since Rho/MRTF/SRF-
mediated signaling is known to regulate pro-fibrotic gene expression arising from multiple 
extracellular signaling pathways, inhibition of this common pathway is hypothesized to be a 
particularly effective way to treat/prevent fibrosis. 
In 2007, two distinct series—a 5-aryl-1,3,4-oxadiazol-2-ylthiopropionic acid (58150-) and 
a bis-amide (222740-) series—of novel inhibitors of Rho/MRTF/SRF-mediated gene expression 
were identified by the Neubig lab through a phenotypic high-throughput screening campaign. 
Both series have produced inhibitors that show promising results in multiple in vitro and in vivo 
models of fibrosis. Due to the phenotypic nature of the assay, the target(s) for both series are 
unknown. Recently, potential biological targets for both series have been identified through 
xvii 
 
proteomics studies using immobilized agarose resin high affinity pull-down probes. Target 
validation efforts for both series were conducted in a collaborative effort between the Neubig, 
Larsen, and Martin labs; and, the successful identification of pirin as a biological target for the 
222740-series is reported. Additionally, through structure-based drug design (SBDD) efforts 
using pirin co-crystal structures, the cellular potency for the series was improved about ten-fold, 
and additional novel bis-amide scaffolds were discovered. 
Also, despite the inability to validate a target for the 58150-series, the cellular activity 
from hit-to-lead was rapidly improved by over 5 orders of magnitude (180 nM to 1 pM). The 
levels of cellular potency and depth of SAR, coupled with the relatively low molecular weight 
(<400 g/mol) of the series, suggests that binding to the unknown molecular target may occur 
through a novel covalent mechanism. In support of this hypothesis, modifications made to the 
scaffold that would presumably reduce covalent reactivity produced inhibitors with significantly 
diminished activities. Nevertheless, the series has no observable cytotoxicity up to 100 µM. As a 
result, two highly potent and orally bioavailable anti-fibrotic agents for the 58150-series were 
developed that dose-dependently reduce CTGF gene expression in vitro and significantly and 




Chapter 1: Introduction 
Fibrosis is characterized by the excessive deposition of extracellular matrix (ECM) 
components in organs and tissues1-4, and ~45% of deaths in the developed world can be 
attributed to fibroproliferative diseases (e.g. cardiac, cirrhosis, scleroderma, pulmonary, renal 
etc.).1,4,5 Despite this surprising statistic, pathological fibrosis remains a highly neglected health 
issue worldwide; the only FDA-approved antifibrotic-specific agents in the U.S. today are 
pirfenidone and Nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF).6,7 The build-
up of collagen-rich scar tissue and the architectural distortion caused by scar retraction in 
organs contribute to the high mortality rate of diseases linked to fibrosis.8 However, even though 
many of the basic molecular and cellular mechanisms for the development of fibrosis are well-
understood, significant gaps of knowledge exist regarding how pathological fibrosis initiates and 
progresses as well as many pertinent details regarding the mechanisms that regulate fibrosis.9,10 
Discerning the regulation of overlapping inflammatory, immunological (innate and adaptive), and 
fibrotic responses that underlie fibrosis presents a major difficulty in understanding the 
pathophysiology of the disease. Because of redundant, overlapping pathways associated with 
these responses, the drug discovery and development landscape for therapeutic agents for 
diseases associated with pathological fibrosis remains convoluted. 
Fibrosis pathology overview: 
The biological intent of wound repair is to reestablish tissue homeostasis and integrity 
after an insult.11 The capability of the wound healing process to proceed properly depends on 
factors such as injury severity and how the inflammatory and redox status of the injury develop 
over time.11,12 Wound repair or scarring, which can be classified as the excessive accumulation 
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of collagen, actin, and fibronectin in epithelial tissue, is initiated when tissue damage occurs, 
causing an intricate cascade of cellular and molecular responses.1,3,4 The wound healing 
process generally consists of initiation, effector cell activation, stem-cell differentiation (e.g. 
epithelial-to-mesenchymal transition (EMT), fibroblast-to-myofibroblast (FMT) transition, etc.), 
extracellular matrix (ECM) elaboration, and dynamic deposition/resorption of ECM components 
(Figure 1).1 
 
Figure 1: General schematic of wound healing and fibrosis 
General schematic of healing, resulting in either proper wound repair (degradation of extracellular matrix 
(ECM) components via appropriate regulation of collagenous and noncollagenous connective tissue 
components (e.g. elastases, cathepsins, matrix metalloproteinases (MMPs), etc.) or fibrosis (continual 
deposition and inefficient clearance and resorption of ECM components). (1) Initiation leads to (2) effector 
cell (e.g. macrophage, neutrophil, T helper cell, etc.) recruitment and activation. These inflammatory and 
immunity cells release pro-fibrotic cytokines (e.g. transcription growth factor (TGF)-β, tumor necrosis 
factors (TNFs), etc.) and produce reactive oxygen species (ROS), leading to the recruitment, proliferation, 
and activation of cell types (e.g. epithelial cells, fibroblasts, etc.) capable of (3) differentiating to 
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myofibroblasts. (4 & 5) Myofibroblasts remodel the microenvironment by increasing mechanical stress 
and tension, which is accomplished by their increased sequestration of ECM components (e.g. αSMA). 
Apoptosis of immune cells, well-orchestrated degradation and resorption of ECM by mainly MMPs, and 
regeneration of epithelial cells leads to proper wound repair; however, in a pathological fibrotic state, 
immune cells, fibroblasts, and myofibroblasts persist, and ECM components are over-produced and not 
resolved, eventually leading to the architectural disruption that can cause organ failure.  
When tissue injury occurs (e.g. physical, chemical, autoimmunity, etc.), pro-inflammatory 
mediators (e.g. histamine, interleukins (ILs), tumor necrosis factors (TNFs), etc.; see Table 1) 
are released during the coagulation cascade, leading to the recruitment of innate and adaptive 
immune cells (e.g. macrophages, mast cells, neutrophils, T helper cells, etc.).12 Recruited innate 
immune cells (e.g. neutrophils and macrophages) scavenge tissue debris and dead cells, and 
kill damaged cells and invading pathogens through both reactive oxygen species (ROS) and 
pro-inflammatory chemokines and cytokines, which in turn amplifies inflammatory reactions and 
leads to the recruitment of additional immune cells.11-13 When the inflammatory phase is 
perpetuated, fibrogenesis is exacerbated, ultimately leading to excessive and prolonged scar 
formation and fibrosis.11,13 
Interestingly, clotting not only reduces blood loss and pathogen invasion, but the 
resulting fibrin-containing clot acts as preliminary ECM scaffolding and provides mechanical 
provision for cellular attachment and proliferation.11,13 The stimulation and proliferation of 
immune cells leads to the release of various pro-fibrotic cytokines (e.g. transcription growth 
factor (TGF)-β, platelet derived growth factor (PDGF), TNFs, ROSs, IL-1B,13,17A, etc.; see 
Table 1) that provide a signal for migration, activation, and proliferation of fibrogenic cell types 
(e.g. fibroblasts, epithelial cells, fibrocytes, endothelial cells, etc.).11-13 Also of importance, innate 
immune cells secrete enzymes (elastases, cathepsins, matrix metalloproteinases (MMPs); see 
Table 1) that can specifically cleave collagenous and non-collagenous connective tissue 
components; a crucial process for ECM homeostasis during the fibrotic response.11,13 
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The unifying hallmark of fibrosis is the differentiation of pluripotent stem cells (e.g. 
fibroblast-to-myofibroblast differentiation, epithelial- or endothelial-to-mesenchymal transition 
(EMT or EndoMT, respectively), etc.) and, ultimately, the excessive deposition of ECM 
components by myofibroblasts.14 EMT or EndoMT are processes epithelial (tissue) or 
endothelial (blood vessel) cell types, respectively, undergo to become mesenchymal stem cells 
that can differentiate into various cell types, including fibroblasts.8,14 During this process, cells 
lose polarity and cell-cell adhesion capabilities and gain migratory and invasive properties. Both 
resident and migratory fibroblasts are key components for the production of excessive ECM. In 
particular, fibroblasts differentiate into a myofibroblast phenotype—as defined by the assembly 
of F-actin—that has an increased production of ECM components, such as 𝛼-smooth muscle 
actin (𝛼-SMA), fibronectin, and collagen (Figure 2).9,14  
The ECM elaboration and contractile forces imparted by myofibroblasts produce the 
architectural distortion observed in tissue fibrosis.15-17 The contractile forces imparted by 
myofibroblasts further perpetuate the fibrotic process through the release of additional pro-
fibrotic cytokines by inflammatory, immune, and fibrotic cell types, circularly tilting the balance 
towards producing superfluous ECM.18 In a normal circumstance, ECM elaboration eventually 
terminates, immune cells undergo apoptosis, excess ECM components are sufficiently 
degraded, and epithelial and endothelial cells regenerate, but when the fibrotic response is 





Figure 2: Fibroblast to myofibroblast differentiation and fibroblast resolution  
Fibroblast differentiation into myofibroblasts is stimulated mainly by TGF-β and mechanical stress 
imparted by damaged ECM at the site of injury. Myofibroblasts secrete excessive amounts of various 
stress fibers (e.g. αSMA) that they utilize to impart contractile forces at the site of injury to properly close 
the wound. Eventually, pro-fibrotic input signals are suppressed and myofibroblasts either undergo 
apoptosis or resolve back to fibroblasts, at which point various enzymes can effectively remodel ECM 
and, ultimately, the surrounding tissue.  
Image derived from Darby et al (2014)19 
 
Immunological mechanisms that regulate fibrosis: 
 During injury, damaged or slain cells release danger signals (e.g. histamine, ILs, TNFs, 
etc.; see Table 1) and crystallized endogenous molecules (e.g. cholesterol, uric acid, etc.) that 
activate the inflammasome.20-22 There are multiple subsets of inflammasome receptors, 
stemming from pattern recognition receptors (PPRs) (e.g. Toll-like receptors (TLRs), nucleotide-
binding oligomerization domain and leucine-rich repeat-containing receptors (NLRs), AIM2-like 
receptors (ALRs) etc.), stimulated during the fibrotic response, and their primary function is to 
activate the inflammatory response by promoting the maturation and secretion of pro-
inflammatory cytokines (e.g. IL-1β, IL-18).23-26 These cytokines promote a highly inflammatory-
specific form of programmed cell death—pyroptosis.27 
6 
 
 At the same time, neutrophils, monocytes, and mast cells—members of the innate 
immune response—are heavily recruited to the affected area by platelet degranulation products 
(e.g. PDGF, TGF-β1, IL-1, etc.) secreted during the inflammatory response by neighboring cells 
within the site of injury (Figure 3).28-30 Neutrophils clean-up the area via phagocytosis, removing 
damaged matrix materials as well as infectious and noninfectious foreign material.31 During the 
fibrotic process, neutrophils also release granules containing various proteases (e.g. elastases, 
cathepsins, etc.) capable of cleaving damaged ECM and ROSs that further prolong the innate 
immune response and pyroptosis as well as promote fibrogenesis.28,29,32 
 
Figure 3: Inflammatory and immune response in wound healing/fibrosis: 
Important inflammatory and immune cells that release pro- and anti-fibrotic cytokines, chemokines, and 
enzymes that regulate the fibrotic process. The roles for many of these mediators are listed in Table 1. 
Image derived from Van Linthout et al (2014)33 
Likewise, macrophages manage the initial reconstruction of the wound 
microenvironment by 1) engulfing and digesting cellular debris and foreign materials 2) 
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secreting enzymes that regulate ECM degradation, such as matrix metalloproteinases (MMPs) 
and tissue inhibitor of metalloproteinases (TIMPs), and 3) release multiple cytokines vital for 
fibrogenesis (Figure 4).34-37 Particularly, M1 macrophages release pro-inflammatory chemokines 
and cytokines, such as ROS, TNF-α, and IL-1β, while M2 macrophages release pro-fibrotic 
cytokines, such as IL-4, IL-10, IL-13, PDGF, VEGF, IGF-1, and TGF-β1, to regulate 
angiogenesis and epithelium, endothelium, and fibroblast proliferation.34,36 Ultimately, 
macrophages offer the appropriate components to support cellular proliferation, propagate the 
immune response, and regulate ECM homeostasis.36 
 
Figure 4: Role of the macrophage in wound healing: 
Macrophages regulate multiple faucets of the fibrotic process. M1 macrophages mainly impart pro-
inflammatory mediators and propagate ECM clearance mechanisms. M2 macrophages mainly secrete 
mediators that promote ECM expression and cell differentiation. An appropriate balance of M1 and M2 
macrophages at various stages of the fibrotic process is essential for the regulation of the fibrotic 
response. 
Image derived from Braga et al (2015)34 
MMPs are metal-dependent extracellular endopeptidases that degrade ECM 
components such as collagens, proteoglycans, laminins, and fibronectin.38,39 MMPs are also 
capable of modulating various cell types by activating latent cytokines, stimulating both pro- and 
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anti-fibrotic effects.38-41 The balance between MMPs and their endogenous inhibitors—TIMPs—
is extremely important for ECM homeostasis.38,40-42 During the fibrotic process, MMPs are 
mainly produced by macrophages, but other cell types, such as mast cells, T cells, neutrophils, 
etc., also play a role regulating MMP and TIMP biosynthesis and activity.40,41,43 For instance, 
MMP biosynthesis can be suppressed without affecting TIMP production via IL-4 and IFN-γ 
released by lymphocytes.44,45 
 Mast cells also release enzymes and cytokines essential for ECM homeostasis. Mast 
cells release histamine, proteoglycans, lipid mediators, chymases, tryptases, and 
carboxypeptidases via degranulation, and they synthesize and release other cytokines, such as 
leukotrienes, prostaglandins, interleukins (e.g. IL-3-6, -10, -13), TNF-α, TGF-β, monocyte 
chemoattractant protein-1 (CCL2), fibroblast growth factor (FGF), and PDGF, just to name a few 
(Figure 5).46-48 Particular to the fibrotic response, the proteases chymase and tryptase can affect 
ECM homeostasis, and they also help modulate connective tissue cells.49-51 For example, these 
proteases stimulate epithelial cell and fibroblast proliferation, fibroblast migration, and 
myofibroblast differentiation.50,52 As for their ability to aid in ECM homeostasis, both proteases 
can activate latent MMPs, TGF-β, and IL-1β, and tryptase can restrain type I collagen and 




Figure 5: Role of the mast cell in wound healing: 
Mast cells are important drivers of the fibrotic response. Along with various pro-inflammatory and pro-
fibrotic cytokines, mast cells release two important proteases—chymase and tryptase. These two 
enzymes are responsible for activating latent cytokines (e.g. TGF- β and IL-1β) and MMPs vital to ECM 
homeostasis. 
Image derived from Bot et al (2015)53 
 As can be seen in Figure 3, there are many other immunological cell types that affect the 
fibrotic response, but the final type discussed here will be T cells (Figure 3 & 6). They release 
cytokines such as interleukins, interferons, and TNFs that regulate the adaptive immune and 
inflammatory responses and contribute to the management of the fibrotic process.11,54,55 In 
particular, Th1 differentiation is promoted by IL-12, and Th1 cells secrete pro-inflammatory 
cytokines, such as IFN-γ and IL-2; and Th2 differentiation is driven by IL-4, and Th2 cells 
produce IL-4, IL-10, and IL-13, which are anti-inflammatory cytokines that can influence a pro-
fibrotic environment for cell types that drive the fibrotic process (e.g. fibroblasts and 
myofibroblasts).11,54 A disproportion between Th1/Th2/Th17 cells has been shown to drive 
inflammation (Th1 dominant) in early stages of fibrotic diseases and pathological fibrosis 




Figure 6: Balance between innate and adaptive immune responses in wound healing/fibrosis: 
This balance is critical for proper regulation of the fibrotic process. In general, Th1 cells release cytokines 
that promote resolution of the fibrotic response, while Th2 cells release cytokines that drive chronic 
inflammation and myofibroblast differentiation. 
Image derived from Wick et al (2013)11 
 
Fibrotic mechanisms that regulate fibrosis: 
 Cytokines released during the inflammatory response markedly recruit pro-fibrotic cells 
to the site of injury where they differentiate, propagate, and produce/deposit excessive ECM to 
repair the wound.4,5,11,28-30,32,56-58 The most important cytokine for the fibrotic process may be 
TGF-β. TGF-β is responsible for stimulating almost all processes of the fibrotic response, 
including the recruitment, proliferation, and differentiation of multiple pro-inflammatory and pro-
fibrotic cell types as well as ECM production and deposition by fibroblasts and myofibroblasts 




Figure 7: TGF-β and Smad signaling in wound healing/fibrosis: 
(A) TGF-β, acting through Smad signaling pathways, regulates multiple actions by various cell types 
important for the fibrotic response. (B) TGF-β/Smad2/3 signaling pathways activate multiple processes 
vital for mesenchymal stem cells, fibroblasts, and myofibroblasts, including differentiation, expression and 
release of growth factors, and secretion and deposition of αSMA and other important ECM components. 
Images derived from (A) Meng et al (2015)62 (B) Kim et al (2018)60 
  The main goal of pro-fibrotic cells during the fibrotic process is to locally increase 
mechanical stress at the site of injury through the production of excessive ECM components 
(e.g. αSMA, collagen, fibronectin, etc.) to properly close and heal the wound; myofibroblasts are 
essential to accomplish this goal.1,19,63 Myofibroblasts are specialized for this role in that they 
express excess αSMA, are contractile (via integrins and cadherins), produce and secrete ECM 
components at a greater rate than other pro-fibrotic cells, and are resistant to apoptosis.63-65 
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Myofibroblast contractile forces are imparted by the mechano-sensory capabilities of highly 
expressed integrins and cadherins on the cell surface (Figure 8).17,66 Myofibroblasts also 
constitutively express high amounts of chemokines, cytokines, and cell surface receptors that 
perpetuate the fibrotic process.67 These characteristics facilitate ECM fiber manipulation, wound 
contraction, and propagation of fibrosis at the site of injury.17,63-66 
 
Figure 8: Role of myofibroblasts in wound healing/fibrosis: 
Myofibroblasts impart contractile forces on the microenvironment. This is accomplished by coordination 
between various cadherins and integrins with, among other ECM components, αSMA. The stiffness, 
deformability, and fiber alignment and compaction coupled with the contractions coordinated by 
myofibroblasts provides a suitable environment for proper wound closure. 
Image derived from Pakshir et al (2018)63 
 Myofibroblasts are not typically found in healthy human tissue; rather they derive from 
multiple cell types, such as epithelial cells, endothelial cells, fibroblasts, multipotent monocytes, 
pericytes, and fibrocytes.68 There are three well-described processes central to myofibroblast 
production: epithelial-to-mesenchymal transition (EMT)69, endothelial-to-mesenchymal transition 
(EndoMT)70, and fibroblast-to-myofibroblast transition (FMT).71 EMT and EndoMT are similar in 
that both processes convert polarized, adhered tissue and blood vessel cells, respectively, to 
migratory, invasive, and apoptotic-resistant mesenchymal cells (Figure 9).72 These cells are 
characterized by their expression of, among many other cytokines, αSMA, fibronectin, N-
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cadherin, and β-catenin.69-71 The main effector of both the EMT and EndoEMT is TGFβ, but 
other mediators (e.g. type I collagen, MMP2, ROSs) stimulate these processes as well.69-71,73 
 
Figure 9: Processes for the differentiation into activated fibroblasts: 
Various cell types undergo different processes to differentiate into an activated fibroblast phenotype. For 
instance, (1) resident fibroblasts proliferate and become activated to release cytokines and ECM 
components at the site of injury; (2) mesenchymal stem cells (e.g. fibrocytes and pericytes) can 
differentiate to an activated fibroblast phenotype; (3) epithelial cells undergo epithelial-to-mesenchymal 
(EMT) transition to form activated fibroblast by breaking away and migrating from the basement 
membrane; (4) endothelial cells from proximal blood vessels migrate to the site of injury and differentiate 
to fibroblasts through the endothelial-to-mesenchymal transition (EndoMT). 
Image derived from Kalluri et al (2010)72 
Mesenchymal stem cells, which can differentiate into fibroblasts, join resident fibroblasts 
at the site of injury after EMT and EndoMT.74 Fibroblasts are pivotal to the wound healing 
process. Not only do they produce and secrete structural proteins (e.g. collagen and elastin), 
adhesive proteins (e.g. laminin and fibronectin), and ground substance (e.g. 
glycosaminoglycans and glycoproteins, which correspondingly help immune cells migrate into 
connective tissue), but they also support various fibrotic processes, such as inflammation, 
innate immunity, blood clotting, angiogenesis, and ECM maintenance and reabsorption.19,67,75 
For example, fibroblasts release lysyl oxidase (Lox), which strengthens collagen fibers by cross-
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linking them, MMPs, and TIMPs to aid in ECM homeostasis.75,76 Moreover, fibroblasts 
synthesize and secrete cytokines (e.g. TGFβ1, IL-1β, IL-33, etc.), chemokines (e.g. CXC and 
CCL2), and ROSs that propagate the immune and inflammatory responses (Figure 3).11,75 
Arguably, fibroblasts’ most crucial role in the fibrotic process is their capability to 
differentiate into myofibroblasts.66,71,75 Along with the mechanical tension created by the site of 
injury and ECM components secreted by fibroblasts, TGF-β is the main promoter of the 
FMT.75,77 When constrained, fibroblasts undergo a transition into a proto-myofibroblast 
phenotype, which begins to take on myofibroblastic characteristics, such as focal adhesion sites 
and production of αSMA, fibronectin, and ED-A fibronectin—an ED-A splice variant (Figure 
10).17,66,75 In the presence of mechanical stress, TGF-β, and ED-A fibronectin, proto-
myofibroblasts fully differentiate to myofibroblasts.17 Among others, Wnt78, Notch79, 
Hedgehog80,81, and Rho82,83 signaling pathways play crucial roles in myofibroblast differentiation 
from progenitor cells, including fibroblasts and mesenchymal stem cells derived from epithelium, 
endothelium, pericytes, multipotent monocytes, and fibrocytes. 
 
Figure 10: Fibroblast-to-myofibroblast transition: 
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The transition of fibroblasts into myofibroblasts is a two-step process. First, fibroblasts begin transitioning 
into a proto-myofibroblast phenotype when mechanical tension created by ECM increases. The proto-
myofibroblast phenotype produces various cadherins and integrins and synthesizes and secretes ECM 
components, such as αSMA. Increased levels of mechanical tension, TGF-β, and ED-A fibronectin drives 
the FMT to completion. Myofibroblasts secrete excessive amounts of ECM components and focal 
adhesion sites (through integrins and cadherins), at which point they can utilize their contractibility to 
close the wound. Myofibroblasts can dedifferentiate back to fibroblasts after pro-fibrotic signaling tapers 
down. 
Image derived from Tomasek et al (2002)17 
Clearance mechanisms that regulate fibrosis: 
There are multiple mechanisms central to resolving the fibrotic process. Effective 
resolution is dependent on, most importantly, removing myofibroblasts from repaired tissue and, 
secondly, resolving excess ECM.84,85 As discussed previously, ECM degradation and resolution 
are tightly controlled by MMPs and TIMPs, and once myofibroblasts are removed, ECM 
synthesis is significantly reduced, and these enzymes can effectively clear excessive 
ECM.38,41,84,85 There are three coordinated mechanisms involved in removing myofibroblasts: 
dedifferentiation, apoptosis, and senescence.  
Myofibroblast dedifferentiation leads to the restoration of progenitor cells (e.g. 
epithelium, endothelium, fibroblasts, etc.) that myofibroblasts originate from.86 The exact 
mechanisms by which myofibroblasts dedifferentiate are not well-understood, but one study 
suggests that inhibition of TGF-β and MAPK-signaling networks together induces marked 
myofibroblast dedifferentiation.87 However, several other factors have been linked to 
myofibroblast dedifferentiation as well.84 
 Yet, myofibroblasts are mainly eliminated from post-fibrotic tissue through apoptosis.84 
Interestingly, evidence suggests that distinct sub-populations of macrophages play a critical role 
in signaling apoptosis of myofibroblasts (Figure 11).36,84,88,89 In models of both toxic liver injury 
and bleomycin-induced lung fibrosis, depletion of macrophages during fibrotic recovery delayed 
the resolution of fibrosis.88,90 Intuitively, this role would make sense since macrophages are a 
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main source of MMPs that specifically degrade ECM, and they clear cellular debris, collagen, 
and apoptotic cells via phagocytosis, and both mechanisms are known to impede the pro-fibrotic 
effects of myofibroblasts.36 
 
Figure 11: Resolution of the fibrotic process: 
Resolution of the fibrotic process is mainly accomplished through apoptosis of myofibroblasts. 
Specialized macrophages may be responsible for releasing chemokines and enzymes critical for either 
promoting or resolving the fibrotic response. As a result of this, some macrophages may play a critical 
role in resolving fibrosis by activating myofibroblast apoptotic signaling pathways. 
Image derived from Ramachandran et al (2012)91 
 Replicative senescence intrinsically limits the amount of cellular divisions a cell can 
undergo92, and it is thought to limit the development of fibrosis during wound repair by restricting 
myofibroblasts’ life-span.84 Studies suggest that myofibroblast senesce during normal wound 
repair, allowing them to take on a gene expression profile that reduces expression of genes 
encoding ECM components, increases ECM-degrading enzyme production, and increases gene 
products predicted to augment myofibroblast clearance by immune cells.93,94 However, 
senescence may be a double-edged sword in myofibroblast elimination during a pathological 
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state of fibrosis as prolonged myofibroblast senescence encourages resistance to apoptosis, 
which, as mentioned above, is the main route of myofibroblast clearance.84,93,94 












Enhances TGFβ-mediated tissue remodeling Murphy et al 
95 
αSMA Myofibroblasts N/A Expressed in excess by myofibroblasts to 
drive the fibrotic process; drives myofibroblast 
contractility vital for wound healing; expression 
driven by TGF- β/Smad2/3 signaling pathway 






Potent chemotaxis cytokine that recruits 
monocytes, T cells, and fibrocytes; up-
regulates TGF-β expression, promoting 
fibroblast collagen synthesis; induces F-actin 
nuclearization, polymerization, and migration 
Sahin et al 57 
and Deng et 
al 97 
chymase Mast cells N/A Serine protease that activates latent TGF-β 
and MMP-9 and inactivates various TIMPs; 
accelerates tissue inflammation and fibrosis 
by converting Ang-I to Ang-II; mainly produces 
pro-fibrotic effects 
Beghdadi et 
al 49 and 
Masubuchi 
et al 51 
Collagen Fibroblasts, 
myofibroblasts 
N/A Multiple types; the main structural protein of 
the extracellular space in connective tissues; 
basement membrane ECM composed mainly 
of collagen type IV; collagen type I promotes 
TGF-β signaling and fibroblast and 








Plays roles in angiogenesis and fibrosis; 
interacts with various receptors, extracellular 
ligands, and ECM proteins; synergistic with 
TGF-β to promote pathological fibrosis; TGF-
β1 induces CTGF in fibroblasts; activates 
myofibroblast differentiation and activation 








Promotes cellular differentiation to 
myofibroblasts; enhances collagen expression 
in fibroblasts; increases myofibroblast survival 
Rodríguez-
Pascual et al 
99 






Diverse family of growth factors that require 
heparins or heparan sulfate for receptor 
binding, meaning proximity to ECM and 
fibroblasts that secrete ECM is required for 
activity; stimulates angiogenesis; stimulates 
proliferation, migration, and differentiation of 
epithelial cells and fibroblasts; chemotactic 
effects on tissue remodeling; inhibits EMT and 
antagonizes TGF-β-mediated effects 
Kim et al 100 
and 
Maddaluno 






Adhesive proteins that connect cells to ECM 
via integrins transmembrane proteins; 
essential for collagen assembly into ECM and 
blood clotting; regulates active TGF-β 
concentrations; protects tissue from TGF-β 
hyperstimulation; degraded by MMPs 
To et al 102 





Stimulates vasodilation; recruits immune and 
inflammatory cells; increases cytokine 
production and secretion 





iNOS Neutrophils, T 
cells, 
macrophages 
N/A Inducible form from a family of enzymes that 
produce NO from L-arginine after binding 
calmodulin; stimulated by IL-1, TNF-α, and 
IFN-γ. 
Iwakiri 104 




Mainly exerts antifibrotic effects; 
downregulates TGF-β1 expression; promotes 
Th1 development and antagonizes Th2 
development; activates iNOS; promotes 
leukocyte migration; antagonizes TGF-β-
induced ECM synthesis mechanisms 








Potent pro-inflammatory cytokine; induces 
production of PDGF and TGFβ 
Borthwick 106 





Pro-inflammatory cytokine that upregulates IL-
33 production, influences Th17-mediated 
inflammation and Th2-driven fibrosis, and 
facilitates myofibroblast pro-fibrotic activity 
Van Linthout 
et al 33 




Suppresses MMP biosynthesis by 
macrophages; drives Th2 development and 
antagonizes Th1 development 
Wick et al 11 




Aids in recruitment, differentiation and 
activation of eosinophils, which may attenuate 
rather than drive fibrosis 
Borthwick et 
al 56 






Shifts wound healing to a chronic 
inflammatory state; well-known roles in 
inflammation, cellular differentiation, and 
fibrosis; increases MMP-1 and TIMP-1 
expression as well as collagen synthesis 
Agarwal et al 
107 
IL-10 Macrophages, 




Inhibits synthesis of pro-inflammatory 
cytokines such as IFN-γ, IL-2, IL-3, and TNFα 
made by Th1 cells and macrophages; affects 
expression of MMP9, iNOS, INF-γ; effects of 
IL-10 are anti-fibrotic 




STAT4 Drives Th1 differentiation from naïve T cells; 
stimulates IFN-γ and TNF-α production from T 
cells 
Huaux et al 
108 





Participates in TGF-β production and 
activation; stimulates proliferation, 
differentiation, and collagen synthesis of/by 
fibroblasts 
Passalacqua 
et al 109 
IL-17 Th17 cells NF-κB, MAPK Stimulates interleukin-6 (IL-6) secretion in 
fibroblasts; increases IL-1 production; 
increases fibroblast proliferation; promotes 
collagen synthesis; attenuates myofibroblast 
transdifferentiation in pathological fibrotic 
states 




MAPK, NF-κB Stimulates natural killer (NK) cells and certain 
T cells to release IFN-γ; various pro-fibrotic 
characteristics such as increased proliferation, 






MAPK, NF-κB Production can be induced by inflammation 
mechanical stress; implicated in both 
inflammatory and fibrotic processes (drives 
production of type 2 cytokines) 
Borthwick 106 





Produced from lysophosphatidylcholine (LPC) 
by autotaxin; encourages cell proliferation, 
angiogenesis, cell survival, and 
migration/invasion; produced in response to 











N/A Breaks down types I-III collagens; may 
promote epithelial cell proliferation and 
migration, and inhibits oxidant production and 
apoptosis; promotes regeneration of epithelial 
cells 
Craig et al 40 
and 
Giannandrea 








Cleaves basement membrane proteins and 
type IV and denatured collagens; latent MMP-
2 is activated by MT-MMPs and TIMP-2 on the 
surfaces of fibroblasts and macrophages; 
promotes EMT by activating latent TGF-β 
Craig et al 40 
and 
Giannandrea 








Latent form activated by tryptase; cleaves type 
IV collagen and basement membrane 
proteins; promotes EMT; activates latent TGF-
β 
Craig et al 40 
and 
Giannandrea 
et al 41 
MMP-7 Epithelium, 
fibrocytes 
N/A Cleaves syndecan-1, allowing neutrophil 
infiltration; promotes fibroblast proliferation by 
cleaving latent heparin-binding epidermal 
growth factor (EGF)-like growth factor (HB-
EGF) and epithelial cell regeneration by 
cleaving E-cadherin 
Craig et al 40 
and 
Giannandrea 










N/A Stored in neutrophil granules and released 
upon activation; regulated by TGF-β1, TNF-α, 
and IL-1β; breaks down types I-III collagens; 
influences multiple processes by modulating 
cellular inflammation, cytokine inactivation, 
and fibroblast activation 
Craig et al 40 
and 
Giannandrea 





N/A Latent form stored in neutrophil granules 
(activated by interacting protease cascade 
including plasmin and MMP-3); stimulates 
collagen contraction when interacting with 
TGF-ß1, involved in removing fibrinogen 
matrix; recruits neutrophils and endothelial 
stem cells; activates latent TGF-ß1 and IL-1β; 
promotes EMT 
Craig et al 40 
and 
Giannandrea 
et al 41 
MMP-12 Macrophages N/A degrades soluble and insoluble elastin; 
influences fibroblast activation and collagen 
production; suppresses expression of other 
anti-fibrotic MMPs 
Craig et al 40 
and 
Giannandrea 
et al 41 
MMP-13 Fibroblasts N/A Breaks down types I-III collagens; regulated 
by TGF-β, IL-1β, IL-6, and TNF-α; activated by 
MMP-2 and MT1-MMP (MMP-14); cleaves 
and inactivate CCL2; processes many other 
cytokines 
Craig et al 40 
and 
Giannandrea 





N/A Induces prostaglandin G/H synthase 2 
(PTGS2), which generates PGE2 (anti-fibrotic 
cytokine) 
Craig et al 40 
and 
Giannandrea 
et al 41 
NO Neutrophils, 
macrophages 
MAPK, NF-κB In an oxidative environment, high levels of NO 
can interact with superoxide (•O−2) to produce 
peroxynitrite, leading to cell toxicity. NO 
engages in various pro-inflammatory and pro-
fibrotic activities such as oxidative burst and 






Induces type I collagen expression; acts on 
mesenchyme and fibroblasts to induce 
Klinkhammer 






proliferation, differentiation, and ECM 
production 
PGE2 N/A Wnt/β-catenin, 
PI3K/Akt 
Suppresses fibrosis by inhibiting fibroblast 
migration, proliferation, collagen synthesis and 
differentiation into myofibroblasts 
Bozyk et al 
113 
ROS Neutrophils, M1 
macrophages, 
endothelium 
TGF- β/SMAD Examples include: hydroxyl radical (•OH), 
hydrogen peroxide (H2O2), superoxide radical 
(•O−2), and ultimately oxygen (O2); increases 
TGF-β1 activation and production; involved in 
various feed-forward and feedback 
mechanisms important for the inflammatory 
and fibrotic responses 




N/A Family (TIMP1-4) of enzymes that bind to and 
inhibit MMP binding site; activated by MMP-2 
& -9; each TIMP inhibits most MMPs, but MT-
MMPs are mainly inhibited by TIMP-2 & -3 
and TIMP-1 coordinates to pro–MMP-9, 
preventing its activation 
Arpino et al 
42 








The main member of the PRRs involved in 
fibrosis; signal the presence of various 
pathogen-associated molecular patterns 
(PAMPs) and damage-associated molecular 
patterns (DAMPs) to innate and adaptive 
immune cells as well as pro-fibrotic cells; main 









SMAD-2/3 axis Main fibrotic effector; drives migration, 
proliferation, and differentiation of fibroblasts; 
stimulates αSMA, fibronectin, pro-fibrotic 
cytokine production; regulates the expression 
of ROS-producing enzymes 
Kim et al 60 
tryptase Mast cells N/A Pro-fibrotic serine protease that activates 
fibroblast proliferation and collagen synthesis; 
cleaves latent MMP-3; activates IL-6 release 










Has both pro-fibrotic and antifibrotic effects 
depending on state of macrophages and 
micro-environment; activates fibroblasts and 
overproduction of ECM; activates expression 
of fibrogenic cytokines; stimulates 
macrophage phagocytosis 





VEGF Promotes angiogenesis; could play a role in 
vascular damage signaling that promotes 
fibroblast activation 
Barratt et al 
116 
Angiotensin (Ang), α-smooth muscle actin (αSMA), C-C motif chemokine ligand 2 (CCL2), connective 
tissue growth factor (CTGF), fibroblast growth factor (FGF), inducible nitric oxide synthase (iNOS), 
interferon-γ (IFN-γ), interleukin (IL), matrix metalloproteinase (MMP), nitric oxide (NO), platelet-derived 
growth factor (PDGF), reactive oxygen species (ROS), tissue inhibitor of metalloproteinase (TIMP), Toll-
like receptor (TLR), transforming growth factor-β (TGF-β), tumor necrosis factor- α (TNF-α), vascular 
endothelial growth factor (VEGF) 
 
Fibrotic signaling pathways:  
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 There are multiple overlapping signaling pathways that regulate various components of 
the wound healing process. Figure 12 represents many important fibrotic signaling pathways 
(e.g. Wnt, TGFβ/Smad, VEGF, TNF, PI3K/AKT, mTOR, etc.)117. While it is difficult to 
encompass all the signaling components central to fibrosis in a single figure, there are many 
reviews that describe important fibrotic signaling pathways in depth.118-122 
 
Figure 12: Some notable signaling pathways in fibrosis: 
TGFβ/Smad promotes production of genes encoding for ECM components (e.g. collagen-1A2 (COL-1A2) 
and αSMA) and cytokines that drive myofibroblast differentiation (e.g. CTGF), EMT and blood clotting 
(e.g. plasminogen activator inhibitor-1 (PAI-1)); VEGF116/PDGF123/FGF100-signaling feeds into various 
pathways that are important for the fibrotic response, such as phosphoinositide 3-kinase (PI3K)124, proto-
oncogene tyrosine-protein kinase Src (Src)125, protein kinase B (Akt)126/mechanistic target of rapamycin 
(mTOR)127; signaling mediated by focal adhesion (e.g. focal adhesion kinase (FAK)) also feeds into 
PI3K/Akt pathways, and it is important for cell migration and myofibroblast activation128; Wnt/β-catenin 
signaling not only plays a central role in organ development, but it is also a critical mediator of the fibrotic 
response129; signaling through tumor necrosis factor-α (TNF-α)115 and janus kinases (JAK)/Signal 
Transducer and Activator of Transcription (STAT)130 are suggested to have mostly anti-fibrotic effects; 




Image derived from Yan et al (2014)117 
 
Therapeutic agents and strategies for fibrotic diseases: 
 Even though many complexities of the fibrotic process are generally well understood, 
including many of the mechanisms that are critical for driving pathological fibrosis, the 
therapeutic landscape for treating fibrotic diseases remains in its infancy. Despite the 
tremendous number of biological processes and targets identified as being potential strategies 
for treating fibrotic diseases, there are currently only two agents specifically approved in the 
U.S. for treating pathological forms of fibrosis—Nintedanib and pirfenidone (Figure 13)—albeit 
they are generally only mildly successful.131-134 The lack of successful fibrotic treatments stems 
from the difficulty of precisely modulating the numerous multifaceted biological processes that 
take place during the fibrotic response (many of which are described in the sections above).12,135 
 
Figure 13: FDA approved anti-fibrotic agents: 
Nintedanib and pirfenidone—two FDA approved therapeutic agents approved for idiopathic pulmonary 
fibrosis (IPF)—are mildly successful therapies used to treat fibrotic diseases. 
Many unsuccessful anti-fibrotic drug development efforts attempt to modulate pro- or 
anti-fibrotic signaling pathways by affecting easily accessible extracellular targets.12,135 However, 
this type of therapeutic approach has generally been problematic because precisely regulating 
the complicated cross-talk that takes place between fibrotic signaling pathways is very 
challenging. Also, many efforts focus on modulating targets that are not only activated during 
the fibrotic response but are also critical for normal cellular functions, which can lead to 
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undesirable side effects that limit therapeutic effectiveness.12,135,136 For example, while TGF- β 
signaling is central to all fibrotic diseases, TGF-β targeted therapies (e.g. antibodies, peptides, 
receptor decoys, small-molecules, etc.) for fibrotic diseases have failed to gain FDA 
approval12,135; unfortunately, not only is TGF-β signaling critical for normal biological functions, 
there are other pro-fibrotic factors in advanced fibrotic diseases that can overcome TGF-β 
inhibition and drive pro-fibrotic signaling pathways.137 Despite the lack of success, alternative 
approaches to targeting TGF-β are still being pursued.12,137 
Even successful therapies are promiscuous and guilty of attempting to control pro-
fibrotic signaling pathways by modulating up-stream targets.12,134,138 For example, Nintedanib 
inhibits multiple pro-fibrotic kinase receptor signaling activities (e.g. VEGFR, PDGFR, and 
FGFR; Figure 14)134,138, and while such pathways may be essential and highly upregulated 
during pathological fibrosis, they also control various processes that not only may help resolve 
the fibrotic response but are also central to normal cellular functions.4,12,134 Unfortunately, 
Nintedanib’s promiscuity has significantly limited its clinical success, producing undesirable off-




Figure 14: Nintedanib’s mechanism of action: 
Nintedanib potently inhibits kinase activity for FGFR, PDGFR, and VEGFR by binding to their intracellular 
ATP binding pockets. This inhibition blocks various downstream fibrotic and angiogenic signaling 
pathways, such as Akt, Src, FAK, ERK, vital for the fibrotic response. 
Image derived from Wollin et al (2015)138 
As for the success of Nintedanib and pirfenidone in the clinic, they are currently only 
capable of slowing disease progression by matters of months in IPF patients, and pirfenidone is 
generally only prescribed to bridge the time between diagnosis and lung transplantation—which 
remains the only intervention method with proven long-term benefit.12,132,136 A critical reason that 
these two drugs lack long-term success is because the resolution of fibrosis requires more than 
simply preventing fibrosis; it also requires restoring organ function, which presents a major 
hurdle in designing therapeutic agents for fibrotic diseases.84,136 However, promising research 
with stem cell therapies is being conducted that will hopefully enhance tissue repair in patients 
diagnosed with fibrotic diseases.136,139  
Based on recent reports for therapeutic strategies for fibrotic diseases84,85,122,131,133,135-
137,140,141, the crucial next step is to develop a therapy that can halt fibrotic disease progression. 
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However, as a result of the multilayered etiology of fibrotic disorders, this has posed a 
challenge. Still, the common belief to accomplish this is to design a therapy that selectively 
targets a mechanism specific to the fibrotic process.140-142 Ideally, the mechanism would be 
regulated by a biological target that is far-downstream within a fibrotic-dependent signaling 
pathway that is highly suppressed or upregulated during pathological fibrosis; for instance, 
modulating a biological target that directly regulates myofibroblast differentiation or controls the 
excessive expression of ECM. 
Many approaches are being conducted to determine the feasibility of therapeutic 
strategies with down-stream targets.140-142 For instance, microRNAs (miRNAs) have emerged as 
a potential therapeutic target.141,142 miRNA are short non-coding nucleic acid polymers that can 
silence mRNA and regulate post-transcriptional gene expression.143 Multiple miRNAs have been 
shown to either be overexpressed or downregulated during fibrotic disease progression, and 
these alterations can change a multitude of fibrotic processes, such as TGF-β-mediated 
signaling and the expression of ECM components.141,142 For example, inhibition of miR-21 with 
anti-miR-21 in mice results in recovery of heart function144, and synthetic overexpression of miR-
29 in mice with cardiac disease post-myocardial infarction (MI) reduces collagen production and 
fibrosis.145 Overall, miR-based therapy has provided strong preclinical indications that it may be 
an effective therapeutic strategy for various fibrotic diseases.141,142 
 Alternatively, peroxisome proliferator-activated receptor (PPAR) agonists have recently 
received attention for their anti-fibrotic capabilities.141 There are three subtypes of PPARs 
(PPARα, PPARβ/δ, and PPARγ), and they are nuclear transcription factors that homodimerize 
with retinoid-X receptors to affect gene transcription.146 Traditionally in the clinic, PPAR agonists 
(e.g. thiazolidinediones (TZDs)) are primarily used to enhance insulin sensitivity to promote 
glucose uptake in diabetes patients, but PPAR agonists have long been known to have anti-
inflammatory properties, and, recently, more studies are revealing their anti-fibrotic properties.147 
For instance, rosiglitazone—a PPARγ agonist—prevented radiation induced pulmonary 
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fibrosis148, and it reduced inflammation and collagen deposition in a bleomycin-induced model of 
dermal fibrosis.149 Unfortunately, many undesirable side effects (e.g. weight gain, edema, bone 
density loss, etc.) have been established throughout the years with PPAR agonists, which has 
limited their use and effectiveness in the clinic.147 While it is unknown if attempts to circumvent 
these side effects by using dual-, pan-, or mixed- agonists will improve PPARs utility as 
antifibrotic agents in the clinic, the results published over the past few years regarding their 
activity is a step in the right direction regarding designing anti-fibrotic agents that modulate 
intranuclear biological targets.141 
Recently, the Neubig lab discovered two novel series of small-molecule inhibitors that 
may modulate down-stream biological targets within signaling pathways that are linked to 
fibrotic processes (discussed in more detail in the next few sections). Based on promising 
results, both series of inhibitors might represent another anti-fibrotic strategy capable of 
targeting down-stream biological targets, potentially bridging the gap between only slowing 
fibrotic disease progression to halting it altogether. 
Rho/MRTF/SRF-regulated gene transcription and fibrosis: 
As mentioned, various overlapping biochemical pathways in a variety of cell types are 
triggered during the fibrotic process; however, Rho-signaling is central to the FMT. Soluble 
profibrotic mediators, such as TGF-β, endothelin, fibronectin, connective tissue growth factor 
(CTGF), lysophosphatidic acid (LPA), etc., induce the FMT through Rho-signaling (Figure 
15).14,121 The Rho family of GTPases and their downstream kinase, Rho-associated kinase 
(ROCK), are known to coordinate with myocardin-related transcription factor (MRTF) and serum 




Figure 15: The role of Rho/MRTF/SRF-signaling in the fibrotic process: 
The fibroblast-to-myofibroblast transition is tightly regulated by Rho/MRTF/SRF signaling. Both soluble 
and mechanical stimuli promote MRTF nuclear translocation in fibroblasts. In the resting state, actin is not 
polymerized, and MRTF is bound to G-actin and sequestered into the cytoplasm. When stress fibers form 
in response to these stimuli, G-actin polymerizes into F-actin and MRTF is released. This allows MRTF to 
translocate into the nucleus via binding to importins followed by MRTF/importin/nuclear pore complex 
(NPC) formation. The MRTF/SRF coactivator complex increases ECM and pro-fibrotic gene expression, 
contributing to the FMT. 
Rho/ROCK-signaling has been shown to participate in both soluble mediator and stiff 
matrix-induced FMT. 121,157 Inhibition of the Rho/ROCK-signaling pathway blocks myofibroblast 
differentiation through the disruption of stress fiber formation in vitro and reduces the severity of 
fibrosis in vivo.152 In addition to interrupting stress fiber formation, modulating Rho/ROCK alters 
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the gene expression profile of (myo)fibroblasts.121,153 A crucial link between simultaneous 
induction of stress fiber formation and altered gene expression during myofibroblast 
differentiation has been identified as MRTF.153 MRTF functions in coordination with SRF as a 
transcriptional coactivator that modulates the expression of myofibroblast genes, including 
smooth muscle aortic alpha-actin (ACTA2), connective tissue growth factor (CTGF), and 
collagen type I alpha 2 (COL1A2).14,150,153 The inhibition of MRTF/SRF-mediated gene 
transcription has been shown to mitigate myofibroblast differentiation and ECM synthesis in 
colonic fibroblasts and human skin fibroblasts from patients with scleroderma.158,159 
Rho/MRTF/SRF-signaling is known to regulate pro-fibrotic genes from multiple extracellular 
signaling pathways156,160-162, and therefore inhibition of this critical signaling pathway might be a 
general way to effectively treat/prevent pathological fibrosis (Figure 16). 
 
Figure 16: Alternative route for treating fibrosis: 
Inhibition of MRTF/SRF signaling, which is important for the fibroblast-to-myofibroblast transition, could 
provide an alternative route to treating fibrotic diseases. 
Image derived from Tsou et al (2014)121 
 
Novel inhibitors of Rho/MRTF/SRF-regulated gene transcription: 
The Neubig and Larsen labs identified Rho/MRTF/SRF-mediated gene transcription 
inhibitors using a high-throughput phenotypic screen utilizing a modified SRE.L reporter assay 
in HEK293T cells.163 Two series of inhibitors have been developed from this assay—the series 
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developed from CCG-1423 was identified from a 2,000 compound screen and that from CCG-
58146 was identified from an 80,000 compound screen (Figure 17).  
 
Figure 17: Hits and leads from the 222740- and 58150-series: 
Structures, potency, and cell-toxicity of two distinct series of Rho/MRTF/SRF-mediated gene transcription 
inhibitors. 
CCG-1423 has been an important probe compound for Rho/MRTF/SRF-regulated gene 
transcription.10,157,158,163-166 However, due to undesirable cytotoxicity and PK properties, the 
series was optimized to CCG-203971167, CCG-222740, and CCG-257081168 (Figure 17). This 
bis-amide series has provided promising in vitro and in vivo results in multiple fibrotic models. 
For instance, CCG-203971 repressed TGF-β-induced α-SMA and COL1A1 transcription and 
protein expression dose dependently in low-passage colonic myofibroblasts (CCD-18co cells), 
and transcriptionally repressed key effector molecules within the RhoA/MRTF-A pathway 
itself.158 Additionally, CCG-203971 increased susceptibility of healthy fibroblasts and fibroblasts 
derived from idiopathic pulmonary fibrosis (IPF) patients to undergo apoptosis, blocked TGF-β1-
induced myofibroblast differentiation, and inhibited TGF-β1-induced expression of fibronectin.169 
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In another study, CCG-203971 inhibited the expression of CTGF, α-SMA, and COL1A1 in both 
fibroblasts derived from scleroderma patients and in LPA stimulated fibroblasts.159 In various 
murine models159,163,166-173, CCG-203971 is capable of reducing lung collagen content, 
promoting myofibroblast apoptosis169, and preventing bleomycin-induced skin thickening and 
collagen deposition.159 
The novel and highly potent 1,3,4-oxadiazole thioether inhibitors CCG-58146 and CCG-
58150 were identified in the larger screen. The series was originally identified as a potential 
inhibitor of cancer metastasis; however, this direction was deprioritized due to the series’ potent 
anti-fibrotic activities. For instance, CCG-58150 not only inhibits expression of the MRTF/SRF 
reporter SRE.L in both HEK-293T and PC-3 cells (Figure 17 & 18A), but it also blocks CTGF 
expression of mRNA in LPA-stimulated fibroblasts (Figure 18B) and abrogates RhoC dependent 
PC-3 migration at sub-nM concentrations with similar potency (Figure 18C). The extremely high 
potency of CCG-58150 may be attributable to a covalent mechanism (discussed in Chapter 2), 
and the binding is apparently highly selective since it displays 0% WST-1 inhibition at 100 µM.  
In vivo, CCG-58150 has shown promising results in the prevention of bleomycin-induced skin 




Figure 18: Potent in vitro activities for CCG-58150: 
A) SRE-Luciferase activity in PC-3 cells with transfected with constitutively active Gα12 to stimulate Rho 
is inhibited by CCG-58150. B) Endogenous CTGF mRNA in NIH-3T3 cells was stimulated with LPA (10 
uM for 30 minutes) in the presence of various concentrations of CCG-58146 (blue) and CCG-58150 (red). 
C) (top) Migration of PC-3 prostate cancer cells in scratch assays has previously been shown to be 
RhoC-dependent. (bottom) CCG-58150 (blue) blocks migration at pM concentrations and CCG-58146 
blocks migration at nM concentrations (red). 
 
Figure 19: Potent in vivo activities for CCG-58150 in fibrotic mice: 
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Skin fibrosis was induced by daily bleomycin injections for two weeks. A group treated with CCG-58150 
(10 mg/kg p.o daily) showed: A & B) reduced skin thickness and C) decreased expression of the MRTF 
target gene CTGF. Skin thickness n=9-10 per group. CTGF n=5 due to limited tissue. ****, p<0.001 vs 
Vehicle, + or *, p<0.05 vs Bleo, Student’s t test. 
The Neubig lab has shown that inhibiting Rho/MRTF/SRF-mediated gene transcription 
decreases myofibroblast differentiation and ECM synthesis.158,159 The likelihood of generating a 
therapeutically important class of anti-fibrotic compounds from either series is highly probable 
due to the fundamental role that serum-regulated gene transcription has in cell survival, 
proliferation, and migration for fibrotic diseases.174 However, to increase the likelihood of this 
success, target identification campaigns to reveal the biological target(s) for both series were 
undertaken. 
Project Goals: 
Until recently, the major focus of the 222740 series has been to improve SRE.L activity 
and ADMET properties, while the emphasis on the 58150 series has been to explore the SAR 
around the aromatic ring. To better understand the mechanism of action for each series, 
additional target identification efforts by designing and synthesizing chemical probes for each 
series were planned. If successful, these target identification campaigns would potentially 
provide a more effective route to generate optimized therapeutic agents as well as provide a 
better understanding of on-target vs. off-target effects for each series. The recent efforts to 
identify the biological target(s) for both series are discussed in Chapter 2. 
Regardless of whether these efforts were successful, another goal of the project was to 
determine the potential anti-fibrotic capabilities of both series by developing pre-clinical 
candidates that could be tested in relevant murine models of fibrosis. This goal required 
improvements in cellular potencies, pharmacokinetic (PK) profiles, and proof-of-concept 
validation in various in vitro models of fibrosis. Recent advancements toward this goal for the 
58150- and 222740-series are discussed in Chapters 3 and 4, respectively. Also, with these 
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Chapter 2: Probe Design and Development/Target Identification 
Brief Target Identification Introduction: 
There are many approaches to identifying unknown biological targets for small-molecule 
inhibitors, such as immobilized resin175,176, photo-affinity177,178, and fluorescent179 probes; 
however, target identification campaigns are frequently multifaceted, time-consuming, and 
expensive to complete.180-184 The first step is often designing and synthesizing a chemical probe 
that retains the observed phenotypic biological activity.175,180,183 This can be challenging for 
many reasons, such as (1) attaching appendages to the small-molecule’s scaffolding can 
change or eliminate relevant biological activity (2) many small-molecule series that require 
target ID campaigns are identified in phenotypic assays, making it difficult to verify relevant 
activity of the probe-mimics or the probe itself (3) the probe design process can be slow in 
general since multiple iterations of probe mimics (and their syntheses) may be required to 
confirm the biological activities relevant to biological target engagement.175,183 
After a probe is produced, the proper pull-down experiments need to be designed and 
conducted.175,178,180,183 Often, the probe alone does not suffice for accurate identification of the 
biological target(s). For instance, various controls, such as a competitor (e.g. active analog 
within the series), a structurally related “inactive” probe, or the solid phased capped without 
compound, can be used to compare protein fragmentation patterns after quantitative proteomic 
analysis.175,178,183 Such control experiments help tease out proteins that non-specifically bind to 
the probe as a whole rather than the portion of the probe containing the small-molecule.  
Moreover, various target identification approaches, such as stable isotope labeling of amino 
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acids in cell culture (SILAC)185, drug affinity responsive target stability (DARTS)186, and 
differential radial capillary action of ligand assay (DRaCALA)187, can enhance the accuracy of 
the proteomic analysis.188 The pull-down experiment may require an even more intricate design 
if the small-molecule/probe only interacts weakly with relevant macromolecule(s), the biological 
target is in low cellular abundance, or the biological target is unstable or susceptible to post-
translational modifications.180,183,188  
Once the proper probe and isolation experiments are designed and conducted, the 
resulting batches of macromolecules collected can be proteolytically cleaved (e.g. trypsin), 
producing fragments of amino acids that can be analyzed for characteristic (and ideally unique) 
sequences by mass spectrometry.183 The ensuing quantitative proteomic analysis of these 
amino acid fragments can be used to generate a list of protein candidates.183,189 After a 
reasonable list is generated, the next step is to validate the biological target(s).181-183,190 
Generally, the candidate list can be narrowed down by searching the literature for 
macromolecules with relevant biological activities; however, validating even just one potential 
biological target can be time-consuming and expensive. For instance, even if a protein 
candidate is found to physically interact with analogs from a series of small-molecules, 
confirming a biological target typically also requires connecting the identified target to the 
phenotypic assay (in vitro) and the disease state (in vivo).181-183,190 
All considered, it is very important to establish valid reasons for pursuing a target 
identification campaign. The exciting in vitro and in vivo biological activity of the 58150- and 








CCG-58150 Series Target Identification Efforts: 
Parts of this subsection have been included in a submitted manuscript entitled “5-Aryl-1,3,4-
oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho-Mediated Gene 
Transcription as Potential Antifibrotic Agents for Scleroderma” by Kahl et al. 
58150 Series Probe Design Rationale: 
The early SAR trends (vide infra) suggested the 58150 series exhibits a covalent 
mechanism of action with the biological target that transduces the series’ biological activity; we 
imagined our probe design would benefit from this proposed mechanism of action. The 
proposed covalent reactivity is implied from both the nM-pM potency and clear activity cliffs 
observed upon minor alterations to various regions of the chemical scaffolding. In our 
preliminary SAR investigation, the importance of the phenyl-substituted oxadiazole ring and the 
carboxylic acid system was highlighted with commercially available compounds (Figure 20). 
Pyridyl (A1 and A2) and furanyl (A3) substituted oxadiazole analogs completely lost all activity 
compared to hit 58146. Attempts to replace the oxadiazole core with other heterocycles (A4-A6) 
were similarly unsuccessful. Replacement of the carboxylic acid with an acetal isostere (A7) led 
to a similar loss in activity. Based on these strongly negative results, we concluded that the 5-
aryl-1,3,4-oxadiazole ring was required for potent activity, and replacing the carboxylic acid 




Figure 20: Preliminary SAR of 58150-series heterocycle and carboxylic acid. 
SRE.L activity in PC-3 cells (mean of n = 3, SEM < 10%). 
Next, using a general Topliss approach, we systematically investigated prototype 
electron donating (methoxy), withdrawing (chloro) and alkyl (methyl) groups at each of the three 
aryl positions (Table 2, A8-A16). Remarkably, this revealed an over 250-fold span of potency 
over just these first 9 analogs; SRE.L IC50s ranged from 6300 nM (A15) to 25 nM (A14). Within 
this small initial group were several clear activity cliffs, including 2-Cl A14 (25 nM) vs 3-Cl A12 
(1500 nM) and 4-Me A9 (34 nM) vs 3-Me 58146 (180 nM) vs 2-Me A15 (6300 nM). We were 
then interested to see if the individual optimum substitutions would be synergistic. From the data 
in Table 2, among the four substitutions investigated at each position, Cl is optimum at R1, Me at 
R2, and Me and OMe at R3. Various dual combinations of these were attempted (58150-A18), 
giving compounds with single digit nM SRE.L IC50s. Also, despite these significant 
improvements in SRE.L activity, all analogs tested were unable to affect cell 
proliferation/viability up to 100 µM as measured by WST-1, highlighting the series lack of 
cytotoxicity at high concentrations. 
The phenotypic SRE.L assay was originally designed as a HTS for cancer therapeutics 
using PC-3 cells.163 However, to improve the throughput of the transfection, the cell line was 
switched to HEK-293T cells. To ensure equivalency in SRE.L potency from one cell line to the 
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other, various analogs were tested in both assay conditions (e.g. 58150, 232120 (Table 3), 
232964 (Chapter 3), etc.). Notable differences in activity were not observed between the two 
transfected cell lines, so the assay was eventually switched to HEK-293T cells.  
The activity was further improved with trisubstituted analogs (A19-A21) that combined 
the best R1, R3-disubstitution analogs (58150 & A17) with the best R2/R4 substituent (Me). This 
resulted in the first sub-nanomolar analogs in the series, with SRE.L potency as high as IC50 = 
20 pM (A19). These extremely tight and potent SAR trends suggest that these inhibitors likely 
interact with a very well-defined binding site on the unknown molecular target.  
Table 2: Systematic SAR investigation of aryl ring: 
 




123859 A8 H H H H 3,500 
123852 A9 H H Cl H 340 
123862 A10 H H Me H 34 
123855 A11 H H OMe H 160 
123851 A12 H Cl H H 1,500 
58146 - H Me H H 180 
211911 A13 H OMe H H 3,600 
232700 A14 Cl H H H 25 
232841 A15 Me H H H 6,300 
232740 A16 OMe H H H 3,100 
58150 - Cl H Cl H 2 (4c) 
232001 A17 Cl H Me H 1.5 
215220 A18 Cl H OMe H 2.6 
258043 A19 Cl Me Me H 0.02c 
258041 A20 Cl H Me Me 0.23c 
258021 A21 Cl H Cl Me 0.32c 
aInhibition of Gα12-stimulated SRE.L activity (mean of n = 3, SEM < 10%) in PC3 cells unless otherwise 
noted. bCell viability and proliferation assay with WST-1 < 5% inhibition up to 100 M inhibitor (mean of n 
= 3, SEM < 10%). cSRE.L assay performed in HEK293T cells (mean of n = 3, SEM < 10%). 
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Replacing the carboxylic acid functionality with neutral methyl amide (A23) was 
unsuccessful (Table 3); however, ethyl ester A22 maintained activity, likely due to hydrolysis by 
non-specific esterases in the biological conditions of the assay. Unfortunately, the t-butyl ester 
homolog was not tested to further confirm this hypothesis. To determine the optimal carbon 
chain length between the oxadiazole and carboxylic acid, analogs bearing linkers from one to 
seven methylenes were synthesized (A25-A30). Considering drug-like properties, we deemed 
the optimal carbon chain length to be three (232120). Interestingly, activity was completely lost 
when there was only one carbon separating the oxadiazole and carboxylic acid (A25). 
Amazingly, while hydroxamic acid replacement was unsuccessful (A26), isosteric replacement 
of the carboxylic acid with a tetrazole (A24) led to an unexpected improvement in activity; this 
recent data warrants further follow up (discussed in Chapter 5). These steep SAR trends are 
evidence for the importance of the carboxylic acid group and its position relative to the 
oxadiazole ring. 
Table 3: Carboxylic acid sidechain SAR: 
 





58150 - (CH2)2 CO2H 4 (2c) >60 
215161 A22 (CH2)2 CO2Et 2.6 - 
232661 A23 (CH2)2 CONHCH3 >100,000 - 
257447 A24 (CH2)2 
 
0.009c - 
215027 A25 CH2 CO2H >100,000 - 
232120 - (CH2)3 CO2H 1.8 (0.84c) >60 
257445 A26 (CH2)3 CONHOH 465c - 
232503 A27 (CH2)4 CO2H 43 - 
232923 A28 (CH2)5 CO2H 0.63 - 
232962 A29 (CH2)6 CO2H 72 - 
232963 A30 (CH2)7 CO2H 24 - 
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aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in PC3 cells. bCell viability and 
proliferation assay with WST-1 < 5% inhibition up to 100 M inhibitor (mean of n = 3, SEM < 10%) up to 
100 M inhibitor. cSRE.L assay performed in HEK293T cells (mean of n = 3, SEM < 10%). dHalf-life in 
mouse liver microsomes. 
Based on (1) our unsuccessful attempts to replace the oxadiazole core with similar 
heterocycles (Figure 20) (2) the steep SAR of the series with regard to both aryl substitution and 
alkanoic acid chain length (Tables 2 & 3) and (3) the extraordinary activity achieved (sub-
nanomolar) with such low molecular weight compounds (further discussed in depth in Chapter 
3), we hypothesized that the oxadiazole thioether core might be engaging with a binding site 
nucleophile covalently as illustrated in Figure 21. Therefore, analogs structurally similar to 
58150 but predicted to be much less capable of reacting with nucleophiles were synthesized 
and tested (Figure 21). In support of the covalent hypothesis, an almost complete loss in activity 
occurred upon replacement of the S with O or CH2 (A31, A32), migration of the S away from the 
heterocyclic core (A33), or alteration (A34) of the core heterocycle.  
Interestingly, activity was maintained when the system was made more susceptible to 
nucleophilic attack with sulfone A36; however, this trend was not observed with all analogs that 
attempted to increase the oxadiazole core electrophilicity (A35), possibly because of an inability 
to engage with the biological target (e.g. rapid elimination of reactive compound by cellular 
milieu or incapable of forming the proper intermediate for target engagement). Additionally, the 
result for sulfone A36 suggests our series may get activated within the cell, either by the 





Figure 21: Hypothetical electrophilic reactivity of 58150-series 
Hypothetical reaction of 58150 with a target nucleophile and SRE.L activity of analogs designed to 
modulate susceptibility of the oxadiazole ring system to nucleophilic attack. 
If this covalent mechanism is ultimately proven, this would be the first example of an 
oxadiazole-thioether heterocyclic system being susceptible to covalent modification by a 
biological target. There are, however, reports in the literature that suggest the oxadiazole 
thioether core is chemically reactive under various conditions.191-193 It is possible that our 
analogs are getting oxidized prior, or subsequent, to binding to the target, forming an activated 
metabolite, like A36. Indeed, the 5-thioalkyl-1,3,4-oxadiazole core is susceptible to oxidation 
and nucleophilic displacement in our hands (Scheme 1) in a manner that is comparable to the 
proposed mechanism in Figure 21, lending additional support to our covalent hypothesis.192,194 




Scheme 1: Reaction exemplifying chemical reactivity of oxadiazole core: 
Reagents and conditions: (a) MeI, Et3N, THF, 25 °C, 2 hr (b) (NH4)6Mo7O24, H2O2, EtOH, 25 °C, 2 hr (c) 
mCPBA, DCM, 25 °C, 2 hr (d) 4-mercaptobutanoic acid, K2CO3, acetone, 25 °C, 1 hr, (e) mCPBA, DCM, 
25 °C, 2 hr. 
Generally, the chances for success of a target identification campaign are assumed to 
increase the higher the affinity of the small-molecule to the biological target, which is 
understandable because high-affinity complexes can be preserved under extensive washing 
conditions, reducing the amount of non-specific binding proteins in quantitative proteomic 
analysis.176,183 However, this implied affinity can be misleading since the assumption is generally 
based on cellular activities, and cellular activity does not necessarily translate to high-affinity 
complexes between the ligand and the biological target that affords the activity.183  
Probes with covalent handles can enhance confidence that the probe will strongly 
engage with the biological target of interest in a pulldown experiment.176,177,188 For instance, the 
photolyzable diazirine functionality is the golden standard in covalent handles (Figure 22).177,195 
This functional group is exceptional in that it is (1) stable to ambient light (in both acidic and 
basic conditions) (2) compact (isosteric in size to methyl) (3) easily accessed synthetically 
through various alkyl ketones and (4) the alkyl carbene intermediate formed upon photo-
activation (355 nm) is highly selective for N—H, S—H, and O—H, and, when insertion into the 
desired biological target cannot occur, this intermediate is rapidly quenched by solvent or 




Figure 22: Pull-down strategy using diazirine functional group: 
Reactivity of the diazirine photoprobe enhances probe pulldown success through carbene intermediate 
formation and rapid reaction with proximal proteins or solvent. 
Since we had strong evidence that our series had an imbedded covalent handle that was 
likely important for activity, we decided to utilize this in our immobilized resin affinity probe 
design (Figure 23). Also, based on the tight SAR, we assumed we would be able to develop a 
structurally very similar inactive control probe. 
 
Figure 23: 58150-series probe design: 
A) The proposed covalent mechanism of CCG-58150 to its biological target. B) The “active” and “inactive” 
resin-bound affinity probes synthesized can be incubated with cell lysates, and then isolated, trypsin 
digested, and proteomic analysis can be performed. 
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First, a “methoxy scan” to probe suitable positions to fasten the PEG-amine linker for 
attachment to the immobilization resin was performed (Figure 24); the SAR generated from the 
methoxy scan analogs further exemplified the tight SAR of the series. Appendages replacing the 
carboxylic acid functional group (A37) or those directly attached to the aliphatic linker (A38-A40) 
eliminated SRE L activity. Critical activity cliffs to design the appropriate active and inactive 
control probes appeared with alterations around the aromatic ring. In general, substitution at the 
para-position was preferred (A43 vs A41 & A42) and, consistent with our previous SAR trends, 
di-substitution at the para and ortho positions provided the best activity profile. For example, 
A44 was up to ten-fold more active than closely related homologs A45 & A46 and ten-thousand-
fold more active than A47.  
 
Figure 24: Methoxy-scan for 58150-series: 
Methoxy-scan of the 58150-scaffold to identify “active” and “inactive” positions for agarose resin tethering. 
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Clearly, A44-A46 exhibited the most attractive substitution pattern to further assess a 
pendant more similar in size to the PEG-amine linker. Therefore, “PEG-mimics” A48-A50 were 
synthesized to validate tolerance for the steric bulk required for immobilized probes (Figure 25). 
A48 retained most of 215220’s activity, and closely related analog A50 was ~1000-fold fold less 
active than A48. These results provided rationale to attach the PEG-amine linker for 
immobilized resin to the para-position for the active probe (similar to A48) and the ortho-position 
for the inactive control probe (similar to A50). 
 
Figure 25: PEG mimic scan for 58150 series: 
CCG-58150-scaffold methoxy-ethoxy-scan of potent methoxy-scan positions 
 
Synthesis of Key 5-aryl-1,3,4-oxadiazol-2-ylthioalkanoic acids for Probe Design:  
The general synthesis of 5-aryl-1,3,4-oxadiazol-2-ylthioalkanoic acids and related 
homologs is summarized in Scheme 2. Aryl bromide 3 was subjected to standard 
lithiation/carboxylation conditions followed by an acidic workup to produce the subsequent aryl 
benzoic acid. Various aromatic benzoic acids (4) were converted to their respective methyl 
esters under standard Fischer esterification conditions, and then converted to the corresponding 
hydrazides (5) by refluxing in MeOH with excess hydrazine hydrate. Refluxing 5 and carbon 
disulfide in EtOH under basic conditions, followed by acidic workup, generated 2-mercapto-5-
aryl-1,3,4-oxadiazoles (1, 6). S-alkylation with either methyl, ethyl, or t-butyl -bromoalkanoates 
and 5-(2-chloroethyl)-1H-tetrazole provided the thioether esters (7, 8, and 215161) and tetrazole 
257447. Hydrolysis of the esters was accomplished with either trifluoroacetic acid (t-butyl 
esters) or sodium hydroxide (methyl esters) to give final carboxylic acids 9. The tert-butyl esters 
became the preferred precursor when n = 2 because basic hydrolysis of the methyl ester 
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intermediates resulted in competing retro-Michael elimination to regenerate the 1, 3, 4-
oxadiazole-2-thiols (1, 6).  Amide 232661 was prepared by conversion of 9 to the corresponding 
acid chloride with oxalyl chloride in DMF/DCM at room temperature, followed by addition of 
methylamine. Carboxylic acid 9 was also easily converted to hydroxylamine 257445 by reacting 
the mix anhydride intermediate generated from ethyl chloroformate with freshly prepared 
hydroxylamine hydrochloride.196 
 
Scheme 2: General scheme for synthesis of 5-aryl-1,3,4-oxadiazol-2-ylthioalkanoic acids and 
related analogs 
Reagents and conditions: (a) n-BuLi, THF, -78 °C 5 min, then CO2 (s) (b) 1N HCl workup (c) H2SO4/MeOH, 
85 °C, 6 hr (d) H4N2•H2O, 85 °C, 14 hr (e) KOH/H2O/EtOH, CS2, 95 °C, 16 hr (f) 1N HCl workup (g) 
acetone, K2CO3, Br-(CH2)n-CO2R’, 25 °C, 5-24 hr (h) Acetone, K2CO3, 5-(2-chloroethyl)-1H-tetrazole, 60 
°C, 48 hr (i) DCM, TFA, 25 °C, 3 hr (j) 1M NaOH, THF, 25 °C, 16 hr (k) oxalyl chloride, DMF, DCM, 25 °C, 
2 hr (l) MeNH2 in EtOH, 25 °C, 16 hr (m) NMM, ClCO2Et, 0 °C, 10 min (n) MeOH, NH2OH•HCl, 25 °C, 45 
min. 
The syntheses of 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)oxy)butanoic acid 
(257223), 2-(((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)methyl)thio)acetic acid (257169), and 
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3-((5-(2,4-dichlorophenyl-1,3,4-thiadiazol-2-yl)oxy)propanoic acid (215240) are depicted in 
Scheme 3. 5a was used as a common starting material for key intermediates 10194, 11197, 1, and 
12198. As reported by Yan et al.194, intermediate 10 was produced through the 
cyclization/rearrangement of 5a with propylene oxide. O-alkylation with t-butyl 4-bromobutyrate 
followed by acidic hydrolysis with trifluoroacetic acid provided carboxylic acid 257223. 
Alternatively, per Sun et al.197, subjecting 5a to bromoacetic acid and POCl3 afforded 
intermediate 11. Basic S-alkylation with potassium carbonate and 2-mercaptoacetic acid 
produced carboxylic acid 257169.  
As described previously (Scheme 2), 2, 4-dichloro-1,3,4-oxadiazole-2-thiol (1) was 
synthesized with refluxing 5a and carbon disulfide under basic conditions, followed by acidic 
workup. 1 was converted to the thiadiazole ether 215240 by subjection to acrylic acid and 
trimethylamine in refluxing THF. These reaction conditions were originally attempted to produce 
carboxylic acids (9) through a Michael reaction (Scheme 4), however the conditions 
unexpectedly produced 215240 (Scheme 5). This transformation further exemplifies the 
reactivity of the 1, 3, 4-oxadiazole core to proximal nucleophiles, and provides support for the 
covalent hypothesis proposed for these inhibitors. Subjecting 1 to the general basic SN2 
conditions with methyl 4-bromobutanoate followed by basic hydrolysis and mCPBA oxidation 
afforded 258126. Thiadiazole intermediate 12 was synthesized with a modified cyclization 
procedure that utilized fuming sulfuric acid.198 O-alkylation with methyl 4-bromobutyrate followed 




Scheme 3: Synthetic routes for alternate core and linker analogs: 
Reagents and conditions: (a) K3PO4, CS2, H2O, 106 °C, 2 hr. (b) propylene oxide, 25 °C, 16 hr (c) DMF, 
K2CO3, Br-(CH2)3-CO2OtBu, 90 °C, 1 hr (d) DCM, TFA, 25 °C, 1 hr (e) POCl3, bromoacetic acid, 106 °C, 
16 hr (f) 2-mercaptoacetic acid, Acetone, K2CO3, 25 °C,  2 hr (g) KOH/H2O/EtOH, CS2, 95 °C, 16 hr (h) 
acrylic acid, Et3N, THF, 70 °C, 16 hr (i) Acetone, K2CO3, Br-(CH2)3-CO2Me, 25 °C, 5 hr (j) 1M NaOH/THF, 
25 °C, 1 hr (k) mCPBA, DCM, 25 °C, 4 hr (l) KOH/H2O/EtOH, CS2, 25 °C, 3 hr, then fuming H2SO4, 25 °C, 
2 hr (m) K2CO3, Br-(CH2)3-CO2Me, DMF, 90 °C, 1 hr (n) 1M NaOH/THF, 25 °C, 1 hr. 
 




Scheme 5: Proposed mechanism for formation of 215240 
 Propanoic acid 257021 was challenging to synthesize (Scheme 6); however, since all 
pathways attempting to install the alkyl chain with nucleophilic displacement with thiol 1 were 
unsuccessful, the synthesis was eventually accomplished utilizing an Ümplong route. 
Unsuccessful routes included: (1) nucleophilic displacement of various epoxides, all of which 
attempts formed rearrangement product 10 (2) nucleophilic displacement of alkyl bromide 14 
followed by reduction of the resulting ketone 15 with various reducing reagents, including 
NaBH4, NaBH(OAc)3, and NaBH3CN (3) Michael conditions using 17.  
Alternatively, affixing the alkyl chain with the nucleophilic thiol 21 and converting the 
1,3,4-oxadiazole core into the electrophile 2 resulted in generation of 257021.199 Michael 
reaction between benzyl mercaptan and Michael acceptor 19 using a weak base produced 
methyl ester intermediate 20. Hydrolysis of methyl ester 20 followed by Birch Reduction and 
acidic workup afforded thiol 21. The synthesis of 257021 concluded nicely with displacement of 




Scheme 6: Attempts to access 257021: 
Reagents and conditions: (a) 1M TBAF in THF, BnSH, 25 °C, 2 hr (b) H2O, MeOH, K2CO3, 25 °C, 16 hr 
(c) Na (o), NH3 (liq), -30 °C, 25 min then HCl workup (d) Acetone, K2CO3, 2, 25 °C, 2 hr. 
 The synthesis for 232961 proceeded smoother (Scheme 7). Starting from lactone 22, 
electrophilic intermediate 23 was accessed through silver (II) oxide-mediate methylation 
followed by a one-pot ring opening, iodination, and esterification with TMSI and MeOH. 
Reacting thiol 1 with electrophile 23 easily produced butanoic acid 232961 with our typical SN2 




Scheme 7: Synthesis of 232961 
Reagents and conditions: (a) DCM, MeI, Ag2O, 70 °C, 1 hr (b) DCM, MeOH, TMSI, -10 °C, 1 hr then 25 
°C, 3 hr (c) Acetone, K2CO3, 1, 25 °C, 4 hr (d) 1M NaOH/THF, 25 °C 1 hr. 
 257222 (Scheme 8) was synthesized utilizing similar chemistry as displayed in Scheme 
7. One-pot ring opening, iodination, and acetylation of tetrahydrofuran 24 was accomplished 
with acetyl chloride and sodium iodide to produce electrophile 25.200 This intermediate was 
subjected to our standard SN2 conditions with thiol 1, generating methyl ester 26. Pentatonic 
acid 257222 was produced by deacetylation with weak base, silver (II) oxide-mediated 
methylation with methyl iodide, followed by basic hydrolysis. 
 
Scheme 8: Synthesis of 257222 
Reagents and conditions: (a) MeCN, CH3COCl, NaI, 25 °C 24 hr (b) Acetone, K2CO3, 1, 25 °C, 1 hr (c) 
MeOH, K2CO3, 25 °C, 30 min (d) DCM, Ag2O, MeI, 70 °C, 1 hr (e) 1M NaOH/THF, 25 °C 1 hr. 
 The ethoxymethoxy functional groups of probe mimic analogs 257156-232964 (Figure 
25) were installed at the beginning of their syntheses (Scheme 9). 27 was converted to benzoic 
acid 30a by TES protection of the phenol, lithiation/carboxylation followed by acidic workup201, 
and then alkylation with 1-bromo-2-methoxyethane and strong base. These alkylation conditions 
were also used to produce 30b. However, likely due to steric or electronic contributions of the 2-




Scheme 9: Synthesis of 30a-c 
Reagents and conditions: (a) TESCl, Et3N, THF, 50 °C, 24 hr (b) sBuLi, cHex, THF, -78 °C, 45 min (c) 
CO2 (s), then HCl workup (d) KOH, EtOH, K2CO3, Br(CH2)2OMe, 95 °C, 24 hr (e) HCl workup (f) DMF, 
K2CO3, Br(CH2)2OMe, 25 °C, 5 hr 
 
Synthesis of Active and Inactive Immobilized Agarose Resin Probes: 
Both “active” (A52) and “inactive” (A53) PEG-amine linker analogs for immobilized probe 
development were synthesized (Scheme 10). Esterification followed by O-akylation of phenols 
4a & 4b using either propargyl benzenesulfonate or benzyl bromide, respectively, provided 
esters 4a’ & 4b’ that were converted to the 5-aryl-2-mercapto-1,3,4-oxadiazoles 6a & 6b as 
previously described.202-205 S-alkylation with t-butyl-3-bromobutanoate followed by reductive and 
Lewis acid-mediated deprotection of the resulting propargyl esters generated 8a & A51. The 
TFA salt form of the PEG-amine linker analogs A52 & A53 were obtained by O-alkylation 
followed by acidic hydrolysis. The final probes were produced by the Neubig lab with NHS-
agarose beads using solid phase amine coupling chemistry followed by blocking of residual 




Scheme 10: Synthetic routes to produce 58150-series active and inactive probes 
 
Biological Target Pull-down and Proteomic Analysis: 
 Through the experimental design shown in Figure 26, a list of protein candidates was 
systematically generated using our active and inactive immobilized affinity resin probes. 
HEK293T cell lysate were treated with “active” (A52) and “inactive” (A53) immobilized probes at 
10 µM. The immobilized probes were washed with PBS to remove non-specifically bound 
membranes and proteins. The Martin lab generated protein fragments for relevant biological 
targets by trypsin digestion of the beads directly, removed the remaining beads by 
centrifugation, and then the resulting supernatants were subjected to mass spectroscopic 
analysis. This analysis consisted of evaluating various fragment batches using spectral counting 
to identify proteins enriched in the active bead samples compared to the inactive bead samples. 
Protein candidates that had an active/inactive enrichment ratio ≥ 2 and relatively high unique 
peptide counts were considered as potential biological targets (Table 4). Efforts to validate the 




Figure 26: Target identification methodology performed for the 58150 series “active” and 
“inactive” agarose resin affinity probes. 
In separate experiments, the “active” (A52) and “inactive” (A53) probes were subjected to cell lysate in 
DMSO and applied to a spin column. These mixtures were incubated at room temperature for 1 hour and 
then the samples were washed with PBS to remove membranes and non-specific proteins. The sample 
beads from each experiment were subjected to trypsin digestion, and the resulting protein fragments were 
analyzed on a Waters mass spectrometer. The average abundance of peptide fragments for each protein 
candidate were compared between “active” and “inactive” probe experiments, producing the enrichment 
ratio, to help consolidate interesting protein candidates. An extensive literature search for relevant biology 
on candidates with an enrichment ratio greater than 2 was performed. Validation efforts for the proteins of 




Table 4: Top 20 protein candidates after proteomic analysis 
Protein Peptide Count Unique Peptide Count Enrichment Ratio 
Deoxycytidylate 
deaminase 
2 1 30.6 
Testican-2 2 1 26.1 
dCTPase 37 32 12.9 
Genome polyprotein 4 1 8.5 
Phosphoglycerate 
mutase 1 
2 1 7.5 
Insulin-like growth 
factor 2 mRNA-
binding protein 3 
4 1 6.6 
RNA-binding protein 
EWS 
4 1 5.9 
UBX domain-
containing protein 1 





3 1 5.3 
Transmembrane 
protein 263 
4 4 5.1 
Desmoglein-1 6 3 4.3 
Selenoprotein H 4 3 4.2 
Junction plakoglobin 3 1 4.0 
Histone H1.4 5 2 3.9 
40S ribosomal 
protein S4, Y isoform 
1 





20 12 3.8 
Tyrosine-protein 
phosphatase non-
receptor type 11 





1 1 3.4 
Cyclin-dependent 
kinase 20 
5 1 3.2 
Fibroblast growth 
factor receptor 2 
9 1 3.1 
Peptide counts refer to the number of peptides identified for a given protein, while unique peptide count 
refers to the number of peptides identified that are completely unique for a given protein. The enrichment 
ratio is the raw mean ratio between peptides identified in the active vs. inactive samples. 
 
Biological Target Validation Efforts: 
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From these results, dCTP pyrophosphatase 1 (dCTPase, DCTPP1, or XTP3TPA) (n = 4) 
was identified as the top candidate protein target for the 58150-series. This protein had an 
enrichment ratio of 12.9, and 32 of the 37 peptides identified for dCTPase from the proteomics 
studies were unique for the macromolecule. dCTPase is an all-α-nucleoside triphosphate (NTP) 
pyrophosphatase that catalyzes the Mg2+-mediated hydrolysis of non-canonical and canonical 
deoxynucleoside triphosphates (dNTPs) to the respective deoxynucleoside monophosphates 
(dNMPs).206 Interestingly, dCTPase has a higher affinity towards 5-modified non-canonical 
dNTPs over canonical dNTPs and rNTPs, ultimately leading to decreased intracellular levels of 
non-canonical dNTPs.206,207 In short, dCTPase is responsible for regulating the global dNTP 
pool, and it also plays an epigenetic “housekeeping” role. dCTPase has been found to be 
strongly associated with cancer. In particular, dCTPase accumulates in the nucleus of multiple 
carcinomas208 and plays a role in gastric and breast cancer stemness.207,209 
Dr. Erika Lisabeth in the Neubig lab took several steps attempting to validate dCTPase 
as a target for this series. First, she showed that knocking down dCTPase led to a decrease in 
the production of LPA-stimulated CTGF mRNA in primary dermal fibroblast cells (Figure 27A). 
Interestingly, the knockdown did not affect TGFβ-stimulated CTGF mRNA production. In a 
similar experiment, 58150 and 232964—a potent inhibitor discussed in more detail in Chapter 
3—inhibited LPA-stimulated CTGF mRNA expression but did not affect TGFβ-stimulated CTGF 
expression (Figure 27B & 27C), a result that correlates to the dCTPase knock-down study 
(Figure 27A). Taken together, these data (1) suggested dCTPase might play a role within our 
SRE L. assay and (2) demonstrated that knocking down dCTPase has selectivity for inhibiting 




Figure 27: Comparison between siRNA dCTPase activity and 58150-series inhibitors in primary 
dermal fibroblast cells: 
A) siRNA dCTPase leads to decreased production of LPA-stimulated CTGF mRNA, but not TGFβ-
stimulated CTGF mRNA production. B & C) 58150 (B) and 232964 (C) decreased LPA-stimulated CTGF 
mRNA expression but did not affect TGFβ-stimulated CTGF mRNA expression. 
Additionally, an attempt to validate this target by synthesizing and testing a literature 
dCTPase inhibitor was made.210 In our SRE L. assay, the resynthesized literature inhibitor 31 
displayed only weak activity (HEK293T SRE L. IC50 = 3,100 nM, n = 3; Figure 28). While the 
literature inhibitor did not display the same SRE.L potency as our inhibitors, the presence of 
activity indicates that dCTPase may play some role within our assay. If dCTPase is a target for 
the 58150-series, since it is not known whether the literature inhibitor binds covalently to 
dCTPase210, my hypothesis is that the literature inhibitor might not interact with dCTPase for 
long enough to elicit the potency we observe for our inhibitors. This could be a result of poor 
membrane permeability, rapid efflux, or cellular metabolism of the inhibitor within the time 




Figure 28: Biological activity for a literature dCTPase inhibitor 
 This data, along with the qPCR results (Figure 27), gave us confidence to test our 
inhibitors in the reported dCTPase Malachite Green assay to determine if our compounds 
directly inhibit purified dCTPase (Figure 29A). A Malachite Green assay is a test for the 
colorimetric detection of inorganic phosphate211—a by-product of dCTPases catalytic reaction. 
Unfortunately, 58150 and 232964 displayed minimal inhibition (IC50 ~ 30 µM and 15 µM, 
respectively) in this assay. Isothermal titration calorimetry (ITC)—a method to test the extent 
that a ligand affects the melting temperature in a dose dependent manner of a protein to obtain 
a Kd212—was also used to directly test our inhibitors’ binding affinity with dCTPase (Figure 29B 
& 29C). Unfortunately, minimal binding was observed for 232964 in these experiments as well 
(Kd ~ 15 uM). While the lack of direct physical binding in these assays does not support 
dCTPase being a biological target for this series, perhaps these conditions don’t impart the 




Figure 29: Direct binding assay with dCTPase and 58150-series analogs: 
(A) Using the Malachite Green assay, dose-dependent inhibition of dCTPase with 58150 and 232964 
after 24-hrs preincubation provided minimal activity; 2-hrs preincubation produced similar results. (B & C) 
Change in enthalpy during ITC assay for 232964 & 58150, respectively, to dCTPase resulted in minimal 
binding affinity for 232964 (Kd ~ 15 uM) and insignificant affinity for 58150. 
The final experiment the Neubig lab performed to attempt to validate this target is a 
global DNA methylation assay (Figure 30). As stated previously, dCTPase plays an important 
role cleaning up non-canonical dNTPs, mainly methylated dNTPs. Short interspersed nuclear 
elements (SINEs) and long interspersed nuclear elements (LINEs) repeats contribute to more 
than 35% of the total genomic DNA mass.213 Specifically, LINE-1 repeats make up roughly 17% 
of the human genome, making LINE-1 promoter a widely used surrogated marker that positively 
correlates with global DNA methylation levels.214 In a preliminary study, the Dr. Lisabeth showed 
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that 58150 and 232964 may increase LINE-1 methylation in a dose-dependent manner in 
primary human dermal fibroblasts compared to untreated cells after 72-hour inhibitor pre-
incubation (Figure 30A). Also, these same inhibitors affected LINE-1 methylation in scleroderma 
cells (Figure 30B).  
 
Figure 30: Global LINE-1 DNA methylation for primary human dermal fibroblasts and scleroderma 
cells after 72-hour inhibitor pre-incubation: 
A) Shows that there is a general dose dependent increase in global DNA methylation for both 58150 and 
232964 in primary human dermal fibroblasts. B) Shows that scleroderma cells are affected by 58150 and 
232964. 
Interpreting these inconclusive methylation results is complicated. In fact, global DNA 
methylation patterns in fibrotic diseases are difficult to interpret altogether. The literature 
suggests that different fibrotic diseases have varying degrees of either increased or decreased 
levels of global DNA methylation.215 As a result, a distinct connection between upregulation or 
downregulation in global DNA methylation and fibrotic diseases has not been reported to date. 
The take away from these results is that our inhibitors might affect global DNA methylation in 
both primary dermal fibroblast and scleroderma cells, and, since dCTPase has been shown to 
regulate global DNA methylation207, this affect may be due to inhibition of dCTPase. 
However, based on the totality of the results, it is unlikely that dCTPase is the biological 
target that imparts the potent SRE.L inhibition by the 58150 series. However, I would like to 
describe three hypothetical scenarios that might help explain the conflicting data between the 
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correlation amid the qPCR results and the lack of a physical interaction between dCTPase and 
58150 and 232964. I think regardless of whether dCTPase is a relevant biological target for this 
series, it is valuable to discuss these scenarios because they still might be applicable to this 
series’ unknown mechanism of action. I will use dCTPase to discuss these scenarios, but 
another potential biological target can be exchanged with dCTPase. 
 First, dCTPase may undergo post-translational modifications in cells that cannot be 
recreated with the biochemical techniques used. As discussed, the literature suggests that 
dCTPase plays an important role in the epigenetic regulation of cells, particularly global 
methylation of DNA. Epigenetic regulators commonly undergo post-translational modifications in 
order to perform their specific functions.216 If dCTPase undergoes post-translational modification 
in cells, then it may be difficult to recreate the “active” state of dCTPase required for our 
inhibitors biochemically. 
 The second possible scenario is that our inhibitors are modified in cells, ultimately 
activating them for covalent interaction with dCTPase. Of note, to test this hypothesis, a sulfone 
derivative (258126, Figure 21) was synthesized and tested in both the SRE L. assay and the 
Malachite Green assay. Unfortunately, despite this inhibitor being equipotent to 58150 in the 
SRE.L assay (Figure 21), it only had minimal activity in the Malachite green assay (data not 
shown). The activity of 258126 in the SRE.L assay is a strongly supportive result that chemical 
modifications to our series within cells may be required for potent biological activity. Yet, the 
lack of binding in the Malachite Green assay could be due to several reasons, such as the 
sulfone not being stable to the assay conditions or the inhibitor not being incubated long enough 
with dCTPase to bind properly.  
 The last hypothesis I present here is our inhibitors could be slow-binding ligands for 
dCTPase. This hypothesis would help explain the extremely tight and deep SAR we observe for 
this series. One could imagine that the inhibitors rapidly bind in a low-affinity enzyme-inhibitor 
complex that undergoes a slow relaxation to a very tight or covalently bound complex.217-219 This 
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hypothesis also explains the weak biochemical binding vs the strong activity in cells. For 
instance, in cells, the enzyme has the time and necessary post-translational machinery to 
undergo the proper relaxation required to elicit the observed biological activity, but, 
biochemically, these mechanisms do not exist, so only the weakly bound low-affinity enzyme-
inhibitor complex is achieved.  
Until very recently, progress towards target identification for the 58150-series was at a 
full stop due to the exciting results obtained for the 222740-series target ID studies (discussed 
in the next subsection). While it is unfortunate that a target has not been determined yet for this 
series, there are still many possible target identification studies that can be performed using 
either our high-affinity agarose resin or propargyl click probes (Discussed in Chapter 5). The 
implied cellular activity profile for these probes (or probe mimics) suggests they are ideal to do 
further target identification studies with. If this series of inhibitors has a complicated mechanism 
of action, more complex target identification experimentation may provide a better path to 
identify the target. 
 
CCG-222740 Series Target Identification Efforts: 
Most of this subchapter has been included in a submitted manuscript entitled “Identification of 
Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Anti-Fibrotic and Anti-
Metastatic Compounds” by Lisabeth et al. 
As mentioned in Chapter 1, subsequent chemical modification and structure-activity 
relationship (SAR) studies for CCG-1423 yielded the nipecotic acid derivatives CCG-100602 
and CCG-203971167,170, which removed the labile and potentially reactive N-alkoxybenzamide 
functionality of CCG-1423 (Figure 31). These analogs provided improved tolerability in vitro and 
in vivo as exemplified by their capability to reduce bleomycin-induced skin and lung 
fibrosis,159,169 and melanoma lung metastasis171 in two separate preclinical murine models. 
Further improvements to the series resulted in CCG-222740 and CCG-232601, which prevented 
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ocular fibrosis and skin fibrosis in vivo.168,173 Recent optimization for metabolic stability yielded 
CCG-257081, which has improved pharmacokinetic properties and was shown to be orally 
active in a bleomycin-induced fibrosis murine model (Figure 32).168 
 




Figure 32: CCG-257081 prevents bleomycin induced fibrosis: 
Mice treated with 50 mg/kg PO qd CCG-257081 had significantly reduced skin thickness as compared to 
vehicle control. (A) Masson’s trichrome stained skin sections from vehicle treated mice (left panel) 
bleomycin treated mice (middle panel) and bleomycin+CCG-257081 treated mice (right panel). N=7 (B) 
Quantification of (A) by measuring the maximal distance between the epidermal-dermal junction and the 
dermal-subcutaneous fat junction ***p<0.001 using One-way ANOVA. (C) Quantification of collagen using 
hydroxyproline measurements *p<0.05 using One-way ANOVA. 
 
Previous Target Identification Attempts: 
Due to the phenotypic nature of the HTS, the identification of biological targets for the 
222740-series has been elusive. Previous target ID efforts using CCG-1423 (Figure 31) have 
generated a couple possible biological targets; however, CCG-1423’s promiscuity (as evidenced 
by poor cellular viability) has marred the reliability that the targets identified as being the ones 
responsible for the series’ biological activity.  
First, it has been reported that CCG-1423 can interact with the N-terminal nuclear 
localization sequence (NLS) in the RPEL domain of MRTF-A, blocking MRTF-A nuclear 
translocation by inhibition of the interaction between MRTF-A and importin α1/β1220; however, 
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attempts by the Neubig lab to tie this interaction into biologically relevant pathways have been 
unsuccessful (data not shown). Alternatively, microarray analysis of gene transcription changes 
in PC3 cells treated with CCG-1423 had significant overlap with effects of Latrunculin B—an 
actin polymerization inhibitor—as well as effects on cell cycle, ER stress, and metastasis gene 
networks, suggesting shared biological targets between these two inhibitors.221 
Lundquist et al. showed that CCG-1423 binds directly to MICAL-2—an atypical actin-
regulatory protein that mediates SRF/MRTF-A-dependent gene transcription via serum.222 
MICAL-2 is proposed to function by inducing redox-dependent depolymerization of nuclear 
actin, ultimately decreasing nuclear G-actin and increasing MRTF-A in the nucleus.222 The major 
issue with this study is that CCG-1423 is one of the most cytotoxic and, thus, highest “off-target” 
liable analogs from our series. For instance, the significant decrease in MICAL-2 enzymatic 
activity of CCG-100594—an analogous compound to CCG-1423 that lacks the liable N-O 
functionality—is evidence that Lundquist et al.’s target ID results may be due to the off-target 
liability of CCG-1423.  
Hayashi et al. took an immobilization probe approach where they non-specifically and 
covalently attached CCG-1423 to Sepharose using a photolizable cross-linker.220,223 They pulled 
down flag tagged MRTF-A, but, again, besides questionable coupling techniques for 
immobilization resin attachment, using CCG-1423 significantly decreases the reliability of their 
findings. Previous target ID efforts in our lab using an acetophenone photo-probe with a 
propargyl Click handle on the CCG-203971 scaffold were inconclusive (Figure 33).224 However, 
we were hopeful that utilizing a more potent and less promiscuous scaffold would be a more 




Figure 33: Tag-free photoprobe approach in whole cells previously attempted in our lab: 
Multiple benzophenone, azide, and acetylene substitutions were tested for potency, but CCG-206559 
provided the best potency/cytotoxicity profile. This probe was irradiated with hν at 350 nm in the presence 
of HEK293T cells, and, after purification, the Click Reaction was performed using InvitrogenTM Click-
iT(R) Reaction Buffer Kit to attach Cy5.5 dye for visualization. In the presence of 20 µg proteins, a faint 
band at 24 kDa in PC3 cells was observed. No further attempts to identify this band have been made. 
Despite multiple potential molecular targets for the series, there has been no robust 
biophysical evidence presented to conclusively designate the biological target that affords the 
biologically activity associated with this series. However, because identifying the target would 
help us develop these exciting antifibrotic agents, we undertook an unbiased mass 
spectrometry-based target identification approach using an immobilized agarose resin affinity 
probe based on the less promiscuous CCG-222740 scaffold.  
222740 Series Probe Design Rationale 
To develop an affinity matrix for target enrichment, CGG-222740 was used as the 
starting chemical scaffold, mostly because of its improved cellular potency and superior 
inhibition of TGFβ-induced ACTA2 gene expression as compared to CCG-203971.168 To identify 
the optimal linker placement, we performed a methoxy scan followed by an ethoxymethoxy scan 
on each aryl ring (Table 5, A54-A58). Taking into consideration the flat SAR, retained potency, 
efficacy, and availability of starting material, we chose to attach the PEG linker at the 5-position 
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of the 3-furyl phenyl ring. Since attaching either small (A54) or large (A59) functional groups at 
the 3-position did not markedly reduce activity, we were confident that attaching the probe linker 
(A62, Table 5) at that position would allow for the probe (32, Figure 34) to maintain acceptable 
binding affinity to the biological target(s).  
Table 5: Exemplary probe development SAR 
 





222740 - H H H Cl 0.4 100 
258524 A54 OMe H H Cl 2 100 
258165 A55 H OMe H Cl 0.83 100 
258166 A56 H H OMe Cl 1.1 100 
258704 A57 H H Cl OMe 0.58 88 
258705 A58 H H H OMe 5.6 100 
258662 A59 O(CH2)2OMe H H Cl 2.3 90 
258742 A60 H O(CH2)2OMe H Cl 2.5 68 
258724 A61 H H O(CH2)2OMe Cl 1.6 99 
262545 A62 O(CH2)2OC(CH2)2NH2•HCl H H Cl ND ND 
aSRE.L assay performed in HEK293T cells (mean of n = 3, SEM < 10%). 
 
Figure 34: Immobilized agarose resin affinity probe for 222740-series 
 
Synthesis of Probe Mimic Analogs and Probe for CCG-222740 Series: 
 The synthesis to generate probe mimics with the methoxy- and ethoxymethoxy-
containing aryl rings on the right side of the piperidine core started from either the commercially 
available carboxylic acid 33 or methyl ester 34, which was synthesized as previously described 
(Scheme 11).168 Commercially available carboxylic acid 33 was subjected to standard HATU 
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amide coupling conditions with commercially available anilines. The final mimic analogs 36 were 
generated after acid mediated Boc-deprotection and subsequent amide coupling with HATU. 
Alternatively, the analogs were built from the left-hand side first to assemble ethoxymethoxy 
analog 258724; this more convergent route would have been preferred from the beginning of 
the synthesis for these analogs, but an efficient route to generate intermediate ester 37 was not 
discovered until most of these probe mimic analogs were generated. 
 
Scheme 11: Synthesis of probe mimic analogs with methoxy or ethoxymethoxy functional groups 
on the right side of the piperidine core 
Conditions: (i) HATU, aniline, DIPEA, DMF, rt (ii) 4M HCl in dioxanes, rt; (iii) HATU, 3-(furan-2-yl)benzoic 
acid, DIPEA, DMF, rt (iv) 4M HCl in dioxanes, rt (v) HATU, 3-(furan-2-yl)benzoic acid, DIPEA, DMF, rt (vi) 
1M NaOH, THF, rt (vii) HATU, 4-chloro-3-(2-methoxyethoxy)aniline, HCl, DIPEA, DMF, rt. 
 Incorporating the methoxy and ethoxymethoxy functionalities to the aryl ring on the left 
side of the piperidine core was not as simple as the analogs with these functionalities on the 
right-hand side, as they required a couple of extra steps to synthesize the necessary starting 





Scheme 12: Synthesis of 39, 40, and 41 
Conditions: (i) Cs2CO3, MeI, DMF, rt225 (ii) TBS-Cl, imidazole, DMF, rt226 (iii) H2SO4, MeOH, reflux (iv) 
BrCH2CH2OMe, K2CO3, DMF, 90 °C227. 
 Although probably unnecessary, unprotected benzoic acids 39 & 41 were esterified, and 
then methyl esters 42a-c were subjected to Suzuki cross coupling chemistry with furan-2-
ylboronic acid, producing benzoic acid intermediates 43a-c (Scheme 13). Since the TBS 
protecting group of intermediate 42b was hydrolyzed during the cross-coupling reaction, this 
provided a handle to install the PEG amine linker, and the availability of this late-stage 
intermediate is one of the reasons why the 3-position was later selected for PEG linker 
attachment. To install the linker, benzoic acid intermediate 43b was esterified, freshly prepared 
2-(2-((t-butoxycarbonyl)amino)ethoxy)ethyl methanesulfonate 228 was coupled to phenol 44 in 
basic alkylation conditions, and then benzoic acid intermediate 46 was generated through 




Scheme 13: Synthesis of 46 
Conditions: (i) H2SO4, MeOH, reflux (ii) furan-2-ylboronic acid, Na2CO3, Pd(PPh3)4, H2O, DME, 100 °C (iii) 
H2SO4, MeOH, reflux (iv) BocHN(CH2)2O(CH2)2OMs, Cs2CO3, DMF, 75 °C (v) 1M NaOH, THF, rt. 
Assembly of probe 32 began with basic hydrolysis of methyl ester 34 followed by HATU-
mediated amide coupling with 4-chloroaniline to produce carbamate 35a (Scheme 14). Acid-
mediated Boc deprotection generated HCl amine salt 47, which was subjected to HATU-
mediated amide coupling conditions with the required benzoic acid intermediates 43a, 43c, and 
46 to produce methoxy probe mimic 258524, ethoxymethoy probe mimic 258662, and Boc 
protected PEG-linker intermediate 48. After acidic hydrolysis, 262545 was generated and linked 
to NHS-agarose beads using solid phase amine coupling chemistry followed by blocking of 
residual reactive groups with ethanolamine to produce 32, which was subsequently used as our 




Scheme 14: Synthesis of 222740-series immobilized probe 
Conditions: (i) 1M NaOH, THF, rt (ii) HATU, 4-chloroaniline, DIPEA, DMF, rt (iii) 4M HCl in Dioxanes, rt 
(iv) HATU, 43a, 43c, & 46, DIPEA, DMF, rt (v) 4M HCl in Dioxanes, rt (vi) NHS-activated agarose resin, 
DMSO, PBS, followed by ethanolamine. 
 
Pirin Identified as A Potential Target of CCG-222740 
The agarose-bound probe (32) was mixed with whole cell lysates from HEK-293T cells 
containing DMSO (unblocked) or 30 µM CCG-222740 (blocked). Beads were then washed 
several times with cold PBS (adapted from229).  Pulldown mixtures were analyzed after trypsin 
digestion and subsequent proteomic analysis (see Experimental). Comparison between the 
normalized peptide abundance in the DMSO control lysates and the CCG-222740 treated cell 
lysates revealed one protein—pirin—that stood out with 5-fold greater peptide abundance in the 
DMSO control lysates and a p-value of 1.3 e-13 (Table 6). Of note, the p-value is a statistical 
measure of the significance between active/blocked lysate calculation. 
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Table 6: List of putative targets for 222740-series 
 
Peptide counts refer to the number of peptides identified for a given protein, while unique peptide count 
refers to the number of peptides identified that are completely unique for a given protein. Normalized 
unblocked/blocked beads is the raw mean ratio between peptides identified in unblocked vs. blocked 
samples. 
Pirin is a well-conserved protein originally identified in a yeast two-hybrid screen with the 
transcription factor NF-1.230 Pirin has also been implicated in NF-κB signaling through its 
interaction with Bcl3—a NF-κB co-activator—and through direct interaction with a p65/p65 
homodimer.231-233 Pirin is expressed ubiquitously, and basal expression is, in part, regulated 
through Nrf2-regulated gene transcription.234  Pirin acts as a redox-sensing transcription factor 
regulator within the nucleus.230 It has been suggested that pirin is important for cell migration 
233,235-237 as well as the epithelial-mesenchymal transition (EMT).238,239 
Two drug discovery campaigns have previously been described for pirin. The first report 
used fluorescently labeled pirin to identify small molecules in an immobilized compound library 
that directly bound to pirin; however, the cellular effects of the identified compound, TPhA 
(Figure 35), were only modest.233 A second study identified CCT251236 while screening for 
inhibitors of the Heat Shock Factor 1 (HSF1) transcription pathway.240 Their target identification 
efforts yielded pirin as the target of CCT251236, which has efficacy in an ovarian cancer model 
in vivo and inhibits melanoma migration in vitro.240 This interesting biological activity and the 
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structural similarities between CCT251236 and the CCG-222740 series (e.g. the central bis-
amide core flanked by substituted-aryl functionalities) provided an initial level of confidence to 
pursue pirin as a biological target for CCG-222740. 
 
Figure 35: Pirin inhibitors and their activities  
First, the Neubig lab tested whether the literature pirin inhibitors, TPhA and CCT251236, 
could inhibit the Gα12-mediated SRE.L assay. While the weak pirin inhibitor TPhA was 
considered inactive in the SRE.L assay, CCT251236 had a remarkable effect on SRE.L activity, 
with an IC50 of 3.3 nM (Figure 36A), without affecting luciferase catalytic activity directly (Figure 
37). This pharmacologically validates pirin in the same Gα12 driven SRE.L Luciferase assay 
that we discovered and developed our series of compounds. Moreover, CCT251236 has nM 
potency in the reported cell-based Heat shock protein (HSP)72 phenotypic assay and binds to 
pirin in vitro with a KD of 44 nM as measured by SPR240, so it is not surprising that CCT251236 
has such a high level of activity in our SRE.L assay.  
In an attempt to further validate pirin’s importance in the SRE.L assay, pirin was 
overexpressed in HEK293T cells with a SRE.L Luciferase reporter. Pirin alone was capable of 
modestly increasing SRE.L driven luciferase expression, suggesting that pirin can enhance 
MRTF/SRF transcription (Figure 36B). Moreover, to determine whether reduction of pirin 
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through siRNA could suppress MRTF-A-dependent SRE.L Luciferase, primary human dermal 
fibroblasts were treated with a Dharmacon smartpool siRNA targeting pirin. MRTF-A-driven 
SRE.L Luciferase was significantly reduced when pirin mRNA levels were decreased. This 
suggests that pirin modulates gene transcription at the MRTF-A level of regulation (Figure 36 C 
and D).  Taken together, these results support interplay between pirin and MRTF- and SRF-
driven luciferase transcription. 
 
Figure 36: Pirin interacts with the MRTF/SRF pathway: 
(A) CCT251236 inhibits Q231L Gα12 activated SRE.L Luciferase in HEK293T cells; n=4 (B) 
Overexpression of C-terminally V5 tagged pirin induces SRE.L Luciferase signal in HEK293T cells. 
Results are expressed as the mean ± SEM. ***p< 0.05 using Student’s t-test; n=3 (C) Knockdown of pirin 
also reduces MRTF-A driven SRE.L Luciferase in primary dermal fibroblasts.  Results are expressed as 
the mean ±SEM **p<0.01 using 2-way ANOVA; n=3 (D) Validation of pirin knockdown using qPCR.  




Figure 37: CCG-222740 and CCT251236 have minimal effects on recombinant luciferase activity. 
Recombinant firefly luciferase was incubated with varying concentrations of CCG-222740 or CCT251236.  
Neither inhibited luciferase activity with 100% efficacy, and CCG-222740 both have an IC50>10-4 M.  n=2. 
The Neubig lab also took a bioinformatics approach to compare a gene expression 
signature of CCG-1423 target genes with 12,922 MSigDB or in-house gene sets (see Erika et 
al). Only 347 (2.7%) of the gene sets showed a statistically significant correlation with the CCG-
1423 regulated genes at the Bonferroni-corrected p-value (p < 3.87x10-6). A siPirin gene set 
was the most significantly enriched (p = 4.44x10-72), with an overlap of 44 genes with the CCG-
1423 signature (Figure 38A). By comparison, the overlap between the Neubig lab’s in-house 
MRTF signature and the CCG-1423 gene signature was only 8 genes (data not shown). 
Therefore, the bioinformatics analysis, comparing the CCG-1423 microarray dataset and the 
siPirin microarray dataset, was very encouraging and consistent with the idea that pirin may be 
a direct target of our series.   
While these results strongly correlate pirin to the SRE.L assay, we still required 
biophysical evidence that the 222740-series interacted with pirin. Therefore, recombinant pirin 
was purified to test whether CCG-222740 and CCG-257081 engaged with pirin in vitro.  As a 
comparison, a structurally related inhibitor that was nearly inactive in our Gα12 induced SRE.L 
assay was also tested (Figure 38B and C). Purified, recombinant pirin was used in isothermal 
titration calorimetery (ITC) experiments to determine the KD of our compounds. CCG-222740 
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and CCG-257081 bound to pirin with a KD of 4.3 µM and 8.5 µM, respectively. The change in 
enthalpy for the ‘inactive’ compound “5” (Figure 38C only)—an inactive analog from the 222740 
series—was much less than either CCG-222740 or CCG-257081; it did not provide a reliable fit 
for binding analysis.  Although this is a small set of compounds, it is encouraging to note that 
two of our lead inhibitors appear to bind to pirin while an inactive compound shows minimal 
binding to pirin in vitro (Figure 38C). 
Furthermore, to understand how our small molecules bind to pirin, we solved high-
resolution x-ray co-crystal structures of pirin in complex with CCG-222740 and CCG-257081 
(1.7 Å and 1.5 Å, respectively) (Figure 38D).  The two compounds bind very similarly, both 
analogs co-crystallized in the R-confirmation with the 4-chloroaniline projecting deep into the 
hydrophobic pocket and the furan/pyridine rings jutting out into solvent (Figure 38D and E). 
There are no direct contacts between the compound and the iron; the interaction is mostly 
mediated by hydrogen bonds with Fe-ligated waters (Figure 38E). When these compound-
bound pirin co-crystal structures are compared to both the inactive (Fe2+ bound) and the active 
(Fe3+ bound) forms described in the literature, a high level of similarity exists. Overall, there is a 
RMSD between 257081-bound pirin and the literature reported Fe2+ bound pirin of 0.251 Å and 
between 257081-bound pirin and the literature reported Fe3+ bound pirin of 0.582 Å.232  
Of note, the RMSD is a measure that provides a comparison between protein 
structures241, so since there is a greater overall distance between Fe3+ bound pirin and 257081-
bound pirin vs. Fe2+ bound pirin and 257081-bound pirin, these results suggest our inhibitors 
may inhibit pirin activation by binding to the Fe2+ state. In summary, a direct interaction between 
pirin and the CCG-222740 series of compounds was confirmed with the co-crystal structures, 
and they may highlight how our series bind to pirin to block Rho-mediated gene transcription. 
The exact mechanism of how small-molecules affect pirin activity is unknown, but these 
results indicate the possibility that our series stabilizes either an oxidized or reduced form of 
pirin, affecting the ability of pirin to bind to co-activators or transcription factors. Of note, it has 
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been shown that only Fe3+ bound pirin binds to p65, whereas Fe2+ bound does not.232  Also, 
CCG-1423 has been shown to displace MRTF-A and SRF from the ACTA2 promoter242, which 
suggests that compound binding to pirin may disrupt a pirin/MRTF-A/SRF/DNA complex.  
Future work will address these and other questions, including exploring the implications of pirin 




Figure 38: Pirin is a molecular target of CCG-222740 and CCG-257081 
(A) Differential gene expression (based on fold change) was calculated for Pirin knockdown (GSE 17551) 
and CCG-1423 treatment (GSE 30188) and found to have high significance and an overlap of 44 genes in 
their datasets. (B) HEK293T cells co-transfected with Q231L Gα12 and a SRE.L Luciferase reporter were 
treated with CCG-222740, CCG-257081 or CCG-258531 (C) Isotherm generated by ITC shows that 
CCG-257081 (black) has a greater enthalpy change upon binding to pirin, as compared to CCG-258531 
(red), indicative of better binding to recombinant pirin.  (D) Crystal structure overlap of pirin bound to 
CCG-222740 (gray) and CCG-257081 (salmon).  (E) Detailed view of the compound binding pocket with 
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overlaid CCG-222740 (gray) and CCG-257081 (salmon) pirin-bound structures.  Also indicated is the 
metal ion (orange) as well as coordinating residues and water molecules (dashed lines), and hydrogen 
bonds (solid lines). 
The CCG-203971/CCG-222740 series is known to inhibit pro-fibrotic signaling, and a 
large body of literature exists that suggests this is through MRTF/SRF.,159,173,243,244 However, 
CCT251236 was used to pharmacologically verify that pirin is involved in TGF-β dependent 
gene expression. Human primary dermal fibroblasts were activated with TGF-β for 24 hours with 
or without CCG-222740 or CCG-257081 as well as CCT251236. All three compounds 
significantly reduced TGF-β induced ACTA2 expression (Figure 39A). ACTA2 is the gene for α-
SMA, which is a marker of myofibroblast transition, and a direct target of MRTF/SRF-mediated 
transcription244. In addition, these compounds were tested against CTGF expression (CCN2). 
CTGF is a pro-fibrotic mediator that is also, in part, regulated by MRTF/SRF.245 Although not as 
potent, a decrease in CTGF mRNA levels was also observed after treatment with all three 
compounds (Figure 39B).   
To further confirm that pirin is involved in TGF-β-mediated gene expression, pirin 
expression was reduced through pirin siRNA. Knockdown of pirin led to a 50% decrease in 
TGF-β induced ACTA2 and CTGF mRNA, further verifying the role of pirin in TGF-β mediated 
gene expression (Figure 39C and 39D). Pirin mRNA levels were reduced 80% in primary dermal 
fibroblasts after siRNA treatment (data not shown) and protein amounts were reduced 




Figure 39: Inhibition or ablation of pirin reduces TGF-β dependent gene expression 
(A) Primary dermal fibroblasts from healthy donors were treated with TGF-β and either vehicle control, 
CCG compounds, or CCT251236.  Levels of ACTA2 were measured by qPCR. Results are expressed as 
the mean ± SEM. ***p< 0.001, ****p<0.0001 using One-way ANOVA; n=3 (B). Similarly, CTGF mRNA 
levels were measured after treatment with TGF-β and pirin inhibitors. Results are expressed as the mean 
± SEM. *p<0.05, **p<0.01 using One-way ANOVA; n=3. (C) Pirin knockdown reduces TGF-β stimulated 
ACTA2 in human primary dermal fibroblasts. Results are expressed as the mean ± SEM ****p<0.0001 
using One-way ANOVA; n=3. Non-targeting siRNA was used in siPirin (-) conditions. (D) Pirin knockdown 
reduces TGF-β stimulated CTGF. Primary dermal fibroblasts were treated similarly to C. The results are 
expressed as the mean ± SEM of ****p=0.0001; n=3. (E) Western blot of pirin protein after siRNA 
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treatment.  The results are expressed as the mean ± SEM of two independent experiments (*p<0.05, 
**p<0.01, using One-way ANOVA). (F) Quantification of E. 
Further work will yield insights into the biology of pirin and how it relates to the 
MRTF/SRF signaling pathway and pro-fibrotic mechanisms. Pirin has been implicated in 
melanoma cell migration, progression, and senescence233,235,246, but has not been explored in 
terms of fibrotic disease. This is the first report implicating pirin in a pro-fibrotic signaling 
pathway, so dissecting the exact role of pirin in TGF-β mechanisms will be an important 
question to address in the future. Also, while pirin is clearly a target for the 222740-series of 
compounds, these results do not prove that pirin is the target that elicits the series’ antifibrotic 
activity. Additional experiments to tie pirin and our series are currently underway, and validation 
efforts for other proteins identified from our pull-down studies may be performed to identify other 
relevant biological targets. Moreover, additional target identification designs and experiments 




Chapter 3: 58150 Series Further SAR Development and Anti-Fibrotic Properties 
Parts of Chapter 3 are included in a submitted manuscript entitled “5-Aryl-1,3,4-oxadiazol-2-
ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho-Mediated Gene 
Transcription as Potential Antifibrotic Agents for Scleroderma” by Kahl et al. 
SAR Development—pM Activity: 
 As discussed in Chapter 2, there is strong evidence that the 58150-series of 
Rho/MRTF/SRF-mediated gene transcription inhibitors proceed through a covalent mechanism 
with the unknown biological target. In summary, this evidence includes: the (1) requirement of 
the oxadiazole core (2) complete loss of potency with analogs predicted to be much less 
capable of reacting with a binding site nucleophile (3) steep SAR for alkanoic acid chain and (4) 
tight SAR for the substituents surrounding the phenyl ring. Also, all analogs tested were unable 
to affect cell proliferation/viability up to 100 µM as measured by WST-1, highlighting the series 
lack of cytotoxicity at high concentrations despite extremely potent cellular activity. In this 
chapter, I will focus on the development of highly potent compounds guided by cellular SRE.L 
activity, and the attempts to improve the in vivo pharmacokinetic (PK) profile for pre-clinical 
testing in murine models of fibrosis. 
 In Chapter 2, a general Topliss approach to probe the SAR surrounding the aromatic 
ring of the 58150 series is briefly discussed; additional aromatic ring SAR for the propanoic acid 
scaffold is shown in Table 7. Ortho-Cl (A14) is clearly preferred over any other substitution 
introduced at the R2 position, meta-Me (58146) for R3, and para-Me (A10) for R4. Out of these 
positions, substitution at the para position appears to be the most well-tolerated regardless of 
the size or electronics of the substituent. Generally, size doesn’t appear to contribute as heavily 
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as electronic effects at the ortho (e.g. A14 vs. A15 & A16), meta (58146 vs. A12 & A13), or 
para (A10 vs. A9 & A11) positions; although, size can play a role (e.g. A63 vs. A14), which is 
further expounded in Table 8. Generally, improvements in activity from combining the top 
substitution patterns are additive, with the biggest exceptions of this being the 2,6-dihalo 
analogs A66 & A67. Interestingly, even combining substitutions that weren’t noteworthy mono-
substituents (e.g. A45 vs. A16 or A68 vs. A15 & A11) led to significant improvements in activity. 
 At the para position, an additive activity boost is achieved by combining ortho-Cl with 
any type of substituent at the para-position (58150-A70). Moreover, a clear size correlation with 
the ortho-Cl/R4 substitution pattern is present: bulky para substituents improve SRE.L activity 
regardless of electronic effects (A69 < 58150 < A44 = A17 < A70). This size dependence is 
consistent with the fact that the para position is the most well-tolerated mono-substitution 
position. Lastly, an amazing additive effect is observed when each of the best aryl mono-
substituents (ortho-Cl (A14), meta-Me (58146), para-Me (A10)) is combined into one analog 
(A19), achieving 20 pM SRE.L activity. Of note, the 2, 3, 4-trisubstitution pattern (A19) improves 
SRE.L activity ten-fold more than 2, 4, 5-trisubstitution (A20 and A21), indicating a clear 
preference for 3-Me over 5-Me. 
Table 7: Sub-nM potent propanoic acid analogs 
 
CCG- Entry R2 R3 R4 R5 R6 SRE.L 
IC50 (nM) 
a, b 
123859 A8 H H H H H 3,500 
262529 A63 F H H H H 4,200c 
232700 A14 Cl H H H H 25 
232841 A15 Me H H H H 6,300 
232740 A16 OMe H H H H 3,100 
262528 A64 CF3 H H H H 1,850c 
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123851 A12 H Cl H H H 1,500 
123853 A65 H Br H H H 6,400 
58146 - H Me H H H 180 
211911 A13 H OMe H H H 3,600 
123852 A9 H H Cl H H 340 
123862 A10 H H Me H H 34 
123855 A11 H H OMe H H 160 
262530 A66 Cl H H H Cl 5,400c 
262527 A67 F H H H F 12,250c 
215180 A45 OMe H Cl H H 38 
215201 A68 Me H OMe H H 23 
58150 - Cl H Cl H H 4.0 
232002 A69 Cl H F H H 25c 
215220 A44 Cl H OMe H H 2.6 
232001 A17 Cl H Me H H 1.5c 
259068 A70 Cl H cPr H H 0.09c 
258043 A19 Cl Me Me H H 0.02c 
258041 A20 Cl H Me Me H 0.23c 
258021 A21 Cl H Cl Me H 0.32c 
Italicized CCG numbers were either purchased or synthesized by Kim Hutchings. aInhibition of Gα12-
stimulated SRE.L activity (mean of n = 3, SEM < 10%) in PC3 cells unless otherwise noted. bCell viability 
and proliferation assay with WST-1 < 5% inhibition up to 100 M inhibitor (mean of n = 3, SEM < 10%). 
cSRE.L assay performed in HEK293T cells (mean of n = 3, SEM < 10%). 
 As mentioned in Chapter 2, the preferred alkanoic acid chain length separating the S of 
the thioether and the carboxylic acid functionality is 3 carbons (butanoic acid, Table 3). 
Therefore, additional butanoic acid 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic acid derivatives were 
made to further investigate the aliphatic SAR of the phenyl ring (Table 8). The preference for 
para-Me over para-Cl carried over from the propanoic acid analogs for both mono- and 2, 4-di-
substituted butanoic acid analogs (A71 vs. A72 and 232120 vs. A73, respectively). Generally, 
bulkier para-aliphatic substituents are preferred (A73 < A75 ≈ 232964 ≈ A79 ≈ A82 < A81 ≈ 
A83), which is consistent with the size trend outlined in Table 7. Interestingly, unsaturated 
substituents are less active than para-aliphatic comparators (e.g. A74 vs. A75 & A78 vs. A79), 
and a clear size limit exists, as can be seen with the decrease in activity for A84; but even these 
less active para substituents are still fairly well-tolerated.  
Again, the para position appeared to be preferred over both meta and ortho positions for 
bulky aliphatic substituents, as a scan of the 3-, 4-, and 5-positions with cyclopropyl (cPr) 
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resulted in a strong preference for R2/R4-disubstitution (e.g. 232964 vs. A76 & A77). Moreover, 
ortho-Cl does not appear to be required for small or large para-aliphatic analogs to maintain 
potency (e.g. A72 vs. A73 & A80 vs. A79, respectively), suggesting bulky alkyl substitution at 
the para position may be required for pM activity but ortho-Cl is not. However, from a metabolic 
standpoint, having the Cl’s presence in the phenyl ring is beneficial, so 2-Cl substitution is 
incorporated in most analogs. 
 Para-alkoxy analogs that explore both size and electronic effects display a similar trend 
as para-alkyl analogs. Importantly, activity is maintained between alkoxy propanoic acid (A18; 
Table 2) and butanoic acid (A85) analogs. Also, pM activity is present for para-ethoxy (A86) and 
para-isopropoxy (A89) derivatives, but a sharp decrease in activity occurs with larger para-
alkoxy analogs (e.g. A90). Since a clear limit in pM potent activity was not established with 
para-alkyl substituents (e.g. A83), the decrease in activity for bulky para-alkoxy analogs may be 
a result of both size and electronic effects. Scanning the ortho- and meta-positions with a bulky 
alkoxy substituent—propargyl—revealed an amazing result: meta substitution (A92) was ~ten-
fold more potent than para substitution (A88), and six-orders in magnitude more potent than 
ortho substitution (A91). Not only does this indicate a clear disfavor of large substitution at the 
ortho position, but the activity difference for these analogs can be utilized as active and inactive 
propargyl Click probes for target identification studies (discussed more in Chapter 5).  
Another surprising result from the butanoic acid SAR is the difference in trisubstituted 
analog activity compared to that for the propanoic acid derivatives. For the propanoic acids, 
ortho-Cl, 3-meta-Me, para-Me substitution (A19) was preferred and consistent with mono-
substituted analogs (A14, 58146, & A10). However, this substitution pattern is clearly disfavored 
for the butanoic acid derivatives (A94), and activity was reduced for the ortho-Cl, 5-meta-Me, 
para-Me substitution (A93) butanoic acid analog compared to the comparator propanoic acid 
derivative (A20). This SAR implies the that a different binding pose is adopted within the 
unknown biological target for both propanoic and butanoic acid analogs, as altering the carbon 
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chain length by just one methylene significantly affects activity that is usually controlled by aryl 
substituents.  
The final surprising trend from these SAR studies is the activity achieved with phenolic 
derivative A95. In the mono-substituted propanoic acid derivatives, Cl was the only substituent 
that had nM levels of activity at the ortho position, and Cl was special in that the activity cliff at 
the ortho position didn’t appear to be controlled by size or electronics. However, ortho-OH 
substitution is clearly also special since A95 achieves pM activity. Other phenolic analogs were 
made but have not been tested yet. 
Mouse liver microsome (MLM) analysis for metabolic stability for the butanoic acid 
analogs was predictable. In general, the 58150 series has an acceptable metabolic stability 
profile, with both propanoic (58150) acid and butanoic (232120) acid derivatives having stability 
greater than 60 mins. Additionally, alkyl substitution on the phenyl ring significantly diminished 
MLM stability (A73, 232964, and A86). This result suggests that while we may be able to 
achieve potent SRE.L activity with alkyl substitution, this substitution may also be problematic 
for the series’ in vivo PK profile. Efforts to improve metabolic activity while maintaining pM 
potent inhibition are discussed later in this chapter. 
Table 8: Sub-pM potent butanoic acid analogs 
 
CCG- Entry R2 R3 R4 R5 SRE.L 
IC50 
(nM) a, b 
MLM T1/2 
(min) c 
232943 A71 H H Cl H 8.6 - 
232924 A72 H H Me H 0.29 - 
232120 - Cl H Cl H 1.8 >60 
232922 A73 Cl H Me H 0.1 28 
262544 A74 Cl H Vinyl H 0.71 - 
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259166 A75 Cl H Et H 0.0004 - 
259066 A76 Cl cPr H H 0.019 - 
232964 - Cl H cPr H 0.001 47 
259067 A77 Cl H H cPr 20 - 
259164 A78 Cl H isopropenyl H 0.009 - 
259165 A79 Cl H iPr H 0.0007 - 
262458 A80 H H iPr H 0.0007 - 
259001 A81 Cl H Pr H <0.0001 - 
259002 A82 Cl H n-Bu H 0.003 - 
259003 A83 Cl H s-Bu H 0.0001 - 
257423 A84 Cl H Ph H 7 - 
262827 A85 Cl H OMe H 2 - 
262687 A86 Cl H OEt H 0.007 19 
262688 A87 Cl H OPr H 0.15 - 
257274 A88 Cl H OCH2C≡C H 0.02 - 
262691 A89 Cl H OiPr H 0.007 >60 
262689 A90 Cl H OBu H 1.2 - 
257291 A91 OCH2C≡C H Cl H 7,600 - 
257631 A92 Cl OCH2C≡C H H 0.005 - 
258042 A93 Cl H Me Me 0.4 - 
258044 A94 Cl Me Me H 4,300 - 
257422 A95 OH H Cl H 0.002 - 
263234 A96 Cl OH H H ND - 
263233 A51 Cl H OH H ND - 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells. bCell viability and 
proliferation assay with WST-1 < 5% inhibition up to 100 M inhibitor (mean of n = 3, SEM < 10%) up to 
100 M inhibitor. cHalf-life in mouse liver microsomes. 
  
Synthesis of pM Potent 5-aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: 
 Many analogs from the previous section were synthesized by the route depicted in 
Scheme 15, which is simplified from Scheme 2 in Chapter 2. Of note, the synthetic route 




Scheme 15: General synthesis of 5-aryl-1,3,4-oxadiazol-2-ylthioalkanoic acids 
Reagents and conditions: (a) H2SO4/MeOH, 85 °C 6 hr.; (b) H2NNH2, 85 °C 14 hr.; (c) KOH/H2O/EtOH, 
CS2, 95 °C 16 hr., (d) 1N HCl workup; (e) acetone, K2CO3, Br-(CH2)n-CO2R’, 25 °C, 5-24 hr; (f) DCM, 
TFA, 25 °C 3 hr; (g) 1M NaOH, THF, 25 °C 16 hr. 
 Alternative routes were required to generate various benzoate ester or hydrazide starting 
materials (Schemes 16-18). For example, aryl hydrazide 50 was not produced through the 
typical esterification route depicted in Scheme 15 because the methyl ester was inaccessible 
using standard Fisher Esterification conditions, so the more reactive acyl chloride 49 was used 
instead (Scheme 16) 
 
Scheme 16: Synthesis of hydrazide intermediate 50 
 Bulky alkyl and alkoxy derivatives were synthesized as shown in Scheme 17. Routes to 
obtain vinyl and isopropyl methyl esters 53a & 53e were performed as previously 
described.247,248 Suzuki coupling of commercially available 51a-c with cyclopropyl boronic acid 
afforded cycloalkyl methyl esters 53b-d. Alkyl methyl esters 53e-h were synthesized by 
alkylating 4k with two equivalents of LDA and the respective alkyl halide, followed by 
esterification. 4-Ph methyl ester 53i was produced using published Suzuki cross-coupling 
89 
 
conditions.249 4-alkoxy aryl derivatives 53j-m were formed by O-alkylation of commercially 
available phenol 52 using cesium carbonate and the respective alkyl halide in DMF. Reduction 
of vinyl intermediate 53a with 2-nitrobenzene-1-sulfonyl chloride and hydrazine hydrate afforded 
ethyl intermediate 53a’. Using chemistry analogous to Scheme 15, these aryl methyl esters 
were converted to respective hydrazides, 5-aryl-2-mercapto-1,3,4-oxadiazoles, thioethers, and 
final carboxylic acids (Table 8). 
 
Scheme 17: Synthesis of 53a-53m and 53a’ 
Reagents and conditions: (a) MeOH, H2SO4, 85 °C, 16 hr (b) Pd(II)OAc2Cl2, K3PO4, P(Cy)3, cyclopropyl 
boronic acid, toluene, H2O, 100 °C, 3 hr (c) LDA (2 eq.), THF, 0 °C, 10 min, then alkyl halide, 0 °C, 1 hr 
(d) MeOH, H2SO4, 85 °C, 16 hr (e) alkyl halide, Cs2CO3, DMF, 75 °C, 1 hr (f) 2-nitrobenzene-1-sulfonyl 
chloride, H2N4, MeCN, 0 °C to 25 °C, 16 hr. 
 Similar to chemistry discussed in Scheme 10, O-propargyl aryl methyl ester starting 
materials 4a’ and 55a,b were accessed by alkylating the respective phenolic methyl esters with 
propargyl benzenesulfonate and K2CO3 in refluxing acetone (Scheme 18). Moreover, phenolic 
5-aryl-1,3,4-oxadiazol-2-ylthioalkanoic acids 257422-263233 were synthesized through late 




Scheme 18: Synthetic route to produce aryl O-propargyl methyl ester starting materials 
 
In Vivo PK Evaluation of CCG-58150, CCG-232120, and CCG-232964: 
Full IV and PO PK analyses were performed on representative analogs 58150, 232120, 
and 232964 (Table 4). Propionic acid 58150 demonstrated good oral bioavailability (67%) and a 
moderate half-life (2 hr).  Rather surprisingly, the corresponding butanoic acid 232120, despite 
apparently similar metabolic stability in vitro, had inferior in vivo PK, with lower oral 
bioavailability and a clearance rate 3-fold higher than 58150. Butanoic acid 232964 also had a 
higher in vivo clearance rate, suggesting that the longer alkanoic acid moiety was a primary site 
of metabolism. 
Table 9: Physical and Pharmacokinetic Parameters for Selected Rho/MRTF/SRF 
Inhibitors 





















58150 4 682 >60 IV, 15 2.0 47350 5.3 88550 - 
PO, 30 2.0 63170 - 34050 67 
232120 1.8 841 >60 IV, 10 1.4 10716 15.5 35650 - 
PO, 20 1.2 11140 - 23150 52 
232964 0.0012 >1000b 47 IV, 3 1.7 3255 15.4 8140 - 
PO, 3 1.6 361 - 397 11 
PO, 10 1.8 1826 - 1433 17 
PO, 30 2.2 9496 - 10053 29 
aThermodynamic solubility analysis was performed by Analiza Inc. using quantitative nitrogen detection. 
(www.analiza.com). bEquilibrium solubility in PBS at 25 °C. cHalf-life in mouse liver microsomes. PK 
parameters were estimated using non-compartmental analysis with Phoenix/WINONLIN. 
In Vivo Metabolic Identification of CCG-232964: 
With the objective of reducing the metabolic susceptibility of 232964 in vivo while 
maintaining SRE.L potency, an in vivo metabolic identification study was performed (Figure 40). 
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The study confirmed that the major routes of oxidation were occurring at the para-cyclopropyl 
substituent and the alkyl carbon chain linking the oxadiazole thioether to the carboxylic acid, 
and minor amounts of oxidation were occurring on the aromatic ring. Not surprisingly, we also 
observed conjugation of the carboxylic acid. 
 
Figure 40: Major sites of metabolism for CCG-232964 in vivo 
 
SAR Development—Improving In Vivo PK Profile: 
 In an attempt to improve metabolic stability and maintain SRE.L activity, fluorinated 
analogs (Table 10) structurally similar to the pM potent alkyl and alkoxy analogs (Table 8) were 
designed. We were initially very optimistic about this design since big, hydrophobic aryl 
substituents produced analogs with sub-pM activity. The trend between SRE.L activity and 
increasing halogen substituent size is recapitulated (e.g. 232120 and A97); but, unfortunately, a 
complete analysis regarding halogen size and activity cannot be discussed since para-F analog 
A98 was not tested. Regardless, the para position is clearly still preferred for fluorinated analogs 
(A100 < A101 < A102), with A102 achieving an improvement in activity (single digit pM) 
comparable to improvements observed for bulky alkyl analogs (Table 8). While every fluoro-
containing, mono-substituted para analog tested (A103-A108) was well-tolerated regardless of 
size, no mono-fluoro- or 2-Cl/4-fluoro-containing (A109-A112) analog achieved the same level 
of activity as bulky aliphatic comparators (Table 8). In all, the SAR in Table 10 exemplifies how 
(1) minute changes to aryl substituents cause huge deviations in activity (2) fluoroalkyl and 
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fluroalkoxy substituents at R4 maintain the maximum MLM stability of Cl, and (3) 2-Cl is superior 
to 2-H. 
Table 10: SAR of fluorinated analogs designed to attempt to improve PK profile of 
aromatic ring 
 




232120 - Cl H Cl 1.8 >60 
257389 A97 Cl H Br 0.002 - 
263236 A98 Cl H F - - 
262526 A99 F H H 350 - 
232922 A73 Cl H Me 0.1 28 
262525 A100 CF3 H H 10,000 - 
263104 A101 Cl CF3 H 330 - 
257390 A102 Cl H CF3 0.0004 >60 
263094 A103 H H CF3 46 - 
263101 A104 H H CHF2 160 - 
263107 A105 H H OCHF2 130 - 
263103 A106 H H OCF3 78  
263100 A107 H H OCH2CF3 240 - 
263106 A108 H H CF(CH3)2 9.5 - 
263105 A109 Cl H CF(CH3)2 0.5 - 
263097 A110 Cl H OCF3 3.6 - 
262687 A86 Cl H OCH2CH3 0.0007 19 
263095 A111 Cl H OCH2CF3 0.8 >60 
263235 A112 Cl OCH2CF3 H - - 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells. bCell viability and 
proliferation assay with WST-1 < 5% inhibition up to 100 M inhibitor (mean of n = 3, SEM < 10%) up to 
100 M inhibitor. cHalf-life in mouse liver microsomes. 
Next, being guided by the SRE.L activity and MLM stability of 232964, we considered 
improving the metabolic stability of the series through bulky cyclic substituents at the para-
position (Table 11). These analogs exemplified that not all substituents with hydrophobic steric 
bulk afford pM potency (e.g. A115-A118); there is clearly a size limit to the para-substituent, as 
already exemplified in Table 8. Moreover, an attempt to create a pro-drug (A113) led to a 
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significant reduction in SRE.L activity, so among the analogs in Tables 10 and 11, 232964 
appeared to be optimal. 
Table 11: SAR of cyclic analogs designed to attempt to improve PK profile of aromatic 
ring 
 




232964 - H cPr H H 0.001 >60 
263086 A113 H cPr H Me 3 ND 
262762 A114 H OcPr H H 1.3 >60 
262690 A115 H OCH2cPr H H 0.11 ND 
263096 A116 H O-oxetanyl H H 370 >60 
263098 A117 H O-oxetanylmethyl H H 35 ND 
263099 A118 H O-1-methyl 
oxetanylmethyl 
H H 42 ND 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells. bCell viability and 
proliferation assay with WST-1 < 5% inhibition up to 100 M inhibitor (mean of n = 3, SEM < 10%) up to 
100 M inhibitor. cHalf-life in mouse liver microsomes. 
We then turned our efforts to improving the stability of the propylene linker, which the 
metabolic ID studies indicated was a major site for metabolism (Figure 40). Our hypothesis was 
that by substituting (Table 12) or cyclizing (Table 13) the alkyl chain, we could further improve in 
vivo PK stability. However, we were concerned about these analogs maintaining SRE.L activity 
because, during probe development for target identification (Chapter 2), the chain length SAR 
was very tight, and we observed complete loss in activity with any appendage attached to the 
alkyl chain (A38-A119; Table 12). Not surprisingly, this trend continued with additional attempts 
to block oxidation α (A120 & A121) or β (A122) to the carboxylic acid. These results convinced 
us that blocking metabolism by attaching appendages to the alkyl chain could not be 




Table 12: SAR of substituted linker analogs designed to attempt to improve PK profile of 
alkyl chain 
 
CCG- Entry G SRE.L IC50 
(nM)a, b 
58150 - (CH2)2 2 
232120 - (CH2)3 0.84 
257021 A38 CH2CHOMe >100,000 
232961 A39 (CH2)2CHOMe >100,000 
257222 A119 (CH2)3CHOMe 100 
257154 A120 (CH2)3CHOH 200c 
262707 A121 (CH2)2C(CH3)2 4,500 
262705 A122 CH2C(cPro)CH2 4,500 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells unless otherwise 
noted. bCell viability and proliferation assay with WST-1 < 5% inhibition up to 100 M inhibitor (mean of n 
= 3, SEM < 10%) up to 100 M inhibitor. cInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 
10%) in PC3 cells. 
Alternatively, cis-cyclobutyl (A123) and cis-cyclopentyl (A125) chains were well-tolerated 
in the SRE. L assay, almost being equipotent to the straight chain linker (232120). Also, a large 
difference in SRE.L activity between cis and trans conformers is present (A123 vs. A124 and 
A125 vs. A126), indicating that a certain sidechain conformation is critical for target binding. 
More evidence for this hypothesis is that, apart from A125, both cis and trans 5- and 6-
membered ring derivatives (A126-A128) were completely inactive. Additionally, while A125 
maintained good potency, it was four-orders in magnitude more potent than the trans conformer 
A126. While a ten-fold improvement in the SRE.L activity was achieved through the combination 
of the 4-cPr (232964) with the cis-cyclobutyl linker (A129), this same improvement in activity did 
not translate for the same design with 4-CF3 (A131). Regardless, we were satisfied with the 
acceptable activity for both A123 and A129, and the preservation between the difference in 
cis/trans activity for this subset of analogs. 
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Table 13: SAR of representative cyclic linker analogs designed to attempt to improve PK 
profile of alkyl chain 
 




232120 - Cl 0 N/A 0.84 >60 
262588 A123 Cl 1 cis 6.4 >60 
262587 A124 Cl 1 trans 550 ND 
263108 A125 Cl 2 cis 15 ND 
263091 A126 Cl 2 trans >100,000 ND 
263092 A127 Cl 3 cis >100,000 ND 
263093 A128 Cl 3 trans >100,000 ND 
232964 - cPr 0 N/A 0.001 47 
263087 A129 cPr 1 cis 0.46 >60 
263088 A130 cPr 1 trans 2.6 ND 
263089 A131 CF3 1 cis 42 ND 
263090 A132 CF3 1 trans 1000 ND 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells unless otherwise 
noted. bCell viability and proliferation assay with WST-1 < 5% inhibition up to 100 M inhibitor (mean of n 
= 3, SEM < 10%) up to 100 M inhibitor. cHalf-life in mouse liver microsomes. 
 
Synthesis of 5-aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids with Improved In Vivo PK: 
 Many 5-aryl-1,3,4-oxadiazol-2-ylthioalkanoic acids discussed in this subsection were 
synthesized as shown in Scheme 15; however, alternative routes for some analogs were 
required (Scheme 19-21). For instance, 4-(1-fluoro)-isopropyl methyl esters 57a,b were 
synthesized from 56a,b by Grignard reaction with acetone followed by fluorination of the tertiary 
alcohol with DAST (Scheme 19). Also, trifluoromethoxy benzoic acid 59 was produced from aryl 




Scheme 19: Synthesis of 57a,b and 59 
4-alkoxy aryl intermediates were formed by O-alkylation of respective phenolic 
compounds using various alkylating agents, bases, solvents, and temperatures (Scheme 20). 
The alkylation conditions that worked well with the alkoxy derivatives displayed in Scheme 17 
were attempted for all intermediates shown in Scheme 20; however, the only successful 
coupling with these conditions for these analogs was using cyclopropylmethoxy intermediate 8a. 
The remaining intermediates mainly didn’t react under these conditions, but alternative routes 
were found. For example, the syntheses for 1-trifluorethoxy aryl methyl esters 62a,b and O-
oxetanyl methyl ester 62c were accomplished with their respective alkyl halides and Cs2CO3 in 
DMSO. Surprisingly, 1-bromocyclopropane did not react in alkylation conditions with DMF, and 
it appeared to decompose per HPLC, but carboxylic acid intermediate 63 was eventually formed 
from phenolic aryl methyl ester 52 in DMA at 155 oC using Cs2CO3 as the base. Finally, O-
oxytanylmethyl and O-1-methyloxetanylmethyl methyl ester intermediates 65a,b were generated 
from the respective freshly prepared oxetanylmethyl methanesulfonate alkylating agents (64a,b) 




Scheme 20: Synthesis of intermediates 60-65a,b 
The cis and trans cyclobutane, cyclopentane, and cyclohexane analogs were 
synthesized by base-catalyzed alkylation of 1, 66a,b with the appropriate cycloalklyl chloride or 
mesylate (67a,b) 251 (Scheme 21). The resulting esters were hydrolyzed under basic conditions 
without epimerization to afford cyclobutylalkonic acid analogs. 
 
Scheme 21: Synthesis of cyclobutane, cyclopentane, and cyclohexane analogs 
Reagents and conditions: (a) cis/trans-methyl 3-chlorocyclobutanecarboxylate, Cs2CO3, NaI, DMSO, 100 
°C, 40 hr (b) cis/trans-methyl 3-((methylsulfonyl)oxy)cyclopentanecarboxylate (67a), NaH, THF, 50 °C, 16 
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hr (c) cis/trans-ethyl 4-((methylsulfonyl)oxy)cyclohexanecarboxylate (67b), Cs2CO3, DMSO, 100 °C, 72 hr 
(d) 1M NaOH, THF, 25 °C, 1-24 hr. 
 
In Vivo PK Evaluation of CCG-262588: 
To determine how much cyclizing the alkyl chain improves in vivo PK profile for the 
series, we compared 2,4-dichloro-cis-cyclobuytyl analog A123 with homologous acyclic 
butanoic acid 232120 (Table 14). The PK profile of A123 was significantly improved, having 2-
fold better in vivo half-life and nearly 5-fold better plasma exposure than acyclic 232120. 
Unfortunately, even though A123 had an estimated 10-fold better exposure than 232964 (Table 
9), this was not enough to overcome the vastly superior (over 1000-fold) potency of 232964. 
Assuming 2-cPr-4-chloro-cis-cyclobuytyl analog A129 would have a similar, if not worse, PK 
profile than A123 (based on comparison of the in vivo PK profiles of 232120 and 232964 (Table 
9)), we elected to not obtain in vivo PK for A129. Also, by the time A129 was synthesized and 
tested, we had already obtained a large amount of in vivo PK data for 232964, and gram 
quantities of 232964 were already made for in vivo testing, so we decided to advance 58150 
and 232964 into in vitro and in vivo models of efficacy.  
Table 14: Pharmacokinetic parameters of 232120 vs. 262588 in plasma following PO 
administration 

















232120 - 1.8 >60 PO, 20 1.2 11140 30 23150 
262588 A123 6.4 >60 PO, 20 2.6 50146 6.7 13600 
aHalf-life during incubation with mouse liver microsomes. 
 
Inhibition of LPA Induced CTGF Expression In Vitro by CCG-58150 and CCG-232964: 
To assess effects on pro-fibrotic gene expression, primary human dermal fibroblasts 
were pre-treated with 58150 or 232964 for 48 or 72 hours (Figure 41). After the pre-incubation, 
cells were stimulated with LPA—a direct activator or the Rho pathway through Gα12/13252—for 
1 hour. Interestingly, after 48 hours, neither 58150 nor 232964 had any significant effect on 
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CTGF gene expression; however, after 72 hours, both inhibitors dose-dependently reduced 
CTGF gene expression, with 232964 being ~100x more potent than 58150. 
 
Figure 41: CCG-58150 and CCG-232964 Inhibit LPA induced CTGF gene expression 
Primary dermal fibroblasts from healthy donors were pre-treated with varying concentrations of CCG-
58150 and CCG-232964 for 48 hours (A) or 72 hours (B) and stimulated with 1 µM LPA for 1 hour.  CTGF 
mRNA levels were measured by qPCR.  Results are expressed as the mean ± SEM.  *p<0.05, **p<0.01 
vs DMSO control using One-way ANOVA; n>3. 
 
Murine Bleomycin Prevention Study with CCG-58150 and CCG-232964: 
We selected a mouse model of dermal fibrosis that entails inhibition of dermal thickening 
induced by bleomycin as our preliminary measure of in vivo efficacy of 58150 and 232964. This 
model has been well-described in the literature159,253,254 and entails daily intracutaneous 
injections of bleomycin with concurrent treatment by drug or vehicle for 14 days. At the end of 
the dosing period, the mice are sacrificed and sections of skin at the injection site are excised 
and analyzed for dermal thickness and hydroxyproline—a major component of collagen and an 
accepted biomarker for collagen content.255  
Based on the high Cmax achieved in the mouse PK study for 58150 (30 mg/kg PO dosing 
(107 M) relative to the SRE.L IC50 (4 nM)), we selected three lower doses for 58150 (0.1, 1 and 
10 mg/kg/day) by oral gavage during bleomycin treatment. 58150 was able to dose-dependently 
reduce both measures of bleomycin-induced fibrotic effects (dermal thickness and 
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hydroxyproline content), having significant effects at 10 mg/kg vs bleomycin/vehicle control 
(Figure 42A and 42B). In a subsequent study, two doses were selected for the more potent but 
less bioavailable compound 232964 (3 and 10 mg/kg PO). The lower dose was calculated 
based on the single dose oral PK data (Table 9) to achieve comparable plasma AUC: SRE.L 
IC50 ratio as the efficacious 10 mg/kg dose of 58150. At the conclusion of this study, 232964 
significantly reduced bleomycin-induced dermal fibrosis at both doses, indicating that it is at 
least 3-fold more potent than 58150 in vivo (Figure 42C-E). The ability of 232964 to prevent 
dermal skin thickening and maintain hydroxyproline levels at nearly baseline-control levels 
highlights the antifibrotic potential of this novel series. 
 
Figure 42: 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic acids prevent bleomycin-induced dermal fibrosis 
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Mice treated with inhibitors displayed significantly reduced skin thickness and collagen content as 
compared to vehicle control (A) Masson’s trichrome stained skin sections from PBS (left panel), 
Bleomycin + Vehicle control (middle panel), and Bleomycin +10 mg/kg 58150 (right panel).  N=10 per 
group (B) Quantification of A, by measuring the distance between the subcutaneous fat and the 
epidermis. *, p<0.05 by using One-way ANOVA (C) Masson’s trichrome stained skin sections for PBS (left 
panel), Bleomycin+Vehicle (middle left panel), Bleomycin +3 mg/kg 232964 (middle right panel) or 
Bleomcyin +10 mg/kg 232964 (right panel). N=7 per group (D) Quantification of C. ****, p<0.0001, using 
One-way ANOVA. (E) Quantification of collagen content by hydroxyproline measurement.  ****, p<0.0001, 
using One-way ANOVA.  
 
Conclusion: 
A novel and highly potent series of inhibitors of Rho/MRTF/SRF-mediated gene 
transcription was developed. The hit—CCG-58146—was discovered during our previously 
reported phenotypic HTS utilizing a SRE.L expression readout. We systematically explored 
modifications to the heterocyclic core, the aromatic ring at C-5, and the alkanoic acid sidechain. 
During this process we observed extremely tight SAR and multiple activity cliffs.  We ultimately 
achieved an astonishing 150,000-fold improvement in SRE.L activity while progressing from hit 
58146 (IC50 = 180 nM) to lead 232964 (IC50 = 0.0012 nM).  This is likely the result of both an 
extremely well-defined binding site on the currently unknown molecular target as well as the 
hypothesized availability of a covalent mode of binding. Selected inhibitors 58150 and 232964 
were able to reduce expression of the pro-fibrotic gene CTGF in LPA-stimulated fibroblasts. In 
improving the series’ activity, we were also able to generate inhibitors with acceptable PK 
profiles for in vivo studies. The potent and dose-dependent anti-fibrotic effects displayed by both 
58150 and 232964 provide an introduction to orally efficacious 5-aryl-1,3,4-oxadiazol-2-
ylthioalkanoic acid Rho/MRTF/SRF-mediate gene transcription inhibitors for potentially treating 
fibrotic diseases. Prior to further development of these inhibitors as anti-fibrotic agents, 
identification of the biological target(s) as well as clarification of the novel covalent mechanism 
of action should be accomplished (Discussed in Chapter 5).  
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Chapter 4: 222740 Series Structure-Based Drug Design with Pirin 
Co-Crystal Structure Comparison: 
Since we had strong evidence that pirin is a biological target for the 222740-series 
(Chapter 2), we attempted to improve SRE.L activity using a structure-based drug design 
(SBDD) approach utilizing the pirin co-crystal structures for CCT251236, CCG-222740 (Figure 
38D,E, 1.7 Å), & CCG-257081 (Figure 43, 1.5 Å). Unfortunately, the natural ligand that 
modulates pirin’s biological activity is currently unknown. Therefore, since the evidence 
suggests pirin may adopt multiple binding orientations to accomplish its biological 
activity223,240,256,257, we hoped that improvements to SRE.L activity for the 222740-series would 
be achieved by designing inhibitors that bound to pirin in a similar manner as CCT251236. 
Secondarily, we hoped that our SBDD efforts would help validate pirin as a target for the 
222740-series. Prior to obtaining the co-crystal structures for CCG-222740 and CCG-257081, 
we reasoned that if the SAR trends reported by Cheeseman et al could be mimicked by SRE.L 
SAR trends for 222740-series analogs that combined certain aspects of the CCT251236 
scaffold, then we would have more evidence that pirin is a biological target for the 222740-
series. However, since we did not have a reliable binding assay to directly determine exactly 
how structural changes affect binding to pirin, we knew we would have to take 
pharmacodynamic properties (e.g. solubility, ClogP, etc.) into consideration during our design, 
complicating the SBDD analysis. Cheeseman et al do report a SPR binding assay for pirin, and 
the Neubig lab has been attempting to set this assay up, but no reliable, high-throughput data 
has been produced to date. So, all SBDD efforts discussed in this chapter were heavily guided 




Figure 43: Co-crystal structure of CCG-257081: 
Co-crystal structure of CCG-257081 (green) bound to pirin in the R-conformation (1.5 Å). Blue shading 
indicates H-bond donating regions and red shading indicates H-bond accepting regions. White regions 
indicate non-polar residues. 
 Likely due to their structural similarities, the CCG-222740 series (e.g. CCG-257081) and 
CCT251236 bind to pirin very similarly to each other (Figure 44). Obvious similarities in the 
binding poses are: (1) the aromatic rings of both series occupy similar space deep within pirin’s 
lipophilic pocket and (2) both series have comparable H-bonding interactions between the water 
molecule bound to pirin’s Fe core and each inhibitor’s bis-amide core. Interestingly, CCT251236 
establishes two additional H-bonding interactions with Asp43 and Glu18 in a highly ordered 
orientation, perhaps accounting for its high binding affinity (Kd, ~20 nM). Also, in the 
CCT251236 co-crystal structure, Glu18 is significantly shifted to engage in a H-bonding 
interaction with the amide N-H of the inhibitor; CCG-222740 or CCG-257081 cannot engage in 
this type of H-bonding interaction because they lack amide N-H’s in this region. Also, 
CCT251236 may have higher affinity to pirin than our series because of a potentially critical π-π 
stacking interaction between CCT251236’s phenyl core and Phe 45 & 53 (Figures 43 & 44). Of 
note, the pyrrolidine appendage on CCT-251238 was implemented by Cheeseman et al to 
CCG-257081
SRE L. IC50 = 0.53 uM
ITC = 3.1 uM
Resolution = 1.5 Å
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improve the poor solubility of the series, and it is projecting into solvent and presumably does 
not interact with pirin; hence, this moiety is not resolved in the co-crystal structure.  
 
Figure 44: Overlay of the CCG-257081 and CCT251236 co-crystal structures 
Overlay of the CCG-257081 (green) and CCT251236 (yellow; PDB 5JCT) co-crystal structures. Residues 
belonging to the CCG-257081 co-crystal structure are displayed in pink, while the residues for the 
CCT251236 co-crystal structure are shown in grey. Blue shading indicates H-bond donating regions and 
red shading indicates H-bond accepting regions. White regions indicate non-polar residues. 
 
CCG-222740/CCT251236 Hybrid Analogs: 
First, we attempted to integrate the CCG-222740 series scaffold with key 
pharmacophores reported by Cheeseman et al that afforded CCT251236’s tight binding with 
pirin (Figure 45).240 These key pharmacophores consisted of: (1) the aromatic core (green) (2) 
the presence of two, secondary amides (pink) (3) the aromatic dioxane pendant (blue). Of note, 
all analogs tested for this series are compared to the activity of 222740 because of the high 
level of variability in SRE.L activity between experimental batches. Hybrid analog 263154 
integrated CCT251236’s aryl bis amide core with 222740’s flanking aryl pendants, and it had 







same level of activity as CCT251236 because Cheeseman et al reported very tight SAR around 
the dioxane aryl functionality of CCT251236; however, this result did further suggest that even if 
the bis-amide core of CCT251236 is critical for tight binding, the pendants flanking the core may 
be equally as important. Interestingly, all attempts to synthesize a hybrid analog lacking the 
methyl group within the aryl core were unsuccessful (not shown), and these failed syntheses 
suggest that the amide α to the methyl group is highly susceptible to hydrolysis, even when in 
weak base, without the methyl present.  
Switching the orientation of one of the amides did not improve activity (A133 vs A134), 
and removal of the aromatic methyl with this bis-amide configuration (A135 & A136), which 
produced analogs no longer susceptible to hydrolysis, also did not lead to an improvement in 
activity. However, the 100-fold difference in activity between A135 and A134 indicates a clear 
conformational preference for the methyl imbedded within the aryl core. These results not only 
suggest that, with the correct aromatic pendants, alternative amide orientations might provide 
high levels of affinity to pirin, but this activity is likely dependent on how the bis-amide and the 
flanking aryl pendants are oriented, which is likely directed by the methyl within the aryl core. 
However, since the goal of these analogs was to investigate the SAR of CCT251236’s bis-
amide core, we looked to explore the effects of the aryl dioxane pendant. 
Cheeseman et al reported an interesting SAR trend with the CCT251236 scaffold: when 
the dioxarine ring system was replaced with mono- or di-methoxy pendants or migrated from the 
3,4-position, the ligand lost all affinity for pirin. We were able to recapitulate this result with 
222740’s central bis-amide core. While less potent than 222740, dioxirane rings attached to 
either aryl ring (e.g. A137 & A138) were significantly more active than homologous di-methoxy 
analogs (A139 & A140), mirroring the SAR trend reported by Cheeseman et al. While we were 
excited by this SAR trend, the lack of activity comparable to CCT251236 for this initial set of 
hybrid compounds suggests there are additional interactions needed to improve the SRE.L 
activity for the 222740 series to the range of potency achieved by CCT251236. While we 
106 
 
wanted the published SAR for CCT251236 to guide our improvements in SRE.L activity for the 
222740-series, we wanted to remain within the limits of novel IP, so we focused our design on 
docking analogs from the 222740 series into the CCT251236 co-crystal structure 5JCT (vide 
infra).  
 
Figure 45: CCT251236/CCG-222740 hybrid analogs and activity in HEK-293T cells 
 
Hybrid Analog Synthesis: 
 The synthetic route for many 222740 analogs was accomplished using the three routes 
depicted in Scheme 22. Starting from the piperidine carboxylic acid 33 or ester 34, a series of 
HATU-mediated amide couplings and deprotections were used to produce bis-amide analogs. 
For example, similar to Route 1 in Scheme 11, the scaffolding is built from right to left in Route 1 
(Scheme 22), introducing the aniline coupling partner first and the furan-2-yl benzoic acid last; 
the same right-to-left construction is depicted in Route 2 but 4-chloroaniline is kept constant and 
the benzoic acid piece is derivatized; analogs were also assembled from left to right, as shown 
in Route 3, generating a late stage carboxylic acid intermediate that was subjected to HATU-
mediated amide coupling conditions to quickly produce bis-amide analogs. The preferred amide 
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coupling conditions consisted of HATU, DIPEA, and DMF at room temperature, and reactions 
were generally left overnight. 
 
Scheme 22: Three general routes used to produce 222740 analogs 
 A similar sequence of amide couplings and deprotections afforded bis-amides with 
aromatic cores (Scheme 23). Depending on the available starting materials, the bis-amides 
were assembled starting from either the left or the right side of the core. In order to accelerate 
the syntheses for analogs 257866 & 257922, amide couplings were done at 150 °C for 1 hr 
(Scheme 24). 
 
Scheme 23: Synthesis of 263154 
(i) 3-(furan-2-yl))benzoic acid, HATU, DIPEA, DMF, 25 °C, 16 hr (ii) 1M NaOH, THF, 45 °C, 1 hr (iii) 4-




Scheme 24: Synthesis of 257866 and 257922 
(i) 4-chloroaniline, HATU, DIPEA, DMF, 25 °C, 1 hr, then 150 °C, 15 min (ii) 4M HCl in dioxanes, 25 °C, 3 
hr (iii) 3-(furan-2-yl))benzoic acid, HATU, DIPEA, DMF, 25 °C, 1 hr, then 150 °C, 2 hr. 
 
Docking Studies and SBDD with 5JCT Co-Crystal Structure: 
Docking studies were performed by Pil Lee using Molecular Operating Environment 
(MOE) docking software. We first wanted to find analogs from the 222740 series that mimicked 
certain interactions CCT251236 made with pirin. In an initial study keeping pirin’s residues 
static, 12 structurally distinct analogs from the 222740-series with varying SRE.L activities were 
docked into the 5JCT co-crystal structure published by the Cheeseman group (Figure 46). 
Structural differences across the selected 222740 analogs included: small and large 
appendages on each aryl ring (A141-A143, A57, A145), an unsaturated bis-amide core (A144), 
and indole-containing aryl pendants that had diverse activities (A146-A150) (Figure 46). We 
hoped that we would see a trend in the binding modes for active vs. inactive analogs that we 
could utilize for our SBDD.  
Of note, propargyl analogs A141-A143 were originally made in parallel to the 
ethoxymethoxy probe mimics discussed in Chapter 2. The original rationale to make these 
analogs was to make propargyl Click probes with a range of SRE.L activity for target 
identification studies. While these analogs did not achieve significant differences in activity, they 
had large pendants that maintained activity compared to 222740, and so we were interested in 




Figure 46: The first set of structurally diverse analogs with varying SRE.L activities docked into a 
co-crystal structure (PDB 5JCT) of CCT251236 and pirin. 
Unfortunately, compared to the co-crystal structures for CCG-222740 and CCG-257081, 
many of the docked analogs had completely flipped binding modes amongst the 5 highest 
scoring poses generated. This phenomenon complicated the analysis of which structural 
changes were important in the next SBDD analogs because we couldn’t be certain that changes 
in SRE.L activity were due to flipped binding modes or not. It should be noted again that the 
222740-series, especially analogs containing indole pendants, is notorious for poor solubility 
and having somewhat inconsistent SRE.L IC50s and maximum efficacies across experimental 
batches, so the percent of CCG-222740 IC50 for each plate is reported. 
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Despite the flipped binding mode complication, one of the more potent indoles (CCG-
258222, Figure 47) consistently docked in a conformation that provided us with a scaffold that 
could be manipulated to potentially modulate SRE.L activity with structural alterations. The 
docking poses for this analog consistently projected the indole ring into pirin’s hydrophobic 
pocket, and the docking suggested the indole N—H and Asp43 could engage in a H-bonding 
interaction. In fact, we were looking for analogs that could achieve such an interaction since we 
deduced it may be critical for ligand affinity since the bis-amide/central core of CCT251236 was 
highly coordinated with Asp43, Glu18, and the water bound to the Fe core.  
 
Figure 47: CCG-258222 docked into CCT251236 co-crystal structure (PDB 5JCT) 
Key interactions between CCT251236 and pirin appear to be between Asp43, Glu18, and HOH406—Fe, 
with hydrophobic interactions in the pocket with the aromatic dioxane ring system. CCG-258222 is 
predicted to be capable of engaging with Asp43 and HOH406. 
From this round of docking, ~15 analogs were designed, synthesized, and tested in the 
SRE.L assay. The goal of these analogs was to not only generate ligands with higher affinity for 
pirin, but to provide additional evidence that SRE.L activity for the 222740-series occurs through 
pirin; however, the latter would only be possible with a direct binding assay to correlate with 
SRE.L. N-1 methyl indole analog A151 displayed almost a ten-fold reduction in SRE.L activity 
111 
 
compared to A150 (Table 15), suggesting, as the docking model predicted, the indole nitrogen 
might be important for pirin binding (Figure 47). Despite this activity difference, this result would 
be more revealing towards the series working through pirin if these analogs were to be tested in 
a direct binding assay. Alternatively, the activity difference between the closely related 
homologs A153-A155 suggests (1) the hydrophobic pocket can accommodate larger aliphatic 
groups, albeit these analogs maintained roughly equipotent activity compared to 222740 and (2) 
4,5-dioxane (A155) is the preferred substitution pattern. However, electronic effects may also 
play a role since the 4,5-difluoro substituted indole analog A152 completely lost SRE.L activity. 
Investigations to see how other changes to indole-containing analogs would affect 
activity were also made. Both 5,6-difluoro- and 5-trifluoromethoxy indole substituted bis-amide 
analogs were used to accomplish this investigation, but since activities were similar between 
both types of indole substitution, only 5-trifluoromethoxy indole-containing analogs are shown in 
Table 16. Attempts to improve solubility (in a similar manner as Cheeseman et al utilized for 
CCT251236) of the indole-containing compounds with A157 led to significant reductions in 
SRE.L activities. Attempts to improve solubility with pyridyl substitution was similarly 
unsuccessful (A158 & A159). Also, while enantiomers A160 & A161 did have significant 
differences in activity, the activity preference for the R-conformation is not supported by our 
docking results because A149 docked mainly in the S-conformation (Figure 47). These 
enantiomers were docked into the 5JCT co-crystal structure, but no noteworthy differences in 
binding were observed (not shown) 
The analysis of this initial docking study is limited by the lack of a direct binding assay 
since we cannot be certain whether differences in activity are a result of physicochemical 
properties or interaction with pirin. Regardless, small changes in activity amongst the analogs 
designed from this docking model were important for our considerations of potential binding 
modes the 222740-series could adopt within pirin. Disappointed we didn’t observe significant 




Table 15: SAR of analogs from the docking studies with CCT co-crystal structure 
 












R1 R2 R3 R4 R5 X 
258222 A149 0.04 10 72 4 H H H F H H 
257941 A150 0.05 13 65 40 H H F H H F 
263415 A151 0.39 70 ND 76 H H F H Me F 
258462 A148 0.01 2.5 17 <2.1 H F F H H H 
263412 A152 >100 ND ND 112 F F H H H F 
263481 A153 3 304 ND 29 H H 
 
H F 
263414 A154 2 419 80 5 H 
 
H H F 
263413 A155 0.26 73 ND 28 
 
H H H F 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells unless otherwise 
noted. bThermodynamic solubility analysis was performed by Analiza Inc. using quantitative nitrogen 
detection. (www.analiza.com). 
 
Table 16: SAR of 5-trifluoromethoxy indole analogs from the docking studies with CCT 
co-crystal structure 
 












* X Y Z R 
258191 A156 0.08 21 82 8.2 rac H H H Cl 
263680 A157 37 18,000 100 151 rac F C C 
 
263681 A158 0.56 329 100 26 rac F C N Cl 
263740 A159 2.8 1,670 100 97 rac F N C Cl 
263658 A160 23 11,500 100 ND S H C C Cl 
263687 A161 0.2 100 100 ND R H C C Cl 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells unless otherwise 




 In an attempt to engage with Asp43 & Glu18, various 5- and 6-membered cycloalkyl bis-
amide analogs that could mimic CCT251236’s bis-amide core were designed and docked into 
the 5JCT co-crystal structure using MOE (Figure 48, PR-VC-21-4 shown as example). We were 
happy to see that the model predicted many of the designed analogs could bind in a similar 
orientation as CCT251236. Importantly, with various docked analogs, both carbonyl groups of 
the bis-amide system appeared to engage with the water molecule bound to the Fe core, and 
(sometimes) both N-H groups could engage with the potentially key residues Asp43 & Glu18. Of 
note, the docking model predicted a flipped binding mode for various designed analogs where 
the furanyl functionality projected deeper into the hydrophobic pocket than the dioxane ring of 
CCT251236 (exemplified in Figure 48). Therefore, we thought that if our designed inhibitors 
could engage with pirin as the docking model suggested, perhaps we could produce a new 
chemotype of potent pirin ligands. 
 






Overlay of an exemplary docking analog— PR-VC-21-4 (seafoam)—and CCT251236 (yellow) in the co-
crystal structure (PDB 5JCT). Green shading indicates hydrophobic regions and pink shading indicates 
hydrophilic regions. 
 Based on these docking results, ~20 five- and six-membered cycloalkyl bis-amide 
analogs were synthesized (Table 17). Despite many analogs from this subset maintaining 
activity comparable to 222740, the results were disappointing since none of these analogs had 
similar SRE.L activity comparable to CCT251236. Additionally, the analog that was the most 
potent and structurally most similar to CCT251236 (A163, 0.06 µM) had very poor efficacy, 
likely due to its meager solubility (this analog had very poor solubility, even in DMSO).  
Table 17: SAR of representative five- and six-membered ring bis-amide analogs that were 
designed to attempt to improve affinity for pirin 
 













1 cis 5.8 2,900 100 656 
263880 A163 
  
2 cis 0.06 30 21 54 
263872 A164 
  
1 cis 0.47 235 96 93 
263876 A165 
  
2 cis 0.86 430 100 299 
263877 A166 
  
1 trans 1.1 550 36 1391 
263879 A167 
  
2 trans 13 6,500 100 213 
263873 A168 
  
1 trans 0.35 175 96 13 
263878 A169 
  
2 trans 1.1 550 100 <1 
257942 A170 
  
1 cis 0.37 93 100 - 
257865 A171 
  





1 trans 20 5000 44 - 
257863 A173 
  
2 trans 4 333 90 - 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells unless otherwise 
noted. bThermodynamic solubility analysis was performed by Analiza Inc. using quantitative nitrogen 
detection. (www.analiza.com). 
 To circumvent the likely solubility issue of A163, I designed and synthesized multiple 
A163 analogs containing a pyrrolidine solubilizing group (the solubilizing group that provided 
Cheeseman et al with the best activity profile for CCT251236) to various locations of the A163 
scaffold (Figure 49). Again, unable to breach even single-digit µM SRE.L activity, the results for 
these analogs were also disappointing; attaching the solubilizing group to either side of the 
A163 bis-amide core (A174 & A175) resulted in an over 200-fold loss of activity vs 222740.  
Likewise, an analog that replaced the central bis-amide core of CCT251236 with A163’s core 
(A176) was still over 100-fold less active than CCG-222740. 
 
Figure 49: 263880 derived analogs attempting to improve solubility 
One potential explanation for these negative results is that pirin may not be able to adopt 
the conformation, as the docking model suggests (Figure 48), required by either 5- or 6-
membered cycloalkyl bis-amide cores to fit the 2-furyl or 4-Cl-aniline aryl functional groups into 
the hydrophobic pocket. As evidence of this hypothesis, the docking model predicts flipped 
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binding poses that can accommodate less favorable interactions with pirin (not shown); notably, 
the highly coordinated H-bonding network is not established by these flipped binding modes. 
This suggests that if the aryl functional groups cannot fit into the hydrophobic pocket in the best 
docking poses, the analog will likely not achieve CCT251236 levels of affinity to pirin because 
the H-bonding network cannot be adopted. Moreover, in support of pirin’s selectivity of aromatic 
pendants that can fit in its hydrophobic pocket, the SAR results reported by Cheeseman et al 
suggests very tight SAR with small structural changes to CCT251236’s pendants located in the 
hydrophobic pocket.  
However, evidence against this explanation is that even when the same CCT251236 
pendants were incorporated into the saturated 6-membered ring core (A176), activity 
significantly decreased. Therefore, another possible explanation for these disappointing results 
is that the bulkier 5- and 6-membered ring systems might prevent the inhibitors from entering 
the somewhat narrow bridge leading towards pirin’s hydrophobic pocket. CCT251236 likely 
easily slides into this bridge region because of the flatness of the bis-amide core. So, flattening 
out the 5- or 6-membered ring systems through unsaturation could potentially circumvent this 
issue. Interestingly, this explanation is consistent with multiple analogs Kim Hutchings made 
earlier in the project (not shown), which achieved noticeable improvements in activity after 
flattening out the piperdine core. Nevertheless, efforts were not made to flatten out the 5- and 6-
bis-amide core because: (1) flattening out the core makes the analogs more like CCT251236, 
eliminating the novelty of this design (2) facile synthetic routes weren’t found (3) flatter cores 
would be expected to have worse metabolic stability than the piperidine (4) at the time we got 
these results, we were following an alternative SAR trend (discussed in the next subsection). 
However, it would be interesting to know if flattening the ring would afford tighter pirin binding. 
Lastly, based on cellular activities alone, we cannot be certain that these analogs do not 
strongly interact with pirin; perhaps these analogs are incapable of crossing the plasma and/or 
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nuclear membranes. Pirin SPR data would help us determine whether the 5- or 6-membered 
ring bis-amide core is a good strategy for designing novel and potent pirin ligands. 
Synthesis of Analogs from Docking SBDD: 
 Propargyloxy aniline (75a,b) and benzoic acid (76) intermediates were made using the 
same chemistry with propargyl benzenesulfonate and potassium carbonate to install the 
propargyl functionality to the respective phenols (Schemes 25 and 26). Protection of 
nucleophilic functionalities was required to block undesirable side-reactions in refluxing acetone. 
Deprotection of these functionalities afforded intermediates that could be subjected to chemistry 
shown in Scheme 22 to produce bis-amide analogs 258741-258704 (Figure 46). 
 
Scheme 25: Synthesis of 75a,b 
(i) Boc2O, THF, 70 °C, 4 hr (ii) propargyl benzenesulfonate, K2CO3, acetone, 65 °C, 3 hr (iii) 4M HCl in 
dioxanes, 25 °C, 4 hr. 
 
Scheme 26: Synthesis of 76 
(i) propargyl benzenesulfonate, K2CO3, acetone, 65 °C, 3 hr (ii) 1M NaOH, THF, 25 °C, 2 hr 
 Unsaturation was easily installed into the piperidine core through chemistry described 
previously (78).258 3-(furan-2-yl))benzoic acid was converted to acyl chloride 77 using oxalyl 
chloride. These two coupling partners were subjected to triethylamine in DCM to produce α,β-
unsaturated carboxylic acid intermediate 79 (Scheme 27), which could then be subjected to 




Scheme 27: Synthesis of 79 
 Dioxinoindole carboxylic acid intermediates 82a-c were produced from 3,4-dioxinamine 
81a using previously described chemistry (Scheme 28).259 First, the diazonium chloride salt was 
produced and reacted with ethyl 2-methylacetoacetate, forming the subsequent hydrazone 
intermediate that was cyclized to the respective 4,5- and 5,6-ethylenedioxyindoles in base. The 
ethyl esters were easily saponified to the carboxy-indole intermediates 82a,b. Adapting this 
chemistry with 2,3-dioxinamine 81b regioselectively afforded carboxy-indole intermediate 82c. 
Similarly, 6,7-difluoroindole intermediate 84 was synthesized via hydrazone formation and acid-
mediated ring closure starting from hydrazine 83 using previously described chemistry (Scheme 
29).260 
 
Scheme 28: Synthesis of dioxinoindole carboxylic acid intermediates 82a-c 
 
Scheme 29: Synthesis of 84 
 Many of the indole-containing bis-amide analogs were formed using HATU-mediated 
amide coupling adapted from synthetic Route 2 in Scheme 22; however, other analogs were 
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converted to acyl chlorides from the respective carboxy-indole intermediates, and then 
subjected to triethylamine and HCl amine salt 47 to produce indole-containing analogs. 
(Scheme 30). This acyl chloride route was adapted from chemistry Kim Hutchings developed to 
synthesize many indole-containing analogs from the 222740-series; however, the HATU-
mediated amide coupling conditions in DMF were found to be more effective since the indoles at 
any stage of the acyl halide route had poor solubility in DCM. 
 
Scheme 30: Alternative route to produce indole-containing analogs 
 263681 & 263740 were synthesized by a modified Route 3 from Scheme 22 starting 
from 5-(trifluoromethoxy)-1H-indole-2-carboxylic acid instead of 3-(furan-2-yl)benzoic acid (not 
shown). 263658 & 263687 were also synthesized by modified Route 2 in Scheme 22 using R- or 
S-5-(trifluoromethoxy)-1H-indole-2-carboxylic acid instead of 3-(furan-2-yl)benzoic acid (not 
shown); these reactions occurred without racemization. 
 Various 5- and 6-membered ring 3-amino carbamates were used to produce bis-amide 
analogs displayed in Scheme 31. The variability in the synthetic routes for these homologous 
analogs is a result of starting material availability. The HATU-mediated amide coupling 
chemistry used for piperidine analogs translated well to generate these bis-amide analogs 
without racemization. Since these reactions occurred without racemization, I was able to 
synthesize the trans-6-membered ring analog 86d starting from the cis/trans 3-amino carbamate 
85d followed by chromatographic separation; diastereomer assignment was done by comparing 
the HNMR/CNMR chemical shifts to carbamate intermediate 86b, which was produced from 




Scheme 31: Synthesis of 263875, 263880, 263877, and 263879 
(i) 4-chlorobenzoic acid, HATU, DIPEA, DMF, 25 °C, 16 hr (ii) 4M HCl in dioxanes, 25 °C, 2 hr (iii) 3-
(furan-2-yl))benzoic acid, HATU, DIPEA, DMF, 25 °C, 16 hr. 
 Cis-3-carboxylic acid intermediate 89 was produced from the cis/trans mixture of di-
carboxylic acid starting material 87 (Scheme 32). This was accomplished using previously 
described chemistry to produce cis-oxabicyclo-2,4-dione intermediate 88.261 This intermediate 
was easily coupled to 4-chloroaniline to produce pure cis-cyclopentanecarboxylic acid 
intermediate 89. HATU-mediated amide coupling of 3-(furan-2-yl)aniline, HCl to 89 completed 
the synthesis of 263872. 
 Having produced pure cis-cyclopentanecarboxylic acid intermediate 89, trans- 
cyclopentanecarboxylic acid was generated from the cis/trans mixture starting material 90a 
(Scheme 33). Of note, not only were cis and trans cyclopentanecarboxylic acid intermediates 
generated from 90a, cis and trans di-4-chloroaniline substituted bis-amide analogs (not shown) 
were also produced. Fortunately, all four products were easily separable by column 
chromatography, and the NMR spectra for both cis and trans cyclopentane carboxylic acid 
intermediates synthesized were compared to the NMR spectra for cis-cyclopentane carboxylic 
acid intermediate 89. Trans-cyclopentanecarboxylic acid intermediate 91a was subjected to 
HATU-mediated amide coupling conditions with 3-(furan-2-yl)aniline, HCl to produce trans-bis-
amide analog 263873. 
 Trans-cyclohexane bis-amide analog 91b was produced starting from trans-
dicyclohexanecarboxylic starting material 90b in a similar sequence as was used to generate 
263878 (Scheme 33). On the other hand, the synthesis for cis-cyclohexane bis-amide analog 
263876 began from carboxylic acid 92, which had a methyl ester protected carboxylic acid 
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(Scheme 33). This route would have obviously been preferred for all bis-amide analogs with this 
amide orientation, but available starting materials led to a wide-array of synthetic routes for 
these analogs. 
 
Scheme 32: Synthesis of 263872 
(i) Ac2O, MW, 150 °C, 30 min (ii) 4-chloroaniline, DMF, 25 °C, 16 hr (iii) 3-(furan-2-yl)aniline, HCl, HATU, 
DIPEA, DMF, 25 °C, 16 hr. 
 
Scheme 33: Synthesis of 263876 
(i) 4-chloroaniline, HATU, DIPEA, DMF, 25 °C, 16 hr (ii) 1M NaOH, THF, 25 °C, 1 hr (iii) 3-(furan-2-
yl)aniline, HCl, HATU, DIPEA, DMF, 25 °C, 16 hr. 
 Fortunately, the starting materials to produce bis-amide analogs shown in Scheme 32 
were available in their pure cis or trans isoforms (94a-c and 96), and all analogs could be easily 




Scheme 34: Synthesis of 257942, 258452, and 257863 
(i) 4-chloroaniline, HATU, DIPEA, DMF, 25 °C, 16 hr (ii) 4M HCl in dioxanes, 25 °C, 2 hr (iii) 3-(furan-2-
yl)benzoic acid, HATU, DIPEA, DMF, 25 °C, 16 hr. 
 
Scheme 35: Synthesis of 257865 
(i) 3-(furan-2-yl)benzoic acid, HATU, DIPEA, DMF, 25 °C, 16 hr (ii) 1M NaOH, THF, 25 °C, 1 hr (iii) 4-
chloroaniline, HATU, DIPEA, DMF, 25 °C, 16 hr. 
 Analogs 264119-264121 were produced from the cis-cyclohexyl 3-amino carbamate 
core, albeit this starting material was manipulated from either side of the core as to install the 
pyrrolidine functionality in the final step (Scheme 36-38). The installation of the pyrrolidine 
functionality began from phenolic starting materials 98 and 101. These intermediates were 
subjected to HATU-mediated coupling conditions with the respective cis-cyclohexyl 3-amino 
carbamate cores to afford analogs 264119 and 264121. Also, since I synthesized CCT251236 
as previously described by Cheeseman et al, I had the required intermediates in stock to easily 
produce analog 264120. 
 
Scheme 36: Synthesis of 264119 
(i) 1-(2-chloroethyl)pyrrolidine, K2CO3, DMF, 100 °C, 4 hr (ii) 1M NaOH, THF 25 °C, 5 hr followed by HCl 




Scheme 37: Synthesis of 264121 
(i) 3-(furan-2-yl)benzoic acid, HATU, DIPEA, DMF, 25 °C, 16 hr (ii) 4M HCl in dioxane, 25 °C, 2 hr (iii) 1-
(2-chloroethyl)pyrrolidine, K2CO3, DMF, 100 °C, 4 hr (iv) 1M NaOH, THF 25 °C, 5 hr followed by HCl 
workup (v) 100, HATU, NMM, DMF, 25 °C, 16 hr. 
 
Scheme 38: Synthesis of 264120 
(i) HATU, DIPEA, DMF, 25 °C, 16 hr (ii) 4M HCl in dioxane, 25 °C, 2 hr (iii) 2-(2-(pyrrolidin-1-
yl)ethoxy)quinoline-6-carboxylic acid, HCl, HATU, NMM, DMF, 25 °C, 16 hr. 
 
Probing Pirin’s Hydrophobic Pocket with CCG-257081-like Analogs: 
We turned our attention to make more subtle changes to the series, and, using the 
257081 co-crystal structure of pirin, designed CCG-257081-derived analogs with appendages 
that could reach deeper into the fairly open hydrophobic pocket (Table 18). First, seeing that 
there were water molecules (HOH70 and HOH138) that could potentially get knocked out of 
pirin’s pocket (Figure 43), I designed and synthesized phenolic (A177) and hydroxymethyl 
(A178) analogs. Unfortunatley, these analogs did not provide the activity we hoped for, 
suggesting these changes likely did not displace or engage with the waters within the pocket. 
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However, 3-Cl (264059) and 3,4-Cl (A179) aniline analogs provided a noticeble improvement in 
SRE.L activity over 4-Cl 222740. Satisfyingly, the tight SAR within pirin’s hydrophobic pocket 
observed in the Cheeseman paper 240 was evident with the 2-Cl aniline derivative (A180). These 
chlorophenyl analogs provided the first distinct and consistant SAR cliff from our SBDD efforts. 
 Intruigued by these results, I synthesized various analogs with hydrophobic 3-
substituents. We observed a change in activity from small (A181) to bulky (A184-A186) 
substituents, ultimately achieving approximately five-fold improved potency compared to CCG-
222740 with 3-cPr and 3-CF3 analogs A184 and A185. Also, this improvement persisted 
regardless of electronic effects (264059 vs. A184-A186). Again, with longer rigid substituents, 
we tried to engage with or knock-out the water molecules deep within the hydrophobic pocket; 
this time, acetylene (A187) and nitrile (A188) substituents were used. While A187 maintained 
the befificial effects of 3-substitution, A188 was not able to, likely suggesting the nitrile has a 
desolvation penalty that limits any potential engagement with the water molecules within the 
hydrophobic pocket. 
Table 18: SAR of analogs designed to attempt to reach deeper into pirin’s the 
hydrophobic pocket. 
  












257081 - H H Cl ~0.2 ND 100 9.8 
263482 A177 H OH Cl 16 ND ND 14 
263741 A178 H CH2OH Cl 0.64 320 100 ND 
264059 - H Cl H 0.08 40 100 ND 
264060 A179 H Cl Cl 0.1 50 100 ND 
264327 A180 Cl H H 7.5 1,320 100 ND 
264321 A181 H Me H 1.4 246 100 ND 
264322 A182 H Et H 0.38 67 100 ND 
264323 A183 H iPr H 0.33 58 100 ND 
264324 A184 H cPr H 0.15 26 100 ND 
264325 A185 H CF3 H 0.12 21 100 ND 
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264326 A186 H OCF3 H 0.29 51 100 ND 
264605 A187 H CCH H 0.29 47 85 ND 
264604 A188 H CN H 1.1 177 100 ND 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells unless otherwise 
noted. bThermodynamic solubility analysis was performed by Analiza Inc. using quantitative nitrogen 
detection. (www.analiza.com). 
We docked many of these 3-substituated analogs into the CCG-257081 co-crystal 
structure to determine how these more potent analog might be engaging with pirin (CCG-
264059 shown as example in Figure 50). Interestingly, the docking results for CCG-264059 
suggest that the 3-Cl substituent actually doesn’t project deeper into the hydrophobic pocket, 
rather it positions the aromatic ring so that the 3-Cl group is butting up against the wall of the 
hydrophobic pocket, potentially improving affinity thorugh hydrophobic interations with pirin. Of 
note, the docking model does not predict this alteration significantly affecting the interaction 
between the bis-amide core and HOH202/284. We hypothesized that if this docking model is 
accurate, we might be able to engage deeper into the pocket occuped by HOH138 and HOH70 
by adding a hydrophobic or hydrophilic substituent to the 5-position of the aniline ring. 
Therefore, we refocused our efforts to producing 3, 5-disubstitued analogs to attempt to further 




Figure 50: CCG-264059 docked into the CCG-257081 co-crystal structure 
Green shading indicates hydrophobic regions and pink shading indicates hydrophilic regions. 
 Many 3,5-disubsituted analogs had improved activity compared to CCG-222740 control 
(Table 19); however, none of the analogs achieved better activity than the 3-substituted analogs 
discussed above (Table 18). Still, there were observable SAR trends for this set of analogs. 
A189 was equipotent to CCG-222740, yet the bulkier Br substituted analog A190 was almost 
10-fold less potent. Also, unlike the 3-substituted analogs, 5-alkyl or alkoxy (A191 & A192) and 
5-fluoro alkyl (A193-A195) substitution maintained or improved activity compared to 222740, 
indicating that perhaps large hydrophobic substituents can fill the pocket to improve affinity. 
Moreover, while hydroxyl analogs A196 & A197 do not appear capable of engaging with the 
waters within the hydrophobic pocket, nitrile A198 may be able to do so. Sadly, none of the 
mono- or di-substituted analogs (Table 18 and 19) produced activity comparable to CCT251236; 
nevertheless, the improvements in activity based on this structure-guided design provide 
additional evidence for pirin being a target that drives the SRE.L activity of the 222740 series.  
CCG-264059
SRE L. IC50 = 0.08 uM
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Table 19: 3,5-disubstituted SAR 
 









264059 - H 0.08 40 100 
265067 A189 Cl 1.4 100 100 
265068 A190 Br 10 757 75 
265069 A191 Me 0.9 67 100 
265070 A192 OMe 1.6 123 100 
265172 A193 F 0.4 31 95 
265173 A194 CF3 0.5 39 100 
265174 A195 OCF3 0.6 42 100 
265071 A196 OH 3.2 242 100 
265072 A197 CH2OH 4.8 362 100 
265171 A198 CN 0.5 39 85 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells unless otherwise 
noted. 
 In an attempt to understand how solubilizing groups would affect SRE.L activity for 
264059 & A179, we attempted to attach a pyrrolidine solubilizing group to the scaffold at a 
location that wouldn’t affect pirin binding (Table 20). We selected the 3-position of the 
benzamide (R1) based on previous SAR trends. While a pyrrolidine solubilizing group reduced 
SRE.L activity ten-fold for A199 and A200 compared to 222740, the solubilizing group was 
better tolerated with the A179 scaffold (A201 and A202) to maintain equipotency to 222740. 
While this is about a 5-fold loss in activity compared to A179 itself, this result suggests attaching 
a solubilizing group to this scaffold may be an amenable way to improve PK properties for the 
series.  
Table 20: SRE.L activity for 264059 and A179 derived analogs with solubilizing groups 
 












Cl H 7.4 1299 90 
264466 A200 
 
Cl H 6.1 1070 85 
264468 A201 
 
Cl Cl 0.63 111 85 
264469 A202 
 
Cl Cl 0.98 172 95 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells unless otherwise 
noted. 
 Next, analogs were designed in an attempt to eliminate the structural alert associated 
with the aniline functional group (upon hydrolysis, anilines can lead to renal toxicity through 
various mechanisms262-266) (Table 21). Inserting nitrogen into an aniline ring is known to 
significantly mitigate toxic effects by reducing binding affinity to CYP1A2 and stabilizing the 
reactive nitrenium ion that forms after metabolic activation.266-269 We thought if these analogs 
maintained SRE.L activity, this design could provide a more suitable candidate for future clinical 
studies. 
Unfortunately, again, the analogs in this subset generally maintained or lost activity 
compared to 222740. Benzylic analogs A203 & A204 and pyrazolo analog A205 were designed 
to probe how deep substituents could penetrate pirin’s hydrophobic pocket and to remove the 
potentially cytotoxic aniline altogether, but they were not tolerated. Swapping the 3-Cl aniline 
ring with 3-Cl pyridyl rings were generally not tolerated either (A206-A208); A209 was the 
exception, having SRE.L activity comparable to 264059. We docked this subset of analogs into 
CCG-257081 co-crystal structure to attempt to explain these SAR trends (not shown); however, 
no obvious differences in binding modes explained these results. 
Table 21: Alternative 3-Cl substituted heterocycle SAR 
 











0.08 40 100 
264058 A203 
 
2.2 1,100 100 
264642 A204 
 
3.9 629 100 
264641 A205 
 
15 2,419 95 
264606 A206 
 
0.99 157 95 
264607 A207 
 
2.1 339 100 
264608 A208 
 
2.8 419 100 
264609 A209 
 
0.37 60 100 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells unless otherwise 
noted. 
 As a follow-up to a previous result from an analog Kim Hutchings made (A210), I 
synthesized analogs that implemented the 3-Cl & 3,4-diCl aniline with 2-F substitution instead of 
3-F substitution on the aryl ring on the left side of the bis-amide core (Table 22); bromo aryl 
intermediates from this batch of analogs were tested as well. We were happy to see that the 
majority of the analogs in this batch maintained activity comparable to 264059 & A179, helping 
validate that 3-Cl & 3,4-Cl substitution is preferred as long as small structural changes are made 
to the left-handed aryl ring. 
Table 22: 2-fluoro, 5-pyridyl substituted bis-amide SAR 
 









257622 A210 4-Pyr H Cl 0.59 369 100 
264464 A211 Br Cl H 0.86 151 95 
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264470 A212 4-Pyr Cl H 0.1 18 90 
264467 A213 Br Cl Cl 0.13 23 100 
264471 A214 4-Pyr Cl Cl 0.14 25 100 
aInhibition of Gα12-stimulated SRE.L (mean of n = 3, SEM < 10%) in HEK293T cells unless otherwise 
noted. 
The final SAR trend discussed in this subsection is an investigation of alternative 
piperidine ring systems. Early in the investigations for the series, A144 (Figure 46) had an 
almost ten-fold improvement in activity compared to 222740 just from adding unsaturation to the 
piperidine ring. Considering how the flatness of the aromatic central bis-amide core of 
CCT251236 might affect its affinity for pirin (discussed above), we designed analogs that would 
modulate the orientation of the bis-amide core and provide us with novel IP. Interestingly, the 3-
Cl aniline substituent that was beneficial for the fully saturated piperidine analog 264059 was 
not advantageous for A215’s activity (Figure 51), which also implies an ability to adopt a 
different binding mode. Furthermore, adding a methyl α to the amide attached to the aniline 
(A216) supported the hypothesis that a flatter core is preferred since this methyl group makes 
the piperdine core bulkier and A216 was 6-fold less potent than 222740. Internal amide A217 
also supports the “flat-core” hypothesis, having a ~7-fold improvement in SRE.L activity 
compared to 222740. Unfortunately, 3-Cl aniline internal amide analog A218 did not inhibit 
SRE.L activity at the same level as A217, but this result can be easily rationalized since A218 
may adopt a completely different conformation within pirin that doesn’t accommodate the 3-Cl 
aniline as well.  
Of note, these internal amide analogs were originally designed to attempt to engage with 
the water-mediated iron core of pirin in a different way than 222740. And while the docking 
model suggests the internal amide doesn’t interact with the water molecules bound to the Fe 
core (Figure 52), the SRE.L activity does suggest this analog is capable of modulating pirin 
more effectively than most other analogs in the 222740-series. The Neubig lab attempted to 
obtain a co-crystal structure with A217 to better understand this improvement in activity; but, 
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even though crystals were produced, A217 did not co-crystalize with pirin during the soak. The 
Neubig lab is currently attempting alternative crystallization techniques to obtain a co-crystal 
structure with this novel analog.   
 
Figure 51: Alternative piperidine ring system SAR 
 
Figure 52: Docking models for A217/A218 analogs 
Docking models for A217/A218 analogs (PR-VC-30 and 31) do not indicate the internal amide carbonyl 
group can interact with the water molecules ligated to the Fe core. 
 
Synthesis of CCG-257081-derived SBDD Analogs: 
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 Since I was previously able to use propargyl functional groups as a protecting group, I 
knew this would be an amenable strategy to produce analog 263482 (Scheme 39). Therefore, 
using intermediate 75b’, 105 was formed from HATU-mediated amide coupling conditions. This 
intermediate was subjected to acid-mediated hydrolysis to free up the amine that was 
subsequently coupled to 3-fluoro-5-(pyridin-4-yl)benzoic acid in HATU-mediated amide coupling 
conditions to produce 258723. Using Pd-mediated reduction conditions, the propargyl 
functionality was removed, producing phenolic analog 263482.  
 
Scheme 39: Synthesis of 263482 
(i) 75b’, HATU, DIPEA, DMF, 25 °C, 16 hr (ii) HCl in dioxanes, 25 °C, 2 hr (iii) 3-fluoro-5-(pyridin-4-
yl)benzoic acid, HATU, NMM, DMF, 25 °C, 16 hr (iv) Pd(PPh3)2Cl2, Et3N, DMF, H2O, 85 °C, 1 hr. 
 Methyl alcohol analog 263741 was generated from (5-amino-2-chlorophenyl)methanol 
(106, Scheme 40), which was synthesized as previously described.270 106 was easily converted 
to carbamate intermediate 107 by TBDPS protection followed by HATU-mediated amide 
coupling with the subsequent aniline and 33. Bis-amide intermediate 108 was produced after 
another round of deprotection/amide coupling. This intermediate was subjected to TBAF to 




Scheme 40: Synthesis of 263741 
(i) TBDPSCl, ImH, DMF, 0 °C to 25 °C, 24 hr (ii) 33, HATU, NMM, DMF, 25 °C, 16 hr (iii) 4M HCl in 
dioxanes, 25 °C, 2 hr (iv) 3-fluoro-5-(pyridin-4-yl)benzoic acid, HATU, NMM, DMF, 25 °C, 16 hr (v) 1M 
TBAF in THF, 25 °C, 1 hr. 
 Most of the 257081-derived bis-amide analogs were produced using either Route 1 or 2 
depicted in Scheme 41. Analogs were either generated from the common carboxylic acid 
intermediate 109 or they were derivatized at the beginning of the synthesis from 33, and 
subsequently added to the pyridyl-containing benzoic acid. Generally, Route 1 was attempted 
first, but many of the anilines were very weak nucleophiles, and, to preserve 109, the chemistry 




Scheme 41: General routes to synthesis 257081-derived bis-amide analogs 
(i) HATU, NMM, DMF, 25 °C, 16 hr (ii) 1M NaOH, THF, 25 °C, 1 hr then HCl workup (iii) aniline or aryl 
amine, HATU, NMM, DMF, 25 °C, 16 hr (iv) aniline or aryl amine, HATU, NMM, DMF, 85 °C, 16 hr (v) 3-
chloro-5-fluoroaniline, EDC•HCl, DMAP, DIPEA, DMF, 85 °C, 16 hr (vi) 4M HCl in dioxanes, 25 °C, 2 hr 
(vii) 3-fluoro-5-(pyridin-4-yl)benzoic acid, HATU, DIPEA, 25 °C, 16 hr. 
 Similar to Schemes 36 and 37, pyrrolidine analogs 264465-264468 were produced from 
benzoic acid intermediate 99 or 113 (Scheme 42). The final amide coupling was accomplished 
using either HCl amine salt 114 or 115. 
 
Scheme 42: Synthesis of 264465, 264466, 264468, and 264469 
(i) 1-(3-chloropropyl)pyrrolidine, K2CO3, DMF, 100 °C, 6 hr (ii) 1M NaOH, THF 25 °C, 2 hr followed by HCl 
workup (iii) 114 or 115, HATU, DIPEA, DMF, 25 °C, 16 hr 
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 Pyridyl analogs 264470 and 264471 were assembled with late stage Suzuki-cross 
coupling chemistry from 264464 and 264467 using 4-pyridyl boronic acid and Tetrakis (Scheme 
43). 
 
Scheme 43: Synthesis of 264470 and 264471 
 Using chemistry similar to Scheme 27, α,β-unsaturated carboxylic acid intermediate 116 
was generated from 78 and the acyl chloride generated from 3-fluoro-5-(pyridin-4-yl)benzoic 
acid (Scheme 44). Simple HATU-mediated amide coupling afforded analog 264643. 
 
Scheme 44: Synthesis of 264643 
(i) (COCl)2 DMF (cat.), DCM, 0 °C to 25 °C, 1 hr (ii) 78, Et3N, DCM, 25 °C, 16 hr (iii) 3-chloroaniline, 
HATU, NMM, DMF, 25 °C, 16 hr. 
 α-methyl carboxylic acid intermediate 117 was produced using methyl ester piperidine 
34 (Scheme 45). Strong base easily removed the proton α to the ester, and this anion was 
quenched with MeI, producing the desired intermediate that was hydrolyzed to intermediate 
117. 
 
Scheme 45: Synthesis of 117 
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 Intermediate 119 was synthesized adapting previously described chemistry (Scheme 
46).271 This chemistry consisted of alkylation of piperidin-2-one using 3-bromobenzyl bromide 
followed by benzylcarboxylation α to the amide using LiHMDS and benzyl chloroformate. 
Suzuki-cross coupling using furan-2-yl boronic acid and Tetrakis not only installed the furan 
functionality, but it also reduced the benzyl group, freeing up the carboxylic acid. Carboxylic acid 
intermediate 120 was then subjected to HATU-mediated amide coupling with either 3- or 4-
chloroaniline. 
 
Scheme 46: Synthesis of 264644 and 264645 
(i) NaH, THF, 0 °C, 2 hr then 25 °C, 4 hr (ii) LiHMDS, THF, -78 °C, 1 hr (iii) furan-2-yl boronic acid, 
Pd(PPh3)4, Na2CO3, DME, H2O, 100 °C, 16 hr (iv) 3- or 4-chloroaniline, HATU, DIPEA, DMF, 25 °C, 16 hr. 
 While there was no precedent to synthesize α,β-unsaturated methyl esters similar to 
123, amide coupling using amine 122 and acyl chloride 121 in triethylamine was attempted 
(Scheme 47). Unfortunately, this reaction produced multiple products, and none of the products 
isolated resembled 123. This result using these simple amide-coupling conditions caused us to 
give up on an analog with this type of piperidine core. 
 
Scheme 47: Attempt to produce alternative piperidine core 123 
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 I also tried to synthesize analogs that removed the external amide functionality (Scheme 
48). We assumed we could (1) improve PK properties of the series by removing this amide, 
which is susceptible to hydrolysis in biological conditions, and (2) potentially improve the fit into 
pirin’s hydrophobic pocket by installing an indazole functionality. While I was eventually able to 
generate mesyl intermediate 125 via selective reduction of the carboxylic acid 33 with BH3•THF 
followed by treatment with mesyl chloride and triethylamine, I struggled to synthesize the 
desired carbamate intermediate 126a,b using 4-chloro-1H-indazole. I eventually worked out 
chemistry to obtain both 126a,b, but I only produced 9 mg each product, and I couldn’t 
distinguish either analog by NMR. Since these analogs were high risk anyways, we abandoned 
attempting to generate analogs with this scaffold. 
 
Scheme 48: Attempts to produce indazole intermediate 126a,b 
 Another interesting analog design that I could not work the chemistry out for was the 
removal of the amide and the implementation of an indolinone in place of the aniline (Scheme 
49); this analog was designed with the same rationale as for the indazole just described. Even 
though I was able to generate a late stage mesyl intermediate (128) by selectively reducing the 
carboxylic acid of 109 followed by mesylation with mesyl chloride and triethylamine, I did not 





Scheme 49: Attempts to produce an indoline-containing analog 
 
Virtual Screen with CCG-222740 Scaffold: 
 In a final effort to remove the potentially toxic 4-chloroaniline group, we performed a 
virtual screen using the co-crystal structure with pirin and CCG-257081. To design non-aniline 
analogs of CCG-257081, Pil Lee performed a virtual screening of a combi-library created 
computationally in MOE. This virtual screening library was developed using the CCG-257081-
scaffolding shown in Table 23 paired with Sigma Aldrich’s amine library of 9997 amines. In 
MOE, keeping the pirin structure static, a virtual combi-library of 6710 bis-amide analogs that 
incorporated commercially available amines was generated. This set of compounds was further 
parsed to 301 non-aniline derivatives by only keeping analogs with molecular weight less than 
550 g/mol. 122 compounds were selected from this set based on the novelty, removing analogs 
with pendants with predictable metabolic liability or cytotoxicity. Subsequently, these virtual 
analogs were subjected to flexible docking with an induced fit using the co-crystal structure for 
CCG-257081. Finally, several compounds were selected for synthesis based on docking score, 
docking pose with additional interactions within pirin, and synthetic feasibility.  
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As an example, the docking result for 265188 (A220) is shown in Figure 53. This analog 
was able to maintain similar interactions with the ligated water molecules as CCG-257081, but 
the docking results suggest the aromatic pendant can fit much deeper into pirin’s hydrophobic 
pocket. From this virtual screen, 13 analogs were produced (Table 23). These analogs remain 
to be tested in the SRE.L assay. 
 
Figure 53: Docking for 265188 
The best docking pose for 265188—an analog generated in a virtual screen using the CCG-257081 
scaffold. 
Table 23: Virtual screen analogs 
 













































Synthesis of Virtual Screen Analogs: 
 The virtual screen analogs were easily synthesized with HATU-mediated amide 
couplings of intermediate 37’ and the various primary amines ordered from Sigma Aldrich 
(Scheme 50). 
 





 Using pirin co-crystal structures with CCT251236, CCG-222740, and CCG-257081, we 
designed 222740-series analogs with modified aryl pendants that we hoped would engage more 
deeply into pirin’s hydrophobic pocket as well as analogs with alternative central bis-amide 
cores that we hoped would interact with the waters ligated to the Fe core of pirin in a similar 
manner as CCT251236. Through these efforts, the SRE.L activity for the 222740-series 
improved by about 10-fold, and certain designs removed structural alerts while retaining this 
improvement in activity. Notably, certain efficacious analogs like A217 may provide novel 
scaffolding, with an internal bis-amide core, that can lead to analogs with an improved PK 
profile. Also, the improvement in activity for pyridyl analog A209 provides confidence that the 
aniline structural alert can be removed by insertion of a nitrogen into the 4-Cl aryl ring.  
Furthermore, if a direct binding assay for pirin is established, the analogs developed 
during this project may provide a launching pad to produce more potent pirin inhibitors from the 
222740-series. While the SRE.L activities may not suggest significant improvements in affinity 
for pirin, a binding assay would confirm or disprove this result, which would ultimately help any 
future drug design for this series since it would confirm if the design or PK/PD an issue. Also, 
since this series already has such exciting biological activity, many of the new analogs reported 
here should be tested for any improvement in PK properties. Regardless if the SRE.L activity of 
the series can be improved further with the 222740-series scaffold, many of the reported 
analogs have a chance to have an improve in vivo PK profile, which could lead to a significant 




Chapter 5: Future Directions 
Overview: 
 Many goals have been accomplished since the outset of this project: (1) chemical 
probes capable of pulling down protein candidates were designed and synthesized, leading to 
the identification of potential targets for both the 58150- and 222740-series of Rho/MRTF/SRF-
mediated gene transcription inhibitors (Chapter 2) (2) hit-to-lead development of extremely 
potent 58150-series analogs produced inhibitors capable of significantly and dose-dependently 
preventing fibrosis in a murine model of bleomycin-induced fibrosis (Chapter 3) and (3) SAR 
exploration of the 222740-series provides an introduction to key pharmacophores necessary for 
engagement to pirin (Chapter 4). 
 Despite these advancements, several critical questions remain unanswered. For 
instance, while a potential list of candidate proteins for the 58150-series was generated using 
the immobilized pull-down probes, target validation efforts have been unsuccessful. Also, while 
target validation efforts for the 222740-series make it clear that pirin is a target for the series, it 
is still not clear whether the series works through other biological targets to afford its activity. 
Potential options to circumvent these issues are discussed in the next few sections. 
 Additionally, while much of the SAR was well-defined for the 58150-series, there are a 
few trends that should be followed-up. There are also several gaps in the SBDD SAR for the 
222740-series that, if explored further, could lead to inhibitors with better affinity for pirin. 
Suggestions for follow-up analogs for both series are discussed in the sections below. 
58150-Series Target Identification using Click Probes: 
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 The most critical question that remains unanswered for the 58150-series is: does the 
oxadiazole core react covalently with the biological target that affords activity? While the SAR 
discussed in Chapter 2 clearly supports this hypothesis, there is no direct evidence for it. The 
ideal way to determine if the series acts covalently is to identify the target for the series. Another 
route to identify the biological target of the 58150-series is to use the previously developed 
propargyl Click probes A88 and A91 instead of the immobilized affinity probes (Figure 54). The 
major advantage of the propargyl probes is they can be incubated with whole cells instead of 
cell lysates. Additionally, this methodology would ensure the potential intracellular activation of 
the oxadiazole core could take place prior to target engagement. Since it is unknown whether 
the biological target for the series is stable to lysate conditions or whether the core needs to be 
activated for covalent reactivity, this route could provide a better way assure the probes are 
interacting with the biological target(s) in a similar manner as they are in the SRE.L assay.  
Additionally, the SRE.L activity ascertained from the propargyl Click probes is more 
definitive than that for the immobilized affinity resin probes. Since we only inferred the SRE.L 
activity of the immobilized affinity probes from ethoxymethoxy mimics, we cannot be certain 
whether the “active” probe used for the pulldown inhibits SRE.L activity, and, therefore, interacts 
with the biological target. Moreover, there is a 250,000-fold difference in activity between the 
structurally similar “active” (A88) and “inactive” (A91) propargyl probes, which should further 




Figure 54: Alternative target identification route for the 58150-series using propargyl Click probes 
instead of immobilized agarose resin probes 
The Martin and Neubig labs are currently performing pulldown experiments with these 
propargyl Click probes to generate a new list of candidate targets. However, if the list of 
candidate targets generated from the pulldown experiments using the propargyl probes does 
not contain biological targets that can be validated, stable isotope labeling by amino acids in cell 
culture (SILAC) enrichment experiments may further improve the pulldown experiment. SILAC 
would be a helpful technique to use if the biological target for the 58150-series is in low cellular 
abundance.181 The technique utilizes the mass difference between “heavy” 12C or 15N 
isotopically enriched cells and “light” normal cells to improve the accuracy of the proteomic 
analysis; the difference in mass of the amino acid fragments from these cells can be compared 
to determine whether amino acid fragments for a particular protein are real or artifactual.181 
222740-Series Target Identification using Photo-Labeled Click Probes: 
 As discussed in Chapter 3, we have strong evidence that pirin is a biological target for 
the 222740-series; however, we are less certain whether the series works through other 
biological targets to afford the observed biological activity. Since we are not sure if the series 
interacts strongly with another potential biological target, a diazirine photoprobe could be used 
to increase the likelihood that the biological target of interest will be pulled down (Figure 55). 
This methodology is particularly useful when (1) affinity to the molecular target or (2) the cellular 
abundance of the target is low.173,188 Moreover, as discussed in the previous subsection, 
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propargyl Click probes could be included in the 222740-series probe design to help ensure the 
probe interacts with any biological targets that are potentially unstable to lysate conditions.  
Since I have already designed synthetic routes to incorporate the propargyl handle into 
the 222740-scaffold (Chapter 2), the new design would require installation of the diazirine 
functionality. As I also mentioned in Chapter 2, many routes to produce diazirine-containing 
probes are reported in the literature. Additionally, since the SAR developed for the PEG-mimic 
analogs (Chapter 2) suggests attachment of large aliphatic substituents is tolerated at various 
locations on the scaffold, I would assume attaching the propargyl functionality to multiple 
positions on the aryl functionalities would maintain SRE.L activity. Nevertheless, a suggested 
photo-Click probe is shown in Figure 55. Since alternative substitution of the 4-Cl aniline ring 
tends to affect SRE.L activity more than alterations made on the other aryl pendant, the 4-Cl 
aniline pendant seems more important for activity, and, therefore, I would install the diazirine 
functionality to the 4-position of the aniline ring. Since the propargyl handle should be partially 
exposed so it can react with azide during the Click reaction, the placement of the propargyl 
handle to the 3-aryl position of the 5-furyl substituted aryl pendant. Of note, difluoro-substitution 
does not significantly affect SRE.L activity (it mainly improves metabolic stability), so this 
functionality can be eliminated from the probe design. All considered, this probe design route 
might be an amenable option to determine whether other biologically relevant targets for the 
222740-series. 
 
Figure 55: Alternative target identification route for the 222740-series using propargyl Click 




58150-Series SAR Gaps: 
 Certain gaps in the SAR for the 58150-series were mentioned in Chapter 3. First, the 
approximate 100-fold increase in activity observed for tetrazole (A24) (Figure 56) should be 
followed-up by directly comparing 58150 and A24’s ability to inhibit LPA-stimulated CTGF gene 
expression as described in Chapter 3. This analog was synthesized a while ago, and the 
preliminary n = 1 data suggested the tetrazole reduced SRE.L activity. However, recently, the n 
= 3 data revealed that the tetrazole significantly improves SRE.L activity. This is the only 
carboxylic acid isostere that has better activity than the carboxylic acid functionality, and, since 
carboxylic acids are notorious for poor in vivo PK, the tetrazole could potentially be used to 
improve the in vivo PK profile of the series. Yet, prior to making additional tetrazole-containing 
analogs, the potent activity of tetrazole A24 should followed up by testing it in the LPA-
stimulated CTGF qPCR assay. If this analog is of equal or greater potency than 232964 in this 
qPCR assay, then it would be important to follow-up this result with in vivo PK analysis, as 
additional analogs containing the tetrazole could lead to novel intellectual property. 
Considering the totality of the SAR obtained for the 58150-series discussed in Chapters 
2 and 3, proposed tetrazole-containing analogs that might maintain pM potency and improve the 
in vivo PK profile of the series are shown in Figure 56. Analogs containing either 4-Cl or 4-cPr 
should be combined with analogs containing either the ethyl, propyl or cyclobutyl as the chain 
(127-129). Since there was significant variation between the activity and in vivo PK profile for 
carboxylic acid homologs, it is important that these follow-up analogs have multiple chain 
lengths and types. I would expect proposed analog 128 will afford the best activity profile; 
however, it is difficult to predict whether the unknown biological target can accommodate the 3-




Figure 56: Proposed follow-up analogs replacing carboxylic acid with tetrazole isostere 
 The other gap in the SAR that should be followed-up is the surprising result for phenol 
analog A95. The 2-OH substitution was the only other functionality in the 2-position that 
maintained or improved upon the activity of 2-Cl substitution. Analogs A96 and A51 (Table 8, 
Chapter 3)—derivatives containing 3- and 4-OH—should be tested before follow-up analogs are 
made, but some proposed analogs are shown in Figure 57. It would be interesting to see if pM 
potent activity comparable to 232964 would be maintained with 2-OH,4-cPr substitution. If it was 
maintained, then an analog with the cyclobutyl chain with this substitution pattern should be 




Figure 57: Proposed follow-up analogs investigating the effects of incorporating 2-OH into the 
58150-series scaffold 
 
222740-Series SBDD Follow-up Analogs: 
Even though the 222740-series SBDD efforts did not produce analogs with comparable 
activity to CCT251236, many promising SAR trends were uncovered. First, it appears that 
activity can be improved by incorporating small, hydrophobic substituents in the aniline aryl 
functionality. This result is promising for future design in that once an optimum bis-amide core is 
discovered, the activity and PK profile of the series could be fine-tuned by incorporating such 
small substituents. Furthermore, as mentioned in Chapter 4, since the 4-Cl aniline has a high 
liability for cytotoxicity, this could be eliminated by swapping out the Cl for a metabolically 
stable, small, hydrophobic substituent (e.g. cPr or CF3). 
 Second, progress towards finding a better bis-amide core system was made. For 
example, internal bis-amide A217 had a three-fold improvement in activity compared to 222740. 
This result suggests the piperidine core can be altered to potentially produce a core with better 
activity. As mentioned, an attempt was made to co-crystalize A217 with pirin, but the inhibitor 
did not soak into the crystals. If a co-crystal structure containing A217 was obtained, it may 
reveal an alternative mode of binding that can be utilized to produce improved analogs. Since 
we don’t have a co-crystal structure, it is difficult to propose additional analogs following-up on 
the internal bis-amide core result, but, based on docking and the SAR for the series (Figure 53), 
incorporating small, hydrophobic substituents into the aryl aniline would be a good place to start 
(Figure 58). Additionally, if A217 adopts a flipped binding mode compared to CCG-222740, 
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analogs with alternative aryl groups in the 3-position of the aryl ring on the left side of the bis-
amide core could produce analogs with higher affinity for pirin. (Figure 58). 
 
Figure 58: Proposed follow-up analogs that explore substituents surrounding the aryl 
functionalities flanking the internal bis-amide core of 264644 
 The last result that could be followed-up on depends on how potent the virtual screen 
analogs discussed in Chapter 4 are compared to 222740. If the docking model is any indication, 
these analogs could bind significantly better to pirin than 222740. Analogs from this batch that 
have significantly better activity than 222740 could be co-crystallized with pirin or at least 
followed up on with SAR to confirm/modify the docking pose. Depending how the analogs bind, 
these co-crystal structures can be used to design additional analogs. 
Conclusion: 
 Throughout this project, significant advances towards the development of both the 
58150- and 222740-series of Rho/MRTF/SRF-mediated gene transcription inhibitors as anti-
fibrotic agents were made. The single greatest accomplishment achieved from this project is the 
development of the 58150-series to pM potent inhibitors capable of dose-dependently and 
significantly preventing fibrosis in mice with bleomycin-induced fibrosis. These exciting results 
justify additional research, such as (1) identifying the biological target (2) determining if the 
series proceeds through a covalent mechanism of action, which could lead to the application of 
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a novel irreversible moiety for drug discovery in general and (3) developing pM potent inhibitors 
with an improved PK profile.  
Another noteworthy accomplishment achieved during this project is the development of 
an immobilized affinity probe capable of pulling down a biological target for the 222740-series. 
While pirin may not be the only target that affords the series’ phenotypic activity, there is strong 
circumstantial evidence that pirin is a molecular target for the series (e.g. co-crystal structures 
with 222740-series analogs, siRNA pirin knocked down fibrotic gene expression, etc.). 
Therefore, in any subsequent pre-clinical studies with the 222740-series, inhibition of pirin 
should be considered as a mechanism of action that affords therapeutic efficacy for the series.  
In all, this research represents a significant advance to introducing novel anti-fibrotic 
agents to the drug development landscape. This research has helped launch FibrosIX, and 






SRE.L Luciferase Assay: 
For luciferase assays using PC3 cells, 20,000 cells/well were plated in a 96- well plate in 10% 
FBS+DMEM.  The next day, cells were transfected with 56 ng of SRE.L Luciferase reporter and 
2 ng/well of either Gα12 Q231L or pcDNA using Lipofectamine 2000 (Life Technologies) and 
Opti-MEM (Gibco).  After 4 h of transfection, media was changed to 0.5% FBS+DMEM and cells 
were treated with compounds or DMSO control overnight. The next day, viability was measured 
using WST-1 (Roche) and absorbance was read at 450 nm. After viability was measured, cells 
were lysed, and luciferase was measured using the Luciferase Assay System (Promega). 
For luciferase assays in 293T cells, see Hutchings et al.168 
58150-Series Target ID Agarose Pulldown Materials and Methods: 
NHS-agarose linking  
10 mM solutions of ‘active’ compound (CCG-257308 (A52)) and ‘inactive’ compound (CCG-
257644 (A53)) were made in 100% DMSO and diluted to 600 µM in PBS.  80 mg of dry NHS-
activated agarose (Thermo-Fisher Cat# 26197) was mixed with 2 mL of either active or inactive 
compound and PBS solution and rotated for 2 hours at room temperature.  Beads were washed 
twice with PBS and the remaining NHS sites were blocked with 1 mL of 1 M ethanolamine.  
Beads were washed again with PBS and resuspended in 2 mL of PBS + 0.05% Na Azide.   
Cell lysate preparation 
HEK293T cells were passaged in DMEM (Gibco, cat#11995065) containing 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin (Gibco) at 37 °C in 5% CO2.  Cells were grown in 
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15 cm plates and lysed in PBS with protease inhibitors (Roche, cat #11836145001) and 
sonicated.  The lysates were spun at 20,000 rpm for 45 mins at 4 °C and the supernatant was 
snap frozen with liquid nitrogen and stored at -80 °C. 
Agarose bead pulldown  
Supernatants were separated into two groups, each approximately 2 mg/mL total protein 
concentration. One group of cell lysate received 10 µM CCG-58150, and the other received 
DMSO control for 30 minutes on ice.  Technical duplicates were incubated on ice for 30’ and 
then 750 µL of each sample was applied to a spin column (Pierce, cat #69705) loaded with 
prepared active (A52) or inactive (A53) agarose resin. Lysates and beads were incubated at 
room temperature with rotation for 1 hour, and immediately washed 3 times with 1 mL chilled 
PBS. Beads were collected and snap frozen and sent on dry ice for liquid chromatography-mass 
spectrometry proteomics analysis. 
222740-Series Target ID Agarose Pulldown Materials and Methods: 
NHS-agarose linking 
A 10 mM solution of CCG-262545 (A62) was made in 100% DMSO and diluted to 600 µM in 
PBS. 160 mg of dry NHS-activated agarose (Thermo-Fisher Cat# 26197) was mixed with 2 mL 
of compound and PBS solution and rotated for 2 hours at room temperature.  Beads were 
washed twice with PBS and the remaining NHS sites were blocked with 1 mL of 1 M 
ethanolamine. Beads were washed again with PBS and resuspended in 2 mL of PBS + 0.05% 
NaN3.   
Cell lysate preparation 
HEK293T cells were passaged in DMEM (Gibco, cat#11995065) containing 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin (Gibco) at 37 °C in 5% CO2.  Cells were grown in 
15 cm plates and lysed in PBS with protease inhibitors (Roche, cat #11836145001) and 
sonicated.  The lysates were spun at 20,000 rpm for 45 mins at 4 °C and the supernatant was 
snap frozen with liquid nitrogen and stored at -80 °C. 
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Agarose bead pulldown  
Supernatants were separated into two groups, each approximately 1 mg/mL total protein 
concentration.  One group received 30 µM CCG-222740, and the other received DMSO control.  
Technical duplicates were incubated on ice for 30 mins and then 750 µL of each sample was 
applied to a spin column (Pierce, cat #69705) loaded with prepared agarose resin. Lysates and 
beads were incubated at room temperature with rotation for 1 hour, and immediately washed 3 
times with 1 mL chilled PBS.  Beads were collected and snap frozen and sent on dry ice for 
liquid chromatography-mass spectrometry proteomics analysis. 
Mass Spectrometry and Proteomic Materials and Methods: 
Mass spectrometry  
Proteomics Sample Preparation. Reagents were obtained from Fisher unless otherwise noted. 
On-bead digests were performed by resuspending each sample in 200 µL of phosphate-
buffered saline (PBS) containing 6M urea. To each sample, dithiothreitol (DTT) was added to a 
final concentration of 5 mM and allowed to sit at room temperature for 30 minutes. 
Iodoacetamide (Sigma) was then added to a final concentration of 30 mM and incubated in the 
dark at room temperature for 30 minutes. Samples were diluted to a final concentration of 1.2 M 
urea and digested overnight with Trypsin-LysC mix (Promega). Following digestion, samples 
were centrifuged at 1000 rpm for 1 minute (Eppendorf Centrifuge 5424) and the supernatant 
was collected. To remove any remaining beads, supernatants were filtered through 
polypropylene Micro Bio-Spin Columns (BioRad) by centrifugation at 5000 rpm with two 200 µL 
washes with PBS. These washes were combined and desalted with Waters Oasis HLB Prime 
µElution Plate according to the manufacturer’s protocol. Samples were then dried on a Savant 
SPD1010 SpeedVac Concentrator. 
Liquid chromatography-mass spectrometry  
Desalted, dried peptides were resuspended in LC-MS grade water with 3% acetonitrile and 
0.1% formic acid. Three LC-MS injections (technical replicates) were made for each biological 
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replicate. LC-MS analysis was performed using a Waters nanoAcquity UPLC system fitted with 
a 5 μm Symmetry C18 trap column (180 μm x 20 mm) and a 1.8 μm HSS T3 analytical column 
(75 μm x 250 mm). Tryptic peptides were loaded onto the trap column for a 10 minute wash, 
followed by analytical separation over a 110 minute gradient (3% acetonitrile to 40% acetonitrile 
over 92 minutes) at a flow rate of 0.5 μL / min. Eluting peptides were introduced into the Synapt-
G2S HDMS traveling wave ion mobility quadrupole time-of-flight mass spectrometer (Waters) by 
electrospray ionization using a pre-cut uncoated 10 μm ID SilicaTip nanospray emitter (New 
Objective). The Synapt-G2S auxiliary pump was used to deliver the lock mass compounds 
[Glu1]-Fibrinopeptide B (100 fmol / μL; Waters) at 400 nL / min through the reference sprayer of 
the nanoLockSpray source. The nanoESI source was set to 70°C with a 3 kV applied potential. 
Data-independent acquisition was performed in positive mode. The quadrupole mass analyzer 
was set to transmit all precursor ions (50-2000 m/z) through to the TOF mass analyzer. 
Precursor ions traveled through the quadrupole mass analyzer and were then separated in the 
traveling wave device using the manufacturer recommended constant wave height of 40 V and 
variable wave velocity of 1000-600 m/s. Low and elevated-energy scans were alternated every 
0.5 seconds (0.05 s interscan delay) to acquire sequential precursor and product ion data. 
Collision energy was applied after ion mobility separation in the transfer cell. In the low-energy 
mode, data were collected at constant collision energy (CE) of 4 eV across all 200 drift bins 
(TOF scans). In high-energy mode, collision energy ramping was applied as follows: 0 eV for 
bins 1-19; 16.4-58.5 eV for bins 20 – 119; and 58.9 – 63.9 eV for bins 120 – 200. Wave 
velocities in the trap and transfer cell were set to 311 m / s and 380 m / s, respectively, with 
wave heights of 4 V. In the trap cell, the N2 gas flow rate was 2.0 mL / min. In the ion mobility 
cell, the He2 and N2 flow rates were set to 180 and 90 mL / min, respectively. The mass 
spectrometer was operated in Resolution mode (V-mode), with a typical resolving power of at 
least 20,000 FWHM. Data were mass corrected post-acquisition by comparison to the doubly-
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charged monoisotopic peak of [Glu1]-Fibrinopeptide B (m/z = 785.843), which was sampled 
every 30 seconds during acquisition.  
Proteomics data analysis  
Raw data were analyzed with ProteinLynx Global SERVER version 3.0.2 (PLGS, Waters 
Corporation), searching against the Uniprot database of the human proteome. The following 
criteria were applied to perform the search: (i) trypsin as digestion enzyme, (ii) one missed 
cleavage allowed, (iii) carbamidomethyl cysteine as a fixed modification and methionine 
oxidation as a variable modification, (iv) a minimum of two identified fragment ions per peptide 
and a minimum of five fragments per protein, and (v) at least two identified peptides per protein. 
The global protein false discovery rate (FDR) was set at 1% using a reversed sequence 
database. Any identified peptides with calculated mass error greater than 10 ppm were not 
considered. Protein abundance fold differences and p-values between active / blocked lysate 
were calculated based on label-free peptide abundances using only unique peptides. 
Gene Expression Analysis:  
Differential gene expression (based on fold change) was calculated for Pirin knockdown (GSE 
17551) and CCG-1423 treatment (GSE 30188). The top 100 downregulated genes were used to 
create gene signatures from the Pirin microarray dataset and the CCG-1423 microarray dataset.  
The C1-C6 and H gene set collections were dowloaded from MSigDB (accessed 09/2017).  The 
hypergeometric distribution between the CCG-1423 gene set and all other gene sets was 
calculated in R to identify statistically significant gene set overlaps.  The pirin target gene set 
has the most significant overlap with the CCG-1423 dataset. 
Protein Purification: 
Pirin protein purification protocol was adapted from 272.  Using site-directed mutagenesis, a stop 
codon was introduced in front of the streptavidin tag and confirmed by sequencing.  Pirin 
plasmid was transformed into BL21 DE3 One Shot cells (Novagen).  A single colony was grown 
in 50 mL LB with 100 ug/mL ampicillin overnight at 37 °C with shaking and transferred to 1 L LB 
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containing 100 µg/mL ampicillin the next day.  Cells were grown until the OD600 reached 0.5 
and then cells were induced with 0.7 mM IPTG for 5 hours at 37 °C.  Cells were lysed in 50 mL 
of 20 mM Tris-HCl pH 8.0, 150 mM NaCl with protease and phosphatase inhibitors (Roche) 
using sonication.  Lysates were spun down at 12,000 rpm for 40 mins at 4 °C and the 
supernatent was loaded onto a pre-equilibrated Ni2+ column (equilibrated with 50 mL of 20 mM 
Tris-HCl pH 8.0, 500 mM NaCl, 10 mM Imidazole).  The column was washed with equilibration 
buffer including 40 mM Imidazole and eluted with equilibration buffer with 150 mM Imidizaole.  
The elution was then further purified on a Superdex 200 Prep Grade column (GE) in 20 mM Tris 
pH 8.0, 150 mM NaCl and analyzed by SDS-PAGE.   
Isothermal Titration Calorimetry:  
Thermodynamic measurements were performed with a VP-ITC Microcalorimeter (MicroCal).  
Purified and concentrated pirin (100 µM) was loaded into the injection syringe in gel filtration 
buffer with addition of DMSO (0.1%).  The compounds were also dissolved in matched gel 
filtration buffer at 10 µM and loaded into the cell. Both protein and compounds were degassed 
for 5 minutes under vacuum.  The first injection of protein was 0.8 µL, all subsequent injections 
were 10 µL, duration 1.5 or 20 seconds, with spacing of 120 or 240 seconds and 29 injections 
total.  A DMSO control experiment was subtracted from each experiment, and data were 
analyzed by a one-site binding model in VP Viewer 200, using the plotting software ORIGIN 7 
(Origin Lab Corp). 
Protein Crystallization:  
Pirin was crystallized by concentrating to 56 mg/mL and setting up hanging drop trays in 24 well 
trays (Hampton Research). Hanging drops were set up with 1 µL of protein and 1 µL of reservoir 
solution (0.1 M Hepes, pH 7.5, 8% Ethylene Glycol, 20% PEG 8000)8 Crystals grew in less than 
1 week at 25 °C and then were soaked in 250 µM CCG-257081 or CCG-222740.  The 
diffraction data were collected at the Life Sciences Collaborative Access Team beamline 21-ID-
D and 21-ID-G at the Advanced Photon Source, Argonne National Laboratory. Data were 
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processed using the HKL2000 package, and iterative model building and refinement were 
carried out using Coot9 and Phenix10, to yield the final refined structures whose statistics are 
detailed in Supplemental Table II.  Structure figures were generated using UCSF Chimera. 
Cell Culture: 
Human primary dermal fibroblasts were grown in DMEM (Gibco) containing 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin (Gibco) at 37 °C in 5% CO2.  All fibroblasts were 
grown in 6-well (for siRNA studies) or 96-well plates (for compound studies). For compound 
studies, the cells were stimulated with TGF-β (10 ng/mL, R&D cat #240-B-002) and co-treated 
with compounds for 24 hours before lysis.  
siRNA-mediated gene silencing: 
ON-TARGET plus SMART pools were commercially synthesized by Dharmacon against human 
pirin (GE, cat # L-012613-00-0005) or non-targeting pool control (GE, cat# D-001810-10-05) 
and were used according to the manufacturer's recommendations. Briefly, normal primary 
dermal fibroblasts (2 x 105) were plated in 6-well culture plates with DMEM containing 10% FBS 
and 1% 100 units/mL antibiotics/antimycotics. The next day, 25 nmol/L siRNA smart pools were 
transfected using DharmaFECT 1 (GE, cat# T-2001-01) dissolved in Opti-MEM media. After 24 
hours of transfection, the media on the cells was changed to DMEM containing 10% FBS and 
1% 100 units/mL antibiotics/antimycotics and were kept for an additional 24 hours before 
changing the media to 0.5% FBS+DMEM and treating with the stimulus. 
RT-PCR: 
10,000 cells were plated in each well of a 96 well plate for 24 hours before changing the media 
to DMEM containing 0.5% FBS and concurrently adding TGFβ as well as compound or DMSO 
control. The cells were lysed in iScript RT-qPCR lysis buffer (Biorad, cat #170-8898), and the 
iTaq Universal SYBR Green One Step Kit was used (BioRad, cat #172-5151) following the 
manufacturer’s instructions. 1 uL of template lysate was added to the RT-qPCR master mix.  
Alternatively, RNA was isolated using the RNeasy Kit (Qiagen) following the manufacturer's 
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protocol. RNA (1 µg) was used as a template for synthesizing complementary DNA utilizing the 
High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). SYBR green qPCR 
(Thermo Fisher Scientific) was performed using a Stratagene Mx3000P (Agilent Technologies) 
and Ct values were analyzed relative to GAPDH expression. Primer sequences used were as 
follows: GAPDH: 5′-GAAGGTGAAGGTCGGAGTCA-3′, 3′-CTGGGGAAGTAACTGGAGTT-5′; 
CTGF: 5′-CAGAGTGGAGCGCCTGTT-3′, 3′-CTGCAGGAGGCGTTGTCA-5′; ACTA2: 5′-
AGCCCAGCCAAGCACTG-3′, -3′-GAGACATTCCGGCCGAAAC-5′ and PIRIN: 5′-
GTGGAGCCTCAGTACCAGGA-3′, 3′-AAATGTGAGCGTGTGGTTGG-5′  
Western blotting: 
Cells were lysed with RIPA buffer containing 10 mM Tris-HCl, 1 mM EDTA, 1% Triton X-100, 
0.1% SDS, 140 mM NaCl, protease inhibitor cocktail (Roche, cat# 11873580001). Cell lysates 
were sonicated for 10 min and centrifuged to pellet insoluble material. The supernatant was 
transferred to labeled Eppendorf tubes and protein concentrations were quantitated using a 
BCA protein assay (Pierce BCA Protein Assay, Thermo Scientific). Protein lysates (40 μg) were 
then run on 10% polyacrylamide gels and transferred to PVDF membranes and blocked in LI-
COR buffer for one hour. Membranes were incubated in 1:1000 diluted primary antibodies pirin 
(Thermo Fisher Scientific, cat # PA5-51441) and GAPDH (Santa Cruz, cat # SC-365062) 
overnight at 4 °C and were incubated in 1:5000 diluted secondary antibodies for one hour at 25 
°C the next day. Blots were visualized using a LI-COR Odyssey Fc and quantified using Image 
Studio software.  
GST-MRTF-A Actin Pulldown: 
GST-MRTFA 10-142 plasmid (in pGEX-4T-2 vector) was transformed into BL21 DE3 One Shot 
cells (Novagen).  A single colony was grown in 50 mL LB with 100 ug/mL ampicillin overnight at 
37 °C with shaking and transferred to 1 L LB containing 100 ug/mL ampicillin the next day.  
Cells were grown until the OD600 reached 0.5 and then cells were induced overnight at 25 °C.  
Cell pellets were resuspended in 50 mL of 50 mM Tris pH 8.0, 300 mM NaCl, 1% Triton-X, 1 
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mM DTT, 1 mM EDTA and protease inhibitors (Roche).  Pellets were sonicated, and lysate was 
centrifuged at 33,000 rpm for 20 mins at 4 °C.  Soluble lysate was bound to Glutathione beads 
overnight and washed with 25 mL lysis buffer without Triton-X and eluted with lysis buffer 
including 40 mM reduced glutathione. Actin lysate was collected from 2 confluent plates of NIH-
3T3 cells that were lysed in 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 3 mM MgCl2, 0.2 mM EGTA, 
0.2 mM ATP, 1 mM DTT, 0.5% Triton-X and protease inhibitors. 
qPCR for LPA-stimulated Expression of CTGF: 
LPA stimulation  
Primary dermal fibroblasts isolated from healthy donors were cultured in DMEM containing 10% 
FBS and 1% Pen/Strep. Prior to LPA stimulation, cells were seeded in 0.5% FBS containing 
DMEM and pre-treated with compounds or DMSO control for 48 or 72 h. After the pre-treatment, 
LPA (1-Oleoyl Lysophosphatidic Acid, Cayman Chemical, Cat #10010093) was added at a final 
concentration of 10 µM for 1 h in DMEM containing 0.5% FBS and 1% Pen/Strep. After LPA 
stimulation, cells were lysed in iScript RT-qPCR lysis buffer (Biorad, Hercules CA, Cat #170-
8898). Cells used for experiments were passaged no more than 8 times. 
qPCR 
For qPCR analysis, the iTaq Universal SYBR Green One Step Kit was used (BioRad, Hercules, 
CA Cat #172-5151) following the manufacturer’s instructions. 1 µL of template lysate was added 
to the RT-qPCR master mix. Primers used were: CTGF Forward 5’-
CAGAGTGGAGCGCCTGTT -3’, CTGF Reverse 5’- TTGTCCGCGAGGTGAGAC-3’, GAPDH 
forward 5’ GAAGGTGAAGGTCGGAGTCA and GAPDH reverse 5’-
TTGAGGTCAATGAAGGGGTC-3’. Fold differences were calculated using the ΔΔCt method 
with GAPDH as a reference. PCR products were analyzed on a 1% agarose gel. 
Metabolic Stability in Mouse Liver Microsomes: 
The metabolic stability was assessed using CD-1 mouse liver microsomes. One micromolar of 
each compound was incubated with 0.5 mg/mL microsomes and 1.7 mM cofactor NADPH in 0.1 
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M phosphate buffer (pH = 7.4) containing 3.3 mM MgCl2 at 37 °C. The DMSO concentration 
was less than 0.1% in the final incubation system. At 0, 5, 10, 15, 30, 45, and 60 min of 
incubation, 40 µL of reaction mixture were taken out, and the reaction is quenched by adding 3-
fold excess of cold acetonitrile containing 100 ng/mL of internal standard for quantification. The 
collected fractions were centrifuged at 15000 rpm for 10 min to collect the supernatant for 
LC−MS/ MS analysis, from which the amount of compound remaining was determined. The 
natural log of the amount of compound remaining was plotted against time to determine the 
disappearance rate and the half-life of tested compounds. 
Pharmacokinetic Studies in Mice: 
All animal experiments in this study were approved by the University of Michigan Committee on 
Use and Care of Animals and Unit for Laboratory Animal Medicine. The abbreviated 
pharmacokinetics for 8j, 8q, and 19f were determined in female CD-1 mice following intravenous 
(iv) and/or orally (po). Compound was dissolved in the vehicle containing 15% (v/v) DMSO, 15% 
(v/v) PEG-400, and 70% (v/v) PBS. Four blood samples (50 μL) were collected over 7 h (at 
0.5h, 2h, 4h, and 7h), centrifuged at 3500 rpm for 10 min, and plasma was frozen at -80˚C for 
later analysis. Plasma concentrations of the compounds were determined by the LC−MS/MS 
method developed and validated for this study. The LC−MS/MS method consisted of a 
Shimadzu HPLC system, and chromatographic separation of tested compound which was 
achieved using a Waters Xbridge-C18 column (5 cm × 2.1 mm, 3.5 μm). An AB Sciex QTrap 
4500 mass spectrometer equipped with an electrospray ionization source (ABI-Sciex, Toronto, 
Canada) in the positive-ion multiple reaction monitoring (MRM) mode was used for detection. All 
pharmacokinetic parameters were calculated by non-compartmental methods using WinNonlin, 
version 3.2 (Pharsight Corporation, Mountain View, CA, USA). 
Bleomycin skin fibrosis for CCG-257081: 
Twenty-Four C57BL/6J mice were ordered from Jackson labs for delivery at 15-16 weeks of 
age. Mice were preconditioned with supplemental chow for two weeks prior to start of 
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experiment. Mice were randomized by weight into three groups (vehicle, CCG-257081, PBS). 
Each group consisted of two cages with four mice per cage. Drug stock solutions were aliquoted 
and stored at 4 °C for the duration of the study. Aliquots were warmed to 37 °C and briefly 
vortexed prior to filling the gavage syringes. Vehicle and CCG-257081 groups received daily 
bleomycin injections (0.1 mL, ID) each afternoon in a defined area of shaved dorsal skin.  PBS 
control group received daily injections (0.1 mL, ID) of PBS in the afternoon. Mice were 
anesthetized with ketamine/xylazine for ID injections. CCG-257081 (50 mg/kg) and the vehicle 
(20% DMSO/50% PEG-400/30% PBS) were administered (PO) in the morning by the University 
of Michigan’s Unit for Laboratory Animal Medicine In-Vivo Animal Core. Mice were weighed 
daily to determine gavage dosage volume. Mice were euthanized after fourteen days of 
treatment by CO2 inhalation/thoracotomy. Skin from the defined area was excised for 
biochemical and histological analysis. A portion of the skin was fixed in neutral buffered formalin 
(10%), washed in 70% ethanol, and paraffin-embedded for Masson's trichrome histological 
staining. Another portion of the skin was snap frozen for hydroxyproline measurement. 
Histological analysis 
Fixed skin was paraffin embedded and sectioned at the University of Michigan Comprehensive 
Cancer Center Histology Core. Skin sections were stained with Masson’s trichrome (Sigma-
Aldrich). Stained sections were analyzed with an Olympus BX51\DP72 microscope. Dermal 
thickness was determined by measuring the maximal distance between the epidermal-dermal 
junction and the dermal-subcutaneous fat junction. Three measurements were averaged from 
each skin section. The measurement was performed using the measurement tool in the 
cellSens imaging software package (Olympus).  
Hydroxyproline assay 
Skin sections were weighed and hydrolyzed in 6M HCl at 120 °C for three hours. Hydrolyzed 
skin supernatant and hydroxyproline standards (Sigma-Aldrich) were transferred to a microplate 
and dried at 60oC. Samples and standards were oxidized with Chloramine T oxidation buffer for 
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5 minutes at room temperature. 4-(Dimethylamino) benzaldehyde was added to the wells and 
incubated at 60 °C until the standard was well-defined (approximately 90 minutes). Absorbance 
was measured at 560 nm using a Synergy HT microplate reader (BioTek Instruments). 
Hydroxyproline values were normalized to tissue weight. 
Bleomycin-Induced Antifibrotic Effects in Mice—CCG-58150: 
During intradermal injections and gavage of test substance mice were anesthetized using 
isoflurane. The back was shaved and the injection site (~1cm2) cleaned with three alternating 
passes of chlorhexidine and warm, sterile saline or water. The periphery of the injection site was 
circled using a sharpie marker as a visual aid. Bleomycin was dissolved in sterile PBS at a 
concentration of 1mg/ml, sterile filtered, and frozen in aliquots appropriately sized for the daily 
injections prior to the start of the dosing period. 100μl of bleomycin or PBS (Vehicle 1) was 
administered to anesthetized mice by intradermal injection using a 0.5cc TB syringe with a 27G 
needle. Following bleomycin or vehicle administration, test substance (CCG-58150) or Vehicle 2 
(20% DMSO/30% PEG/50% PBS) was administered by oral gavage at 10μL/gram of body 
weight. Mice received daily clinical observations, injections of vehicle/bleomycin and oral 
vehicle/test substance for 14 days. Mice were weighed weekly and were euthanized on Day 15. 
The bleomycin injection site was visually assessed, and apparent fibrosis was graded as Not 
Detectable (0), Mild Fibrosis (1), Moderate Fibrosis (2) or Severe Fibrosis (3), based on the 
appearance of lesion. A terminal blood sample was collected for determination of serum 
chemistry values. The liver was collected and fixed in neutral buffered formalin, slides prepared 
and stained with Hematoxolin and eosin (H&E). The skin at the injection site was excised to 
contain a few mm of normal skin around the perimeter of the fibrotic skin. A small section 
(~5x2mm) of the fibrotic skin was collected using a scalpel, placed in a microfuge tube, snap 
frozen in liquid nitrogen, and stored at -80°C for future evaluation by the sponsor. The remaining 
tissue was pinned flat and fixed in 10% buffered formalin at room temperature. After fixation for 
at least 24 h, the skin was cut into 1-2mm wide strips and embedded in paraffin with the tissue 
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cross section facing up and all strips oriented in the same direction in the cassette. Slides were 
prepared and stained with H & E and Masson’s trichrome. All slides and frozen tissue were sent 
to the Sponsor at study completion. 
Bleomycin-Induced Antifibrotic Effects in Mice—CCG-232964: 
C57BL/6J mice were ordered from Jackson labs for delivery at 15-16 weeks of age. Mice were 
preconditioned with supplemental chow for two weeks prior to start of experiment. Mice were 
randomized by weight into four groups (vehicle, CCG-232964 (3 mg/kg), CCG-232964 (10 
mg/kg), PBS). Each group consisted of two cages with four mice per cage. Drug stock solutions 
were aliquoted and stored at 4 °C for the duration of the study. Aliquots were warmed to 37 °C 
and briefly vortexed prior to filling the gavage syringes. Vehicle and CCG-232964 groups 
received daily bleomycin injections (0.1mL, ID) each afternoon in a defined area of shaved 
dorsal skin.  PBS control group received daily injections (0.1mL, ID) of PBS in the afternoon. 
Mice were anesthetized with ketamine/xylazine for ID injections. CCG-232964 (3 or 10 mg/kg) 
and the vehicle (20% DMSO/50% PEG-400/30% PBS) were administered (po) in the morning 
by the University of Michigan’s Unit for Laboratory Animal Medicine In-Vivo Animal Core. Mice 
were weighed daily to determine gavage dosage volume. Mice were euthanized after fourteen 
days of treatment by CO2 inhalation/thoracotomy. Skin from the defined area was excised for 
biochemical and histological analysis. A portion of the skin was fixed in neutral buffered formalin 
(10%), washed in 70% ethanol, and paraffin embedded for Masson's trichrome histological 
staining. Another portion of the skin was snap frozen for hydroxyproline measurement. 
Fixed skin was paraffin embedded and sectioned at the University of Michigan Comprehensive 
Cancer Center Histology Core. Skin sections were stained with Masson’s trichrome (Sigma-
Aldrich). Stained sections were analyzed with an Olympus BX51\DP72 microscope. Dermal 
thickness was determined by measuring the maximal distance between the epidermal-dermal 
junction and the dermal-subcutaneous fat junction. Three measurements were averaged from 
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each skin section. The measurement was performed using the measurement tool in the 
cellSens imaging software package (Olympus). 
Skin sections were weighed and hydrolyzed in 6M HCl at 120 °C for three h. Hydrolyzed skin 
supernatant and hydroxyproline standards (Sigma-Aldrich) were transferred to a microplate and 
dried at 60 °C. Samples and standards were oxidized with Chloramine T oxidation buffer for 5 
minutes at room temperature. 4-(Dimethylamino) benzaldehyde was added to the wells and 
incubated at 60 °C until the standard was well defined. Absorbance was measured at 560 nm 
using a Synergy HT microplate reader (BioTek Instruments). Hydroxyproline values were 
normalized to tissue weight.   
Docking With Pirin Co-Crystal Structures: 
The protein structures were prepared to correct the common errors associated with the 
crystallographic data by capping the terminal residues, completing residues with missing atoms, 
and selecting appropriate alternate locations for atoms with fractional occupancies. Hydrogens 
were added and optimized for optimal hydrogen bond network, charges were calculated, and 
the tethered energy minimization was performed to relieve bad crystallographic contacts or 
other bad geometries. Co-crystallized ligand atoms defined the binding site. The ligand 
molecules were drawn in ChemDraw Professional 16.0.1.4 (77) and saved as sdf file. The chiral 
compounds were saved with the chiral center specified. The Amber10:EHT was used for the 
force field in the docking. We mostly used the rigid docking since the rigid docking of the ligand 
in 5jct.pdb reproduced the crystal structure of the bound ligand with the root mean square 
deviation (rmsd) of 0.3 A. 
Virtual Screen Using 222740-Scaffold in CCG-222740 Co-Crystal Structure: 
To design non-aniline analogs of CCG-257081, we performed a virtual screening of the combi-
library created computationally. The chemical structures of a list of 9997 commercially available 
amines were obtained from Sigma Aldrich’s website. A virtual combi-library of 6710 compounds 
was created by replacing the 4-chloro anilines in the CCG-257081 with the commercially 
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available amines in MOE. Out of this library, a set of 301 non-aniline compounds was saved 
after applying molecular weight less than 550 and by removing 68 aniline compounds. 122 
compounds were selected based on the novelty of chemical structures and subsequently were 
subjected to the flexible docking with the induced fit option in the binding pocket of the X-ray 
crystal structure of Pirin complexed with CCG-257081. Finally, several compounds were 
selected for synthesis based on the docking scores, docking poses with additional interactions 
with the enzyme, and the synthetic feasibility. 
General Chemistry Info: 
All reagents were used without further purification as received from commercial sources unless 
noted otherwise. 1H NMR and 13C NMR spectra were taken in DMSO-d6, MeOD-d4, or CDCl3 at 
room temperature on Varian Inova 400 MHz or Varian Inova 500 MHz instruments. Reported 
chemical shifts for the 1H NMR and 13C NMR spectra were recorded in parts per million (ppm) 
on the δ scale from an internal standard of residual tetramethylsilane (0 ppm). Mass 
spectrometry data were obtained on either a Micromass LCT or Agilent Q-TOF. An Agilent 1100 
series HPLC with an Agilent Zorbax Eclipse Plus−C18 column (3.5 μM, 4.6 x 100 mm) was 
used to determine purity of biologically tested compounds. All tested compounds were 
determined to be >95% pure using a 6-minute gradient of 10-90% acetonitrile in water followed 
by a 2-minute hold at 90% acetonitrile at a flow rate of 1 mL/min with detection at 254 nm. 
Purification was accomplished using silica gel 40-63µm 60Å for column chromatography. 
Purification of some final compounds required Waters semipreparative HPLC with a Vydac 
protein and peptide C18 reverse phase column, using a linear gradient of 0% solvent B (0.1% 
TFA in acetonitrile) in solvent A (0.1% TFA in water) to 100% solvent B in solvent A at a rate 1% 
per minute and monitoring UV absorbance at 230 nm. 
General Methods: 
Method A: General Procedure for Fisher Esterification of Carbocyclic Acids 
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The appropriate acid (1.0 eq) was dissolved in MeOH (2-4 mL/1 mmol), and 98% sulfuric acid (1 
eq) was added. The mixture was heated to reflux 4-16 h. The reaction solution was cooled to 
room temperature and concentrated in vacuo. The resulting crude residue was dissolved in a 
sat. NaHCO3 (aq) solution and extracted with DCM. The combined organic layers were washed 
with brine, dried over MgSO4 and concentrated to afford the desired ester. Yields: 50%-100% 
Method B: General Procedure for O-Alkylation Using Propargyl Benzenesulfonate: 
In a round-bottomed flask the starting phenol (1.0 eq) was dissolved in acetone (2-30 mL) and 
placed under inert atmosphere. K2CO3 (1.3 eq) and prop-2-yn-benzenesulfonate (1.5 eq) were 
added and the reaction proceeded at reflux (60 °C) for 3 hr under inert atmosphere. Acetone 
was evaporated in vacuo and the residue was taken up in water (2-30 mL). The product was 
extracted with EtOAc (3 x 30 mL), washed with brine, dried with MgSO4, and the solvent 
evaporated. The oil was subjected to silica gel chromatography eluting with 15% EtOAc: 85% 
Hex. The fractions containing product were concentrated in vacuo to produce white powder. 
Yields: 76-92%. 
Method C: General Procedure for Hydrazine Coupling of Aryl Methyl Carboxylates 
In a round-bottomed flask, the starting aryl ester (1.0 eq) was dissolved in MeOH (2-4 
mL/mmol), and hydrazine hydrate (10 eq) was added. The solution was heated to reflux (85 °C) 
for overnight. The reaction was cooled to 25 °C and concentrated in vacuo. The residue was 
taken up in DCM, partitioned between water, and the product was extracted with DCM (3 x 20 
mL). The combined organic layers were washed with brine, dried with MgSO4, and concentrated 
in vacuo to obtain white crystals. Yields: 70-100% 
Method D: General Procedure for 1, 3, 4-oxadiazole-thiol Cyclization of Aryl Hydrazides 
In a round-bottomed flask, the appropriate aryl hydrazide (1eq) was dissolved in a 0.1 M 
solution of KOH (1 eq) in EtOH (2-4 mL/mol)/H2O (10 eq) and placed under nitrogen. Carbon 
disulfide (1 eq) was added and the reaction was heated to reflux (95 °C) overnight. Upon 
completion, most of the EtOH was evaporated in vacuo and the residue was cooled to 0 °C. The 
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product was acidified to pH 1 with 1 N HCl, and the subsequent white precipitate was filtered 
and dried under vacuum. Yields: 50-90% 
Method E: General Procedure for Alkyl Halide Coupling of 1,3,4-Oxadiazole-2-Thiols 
The starting thiol (1 eq), acetone (2-4 mL/1 mmol), and potassium carbonate (1.3 eq) were 
combined in a round-bottomed flask. The alkyl halide (1.3 eq mmol) was added to the solution 
and the reaction was stirred under nitrogen at 25 °C overnight. The crude mixture was 
concentrated in vacuo, and the residue was partitioned between DCM and water. The product 
was extracted with DCM (3 x 15 mL), washed with brine (30 mL), dried with MgSO4, and 
concentrated in vacuo. The oil was subjected to silica gel chromatography eluting with 30-80% 
EtOAc: Hex. The fractions containing product were concentrated; and, after sitting overnight, 
some of the subsequent oils produced white solid. Yields: 50-95% 
Method F: General Procedure for Acidic Ester Hydrolysis of t-Butyl Esters 
In a round-bottomed flask the appropriate t-butyl ester (1 eq) was dissolved in DCM (2-4 mL/1 
mmol). Trifluoroacetic acid (25 eq) was added and reaction was stirred under nitrogen at 25 °C 
for 3 h. The crude mixture was concentrated in vacuo and then dissolved in a minimal amount of 
EtOAc. The product was triturated out with Hex, and the subsequent white precipitate was 
filtered and dried under vacuum. Yields: 20-90% 
Method G: General Procedure for Basic Ester Hydrolysis of Methyl Esters 
In a round-bottomed flask, the starting methyl ester (1 eq) was dissolved in THF (1-2 mL/1 
mmol). 1 M NaOH (1-2 mL/1 mmol) was added to the solution and the reaction was stirred at 25 
°C for 3 h. The THF was evaporated in vacuo, and then the aqueous layer was acidified with 1 
N HCl (7 mL). The product was extracted with EtOAc (3 x 15 mL), washed with brine (3 x 10 
mL), dried with MgSO4, and concentrated in vacuo. The residue was dissolved in minimal 
EtOAc and the product was triturated with Hex, producing a white precipitate that was filtered 
and dried under vacuum. Yields: 50-90% 
Method H: General Procedure for Suzuki Cross Coupling (222740-Series):  
168 
 
In a round bottomed flask, aryl halide (1 eq), furan-2-ylboronic acid (1.2 eq), Tetrakis® (0.05 
eq), and Na2CO3 (2.5 eq) were dissolved in DME (2-10 mL) and H2O (2-10 mL). The solution 
was degassed, and then heated at 100 °C for 16 hr under Ar2. The solution was filtered through 
a pad of Celite® to remove particulates. The filtrate was acidified with 1N HCl (15 mL), and the 
product was extracted with EtOAc (3 x 15 mL), washed with brine (1 x 15 mL), dried with 
MgSO4, and concentrated in vacuo. The subsequent oil was subjected to silica gel 
chromatography eluting with 5% MeOH: 95% DCM. The fractions containing product were 
concentrated in vacuo. Yields: 30-88% 
Method I: General Procedure for Amide Coupling Using HATU:  
In a round bottomed flask, the carboxylic acid (1 eq) was dissolved in DMF (2-10 mL), and 
HATU (1.5 eq), desired aniline (1.1 eq), and DIPEA (3-4 eq) were added, respectively. The 
reaction was stirred at 25 °C for 16 hr, and then quenched with brine (10 mL). The product was 
extracted with EtOAc (3 x 15 mL), dried with MgSO4, and concentrated in vacuo. The 
subsequent oil was subjected to silica gel chromatography eluting with 15% EtOAc: 85% Hex. 
The fractions containing product were concentrated in vacuo. Yields: 15-100% 
Method J: General Procedure for Boc-Deprotection: 
In a round-bottomed flask or scintillation vial, the Boc-amine (1 eq) was dissolved in 4 M 
HCl/Dioxanes (1.5-10 mL) and the reaction was stirred at 25 °C for 1 hr. The solvents were 
evaporated in vacuo, and the subsequent solid was taken into the next step without further 
purification. Yields: quant. 
Method K: General Procedure for Suzuki Cross Coupling (58150-Series) 
The appropriate aryl bromide (1 eq) was dissolved in toluene (2-4 mL/1 mmol) and degassed 
under inert atmosphere. H2O (10 eq), potassium phosphate dibasic (3.5 eq), cyclopropyl boronic 
acid (1.2 eq), tricyclohexylphosphine (0.1 eq), and palladium (II) acetate (0.15 eq) were added. 
The mixture was heated at reflux (100 °C) for 3 hr under N2. The mixture was cooled to 25 °C 
and H2O was added. The product was extracted with EtOAc (3 x 15 mL), washed with brine (2 x 
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15 mL), dried with MgSO4, and concentrated in vacuo. The yellow residue was subjected to 
silica gel chromatography eluting with 2.5% EtOAc: 97.5% Hex. Yields: 70-95% 
Method L: General Procedure for O-Alkylation: 
In a round-bottomed flask, the respective phenol (1 eq) was dissolved in 1-3 mL DMF. The 
respective alkyl halide (1.3 eq) along with Cs2CO3 (5 eq) were added and the reaction was 
stirred at 75 °C for 1 hr. The reaction was diluted with 10 mL brine and extracted with EtOAc (3x 
10 mL). The organic layers were combined, dried with MgSO4, and evaporated. The subsequent 
oil was subjected to silica gel chromatography eluting with 15% EtOAc: 75% Hex. The fractions 
containing product were concentrated in vacuo to produce colorless oil. Yields: 84-98% 
Method M: General Procedure for Acyl Chloride Formation: 
In a flame dried round bottomed flask or scintillation vial, the benzoic acid (1 eq) was dissolved 
in DCM (1-4 mL) and DMF (5-30 µL) was added. The solution was cooled to 0 °C and (COCl)2 
(1.1 eq) was added dropwise. The solution was stirred at 0 °C for 10 min and then at 25 °C for 1 
hr. The reaction was concentrated in vacuo and the remaining (COCl)2 was azeotroped with 
DCM (2 x 10 mL) to produce solid that was taken into next reaction without further purification.  
Method N: General Procedure for Amide Coupling using Acyl Halide: 
The respective amine or aniline (1 eq) was dissolved in DCM (1-5 mL) and Et3N (4-6 eq) was 
added. The reaction was cooled to 0 °C and the respective acyl chloride in a solution of DCM 
was added dropwise. The reaction was stirred at 25 °C for 16 hr and then acidified with 1N HCl 
(7 mL). The product was extracted with DCM (3 x 15 mL), washed with brine (3 x 15 mL), dried 
with MgSO4, and concentrated in vacuo. The oil was subjected to silica gel chromatography. 
The fractions containing product were concentrated to produce solid. 
58150-Series Target Identification Analog Procedures (Chapter 2): 
methyl-2,2-dimethoxypropanoate. methyl-2-oxopropanoate (1.77 mL, 19.6 mmol), p-
toluenesulfonic acid (1.86 g, 9.8 mmol), trimethylorthoformate (2.6 mL, 23.5 mmol), and 
methanol (3.96 mL) were combined in a 50 mL round-bottomed flask and stirred under nitrogen 
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at 55 °C for 24 hr. The reaction was cooled to 0 °C and 30% sodium methoxide was added 
portion-wise. The crude mixture was concentrated in vacuo and dried under vacuum. The 
product was distilled at 50 °C/ 30 mm Hg as colorless oil. Yield=60%. 1H NMR (401 MHz, 
CDCl3-d) 𝛿 ppm 3.75 (s, 3H) 3.22 (s, 6H) 1.46 (s, 3H). 
methyl-2-methoxyacrylate. In a 50 mL round-bottomed flask methyl-2,2-dimethoxypropanoate 
(1.74 g, 11.74 mmol), p-toluenesulfonic acid (0.067 g, 0.357 mmol), and hydroquinone (0.052 g, 
0.470 mmol) were combined. The mixture was heated at 150 °C under ambient pressure while 
distilling MeOH byproduct. After about 4 mL of MeOH was collected (~5hr) the reaction mixture 
was cooled to 25 °C. The product was then distilled at 60 oC/ 30 mm Hg as colorless oil. 
Yield=64%. 1H NMR (401 MHz, CDCl3-d) 𝛿 ppm 5.37 (d, J = 2.7 Hz, 1H) 4.64 (d, J = 2.7 Hz, 1H) 
3.82 (s, 3H) 3.29 (s, 3H). 
methyl 3-(benzylthio)-2-methoxypropanoate. In a 50 mL round-bottomed flask methyl 2-
methoxyacrylate (0.71 g, 6.14 mmol) was dissolved in THF (5 mL) and cooled to 0 °C. 
benzylmercaptan (0.76g, 6.14 mmol, 0.72 mL) dissolved in 1 M TBAF (in THF) (5.0 mL, 5.0 
mmol) was added and the mixture was stirred under nitrogen at 25 °C for 2 hr. The reaction was 
quenched with water (20 mL) and the product was extracted with EtOAc (3x 15 mL). The 
organic layer was washed with brine, dried with magnesium sulfate, and evaporated, providing 
yellow oil. The residue was subjected to silica gel chromatography eluting with 10% EtOAc: 90% 
Hex. The fractions containing product were concentrated in vacuo to produce colorless oil. 
Yield=42.4%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.34-7.24 (m, 5H) 3.90 (m, 1H) 3.79 (s, 2H) 
3.76 (s, 3H) 3.42 (s, 3H) 2.82-2.69 (m, 2H); TOF ES+ MS: (M+H) 241.1; HPLC Ret: 8.80 min. 
3-(benzylthio)-2-methoxypropionic acid. In a 100 mL round-bottomed flask methyl 3-
(benzylthio)-2-methoxypropanoate (0.63 g, 2.60 mmol) was dissolved in H2O:MeOH (2:10 mL). 
Potassium carbonate (0.61 g, 4.43 mmol) was added and the reaction was stirred at 25 °C for 
16 h. The reaction was quenched with sat. NH4Cl (10 mL) and then acidified to pH ~ 1 with 1N 
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HCl (12 mL). The product was extracted with EtOAc (3x 20 mL). The organic layer was washed 
with brine, dried with magnesium sulfate, and evaporated, providing colorless oil. Yield=92%. 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.36-7.22 (m, 5H) 3.94 (m, 1H) 3.81 (s, 2H) 3.47 (s, 3H) 2.90-
2.73 (m, 2H); HPLC Ret: 5.86 min. 
3-mercapto-2-methoxypropionic acid. In a 100 mL round-bottomed three neck flask 3-
(benzylthio)-2-methoxypropanoic acid (0.54 g, 2.40 mmol) was dissolved in liquid ammonia (12 
mL) at -30 °C under inert atmosphere. Sodium metal (0.221 g, 9.40 mmol) was added portion-
wise, turning the solution deep blue. The reaction was stirred under inert atmosphere at -30 °C 
for 30 min. The ammonia was removed with a constant flow of N2 at -10 oC, causing the reaction 
to go from deep blue to clear. The reaction was quenched with H2O (10 mL) and then acidified 
to pH ~ 2 with 1N HCl (20 mL). The product was extracted with EtOAc (3x 50 mL). The organic 
layer was dried with magnesium sulfate and then evaporated, providing colorless oil. 
Yield=84%. 1H NMR (400 MHz, CDCl3-d) 𝛿 ppm 9.49 (br. s. 1H) 4.01 (m, 1H) 3.53 (s, 3H) 2.98-
2.90 (m, 2H) 1.78 (t, J = 8.5 Hz, 1H). 
tert-butyl oxirane-2-carboxylate: mCPBA (4.85 g, 28.1 mmol) and tert-butyl acrylate (3.0 g, 
23.41 mmol) were dissolved in DCM (100 mL) and heated at 55 °C for 48 hr. The reaction was 
concentrated in vacuo and the residue was partitioned between EtOAc (30 mL) and water (30 
mL). The product was extracted with EtOAc (3x 30 mL), washed with saturated sodium 
carbonate (3x 30 mL) and brine (3x 30 mL), dried with magnesium sulfate, and concentrated in 
vacuo. The product was dried on under vacuum while allowing any remaining m-chlorobenzoic 
acid to crystalize. The colorless oil was filtered through a cotton-plugged pipette. Yield=81%. 1H 
NMR (401 MHz, CDCl3-d) 𝛿 ppm 3.32 (dd, J = 4.0, 2.5 Hz, 1H) 2.90 (qd, J = 6.5, 3.3 Hz, 2H) 
1.50 (s, 9H). 
3-methoxydihydrofuran-2(3H)-one. 3-hydroxydihydrofuran-2(3H)-one (2.0 g, 1.5 mL, 19.59 
mmol) was dissolved in 20 mL DCM. Silver oxide (18.16 g, 78.0 mmol) and iodomethane (27.8 
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g, 12.25 mL, 196.0 mmol) were added and the reaction was heated to reflux (70 °C) for 1 hr. 
The mixture was cooled and filtered through a pad of celite. The solvent was evaporated to 
dryness in vacuo to produce yellow oil. Yield=94%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 4.47-
4.18 (m, 2H) 4.05 (t, J = 7.7 Hz, 1H) 3.57 (s, 3H) 2.60-2.18 (m, 2H). 
methyl 4-iodo-2-methoxybutanoate. 3-methoxydihydrofuran-2(3H)-one (1.0 g, 8.61 mmol) 
was dissolved in 30 mL DCM and placed under inert atmosphere. MeOH (0.276 g, 0.35 mL, 
8.61 mmol) was added and the reaction was cooled to -10 °C. Iodotrimethylsilane (1.90 g, 1.29 
mL, 9.47 mmol) was added dropwise over a time of 15 min, after which the solution was stirred 
at -10 °C for 1 hr. The reaction was warmed up to 25 °C and stirred for 3 hr. The solution was 
washed with sat. NaHCO3 (20 mL), 10% Na2S2O3 (20 mL), and brine (20 mL). The organic layer 
was dried with MgSO4 and concentrated in vacuo to produce yellow oil. Yield=68%. 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 4.45-4.24 (m, 2H) 4.02 (t, J = 7.7 Hz, 1H) 3.76 (s, 3H) 3.56 (s, 3H) 
2.36-2.18 (m, 2H). 
Methyl-2-acetoxy-5-iodopentanoate. Methyl tetrahydrofuran-2-carboxylate (1.1g, 8.45 mmol, 
1.0 mL) and sodium iodide (2.5g, 16.9 mmol) were dissolved in 10 mL acetonitrile and cooled to 
0 °C. Acetyl chloride (1.33g, 16.9 mmol, 1.2 mL) was added dropwise and the reaction took 
place at 25 °C for 24 hours. The reaction was quenched with concentrated sodium bicarbonate 
(30 mL). The product was extracted with Et2O (3x 15 mL) and the organic layers were 
combined, washed with 10% sodium thiosulfate (15 mL) and brine (15 mL). The solvent was 
dried with MgSO4and concentrated to dryness, producing yellow oil. Yield=99%. 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 5.02 (tq, J = 5.0, 2.9, 2.3 Hz, 1H) 3.76 (s, 3H) 3.20 (q, J = 7.0 Hz, 2H) 
2.15 (s, 3H) 2.00-1.89 (m, 4H). 
t-butyl (2-(2-hydroxyethoxy)ethyl)carbamate. In a 100-mL round bottomed flask, 2-(2-
aminoethoxy)ethanol (2 g, 19.02 mmol) was dissolved in a H2O (20 mL) and dioxane (10 mL) 
solution. Potassium hydroxide (1.2 g, 20.9 mmol) was dissolved and the solution was cooled to 
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0 °C. Boc anhydride (4.6 g, 20.9 mmol) was slowly added and the reaction was stirred at 0 °C 
for 1 hr, after which the solution was warmed to room temperature and stirred for 4 hr. The 
product was extracted with DCM (3 x 30 mL), washed with brine, dried with MgSO4, and the 
solvent evaporated. The oil was subjected to silica gel chromatography eluting with 70% EtOAc: 
30% Hex. The fractions containing product were concentrated in vacuo to produce pale yellow 
oil. Yield=86%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 5.13 (br. s, 1H) 3.74 (t, J = 5.5 Hz, 2H) 
3.59-3.55 (m, 4H) 3.33 (q, J = 5.5 Hz, 2H) 1.45 (s, 9H). 
2-(2-((t-butoxycarbonyl)amino)ethoxy)ethyl methanesulfonate. t-butyl (2-(2-
hydroxyethoxy)ethyl)carbamate (1.06 g, 5.16 mmol, 1.0 mL), trimethylamine (1.05 g, 10.33 
mmol, 1.44 mL), methanesulfonyl chloride (0.77 g, 6.71 mmol, 0.52 mL), and THF (20 mL) were 
combined and stirred at 25 °C for 3 hr. The trimethylamine hydrochloride salt was filtered 
through a pad of Celite and the filtrate was concentrated in vacuo. The subsequent oil was 
subjected to silica gel chromatography eluting with 50% EtOAc: 50% Hex. The fractions 
containing product were concentrated in vacuo to produce pale yellow oil. Yield=96%. 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 4.92 (br. s, 1H) 4.37 (t, J = 5.2 Hz, 2H) 3.73 (t, J = 5.2 Hz, 2H) 3.56 
(t, J = 5.2 Hz, 2H) 3.33 (q, J = 5.5 Hz, 2H) 3.07 (s, 3H) 1.45 (s, 9H). 
(2,6-dichlorophenoxy)triethylsilane. In a 250 mL round-bottomed flask, 2,6-dichlorophenol (5 
g, 30.7 mmol) was dissolved in tetrahydrofuran (150 mL), and triethylamine (6.38 mL, 46 mmol) 
was added. Chlorotriethylsilane (7.72 mL, 46 mmol) was added dropwise prior to heating under 
nitrogen at 50 °C for 28 hr. Once the solution was cooled to room temperature it was washed 
thrice with both 10% citric acid (3x 50 mL) and saturated sodium carbonate (3 x 50 mL). The 
organic layer was washed with brine, dried with MgSO4, and concentrated in vacuo. The product 
was isolated as colorless oil from a silica plug eluting with hexanes. Yield=84%. 1H NMR (401 
MHz, CDCl3-d) 𝛿 ppm 7.28-7.20 (m, 2H) 6.82 (t, J = 8.1 Hz, 1H) 1.04-0.88 (m, 9H) 0.82 (q, J = 
7.7 Hz, 6H); HPLC Ret: 10.11 min. 
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(2-chlorophenoxy)triisopropylsilane. In a 250 mL round-bottomed flask, 2-chlorophenol (5 g, 
38.9 mmol, 3.96 mL) was dissolved in DMF (15 mL). Imidazole (2.65 g, 38.9 mmol) and 
triisopropylsilane chloride (7.5 g, 38.9 mmol, 8.24 mL) were added and the reaction was stirred 
at 25 °C for 24 hr. The reaction was diluted with 20 mL H2O and the product was extracted with 
DCM (3 x 40 mL). The organic layers were combined and washed with brine, dried with MgSO4, 
and concentrated in vacuo. The resulting oil was subjected to a silica plug eluting with hexanes, 
producing colorless oil. Yield=89%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.33 (td, J = 8.0, 1.5 
Hz, 1H) 7.09 (td, J = 8.3, 1.6 Hz, 1H) 6.93-6.81 (m, 2H) 1.38-1.24 (m, 3H) 1.12 (d, J = 7.5 Hz, 
21H); HPLC Ret: 9.35 min. 
2,4-dichloro-3-hydroxybenzoic acid. (2,6-dichlorophenoxy)triethylsilane (2.3 g, 8.30 mmol) 
was added to an oven dried 100 mL round-bottomed flask charged with a stir bar containing 
tetrahydrofuran (12 mL). The solution was placed under nitrogen, cooled to -78 °C, and sec-
butyllithium in cyclohexane (1.4 M, 6.52 mL) was added dropwise. The reaction proceeded for 
45 min at -78 °C, and then was quickly poured over dry ice (7.3 g, 166 mmol) in a 150 mL 
beaker. Once the crude mixture warmed to 25 °C, 1N HCl (10.3 mL, 10.29 mmol) was added 
and stirred for 10 min. The product was extracted with EtOAc (3x 20 mL), washed with brine (3x 
10 mL), dried over MgSO4, and concentrated in vacuo. The crude extract was dissolved in 
EtOAC (20 mL) and a base wash with sodium bicarbonate (3x 10 mL) was performed. The 
subsequent aqueous layer was acidified to pH 3 with 1N HCl (25 mL) and the product was 
extracted with EtOAc (3x 20 mL). The organic layer was dried over MgSO4 and, upon 
evaporation; the product was isolated as a fine white powder. Yield=20%. 1H NMR (401 MHz, 
DMSO-d6) 𝛿 ppm 13.41 (br. s., 1H) 10.38 (s, 1H) 7.83 (s, 1H) 7.44 (d, J = 8.4 Hz, 1H) 7.23 (d, J 
= 8.4 Hz, 1H). 
2-chloro-3-hydroxybenzoic acid. (2-chlorophenoxy)triisopropylsilane (2.8 g, 9.83 mmol) was 
added to an oven dried 100 mL round-bottomed flask charged with a stir bar containing 
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tetrahydrofuran (12 mL). The solution was placed under nitrogen, cooled to -78 °C, and sec-
butyllithium in cyclohexane (1.3 M, 9.1 mL) was added dropwise. The reaction proceeded for 1 
hr at -78 °C, and then was quickly poured over fresh dry ice. Once the crude mixture warmed to 
25 °C, 1N HCl (15 mL) was added and stirred for 10 min. The product was extracted with Et2O 
(3x 50 mL), washed with brine, dried over MgSO4, and concentrated in vacuo. The oil was 
dissolved in 1M TBAF in THF (9.83 mmol, 9.8 mL) the reaction was stirred at 25 °C for 2 hr. The 
solvent was evaporated in vacuo and the product (TBAF salt form) was crystalized with toluene 
to produce white platelets. Yield=42%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.60 (br. s., 1H) 
6.86 (t, J = 7.7 Hz, 1H) 6.73 (q, J = 8.0 Hz, 1H) 6.56 (dd, J = 7.4, 1.6 Hz, 1H) 3.20-3.13 (m, 8H) 
1.56 (t, 6.1 Hz, 8H) 1.30 (h, 7.4 Hz, 8H) 0.93 (t, 7.3 Hz, 12H); HPLC Ret: 3.93 min. 
methyl 4-chloro-2-hydroxybenzoate. Method A starting from 4-chloro-2-hydroxybenzoic acid 
(2.0 g, 11.59 mmol) gave 3 methyl 4-chloro-2-hydroxybenzoate as yellow oil (1.21 g, 56%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.78 (dd, J = 8.6, 1.0 Hz, 1H) 6.96 (dd, J = 2.0, 1.0 Hz, 1H) 
6.93-6.84 (m, 1H) 3.94 (s, 3H); TOF ES+ MS: (M+H) 187.4; HPLC Ret: 7.63 min. 
methyl 2-chloro-4-hydroxybenzoate. Method A starting from 2-chloro-4-hydroxybenzoic acid 
(1.0 g, 6.08 mmol) gave methyl 2-chloro-4-hydroxybenzoate as tan powder (1.14 g, quant); 
HPLC Ret: 5.72 min. 
methyl 2-chloro-3-hydroxybenzoate. Method A starting from 2-chloro-3-hydroxybenzoic acid 
(0.7 g, 4.06 mmol) gave methyl 2-chloro-3-hydroxybenzoate as colorless oil (0.4 g, 53%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.45 (dd, J = 7.6, 1.7 Hz, 1H) 7.28-7.16 (m, 2H) 3.93 (s, 3H); 
HPLC Ret: 5.42 min. 
2,4-dichloro-3-(2-methoxyethoxy)benzoic acid. In a 50 mL round-bottomed flask 2,4-
dichloro-3-hydroxybenzoic acid (0.25 g, 1.21 mmol) was dissolved in EtOH (3 mL) and placed 
under nitrogen. A 0.11 M solution of KOH (0.156 g, 2.78 mmol) in EtOH (1.5 mL) and 1-bromo-
2-methyoxyethane (0.147 mL, 1.57 mmol) were added to the solution. The reaction was heated 
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to reflux (95 °C) for 24 hr. To drive the reaction to completion, another batch of 0.1 M KOH in 
EtOH (1 mL, 0.1 g) was added and heated to reflux (95 °C) for 2 hr. The crude mixture was 
concentrated in vacuo, diluted with H2O (10 mL), and acidified to pH 1 with 1N HCl (2.5 mL). 
The product was extracted with EtOAc (3 x 10 mL), washed with brine (3 x 10 mL), dried with 
MgSO4, and concentrated in vacuo to obtain light brown oil. Yield=94%. 1H NMR (401 MHz, 
DMSO-d6) 𝛿 ppm 13.55 (s, 1H) 7.62-7.50 (m, 2H) 4.13 (t, J = 4.0 Hz, 2H) 3.71 (t, J = 4.0 Hz, 
2H) 3.17 (s, 3H); TOF ES- MS: (M-H) 264.9; HPLC Ret: 3.76 min. 
methyl 4-chloro-2-(2-methoxyethoxy)benzoate. methyl 4-chloro-2-hydroxybenzoate (1.2 g, 
6.43 mmol) was dissolved in 20 mL DMF. K2CO3 (1.78 g, 12.86 mmol) and 1-bromo-2-
methoxyethane (1.16 g, 0.81 mL, 8.36 mmol) were added and the mixture was stirred at 90 °C 
for 4 hr. DMF was removed in vacuo and residue was partitioned between H2O (15 mL) and 
DCM (15 mL). The product was extracted with DCM (3x 15 mL), washed with brine (20 mL), 
dried with MgSO4, and concentrated in vacuo. The crude oil was subjected to silica gel 
chromatography eluting with 20% EtOAc: 80% Hex. The fractions containing product were 
concentrated to produce faint yellow/colorless oil. Yield=95%. 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 7.76 (dd, J = 8.0, 4.9 Hz, 1H) 7.02-6.93 (m, 2H) 4.17 (t, J = 5.0 Hz, 2H) 3.87 (s, 3H) 3.80 (t, 
J = 5.0 Hz, 2H) 3.47 (s, 3H); TOF ES+ MS: (M+H) 245.0; HPLC Ret: 6.75 min. 
2-chloro-4-(2-methoxyethoxy)benzoic acid. In a 250 mL round-bottomed flask 2-chloro-4-
hydroxybenzoic acid (3.5 g, 20.28 mmol) was dissolved in EtOH (40 mL) and placed under 
nitrogen. A 0.11 M solution of KOH (2.62 g, 46.6 mmol) in EtOH (25 mL) and 1-bromo-2-
methyoxyethane (2.5 mL, 26.5 mmol) were added to the solution. The reaction was heated to 
reflux (95 °C) for 24 hr. A second batch of 0.1 M KOH in EtOH (2 g, 40.0 mmol, 20 mL) was 
added and heated to reflux (95 °C) for 2 hr. The crude mixture was concentrated in vacuo, 
diluted with H2O (175 mL), and acidified on ice to pH 1 with 1N HCl (20 mL). The tan precipitate 
that formed was filtered and dried under vacuum. Yield=66%. 1H NMR (401 MHz, MeOD-d4) 𝛿 
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ppm 7.90 (d, 7.2 Hz, 1H) 7.06 (s, 1H) 6.95 (d, 7.2 Hz, 1H) 4.17 (t, 6.3 Hz, 2H) 3.74 (t, 6.3 Hz, 
2H) 3.41 (s, 3H); TOF ES- MS: (M-H) 229.9; HPLC Ret: 5.33 min. 
methyl 2-chloro-4-(prop-2-yn-1-yloxy)benzoate. Method B starting from methyl 2-chloro-4-
hydroxybenzoate (1.8 g, 9.8 mmol) gave methyl 2-chloro-4-(prop-2-yn-1-yloxy)benzoate as 
white solid (1.98 g, 90%); 1H NMR (400 MHz, CDCl3-d) 𝛿 ppm 7.89 (d, J = 8.8 Hz, 1H) 7.06 (d, J 
= 2.5 Hz, 1H) 6.91 (dd, J = 8.8, 2.5 Hz, 1H) 4.73 (d, J = 2.4 Hz, 2H) 3.90 (s, 3H) 2.58 (t, J = 2.4 
Hz, 1H); TOF ES+ MS: (M+H) 224.9; HPLC Ret: 6.99 min.  
methyl 4-chloro-2-(prop-2-yn-1-yloxy)benzoate. Method B starting from methyl 4-chloro-2-
hydroxybenzoate (2.0 g, 10.6 mmol) gave methyl 4-chloro-2-(prop-2-yn-1-yloxy)benzoate as 
yellow oil (2.26 g, 92%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.78 (d, J = 8.3, 1H) 7.13 (d, J = 
1.8 Hz, 1H) 7.03 (dd, J = 8.4, 1.9 Hz, 1H) 4.79 (d, J = 2.3 Hz, 2H) 3.88 (s, 3H) 2.58 (t, J = 2.3 
Hz, 1H); TOF ES+ MS: (M+Na) 247.0; HPLC Ret: 6.92 min. 
methyl 2-chloro-3-(prop-2-yn-1-yloxy)benzoate. Method B starting from methyl 2-chloro-3-
hydroxybenzoate (0.37 g, 2.0 mmol) gave methyl 2-chloro-3-(prop-2-yn-1-yloxy)benzoate as 
yellow oil (0.34 g, 76%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.40 (dd, J = 7.7, 1.6 Hz, 1H) 7.29 
(t, 8.3 Hz, 1H) 7.23 (dd, J = 8.3, 1.5 Hz, 1H) 4.81 (d, J = 2.4 Hz, 2H) 3.93 (s, 3H) 2.55 (t, J = 2.4 
Hz, 1H); TOF ES+ MS: (M+H) 225.0; HPLC Ret: 6.74 min. 
methyl 2-(benzyloxy)-4-chlorobenzoate. Methyl 4-chloro-2-hydroxybenzoate (1.0 g, 5.36 
mmol) was dissolved in 15 mL DMF. K2CO3 (1.48 g, 10.72 mmol) and benzyl bromide (1.10 g, 
6.43 mmol, 0.77 mL) were added and the mixture was stirred at 90 oC for 4 hr. DMF was 
removed in vacuo and the resulting oil was diluted with 20 mL H2O and extracted with DCM (3x 
20 mL). The organic layers were combined, washed with brine, dried with MgSO4, and 
evaporated. The subsequent oil was subjected to silica gel chromatography eluting with 10% 
EtOAc: 90% Hex. The fractions containing product were concentrated in vacuo to produce 
colorless oil. Yield=86%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.78 (d, J = 8.3, 1H) 7.52-7.45 (m, 
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2H) 7.43-7.36 (m, 2H) 7.32 (t, J = 7.4 Hz, 1H) 7.03-6.94 (m, 2H) 5.15 (s, 2H) 3.88 (s, 3H); TOF 
ES+ MS: (M+Na) 298.9; HPLC Ret: 8.17 min. 
2,4-dichloro-3-(2-methoxyethoxy)benzohydrazide. Method A followed by Method C starting 
from 2,4-dichloro-3-(2-methoxyethoxy)benzoic acid (0.3 g, 1.4 mmol) gave 2,4-dichloro-3-(2-
methoxyethoxy)benzohydrazide as tan solid (0.22 g, 70%); 1H NMR (401 MHz, DMSO-d6) 𝛿 
ppm 10.61 (s, 1H) 7.59-7.46 (m, 2H) 4.51 (br. s., 2H) 4.12 (t, J = 4.7 Hz, 2H) 3.70 (t, J = 4.0 Hz, 
2H) 3.32 (s, 3H); HPLC Ret: 4.27 min. 
2-chloro-4-(2-methoxyethoxy)benzohydrazide. (DJK-1-8). Method A followed by Method C 
starting from 2-chloro-4-(2-methoxyethoxy)benzoic acid (3 g, 13.01 mmol) gave 2-chloro-4-(2-
methoxyethoxy)benzohydrazide as tan solid (3.2 g, 67%); 1H NMR (401 MHz, DMSO-d6) 𝛿 ppm 
9.44 (s, 1H) 7.32 (d, 7.2 Hz, 1H) 7.06 (s, 1H) 6.94 (d, J = 7.2 Hz, 1H) 4.44 (br. s., 2H) 4.15 (t, 
6.4 Hz, 2H) 3.64 (t, 6.3 Hz, 2H) 3.31 (s, 3H); TOF ES+ MS: (M+H) 245.0; HPLC Ret: 3.74 min. 
4-chloro-2-(2-methoxyethoxy)benzohydrazide. (DJK-1-70). Method C starting from methyl 4-
chloro-2-(2-methoxyethoxy)benzoate (1.0 g, 4.1 mmol) gave 4-chloro-2-(2-
methoxyethoxy)benzohydrazide as white solid (0.86 g, 86%); 1H NMR (401 MHz, CDCl3-d) 𝛿 
ppm 9.17 (br. s., 1H) 8.12 (d, J = 8.4 Hz, 1H) 7.09 (dd, J = 8.5, 1.9 Hz, 2H) 6.96 (d, J = 1.9 Hz, 
1H) 4.28-4.21 (m, 2H) 4.16 (br. s., 2H) 3.84-3.76 (m, 2H) 3.50 (s, 3H); TOF ES+ MS: (M+H) 
245.0; HPLC Ret: 4.48 min. 
2-chloro-4-(prop-2-yn-1-yloxy)benzohydrazide. Method C starting from methyl 2-chloro-4-
(prop-2-yn-1-yloxy)benzoate (2.0 g, 8.8 mmol) gave 2-chloro-4-(prop-2-yn-1-
yloxy)benzohydrazide as yellow solid (1.48 g, 75%); 1H NMR (400 MHz, CDCl3-d) 𝛿 ppm 7.77 
(br. s., 1H) 7.64 (d, 8.7 Hz, 1H) 7.00 (d, J = 2.5 Hz, 1H) 6.92 (dd, J = 8.7, 2.5 Hz, 1H) 4.72 (d, J 




4-chloro-2-(prop-2-yn-1-yloxy)benzohydrazide. Method C starting from methyl 4-chloro-2-
(prop-2-yn-1-yloxy)benzoate (2.0 g, 8.9 mmol) gave 4-chloro-2-(prop-2-yn-1-
yloxy)benzohydrazide as yellow solid (0.6 g, 32%); 1H NMR (400 MHz, CDCl3-d) 𝛿 ppm 8.71 (d, 
8.5 Hz, 1H) 8.14 (d, J = 2.5 Hz, 1H) 7.12 (dd, J = 8.5, 2.6 Hz, 1H) 4.84 (d, J = 2.5 Hz, 2H) 4.19 
(br. s., 2H) 2.66 (t, J = 2.8 Hz, 1H); TOF ES+ MS: (M+H) 225.0; HPLC Ret: 4.38 min. 
2-chloro-3-(prop-2-yn-1-yloxy)benzohydrazide. Method C starting from methyl 2-chloro-3-
(prop-2-yn-1-yloxy)benzoate (0.34 g, 1.5 mmol) gave 2-chloro-3-(prop-2-yn-1-
yloxy)benzohydrazide as white solid (0.26 g, 76%); 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 9.52 
(br. s., 1H) 7.35 (dd, J = 8.4, 7.5 Hz, 1H) 7.26 (dd, 8.4, 1.4 Hz, 1H) 6.97 (dd, J = 8.4, 1.4 Hz, 1H) 
4.95 (d, J = 2.4 Hz, 2H) 4.47 (br. s., 2H) 3.63 (t, J = 2.4 Hz, 1H); TOF ES+ MS: (M+H) 225.0; 
HPLC Ret: 6.39 min. 
methyl 2-(benzyloxy)-4-chlorobenzoate. Method C starting from methyl 2-(benzyloxy)-4-
chlorobenzoate (1.2 g, 4.3 mmol) gave 2-(benzyloxy)-4-chlorobenzohydrazide as white solid 
(1.19 g, 99%); 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 9.22 (s, 1H) 7.62 (d, J = 8.2 Hz, 1H) 7.50-
7.43 (m, 2H) 7.45-7.36 (m, 2H) 7.37-7.30 (m, 1H) 7.27 (d, J = 1.9 Hz, 1H) 7.08 (dd, J = 8.3, 1.9 
Hz, 1H) 5.26 (s, 2H); TOF ES+ MS: (M+Na) 277.0; HPLC Ret: 5.76 min. 
5-(2,4-dichloro-3-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting 
from 2,4-dichloro-3-(2-methoxyethoxy)benzohydrazide (0.22 g, 0.79 mmol) gave 5-(2,4-dichloro-
3-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazole-2-thiol as yellow solid (0.09 g, 35%); 1H NMR 
(400 MHz, CDCl-d) 𝛿 ppm 7.70 (dd, 2H) 4.19 (t, J = 6.3 Hz, 2H) 3.73 (t, J = 6.3 Hz, 2H) 3.39 (s, 
3H); TOF ES- MS: (M-H) 320.9; HPLC Ret: 6.68 min. 
5-(2-chloro-4-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-
chloro-4-(2-methoxyethoxy)benzohydrazide (2.0 g, 8.2 mmol) gave 5-(2-chloro-4-(2-
methoxyethoxy)phenyl)-1,3,4-oxadiazole-2-thiol as yellow solid (1.92 g, 82%); 1H NMR (401 
MHz, CDCl3-d) 𝛿 ppm 7.88 (d, J = 8.8 Hz, 1H) 6.88 (s, 1H) 6.80 (d, J = 8.8 Hz, 1H) 4.07 (t, J = 
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9.0 Hz, 2H) 3.70 (t, J = 9.0 Hz, 2H) 3.39 (s, 3H); 13C NMR (401 MHz, CDCl3-d) 𝛿 ppm 167.09, 
160.77, 132.03, 131.66, 131.55, 125.23, 116.20, 113.40, 70.59, 67.71, 59.20; TOF ES- MS: (M-
H) 284.9; HPLC Ret: 6.24 min. 
5-(4-chloro-2-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 4-
chloro-2-(2-methoxyethoxy)benzohydrazide (0.86 g, 3.5 mmol) gave 5-(4-chloro-2-(2-
methoxyethoxy)phenyl)-1,3,4-oxadiazole-2-thiol as white solid (0.81 g, 80%); 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 11.38 (br. s., 1H) 7.78-7.74 (m, 1H) 7.09-7.05 (m, 2H) 4.36-4.28 (m, 2H) 
3.88 (t, J = 4.8 Hz, 2H) 3.51 (s, 3H); TOF ES+ MS: (M+H) 287.0; HPLC Ret: 6.50 min. 
5-(2-chloro-4-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-
chloro-4-(prop-2-yn-1-yloxy)benzohydrazide (1.5 g, 6.6 mmol) gave 5-(2-chloro-4-(prop-2-yn-1-
yloxy)phenyl)-1,3,4-oxadiazole-2-thiol as yellow solid (1.45 g, 83%); 1H NMR (500 MHz, DMSO-
d6) 𝛿 ppm 7.92 (d, 8.8 Hz, 1H) 7.40 (d, J = 2.5 Hz, 1H) 7.24 (dd, J = 8.9, 2.6 Hz, 1H) 5.03 (d, J = 
2.4 Hz, 2H) 2.71 (t, J = 2.4 Hz, 1H); TOF ES+ MS: (M+H) 266.9; HPLC Ret: 6.58 min. 
5-(2-chloro-4-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 4-
chloro-2-(prop-2-yn-1-yloxy)benzohydrazide (0.64 g, 2.9 mmol) gave 5-(4-chloro-2-(prop-2-yn-1-
yloxy)phenyl)-1,3,4-oxadiazole-2-thiol as yellow solid (0.75 g, 99%); 1H NMR (400 MHz, DMSO-
d6) 𝛿 ppm 7.76 (d, 8.4 Hz, 1H) 7.41 (d, J = 1.8 Hz, 1H) 7.21 (dd, J = 8.4, 1.8 Hz, 1H) 5.03 (d, J = 
2.3 Hz, 2H) 3.68 (t, J = 2.3 Hz, 1H); TOF ES+ MS: (M+H) 267.0; HPLC Ret: 6.62 min. 
5-(2-chloro-3-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-
chloro-3-(prop-2-yn-1-yloxy)benzohydrazide (0.26 g, 1.15 mmol) gave 5-(2-chloro-3-(prop-2-yn-
1-yloxy)phenyl)-1,3,4-oxadiazole-2-thiol as yellow solid (0.3 g, 98%); 1H NMR (400 MHz, 




5-(2-(benzyloxy)-4-chlorophenyl)-1,3,4-oxadiazol-2-thiol. Method D starting from methyl 2-
(benzyloxy)-4-chlorobenzoate (1.2 g, 4.34 mmol) gave 5-(2-(benzyloxy)-4-chlorophenyl)-1,3,4-
oxadiazol-2-thiol as white solid (1.3 g, 93%); 1H NMR (400 MHz, DMSO-d6) 𝛿 ppm 12.41 (br. s., 
1H) 7.77 (d, J = 8.4 Hz, 1H) 7.52 (d, J = 1.9 Hz, 1H) 7.47-7.27 (m, 5H) 7.20 (dd, J = 8.4, 1.9 Hz, 
1H) 5.33 (s, 2H); TOF ES+ MS: (M+Na) 341.0; HPLC Ret: 7.64 min. 
5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-ol. In a 50 mL round bottomed flask 2,4-
dichlorobenzohydrazide (0.5g, 2.44 mmol), K3PO4 (0.52, 2.44 mmol), and CS2 (0.19g, 0.15 mL, 
2.44 mmol) were stirred in 10 mL of H2O for 10 min at 25 °C. The reaction was then stirred at 
reflux (106 °C) for 2 hr and then cooled to 25 °C. propylene oxide (0.14 g, 2.44 mmol, 0.17 mL) 
was added and the reaction was stirred at 25 °C for 16 hr. The product was extracted with 
EtOAc (3x 15 mL), washed with brine, dried with MgSO4. and the solvent was evaporated. The 
residue was subjected to silica gel chromatography eluting with 20% EtOAc: 80% Hex. The 
fractions containing product were concentrated in vacuo to produce white solid. Yield=23% (2 
steps). 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.18 (br. s., 1H) 7.83-7.73 (m, 1H) 7.57-7.55 (m, 
1H) 7.41-7.38 (m, 1H); TOF ES+ MS: (M+H) 228.9; HPLC Ret: 6.39 min. 
5-(2, 4-dichlorophenyl)-1,3,4-thiadiazole-2-thiol. 2, 4-dichlorobenzohydrazide (0.5 g, 2.44 
mmol) was dissolved in a 0.1 M solution of KOH (0.27 g, 4.88 mmol) in EtOH/H2O (10 mL/0.44 
mL, 24.4 mmol mmol) and placed under nitrogen. Carbon disulfide (0.44 g, 7.32 mmol 0.44 mL) 
was added and the reaction was stirred at 25 °C for 3 hr. The solid that formed was filtered and 
dried in vacuo. The solid was subjected to fuming sulfuric acid (3 mL) and stirred under N2 for 2 
hr. Upon completion the reaction was diluted with 30 mL H2O and the subsequent solid was 
filtered and dried in vacuo. Yellow solid. Yield=40.5%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 
9.35 (br. s., 1H) 7.93 (d, J = 8.5 Hz, 1H) 7.71 (d, J = 8.4 Hz, 1H) 7.51 (dd, J = 8.4, 2.1 Hz, 1H); 
TOF ES- MS: (M-H) 262.9; HPLC Ret: 7.45 min. 
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2-(bromomethyl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole. In a 100 mL round bottomed flask 
2,4-dichlorobenzohydrazide (0.5 g, 2.44 mmol) and bromoacetic acid (0.34 g, 2.44 mmol) were 
combined under inert atmosphere. The reagents were dissolved in POCl3 (5.0 mL) and stirred at 
reflux (106 °C) for 16 hr. The reaction was cooled to room temperature and poured over ice 
water (5 mL). The solution was neutralized to pH ~ 9 with NaHCO3 (20%  sat) causing a 
yellow precipitate to form. The product was extracted with EtOAc (3x 25 mL), washed with brine, 
dried with MgSO4, and the solvents were evaporated producing brown oil. The impurities were 
triturated out with EtOAc:Hex (tan solid) and the mother liquor was evaporated to provide the 
desired product as white/tan solid. Yield=49%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.97 (d, J = 
8.3, 1H) 7.60 (s, 1H) 7.42 (dd, J = 8.3, 2.2 Hz, 1H) 4.62 (s, 2H); TOF ES+ MS: (M+MeOH+Na) 
359.9; HPLC Ret: 7.42 min. 
2-(2-chloro-4-cyclopropylphenyl)-5-(chloromethyl)-1,3,4-oxadiazole. In a 25 mL round 
bottomed flask 2-chloro-4-cyclopropylbenzohydrazide (0.15 g, 0.1 mmol) and chloroacetic acid 
(0.07 g, 0.71 mmol) were combined under inert atmosphere. The reagents were dissolved in 
POCl3 (1.5 mL) and stirred at reflux (106 °C) for 6 hr. The reaction was cooled to room 
temperature and poured over ice water (5 mL). The product was extracted with EtOAc (3x 20 
mL), washed with brine, dried with MgSO4, and the solvents were evaporated producing brown 
oil. The impurities were crystalized with EtOAc:Hex to provide white solid. Yield=56%. 1H NMR 
(500 MHz, DMSO-d6) 𝛿 ppm 7.36 (dd, J = 8.3, 1.5 Hz, 1H) 7.25 (s, 1H) 7.13 (dd, J = 8.3, 1.6 Hz, 
1H) 4.18 (s, 2H) 1.09-0.98 (m, 2H) 0.79-0.74 (m, 2H); HPLC Ret: 7.52 min. 
2-(2,4-dichlorophenyl)-5-(methylthio)-1,3,4-oxadiazole. 5-(2,4-dichlorophenyl)-1,3,4-
oxadiazole-2-thiol (0.25 g, 1.01 mmol) was dissolved in 5 mL THF. Triethylamine (0.12 g, 0.17 
mL, 1.21 mmol) and iodomethane (0.16 g, 0.07 mL, 1.11 mmol) were added and the mixture 
was stirred at 25 °C for 2 hr. The reaction was quenched with 5 mL H2O. The product was 
extracted with EtOAc (3x, 15 mL), washed with brine (20 mL), dried with MgSO4, and 
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concentrated in vacuo. The residue was dissolved in minimal EtOAc and the product was 
triturated with Hex, producing a white precipitate that was filtered and dried under vacuum. 
Yield=81%. 1H NMR (401 MHz, CDCl3-d) 𝛿 ppm 7.91 (d, J = 8.5 Hz, 1H) 7.57 (d, J = 2.1 Hz, 1H) 
7.39 (dd, J = 8.5, 2.1 Hz, 1H) 2.79 (s, 3H); TOF ES+ MS: (M+H) 260.9; HPLC Ret: 7.57 min. 
2-(2,4-dichlorophenyl)-5-(methylsulfonyl)-1,3,4-oxadiazole.  
Method 1: 2-(2,4-dichlorophenyl)-5-(methylthio)-1,3,4-oxadiazole (0.215 g, 0.823 mmol) was 
dissolved in 5 mL EtOH and cooled to 0 °C. Ammonium molybdate tetrahydrate (0.20 g, 0.165 
mmol) and hydrogen peroxide (0.28 g, 0.25 mL, 2.47 mmol) were added and stirred at 25 °C for 
2 hr. The reaction was quenched with 10% sodium thiosulfate (10 mL). The product was 
extracted with EtOAc (3x, 15 mL), washed with brine (20 mL), dried with MgSO4, and 
concentrated in vacuo. The yellow residue was subjected to silica gel chromatography eluting 
with 20% EtOAc: 80% Hex. The fractions containing product were concentrated in vacuo to 
produce white solid. Yield=54%. 1H NMR (401 MHz, CDCl3-d) 𝛿 ppm 8.02 (d, J = 8.5 Hz 1H) 
7.64 (d, J = 2.0 Hz 1H) 7.47 (dd, J = 8.5, 2.0 Hz, 1H) 3.55 (s, 3H); TOF ES+ MS: (M+H) 292.9; 
HPLC Ret: 6.96 min. 
Method 2: 2-(2,4-dichlorophenyl)-5-(methylthio)-1,3,4-oxadiazole (0.3 g, 1.15 mmol) was 
dissolved in 5 mL DCM. mCPBA (0.57 g, 2.30 mmol) was added and the reaction was stirred at 
25 °C for 2 hr. The solvent was evaporated, and the yellow residue was subjected to silica gel 
chromatography eluting with 20% EtOAc: 80% Hex. The fractions containing product were 
concentrated in vacuo to produce white solid. Yield=64%. 
tert-butyl-3-((5-(2,4-dichloro-3-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoate. Method E starting from 5-(2,4-dichloro-3-(2-methoxyethoxy)phenyl)-1,3,4-
oxadiazole-2-thiol (0.9 g, 0.28 mmol) and t-butyl-3-bromopropanoate (0.07 g, 0.34 mmol) gave 
tert-butyl-3-((5-(2,4-dichloro-3-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate 
as colorless oil (0.09 g, 64%); 1H NMR (401 MHz, CDCl3-d) 𝛿 ppm 7.65 (d, J = 8.6 Hz, 1H) 7.43 
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(d, J = 8.5 Hz, 1H) 4.31-4.21 (m, 2H) 3.87-3.79 (m, 2H) 3.51 (t, J = 6.8 Hz, 2H) 3.49 (s, 3H) 2.86 
(t, J = 6.8 Hz, 2H) 1.47 (s, 9H); TOF ES+ MS: (M+H) 249.0; HPLC Ret: 8.51 min. 
tert-butyl-3-((5-(2-chloro-4-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoate. Method E starting from 5-(2-chloro-4-(2-methoxyethoxy)phenyl)-1,3,4-
oxadiazole-2-thiol (1.0 g, 3.5 mmol) and t-butyl-3-bromopropanoate (0.9 g, 4.2 mmol) gave tert-
butyl-3-((5-(2-chloro-4-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate as 
colorless oil (0.78 g, 54%); 1H NMR (401 MHz, CDCl3-d) 𝛿 ppm 7.86 (d, J = 8.8 Hz, 1H) 7.08 (d, 
J = 2.5 Hz, 1H) 6.95 (dd, J = 8.8, 2.5 Hz, 1H) 4.21-4.07 (m, 2H) 3.81-3.72 (m, 2H) 3.50 (t, J = 
6.8 Hz, 2H) 3.47 (s, 3H) 2.86 (t, J = 6.8 Hz, 2H) 1.47 (s, 9H); 13C NMR (401 MHz, CDCl3-d) 𝛿 
ppm 172.47, 163.73, 161.81, 133.31, 132.57, 117.03, 114.94, 114.88, 81.02, 70.48, 68.27, 
61.14, 58.59, 35.29, 28.74, 25.56, 21.16, 14.78; HPLC Ret: 8.09 min. 
tert-butyl 3-((5-(4-chloro-2-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoate. Method E starting from 5-(4-chloro-2-(2-methoxyethoxy)phenyl)-1,3,4-
oxadiazole-2-thiol (0.2 g, 0.7 mmol) and t-butyl-3-bromopropanoate (0.18 g, 0.84 mmol) gave 
tert-butyl 3-((5-(4-chloro-2-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate as 
colorless oil (0.24 g, 83%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.94-7.74 (m, 1H) 7.09-7.03 (m, 
2H) 4.23 (t, J = 3.5 Hz, 2H) 3.82 (t, J = 3.5 Hz, 2H) 3.49 (t, J = 6.8 Hz, 2H) 3.47 (s, 3H) 2.85 (t, J 
= 6.8 Hz, 2H) 1.47 (s, 9H); TOF ES+ MS: (M+H) 415.1; HPLC Ret: 8.28 min. 
methyl 4-((5-(2-chloro-4-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(2-chloro-4-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.25 g, 
0.87 mmol) and methyl 4-bromobutanoate (0.19 g, 1.1 mmol) gave methyl 4-((5-(2-chloro-4-(2-
methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.22 g, 64%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.88 (d, J = 7.4 Hz, 1H) 7.09 (d, J = 4.0 Hz, 1H) 6.96 (dd, J = 
7.1, 2.8 Hz, 1H) 4.19 (t, J = 9.3 Hz, 2H) 3.78 (t, J = 9.3 Hz, 2H) 3.70 (s, 3H) 3.47 (s, 3H) 3.36 (t, 
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J = 7.2 Hz, 2H) 2.54 (t, J = 7.3 Hz, 3H) 2.20 (p, J = 7.0 Hz, 2H); TOF ES+ MS: (M+H) 386.9; 
HPLC Ret: 7.01 min. 
t-butyl-4-((5-(2-chloro-4-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(2-chloro-4-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.5 g, 
1.9 mmol) and t-butyl-4-bromobutanoate (0.46 g, 2.06 mmol) gave t-butyl-4-((5-(2-chloro-4-
(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.44 g, 58%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.90 (d, 8.8 Hz, 1H) 7.14 (d, J = 2.5 Hz, 1H) 7.00 (dd, J = 8.8, 
2.6 Hz, 1H) 4.76 (d, J = 2.4 Hz, 2H) 3.34 (t, J = 7.2 Hz, 2H) 2.59 (t, J = 2.4 Hz, 1H) 2.43 (t, J = 
7.2 Hz, 2H) 2.15 (p, J = 7.2 Hz, 2H) 1.45 (s, 9H); TOF ES+ MS: (M+H) 409.9; HPLC Ret: 8.35 
min. 
t-butyl-4-((5-(4-chloro-2-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(4-chloro-2-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.2 g, 
0.75 mmol) and t-butyl-4-bromobutanoate (0.2 g, 0.9 mmol) gave t-butyl-4-((5-(4-chloro-2-(prop-
2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as yellow oil (0.17 g, 56%); 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 7.87 (d, 8.4 Hz, 1H) 7.20 (d, J = 1.8 Hz, 1H) 7.11 (dd, J = 8.4, 1.9 
Hz, 1H) 4.85 (d, J = 2.4 Hz, 2H) 3.33 (t, J = 7.2 Hz, 2H) 2.60 (t, J = 2.4 Hz, 1H) 2.42 (t, J = 7.2 
Hz, 2H) 2.14 (p, J = 7.2 Hz, 2H) 1.45 (s, 9H); TOF ES+ MS: (M+H) 408.1; HPLC Ret: 8.36 min. 
methyl 4-((5-(2-chloro-3-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(2-chloro-3-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.3 g, 
1.13 mmol) and methyl 4-bromobutanoate (0.27 g, 1.46 mmol) gave methyl 4-((5-(2-chloro-3-
(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as white solid (0.21 g, 50%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.58 (d, 8.4 Hz, 1H) 7.37 (d, J = 1.9 Hz, 1H) 7.27 (dd, J = 8.4, 
1.9 Hz, 1H) 4.84 (d, J = 2.4 Hz, 2H) 3.69 (s, 3H) 3.36 (t, J = 7.2 Hz, 2H) 2.60 (t, J = 2.4 Hz, 1H) 




t-butyl-4-((5-(2-(benzyloxy)-4-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(2-(benzyloxy)-4-chlorophenyl)-1,3,4-oxadiazol-2-thiol (1.0 g, 3.1 mmol) and t-
butyl-4-bromobutanoate (0.9 g, 4.1 mmol) gave t-butyl-4-((5-(2-(benzyloxy)-4-chlorophenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (1.06 g, 73%); 1H NMR (500 MHz, CDCl3-d) 
𝛿 ppm 7.89 (d, J = 8.3 Hz, 1H) 7.54-7.47 (m, 2H) 7.41 (t, J = 7.5 Hz, 2H) 7.40-7.29 (m, 1H) 
7.12-7.04 (m, 2H) 5.21 (s, 2H) 3.27 (t, J = 7.1 Hz, 2H) 2.38 (t, J = 7.2 Hz, 2H) 2.08 (p, J = 7.4 
Hz, 2H) 1.45 (s, 9H); TOF ES+ MS: (M+H) 461.1; HPLC Ret: 9.49 min. 
methyl 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-2-methoxybutanoate. Method E 
starting from 5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-thiol (0.2 g, 0.81 mmol) and methyl 4-
iodo-2-methoxy)butanoate (0.25 g, 0.97 mmol) gave methyl 4-((5-(2,4-dichlorophenyl)-1,3,4-
oxadiazol-2-yl)thio)-2-methoxybutanoate as colorless oil (0.21 g, 67%); 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 7.91 (d, J = 8.5, 1H) 7.57 (d, J = 2.0 Hz, 1H) 7.39 (dd, J = 8.5, 2.1 Hz, 1H) 3.97 
(dd, J = 8.7, 4.0 Hz, 1H) 3.78 (s, 3H) 3.44 (s, 3H) 2.42-2.21 (m, 2H); 13C NMR (500 MHz, CDCl3-
d) 𝛿 ppm 172.21, 164.89, 163.39, 138.03, 133.72, 131.54, 131.17, 127.60, 121.39, 78.33, 
58.40, 52.13, 32.32, 28.37; TOF ES+ MS: (M+H) 377.0; HPLC Ret: 7.87 min. 
methyl 2-acetoxy-5-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)pentanoate Method E 
starting from 5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-thiol (0.5 g, 2.0 mmol) and methyl 2-
acetoxy-5-iodopentanoate (0.73 g, 2.4 mmol) gave methyl 2-acetoxy-5-((5-(2,4-dichlorophenyl)-
1,3,4-oxadiazol-2-yl)thio)pentanoate as colorless oil (0.78 g, 92%); 1H NMR (500 MHz, CDCl3-d) 
𝛿 ppm 7.91 (d, J = 8.5, 1H) 7.57 (s, 1H) 7.40 (dd, J = 8.5, 2.3 Hz, 1H) 5.06 (dd, J = 4.5, 1.9 Hz, 
1H) 3.76 (s, 3H) 3.34 (dt, J = 8.8, 5.7 Hz, 2H) 3.15 (s, 3H) 2.11-1.96 (m, 4H) ; TOF ES+ MS: 
(M+H) 418.9; HPLC Ret: 7.96 min. 
methyl 5-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-2-hydroxypentanoate. methyl 
2-acetoxy-5-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)pentanoate (0.78 g, 1.86 mmol) 
was dissolved in MeOH (8 mL) and K2CO3 (0.26 g, 1.86 mmol) was added. The reaction was 
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stirred at 25 °C for 30 min upon which the MeOH was removed in vacuo. The product was 
extracted with EtOAc (3x 15 mL) and the organic layers were combined, washed with brine, 
dried with MgSO4, and evaporated. The residue was subjected to silica gel chromatography 
eluting with 30% EtOAc: 70% Hex. The fractions containing product were concentrated in vacuo 
to produce white oil. Yield=49%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.91 (d, J = 8.4 Hz, 1H) 
7.57 (s, 1H) 7.39 (dd, J = 8.4, 2.1 Hz, 1H) 4.26 (ddd, J = 7.9, 5.0, 3.1 Hz, 1H) 3.80 (s, 3H) 3.36 
(t, J = 6.7 Hz, 2H) 2.11-1.94 (m, 4H); TOF ES+ MS: (M+H) 398.9; HPLC Ret: 7.03 min. 
methyl 5-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-2-methoxypentanoate. In a 15 
mL pressure vessel methyl 5-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-2-
hydroxypentanoate (0.2 g, 0.53 mmol) was dissolved in DCM (5.0 mL). Ag2O (0.5 g, 2.12 mmol) 
and MeI (0.75 g, 5.3 mmol, 0.33 mL) were added and the reaction was stirred at 60 °C for 18 hr. 
The solids were filtered through a pad of Celite and the mother liquor was evaporated. The 
residue was subjected to silica gel chromatography eluting with 20% EtOAc: 80% Hex. The 
fractions containing product were concentrated in vacuo to produce yellow oil. Yield=39%. 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.91 (d, J = 8.5 Hz, 1H) 7.57 (d, J = 2.1 Hz, 1H) 7.39 (dd, J = 
8.5 , 2.1 Hz, 1H) 3.82 (ddd, J = 7.4, 4.2, 2.1 Hz, 1H) 3.77 (s, 3H) 3.40 (s, 3H) 3.34 (t, J = 7.0 Hz, 
2H) 2.10-1.81 (m, 4H); TOF ES+ MS: (M+H) 390.9; HPLC Ret: 7.96 min. 
tert-butyl-3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)2-hydroxypropanoate. In a 50 
mL round-bottomed flask, 5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-2-thiol (0.5 g, 2.023 mmol) 
was dissolved in THF (10 mL) and combined with 1 M TBAF in THF (3.0 mL, 3.04 mmol) and 
tert-butyl oxirane-2-carboxylate (2.8 g, 20.23 mmol). The mixture was stirred under nitrogen at 
25 °C for 36 hr and, upon completion, concentrated in vacuo. The residue was subjected to 
silica gel chromatography eluting with 25% EtOAc: 75% Hex. The fractions containing product 
were concentrated in vacuo to produce faint yellow oil, which crystallized upon standing. 
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Yield=38%. 1H NMR (401 MHz, DMSO-d6) 𝛿 ppm 7.99 (d, 1H) 7.91 (s, 1H) 7.66 (d, 1H) 5.99 (d, 
1H) 4.33 (t, 1H) 3.67-3.48 (m, 2H) 1.40 (s, 9H); HPLC Ret: 7.90 min. 
2-(((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)methyl)thio)acetic acid. (CCG-257169). 2-
mercaptoacetic acid (0.13 g, 1.36 mmol, 0.10 mL) was dissolved in acetone (5 mL) and K2CO3 
(0.19 g, 1.36 mmol) and 2-(bromomethyl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole (0.35 g, 1.14 
mmol) were added. The reaction was stirred at 25 °C for 24 hr and the solvent was removed in 
vacuo. The residue was taken up in H2O (2 mL) and acidified to pH ~ 1 with 1 N HCl (3 mL). 
The product was extracted with DCM (3x 15 mL), washed with brine, dried with MgSO4, and the 
solvent was evaporated in vacuo. The residue was subjected to silica gel chromatography 
eluting with 5% MeOH: 95% DCM: 0.01% AcOH. The fractions containing product were 
concentrated and the residue was triturated with DCM. The product was filtered producing white 
crystals. Yield=20%. 1H NMR (400 MHz, DMSO-d6) 𝛿 ppm 12.73 (br. s., 1 H) 7.96 (d, J = 8.4, 
1H) 7.89 (d, J = 2.1, 1H) 7.65 (dd, J = 8.5, 2.1 Hz, 1H) 4.62 (s, 2H) 3.46 (s, 2H); 13C NMR (400 
MHz, DMSO-d6) 𝛿 ppm 171.17, 165.24, 162.28, 137.57, 133.27, 132.91, 131.20, 128.81, 
121.93, 33.93, 24.95; TOF ES+ MS: (M+H) 318.9; HPLC Ret: 6.13 min. 
3-(((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)methyl)thio)propanoic acid. 
(CCG-259013). 3-mercaptopropionic acid (0.024 g, 0.22 mmol, 0.02 mL) was dissolved in 
acetone (1.5 mL) and K2CO3 (0.031 g, 0.22 mmol) and 2-(2-chloro-4-cyclopropylphenyl)-5-
(chloromethyl)-1,3,4-oxadiazole (0.05 g, 0.19 mmol) were added. The reaction was stirred at 25 
°C for 24 hr and the solvent was removed in vacuo. The residue was taken up in H2O (2 mL) 
and acidified to pH ~ 1 with 1 N HCl (3 mL). The product was extracted with EtOAc (3x 15 mL), 
washed with brine, dried with MgSO4, and the solvent was evaporated in vacuo. The residue 
was subjected to silica gel chromatography eluting with 2% to 5% MeOH DCM: 0.01% AcOH. 
The fractions containing product were concentrated and the product was crystalized from 
EtOAc/Hex producing white powder. Yield=20%. 1H NMR (500 MHz, MeOD) 𝛿 ppm 7.50 (d, J = 
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8.0 Hz, 1H) 7.19 (d, J = 1.7 Hz, 1H) 7.08 (dd, J = 8.0, 1.7 Hz, 1H) 3.33 (s, 2H) 2.93 (t, J = 7.1 
Hz, 2H) 2.69 (t, J = 7.1 Hz, 2H) 1.95-1.88 (m, 1H) 1.10-0.98 (m, 2H) 0.79-0.69 (m, 2H); 13C NMR 
(500 MHz, MeOD) 𝛿 ppm 174.25, 169.98, 167.21, 149.21, 131.22, 130.31, 129.13, 126.70, 
123.59, 33.78, 32.73, 27.06, 14.54, 9.18; TOF ES+ MS: (M+H2O) 357.1; HPLC Ret: 5.21 min. 
tert-butyl 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)oxy)butanoate. 5-(2,4-
dichlorophenyl)-1,3,4-oxadiazol-2-ol (0.06 g, 0.251 mmol) was dissolved in DMF (2 mL). K2CO3 
(0.045 g, 0.33 mmol) and tert-butyl 4-bromobutanoate (0.07 g, 0.33 mmol, 0.06 mL) were added 
and the reaction was stirred at 90 °C for 1 hr. The solvent was removed in vacuo and the 
residue was partitioned between H2O (10 mL) and DCM (10 mL). The product was extracted 
with DCM (3x 10 mL), washed with brine, dried with MgSO4, and evaporated. The oil was 
subjected to silica gel chromatography eluting with 10% EtOAc: 90% Hex. The fractions 
containing product were concentrated in vacuo to produce white solid. Yield=62%. 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.75 (d, J = 8.5, 1H) 7.54 (d, J = 2.1 Hz, 1H) 7.37 (dd, J = 8.5, 2.1 Hz, 
1H) 3.88 (t, J = 6.8 Hz, 2H) 2.36 (t, J = 7.3 Hz, 2H) 2.10 (p, J = 7.1 Hz, 2H) 1.45 (s, 9H); TOF 
ES+ MS: (M+Na) 396.9; HPLC Ret: 8.72 min. 
methyl 4-((5-(2,4-dichlorophenyl)-1,3,4-thiadiazol-2-yl)thio)butanoate. Potassium carbonate 
(0.17 g, 1.24 mmol) and methyl 4-bromobutryate (0.22 g, 1.24 mmol, 0.17 mL) were added to 5-
(2,4-dichlorophenyl)-1,3,4-thiadiazole-2-thiol (0.25 g, 0.95 mmol) dissolved in DMF (5 mL). The 
mixture was stirred at 90 °C for 1 hr. The DMF was evaporated, the oil was diluted with H2O, 
and product was extracted with DCM (3 x 15 mL). The organic layers were combined, washed 
with brine, and evaporated. The oil was subjected to silica gel chromatography eluting with 20% 
EtOAc: 80% Hex. The fractions containing product were concentrated to produce white solid. 
Yield=35%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.80 (d, J = 8.4 Hz, 1H) 7.48 (d, J = 2.0 Hz, 1H) 
7.31 (dd, J = 8.4, 2.1 Hz, 1H) 4.38 (t, J = 6.3 Hz, 2H) 3.68 (s, 3H) 2.50 (t, J = 7.4 Hz, 2H) 2.11 




(2-chloro-4-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate (0.1 g, 0.25 mmol) 
was dissolved in 2:1 DMF/H2O solution. Bis(triphenylphosphine)palladium(II) chloride (0.01 g, 
0.015 mmol) and trimethylamine (0.2 g, 1.96 mmol, 0.27 mL) were added and the reaction was 
stirred under nitrogen at 80 °C for 5 hr. The reaction was quenched with H2O (5 mL) and 
acidified to pH ~ 1 with 1N HCl (2 mL). The product was extracted with EtOAc (3 x 15 mL), and 
the resulting organic layer was washed with brine (20 mL), dried with MgSO4, and evaporated. 
The oil was subjected to silica gel chromatography eluting with 40% EtOAc: 60% Hex. The 
fractions containing product were concentrated in vacuo to produce yellow solid. Similar analogs 
were made in an analogous fashion. Yield=52%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.80 (d, 
8.6 Hz, 1H) 7.07 (d, J = 2.5 Hz, 1H) 6.89 (dd, J = 8.6, 2.5 Hz, 1H) 3.33 (t, J = 2.4 Hz, 1H) 2.43 
(t, J = 7.2 Hz, 2H) 2.15 (p, J = 7.2 Hz, 2H) 1.46 (s, 9H); TOF ES+ MS: (M+Na) 393.0; HPLC Ret: 
7.37 min. 
methyl 4-((5-(2-chloro-3-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. *note: methyl 
4-((5-(2-chloro-3-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate used as starting 
material; silica gel chromatography eluting with 35% EtOAc to 50% EtOAc: 65% Hex to 50% 
Hex: 0.01% AcOH. White solid. Yield=41%; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.37 (dt, 7.8, 
1.2 Hz, 1H) 7.30 (t, J = 8.1 Hz, 1H) 7.15 (dd, J = 8.2, 1.4 Hz, 1H) 3.67 (s, 3H) 3.37 (t, J = 7.2 
Hz, 2H) 2.54 (t, J = 7.2 Hz, 2H) 2.16 (p, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 329.0; HPLC Ret: 
6.02 min. 
4-((5-(4-chloro-2-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-257422). 
tert-butyl 4-((5-(2-(benzyloxy)-4-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate (0.085 g, 
0.195 mmol) was dissolved in 0.5 mL ethane thiol. Boron trifluoride etherate (0.183 g, 1.289 
mmol, 0.06 mL) was added and the reaction was stirred at 25 oC for 1 hr. The reaction was 
quenched with 5 mL H2O and the product was extracted with Et2O (3 x 20 mL). The organic 
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layers were combined, washed with brine, dried with MgSO4, and evaporated, producing a white 
powder. Yield=98%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 12.18 (br. s., 1H) 8.03 (d, J = 1.9 Hz, 
1H) 7.90 (d, J = 8.4 Hz, 1H) 7.78 (dd, J = 8.4, 1.9 Hz, 1H) 3.33 (t, J = 2.4 Hz, 1H) 2.39 (t, J = 7.3 
Hz, 2H) 2.00 (p, J = 7.3 Hz, 2H); HPLC Ret: 6.90 min. 
tert-butyl 4-((5-(4-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)-2-chlorophenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate. tert-butyl 4-((5-(2-chloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.047 g, 0.13mmol) was dissolved in 1 mL DMF. Freshly prepared 2-(2-((tert-
butoxycarbonyl)amino)ethoxy)ethyl methanesulfonate (0.033 g, 0.12 mmol) along with Cs2CO3 
(0.19 g, 0.58 mmol) were added and the reaction was stirred at 75 oC for 1.5 hr. The DMF was 
evaporated and the resulting oil was diluted with 10 mL H2O and extracted with DCM (3 x 10 
mL). The organic layers were combined, washed with brine, dried with MgSO4, and evaporated. 
The subsequent oil was subjected to silica gel chromatography eluting with 60% EtOAc: 40% 
Hex. The fractions containing product were concentrated in vacuo to produce pale yellow oil. 
Similar compounds were made in an analogous fashion. Yield=93%. 1H NMR (400 MHz, CDCl3-
d) 𝛿 ppm 7.88 (d, 8.8 Hz, 1H) 7.08 (d, J = 2.5 Hz, 1H) 6.94 (dd, J = 8.8, 2.5 Hz, 1H) 4.94 (br. s, 
1H) 4.16 (t, J = 5.2 Hz, 2H) 3.84 (t, J = 5.6 Hz, 2H) 3.62 (t, J = 5.2 Hz, 2H) 3.37-3.32 (m, 4H) 
2.43 (t, J = 7.2 Hz, 2H) 2.16 (p, J = 7.2 Hz, 2H) 1.45 (s, 18H); TOF ES+ MS: (M+H) 557.9; HPLC 
Ret: 8.58 min. 
4-((5-(2-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)-4-chlorophenyl)-1,3,4-oxadiazol-
2-yl)thio)butanoate. *note: 4-((5-(4-chloro-2-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic 
acid (0.06 g, 0.19 mmol) used as starting material; reaction done at 90 oC for 3 hr; silica gel 
chromatography eluting with 40% EtOAc: 60% Hex. Colorless oil. Yield=77%; 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.83 (d, 8.5 Hz, 1H) 7.73 (d, J = 1.3 Hz, 1H) 7.54 (dd, J = 8.5, 2.0 Hz, 1H) 
5.30 (br. s, 1H) 4.25 (t, J = 5.6 Hz, 2H) 3.66 (t, J = 5.2 Hz, 2H) 3.54 (t, J = 5.2 Hz, 2H) 3.40-3.31 




(2,4-dichlorophenyl)-1,3,4-oxadiazole-2-thiol (0.2 g, 0.81 mmol), potassium carbonate (0.145 g, 
1.05 mmol), and 5-(2-chloroethyl)-1H-tetrazole (0.14 g, 1.05 mmol) were dissolved in acetone (5 
mL). The mixture was stirred at 60 °C for 2 days. The acetone was removed in vacuo and the 
remaining oil was diluted in 5 mL H2O, acidified to pH ~ 1 with 1N HCl, and extracted with 
EtOAc (3 x 15 mL). The organic layers were combined, washed with brine, dried with MgSO4, 
and evaporated in vacuo. The solid obtained was subjected to silica gel chromatography eluting 
with 1% MeOH: 99% DCM. The fractions containing product were concentrated in vacuo to 
produce white solid. Yield=38%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 8.00 (d, J = 8.5 Hz, 1H) 
7.92(d, J = 2.1 Hz, 1H) 7.67 (dd, J = 8.5, 2.2 Hz, 1H) 3.74 (t, J = 7.0 Hz, 2H) 3.50 (t, J = 7.0 Hz, 
2H) 3.40 (br. s., 1H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 164.47, 163.05, 137.61, 133.17, 
132.75, 131.21, 128.65, 121.61, 30.10, 23.94; TOF ES- MS: (M+H) 342.9; HPLC Ret: 6.32 min; 
96% pure. 
3-((5-(2,4-dichloro-3-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid 
(CCG-224500). Method F starting from tert-butyl-3-((5-(2,4-dichloro-3-(2-
methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate (0.08 g, 0.18 mmol) gave 3-((5-
(2,4-dichloro-3-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid as white 
crystals (0.09 g, 64%); 1H NMR (401 MHz, CDCl3-d) 𝛿 ppm 7.65 (d, J = 8.0 Hz, 1H) 7.43 (d, J = 
8.0 Hz, 1H) 4.25 (t, J = 4.0 Hz, 2H) 3.83 (t J = 4.0 Hz, 2H) 3.55 (t, J = 8.0 Hz, 2H) 3.48 (s, 3H) 
3.05 (t, J = 8.0 Hz, 2H); TOF ES+ MS: (M+H) 393.24; HPLC Ret: 6.32 min; 97.5% pure. 
3-((5-(2-chloro-4-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid 
(CCG-224480). Method F starting from tert-butyl-3-((5-(2-chloro-4-(2-methoxyethoxy)phenyl)-
1,3,4-oxadiazol-2-yl)thio)propanoate (0.3 g, 0.72 mmol) gave 3-((5-(2-chloro-4-(2-
methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid as white crystals (0.22 g, 85%); 
1H NMR (401 MHz, CDCl3-d) 𝛿 ppm 7.86 (d, J = 8.0 Hz, 1H) 7.08 (d, J = 4.0 Hz, 1H) 6.94 (dd, J 
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= 8.0, 4.0 Hz, 1H) 4.18 (t, J = 4.0 Hz, 2H) 3.78 (t, J = 4.0 Hz, 2H) 3.53 (t, J = 8.0 Hz, 2H) 3.46 
(s, 3H) 3.02 (t, J = 8.0 Hz, 2H); 13C NMR (401 MHz, CDCl3-d) 𝛿 ppm 175.92, 163.91, 161.44, 
134.12, 131.96, 116.98, 115.22, 113.87, 70.59, 67.82, 59.25, 33.92, 27.02, 14.17; TOF ES+ 
MS: (M+H) 359.0; HPLC Ret: 5.85 min; 92.7% pure. 
3-((5-(4-chloro-2-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid. 
(CCG-232942). Method F starting from tert-butyl-3-((5-(4-chloro-2-(2-methoxyethoxy)phenyl)-
1,3,4-oxadiazol-2-yl)thio)propanoate (0.24 g, 0.58 mmol) gave 3-((5-(4-chloro-2-(2-
methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid as white powder (0.15 g, 69%); 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.87-7.82 (m, 1H) 7.07-7.05 (m, 2H) 4.24 (t, J = 5.0 Hz, 2H) 
3.83 (t, J = 5.0 Hz, 2H) 3.52 (t, J = 6.8 Hz, 2H) 3.46 (s, 3H) 3.00 (t, J = 6.8 Hz, 2H); 13C NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 175.48, 163.84, 157.38, 138.88, 131.01, 121.49, 113.97, 111.65, 
70.62, 68.93, 59.39, 34.02, 27.06, 14.17; TOF ES+ MS: (M+H) 359.0; HPLC Ret: 6.148 min; 
98% pure. 
4-((5-(2-chloro-4-(2-methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-
257156). Method G starting from methyl 4-((5-(2-chloro-4-(2-methoxyethoxy)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate (0.22 g, 0.56 mmol) gave 4-((5-(2-chloro-4-(2-
methoxyethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white powder (0.14 g, 65%); 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.25 (br. s., 1H) 7.87 (d, J = 8.8 Hz, 1H) 7.08 (d, J = 2.1 Hz, 
1H) 6.95 (dd, J = 8.5, 2.0 Hz, 1H) 4.21-4.15 (m, 2H) 3.81-3.75 (m, 2H) 3.46 (s, 3H) 3.37 (t, J = 
7.2 Hz, 2H) 2.58 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 373.0; HPLC 
Ret: 6.03 min; 97 % pure. 
4-((5-(2-chloro-4-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-
257274). Method F starting from t-butyl-4-((5-(2-chloro-4-(prop-2-yn-1-yloxy)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate (0.15 g, 0.37 mmol) gave 4-((5-(2-chloro-4-(prop-2-yn-1-
yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white powder (0.12 g, 97%); 1H NMR 
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(500 MHz, CDCl3-d) 𝛿 ppm 9.99 (br. s., 1H) 7.90 (d, 8.8 Hz, 1H) 7.14 (d, J = 2.5 Hz, 1H) 7.00 
(dd, J = 8.8, 2.6 Hz, 1H) 4.76 (d, J = 2.4 Hz, 2H) 3.37 (t, J = 7.1 Hz, 2H) 2.59 (m, 3H) 2.22 (p, J 
= 7.1 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.81, 164.17, 164.04, 160.00, 134.12, 
131.97, 117.44, 116.06, 114.05, 76.70, 56.19, 32.24, 31.59, 24.34; TOF ES+ MS: (M+H) 353.0; 
HPLC Ret: 6.35 min; 98% pure. 
4-((5-(4-chloro-2-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-
257291). Method F starting from t-butyl-4-((5-(4-chloro-2-(prop-2-yn-1-yloxy)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate (0.1 g, 0.25 mmol) gave 4-((5-(4-chloro-2-(prop-2-yn-1-
yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as yellow solid (0.08 g, 89%); 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 9.36 (br. s., 1H) 7.84 (d, 8.3 Hz, 1H) 7.22 (d, J = 1.3 Hz, 1H) 7.12 
(dd, J = 8.4, 1.4 Hz, 1H) 4.86 (d, J = 2.3 Hz, 2H) 3.38 (t, J = 7.1 Hz, 2H) 2.61-2.59 (m, 3H) 2.20 
(p, J = 7.1 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.78, 164.37, 163.40, 156.00, 
139.21, 130.98, 122.17, 114.42, 111.34, 77.34, 56.71, 32.18, 31.54, 24.28; TOF ES+ MS: (M+H) 
353.0; HPLC Ret: 6.40 min; 95% pure. 
4-((5-(2-chloro-3-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-
257631). Method G starting from methyl 4-((5-(2-chloro-3-(prop-2-yn-1-yloxy)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate (0.05 g, 0.14 mmol) gave 4-((5-(2-chloro-3-(prop-2-yn-1-
yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid (0.048 g, 100%); 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 7.58 (dd, 7.8, 1.4 Hz, 1H) 7.37 (t, J = 8.1 Hz, 1H) 7.28 (dd, J = 8.1, 
1.4 Hz, 1H) 4.85 (d, J = 2.4 Hz, 2H) 3.39 (t, J = 7.1 Hz, 2H) 2.61-2.59 (m, 3H) 2.23 (p, J = 7.1 
Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.65, 164.78, 164.08, 154.11, 134.23, 127.46, 
124.48, 123.7, 116.87, 77.44, 57.17, 32.21, 31.59, 24.33; TOF ES+ MS: (M+H) 353.0; HPLC 
Ret: 6.20 min; 95% pure. 
4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-2-methoxybutanoic acid (CCG-
232961). Method G starting from methyl 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-2-
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methoxybutanoate (0.2 g, 0.33 mmol) gave 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-
2-methoxybutanoic acid as white powder (0.11 g, 55%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
8.77 (br. s., 1H) 7.91 (d, J = 8.5 Hz, 1H) 7.57 (d, J = 1.7 Hz, 1H) 7.39 (dd, J = 8.5, 1.7 Hz, 1H) 
4.02 (ddd, J = 8.7, 4.0, 1.3 Hz, 1H) 3.50 (s, 3H) 3.47-3.42 (m, 2H) 2.49-2.28 (m, 2H); 13C NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 175.86, 164.92, 163.44, 138.14, 133.75, 131.60, 131.19, 127.63, 
121.26, 78.06, 58.60, 31.98, 28.20, 14.11; TOF ES+ MS: (M+H) 363.0; HPLC Ret: 6.78 min; 
99% pure. 
5-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-2-methoxypentanoic acid. (CCG-
257222). Method G starting from methyl 5-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-2-
methoxypentanoate (0.08 g, 0.20 mmol) gave 5-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)-2-methoxypentanoic acid as white oil (0.07 g, 88%);. 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 9.27 (br. s., 1H) 7.91 (d, J = 8.4, 1H) 7.57 (d, J = 2.3 1H) 7.39 (dd, J = 8.4, 2.3 Hz, 1H) 
3.87 (dt, J = 7.5, 4.2 Hz, 1H) 3.46 (s, 3H) 3.36 (t, J = 7.4 Hz, 2H) 2.13-1.95 (m, 4H); 13C NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 177.25, 165.21, 163.33, 138.06, 131.58, 131.17, 127.61, 121.37, 
79.43, 58.45, 32.14, 31.10, 25.12, 20.75; TOF ES+ MS: (M+H) 376.9; HPLC Ret: 6.93 min; 95% 
pure. 
4-((5-(2,4-dichlorophenyl)-1,3,4-thiadiazol-2-yl)thio)butanoic acid. (CCG-257446). Method 
G starting from methyl 4-((5-(2,4-dichlorophenyl)-1,3,4-thiadiazol-2-yl)thio)butanoate (0.12 g, 
0.73 mmol) gave 4-((5-(2,4-dichlorophenyl)-1,3,4-thiadiazol-2-yl)thio)butanoic acid as white solid 
(0.08 g, 73%);. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.25 (d, J = 8.6 Hz, 1H) 7.54 (d, J = 2.1 Hz, 
1H) 7.40 (dd, J = 8.6, 2.1 Hz, 1H) 3.48 (t, J = 7.1 Hz, 2H) 2.60 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.1 
Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 167.02, 162.72, 137.16, 132.90, 131.51, 130.32, 





acid. (CCG-257308). Method F starting from tert-butyl 4-((5-(4-(2-(2-((tert-
butoxycarbonyl)amino)ethoxy)ethoxy)-2-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate (0.06 
g, 0.11 mmol) gave 4-((5-(4-(2-(2-(aminoethoxy)ethoxy)-2-chlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as white oil (0.054 g, 99%); 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 8.99 (br. 
s., 1H) 7.81 (br. s., 3H) 7.71 (d, 8.8 Hz, 1H) 7.21 (d, J = 2.5 Hz, 1H) 7.06 (dd, J = 8.8, 2.5 Hz, 
1H) 4.19 (t, J = 5.3 Hz, 2H) 3.74 (t, J = 5.4 Hz, 2H) 3.60 (t, J = 5.3 Hz, 2H) 3.24 (t, J = 7.2 Hz, 
2H) 2.94 (t, J = 5.6 Hz, 2H) 2.32 (t, J = 7.3 Hz, 2H) 1.93 (p, J = 7.3 Hz, 2H); 19F NMR (500 MHz, 
DMSO-d6) 𝛿 ppm 74.30; 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 174.09, 164.11, 163.67, 161.71, 
133.36, 132.68, 117.12, 115.03, 114.93, 69.00, 68.37, 67.25, 39.01, 32.64, 31.96, 25.01; TOF 
ES+ MS: (M+H) 403.9; HPLC Ret: 4.62 min; 95% pure. 
4-((5-(2-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)-4-chlorophenyl)-1,3,4-oxadiazol-
2-yl)thio)butanoic acid. Method F starting from tert-butyl 4-((5-(2-(2-(2-((tert-
butoxycarbonyl)amino)ethoxy)ethoxy)-4-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate (0.07 
g, 0.14 mmol) gave 4-((5-(2-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)-4-chlorophenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoic acid as yellow oil (0.07 g, quant); 1H NMR (500 MHz, DMSO-
d6) 𝛿 ppm 7.87 (br. s., 3H) 7.80 (d, 8.4 Hz, 1H) 7.73 (d, J = 1.9 Hz, 1H) 7.55 (dd, J = 8.5, 1.9 Hz, 
1H) 5.18-5.09 (m, 3H) 4.29 (t, J = 5.3 Hz, 2H) 3.81-3.70 (m, 4H) 3.35 (t, J = 6.7 Hz, 2H) 3.29 
(br. s., 2H) 2.55 (t, J = 6.9 Hz, 2H) 2.20 (p, J = 7.0 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 
172.87, 165.53, 163.51, 134.08, 133.72, 131.60, 130.67, 126.48, 121.27, 77.20, 69.41, 66.16, 
63.18, 40.00, 32.61, 31.50, 24.68; HPLC Ret: 5.64 min. 
5-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-2-hydroxypentanoic acid (CCG-
257154). In a 50 mL round bottomed flask methyl 5-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)-2-hydroxypentanoate (0.34 g, 0.90 mmol) was dissolved in THF (4 mL) and cooled to 0 
°C under an inert atmosphere. 60% NaH in mineral oil (0.043 g, 1.10 mmol) and MeI (0.13 g, 
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0.90 mmol, 0.056 mL) were added and the reaction was stirred at 0 °C for 30 min. The solvent 
was evaporated, and the residue was acidified with 1N HCl (5 mL). The product was extracted 
with EtOAc (3x 15 mL), washed with brine, dried with MgSO4, and concentrated in vacuo. The 
product was dissolved in a minimal amount of EtOAc and triturated with hexane to provide white 
solid. Yield=44.3%. 1H NMR (400 MHz, CDCl3-d) 𝛿 ppm 7.88 (d, J = 8.5, 1H) 7.55 (d, J = 2.0. 
1H) 7.39 (dd, J = 8.5, 2.1 Hz, 1H) 4.36 (dd, J = 7.8, 3.0 Hz, 1H) 3.35 (t, J = 6.8 Hz, 2H) 2.15-
1.98 (m, 4H); 13C NMR (400 MHz, CDCl3-d) 𝛿 ppm 177.32, 165.69, 163.29, 138.25, 133.72, 
131.62, 131.29, 127.61, 121.02, 69.67, 32.49, 31.91, 25.12; TOF ES+ MS: (M+H) 384.9; HPLC 
Ret: 6.27 min; 95% pure. 
3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-2-methoxypropanoic acid. (CCG-
257021). 2-(2,4-dichlorophenyl)-5-(methylsulfonyl)-1,3,4-oxadiazole (0.25 g, 0.853 mmol) was 
dissolved in 10 mL acetone. K2CO3 (0.141 g, 1.02 mmol) and 3-mercapto-2-methoxypropanoic 
acid (0.139 g, 1.02 mmol) were added and the mixture was stirred at 25 °C for 2 hr. The 
acetone was removed in vacuo and the remaining residue was partitioned between water (5 
mL) and DCM (5 mL). The aqueous was acidified to pH ~ 1 with 1N HCl (15 mL) and the 
product was extracted with EtOAc (3x 15 mL). The organic layers were washed with brine (20 
mL), dried with MgSO4, and concentrated in vacuo. The residue was dissolved in minimal 
EtOAc and the product was triturated with Hex, producing a white precipitate that was filtered 
and dried under vacuum. Yield=64%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.92 (d, J = 8.5Hz, 
1H) 7.58 (d, J = 3.0 Hz, 1H) 7.40 (dd, J = 8.5, 3.0 Hz, 1H) 4.28 (td, J = 7.7, 3.8 Hz, 1H) 3.88-
3.83 (m, 2H) 3.56 (s, 3H); TOF ES+ MS: (M+H) 350.9; HPLC Ret: 6.65 min; 95.1 % pure. 
4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-N-hydroxybutanamide. (CCG-257445). 
4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (0.1 g, 0.3 mmol) was 
dissolved in 3 mL Et2O and cooled to 0 °C. Ethyl chloroformate (0.04g, 0.36 mmol, 0.035 mL)) 
and N-methylmorpholine (0.04 g, 0.39 mmol, 0.043 mL) were added and the reaction was 
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stirred at 0 °C for 10 min. The salt was filtered and the filtrate was added to a round bottomed 
flask containing freshly prepared hydroxylamine (0.042 g, 0.6 mmol) in MeOH (4 mL). The 
reaction was stirred at 25 °C for 45 min. The solvent was evaporated and the solid obtained was 
subjected to silica gel chromatography eluting with 10% MeOh: 90% DCM. The fractions 
containing product were concentrated in vacuo to produce white solid. Yield=25%. 1H NMR (500 
MHz, DMSO-d6) 𝛿 ppm 10.45 (br. s., 1H) 8.74 (s, 1H) 8.00 (d, J = 8.4 Hz, 1H) 7.92 (d, J = 2.1 
Hz, 1H) 7.66 (dd, J = 8.4, 2.2 Hz, 1H) 3.36-3-30 (m, 2H) 2.14 (t, J = 7.3 Hz, 2H) 2.01 (p, J = 7.3 
Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 179.71, 168.50, 164.98, 162.95, 137.98, 132.77, 
131.17, 128.64, 121.70, 32.12, 31.29, 25.63; TOF ES- MS: (M-H) 246.9; HPLC Ret: 5.73 min; 
95% pure. 
4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)sulfonyl)butanoic acid (CCG-258126). 4-((5-
(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (0.05 g, 0.15 mmol) was dissolved 
in 1 mL DCM. 70% mCPBA (0.08 g, 0.33 mmol) was added and the reaction was stirred at 25 
°C for 4 hr. The solvent was evaporated, and the yellow residue was subjected to silica gel 
chromatography eluting with 5% MeOH: 95% DCM. The fractions containing product were 
concentrated in vacuo to produce white solid. The solid was crystalized with EtOAc/Hex to 
produce white powder. Yield=58%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 12.31 (br. s, 1H) 8.10 
(d, J = 8.5 Hz, 1H) 8.00 (J = 2.0 Hz, 1H) 7.74 (dd, J = 8.5, 2.1 Hz, 1H) 3.83 (t, J = 7.3 Hz, 2H) 
2.43 (t, J = 7.3 Hz, 2H) 2.01 (p, J = 7.5 Hz, 2H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 173.73, 
164.02, 161.87, 138.74, 133.93, 133.60, 131.45, 128.83, 120.84, 54.32, 31.71, 17.93; TOF E- 
MS: (M-H) 364.98; HPLC Ret: 6.56 min; 99% pure. 
222740-Series Target Identification Analog Procedures (Chapter 2): 
1-tert-butyl 3-methyl 5-oxopiperidine-1,3-dicarboxylate. In a flame dried 50-mL round 
bottomed flask, (COCl)2 (0.71 g, 0.49 mL, 5.6 mmol) was dissolved in DCM (15 mL) and cooled 
to -78 °C. DMSO (0.87 g, 0.79 mL, 11.2 mmol) was added and the solution was stirred for 15 
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min. 1-tert-butyl 3-methyl 5-hydroxypiperidine-1,3-dicarboxylate (1.0 g, 3.86 mmol) dissolved in 
DCM (5 mL) was added dropwise and the reaction was stirred at -78 °C for 15 min. Et3N (1.76 
g, 2.42 mL, 17.4 mmol) was added, the reaction stirred at -78 °C for 30 min, and then at 25 °C 
for 2 hr. The reaction was quenched with sat. NaHCO3 (20 mL). The product was extracted with 
DCM (3 x 20 mL), washed with brine (3 x 15 mL), dried with MgSO4, and concentrated in vacuo. 
The oil was subjected to silica gel chromatography eluting with 25% EtOAc: 75% Hex. The 
fractions containing product were concentrated to produce yellow solid. Yield=85%. 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 4.01 (s, 2H) 3.88-3.77 (m, 2H) 3.73 (s, 3H) 3.07 (p, 6.1 Hz, 1H) 2.74 
(dd, 16.9, 7.4 Hz, 1H) 2.63 (dd, 16.9, 5.8 Hz, 1H) 1.46 (s, 9H); QTOF ES+ MS: (M+MeOH+Na) 
312.14. 
1-tert-butyl 3-methyl 5,5-difluoropiperidine-1,3-dicarboxylate. In a flame dried 50-mL round 
bottomed flask, 1-tert-butyl 3-methyl 5-oxopiperidine-1,3-dicarboxylate (0.84 g, 3.28 mmol) was 
dissolved in DCM (15 mL) and cooled to -78 °C. DAST (1.06 g, 0.87 mL, 6.56 mmol) was added 
and the solution was stirred for 1 hr, and then at 25 °C for 1 hr. The reaction was quenched with 
sat. NaHCO3 (20 mL). The product was extracted with DCM (3 x 20 mL), washed with brine (3 x 
15 mL), dried with MgSO4, and concentrated in vacuo. The oil was subjected to silica gel 
chromatography eluting with 15% EtOAc: 85% Hex. The fractions containing product were 
concentrated to produce yellow solid. Yield=83%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 4.49-4.22 
(m, 2H) 3.72 (s, 3H) 3.09-2.90 (m, 2H) 2.85-2.75 (m, 2H) 2.00 (dtd, 31.5, 13.0, 4.8 Hz, 1H) 1.47 
(s, 9H); QTOF ES+ MS: (M+Na) 302.12. 
1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid. In a 25 mL round-
bottomed flask 1-tert-butyl 3-methyl 5,5-difluoropiperidine-1,3-dicarboxylate (0.32 g, 1.15 mmol) 
was dissolved in THF (3.0 mL). 1 M NaOH (3.0 mL) was added to the solution and the reaction 
was stirred at 25 °C for 1 hr. The THF was evaporated in vacuo and then the solution was 
acidified with 1 N HCl (7 mL). The product was extracted with EtOAc (3x 20 mL), washed with 
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brine (3x 15 mL), dried with MgSO4, and concentrated in vacuo. The residue was crystalized 
with EtOAc/Hex, producing a white precipitate that was filtered and dried under vacuum. 
Yield=79%. QTOF ES- MS: (M-H) 264.10. 
methyl 3-bromo-5-methoxybenzoate. In a 50 mL round bottomed flask, 3-bromo-5-
hydroxybenzoic acid (0.5 g, 2.3 mmol) was dissolved in DMF (10 mL). Cs2CO3 (2.25 g, 6.91 
mmol) and (after 10 mins stirring) MeI (0.82 g, 0.36 mL, 5.76 mmol) were added. The reaction 
took place at 25 °C for 16 hr. The product was extracted with EtOAc (3 x 20 mL), washed with 
brine (2 x 15 mL), and concentrated in vacuo to afford brown oil. Yield = 97%. 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.76 (t, 1.5 Hz, 1H) 7.49 (dd, J = 2.5, 1.3 Hz, 1H) 7.24 (t, J = 2.1 Hz, 1H) 
3.94 (s, 3H) 3.84 (s, 3H); QTOF ES+ MS: (M+H) 246.98; HPLC Ret: 7.64 min. 
methyl 3-bromo-5-((tert-butyldimethylsilyl)oxy)benzoate. Methyl 3-bromo-5-
hydroxybenzoate (0.47 g, 2.03 mmol) was dissolved in DMF (5.0 mL), and then ImH (0.18 g, 
2.64 mmol) and TBS-Cl (0.34 g, 2.24 mmol) were added. The reaction was stirred at 25 oC for 
16 hr. The reaction was partitioned between H2O and 1:1 EtOAc/Hex, and the product was 
extracted with 1:1 EtOAc/Hex (3 x 20 mL). The organic layers were combined, washed with 
brine (3x 10 mL), dried with MgSO4, and concentrated in vacuo to produce orange oil. 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 7.77 (t, J = 1.4 Hz, 1H) 7.42 (dd, J = 2.3, 1.1 Hz, 1H) 7.18 (dd, J = 
4.2, 0.7 Hz, 1H) 3.91 (s, 3H) 0.99 (s, 9H) 0.23 (s, 6H); 13C NMR (126 MHz, CDCl3-d) 𝛿 ppm 
165.58, 156.45, 132.67, 127.72, 125.56, 122.39, 119.88, 52.37, 25.53, 18.13, -4.51; QTOF ES- 
MS: (M+H) 347.05. 
methyl 3-bromo-5-(2-methoxyethoxy)benzoate. 3-bromo-5-hydroxybenzoic acid (1.0 g, 4.61 
mmol) was dissolved in 20 mL MeOH. Sulfuric acid (0.59 g, 0.3 mL, 5.99 mmol) was added 
dropwise and the reaction mixture was heated at reflux (95 °C) for 16 hr. MeOH was removed in 
vacuo and the residue was diluted in 15 mL H2O. The product was extracted with EtOAc (3x 15 
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mL), washed with brine (2 x 10 mL), dried with MgSO4, and concentrated in vacuo. The resulting 
oil was triturated with EtOAc/Hex to produce pale orange powder. The freshly synthesized 
methyl 3-bromo-5-hydroxybenzoate (0.2 g, 0.87 mmol) was dissolved in DMF (4.0 mL), and 
then K2CO3 (0.24 g, 1.73 mmol) and 1-bromo-2-methoxyethane (0.16 g, 1.13 mmol, 0.11 mL) 
were added. The reaction was stirred at 90 oC for 1 hr. After the reaction cooled to 25 oC, brine 
was added, and the product was extracted with DCM (3 x 20 mL). The organic layers were 
combined, washed with brine (2 x 10 mL), dried with MgSO4, and concentrated in vacuo. The 
subsequent oil was subjected to silica gel chromatography eluting with 100% EtOAc. The 
fractions containing product were concentrated in vacuo to produce orange oil. Yield = 85%. 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.75 (t, J = 1.4 Hz, 1H) 7.51 (dd, J = 2.5, 1.3 Hz, 1H) 7.29 (dd, 
J = 2.5, 1.3 Hz, 1H) 4.14 (t, J = 4.5 Hz, 2H) 3.90 (s, 3H) 3.76 (t, J = 4.5 Hz, 2H) 3.44 (s, 3H);  13C 
NMR (126 MHz, CDCl3-d) 𝛿 ppm 165.51, 159.37, 132.62, 125.06, 122.78, 122.61, 114.01, 
70.66, 67.86, 59.18, 52.39; QTOF ES- MS: (M+H) 289.01; HPLC Ret: 7.37 min. 
3-(furan-2-yl)-5-methoxybenzoic acid. Method H starting from methyl 3-bromo-5-
methoxybenzoate (0.55 g, 2.24 mmol) gave 3-(furan-2-yl)-5-methoxybenzoic acid as white solid 
(0.28 g, 58%); 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 13.22 (br. s, 1H) 7.88 (t, 1.5 Hz, 1H) 7.80 
(d, J = 1.7 Hz, 1H) 7.49 (dd, J = 1.6 Hz, 1H) 7.38 (d, J = 1.4 Hz, 1H) 7.11 (d, J = 3.4 Hz, 1H) 
6.64 (dd, J = 3.4, 1.8 Hz, 1H) 3.88 (s, 3H); 13C NMR (126 MHz, DMSO-d6) 𝛿 ppm 167.29, 
160.17, 152.38, 143.82, 133.37, 132.28, 124.39, 114.29, 113.53, 112.63, 107.54, 55.92; QTOF 
ES- MS: (M-H) 217.11; HPLC Ret: 6.35 min. 
3-(furan-2-yl)-5-(2-methoxyethoxy)benzoic acid. Method H starting from methyl 3-bromo-5-
(2-methoxyethoxy)benzoate (0.2 g, 0.69 mmol) gave 3-(furan-2-yl)-5-(2-methoxyethoxy)benzoic 
acid as white solid (0.18 g, 98%); 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 13.20 (br. s, 1H) 7.87 (t, 
1.4 Hz, 1H) 7.80 (d, J = 1.8 Hz, 1H) 7.52 (t, J = 2.0 Hz, 1H) 7.42 (t, J = 2.2 Hz, 1H) 7.12 (d, J = 
3.4 Hz, 1H) 6.63 (dd, J = 3.4, 1.8 Hz, 1H) 4.23 (t, J = 4.5 Hz, 2H) 3.71 (t, J = 4.5 Hz, 2H) 3.34 
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(s, 3H); 13C NMR (126 MHz, DMSO-d6) 𝛿 ppm 167.27, 159.41, 152.36, 143.82, 133.37, 132.30, 
124.49, 122.10, 114.18, 112.63, 107.57, 70.73, 67.79, 58.61; QTOF ES- MS: (M-H) 261.08; 
HPLC Ret: 6.17 min. 
3-(furan-2-yl)-5-hydroxybenzoic acid. Method H starting from methyl 3-bromo-5-((tert-
butyldimethylsilyl)oxy)benzoate (0.59 g, 1.71 mmol) gave 3-(furan-2-yl)-5-hydroxybenzoic acid 
as white solid (0.26 g, 74%); 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 13.00 (br. s, 1H) 9.97 (s, 1H) 
7.80-7.71 (m, 2H) 7.38-7.27 (m, 2H) 7.00 (d, J = 3.4 Hz, 1H) 6.61 (dd, J = 3.5, 1.8 Hz, 1H); 13C 
NMR (126 MHz, DMSO-d6) 𝛿 ppm 167.46, 158.32, 152.63, 143.62, 133.21, 132.17, 122.69, 
115.74, 114.64, 112.58, 107.00; QTOF ES- MS: (M-H) 203.03; HPLC Ret: 5.42 min. 
methyl 3-(furan-2-yl)-5-(prop-2-yn-1-yloxy)benzoate. Method A followed by Method B starting 
from 3-(furan-2-yl)-5-hydroxybenzoic acid (0.15 g, 0.74 mmol) gave methyl 3-(furan-2-yl)-5-
(prop-2-yn-1-yloxy)benzoate as white solid (0.05 g, 81% over 2 steps); HPLC Ret: 7.60 min. 
methyl 3-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)-5-(furan-2-yl)benzoate. Methyl 
3-(furan-2-yl)-5-hydroxybenzoate (0.05 g, 0.23 mmol) was dissolved in 1 mL DMF. Freshly 
prepared 2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethyl methanesulfonate (0.06 g, 0.21 mmol) 
along with Cs2CO3 (0.1 g, 0.31 mmol) were added, and the reaction was stirred at 75 oC for 2 hr. 
The reaction was diluted with 10 mL brine and extracted with DCM (3 x 15 mL). The organic 
layers were combined, dried with MgSO4, and evaporated. The subsequent oil was subjected to 
silica gel chromatography eluting with 30% EtOAc: 70% Hex. The fractions containing product 
were concentrated in vacuo to produce pale yellow oil. Yield=86%. 1H NMR (500 MHz, CDCl3-d) 
𝛿 ppm 7.94 (t, 1.4 Hz, 1H) 7.51-7.42 (m, 2H) 6.72 (d, J = 3.3 Hz, 1H) 6.48 (dd, J = 3.4, 1.8 Hz, 
1H) 5.00 (br. s, 1H) 4.22 (t, J = 5.7 Hz, 2H) 3.93 (s, 3H) 3.85 (t, J = 5.5 Hz, 2H) 3.62 (t, J = 5.3 
Hz, 2H) 3.36 (q, J = 5.7 Hz, 2H) 1.43 (s, 9H); 13C NMR (126 MHz, DMSO-d6) 𝛿 ppm 166.62, 
159.06, 152.73, 142.49, 132.30, 131.85, 125.18, 122.88, 117.89, 114.85, 113.61, 111.79, 
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106.19, 70.47, 69.42, 67.72, 52.24, 40.35, 28.36; TOF ES+ MS: (M+H) 406.2; HPLC Ret: 7.89 
min. 
3-(furan-2-yl)-5-(prop-2-yn-1-yloxy)benzoic acid. (DJK-4-85). Method G starting from methyl 
3-(furan-2-yl)-5-(prop-2-yn-1-yloxy)benzoate (0.05 g, 0.21 mmol) gave 3-(furan-2-yl)-5-(prop-2-
yn-1-yloxy)benzoic acid as yellow solid (0.05 g, quant); 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 
13.19 (br. s, 1H) 7.87 (t, J = 1.4 Hz, 1H) 7.80 (dd, J = 1.9, 0.7 Hz, 1H) 7.54 (dd, J = 2.5, 1.5 Hz, 
1H) 7.43 (dd, J = 2.6, 1.3 Hz, 1H) 7.11 (dd, J = 3.4, 0.8 Hz, 1H) 6.63 (dd, J = 3.4, 1.8 Hz, 1H) 
4.94 (d, J = 2.4 Hz, 2H) 3.36 (t, J = 2.4 Hz, 1H); HPLC Ret: 6.50 min. 
3-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)-5-(furan-2-yl)benzoic acid. Method G 
starting from methyl 3-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)-5-(furan-2-yl)benzoate 
(0.07 g, 0.18 mmol) gave 3-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)-5-(furan-2-
yl)benzoic acid as white solid (0.07 g, 96%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 11.17 (br. s, 
1H) 8.00 (s, 1H) 7.55-7.46 (m, 3H) 6.73 (d, J = 3.4 Hz, 1H) 6.51-6.45 (m, 1H) 5.04 (br. s, 1H) 
4.22 (t, J = 4.6 Hz, 2H) 3.85 (t, J = 4.5 Hz, 2H) 3.64 (t, J = 4.6 Hz, 2H) 3.41-3.32 (m, 2H) 1.44 (s, 
9H); 13C NMR (126 MHz, CDCl3-d) 𝛿 ppm 170.94, 159.10, 152.60, 142.56, 132.42, 131.17, 
125.71, 123.58, 118.47, 115.56, 113.96, 111.81, 106.30, 70.47, 69.44, 67.72, 40.35, 28.38; 
TOF ES+ MS: (M+H) 391; HPLC Ret: 6.80 min. 
tert-butyl (4-chloro-3-hydroxyphenyl)carbamate. In a 100 mL round bottomed flask 5-amino-
2-chlorophenol (0.5 g, 3.5 mmol) was dissolved in THF (15 mL), and Boc2O (0.84 g, 3.8 mmol) 
was added. The reaction was stirred at 70 oC for 4 hr, and then diluted with Et2O (70 mL). The 
product was washed with 10% citric acid (2 x 30 mL) and brine (3 x 20 mL), dried with MgSO4, 
and concentrated in vacuo to afford orange oil. Analogous compounds were synthesized with 
this procedure. Yield=100%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.19 (s, 1H) 7.13 (d, J = 2.5 
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Hz, 1H) 6.87 (dd, J = 8.7, 2.5 Hz, 1H) 6.44 (s, 1H) 5.52 (s, 1H) 1.52 (s, 9H); QTOF ES+ MS: 
(M+Na) 266.06; HPLC Ret: 6.69 min. 
tert-butyl (4-chloro-2-hydroxyphenyl)carbamate. Brown solid. Yield=95%. 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 8.42 (s, 1H) 7.00-6.91 (m, 2H) 6.83 (dd, J = 8.5, 2.3 Hz, 1H) 6.57 (s, 1H) 
1.53 (s, 9H); QTOF ES+ MS: (M+Na) 266.06; HPLC Ret: 7.40 min. 
tert-butyl (4-chloro-3-(prop-2-yn-1-yloxy)phenyl)carbamate. Method B starting from tert-
butyl (4-chloro-3-hydroxyphenyl)carbamate (0.30 g, 1.23 mmol) gave tert-butyl (4-chloro-3-
(prop-2-yn-1-yloxy)phenyl)carbamate as white solid (0.12 g, 35%); 1H NMR (500 MHz, CDCl3-d) 
𝛿 ppm 7.32 (d, J = 2.3, 1H) 6.84 (dd, J = 8.6, 2.3 Hz, 1H) 6.48 (s, 1H) 4.77 (d, J = 2.4 Hz, 2H) 
2.55 (t, J = 2.4 Hz, 1H) 1.52 (s, 9H); TOF ES+ MS: (M+Na) 304.07. 
tert-butyl (4-chloro-2-(prop-2-yn-1-yloxy)phenyl)carbamate. Method B starting from tert-
butyl (4-chloro-2-hydroxyphenyl)carbamate (0.3 g, 1.23 mmol) gave tert-butyl (4-chloro-2-(prop-
2-yn-1-yloxy)phenyl)carbamate as white solid (0.28 g, 81%); 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 8.05 (d, J = 8.6, 1H) 6.99-6.91 (m, 3H) 4.74 (d, J = 2.4 Hz, 2H) 2.58 (t, J = 2.4 Hz, 1H) 1.52 
(s, 9H); TOF ES+ MS: (M+Na) 304.07; HPLC Ret: 8.30 min. 
tert-butyl (4-chloro-3-(2-methoxyethoxy)phenyl)carbamate. tert-butyl (4-chloro-3-
hydroxyphenyl)carbamate (0.3 g, 1.23 mmol) was dissolved in DMF (6.0 mL) and K2CO3 (0.34 
g, 2.46 mmol) and 1-bromo-2-methoxyethane (0.22 g, 1.60 mmol, 0.16 mL) were added. The 
reaction was stirred at 90 oC for 1 hr. After the reaction cooled to 25 oC brine was added and the 
product was extracted with DCM (3 x 20 mL). The organic layers were combined, washed with 
brine (3x 10 mL), dried with MgSO4, and concentrated in vacuo. The subsequent oil was 
subjected to silica gel chromatography eluting with 15% EtOAc: 85% Hex. The fractions 
containing product were concentrated in vacuo to produce white solid. Similar compounds were 
made in an analogous fashion. Yield = 44%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.31 (s, 1H) 
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7.22 (d, J = 8.6 Hz, 1H) 6.70 (dd, J = 8.6, 2.4 Hz, 1H) 6.46 (s, 1H) 4.19 (t, J = 4.5 Hz, 2H) 3.80 
(t, J = 4.5 Hz, 2H) 3.48 (s, 3H) 1.51 (s, 9H); QTOF ES+ MS: (M+Na) 324.10. 
tert-butyl (4-chloro-2-(2-methoxyethoxy)phenyl)carbamate. Red oil. Yield = 43.3%. 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 8.04 (s, 1H) 7.28 (s, 1H) 6.95 (dd, J = 8.7, 2.3 Hz, 1H) 6.88 (s, 1H) 
4.14 (t, J = 4.5 Hz, 2H) 3.73 (t, J = 4.5 Hz, 2H) 3.46 (s, 3H) 1.52 (s, 9H); QTOF ES+ MS: 
(M+Na) 324.10. 
tert-butyl 5-((4-chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate. Method I 
starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.05 g, 0.19 mmol) 
and 4-chloroaniline (0.04 g, 0.19 mmol) gave tert-butyl 5-((4-chlorophenyl)carbamoyl)-3,3-
difluoropiperidine-1-carboxylate as white solid (0.05 g, 64%); 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 8.16 (br.s, 1H) 7.51 (d, J = 8.7 Hz, 1H) 7.29 (d, J = 8.6, 2H) 4.05 (br. s, 2H) 3.41-3.30 (m, 
2H) 2.80-2.75 (m, 1H) 2.51-2.30 (m, 2H) 1.48 (s, 9H); QTOF ES+ MS: (M+Na) 397.11; HPLC 
Ret: 8.06 min. 
tert-butyl 5-((4-chloro-2-methoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate.  
Method I starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.05 g, 
0.19 mmol) and 4-chloro-2-methoxyaniline (0.05 g, 0.19 mmol) gave tert-butyl 5-((4-chloro-2-
methoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as yellow solid (0.06 g, 84%); 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.61 (br.s, 1H) 7.87 (d, J = 8.6 Hz, 1H) 7.12 (d, J = 2.3 Hz, 
1H) 6.97 (dd, J = 8.5, 2.3 Hz, 1H) 4.12 (br. s, 2H) 3.85 (s, 3H) 3.76 (s, 2H) 3.10-3.02 (m, 1H) 
2.35-2.10 (m, 2H) 1.42 (s, 9H); QTOF ES+ MS: (M+H) 405.14; HPLC Ret: 8.17 min. 
tert-butyl 5-((4-chloro-3-methoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate. 
Method I starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.05 g, 
0.19 mmol) and 4-chloro-3-methoxyaniline (0.05 g, 0.19 mmol) gave tert-butyl 5-((4-chloro-3-
methoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as white solid (0.05 g, 63%); 1H 
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NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.35 (br.s, 1H) 7.51 (d, J = 2.3 Hz, 1H) 7.34 (d, J = 8.6 Hz, 
1H) 7.17 (dd, J = 8.7, 2.2 Hz, 1H) 4.14 (br. s, 2H) 3.81 (s, 3H) 3.32 (s, 2H) 2.85-2.80 (m, 1H) 
2.35-2.10 (m, 2H) 1.42 (s, 9H); QTOF ES+ MS: (M+H) 405.14; HPLC Ret: 7.95 min. 
tert-butyl 5-((3-chloro-4-methoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate. 
Method I starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.05 g, 
0.19 mmol) and 3-chloro-4-methoxyaniline (0.05 g, 0.19 mmol) gave tert-butyl 5-((3-chloro-4-
methoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as white solid (0.07 g, 88%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.92 (br.s, 1H) 7.64 (br. s, 1H) 7.38 (dd, J = 8.8, 1H) 6.88 (d, J 
= 8.8 Hz, 1H) 4.04 (br. s, 2H) 3.88 (s, 3H) 3.40-3.32 (m, 2H) 2.79-2.73 (m, 1H) 2.48-2.28 (m, 
2H) 1.48 (s, 9H); QTOF ES+ MS: (M+Na) 427.12; HPLC Ret: 7.82 min. 
tert-butyl 3,3-difluoro-5-((4-methoxyphenyl)carbamoyl)piperidine-1-carboxylate. Method I 
starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.05 g, 0.19 mmol) 
and 4-methoxyaniline (0.02 g, 0.19 mmol) gave tert-butyl 3,3-difluoro-5-((4-
methoxyphenyl)carbamoyl)piperidine-1-carboxylate as white solid (0.07 g, 95%); 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.70 (br. s, 1H) 7.43 (d, J = 8.0, 2H) 6.86 (d, J = 8.1 Hz, 2H) 4.10 (br. s, 
2H) 3.79 (s, 3H) 3.29-3.19 (m, 2H) 2.78-2.74 (m, 1H) 2.47-2.29 (m, 2H) 1.48 (s, 9H); QTOF ES+ 
MS: (M+Na) 393.16; HPLC Ret: 7.39 min. 
tert-butyl 5-((4-chloro-2-(prop-2-yn-1-yloxy)phenyl)carbamoyl)-3,3-difluoropiperidine-1-
carboxylate. Method J followed by Method I starting from tert-butyl (4-chloro-2-(prop-2-yn-1-
yloxy)phenyl)carbamate (0.06 g, 0.19 mmol) and 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-
3-carboxylic acid (0.05 g, 0.19 mmol) gave tert-butyl 5-((4-chloro-2-(prop-2-yn-1-
yloxy)phenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as white solid (0.06 g, 71%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.28 (d, J = 8.7 Hz, 1H) 7.83 (s, 1H) 7.05-6.99 (m, 2H) 4.80 (d, 
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J = 2.3 Hz, 2H) 4.45-4.29 (m, 2H) 3.11-2.85 (m, 2H) 2.82-2.72 (m, 1H) 2.63 (d, J = 2.6 Hz, 1H) 
2.48-2.15 (m, 2H) 1.49 (s, 9H); QTOF ES+ MS: (M+H) 429.14; HPLC Ret: 8.14 min. 
tert-butyl 5-((4-chloro-2-(2-methoxyethoxy)phenyl)carbamoyl)-3,3-difluoropiperidine-1-
carboxylate. Method J followed by Method I starting from tert-butyl (4-chloro-2-(2-
methoxyethoxy)aniline (0.06 g, 0.19 mmol) and 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-
carboxylic acid (0.05 g, 0.19 mmol) gave tert-butyl 5-((4-chloro-2-(2-
methoxyethoxy)phenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as white solid (0.06 g, 
73%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.48 (br. s, 1H) 8.28 (d, J = 8.7 Hz, 1H) 7.03-6.94 
(m, 2H) 4.48-4.30 (m, 2H) 4.14 (t, J = 4.5 Hz, 2H) 3.74 (t, J = 4.5 Hz, 2H) 3.48 (s, 3H) 3.02-2.75 
(m, 4H) 2.42-2.18 (m, 2H) 1.48 (s, 9H); QTOF ES+ MS: (M+H) 449.17; HPLC Ret: 8.23 min. 
methyl 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxylate. Method J followed by 
Method I starting from 1-tert-butyl 3-methyl 5,5-difluoropiperidine-1,3-dicarboxylate (0.12 g, 0.44 
mmol) and 3-(furan-2-yl)benzoic acid (0.08 g, 0.44 mmol) gave methyl 5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxylate as yellow oil (0.13 g, 84%); 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 7.79-7.70 (m, 2H) 7.51-7.41 (m, 2H) 7.33-7.23 (m, 1H) 6.71 (d, J = 3.4 Hz, 1H) 6.49 (dd, J 
= 3.4, 1.8 Hz, 1H) 4.97 (br. s, 1H) 3.74 (br. s, 3H) 3.32-3.15 (m, 2H) 3.08-2.88 (m, 2H) 2.65-2.51 
(m, 2H); QTOF ES+ MS: (M+H) 350.12; HPLC Ret: 7.02 min. 
5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxylic acid. Method G starting from 
methyl 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxylate (0.13 g, 0.36 mmol) gave 
5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxylic acid as white solid (0.12 g, quant); 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.79-7.71 (m, 2H) 7.51-7.42 (m, 2H) 7.33-7.23 (m, 1H) 6.71 
(d, J = 3.4 Hz, 1H) 6.49 (dd, J = 3.4, 1.8 Hz, 1H) 4.94 (br. s, 1H) 3.35-3.21 (m, 2H) 3.10-2.92 




carboxamide (CCG-258165). Method J followed by Method I starting from tert-butyl 5-((4-
chloro-2-methoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.06 g, 0.16 mmol) 
and 3-(furan-2-yl)benzoic acid (0.03 g, 0.16 mmol) gave N-(4-chloro-2-methoxyphenyl)-5,5-
difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide as yellow solid (0.05 g, 65%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.25 (br.s, 1H) 8.00 (br. s, 1H) 7.79-7.76 (m, 2H) 7.50-7.41 (m, 
2H) 7.31 (d, J = 7.7 Hz, 1H) 6.94 (d, 8.7 Hz, 1H) 6.87 (br. s, 1H) 6.70 (d, J = 3.4 Hz, 1H) 6.49 
(dd, J = 3.4, 1.8 Hz, 1H) 4.12 (br. s, 2H) 3.89 (br. s, 3H) 3.43-3.24 (m, 1H) 3.10-2.92 (m, 2H) 
2.48-2.29 (m, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 171.12, 168.19, 152.76, 148.63, 
142.63, 134.93, 131.44, 129.39, 129.15, 125.88, 125.48, 122.59, 120.84, 120.78, 120.69, 
111.84, 110.85, 106.07, 60.38, 55.96, 44.39, 41.40, 35.38, 21.00; QTOF ES+ MS: (M+H) 
475.12; HPLC Ret: 7.98 min; 96% pure.  
N-(4-chloro-3-methoxyphenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-
carboxamide (CCG-258166). Method J followed by Method I starting from tert-butyl 5-((4-
chloro-3-methoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.05 g, 0.12 mmol) 
and 3-(furan-2-yl)benzoic acid (0.02 g, 0.12 mmol) gave N-(4-chloro-3-methoxyphenyl)-5,5-
difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide as yellow solid (0.05 g, 88%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.53 (br.s, 1H) 7.78-7.72 (m, 2H) 7.51-7.42 (m, 3H) 7.30 (d, J 
= 7.6 Hz, 1H) 7.20 (d, 8.5 Hz, 1H) 6.87 (d, J = 8.5 Hz, 1H) 6.68 (d, J = 3.4 Hz, 1H) 6.47 (dd, J = 
3.4, 1.8 Hz, 1H) 4.04 (br. s, 2H) 3.83 (br. s, 3H) 3.43 (dd, J = 26.5, 14.0, 1H) 3.22 (t, J = 12.1 
Hz, 1H) 2.96 (dq, J = 11.1, 6.3, 5.3 Hz, 1H) 2.52-2.30 (m, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 
ppm 171.20, 168.57, 155.03, 152.36, 142.78, 137.88, 134.59, 131.76, 129.85, 125.78, 125.40, 
122.17, 118.83, 117.45, 112.31, 111.92, 106.34, 104.36, 60.42, 56.04, 44.49, 40.90, 34.99, 




carboxamide. (CCG-258704). Method J followed by Method I starting from tert-butyl 5-((3-
chloro-4-methoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.07 g, 0.17 mmol) 
and 3-(furan-2-yl)benzoic acid (0.03 g, 0.16 mmol) gave N-(3-chloro-4-methoxyphenyl)-5,5-
difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide as white solid (0.07 g, 86%); 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 9.25 (br.s, 1H) 7.75 (br. s, 2H) 7.54 (br. s, 1H) 7.49-7.42 (m, 2H) 
7.32 (dd, 25.3, 8.2 Hz, 2H) 6.79 (d, J = 8.9 Hz, 1H) 6.69 (d, J = 3.4 Hz, 1H) 6.48 (dd, J = 3.3, 
1.8 Hz, 1H) 4.84 (s, 1H) 4.02 (br. s, 1H) 3.83 (s, 3H) 3.43 (dd, J = 26.3, 14.0, 1H) 3.22 (t, J = 
10.5 Hz, 1H) 2.94 (td, J = 10.7, 5.2 Hz, 1H) 2.55-2.30 (m, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 
ppm 168.31, 152.48, 151.88, 142.71, 134.64, 131.67, 129.33, 125.71, 125.49, 122.47, 122.21, 
119.64, 118.86, 112.03, 111.87, 106.26, 60.41, 56.31, 44.44, 40.69, 34.92, 21.05; QTOF ES+ 
MS: (M+H) 475.12; HPLC Ret: 7.67 min; 97% pure. 
5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-(4-methoxyphenyl)piperidine-3-carboxamide. 
(CCG-258705). Method J followed by Method I starting from tert-butyl 5-((4-
methoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.07 g, 0.18 mmol) and 3-
(furan-2-yl)benzoic acid (0.03 g, 0.18 mmol) gave 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-(4-
methoxyphenyl)piperidine-3-carboxamide as white solid (0.07 g, 84%); 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 8.81 (br.s, 1H) 7.78-7.71 (m, 2H) 7.49-7.39 (m, 4H) 6.69 (d, J = 3.4 Hz, 1H) 
6.48 (dd, J = 3.3, 1.7 Hz, 1H) 6.30 (d, J = 7.7 Hz, 1H) 4.81 (s, 1H) 4.01 (br. s, 1H) 3.76 (s, 3H) 
3.42 (dd, J = 26.4, 14.0, 1H) 3.24 (br. s, 1H) 2.93 (br. s, 1H) 2.57-2.33 (m, 2H); 13C NMR (500 
MHz, CDCl3-d) 𝛿 ppm 168.15, 156.51, 152.60, 142.67, 131.56, 129.25, 125.68, 125.62, 122.36, 
121.74, 114.05, 111.85, 106.19, 60.40, 55.43, 44.45, 40.76, 21.04; QTOF ES+ MS: (M+H) 
441.16; HPLC Ret: 7.30 min; 97% pure. 
N-(4-chlorophenyl)-5,5-difluoro-1-(3-(furan-2-yl)-5-methoxybenzoyl)piperidine-3-
carboxamide (CCG-258524). Method J followed by Method I starting from tert-butyl 5-((4-
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chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.08 g, 0.23 mmol) and 3-(furan-
2-yl)-5-methoxybenzoic acid (0.05 g, 0.23 mmol) gave N-(4-chlorophenyl)-5,5-difluoro-1-(3-
(furan-2-yl)-5-methoxybenzoyl)piperidine-3-carboxamide as white solid (0.09 g, 83%); 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 9.26 (br. s, 1H) 7.55-7.45 (m, 3H) 7.32-7.20 (m, 4H) 6.83 (s, 1H) 
6.67 (d, J = 3.4 Hz, 1H) 6.48 (dd, J = 3.4, 1.8 Hz, 1H) 4.04 (br. s, 2H) 3.84 (s, 3H) 3.45-3.39 (m, 
1H) 3.24 (t, J = 11.9 Hz, 1H) 2.95-2.88 (m, 1H) 2.51-2.30 (m, 2H) 13C NMR (126 MHz, CDCl3-d) 
𝛿 ppm 168.36, 160.20, 152.41, 142.72, 128.93, 126.98, 125.47, 121.14, 120.97, 118.78, 
116.62, 114.68, 111.89, 106.51, 104.25, 60.41, 55.81, 44.47, 40.79, 35.60, 21.14; QTOF ES+ 
MS: (M+H) 475.12; HPLC Ret: 8.00 min; 98% pure. 
N-(4-chloro-3-(prop-2-yn-1-yloxy)phenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-
3-carboxamide. (CCG-258723). Method J followed by Method I starting from tert-butyl (4-
chloro-3-(prop-2-yn-1-yloxy)phenyl)carbamate (0.03 g, 0.11 mmol) and 5,5-difluoro-1-(3-(furan-
2-yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.09 mmol) gave N-(4-chloro-3-(prop-2-yn-1-
yloxy)phenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide as white solid (0.02 
g, 46%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.53 (br. s, 1H) 7.76 (d, J = 7.8 Hz, 2H) 7.56 (br. s, 
1H) 7.46 (dd, J = 9.0, 4.7 Hz, 2H) 7.33-7.20 (m, 2H) 7.04-6.99 (m, 1H) 6.69 (d, J = 3.4 Hz, 1H) 
6.48 (dd, J = 3.4, 1.8 Hz, 1H) 4.84 (d, J = 13.4 Hz, 1H) 4.74-4.70 (m, 2H) 4.03 (br. s, 1H) 3.44 
(dd, J = 26.5, 13.9 Hz, 1H) 3.23 (t, J = 11.8 Hz, 1H) 2.97 (dt, J = 11.9, 6.4 Hz, 1H) 2.50-2.35 (m, 
2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 172.37, 168.53, 153.11, 152.38, 142.78, 137.72, 
134.56, 131.74, 130.16, 129.35, 125.80, 125.47, 122.21, 118.20, 113.41, 111.91, 109.02, 
106.34, 77.77, 76.23, 60.41, 56.80, 44.52, 40.89, 34.95, 21.05; QTOF ES+ MS: (M+H) 499.12; 
HPLC Ret: 7.83 min; 97% pure. 
N-(4-chloro-3-(2-methoxyethoxy)phenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-
carboxamide. (CCG-258724). Method J followed by Method I starting from tert-butyl (4-chloro-
3-(2-methoxyethoxy)phenyl)carbamate (0.03 g, 0.1 mmol) and 5,5-difluoro-1-(3-(furan-2-
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yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.1 mmol) gave N-(4-chloro-3-(2-
methoxyethoxy)phenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide as 
colorless oil (0.02 g, 52%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.45 (br. s, 1H) 7.75 (br. s, 2H) 
7.49-7.39 (m, 3H) 7.35-7.18 (m, 2H) 6.95-6.89 (m, 1H) 6.68 (d, J = 3.4 Hz, 1H) 6.48 (dd, J = 3.4, 
1.8 Hz, 1H) 4.84 (d, J = 13.2 Hz, 1H) 4.16-4.08 (m, 3H) 4.03 (br. s, 1H) 3.81-3.74 (m, 2H) 3.48-
3.41 (m, 5H) 3.21 (t, J = 12.2 Hz, 1H) 2.93 (dt, J = 11.3, 4.2 Hz, 1H) 2.52-2.30 (m, 2H); 13C NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 172.20, 168.49, 154.40, 152.40, 142.77, 137.73, 134.56, 131.71, 
130.48, 129.35, 125.77, 125.48, 122.21, 118.12, 112.71, 111.90, 108.39, 106.32, 105.77, 70.71, 
68.76, 60.41, 59.38, 52.83, 44.52, 40.86, 34.94, 21.05; QTOF ES+ MS: (M+H) 519.15; HPLC 
Ret: 7.79 min; 97% pure. 
N-(4-chloro-2-(prop-2-yn-1-yloxy)phenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-
3-carboxamide. (CCG-258741). Method J followed by Method I starting from tert-butyl 5-((4-
chloro-2-(prop-2-yn-1-yloxy)phenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.055 g, 
0.13 mmol) and 3-(furan-2-yl)benzoic acid (0.024 g, 0.13 mmol) gave N-(4-chloro-2-(prop-2-yn-
1-yloxy)phenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide as white solid 
(0.05 g, 73%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.29 (br. s, 1H) 7.97 (br. s, 1H) 7.79-7.72 (m, 
2H) 7.51-7.43 (m, 2H) 7.32 (d, J = 7.6 Hz, 1H) 7.05-6.97 (m, 2H) 6.71 (d, J = 3.4 Hz, 1H) 6.50 
(dd, J = 3.4, 1.8 Hz, 1H) 4.93 (br. s, 1H) 4.80 (br. s, 2H) 4.08 (br. s, 1H) 3.40-3.29 (m, 1H) 3.06 
(br. s, 1H) 2.94 (br. s, 1H) 2.49-2.32 (m, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 173.99, 
163.45, 155.84, 152.76, 142.63, 137.04, 134.91, 131.45, 129.27, 129.16, 125.51, 122.63, 
122.01, 121.17, 120.02, 112.75, 111.84, 106.07, 93.95, 78.01, 60.38, 56.97, 43.61, 41.25, 
34.48, 22.82; QTOF ES+ MS: (M+H) 499.12; HPLC Ret: 7.97 min; 98% pure. 
N-(4-chloro-2-(2-methoxyethoxy)phenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-
carboxamide. (CCG-258742). Method J followed by Method I starting from tert-butyl 5-((4-
chloro-2-(2-methoxyethoxy)phenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.05 g, 0.13 
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mmol) and 3-(furan-2-yl)benzoic acid (0.03 g, 0.13 mmol) gave N-(4-chloro-2-(2-
methoxyethoxy)phenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide as white 
solid (0.04 g, 61%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.71 (br. s, 1H) 8.28 (br. s, 1H) 7.78-
7.71 (m, 2H) 7.51-7.42 (m, 2H) 7.31 (d, J = 7.6 Hz, 1H) 7.02-6.93 (m, 2H) 6.71 (d, J = 3.4 Hz, 
1H) 6.49 (dd, J = 3.4, 1.8 Hz, 1H) 4.95 (br. s, 1H) 4.19-4.00 (m, 3H) 3.79-3.72 (m, 2H) 3.50 (s, 
3H) 3.41-3.22 (m, 1H) 2.99 (br. s, 1H) 2.53-2.28 (m, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 
171.47, 167.02, 152.78, 142.61, 131.45, 129.13, 129.04, 125.49, 121.25, 111.82, 106.06, 77.20, 
70.62, 60.33, 59.06, 53.02, 44.33, 39.21, 34.87, 21.02; QTOF ES+ MS: (M+H) 519.15; HPLC 
Ret: 8.02 min; 98% pure. 
N-(4-chlorophenyl)-5,5-difluoro-1-(3-(furan-2-yl)-5-(2-methoxyethoxy)benzoyl)piperidine-3-
carboxamide. (CCG-258662). Method J followed by Method I starting from tert-butyl 5-((4-
chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.04 g, 0.14 mmol) and 3-(furan-
2-yl)-5-(2-methoxyethoxy)benzoic acid (0.04 g, 0.14 mmol) gave N-(4-chlorophenyl)-5,5-
difluoro-1-(3-(furan-2-yl)-5-(2-methoxyethoxy)benzoyl)piperidine-3-carboxamide as yellow solid 
(0.06 g, 83%); Rotomers included 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.52 (br. s, 1H) 9.34 (br. 
s, 0.5H) 7.50-7.40 (m, 3.5H) 7.34-7.29 (m, 2H) 7.24-7.15 (m, 2.5H) 6.88 (br. s, 0.5H) 6.84 (br. s, 
1H) 6.65 (d, J = 3.4 Hz, 1H) 6.49-6.44 (m, 1H) 4.90-4.76 (m, 1.5H) 4.09 (ddt, J = 26.7, 9.0, 5.0 
Hz, 3.5Hz) 3.94 (br. s, 0.5H) 3.72 (dt, J = 15.8, 4.6 Hz, 3H) 3.44 (s, 3H) 3.37 (s, 1.5H) 3.15 (t, J 
= 12.3 Hz, 1.5H) 2.92 (tq, J = 13.6, 8.6, 6.4 Hz, 1.5H) 2.52-2.27 (m, 4H); 13C NMR (126 MHz, 
CDCl3-d) 𝛿 ppm 171.97, 170.53, 168.50, 168.40, 159.38, 152.30, 142.74, 136.59, 135.74, 
133.00, 129.25, 128.83, 123.44, 122.15, 121.23, 120.06, 114.79, 112.01, 111.65, 106.56, 70.81, 
70.62, 67.89, 67.61, 59.19, 52.70, 44.42, 40.72, 34.95, 29.68; QTOF ES+ MS: (M+H) 519.15; 
HPLC Ret: 7.88 min; 97% pure. 
N-(4-chlorophenyl)-5,5-difluoro-1-(3-(furan-2-yl)-5-(prop-2-yn-1-yloxy)benzoyl)piperidine-
3-carboxamide. (CCG-258744). Method J followed by Method I starting from tert-butyl 5-((4-
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chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.07 g, 0.21 mmol) and 3-(furan-
2-yl)-5-(prop-2-yn-1-yloxy)benzoic acid (0.05 g, 0.21 mmol) gave N-(4-chlorophenyl)-5,5-
difluoro-1-(3-(furan-2-yl)-5-(prop-2-yn-1-yloxy)benzoyl)piperidine-3-carboxamide as white solid 
(0.05 g, 52%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.19 (br. s, 1H) 7.50-7.43 (m, 3H) 7.36 (d, J 
= 1.9 Hz, 2H) 7.23 (d, J = 8.2 Hz, 2H) 6.90 (t, J = 1.9 Hz, 1H) 6.68 (d, J = 3.4 Hz, 1H) 6.48 (dd, 
J = 3.4, 1.8 Hz, 1H) 4.82-4.69 (m, 3H) 4.05 (br. s, 1H) 3.44 (dd, J = 25.1, 14.0, 1H) 3.26 (t, J = 
12.1 Hz, 1H) 2.96-2.89 (m, 2H) 2.53 (t, J = 2.4 Hz, 1H) 2.51-2.34 (m, 2H); 13C NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 168.35, 157.98, 152.19, 142.84, 133.08, 128.89, 121.17, 115.62, 112.40, 
112.13, 111.92, 109.99, 106.69, 77.76, 76.31, 60.40, 56.01, 44.47, 40.77, 21.05; QTOF ES+ 
MS: (M+H) 499.12; HPLC Ret: 7.99 min; 96% pure. 
tert-butyl (2-(2-(3-(5-((4-chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carbonyl)-5-
(furan-2-yl)phenoxy)ethoxy)ethyl)carbamate. Method J followed by Method I starting from 
tert-butyl 5-((4-chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.06 g, 0.17 mmol) 
and 3-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)-5-(furan-2-yl)benzoic acid (0.068 g, 0.17 
mmol) gave tert-butyl (2-(2-(3-(5-((4-chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carbonyl)-
5-(furan-2-yl)phenoxy)ethoxy)ethyl)carbamate as white solid (0.06 g, 52%); Rototmers included 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.43 (br. s, 1H) 7.51-7.44 (m, 3H) 7.31 (br. s, 2H) 7.21 (d, J 
= 8.3 Hz, 2H) 6.84 (br. s, 1H) 6.67 (d, J = 3.4 Hz, 1H) 6.47 (br. s, 1H) 5.01 (br. s, 1H) 4.84 (d, J 
= 13.2 Hz, 1H) 4.18-4.01 (m, 3H) 3.85 (t, J = 4.8 Hz, 2H) 3.60 (t, J = 5.5Hz, 2H) 3.47-3.31 (m, 
4H) 3.23-3.16 (m, 1H) 3.01-2.93 (m, 1H) 2.51-2.35 (m, 2.5H) 1.43 (s, 9H); 13C NMR (126 MHz, 
CDCl3-d) 𝛿 ppm 171.91, 168.55, 159.37, 156.06, 152.35, 142.74, 136.59, 135.80, 132.95, 
128.83, 121.25, 118.89, 114.87, 111.92, 106.56, 79.38, 70.45, 69.33, 67.75, 52.77, 44.43, 
40.79, 40.37, 35.03, 29.69, 28.40; QTOF ES+ MS: (M+H) 648.23; HPLC Ret: 8.12 min. 
1-(3-(2-(2-aminoethoxy)ethoxy)-5-(furan-2-yl)benzoyl)-N-(4-chlorophenyl)-5,5-




yl)phenoxy)ethoxy)ethyl)carbamate (0.02 g, 0.03 mmol) gave 1-(3-(2-(2-aminoethoxy)ethoxy)-5-
(furan-2-yl)benzoyl)-N-(4-chlorophenyl)-5,5-difluoropiperidine-3-carboxamide, HCl as white oil 
(0.18 g, quant); 1H NMR (400 MHz, 80 oC, DMSO-d6) 𝛿 ppm 10.38 (s, 1H) 8.09 (br. s, 3H) 7.71 
(dd, J = 1.8, 0.8 Hz, 1H) 7.68-7.60 (m, 2H) 7.42-7.26 (m, 4H) 7.01 (d, J = 3.4 Hz, 1H) 6.89 (dd, J 
= 2.6, 1.4 Hz, 1H) 6.58 (dd, J = 3.4, 1.8 Hz, 1H) 4.30-4.21 (m, 3H) 3.84 (t, J = 4.7 Hz, 2H) 3.75 
(t, J = 4.7 Hz, 2H) 3.53-3.47 (m, 2H) 3.31-3.21 (m, 1H) 3.04-2.96 (m, 3H) 2.55-2.47 (m, 1H) 
2.46-2.18 (m, 1H); Rotomers included 13C NMR (400 MHz, 80 oC, DMSO-d6) 𝛿 ppm 169.77, 
169.64, 159.47, 152.63, 143.89, 143.54, 138.23, 137.74, 132.62, 129.09, 128.64, 127.79, 
121.93, 121.60, 120.26, 115.24, 114.78, 112.83, 112.60, 112.39, 111.92, 111.47, 107.72, 
107.36, 69.65, 69.72, 69.19, 68.31, 67.51, 67.28, 67.12, 67.00, 66.88, 66.77, 66.63, 39.16, 
35.62, 35.78, 35.05; QTOF ES+ MS: (M+H) 548.18; HPLC Ret: 5.98 min; 92% pure. 
58150-Series Drug Development Procedures (Chapter 3): 
oxetan-3-ylmethyl methanesulfonate. In a 25 mL round-bottomed flask, oxetan-3-olmethanol 
(0.1 g, 0.09 mL, 1.14 mmol) was dissolved in 2 mL DCM and cooled to 0 °C. Et3N (0.29 g, 0.4 
mL, 2.8 mmol) was added followed by a slow addition of MsCl (0.16 g, 0.11 mL, 1.4 mmol). The 
solution was warmed to 25 °C and stirred for 2 hr. The reaction was quenched with sat. 
NaHCO3 and extracted with DCM (3 x 20 mL). The organic layers were combined, washed with 
brine, and concentrated in vacuo to produce orange oil. Similar compounds were made in a 
similar fashion. Yield=quant. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 4.78-4.76 (m, 2H) 4.51-4.44 
(m, 4H) 3.45-3.33 (m, 1H) 3.06 (s, 3H). 
(3-methyloxetan-3-yl)methyl methanesulfonate. Orange oil. Yield=quant. 1H NMR (500 MHz, 




cis/trans-methyl 3-hydroxycyclopentanecarboxylate. In a 25 mL round-bottomed flask, 
methyl 3-oxocyclopentanecarboxylate (0.25 g, 0.22 mL, 1.76 mmol) was dissolved in 5 mL 
MeOH and cooled to 0 °C. NaBH4 (0.07 g, 1.76 mmol) was added and the reaction was stirred 
at 0 °C for 1 hr. The reaction was quenched with 1 N HCl and the product was extracted with 
EtOAc (3 x 20 mL). The organic layers were combined, washed with brine, and evaporated in 
vacuo to produce red oil. Yield = 88%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 4.46 (tt, J = 5.3, 2.7 
Hz, 0.34H) 4.33 (tt, J = 5.5, 3.0 Hz, 1H) 3.71 (s, 3H) 3.68 (s, 1.3H) 3.12-3.05 (m, 0.3H) 2.89 
(tdd, J = 9.2, 6.5, 4.5 Hz, 1H) 2.18-1.60 (m, 8H). ~3:1 diastereomer ratio. 
cis/trans- methyl 3-((methylsulfonyl)oxy)cyclopentanecarboxylate. In a 25 mL round-
bottomed flask, cis/trans-methyl 3-hydroxycyclopentanecarboxylate (0.22 g, 1.5 mmol) and Et3N 
(0.39 g, 0.54 mL, 3.9 mmol) were dissolved in 4 mL DCM. The reaction was cooled to 0 °C and 
methanesulfonyl chloride (0.2 g, 0.14 mL, 1.8 mmol) was added. The reaction was warmed to 
room temperature where the reaction proceded for 2 hours. The reaction was quenched with 
NaHCO3, and the product was extracted with DCM (3 x 20 mL). The organic layers were 
combined, washed with brine, and concentrated in vacuo producing colorless oil. Similar 
analogs were made in an analogous fashion. Yield = 99%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
5.29-5.23 (m, 0.32H) 5.16 (tt, J = 5.9, 4.0 Hz, 1H) 3.70 (s, 3H) 3.68 (s, 1.3H) 3.13-3.02 (m, 
0.3H) 3.01 (s, 3H) 2.99 (s, 1.2H) 2.90-2.78 (m, 1H) 2.40-1.85 (m, 8H). ~3:1 diastereomer ratio. 
cis/trans- ethyl 4-((methylsulfonyl)oxy)cyclohexanecarboxylate. Yellow oil. Yield = quant. 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 4.97-4.90 (m, 0.5H) 4.69-4.61 (m, 0.5H) 4.14 (m, 2H) 3.17-
3.07 (m, 1H) 3.03 (s, 1.5H) 2.99 (s, 1.5H) 2.43-2.28 (m, 1H) 2.23-1.90 (m, 4H) 1.84-1.56 (m, 
5H) 1.44-1.40 (m, 1.5H) 1.29-1.23 (m, 3H). ~1:1 diastereomer ratio. 
2,4-dichloro-5-methylbenzoic acid. 1-bromo-2,4-dichloro-5-methylbenzene (0.11 g, 0.46 
mmol) was added to a flame dried 100 mL round-bottomed flask charged with a stir bar 
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containing tetrahydrofuran (2.0 mL). The solution was placed under Ar2, cooled to -78 °C, and n-
butyllithium in hexanes (1.2 M, 0.42 mL) was added dropwise. The reaction proceeded for 5 min 
at -78 °C, and then was quickly poured over dry ice (10 g) in a 150 mL beaker. The solvents 
were evaporated in vacuo and the subsequent oil was partitioned between H2O and hexanes. 
The aqueous was washed with hexanes (3 x 10 mL) and then 1N HCl (7 mL) was added. The 
product was extracted with EtOAc (3x 20 mL), washed with brine (3x 10 mL), dried over MgSO4, 
and concentrated in vacuo to produce white powder. Similar compounds were made in an 
analogous fashion. Yield=100%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.90 (s, 1H) 7.50 (s, 1H) 
2.39 (s, 3H); HPLC Ret: 6.59 min. 
2-chloro-4-(trifluoromethoxy)benzoic acid. Orange solid. Yield=96%. 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 8.11 (d, J = 8.7 Hz, 1H) 7.39 (d, J = 1.7 Hz, 1H) 7.22 (dd, J = 8.8, 1.7 Hz, 1H); 
HPLC Ret: 6.65 min. 
2-chloro-4-cyclopropoxybenzoic acid. methyl 2-chloro-4-hydroxybenzoate (0.25 g, 1.34 
mmol) was dissolved in 2.0 mL DMA. Bromocyclopropane (0.54 g, 4.42 mmol) along with 
Cs2CO3 (1.4 g, 4.42 mmol) were added and the reaction was stirred at 155 oC for 24 hr. The 
reaction was diluted with 10 mL H2O and washed with EtOAc (3x 10 mL). The aqueous layer 
was acidified to pH ~1 with 1N HCl and the product was extracted with EtOAc (3x 15 mL). The 
organic layers were combined, washed with brine, dried with MgSO4, and evaporated. The 
subsequent oil was subjected to silica gel chromatography eluting with 45% EtOAc: 55% Hex: 
0.01% AcOH. The fractions containing product were concentrated in vacuo to produce white 
solid. Yield=65%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 13.00 (br. s, 1H) 7.84 (d, 8.7 Hz, 1H) 
7.20 (d, J = 2.5 Hz, 1H) 6.99 (dd, J = 8.8, 2.5 Hz, 1H) 3.98 (tt, J = 6.1, 2.9 Hz, 1H) 0.87-0.79 (m, 
2H) 0.70 (tdd, J = 5.9, 3.0, 1.5, 2H); TOF ES+ MS: (M+H) 213.03; HPLC Ret: 6.33 min. 
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methyl 2-chloro-4-(2,2,2-trifluoroethoxy)benzoate. In a 50 mL round-bottomed flask methyl 
2-chloro-4-hydroxybenzoate (0.3 g, 1.6 mmol) was dissolved in 6 mL anhydrous DMSO. 
Cs2CO3 (0.68 g, 2.09 mmol) and 1, 1, 1-trifluoro-2-iodoethane (0.44 g, 0.21 mL, 2.09 mmol) 
were added and the reaction was heated at 105 °C for 16 hr. The reaction was cooled, diluted 
with H2O, and extracted with EtOAc (3 x 20 mL). The organic layers were combined, washed 
with brine, and concentrated in vacuo. The yellow residue was subjected to silica gel 
chromatography eluting with 5% EtOAc Hex. The fractions containing product were 
concentrated in vacuo to produce yellow solid. Similar analogs were made in an analgous 
fashion. Yield=41%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.91 (d, J = 8.8 Hz, 1H) 7.03 (d, J = 
2.6 Hz, 1H) 6.88 (dd, J = 8.8, 2.6 Hz, 1H) 4.39 (q, J = 7.8 Hz, 2H) 3.91 (s, 3H); TOF ES+ MS: 
(M+H) 269.1; HPLC Ret: 7.50 min. 
methyl 2-chloro-4-(oxetan-3-yloxy)benzoate. *8 hr rxn time and 25% EtOAc: 75% Hex to 
35%: EtOAc: 65% Hex chromatography. Yellow solid. Yield=70%. 1H NMR (500 MHz, CDCl3-d) 
𝛿 ppm 7.87 (d, J = 8.7 Hz, 1H) 6.76 (d, J = 2.5 Hz, 1H) 6.64 (dd, J = 8.8, 2.5 Hz, 1H) 5.28-5.20 
(m, 2H) 5.02-4.95 (m, 2H) 4.78-4.72 (m, 2H) 3.90 (s, 3H); HPLC Ret: 6.39 min. 
methyl 2-chloro-4-(oxetan-3-ylmethoxy)benzoate. methyl 2-chloro-4-hydroxybenzoate (0.16 
g, 0.88 mmol) was dissolved in 3.0 mL DMF. oxetan-3-ylmethyl methanesulfonate (0.19 g, 1.14 
mmol) along with K2CO3 (0.16 g, 1.14 mmol) were added and the reaction was stirred at 90 oC 
for 1.5 hr. The reaction was diluted with 10 mL brine and extracted with DCM (3x 15 mL). The 
organic layers were combined, dried with MgSO4, and evaporated. The subsequent oil was 
subjected to silica gel chromatography eluting with 30% EtOAc Hex. The fractions containing 
product were concentrated in vacuo to produce yellow oil. Similar analogs were made in an 
analogous fashion. Yield=83%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.89 (d, J = 8.8 Hz, 1H) 
6.99 (d, J = 2.5 Hz, 1H) 6.84 (dd, J = 8.8, 2.5 Hz, 1H) 4.89 (dd, J = 7.8, 6.3 Hz, 2H) 4.56 (t, J = 
6.1 Hz, 2H) 4.24 (d, J = 6.7 Hz, 2H) 3.90 (s, 3H) 3.50-3.40 (m, 1H); HPLC Ret: 6.38 min. 
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methyl 2-chloro-4-(oxetan-3-ylmethoxy)benzoate. Column: 40% EtOAc: 60% Hex. Yellow oil. 
Yield=92%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.89 (d, J = 8.8 Hz, 1H) 7.02 (d, J = 2.5 Hz, 1H) 
6.86 (dd, J = 8.8, 2.5 Hz, 1H) 4.60 (d, J = 6.0 Hz, 2H) 4.47 (d, J = 6.0 Hz, 2H) 4.07 (s, 2H) 3.90 
(s, 3H) 1.44 (s, 3H); HPLC Ret: 6.91 min. 
tert-butyl 4-bromo-2-chlorobenzoate. In a 50 mL round-bottomed flask, 4-bromo-2-
chlorobezoic acid (0.5 g, 2.12 mmol) was dissolved in THF (10 mL). Boc anhydride (0.56 g, 2.55 
mmol), DMAP (0.08 g, 0.64 mmol), and Et3N (0.32 g, 3.2 mmol, 0.44 mL) were added, and 
reaction was stirred at 25 °C for 16 hr. The reaction was diluted with EtOAc (50 mL), washed 
with water (2 x 20 mL) and brine, dried with MgSO4, and concentrated in vacuo. The yellow 
residue was subjected to silica gel chromatography eluting with 2% to 5% EtOAc Hex. The 
fractions containing product were concentrated in vacuo to produce colorless oil. Yield = 58%. 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.65-7.58 (m, 2H) 7.43 (dd, J = 8.0, 1.9 Hz, 1H) 1.60 (s, 
9H) TOF ES+ MS: (M+Na) 315.2; HPLC Ret: 9.10 min. 
methyl 4-bromo-2-chlorobenzoate. Method A starting from 4-bromo-2-chlorobenzoic acid (1.0 
g, 4.25 mmol) gave methyl 4-bromo-2-chlorobenzoate as yellow oil (0.93 g, 87%); 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.72 (d, J = 8.4 Hz, 1H) 7.64 (d, J = 1.5 Hz, 1H) 7.46 (dd, J = 8.4, 1.6 Hz, 
1H) 3.93 (s, 3H); TOF ES+ MS: (M+H) 248.9; HPLC Ret: 7.71 min. 
methyl 3-bromo-2-chlorobenzoate. Method A starting from 3-bromo-2-chlorobenzoic acid (0.5 
g, 2.12 mmol) gave methyl 3-bromo-2-chlorobenzoate as colorless oil (0.52 g, 98%); 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 7.77 (dd, J = 8.0, 0.8 Hz, 1H) 7.68 (dd, J = 7.7, 0.8, 1H) 7.19 (td, J = 
7.9, 0.8 Hz, 1H) 3.94 (s, 3H); TOF ES+ MS: (M+H) 250.9; HPLC Ret: 7.44 min. 
methyl 2,6-difluorobenzoate. Method A starting from 2,6-difluorobenzoic acid (0.5 g, 3.16 
mmol) gave methyl 2,6-difluorobenzoate as tan oil (0.43 g, 78%); 1H NMR (500 MHz, CDCl3-d)) 
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𝛿 7.42 (ttd, J = 8.5, 6.2, 0.8 Hz, 1H), 7.26 (s, 0H), 7.03 – 6.91 (m, 2H), 3.96 (d, J = 0.8 Hz, 3H); 
TOF ES+ MS: (M+Na) 195; HPLC Ret: 6.38 min. 
methyl 2-chloro-4-cyclopropoxybenzoate. Method A starting from 2-chloro-4-
cyclopropoxybenzoic acid (0.5 g, 3.16 mmol) gave methyl 2-chloro-4-cyclopropoxybenzoate as 
colorless oil (0.21 g, 66%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.86 (d, 8.5 Hz, 1H) 7.14 (d, J = 
2.5 Hz, 1H) 6.94 (dd, J = 8.8, 2.4 Hz, 1H) 3.90 (s, 3H) 3.77 (tt, J = 6.4, 3.0 Hz, 1H) 0.88-0.75 (m, 
4H); TOF ES+ MS: (M+H) 226.14; HPLC Ret: 7.67 min. 
methyl 2-chloro-4-iodobenzoate. Method A starting from 2-chloro-4-iodobenzoic acid (1.0 g, 
3.54 mmol) gave methyl 2-chloro-4-iodobenzoate as yellow oil (1.02 g, 97%); 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.85 (d, 1.6 Hz, 1H) 7.67 (dd, J = 8.2, 1.7 Hz, 1H) 7.55 (d, J = 8.2 Hz, 1H) 
3.91 (s, 3H); HPLC Ret: 7.88 min. 
methyl 2-chloro-4-(trifluoromethoxy)benzoate. Method A starting from 2-chloro-4-
(trifluoromethoxy)benzoic acid (0.21 g, 0.87 mmol) gave methyl 2-chloro-4-
(trifluoromethoxy)benzoate as white oil (0.05 g, 24%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.92 
(d, J = 8.7 Hz, 1H) 7.33 (d, J = 2.3 Hz, 1H) 7.18 (dd, J = 8.7, 2.4 Hz, 1H) 3.94 (s, 3H); HPLC 
Ret: 7.90 min. *CF3 group may be unstable to refluxing acid. 
methyl 4-(2,2,2-trifluoroethoxy)benzoate. Method A starting from 4-(2,2,2-
trifluoroethoxy)benzoic acid (0.5 g, 2.3 mmol) gave methyl 4-(2,2,2-trifluoroethoxy)benzoate as 
yellow oil (0.4 g, 75%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.03 (d, J = 8.6 Hz, 2H) 6.97 (d, J = 
8.6 Hz, 2H) 4.41 (q, 8.0 Hz, 2H) 3.90 (s, 3H); HPLC Ret: 7.23 min. 
methyl 4-(difluoromethyl)benzoate. Method A starting from 4-(difluoromethyl)benzoic acid 
(0.5 g, 2.9 mmol) gave methyl 4-(difluoromethyl)benzoate as white solid (0.49 g, 90%); 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 8.13 (d, J = 8.0 Hz, 2H) 7.59 (d, J = 8.0 Hz, 2H) 6.69 (t, 56.1 Hz, 1H) 
3.95 (s, 3H); HPLC Ret: 6.79 min. 
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methyl 2-chloro-3-(trifluoromethyl)benzoate. Method A starting from 2-chloro-3-
(trifluoromethyl)benzoic acid (0.5 g, 2.2 mmol) gave methyl 2-chloro-3-(trifluoromethyl)benzoate 
as yellow oil (0.51 g, 95%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.91-7.80 (m, 2H) 7.44 (t, J = 
7.9 Hz, 1H) 3.97 (s, 3H); HPLC Ret: 7.47 min. 
methyl 4-(difluoromethoxy)benzoate. Method A starting from 4-(difluoromethoxy)benzoic acid 
(0.3 g, 1.6 mmol) gave methyl 4-(difluoromethoxy)benzoate as colorless oil (0.27 g, 83%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.06 (d, J = 8.4 Hz, 2H) 7.16 (d, J = 8.4 Hz, 2H) 6.59 (t, 73.2 
Hz, 1H) 3.92 (s, 3H). 
methyl 2-chloro-4-cyclopropylbenzoate. Method K starting from methyl 4-bromo-2-
chlorobenzoate (0.27 g, 1.1 mmol) gave methyl 2-chloro-4-cyclopropylbenzoate as yellow oil 
(0.12 g, 51%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.81-7.70 (m, 1H) 7.15-7.12 (m, 1H) 7.03-
6.94 (m, 1H) 3.90 (s, 3H) 1.95-1.84 (m, 1H) 1.11-1.00 (m, 2H) 0.81-0.70 (m, 2H); TOF ES+ MS: 
(M+H) 211.0; HPLC Ret: 7.29 min. 
methyl 2-chloro-3-cyclopropylbenzoate. Method K starting from methyl 3-bromo-2-
chlorobenzoate (0.52 g, 2.1 mmol) gave methyl 2-chloro-3-cyclopropylbenzoate as yellow oil 
(0.43 g, 97%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.51 (dd, J = 7.7, 1.7 Hz, 1H) 7.21 (t, J = 7.7 
Hz, 1H) 7.10 (dd, J = 7.8, 1.6 Hz, 1H) 3.94 (s, 3H) 2.29-2.21 (m, 1H) 1.09-0.96 (m, 2H) 0.71-
0.66 (m, 2H); TOF ES+ MS: (M+H) 211.0; HPLC Ret: 7.31 min. 
methyl 2-chloro-5-cyclopropylbenzoate. Method K starting from methyl 5-bromo-2-
chlorobenzoate (0.5 g, 2.0 mmol) gave methyl 2-chloro-5-cyclopropylbenzoate as yellow oil 
(0.35 g, 83%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.51 (d, J = 1.6 Hz, 1H) 7.33 (d, J = 8.2 Hz, 
1H) 7.11 (dd, J = 7.9, 1.5 Hz, 1H) 3.93 (s, 3H) 1.93-1.86 (m, 1H) 1.05-0.98 (m, 2H) 0.73-0.68 
(m, 2H); TOF ES+ MS: (M+H) 211.0; HPLC Ret: 7.31 min. 
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Methyl 3-chloro-[1, 1’-biphenyl]-4-carboxylate. In a 100 mL round bottomed flask, methyl 4-
bromo-2-chlorobenzoate (0.5 g, 2.00 mmol), phenyl boronic acid (0.269 g, 2.21 mmol), 
palladium (II) acetate (0.045 g, 0.2 mmol), triphenylphosphine (0.026 g, 0.1 mmol) and sodium 
carbonate (0.64 g, 6.01 mmol) were combined in a solution of DMF (10 mL) and H2O (1 mL). 
The mixture was stirred under N2 at 80 oC for 1 hr and the catalyst was filtered through a pad of 
Celite. The solvents were removed in vacuo and the product was diluted with 25 mL H2O and 
extracted with DCM (3x 25 mL). The organic layers were combined, washed with brine, dried 
with MgSO4, and evaporated. The subsequent oil was subjected to silica gel chromatography 
eluting with 5% EtOAc: 95% Hex. The fractions containing product were concentrated in vacuo 
to produce white powder. Yield=79%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.93 (d, J = 8.2, 1H) 
7.69 (d, J = 1.5 Hz, 1H) 7.62-7.56 (m, 2H) 7.56-7.50 (m, 1H) 7.51-7.44 (m, 2H) 7.45-7.38 (m, 
1H) 3.95 (s, 3H); TOF ES+ MS: (M+H) 247.0; HPLC Ret: 8.22 min. 
tert-butyl 2-chloro-4-(prop-1-en-2-yl)benzoate. In a 100 mL round-bottomed flask, tert-butyl 
4-bromo-2-chlorobenzoate (0.36 g, 1.24 mmol) and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-
dioxaborolane (0.22 g, 1.3 mmol) were dissolved in a solution of 1,4-dioxane:H2O (13 mL:3.25 
mL). The solution was degassed and sodium carbonate (0.27 g, 2.53 mmol) and tetrakis (0.14 
g, 0.012 mmol) were added. The reaction was stirred under Ar2 at 90 °C for 16 hr. The volatile 
solvents were removed in vacuo, and the solution was diluted with water (10 mL). The product 
was extracted with DCM (3x, 25 mL), washed with brine (20 mL), dried with MgSO4, and 
concentrated in vacuo. The yellow residue was subjected to silica gel chromatography eluting 
with 2% EtOAc: 98% Hex. The fractions containing product were concentrated in vacuo to 
produce faint yellow oil. Yield=88%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.71 (dd, J = 8.2, 4.2 
Hz, 1H) 7.48 (s, 1H) 7.37 (dd, J = 7.9, 1.8 Hz, 1H) 5.43 (s, 1H) 5.18 (s, 1H) 1.61 (s, 9H) 1.55 (s, 
3H); TOF ES+ MS: (M+H) 253.1; HPLC Ret: 9.25 min. 
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methyl 2-chloro-4-(prop-1-en-2-yl)benzoate. In a 25 mL round-bottomed flask, tert-butyl 2-
chloro-4-(prop-1-en-2-yl)benzoate (0.14 g, 0.53 mmol) was dissolved in 1.5 mL DCM and 1.5 
mL TFA. The reaction was stirred at 25 °C for 1 hr and then concentrated in vacuo. The 
resulting white solid was taken up in 3 mL MeOH and sulfuric acid (0.07 g, 0.66 mmol, 0.04 mL) 
was added. The reaction was stirred at 85 °C for 16 hr. The solution was concentrated in vacuo 
and the residue was taken up in DCM (20 mL) and partitioned between water (20 mL). The 
product was extracted with DCM (3x 20 mL), washed with brine (40 mL), dried with MgSO4, and 
concentrated in vacuo to obtain yellow oil. The yellow residue was subjected to silica gel 
chromatography eluting with 5% EtOAc Hex. The fractions containing product were 
concentrated in vacuo to produce colorless oil. Yield=50% (2-steps). 1H NMR (500 MHz, CDCl3-
d) 𝛿 ppm 7.82 (dd, J = 8.2, 1.6 Hz, 1H) 7.53 (s, 1H) 7.39 (dd, J = 8.2, 1.6 Hz, 1H) 5.47 (s, 1H) 
5.22 (s, 1H) 3.93 (s, 3H) 2.14 (s, 3H); TOF ES+ MS: (M+H) 211.1; HPLC Ret: 8.00 min. 
methyl 2-chloro-4-vinylbenzoate. methyl 4-bromo-2-chlorobenzoate (0.54 g, 2.16 mmol) was 
dissolved in 8 mL of DMF (degassed) under inert atmosphere. Vinyl n-tributyl tin (1.4 g, 1.3 mL, 
4.33 mmol) and Tetrakis (0.25 g, 0.22 mmol) were added, and the mixture was heated at 100 °C 
for 1 hr under N2. The mixture was cooled to 25 °C and 10 mL H2O was added. The product 
was extracted with EtOAc (3 x 20 mL), washed with brine (20 mL), dried with MgSO4, and 
concentrated in vacuo. The yellow residue was subjected to silica gel chromatography eluting 
with 2.5% EtOAc: 97.5% Hex. The fractions containing product were concentrated in vacuo to 
produce colorless oil. Yield=82%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.82 (dd, J = 8.1, 1.3 Hz, 
1H) 7.47 (d, J = 1.6 Hz, 1H) ) 7.32 (dd, J = 8.1, 1.5 Hz, 1H) 6.67 (ddd, J = 17.6, 10.8, 1.2 Hz, 
1H) 5.86 (dd, J = 17.5, 1.3 Hz, 1H) 5.42 (dd, 10.9, 1.3 Hz, 1H) 3.93 (s, 3H); TOF ES+ MS: 
(M+H) 197.0; HPLC Ret: 7.50 min. 
methyl 2-chloro-4-ethylbenzoate. In a flamed dried 25 mL round bottomed flask, methyl 2-
chloro-4-vinylbenzoate (0.12 g, 0.59 mmol) and 2-nitrobenzene-1-sulfonyl chloride (0.26 g, 1.19 
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mmol) were dissolved in 3 mL dry MeCN. The solution was cooled to 0 °C and hydrazine 
hydrate (0.08 g, 0.07 mL, 2.4 mmol) was slowly added. The reaction was warmed to 25 °C and 
stirred vigorously for 16 hr under N2. Upon completion, the reaction was quenched with water 
(15 mL) and the product was extracted with EtOAc (4 x 20 mL). The layers were combined, 
dried with MgSO4, and concentrated in vacuo. The yellow residue was subjected to silica gel 
chromatography eluting with 2.5% EtOAc: 97.5% Hex. The fractions containing product were 
concentrated in vacuo to produce yellow oil. Yield=66%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
7.78 (dd, J = 8.0, 1.0 Hz, 1H) 7.29 (d, J = 1.6 Hz, 1H) 7.13 (dd, J = 8.2, 1.3 Hz, 1H) 3.92 (s, 3H) 
2.66 (q, J = 7.6 Hz, 2H) 1.25 (t, J = 7.6 Hz, 3 Hz); TOF ES+ MS: (M+H) 199.1; HPLC Ret: 7.73 
min. 
methyl 2-chloro-4-propylbenzoate. In a flame dried 25 mL round-bottomed flask, 2-chloro-4-
methylbenzoic acid (0.1 g, 0.59 mmol) was dissolved in THF (1.0 mL). The solution was cooled 
to 0 °C and LDA (0.13 g, 1.2 mmol, 2.5 mL) was added. The reaction was stirred at 0 °C for 10 
mins, and then ethyl iodide (0.14 g, 0.88 mmol, 0.07 mL) was added. After stirring at 0 °C for 1 
hour, the reaction was quenched with 1N HCl (10 mL). The product was extracted with EtOAc (3 
x 20 mL), washed with brine, dried with MgSO4, and concentrated in vacuo. HPLC Ret: 6.87 
min. The subsequent oil was taken up in MeOH (3.0 mL), and sulfuric acid (0.07 g, 0.76 mmol, 
0.04 mL) was added. The solution was heated to reflux (85 °C) for 16 hr. The MeOH was 
removed in vacuo, and the product was extracted with EtOAc (3 x 20 mL), washed with brine, 
dried with MgSO4, and concentrated in vacuo. The yellow residue was subjected to silica gel 
chromatography eluting with 2% EtOAc: 98% Hex. The fractions containing product were 
concentrated in vacuo to produce colorless oil. Similar derivatives were made in an analogous 
fashion. Yield=25%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.77 (d, J = 8.0 Hz, 1H) 7.27 (d, J = 
1.6 Hz, 1H) ) 7.11 (dd, J = 8.1, 1.6 Hz, 1H) 3.92 (s, 3H) 2.59 (t, J = 7.4 Hz, 2H) 1.65 (h, J = 7.4 
Hz, 2H) 0.94 (t, J = 7.4 Hz, 3H); TOF ES+ MS: (M+H) 213.1; HPLC Ret: 8.22 min. 
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methyl 4-butyl-2-chlorobenzoate. (1-bromoproane used as alkylating agent). HPLC Ret 
(acid): 7.36 min. Colorless oil. Yield = 53%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.77 (d, J = 8.0 
Hz, 1H) 7.27 (d, J = 1.6 Hz, 1H) 7.11 (dd, J = 8.0, 1.5 Hz, 1H) 3.92 (s, 3H) 2.62 (t, J = 7.4 Hz, 
2H) 1.69-1.53 (m, 2H) 1.35 (h, J = 7.3 Hz, 2H) 0.93 (t, J = 7.4 Hz, 3H); TOF ES+ MS: (M+H) 
227.1; HPLC Ret: 8.75 min. 
methyl 2-chloro-4-isobutylbenzoate. (2-bromopropane used as alkylating agent). HPLC Ret 
(acid): 7.26 min. Colorless oil. Yield = 25%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.77 (d, J = 7.9 
Hz, 1H) 7.25 (d, J = 1.6 Hz, 1H) 7.09 (dd, J = 8.0, 1.6 Hz, 1H) 3.92 (s, 3H) 2.48 (d, J = 7.2 Hz, 
2H) 1.88 (dp, J = 13.5, 6.8 Hz, 1H) 0.91 (d, J = 6.6 Hz, 6H); TOF ES+ MS: (M+H) 227.1; HPLC 
Ret: 8.63 min. 
methyl 4-(2-hydroxypropan-2-yl)benzoate. In a 100 mL round-bottomed flask, methyl 4-
iodobenzoate (1.0 g, 3.8 mmol) was dissolved in 10 mL THF and cooled to 0 °C. 2M iPrMgCl in 
THF (2.0 mL, 4.01 mmol) was added dropwise and the reaction was stirred at -40 °C for 1.5 hr. 
Acetone (0.33 g, 0.42 mL, 5.7 mmol) was then added and the reaction was stirred at 25 °C for 1 
hr. The reaction was quenched with MeOH and then diluted with H2O. The product was 
extracted with EtOAc (3 x 15 mL), and the organic layers were combined, washed with brine, 
dried with MgSO4, and concentrated in vacuo. The subsequent oil was subjected to silica gel 
chromatography eluting with 20% EtOAc Hex. The fractions containing product were 
concentrated in vacuo to produce colorless oil. Similar analogs were made in an analogous 
fashion. Yield=16% *low yield attributed to rxn temp being too low (supposed to be at -20). 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.00 (d, J = 7.4 Hz, 2H) 7.56 (d, J = 7.4 Hz, 2H) 3.91 (s, 3H) 
1.60 (s, 6H); HPLC Ret: 5.60 min. 
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methyl 2-chloro-4-(2-hydroxypropan-2-yl)benzoate.  Column: 30% EtOAc Hex. Colorless oil. 
Yield=53%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.81 (d, J = 8.2 Hz, 1H) 7.59 (d, J = 1.7 Hz, 1H) 
7.41 (dd, J = 8.2, 1.8 Hz, 1H) 3.93 (s, 3H) 1.58 (s, 6H); HPLC Ret: 6.09 min. 
methyl 2-chloro-4-(2-fluoropropan-2-yl)benzoate. In a flame dried 25-mL round bottomed 
flask, methyl 2-chloro-4-(2-hydroxypropan-2-yl)benzoate (0.11 g, 0.48 mmol) was dissolved in 
DCM (2 mL) and cooled to -78 °C. DAST (0.08 g, 0.06 mL, 0.48 mmol) was added and the 
solution was stirred at 25 °C for 2 hr. The reaction was diluted with H2O, and the product was 
extracted with DCM (3 x 20 mL). The organic layers were combined, washed with brine (2 x 15 
mL), dried with MgSO4, and concentrated in vacuo. The oil was subjected to silica gel 
chromatography eluting with 2.5% EtOAc: 97.5% Hex to 5% EtOAc: 95% Hex. The fractions 
containing product were concentrated to produce colorless oil. Similar derivatives were made in 
an analogous fashion. Yield=51%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.83 (d, J = 8.2 Hz, 1H) 
7.47 (d, J = 1.7 Hz, 1H) 7.30 (dd, J = 8.2, 1.7 Hz, 1H) 3.93 (s, 3H) 1.70 (d, J = 1.5 Hz, 3H) 1.65 
(d, J = 1.5 Hz, 3H); 19F NMR (500 MHz, CDCl3-d) 𝛿 ppm -139.4 (hept., 1H); HPLC Ret: 8.02 
min. 
methyl 4-(2-fluoropropan-2-yl)benzoate. Colorless oil. Yield=47%. 1H NMR (500 MHz, CDCl3-
d) 𝛿 ppm 8.03 (d, J = 8.4 Hz, 2H) 7.45 (d, J = 8.4 Hz, 2H) 3.92 (s, 3H) 1.72 (d, J = 1.3 Hz, 3H) 
1.67 (d, J = 1.3 Hz, 3H); 19F NMR (500 MHz, CDCl3-d) 𝛿 ppm -138.9 (hept., 1H); HPLC Ret: 
7.74 min. 
2-chloro-4-methylbenzohydrazide. Method A followed by Method C starting from 2-chloro-4-
methylbenzoic acid (1.0 g, 5.9 mmol) gave 2-chloro-4-methylbenzohydrazide as white solid (0.79 
g, 73% (2 steps)); 1H NMR (401 MHz, CDCl3-d) 𝛿 ppm 7.63 (s, 1H) 7.55 (d, J = 7.9 Hz, 1H) 7.22 




2-chloro-4-fluorobenzohydrazide. Method A followed by Method C starting from 2-chloro-4-
fluorobenzoic acid (1.0 g, 5.7 mmol) gave 2-chloro-4-fluorobenzohydrazide as white solid (0.33 
g, 73% (2 steps)); 1HNMR (401 MHz, DMSO-d6) 𝛿 ppm 9.58 (s, 1H) 7.54-7.41 (m, 2H) 7.30-7.25 
(m, 1H) 4.50 (br. s., 2H); HPLC Ret: 3.43 min. 
2,4-dichlorobenzohydrazide. Method A followed by Method C starting from 2,4-
dichlorobenzoic acid (3.0 g, 15.7 mmol) gave 2,4-dichlorobenzohydrazide as white solid (0.33 g, 
96% (2 steps)); HPLC Ret: 4.20 min. 
2,4-dichloro-5-methylbenzohydrazide. Method A followed by Method C starting from 2,4-
dichloro-5-methylbenzoic acid (0.09 g, 0.46 mmol) gave 2,4-dichloro-5-methylbenzohydrazide 
as white solid (0.07 g, 72% (2 steps)); 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 9.56 (br. s., 1H) 
7.63 (s, 1H) 7.40 (s, 1H) 4.49 (br. s., 2H) 2.32 (s, 3H); QTOF ES+ MS: (M+H) 219.0; HPLC Ret: 
4.74 min. 
2-chloro-4,5-dimethylbenzohydrazide. Method A followed by Method C starting from 2-chloro-
4,5-dimethylbenzoic acid (0.25 g, 1.35 mmol) gave 2-chloro-4,5-dimethylbenzohydrazide as 
white solid (0.24 g, 90% (2 steps)); 1H NMR (501 MHz, DMSO-d6) 𝛿 ppm 9.43 (br. s., 1H) 7.26 
(s, 1H) 7.16 (s, 1H) 4.44 (br. s., 2H) 2.23 (s, 3H) 2.19 (s, 3H); QTOF ES+ MS: (M+H) 199.1; 
HPLC Ret: 4.41 min. 
2-chloro-3,4-dimethylbenzohydrazide. Method A followed by Method C starting from 2-chloro-
3,4-dimethylbenzoic acid (0.25 g, 1.35 mmol) gave 2-chloro-3,4-dimethylbenzohydrazide as 
white solid (0.27 g, 100% (2 steps)); 1H NMR (501 MHz, DMSO-d6) 𝛿 ppm 9.42 (br. s., 1H) 7.16 
(d, J = 7.7 Hz, 1H) 7.07 (d, J = 7.7 Hz, 1H) 4.43 (br. s., 2H) 2.32 (s, 3H) 2.29 (s, 3H); QTOF ES+ 
MS: (M+H) 199.1; HPLC Ret: 4.33 min. 
2-chloro-4-(trifluoromethyl)benzohydrazide. (DJK-2-73). Method A followed by Method C 
starting from 2-chloro-4-(trifluoromethyl)benzoic acid (1.1 g, 4.4 mmol) gave 2-chloro-4-
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(trifluoromethyl)benzohydrazide as white solid (1.04 g, 98%); 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 7.75 (d, J = 8.1, 1H) 7.70 (d, J = 1.7 Hz, 1H) 7.60 (dd, J = 8.0, 1.7 Hz, 1H) 7.50 (br. s., 1H) 
3.94 (br. s., 2H); TOF ES+ MS: (M+H) 239.0; HPLC Ret: 4.48 min. 
2-chloro-4-cyclopropylbenzohydrazide. Method C starting from methyl 2-chloro-4-
cyclopropylbenzoate (0.12 g, 0.55 mmol) gave 2-chloro-4-cyclopropylbenzohydrazide as white 
solid (0.1 g, 85%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.63-7.52 (m, 1H) 7.09 (s, 1H) 7.02-7.00 
(m, 1H) 4.12 (br. s., 2H) 1.93-1.84 (m, 1H) 1.05 (dtd, J = 6.4, 4.8, 1.3 Hz, 2H) 0.74 (dtd, J = 6.4, 
4.8, 1.3 Hz, 2H); TOF ES+ MS: (M+H) 211.0; HPLC Ret: 4.64 min. 
4-bromo-2-chlorobenzohydrazide. Method C starting from methyl 4-bromo-2-chlorobenzoate 
(0.29 g, 1.14 mmol) gave 4-bromo-2-chlorobenzohydrazide as white solid (0.28 g, 97%); 1H 
NMR (400 MHz, DMSO-d6) 𝛿 ppm 7.42 (d, J = 8.2, 1H) 7.31 (s, 1H) 7.19 (dd, J = 8.2, 1.9 Hz, 
1H); TOF ES+ MS: (M+H) 249.0; HPLC Ret: 4.48 min. 
3-chloro-[1, 1’-biphenyl]-4-carbohydrazide. Method C starting from methyl 3-chloro-[1, 1’-
biphenyl]-4-carboxylate (0.39 g, 1.58 mmol) gave 3-chloro-[1, 1’-biphenyl]-4-carbohydrazide as 
white solid (0.37 g, 94%); 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 9.62 (d, J = 26.9 Hz, 1H) 7.87-
7.61 (m, 3H) 7.57-7.34 (m, 5H) 4.53 (d, J = 24.8 Hz, 2H); TOF ES+ MS: (M+H) 247.0; HPLC 
Ret: 5.36 min. 
2-chloro-4-propylbenzohydrazide. Method C starting from methyl 2-chloro-4-propylbenzoate 
(0.03 g, 0.15 mmol) gave 2-chloro-4-propylbenzohydrazide as white solid (0.03 g, quant); HPLC 
Ret: 5.00. 
4-butyl-2-chlorobenzohydrazide. Method C starting from methyl 4-butyl-2-chlorobenzoate 




2-chloro-4-isobutylbenzohydrazide. Method C starting from methyl 2-chloro-4-
isobutylbenzoate (0.03 g, 0.13 mmol) gave 2-chloro-4-isobutylbenzohydrazide as white solid 
(0.03 g, quant); HPLC Ret: 5.40. 
2-chloro-3-cyclopropylbenzohydrazide. Method C starting from methyl 2-chloro-3-
cyclopropylbenzoate (0.43 g, 2.02 mmol) gave 2-chloro-3-cyclopropylbenzohydrazide as white 
solid (0.40 g, 95%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.33 (dd, J = 7.3, 1.4 Hz, 1H) 7.24 (t, J 
= 7.5 Hz, 1H) 7.06 (dd, J = 7.8, 1.6 Hz, 1H) 4.14 (d, J = 4.2 Hz, 2H) 2.20 (tt, J = 8.6, 5.3 Hz, 1H) 
1.09-0.96 (m, 2H) 0.74-0.63 (m, 2H); TOF ES+ MS: (M+H) 211.0; HPLC Ret: 4.55 min. 
2-chloro-5-cyclopropylbenzohydrazide. Method C starting from methyl 2-chloro-5-
cyclopropylbenzoate (0.35 g, 1.64 mmol) gave 2-chloro-5-cyclopropylbenzohydrazide as white 
solid (0.33 g, 96%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.41 (br. s., 1H) 7.36 (d, J = 2.3 Hz, 
1H) 7.28 (dd, J = 8.3, 0.8 Hz, 1H) 7.08 (dd, J = 8.3, 2.3 Hz, 1H) 1.89 (tt, J = 8.6, 5.0 Hz, 1H) 
1.08-0.94 (m, 2H) 0.76-0.64 (m, 2H); TOF ES+ MS: (M+H) 211.0; HPLC Ret: 4.59 min. 
2-chloro-4-(prop-1-en-2-yl)benzohydrazide. Method C starting from methyl 2-chloro-4-(prop-
1-en-2-yl)benzoate (0.05 g, 0.24 mmol) gave 2-chloro-4-(prop-1-en-2-yl)benzohydrazide as 
white solid (0.05 g, quant); HPLC Ret: 4.76. 
2-chloro-4-vinylbenzohydrazide. Method C starting from methyl 2-chloro-4-vinylbenzoate 
(0.12 g, 0.59 mmol) gave 2-chloro-4-vinylbenzohydrazide as yellow solid (0.09 g, 76%); 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 7.65 (dd, J = 8.0, 1.3 Hz, 1H) 7.44 (m, 2H) 7.36 (dd, J = 8.2, 1.3 Hz, 
1H) 6.66 (dd, J = 17.5, 10.9 Hz, 1H) 5.84 (d, J = 17.5 Hz, 1H) 5.41 (d, 10.7 Hz, 1H) 4.14 (br. s, 
2H); TOF ES+ MS: (M+H) 197.0; HPLC Ret: 4.43 min. 
2-chloro-4-ethylbenzohydrazide. Method C starting from methyl 2-chloro-4-ethylbenzoate 
(0.08 g, 0.39 mmol) gave 2-chloro-4-ethylbenzohydrazide as white solid (0.075 g, 98%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.61 (dd, J = 7.9, 1.1 Hz, 1H) 7.45 (br. s, 1H) 7.26 (d, J = 1.1 
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Hz, 1H) 7.17 (dd, J = 8.4, 1.4 Hz, 1H) 4.13 (br. s, 2H) 2.66 (q, J = 7.6 Hz, 2H) 1.24 (t, J = 7.6 
Hz, 3H); TOF ES+ MS: (M+H) 199.1; HPLC Ret: 4.61 min. 
2-(trifluoromethyl)benzohydrazide. Method C starting from methyl 2-(trifluoromethyl)benzoate 
(0.5 g, 2.45 mmol) gave 2-(trifluoromethyl)benzohydrazide as white solid (0.38 g, 76%); 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 7.73 (dd, J = 7.7, 1.3 Hz, 1H) 7.65-7.48 (m, 3H) 6.98 (br. s, 1H) 4.12 
(br. s, 2H); TOF ES+ MS: (M+H) 205.1; HPLC Ret: 3.25 min. 
2,6-difluorobenzohydrazide. Method C starting from methyl 2,6-difluorobenzoate (0.43 g, 2.48 
mmol) gave 2,6-difluorobenzohydrazide as white solid (0.14 g, 33%); 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 7.41 (ttd, J = 8.7, 6.7, 0.8 Hz, 1H) 7.01-6.93 (m, 2H) 4.15 (br. s, 2H); TOF ES+ 
MS: (M+H) 173.1; HPLC Ret: 3.66 min. 
2-chloro-4-cyclopropoxybenzohydrazide. Method C starting from methyl 2-chloro-4-
cyclopropoxybenzoate (0.21 g, 0.93 mmol) gave 2-chloro-4-cyclopropoxybenzohydrazide as 
white solid (0.21 g, 98%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.69 (d, 8.7 Hz, 1H) 7.54 (br. s, 
1H) 7.09 (d, J = 2.4 Hz, 1H) 6.99 (dd, J = 8.7, 2.4 Hz, 1H) 4.13 (br. s, 2H) 3.80-3.72 (m, 1H) 
0.88-0.73 (m, 4H); TOF ES+ MS: (M+H) 227.06; HPLC Ret: 4.57 min. 
2-chloro-4-(2,2,2-trifluoroethoxy)benzohydrazide. Method C starting from methyl 2-chloro-4-
(2,2,2-trifluoroethoxy)benzoate (0.18 g, 0.65 mmol) gave 2-chloro-4-(2,2,2-
trifluoroethoxy)benzohydrazide as white solid (0.15 g, 87%); 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 7.74 (d, 8.7 Hz, 1H) 7.50 (br. s, 1H) 7.01 (d, J = 2.6 Hz, 1H) 6.92 (dd, J = 8.7, 2.6 Hz, 1H) 
4.39 (q, J = 7.9 Hz, 2H) 4.13 (d, J = 4.3 Hz, 2H); TOF ES+ MS: (M+H) 269.03; HPLC Ret: 4.81 
min. 
2-chloro-4-(oxetan-3-yloxy)benzohydrazide. Method C starting from methyl 2-chloro-4-
(oxetan-3-yloxy)benzoate (0.27 g, 1.13 mmol) gave 2-chloro-4-(oxetan-3-yloxy)benzohydrazide 
as white solid (0.2 g, 72%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.69 (d, 8.7 Hz, 1H) 7.51 (br. s, 
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1H) 6.74 (d, J = 2.5 Hz, 1H) 6.67 (dd, J = 8.7, 2.5 Hz, 1H) 5.22 (pd, 6.0, 1.0 Hz, 1H) 4.98 (t, J = 
7.1 Hz, 2H) 4.74 (dd, J = 7.3, 5.1 Hz, 2H) 4.12 (d, J = 4.1 Hz, 2H); TOF ES+ MS: (M+H) 243.05; 
HPLC Ret: 3.10 min. 
2-chloro-4-(trifluoromethoxy)benzohydrazide. Method C starting from methyl 2-chloro-4-
(trifluoromethoxy)benzoate (0.05 g, 0.21 mmol) gave 2-chloro-4-
(trifluoromethoxy)benzohydrazide as white solid (0.04 g, 74%); 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 7.73 (d, 8.6 Hz, 1H) 7.39 (br. s, 1H) 7.31 (d, J = 2.1 Hz, 1H) 7.22 (dd, J = 8.8, 2.1 Hz, 1H) 
4.15 (br. s, 2H); TOF ES+ MS: (M+H) 255.01; HPLC Ret: 4.97 min. 
2-chloro-4-(oxetan-3-ylmethoxy)benzohydrazide. Method C starting from methyl 2-chloro-4-
(oxetan-3-ylmethoxy)benzoate (0.19 g, 0.73 mmol) gave 2-chloro-4-(oxetan-3-
ylmethoxy)benzohydrazide as white solid (0.15 g, 80%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
7.73 (d, 8.6 Hz, 1H) 7.54 (br. s, 1H) 6.96 (d, J = 2.4 Hz, 1H) 6.89 (dd, J = 8.8, 2.4 Hz, 1H) 4.89 
(td, 6.1, 3.0 Hz, 2H) 4.56 (td, J = 6.1, 3.0 Hz, 2H) 4.23 (dd, J = 6.7, 3.0 Hz, 2H) 4.13 (br. s, 2H) 
3.48-3.41 (m, 1H); TOF ES+ MS: (M+H) 257.07; HPLC Ret: 3.65 min. 
2-chloro-4-((3-methyloxetan-3-yl)methoxy)benzohydrazide. Method C starting from methyl 
2-chloro-4-((3-methyloxetan-3-yl)methoxy)benzoate (0.19 g, 0.71 mmol) gave 2-chloro-4-((3-
methyloxetan-3-yl)methoxy)benzohydrazide as white solid (0.17 g, 90%); 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 7.73 (d, 8.6 Hz, 1H) 7.56 (br. s, 1H) 6.99 (d, J = 2.4 Hz, 1H) 6.91 (dd, J = 8.8, 
2.4 Hz, 1H) 4.60 (dd, J = 6.1, 3.3 Hz, 2H) 4.47 (dd, J = 6.1, 3.4 Hz, 2H) 4.13 (br. s, 2H) 4.06 (s, 
2H) 1.44 (s, 3H); TOF ES+ MS: (M+H) 271.08; HPLC Ret: 4.21 min. 
4-(2,2,2-trifluoroethoxy)benzohydrazide. Method C starting from methyl 4-(2,2,2-
trifluoroethoxy)benzoate (0.4 g, 1.71 mmol) gave 4-(2,2,2-trifluoroethoxy)benzohydrazide as 
white solid (0.36 g, 89%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.75 (d, 8.8 Hz, 2H) 7.26 (br. s, 
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1H) 7.00 (d, J = 8.8 Hz, 2H) 4.40 (q, J = 8.0 Hz, 2H) 4.09 (d, J = 3.8 Hz, 2H); TOF ES+ MS: 
(M+H) 235.07; HPLC Ret: 4.65 min. 
4-(difluoromethyl)benzohydrazide. Method C starting from methyl 4-(difluoromethyl)benzoate 
(0.49 g, 2.6 mmol) gave 4-(difluoromethyl)benzohydrazide as white solid (0.36 g, 73%); 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 7.84 (d, 7.8 Hz, 2H) 7.61 (d, J = 7.8 Hz, 2H) 7.37 (br. s, 1H) 6.69 (t, 
J = 56.2 Hz, 1H) 4.12 (br. s, 2H); TOF ES+ MS: (M+H) 187.07; HPLC Ret: 3.84 min. 
4-(trifluoromethoxy)benzohydrazide. Method C starting from methyl 4-
(trifluoromethoxy)benzoate (0.5 g, 2.3 mmol) gave 4-(trifluoromethoxy)benzohydrazide as white 
solid (0.5 g, 100%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.80 (d, J = 8.0 Hz, 2H) 7.36 (br. s, 1H) 
7.33-7.25 (m, 2H) 4.11 (br.s, 2H); TOF ES+ MS: (M+H) 221.05; HPLC Ret: 4.71 min. 
2-chloro-3-(trifluoromethyl)benzohydrazide. Method C starting from methyl 2-chloro-3-
(trifluoromethyl)benzoate (0.5 g, 2.1 mmol) gave 2-chloro-3-(trifluoromethyl)benzohydrazide as 
white solid (0.47 g, 92%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.80 (d, 8.1 Hz, 1H) 7.69 (d, J = 
8.1 Hz, 1H) 7.46 (t, J = 7.7 Hz, 1H) 7.20 (br. s, 1H) 4.16 (br. s, 2H); TOF ES+ MS: (M+H) 
239.02; HPLC Ret: 4.71 min. 
2-chloro-4-(2-fluoropropan-2-yl)benzohydrazide. Method C starting from methyl 2-chloro-4-
(2-fluoropropan-2-yl)benzoate (0.2 g, 0.82 mmol) gave 2-chloro-4-(2-fluoropropan-2-
yl)benzohydrazide as white solid (0.24 g, 96%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.67 (d, 8.1 
Hz, 1H) 7.47-7.42 (m, 2H) 7.32 (dd, J = 8.1, 1.7 Hz, 1H) 4.15 (d, J = 4.3 Hz, 2H) 1.69 (s, 3H) 
1.65 (s, 3H); TOF ES+ MS: (M+H) 231.07; HPLC Ret: 4.76 min. 
4-(2-fluoropropan-2-yl)benzohydrazide. Method C starting from methyl 4-(2-fluoropropan-2-
yl)benzoate (0.06 g, 0.29 mmol) gave 4-(2-fluoropropan-2-yl)benzohydrazide as white solid 
(0.03 g, 53%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.74 (d, 8.0 Hz, 2H) 7.46 (d, J = 8.0 Hz, 2H) 
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7.30 (br. s, 1H) 4.10 (br. s, 2H) 1.71 (s, 3H) 1.67 (s, 3H); TOF ES+ MS: (M+H) 197.11; HPLC 
Ret: 4.51 min. 
4-(difluoromethoxy)benzohydrazide. Method C starting from methyl 4-
(difluoromethoxy)benzoate (0.27 g, 1.32 mmol) gave 4-(difluoromethoxy)benzohydrazide as 
white solid (0.23 g, 87%); 1H NMR (400 MHz, CDCl3-d) 𝛿 ppm 7.77 (d, J = 8.5 Hz, 2H) 7.30 (br. 
s, 1H) 7.19 (d, J = 8.5 Hz, 2H) 6.58 (t, J = 73.1 Hz, 1H) 4.10 (br. s, 2H); TOF ES+ MS: (M+H) 
203.06; HPLC Ret: 4.19 min. 
2,6-dichlorobenzohydrazide. In a 100 mL round bottomed flask hydrazine hydrate (0.18 g, 
0.18 mL, 2.63 mmol) and Et3N (0.27 g, 0.37 mL, 2.63 mmol) were dissolved in DCM (10 mL). 
The solution was cooled to -78 °C and 2,6-dichlorobenzoyl chloride (0.5 g, 0.34 mL, 2.39 mmol) 
was added. The reaction was stirred at -78 °C for 1 hr and then 25 °C for 2 hr. The reaction was 
diluted with water (25 mL) and the product was extracted with DCM (3 x 25 mL). The organic 
layers were combined, washed with brine, dried with MgSO4, and concentrated in vacuo to 
produce white solid. Yield=98%. 1H NMR (501 MHz, CDCl3-d) 𝛿 ppm 7.38-7.27 (m, 3H) 6.99 (br. 
s, 1H) 4.16 (br. s, 2H); TOF ES+ MS: (M+H) 205.0; HPLC Ret: 2.94 min. 
5-(2-chloro-4-methylphenyl)-1,3,4-oxadiaole-2-thiol. Method D starting from 2-chloro-4-
methylbenzohydrazide (0.3 g, 1.63 mmol) gave 5-(2-chloro-4-methylphenyl)-1,3,4-oxadiaole-2-
thiol as white solid (0.29 g, 77%); 1H NMR (401 MHz, DMSO-d6) 𝛿 ppm 7.80 (d, J = 8.0 Hz, 1H) 
7.55 (s, 1H) 7.37 (d, J = 8.1 Hz, 1H) 2.39 (s, 3H); HPLC Ret: 6.69 min. 
5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiaole-2-thiol. Method D starting from 2-chloro-4-
fluorobenzohydrazide (0.3 g, 1.59 mmol) gave 5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiaole-2-
thiol as tan solid (0.28 g, 76%); 1HNMR (401 MHz, DMSO-d6) 𝛿 ppm 7.98 (dd, J = 8.9, 6.0 Hz, 
1H) 7.76 (dd, J = 8.9, 2.6 Hz, 1H) 7.45 (t, J = 8.0 Hz, 1H); HPLC Ret: 6.42 min. 
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5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2,4-
dichlorobenzohydrazide (1.0 g, 4.88 mmol) gave 5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-2-thiol 
as white solid (0.99 g, 82%); 1H NMR (401 MHz, MeOD-d4) 𝛿 ppm 7.91 (d, 1H) 7.72 (s, 1H) 7.53 
(d, 1H); 13C NMR (401 MHz, MeOD-d4) 𝛿 ppm 178.47, 158.18, 138.04, 133.37, 131.24, 130.84, 
127.62, 120.63; TOF ES- MS: (M-H) 246.9; HPLC Ret: 6.97 min. 
5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-chloro-
4-cyclopropylbenzohydrazide (0.1 g, 0.48 mmol) gave 5-(2-chloro-4-cyclopropylphenyl)-1,3,4-
oxadiazole-2-thiol as yellow solid (0.08 g, 70%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.53 (br. 
s., 1H) 7.81-7.73 (m, 1H) 7.23 (s, 1H) 7.08 (dd, J = 8.2, 1.8 Hz, 1H) 1.96-1.91 (m, 1H) 1.12 (dt, J 
= 6.8, 4.8, Hz, 2H) 0.81 (dt, J = 6.8, 4.8, Hz, 2H); TOF ES+ MS: (M+H) 253.0; HPLC Ret: 7.14 
min. 
5-(4-bromo-2-chlorophenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 4-bromo-2-
chlorobenzohydrazide (0.28 g, 1.11 mmol) gave 5-(4-bromo-2-chlorophenyl)-1,3,4-oxadiazole-2-
thiol as white solid (0.26 g, 81%); 1H NMR (400 MHz, DMSO-d6) 𝛿 ppm 7.99 (d, J = 8.2 Hz, 1H) 
7.84-7.72 (m, 2H); TOF ES+ MS: (M+Na) 292.9; HPLC Ret: 7.06 min. 
5-(2-chloro-4-((trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-
chloro-4-((trifluoromethyl)benzohydrazide (1.0 g, 4.19 mmol) gave 5-(2-chloro-4-
((trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol as white solid (0.59 g, 59%); 1H NMR (500 
MHz, DMSO-d6) 𝛿 ppm 8.16-8.09 (m, 2H) 7.95-7.89 (m, 1H); TOF ES+ MS: (M+H) 280.1 HPLC 
Ret: 7.14 min. 
5-(3-chloro-[1, 1’-biphenyl]-4-yl)-1, 3, 4-oxadiazole-2-thiol. Method D starting from 3-chloro-
[1,1’-biphenyl]-4-carbohydrazide (0.37 g, 1.5 mmol) gave 5-(3-chloro-[1, 1’-biphenyl]-4-yl)-1, 3, 
4-oxadiazole-2-thiol as white solid (0.38 g, 88%); 1H NMR (400 MHz, DMSO-d6) 𝛿 ppm 8.02-
234 
 
7.93 (m, 2H) 7.80-7.72 (m, 3H) 7.53-7.40 (m, 3H); TOF ES+ MS: (M+H) 289.0; HPLC Ret: 7.69 
min. 
5-(2,4-dichloro-5-methylphenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2,4-
dichloro-5-methylbenzohydrazide (0.07 g, 0.33 mmol) gave 5-(2,4-dichloro-5-methylphenyl)-
1,3,4-oxadiazole-2-thiol as yellow solid (0.07 g, 85%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
10.30 (br. s., 1H) 7.80 (s, 1H) 7.57 (s, 1H) 2.42 (s, 3H); QTOF ES+ MS: (M+H) 261.0; HPLC 
Ret: 7.23 min. 
5-(2-chloro-4,5-dimethylphenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-chloro-
4,5-dimethylbenzohydrazide (0.24 g, 1.21 mmol) gave 5-(2-chloro-4,5-dimethylphenyl)-1,3,4-
oxadiazole-2-thiol as white solid (0.22 g, 76%); 1H NMR (501 MHz, CDCl3-d) 𝛿 ppm 11.03 (br. 
s., 1H) 7.69 (s, 1H) 7.32 (s, 1H) 2.32 (br. s., 6H); QTOF ES+ MS: (M+H) 241.02; HPLC Ret: 
7.00 min. 
5-(2-chloro-3,4-dimethylphenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-chloro-
3,4-dimethylbenzohydrazide (0.27 g, 1.36 mmol) gave 5-(2-chloro-3,4-dimethylphenyl)-1,3,4-
oxadiazole-2-thiol as white solid (0.28 g, 86%); 1H NMR (501 MHz, CDCl3-d) 𝛿 ppm 10.71 (br. 
s., 1H) 7.62 (d, J = 7.7 Hz, 1H) 7.21 (d, J = 8.0 Hz, 1H) 2.41 (br. s., 6H); QTOF ES+ MS: (M+H) 
241.02; HPLC Ret: 6.97 min. 
5-(2-chloro-4-propylphenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-chloro-4-
propylbenzohydrazide (0.03 g, 0.15 mmol) gave 5-(2-chloro-4-propylphenyl)-1,3,4-oxadiazole-2-
thiol as white solid (0.03 g, 71%); *post acidification, product was extracted with EtOAc (3 x 15 
mL), washed with brine, dried with MgSO4, concentrated in vacuo; 1H NMR (500 MHz, CDCl3-d) 
𝛿 ppm 10.36 (br. s., 1H) 7.82 (d, J = 8.1 Hz, 1H) 7.37 (d, J = 1.5 Hz, 1H) 7.26 (dd, J = 8.0, 1.5 
Hz, 1H) 2.64 (t, J = 7.6 Hz, 2H) 1.66 (h, J = 7.4 Hz, 2H) 0.96 (t, J = 7.5 Hz, 3H); QTOF ES+ MS: 
(M+H) 255.0; HPLC Ret: 7.63 min. 
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5-(4-butyl-2-chlorophenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 4-butyl-2-
chlorobenzohydrazide (0.07 g, 0.31 mmol) gave 5-(4-butyl-2-chlorophenyl)-1,3,4-oxadiazole-2-
thiol as white solid (0.06 g, 71%); *post acidification, product was extracted with EtOAc (3 x 15 
mL), washed with brine, dried with MgSO4, concentrated in vacuo; 1H NMR (500 MHz, CDCl3-d) 
𝛿 ppm 7.81 (d, J = 8.1 Hz, 1H) 7.37 (d, J = 1.4 Hz, 1H) 7.25 (dd, J = 8.1, 1.5 Hz, 1H) 2.66 (t, J = 
7.8 Hz, 2H) 1.64 (p, J = 7.4 Hz, 2H) 1.36 (h, J = 7.5 Hz, 2H) 0.94 (t, J = 7.4 Hz, 3H); QTOF ES+ 
MS: (M+H) 267.1; HPLC Ret: 8.06 min. 
5-(2-chloro-4-isobutylphenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-chloro-4-
isobutylbenzohydrazide (0.03 g, 0.13 mmol) gave 5-(2-chloro-4-isobutylphenyl)-1,3,4-
oxadiazole-2-thiol as white solid (0.03 g, 87%); *post acidification, product was extracted with 
EtOAc (3 x 15 mL), washed with brine, dried with MgSO4, concentrated in vacuo; 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 10.27 (br. s., 1H) 7.82 (d, J = 8.1 Hz, 1H) 7.36 (d, J = 1.5 Hz, 1H) 7.20 
(dd, J = 8.0, 1.6 Hz, 1H) 2.53 (d, J = 7.3 Hz, 2H) 1.92 (dp, J = 13.6, 6.9 Hz, 1H) 0.92 (d, J = 7.4 
Hz, 6H); QTOF ES+ MS: (M+H) 267.1; HPLC Ret: 7.96 min. 
5-(2-chloro-3-cyclopropylphenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-chloro-
3-cyclopropylbenzohydrazide (0.2 g, 0.95 mmol) gave 5-(2-chloro-3-cyclopropylphenyl)-1,3,4-
oxadiazole-2-thiol as yellow solid (0.13 g, 55%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.56 (br. 
s., 1H) 7.69 (dd, J = 7.8, 1.6 Hz, 1H) 7.32 (t, J = 7.8 Hz, 1H) 7.19 (dd, J = 7.8, 1.6 Hz, 1H) 2.27 
(ddd, J = 13.9, 8.6, 5.4 Hz, 1H) 1.15-1.03 (m, 2H) 0.77-0.65 (m, 2H); TOF ES+ MS: (M+H) 
251.0; HPLC Ret: 7.16 min. 
5-(2-chloro-5-cyclopropylphenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-chloro-
5-cyclopropylbenzohydrazide (0.15 g, 0.71 mmol) gave 5-(2-chloro-5-cyclopropylphenyl)-1,3,4-
oxadiazole-2-thiol as white solid (0.15 g, 81%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.58 (br. 
s., 1H) 7.59 (d, J = 2.3 Hz, 1H) 7.42 (d, J = 8.3 Hz, 1H) 7.18 (dd, J = 8.4, 2.3 Hz, 1H) 1.94 (ddd, 
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J = 13.4, 8.4, 5.1 Hz, 1H) 1.11-0.99 (m, 2H) 0.79-0.68 (m, 2H); TOF ES+ MS: (M+H) 251.0; 
HPLC Ret: 7.19 min. 
5-(2-chloro-4-(prop-1-en-2-yl)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-
chloro-4-(prop-1-en-2-yl)benzohydrazide (0.05 g, 0.24 mmol) gave 5-(2-chloro-4-(prop-1-en-2-
yl)phenyl)-1,3,4-oxadiazole-2-thiol as yellow solid (0.06 g, 100%); *post acidification, product 
was extracted with EtOAc (3 x 15 mL), washed with brine, dried with MgSO4, concentrated in 
vacuo; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.21 (br. s., 1H) 7.91-7.86 (m, 1H) 7.62 (d, J = 1.8 
Hz, 1H) 7.50 (dd, J = 8.3, 1.8 Hz, 1H) 5.53 (s, 1H) 5.29 (s, 1H) 2.17 (s, 3H); TOF ES+ MS: 
(M+H) 253.0; HPLC Ret: 7.30 min. 
5-(2-chloro-4-vinylphenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-chloro-4-
vinylbenzohydrazide (0.09 g, 0.45 mmol) gave 5-(2-chloro-4-vinylphenyl)-1,3,4-oxadiazole-2-
thiol as yellow solid (0.09 g, 83%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.34 (br. s, 1H) 7.88 
(dd, J = 8.1, 1.1 Hz, 1H) 7.57 (d, J = 1.5 Hz, 1H) 7.43 (dd, J = 8.4, 1.6 Hz, 1H) 6.70 (dd, J = 
17.6, 10.9 Hz, 1H) 5.92 (dd, J = 17.6, 1.1 Hz, 1H) 5.49 (dd, 10.9, 1.1 Hz, 1H); TOF ES+ MS: 
(M+H) 239.1; HPLC Ret: 6.95 min. 
5-(2-chloro-4-ethylphenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-chloro-4-
ethylbenzohydrazide (0.08 g, 0.38 mmol) gave 5-(2-chloro-4-ethylphenyl)-1,3,4-oxadiazole-2-
thiol as white solid (0.08 g, 87%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.44 (br. s, 1H) 7.83 (dd, 
J = 8.1, 1.5 Hz, 1H) 7.40 (d, J = 1.5 Hz, 1H) 7.25 (dd, J = 8.1, 1.3 Hz, 1H) 2.71 (q, J = 7.6 Hz, 
2H) 1.28 (t, J = 7.6 Hz, 3H); HPLC Ret: 7.16 min. 
5-(2-(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-
(trifluoromethyl)benzohydrazide (0.38 g, 1.85 mmol) gave 5-(2-(trifluoromethyl)phenyl)-1,3,4-
oxadiazole-2-thiol as white solid (0.41 g, 90%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.64 (br. s, 
1H) 7.98-7.85 (m, 2H) 7.77-7.70 (m, 2H); TOF ES+ MS: (M+Na) 271.2; HPLC Ret: 6.49 min. 
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5-(2-fluorophenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-fluorobenzohydrazide 
(0.3 g, 1.95 mmol) gave 5-(2-fluorophenyl)-1,3,4-oxadiazole-2-thiol as tan solid (0.30 g, 79%); 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.78 (br. s, 1H) 7.92 (ddd, J = 7.9, 7.0, 1.8 Hz, 1H) 7.58 
(dddd, J = 8.4, 7.5, 5.0, 1.8 Hz, 1H) 7.36-7-23 (m, 2H); TOF ES+ MS: (M+H) 195.1; HPLC Ret: 
5.90 min. 
5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2,6-
difluorobenzohydrazide (0.14 g, 0.81 mmol) gave 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-thiol 
as white solid (0.15 g, 83%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.73 (br. s, 1H) 7.57 (tt, J = 
8.5, 6.1 Hz, 1H) 7.14-7.06 (m, 2H); TOF ES+ MS: (M+H) 215.0; HPLC Ret: 5.88 min. 
5-(2,6-dichlorophenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2,6-
dichlorobenzohydrazide (0.48 g, 2.33 mmol) gave 5-(2,6-dichlorophenyl)-1,3,4-oxadiazole-2-
thiol as white solid (0.49 g, 86%); 1H NMR (501 MHz, CDCl3-d) 𝛿 ppm 10.86 (br. s, 1H) 7.49-
7.46 (m, 3H); TOF ES+ MS: (M+H) 246.0; HPLC Ret: 6.56 min. 
5-(2-chloro-4-cyclopropoxyphenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-
chloro-4-cyclopropoxybenzohydrazide (0.2 g, 0.88 mmol) gave 5-(2-chloro-4-
cyclopropoxyphenyl)-1,3,4-oxadiazole-2-thiol as yellow solid (0.18 g, 78%); 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 10.36 (br. s, 1H) 7.84 (d, 8.8 Hz, 1H) 7.24 (d, J = 2.5 Hz, 1H) 7.06 (dd, J = 8.8, 
2.5 Hz, 1H) 3.85-3.77 (m, 1H) 0.92-0.79 (m, 4H); TOF ES+ MS: (M+H) 269.01; HPLC Ret: 7.13 
min. 
5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 4-
(trifluoromethyl)benzohydrazide (0.25 g, 1.23 mmol) gave 5-(4-(trifluoromethyl)phenyl)-1,3,4-
oxadiazole-2-thiol as white solid (0.26 g, 86%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.66 (br. s, 
1H) 8.07 (d, J = 8.1 Hz, 2H) 7.79 (d, J = 8.1 Hz, 2H); HPLC Ret: 6.92 min. 
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5-(2-chloro-4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 
2-chloro-4-(2,2,2-trifluoroethoxy)benzohydrazide (0.15 g, 0.57 mmol) gave 5-(2-chloro-4-(2,2,2-
trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol as white solid (0.15 g, 86%); 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 10.46 (br. s, 1H) 7.90 (d, J = 8.9 Hz, 1H) 7.15 (d, J = 1.9 Hz, 1H) 7.00 (dd, J = 
8.9, 2.0 Hz, 1H) 4.43 (q, J = 7.8 Hz, 2H); HPLC Ret: 7.01 min. 
5-(2-chloro-4-(oxetan-3-yloxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-
chloro-4-(oxetan-3-yloxy)benzohydrazide (0.20 g, 0.81 mmol) gave 5-(2-chloro-4-(oxetan-3-
yloxy)phenyl)-1,3,4-oxadiazole-2-thiol as white solid (0.19 g, 81%); 1H NMR (500 MHz, CDCl3-d) 
𝛿 ppm 10.61 (br. s, 1H) 7.85 (d, 8.8 Hz, 1H) 6.87 (d, J = 2.5 Hz, 1H) 6.74 (dd, J = 8.9, 2.6 Hz, 
1H) 5.27 (pd, 6.0, 1.0 Hz, 1H) 5.02 (t, J = 7.1 Hz, 2H) 4.78 (dd, J = 7.3, 5.1 Hz, 2H); TOF ES- 
MS: (M-H) 282.99; HPLC Ret: 6.03 min. 
5-(2-chloro-4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-
chloro-4-(trifluoromethoxy)benzohydrazide (0.04 g, 0.16 mmol) gave 5-(2-chloro-4-
(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-thiol as white solid (0.03 g, 71%); 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 10.33 (br. s, 1H) 7.97 (d, 8.7 Hz, 1H) 7.44 (d, J = 2.1 Hz, 1H) 7.30 (dd, J 
= 8.7, 2.1 Hz, 1H); TOF ES- MS: (M-H) 294.96; HPLC Ret: 7.30 min. 
5-(2-chloro-4-(oxetan-3-ylmethoxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 
2-chloro-4-(oxetan-3-ylmethoxy)benzohydrazide (0.15 g, 0.58 mmol) gave 5-(2-chloro-4-
(oxetan-3-ylmethoxy)phenyl)-1,3,4-oxadiazole-2-thiol as white solid (0.15 g, 88%); 1H NMR (500 
MHz, DMSO-d6) 𝛿 ppm 7.83 (d, 8.8 Hz, 1H) 7.32 (d, J = 2.5 Hz, 1H) 7.15 (dd, J = 8.9, 2.5 Hz, 
1H) 4.71 (dd, J = 7.9, 6.1 Hz, 2H) 4.43 (t, J = 6.0 Hz, 2H) 4.35 (d, J = 6.7 Hz, 2H) 3.41 (hept., 
6.9 Hz, 1H); TOF ES- MS: (M-H) 297.01; HPLC Ret: 6.01 min. 
5-(2-chloro-4-((3-methyloxetan-3-yl)methoxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D 
starting from 2-chloro-4-((3-methyloxetan-3-yl)methoxy)benzohydrazide (0.17 g, 0.63 mmol) 
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gave 5-(2-chloro-4-((3-methyloxetan-3-yl)methoxy)phenyl)-1,3,4-oxadiazole-2-thiol as white 
solid (0.16 g, 79%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.43 (br. s, 1H) 7.86 (d, 8.9 Hz, 1H) 
7.12 (d, J = 2.5 Hz, 1H) 6.98 (dd, J = 8.9, 2.5 Hz, 1H) 4.62 (d, J = 6.1 Hz, 2H) 4.50 (d, J = 6.1 
Hz, 2H) 4.12 (s, 2H) 1.46 (s, 3H); TOF ES- MS: (M-H) 311.03; HPLC Ret: 6.46 min. 
5-(4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 4-(2,2,2-
trifluoroethoxy)benzohydrazide (0.36 g, 1.5 mmol) gave 5-(4-(2,2,2-trifluoroethoxy)phenyl)-
1,3,4-oxadiazole-2-thiol as white solid (0.37 g, 89%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.24 
(br. s, 1H) 7.92 (d, J = 8.9 Hz, 2H) 7.07 (d, J = 8.8 Hz, 2H) 4.43 (q, J = 7.9 Hz, 2H); TOF ES- 
MS: (M-H) 275.01; HPLC Ret: 6.83 min. 
5-(4-(difluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 4-
(difluoromethyl)benzohydrazide (0.36 g, 1.9 mmol) gave 5-(4-(difluoromethyl)phenyl)-1,3,4-
oxadiazole-2-thiol as white solid (0.31 g, 72%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.55 (br. s, 
1H) 8.04 (d, J = 8.0 Hz, 2H) 7.67 (d, J = 8.0 Hz, 2H) 6.71 (t, J = 56.0 Hz, 1H); TOF ES- MS: (M-
H) 227.01; HPLC Ret: 6.39 min. 
 
5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 4-
(trifluoromethoxy)benzohydrazide (0.3 g, 1.4 mmol) gave 5-(4-(trifluoromethoxy)phenyl)-1,3,4-
oxadiazole-2-thiol as white solid (0.32 g, 90%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.48 (br. s, 
1H) 7.99 (d, J = 9.0 Hz, 2H) 7.37 (d, J = 9.0 Hz, 2H); TOF ES- MS: (M-H) 260.99; HPLC Ret: 
7.05 min. 
5-(2-chloro-3-(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 2-
chloro-3-(trifluoromethyl)benzohydrazide (0.3 g, 1.26 mmol) gave 5-(2-chloro-3-
(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol as white solid (0.19 g, 55%); 1H NMR (500 
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MHz, CDCl3-d) 𝛿 ppm 10.49 (br. s, 1H) 8.08 (d, J = 7.9 Hz, 1H) 7.93 (d, J = 7.9 Hz, 1H) 7.57 (t, 
J = 7.9 Hz, 1H); TOF ES- MS: (M-H) 278.96; HPLC Ret: 6.96 min. 
5-(2-chloro-4-(2-fluoropropan-2-yl)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 
2-chloro-4-(2-fluoropropan-2-yl)benzohydrazide (0.24 g, 1.04 mmol) gave 5-(2-chloro-4-(2-
fluoropropan-2-yl)phenyl)-1,3,4-oxadiazole-2-thiol as white solid (0.25 g, 88%); 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 10.62 (br. s, 1H) 7.91 (d, 8.3 Hz, 1H) 7.59 (d, J = 1.4 Hz, 1H) 7.41 (dd, J 
= 8.3, 1.4 Hz, 1H) 1.73 (d, J = 1.1 Hz, 3H) 1.68 (d, J = 1.1 Hz, 3H); TOF ES- MS: (M-H) 271.01; 
HPLC Ret: 7.15 min. 
5-(4-(2-fluoropropan-2-yl)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 4-(2-
fluoropropan-2-yl)benzohydrazide (0.03 g, 0.15 mmol) gave 5-(4-(2-fluoropropan-2-yl)phenyl)-
1,3,4-oxadiazole-2-thiol as white solid (0.04 g, 100%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
10.38 (br. s, 1H) 7.93 (d, J = 8.8 Hz, 2H) 7.53 (d, J = 8.8 Hz, 2H) 1.73 (d, J = 0.8 Hz, 3H) 1.69 
(d, J = 0.8 Hz, 3H); TOF ES- MS: (M-H) 237.05; HPLC Ret: 6.87 min. 
5-(4-(difluoromethoxy)phenyl)-1,3,4-oxadiazole-2-thiol. Method D starting from 4-
(difluoromethoxy)benzohydrazide (0.23 g, 1.2 mmol) gave 5-(4-(difluoromethoxy)phenyl)-1,3,4-
oxadiazole-2-thiol as white solid (0.22 g, 77%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.59 (br. s, 
1H) 7.96 (d, J = 8.7 Hz, 2H) 7.26 (d, J = 8.8 Hz, 2H) 6.61 (t, J = 72.7 Hz, 1H); TOF ES- MS: (M-
H) 243.00; HPLC Ret: 6.47 min. 
tert-butyl-3-((5-(2-chloro-4-methylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate. Method E 
starting from 5-(2-chloro-4-methylphenyl)-1,3,4-oxadiazole-2-thiol (0.25 g, 1.1 mmol) and t-butyl-
3-bromopropanoate (0.28 g, 1.3 mmol) gave tert-butyl-3-((5-(2-chloro-4-methylphenyl)-1,3,4-
oxadiazol-2-yl)thio)propanoate as white solid (0.27 g, 70%); 1H NMR (401 MHz, DMSO-d6) 𝛿 
ppm 7.86 (d, J = 8.1 Hz, 1H) 7.56 (d, J = 1.5 Hz, 1H) 7.37 (d, J = 8.2 Hz, 1H) 3.45 (t, J = 6.8 Hz, 
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2H) 2.82 (t, J = 6.8 Hz, 2H) 2.40 (s, 3H) 1.41 (s, 9H); TOF ES+ MS: (M+H) 354.0; HPLC Ret: 
8.66 min. 
tert-butyl-3-((5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate. Method E 
starting from 5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiazole-2-thiol (0.25 g, 1.1 mmol) and t-butyl-
3-bromopropanoate (0.27 g, 1.3 mmol) gave tert-butyl-3-((5-(2-chloro-4-fluorophenyl)-1,3,4-
oxadiazol-2-yl)thio)propanoate as yellow oil (0.28 g, 73%); Column: 0% EtOAc: 100% Hex to 
30% EtOAc: 70% Hex; 1HNMR (401 MHz, DMSO-d6) 𝛿 ppm 8.05 (dd, J = 8.8, 6.1 Hz, 1H) 7.76 
(dd, J = 8.9, 2.6 Hz, 1H) 7.48 (ddd, J = 8.9, 8.1, 2.6 Hz, 1H) 3.46 (t, J = 6.8 Hz, 2H) 2.82 (t, J = 
6.8 Hz, 2H) 1.42 (s, 9H); TOF ES+ MS: (M+H) 356.9; HPLC Ret: 8.36 min. 
tert-butyl 3-((5-(2,4-dichloro-5-methylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate. Method 
E starting from 5-(2,4-dichloro-5-methylphenyl)-1,3,4-oxadiazole-2-thiol (0.07 g, 0.28 mmol) and 
t-butyl-3-bromopropanoate (0.07 g, 0.34 mmol) gave tert-butyl 3-((5-(2,4-dichloro-5-
methylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate as green oil (0.09 g, 82%); Column: 15% 
EtOAc: 85% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.84 (s, 1H) 7.55 (s, 1H) 3.51 (t, J = 6.8 
Hz, 2H) 2.86 (t, J = 6.8 Hz, 2H) 2.42 (s, 3H) 1.47 (s, 9H); QTOF ES+ MS: (M+H) 389.0; HPLC 
Ret: 8.95 min. 
tert-butyl 3-((5-(2-chloro-4,5-dimethylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate. Method 
E starting from 5-(2-chloro-4,5-dimethylphenyl)-1,3,4-oxadiazole-2-thiol (0.11 g, 0.46 mmol) and 
t-butyl-3-bromopropanoate (0.08 g, 0.55 mmol) gave tert-butyl 3-((5-(2-chloro-4,5-
dimethylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate as colorless oil (0.13 g, 77%); Column: 
10% EtOAc: 90% Hex; 1H NMR (501 MHz, CDCl3-d) 𝛿 ppm 7.71 (s, 1H) 7.30 (s, 1H) 3.49 (t, J = 
6.9 Hz, 2H) 3.32 (s, 3H) 2.86 (t, J = 6.8 Hz, 2H) 2.28 (s, 3H) 1.47 (s, 9H); QTOF ES+ MS: 
(M+H) 369.1; HPLC Ret: 7.81 min. 
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tert-butyl 3-((5-(2-chloro-3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate. Method 
E starting from 5-(2-chloro-3,4-dimethylphenyl)-1,3,4-oxadiazole-2-thiol (0.14 g, 0.56 mmol) and 
t-butyl-3-bromopropanoate (0.09 g, 0.67 mmol) gave tert-butyl 3-((5-(2-chloro-3,4-
dimethylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate as colorless oil (0.17 g, 80%); Column: 
20% EtOAc: 80% Hex; 1H NMR (501 MHz, CDCl3-d) 𝛿 ppm 7.61 (d, J = 7.9 Hz, 1H) 7.18 (d, J = 
7.9 Hz, 1H) 3.49 (t, J = 6.8 Hz, 2H) 3.42 (s, 3H) 2.86 (t, J = 6.9 Hz, 2H) 2.38 (s, 3H) 1.47 (s, 
9H); QTOF ES+ MS: (M+H) 369.1; HPLC Ret: 7.63 min. 
tert-butyl 3-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate. 
Method E starting from 5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazole-2-thiol (0.03 g, 0.12 
mmol) and t-butyl-3-bromopropanoate (0.03 g, 0.14 mmol) gave tert-butyl 3-((5-(2-chloro-4-
cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate as colorless oil (0.04 g, 93%); Column: 
5% EtOAc: 95% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.81 (d, J = 8.1, 1H) 7.20 (d, J = 1.7 
Hz, 1H) 7.05 (dd, J = 8.2, 1.7 Hz, 1H) 3.49 (t, J = 6.8 Hz, 2H) 2.86 (t, J = 6.8 Hz, 2H) 1.92 (ddd, 
J = 13.4, 8.7, 5.0 Hz, 1H) 1.47 (s, 9H) 1.13-1.04 (m, 2H) 0.79 (dt, J = 6.8, 4.9 Hz, 2H); TOF ES+ 
MS: (M+H) 381.1; HPLC Ret: 8.98 min. 
tert-butyl 3-((5-(2,6-difluorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate. Method E starting 
from 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-thiol (0.07 g, 0.33 mmol) and t-butyl-3-
bromopropanoate (0.08 g, 0.39 mmol) gave tert-butyl 3-((5-(2,6-difluorophenyl)-1,3,4-oxadiazol-
2-yl)thio)propanoate as colorless oil (0.09 g, 83%); Column: 18% EtOAc: 82% Hex; 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 7.51 (tt, J = 8.5, 6.1 Hz, 1H) 7.12-7.04 (m, 2H) 3.51 (t, J = 6.8 Hz, 
2H) 2.87 (t, J = 6.8 Hz, 2H) 1.47 (s, 9H); TOF ES+ MS: (M+H) 343.1; HPLC Ret: 7.83 min. 
tert-butyl 3-((5-(2-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate. Method E 
starting from 5-(2-(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol (0.07 g, 0.28 mmol) and t-
butyl-3-bromopropanoate (0.07 g, 0.34 mmol) gave tert-butyl 3-((5-(2-(trifluoromethyl)phenyl)-
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1,3,4-oxadiazol-2-yl)thio)propanoate as colorless oil (0.09 g, 88%); Column: 18% EtOAc: 82% 
Hex; 1H NMR (501 MHz, CDCl3-d) 𝛿 ppm 8.06-8.00 (m, 1H) 7.85 (dd, J = 7.2, 1.8 Hz, 1H) 7.75-
7.64 (m, 2H) 3.49 (t, J = 6.9 Hz, 2H) 2.85 (t, J = 6.9 Hz, 2H) 1.47 (s, 9H); TOF ES+ MS: (M+H) 
375.1; HPLC Ret: 8.30 min. 
tert-butyl 3-((5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate. Method E starting 
from 5-(2-fluorophenyl)-1,3,4-oxadiazole-2-thiol (0.07 g, 0.36 mmol) and t-butyl-3-
bromopropanoate (0.09 g, 0.43 mmol) gave tert-butyl 3-((5-(2-fluorophenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoate as colorless oil (0.1 g, 88%); Column: 18% EtOAc: 82% Hex; 1H NMR (501 
MHz, CDCl3-d) 𝛿 ppm 8.04-7.97 (m, 1H) 7.52 (ddddd, J = 8.3, 7.5, 5.0, 1.8, 0.7 Hz, 1H) 7.32-
7.20 (m, 2H) 3.51 (t, J = 6.8 Hz, 2H) 2.86 (t, J = 6.8 Hz, 2H) 1.47 (s, 9H); TOF ES+ MS: (M+H) 
325.1; HPLC Ret: 7.88 min. 
tert-butyl 3-((5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate. Method E starting 
from 5-(2,6-dichlorophenyl)-1,3,4-oxadiazole-2-thiol (0.07 g, 0.28 mmol) and t-butyl-3-
bromopropanoate (0.07 g, 0.34 mmol) gave tert-butyl 3-((5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-
2-yl)thio)propanoate as colorless oil (0.09 g, 84%); Column: 15% EtOAc: 85% Hex; 1H NMR 
(501 MHz, CDCl3-d) 𝛿 ppm 7.45-7.39 (m, 3H) 3.52 (t, J = 6.5 Hz, 2H) 2.87 (t, J = 6.5 Hz, 2H) 
1.48 (s, 9H); TOF ES+ MS: (M+H) 375.0; HPLC Ret: 8.53 min. 
t-butyl 4-((5-(4-bromo-2-chlorophenyl)-1,3,4-oxadiazole-2-yl)thio)butanoate. Method E 
starting from 5-(2-chloro-4-bromophenyl)-1,3,4-oxadiazole-2-thiol (0.26 g, 0.89 mmol) and t-
butyl-4-bromobutanoate (0.26 g, 1.2 mmol) gave t-butyl 4-((5-(4-bromo-2-chlorophenyl)-1,3,4-
oxadiazole-2-yl)thio)butanoate as colorless oil (0.32 g, 84%); Column: 10% EtOAc: 90% Hex; 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.83 (d, J = 8.4 Hz, 1H) 7.73 (d, J = 1.9 Hz, 1H) 7.54 (dd, J = 
8.4, 1.9 Hz, 2H) 3.36 (t, J = 7.2 Hz, 2H) 2.43 (t, J = 7.2 Hz, 2H) 2.16 (p, J = 7.2 Hz, 2H) 1.45 (s, 
9H); TOF ES+ MS: (M+H) 434.9; HPLC Ret: 9.22 min. 
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methyl-4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E starting 
from 5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-2-thiol (0.2 g, 0.81 mmol) and methyl 4-
bromobutanoate (0.13 g, 0.97 mmol) gave methyl-4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate as white solid (0.19 g, 66%); Column: 20% EtOAc: 80% Hex; 1H NMR (401 
MHz, DMSO-d6) 𝛿 ppm 8.00 (d, J = 8.5 Hz, 1H) 7.92 (d, J = 2.1 Hz, 1H) 7.66 (dd, J = 8.5, 2.1 
Hz, 1H) 3.60 (s, 3H) 3.35 (t, J = 7.4 Hz, 2H) 2.50 (t, J = 7.4 Hz, 2H) 2.12-1.97 (m, 2H); TOF ES+ 
MS: (M+H) 346.9; HPLC Ret: 7.94 min. 
methyl 4-((5-(2-chloro-4-methylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(2-chloro-4-methylphenyl)-1,3,4-oxadiazole-2-thiol (0.02 g, 0.10 mmol) and 
methyl 4-bromobutanoate (0.01 g, 0.12 mmol) gave methyl 4-((5-(2-chloro-4-methylphenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.02 g, 70%); Column: 20% EtOAc: 80% 
Hex; 1H NMR (401 MHz, CDCl3-d) 𝛿 ppm 7.84 (d, J = 8.0 Hz, 1H) 7.36 (d, J = 1.2 Hz, 1H) 7.18 
(dd, J = 8.0, 1.2 Hz, 1H) 3.69 (s, 3H) 3.36 (t, J = 7.1 Hz, 2H) 2.53 (t, J = 7.2 Hz, 2H) 2.41 (s, 3H) 
2.22 (p, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 327.0; HPLC Ret: 7.62 min. 
ethyl 6-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)hexanoate. Method E starting from 
5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-2-thiol (0.25 g, 1.0 mmol) and ethyl 6-bromohexanoate 
(0.08 g, 1.2 mmol) gave ethyl 6-((5-(2-chloro-4-methylphenyl)-1,3,4-oxadiazol-2-
yl)thio)hexanoate as colorless oil (0.33 g, 84%); Column: 15% EtOAc: 85% Hex; 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.91 (d, J = 7.3 Hz, 1H) 7.57 (d, J = 1.0 Hz, 1H) 7.38 (dd, J = 7.3, 1.0 Hz, 
1H) 4.14 (q, J = 7.2 Hz, 2H) 3.31 (t, J = 7.3 Hz, 2H) 2.34 (t, J = 7.4 Hz, 2H) 1.89 (p, J = 7.5 Hz, 
2H) 1.69 (q, J = 7.6 Hz, 2H) 1.52 (q, J = 6.3 Hz, 2H) 1.26 (t, J = 7.1 Hz, 3H); TOF ES+ MS: 
(M+H) 389.0; HPLC Ret: 8.86 min. 
methyl 4-((5-(p-tolyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E starting from 5-(p-tolyl)-
1,3,4-oxadiazole-2-thiol (0.25 g, 1.3 mmol) and methyl 4-bromobutanoate (0.28 g, 1.56 mmol) 
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gave methyl 4-((5-(p-tolyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as white solid (0.29 g, 76%); 
Column: 20% EtOAc: 80% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 2.20 (q, J = 7.1 Hz, 2H) 
2.42 (s, 3H) 2.53 (t, J = 7.2 Hz, 2H) 3.36 (t, J = 7.1 Hz, 2H) 3.69 (s, 3H) 7.30 (dd, J = 8.2, 3.7 
Hz, 2H) 7.92-7.86 (m, 2H); TOF ES+ MS: (M+H) 293.1; HPLC Ret: 7.33 min. 
methyl 4-((5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E starting from 5-
(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol (0.25 g, 1.2 mmol) and methyl 4-bromobutanoate (0.26 
g, 1.4 mmol) gave methyl 4-((5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as white 
solid (0.29 g, 80%); Column: 20% EtOAc: 80% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.98-
7.91 (m, 2H) 7.51-7.44 (m, 2H) 3.70 (s, 3H) 3.37 (t, J = 7.2 Hz, 2H) 2.53 (t, J = 7.2 Hz, 2H) 2.20 
(q, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 313.0; HPLC Ret: 7.54 min. 
methyl 7-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)heptanoate. Method E starting 
from 5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-2-thiol (0.2 g, 0.81 mmol) and methyl 7-
bromoheptanoate (0.22 g, 0.97 mmol) gave methyl 7-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)heptanoate as colorless oil (0.28 g, 88%); Column: 20% EtOAc: 80% Hex; 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.91 (d, J = 8.5, 1H) 7.56 (d, J = 2.1 Hz, 1H) 7.39 (dd, J = 8.5, 2.1 Hz, 
1H) 3.67 (s, 3H) 3.30 (t, J = 7.3 Hz, 2H) 2.32 (t, J = 7.5 Hz, 2H) 1.91-1.81 (m, 2H) 1.71-1.60 (m, 
2H) 1.54-1.44 (m, 2H) 1.40-1.35 (m, 2H); TOF ES+ MS: (M+Na) 411.0; HPLC Ret: 8.85 min. 
ethyl 8-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)octanoate. Method E starting from 
5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-2-thiol (0.2 g, 0.81 mmol) and ethyl 8-bromooctanoate 
(0.24 g, 0.97 mmol) gave ethyl 8-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)octanoate as 
colorless oil (0.33 g, 99%); Column: 15% EtOAc: 85% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
7.91 (d, J = 8.5, 1H) 7.56 (s, 1H) 7.39 (dd, J = 8.5, 1.9 Hz, 1H) 4.13 (q, J= 7.1 Hz, 3H) 3.30 (t, J 
= 7.0 Hz, 2H) 2.29 (t, J = 7.5 Hz, 2H) 1.85 (p, J= 7.4 Hz, 2H) 1.63 (p, J= 7.5 Hz, 2H) 1.47 (q, J= 
246 
 
7.4 Hz, 2H) 1.42-1.32 (m, 4H) 1.26 (t, J= 7.2 Hz, 3H); TOF ES+ MS: (M+H) 417.0; HPLC Ret: 
9.732 min. 
methyl 4-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate (CCG-
263086). Method E starting from 5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazole-2-thiol (0.08 
g, 0.33 mmol) and methyl 4-bromobutanoate (0.07 g, 0.40 mmol) gave methyl 4-((5-(2-chloro-4-
cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as white oil (0.07 g, 64%); Column: 20% 
EtOAc: 80% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.81 (d, J = 8.2 Hz, 1H) 7.19 (s, 1H) 7.05 
(dd, J = 8.2, 1.7 Hz, 1H) 3.69 (s, 3H) 2.37 (t, J = 7.2 Hz, 2H) 2.58 (t, J = 7.1 Hz, 2H) 2.20 (p, J = 
7.2 Hz, 2H) 1.96-1.91 (tt, J = 8.4, 5.0 Hz, 1H) 1.08 (dt, J = 6.9, 4.9 Hz, 2H) 0.78 (dt, J = 6.9, 4.9 
Hz, 2H); TOF ES+ MS: (M+H) 353.0; HPLC Ret: 8.01 min; 94% pure.  
methyl 4-((5-(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol (0.25 g, 
0.89 mmol) and methyl 4-bromobutanoate (0.21 g, 1.2 mmol) gave methyl 4-((5-(2-chloro-4-
(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.16 g, 47%); 
Column: 20% EtOAc: 80% Hex; HPLC Ret: 7.98 min. 
Methyl 4-((5-(3-chloro-[1, 1’-biphenyl]-4-yl)-1, 3, 4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(3-chloro-[1,1’-biphenyl]-4-yl)-1,3,4-oxadiazole-2-thiol (0.37 g, 1.28 mmol) and 
methyl 4-bromobutanoate (0.30 g, 1.7 mmol) gave methyl 4-((5-(3-chloro-[1, 1’-biphenyl]-4-yl)-1, 
3, 4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.37 g, 75%); Column: 20% EtOAc: 80% 
Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.03 (d, J = 8.2 Hz, 1H) 7.77 (d, J = 1.8 Hz, 1H) 7.64-
7.58 (m, 3H) 7.52-7.39 (m, 3H) 3.70 (s, 3H) 3.38 (t, J = 7.1 Hz, 2H) 2.54 (t, J = 7.2 Hz, 2H) 2.22 
(p, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 389.0; HPLC Ret: 8.00 min. 
methyl 4-((5-(2-chloro-4,5-dimethylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(2-chloro-4,5-dimethylphenyl)-1,3,4-oxadiazole-2-thiol (0.11 g, 0.46 mmol) and 
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methyl 4-bromobutanoate (0.08 g, 0.55 mmol) gave methyl 4-((5-(2-chloro-4,5-dimethylphenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.11 g, 73%); Column: 20% EtOAc: 80% 
Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.72 (s, 1H) 7.30 (s, 1H) 3.69 (s, 3H) 3.35 (t, J = 7.2 
Hz, 2H) 3.32 (s, 3H) 2.53 (t, J = 7.2 Hz, 2H) 2.28 (s, 3H) 2.21 (p, J = 7.2 Hz, 2H); QTOF ES+ 
MS: (M+H) 341.1; HPLC Ret: 6.76 min. 
methyl 4-((5-(2-chloro-3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(2-chloro-3,4-dimethylphenyl)-1,3,4-oxadiazole-2-thiol (0.14 g, 0.56 mmol) and 
methyl 4-bromobutanoate (0.12 g, 0.67 mmol) gave methyl 4-((5-(2-chloro-3,4-dimethylphenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.15 g, 80%); Column: 25% EtOAc: 75% 
Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.61 (d, J = 8.0 Hz, 1H) 7.18 (d, J = 7.9 Hz, 1H) 3.69 
(s, 3H) 3.35 (t, J = 7.2 Hz, 2H) 3.42 (s, 3H) 2.53 (t, J = 7.2 Hz, 2H) 2.38 (s, 3H) 2.21 (p, J = 7.2 
Hz, 2H); QTOF ES+ MS: (M+H) 341.1; HPLC Ret: 6.67 min. 
methyl 4-((5-(2-chloro-4-vinylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. (CCG-262544). 
Method E starting from 5-(2-chloro-4-vinylphenyl)-1,3,4-oxadiazole-2-thiol (0.08 g, 0.36 mmol) 
and methyl 4-bromobutanoate (0.06 g, 0.40 mmol) gave methyl 4-((5-(2-chloro-4-vinylphenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate as white powder (0.07 g, 65%); Column: 20% EtOAc: 80% 
Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.92 (d, J = 8.2 Hz, 1H) 7.56 (d, J = 1.6 Hz, 1H) 7.41 
(dd, J = 8.2, 1.7 Hz, 1H) 6.69 (dd, J = 17.6, 10.8 Hz, 1H) 5.89 (d, J = 17.5 Hz, 1H) 5.45 (d, 10.9 
Hz, 1H) 3.70 (s, 3H) 3.37 (t, J = 7.1 Hz, 2H) 2.54 (t, J = 7.2 Hz, 2H) 2.21 (p, J = 7.2 Hz, 2H); 
TOF ES+ MS: (M+H) 339.06; HPLC Ret: 7.82 min; 96% pure. 
methyl 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-2,2-dimethylbutanoate. Method 
E starting from 5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-2-thiol (0.1 g, 0.41 mmol) and methyl 4-
bromo-2,2-dimethylbutanoate (0.11 g, 0.53 mmol) gave methyl 4-((5-(2,4-dichlorophenyl)-1,3,4-
oxadiazol-2-yl)thio)-2,2-dimethylbutanoate as white oil (0.1 g, 69%); Reaction proceeded for 24 
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hrs; Column: 10% EtOAc: 90% Hex 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.91 (d, J = 8.5 Hz, 1H) 
7.57 (d, J = 2.1 Hz, 1H) 7.39 (dd, J = 8.6, 2.1 Hz, 1H) 3.70 (s, 3H) 3.29-3.22 (m, 2H) 2.14-2.07 
(m, 2H) 1.27 (s, 6H); TOF ES+ MS: (M+H) 375.0; HPLC Ret: 8.80 min. 
methyl 4-((5-(2-chloro-4-cyclopropoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method 
E starting from 5-(2-chloro-4-cyclopropoxyphenyl)-1,3,4-oxadiazole-2-thiol (0.1 g, 0.37 mmol) 
and methyl 4-bromobutanoate (0.08 g, 0.45 mmol) gave methyl 4-((5-(2-chloro-4-
cyclopropoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.11 g, 78%); Column: 
20% EtOAc: 80% Hex 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.86 (d, 8.8 Hz, 1H) 7.24 (d, J = 2.5 
Hz, 1H) 7.04 (dd, J = 8.8, 2.5 Hz, 1H) 3.83-3.76 (m, 1H) 3.69 (s, 3H) 3.35 (t, J = 7.2 Hz, 2H) 
2.53 (t, J = 7.2 Hz, 2H) 2.20 (p, J = 7.2 Hz, 2H) 0.90-0.78 (m, 4H); TOF ES+ MS: (M+H) 368.06; 
HPLC Ret: 7.94 min. 
methyl 4-((5-(2-chloro-4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(2-chloro-4-methoxyphenyl)-1,3,4-oxadiazole-2-thiol (0.1 g, 0.41 mmol) and 
methyl 4-bromobutanoate (0.09 g, 0.5 mmol) gave methyl 4-((5-(2-chloro-4-methoxyphenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.12 g, 82%); Column: 25% EtOAc: 85% 
EtOAc to 45% EtOAc: 55% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.88 (d, J = 8.8 Hz, 1H) 
7.05 (dd, J = 2.5 Hz, 1H) 6.92 (dd, J = 8.8, 2.5 Hz, 1H) 3.87 (s, 3H) 3.69 (s, 3H) 3.35 (t, J = 7.1 
Hz, 2H) 2.53 (t, J = 7.2 Hz, 2H) 2.20 (p, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 343.1; HPLC Ret: 
7.31 min. 
methyl 4-((5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol (0.08 g, 0.31 mmol) and 
methyl 4-bromobutanoate (0.07 g, 0.4 mmol) gave methyl 4-((5-(4-(trifluoromethyl)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate as white solid (0.09 g, 87%); Column: 15% EtOAc: 75% Hex to 
20% EtOAc: 80% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.14 (d, J = 8.2 Hz, 2H) 7.77 (d, J = 
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8.2 Hz, 2H) 3.70 (s, 3H) 3.39 (t, J = 7.2 Hz, 2H) 2.54 (t, J = 7.1 Hz, 2H) 2.22 (p, J = 7.1 Hz, 2H); 
TOF ES+ MS: (M+H) 347.07; HPLC Ret: 7.75 min. 
methyl 4-((5-(2-chloro-4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(2-chloro-4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.08 
g, 0.26 mmol) and methyl 4-bromobutanoate (0.06 g, 0.34 mmol) gave methyl 4-((5-(2-chloro-4-
(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as white solid (0.08 g, 75%); 
Column: 25% EtOAc: 75% Hex to 30% EtOAc: 70% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
7.94 (d, J = 8.8 Hz, 1H) 7.12 (d, J = 1.1 Hz, 1H) 6.98 (dd, J = 8.8, 1.1 Hz, 1H) 4.42 (q, J = 8.5 
Hz, 2H) 3.70 (s, 3H) 3.36 (t, J = 7.1 Hz, 2H) 2.53 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.0 Hz, 2H); 
TOF ES+ MS: (M+H) 411.04; HPLC Ret: 7.78 min. 
methyl 4-((5-(2-chloro-4-(oxetan-3-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(2-chloro-4-(oxetan-3-yloxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.08 g, 
0.26 mmol) and methyl 4-bromobutanoate (0.06 g, 0.34 mmol) gave methyl 4-((5-(2-chloro-4-
(oxetan-3-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.07 g, 70%); 
Column: 40% EtOAc: 60% Hex to 80% EtOAc: 20% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
7.88 (d, 8.8 Hz, 1H) 6.85 (d, J = 2.6 Hz, 1H) 6.73 (dd, J = 8.8, 2.6 Hz, 1H) 5.26 (pd, 6.0, 1.0 Hz, 
1H) 5.01 (t, J = 7.1 Hz, 2H) 4.77 (dd, J = 7.3, 5.1 Hz, 2H) 3.69 (s, 3H) 3.35 (t, J = 7.2 Hz, 2H) 
2.53 (t, J = 7.2 Hz, 2H) 2.20 (p, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 285.06; HPLC Ret: 6.03 
min. 
methyl 4-((5-(2-chloro-4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(2-chloro-4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.03 g, 
0.11 mmol) and methyl 4-bromobutanoate (0.03 g, 0.15 mmol) gave methyl 4-((5-(2-chloro-4-
(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.03 g, 70%); 
Column: 15% EtOAc: 85% Hex. Colorless oil. Yield = 70%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
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8.02 (d, J = 8.7 Hz, 1H) 7.42 (d, J = 2.1 Hz, 1H) 7.27 (dd, J = 8.8, 2.1 Hz, 1H) 3.70 (s, 3H) 3.37 
(t, J = 7.1 Hz, 2H) 2.53 (t, J = 7.2 Hz, 2H) 2.22 (p, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 397.02; 
HPLC Ret: 8.15 min. 
methyl 4-((5-(2-chloro-4-(oxetan-3-ylmethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(2-chloro-4-(oxetan-3-ylmethoxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.08 
g, 0.27 mmol) and methyl 4-bromobutanoate (0.06 g, 0.35 mmol) gave methyl 4-((5-(2-chloro-4-
(oxetan-3-ylmethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as yellow solid (0.07 g, 69%); 
Column: 60% EtOAc: 40% Hex to 80% EtOAc: 20% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
7.89 (d, 8.8 Hz, 1H) 7.08 (d, J = 2.6 Hz, 1H) 6.93 (dd, J = 8.8, 2.6 Hz, 1H) 4.90 (dd, J = 7.7, 6.4 
Hz, 2H) 4.57 (t, J = 6.0 Hz, 2H) 4.26 (dd, J = 6.6, 1.1 Hz, 2H) 3.69 (s, 3H) 3.47 (hept., 7.2 Hz, 
1H) 3.35 (t, J = 7.2 Hz, 2H) 2.53 (t, J = 7.2 Hz, 2H) 2.21 (p, J = 7.2 Hz, 2H); TOF ES+ MS: 
(M+H) 399.08; HPLC Ret: 6.78 min. 
methyl 4-((5-(2-chloro-4-((3-methyloxetan-3-yl)methoxy)phenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate. Method E starting from 5-(2-chloro-4-((3-methyloxetan-3-
yl)methoxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.08 g, 0.26 mmol) and methyl 4-bromobutanoate 
(0.06 g, 0.33 mmol) gave methyl 4-((5-(2-chloro-4-((3-methyloxetan-3-yl)methoxy)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate as colorless oil (0.08 g, 80%); Column: 70% EtOAc: 30% Hex; 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.90 (d, 8.8 Hz, 1H) 7.10 (d, J = 2.6 Hz, 1H) 6.96 (dd, J = 8.8, 
2.5 Hz, 1H) 4.64 (d, J = 6.1 Hz, 2H) 4.48 (d, J = 6.1 Hz, 2H) 4.10 (s, 2H) 3.70 (s, 3H) 3.36 (t, J = 
7.1 Hz, 2H) 2.53 (t, J = 7.1 Hz, 2H) 2.22 (p, J = 7.1 Hz, 2H) 1.46 (s, 3H); TOF ES+ MS: (M+H) 
413.10; HPLC Ret: 7.25 min. 
methyl 4-((5-(4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method 
E starting from 5-((4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.08 g, 0.27 mmol) 
and methyl 4-bromobutanoate (0.06 g, 0.35 mmol) gave methyl 4-((5-(4-(2,2,2-
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trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as white solid (0.08 g, 79%); Column: 
30% EtOAc: 70% Hex to 40% EtOAc: 60% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.98 (d, J 
= 8.0 Hz, 2H) 7.05 (d, J = 8.0 Hz, 2H) 4.42 (q, J = 8.0 Hz, 2H) 3.69 (s, 3H) 3.35 (t, J = 7.1 Hz, 
2H) 2.53 (t, J = 7.2 Hz, 2H) 2.20 (p, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 377.08; HPLC Ret: 
7.48 min. 
methyl 4-((5-(4-(difluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(4-(difluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol (0.08 g, 0.29 mmol) and 
methyl 4-bromobutanoate (0.07 g, 0.37 mmol) gave methyl 4-((5-(4-(difluoromethyl)phenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate as white solid (0.09 g, 89%); Column: 30% EtOAc: 70% Hex 
to 35% EtOAc: 65% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.11 (d, J = 8.0 Hz, 2H) 7.65 (d, J 
= 8.0 Hz, 2H) 6.70 (t, J = 56.2 Hz, 1H) 3.70 (s, 3H) 3.38 (t, J = 7.2 Hz, 2H) 2.54 (t, J = 7.2 Hz, 
2H) 2.22 (p, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 329.08; HPLC Ret: 7.14 min. 
methyl 4-((5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.08 g, 0.29 mmol) and 
methyl 4-bromobutanoate (0.07 g, 0.37 mmol) gave methyl 4-((5-(4-(trifluoromethoxy)phenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate as white solid (0.09 g, 89%); Column: 15% EtOAc: 85% Hex 
to 25% EtOAc: 75% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.06 (d, J = 8.1 Hz, 2H) 7.34 (d, J 
= 8.1 Hz, 2H) 3.70 (s, 3H) 3.37 (t, J = 7.2 Hz, 2H) 2.53 (t, J = 7.2 Hz, 2H) 2.21 (p, J = 7.2 Hz, 
2H); TOF ES+ MS: (M+H) 363.06; HPLC Ret: 7.85 min. 
methyl 4-((5-(2-chloro-3-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(2-chloro-3-(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol (0.08 g, 
0.27 mmol) and methyl 4-bromobutanoate (0.06 g, 0.35 mmol) gave methyl 4-((5-(2-chloro-3-
(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as white solid (0.09 g, 85%); 
Column: 30% EtOAc: 70% Hex to 35% EtOAc: 65% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
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8.10 (d, J = 7.9 Hz, 1H) 7.89 (d, J = 7.9 Hz, 1H) 7.53 (t, J = 8.0 Hz, 1H) 3.70 (s, 3H) 3.39 (t, J = 
7.1 Hz, 2H) 2.54 (t, J = 7.2 Hz, 2H) 2.22 (p, J = 7.1 Hz, 2H); TOF ES+ MS: (M+H) 381.03; HPLC 
Ret: 7.81 min. 
methyl 4-((5-(2-chloro-4-(2-fluoropropan-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(2-chloro-4-(2-fluoropropan-2-yl)phenyl)-1,3,4-oxadiazole-2-thiol (0.08 
g, 0.28 mmol) and methyl 4-bromobutanoate (0.07 g, 0.36 mmol) gave methyl 4-((5-(2-chloro-4-
(2-fluoropropan-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.09 g, 86%); 
Column: 25% EtOAc: 75% Hex to 35% EtOAc: 65% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
7.94 (d, J = 8.2 Hz, 1H) 7.56 (d, J = 1.7 Hz, 1H) 7.38 (dd, J = 8.3, 1.8 Hz, 1H) 3.70 (s, 3H) 3.37 
(t, J = 7.1 Hz, 2H) 2.54 (t, J = 7.2 Hz, 2H) 2.22 (p, J = 7.2 Hz, 2H) 1.72 (s, 3H) 1.68 (s, 3H); TOF 
ES+ MS: (M+H) 373.08; HPLC Ret: 7.96 min. 
methyl 4-((5-(4-(2-fluoropropan-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(4-(2-fluoropropan-2-yl)phenyl)-1,3,4-oxadiazole-2-thiol (0.04 g, 0.15 mmol) and 
methyl 4-bromobutanoate (0.04 g, 0.20 mmol) gave methyl 4-((5-(4-(2-fluoropropan-2-
yl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.04 g, 69%); Column: 25% 
EtOAc: 75% Hex to 35% EtOAc: 65% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.00 (d, J = 8.1 
Hz, 2H) 7.51 (d, J = 8.2 Hz, 2H) 3.70 (s, 3H) 3.37 (t, J = 7.2 Hz, 2H) 2.54 (t, J = 7.2 Hz, 2H) 2.22 
(p, J = 7.2 Hz, 2H) 1.74 (s, 3H) 1.69 (s, 3H); TOF ES+ MS: (M+H) 339.12; HPLC Ret: 7.65 min. 
methyl 4-((5-(4-(difluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(4-(difluoromethoxy)phenyl)-1,3,4-oxadiazole-2-thiol (0.08 g, 0.31 mmol) and 
methyl 4-bromobutanoate (0.07 g, 0.40 mmol) gave methyl 4-((5-(4-(difluoromethoxy)phenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate as white solid (0.08 g, 72%); Column: 30% EtOAc: 70% Hex 
to 35% EtOAc: 65% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.02 (d, J = 8.8 Hz, 2H) 7.25 (d, J 
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= 8.8 Hz, 2H) 6.59 (t, J = 73.1 Hz, 1H) 3.69 (s, 3H) 3.36 (t, J = 7.2 Hz, 2H) 2.53 (t, J = 7.2 Hz, 
2H) 2.20 (p, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 345.07; HPLC Ret: 7.20 min. 
methyl 4-((5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiazole-2-thiol (0.02 g, 0.09 mmol) and methyl 
4-bromobutanoate (0.02 g, 0.11 mmol) gave methyl 4-((5-(2-chloro-4-fluorophenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate as white solid (0.01 g, 49%); Column: 25% EtOAc: 75% Hex; 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.96 (ddd, J = 9.4, 6.1, 3.3 Hz, 1H) 7.29 (dt, J = 8.5, 2.8 Hz, 
1H) 7.13 (dd, J = 8.8, 2.1 Hz, 1H) 3.69 (s, 3H) 3.36 (t, J = 7.1 Hz, 2H) 2.53 (t, J = 7.2 Hz, 2H) 
2.21 (p, J = 7.2 Hz, 2H); TOF ES+ MS: (M+H) 331.03; HPLC Ret: 7.30 min. 
trans-methyl 3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)cyclobutanecarboxylate 
& cis-methyl 3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)cyclobutanecarboxylate. 
5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-2-thiol (0.1 g, 0.41 mmol), cesium carbonate (0.17 g, 
0.51 mmol), and sodium iodide (0.006 g, 0.04 mmol) were dissolved in 2 mL DMSO. Methyl 3-
chlorocyclobutanecarboxylate (0.09 g, 0.61 mmol, 0.08 mL) was added and the mixture was 
stirred at 100 °C for 40 hr. The reaction was diluted with EtOAc and H2O, and product was 
extracted with EtOAc (3 x 15 mL). The organic layers were combined, washed with brine (2 x 15 
mL), and evaporated in vacuo. The oil was subjected to silica gel chromatography eluting with 
15% EtOAc: 75% Hex. The diastereomers were separated and fractions containing products 
were concentrated to produce colorless oils. Similar compounds were made in an analogous 
fashion. Trans-isomer yield=11% & cis-isomer yield=22%. Trans: 1H NMR (500 MHz, CDCl3-d) 
𝛿 ppm 7.91 (d, J = 8.5 Hz, 1H) 7.57 (d, J = 2.0 Hz, 1H) 7.39 (dd, J = 8.5, 2.0 Hz, 1H) 4.48-4.38 
(m, 1H) 3.73 (s, 3H) 3.40 (tt, J = 10.4, 5.7 Hz, 1H) 2.94 (tt, J = 8.4, 5.8 Hz, 2H) 2.56 (dtd, J = 
13.3, 6.4, 2.4 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 174.87, 164.01, 163.34, 138.08, 
133.74, 131.58, 131.19, 127.61, 121.39, 52.07, 37.62, 35.22, 32.73; **NOSEY attached; TOF 
ES+ MS: (M+H) 359.0; HPLC Ret: 8.02 min. cis: 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.90 (d, J 
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= 8.5 Hz, 1H) 7.57 (d, J = 2.0 Hz, 1H) 7.39 (dd, J = 8.5, 2.0 Hz, 1H) 4.30 (p, J = 8.6 Hz, 1H) 
3.71 (s, 3H) 3.17 (p = 8.9 Hz, 1H) 2.95-2.85 (m, 2H) 2.55 (qd, J = 9.7, 2.9 Hz, 2H); 13C NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 173.80, 164.17, 163.30, 138.03, 133.72, 131.57, 131.16, 127.59, 
121.39, 52.02, 35.45, 34.45, 33.77; **NOSEY attached; TOF ES+ MS: (M+H) 359.0; HPLC Ret: 
7.89 min. *NOSEY shows neighboring cis protons and does not show trans protons. 
cis-methyl 3-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-
yl)thio)cyclobutanecarboxylate & trans-methyl 3-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-
oxadiazol-2-yl)thio)cyclobutanecarboxylate. Column: 15% EtOAc: 75% Hex. cis-isomer 
yield=50% & trans-isomer yield=30%. cis: 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.81 (d, J = 8.2 
Hz, 1H) 7.20 (d, J = 1.7 Hz, 1H) 7.05 (dd, J = 8.2, 1.7 Hz, 1H) 4.35-4.23 (m, 1H) 3.71 (s, 3H) 
3.23-3.11 (m, 1H) 2.98-2.84 (m, 2H) 2.61-2.49 (m, 2H) 1.98-1.87 (m, 1H) 1.09 (tdd, J = 6.6, 5.6, 
3.8 Hz, 2H) 0.79 (tdd, J = 6.4, 4.8, 2.5 Hz, 2H); **NOSEY attached; TOF ES+ MS: (M+H) 365.1; 
HPLC Ret: 8.26 min. trans: 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.82 (d, J = 7.8 Hz, 1H) 7.20 (d, 
J = 1.8 Hz, 1H) 7.05 (dd, J = 7.4, 2.0 Hz, 1H) 4.41 (tddd, J = 10.0, 8.5, 5.9, 2.2 Hz, 1H) 3.73 (s, 
3H) 3.45-3.34 (m, 1H) 2.99-2.90 (m, 2H) 2.60-2.50 (m, 2H) 1.97-1.87 (m, 1H) 1.09 (tdd, J = 6.6, 
3.8, 2.0 Hz, 2H) 0.79 (tdd, J = 6.5, 4.9, 2.4 Hz, 2H); **NOSEY attached; TOF ES+ MS: (M+H) 
365.1; HPLC Ret: 8.40 min. *NOSEY shows neighboring cis protons and does not show trans 
protons. 
cis- methyl 3-((5-(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)cyclobutanecarboxylate & trans- methyl 3-((5-(2-chloro-4-(trifluoromethyl)phenyl)-
1,3,4-oxadiazol-2-yl)thio)cyclobutanecarboxylate. Column: 15% EtOAc: 75% Hex. cis-isomer 
yield=34% & trans-isomer yield=18%. cis: 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.11 (d, J = 8.2 
Hz, 1H) 7.80 (d, J = 1.7 Hz, 1H) 7.66 (dd, J = 8.5, 1.8 Hz, 1H) 4.33 (td, J = 7.7, 1.5 Hz, 1H) 3.71 
(s, 3H) 3.25-3.13 (m, 1H) 3.02-2.81 (m, 2H) 2.62-2.50 (m, 2H); **NOSEY attached; TOF ES+ 
MS: (M+H) 393.0; HPLC Ret: 8.21 min. trans: 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.12 (d, J = 
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8.2 Hz, 1H) 7.82 (d, J = 1.7 Hz, 1H) 7.67 (dd, J = 8.7, 1.8 Hz, 1H) 4.51-4.41 (m, 1H) 3.74 (s, 3H) 
3.45-3.37 (m, 1H) 3.00-2.91 (m, 2H) 2.62-2.51 (m, 2H); **NOSEY attached; TOF ES+ MS: 
(M+H) 393.0; HPLC Ret: 8.31 min. *NOSEY shows neighboring cis protons and does not show 
trans protons. 
cis- ethyl 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)cyclohexanecarboxylate & 
trans- ethyl 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)cyclohexanecarboxylate. 
*Sodium iodide not used and ethyl 4-((methylsulfonyl)oxy)cyclohexanecarboxylate used as 
alkylating agent. Column: 15% EtOAc: 85% Hex. cis-isomer yield=47% & trans-isomer 
yield=25%. cis: 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.91 (d, J = 8.5 Hz, 1H) 7.57 (d, J = 1.9 Hz, 
1H) 7.39 (dd, J = 8.5, 1.9 Hz, 1H) 4.21-4.10 (m, 3H) 2.57-2.47 (m, 1H) 2.13-1.95 (m, 6H) 1.90-
1.79 (m, 2H) 1.27 (t, J = 7.2 Hz, 3H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 174.62, 165.01, 
163.15, 137.94, 133.70, 131.54, 131.14, 127.57, 121.47, 60.43, 45.63, 40.79, 30.17, 25.51, 
14.23; TOF ES+ MS: (M+H) 373.02; TOF ES+ MS: (M+H) 401.05; HPLC Ret: 9.18 min. trans: 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.92 (dd, J = 8.5, 3.6 Hz, 1H) 7.57 (q, J = 2.0 Hz, 1H) 7.39 
(dq, J = 8.5, 2.1 Hz, 1H) 4.14 (q, J = 7.1 Hz, 2H) 3.78-3.68 (m, 1H) 2.42-2.31 (m, 3H) 2.18-2.09 
(m, 2H) 1.69-1.55 (m, 4H) 1.26 (t, J = 7.1 Hz, 3H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 174.87, 
164.44, 163.23, 138.00, 133.68, 131.56, 131.16, 127.59, 121.44, 60.43, 45.61, 42.04, 32.26, 
28.71, 14.19; TOF ES+ MS: (M+H) 401.05; HPLC Ret: 9.33 min. *No conclusive information 
was deduced from the NOSEYs. No conclusive information was deduced from the predicted 
MestraNova NMR spectrum. The isomers were assigned based on their physical behaviors. 
Generally, the trans isomers (4 & 5 membered rings) elute from silica gel column before cis 
isomers. Also, the trans ester isomers are crystalline post column chromatography. The isomer 
that had these two characteristics was assigned as the trans isomer. If the isomers have some 
unexpected activity then I will need to more concretely define these isomers. 
256 
 
cis- methyl 3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)cyclopentanecarboxylate 
trans- methyl 3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)cyclopentanecarboxylate. In a 50 mL round-bottomed flask, 5-(2,4-dichlorophenyl)-
1,3,4-oxadiazole-2-thiol (0.2 g, 0.81 mmol) was dissolved in 2 mL THF. 95% NaH (0.07 g, 0.85 
mmol) was added and the reaction proceeded at 25 °C for 30 min. methyl 3-
((methylsulfonyl)oxy)cyclopentanecarboxylate (0.33 g, 1.50 mmol) in THF (2 mL) was added 
dropwise and the solution was stirred at 50 °C for 16 hr. The reaction was partitioned between 
sat. NaHCO3 and EtOAc, and the product was extracted with EtOAc (3 x 20 mL). The organic 
layers were combined, dried with MgSO4, and concentrated in vacuo. The oil was subjected to 
silica gel chromatography eluting with 10% EtOAc: 90% Hex to 20% EtOAc: 80% Hex. The 
diastereomers were separated and fractions containing products were concentrated to produce 
colorless oils. cis-isomer yield=75% & trans-isomer yield=25%. cis: 1H NMR (500 MHz, CDCl3-
d) 𝛿 ppm 7.91 (d, J = 8.4 Hz, 1H) 7.57 (d, J = 2.1 Hz, 1H) 7.39 (dd, J = 8.5, 2.1 Hz, 1H) 4.27-
4.17 (m, 1H) 3.70 (s, 3H) 3.14-3.03 (m, 1H) 2.59-2.55 (m, 1H) 2.50-2.32 (m, 1H) 2.24-2.14 (m, 
1H) 2.00-1.95 (m, 1H) 1.91-1.80 (m, 1H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 175.58, 164.72, 
163.24, 138.01, 133.70, 131.57, 131.55, 127.59, 121.41, 51.96, 45.56, 42.45, 37.02, 33.20, 
28.84; TOF ES+ MS: (M+H) 373.02; HPLC Ret: 8.50 min. trans: 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 7.86 (d, J = 8.5 Hz, 1H) 7.58 (d, J = 2.0 Hz, 1H) 7.41 (dd, J = 8.6, 1.5 Hz, 1H) 5.30-5.24 
(m, 1H) 3.72 (s, 3H) 3.22 (p, J = 8.0 Hz, 1H) 2.49-2.42 (m, 1H) 2.38-2.10 (m, 3H) 2.12-1.92 (m, 
2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 175.60, 175.08, 156.30, 138.59, 133.79, 131.50, 
130.84, 127.71, 119.86, 59.63, 51.99, 42.44, 34.45, 31.02, 28.65; TOF ES+ MS: (M+H) 373.02; 
HPLC Ret: 8.69 min. *No conclusive information was deduced from the NOSEYs. However, 
comparisons between the experimental CNMR chemical shifts to MestreNova predicted CNMR 
(attached) chemical shifts was used to assign cis and trans isomers; the experimental and 
predicted shifts were extremely close. Also of note, the cis isomer had a 10% impurity that was 
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structurally very similar to the desired product; it was deduced that this impurity was the 5-
membered ring conformer (see DJK-7-15 for evidence). 
tert-butyl 4-((5-(2-chloro-4-propylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(2-chloro-4-propylphenyl)-1,3,4-oxadiazole-2-thiol (0.03 g, 0.11 mmol) and t-butyl 
4-bromobutanoate (0.03 g, 0.13 mmol) gave tert-butyl 4-((5-(2-chloro-4-propylphenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate as colorless oil (0.03 g, 62%); Column: 10% EtOAc: 90% Hex; 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.85 (dd, J = 8.0, 1.3 Hz, 1H) 7.27 (s, 1H) 7.20 (dd, J = 8.0, 
1.5 Hz, 1H) 3.34 (t, J = 7.2 Hz, 2H) 2.63 (t, J = 7.6 Hz, 2H) 2.43 (t, J = 7.3 Hz, 2H) 2.16 (p, J = 
7.3 Hz, 2H) 1.68 (h, J = 7.5 Hz, 2H) 1.46 (s, 9H) 0.96 (t, J = 7.5 Hz, 3H); TOF ES+ MS: (M+H) 
397.1; HPLC Ret: 9.81 min. 
tert-butyl 4-((5-(4-butyl-2-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(4-butyl-2-chlorophenyl)-1,3,4-oxadiazole-2-thiol (0.06 g, 0.22 mmol) and t-butyl 
4-bromobutanoate (0.06 g, 0.26 mmol) gave tert-butyl 4-((5-(4-butyl-2-chlorophenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate as colorless oil (0.05 g, 54%); Column: 15% EtOAc: 85% Hex; 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.84 (dd, J = 8.0, 1.2 Hz, 1H) 7.35 (s, 1H) 7.19 (dd, J = 8.2, 
1.4 Hz, 1H) 3.34 (t, J = 7.2 Hz, 2H) 2.65 (t, J = 7.8 Hz, 2H) 2.43 (t, J = 7.2 Hz, 2H) 2.16 (p, J = 
7.3 Hz, 2H) 1.59 (h, J = 7.5 Hz, 2H) 1.45 (s, 9H) 1.37 (p, J = 7.2 Hz, 2H) 0.94 (t, J = 7.3 Hz, 3H); 
TOF ES+ MS: (M+H) 411.2; HPLC Ret: 10.53 min. 
tert-butyl 4-((5-(2-chloro-4-isobutylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(2-chloro-4-isobutylphenyl)-1,3,4-oxadiazole-2-thiol (0.03 g, 0.11 mmol) and t-
butyl 4-bromobutanoate (0.03 g, 0.13 mmol) gave tert-butyl 4-((5-(2-chloro-4-isobutylphenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.03 g, 61%); Column: 15% EtOAc: 85% 
Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.84 (dd, J = 8.0, 1.4 Hz, 1H) 7.34 (s, 1H) 7.18 (dd, J 
= 8.0, 1.6 Hz, 1H) 3.34 (t, J = 7.2 Hz, 2H) 2.52 (d, J = 7.2 Hz, 2H) 2.43 (t, J = 7.2 Hz, 2H) 2.15 
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(p, J = 7.2 Hz, 2H) 1.91 (dp, J = 13.6, 6.8 Hz, 1H) 1.45 (s, 9H) 0.93 (d, J = 6.6 Hz, 6H); TOF 
ES+ MS: (M+H) 411.2; HPLC Ret: 10.33 min. 
tert-butyl 4-((5-(2-chloro-3-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method 
E starting from 5-(2-chloro-3-cyclopropylphenyl)-1,3,4-oxadiazole-2-thiol (0.05 g, 0.2 mmol) and 
t-butyl 4-bromobutanoate (0.05 g, 0.24 mmol) gave tert-butyl 4-((5-(2-chloro-3-
cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.06 g, 82%); Column: 
5% EtOAc: 95% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.69 (dd, J = 7.7, 1.6 Hz, 1H) 7.29 (t, 
J = 7.8 Hz, 1H) 7.15 (dd, J = 7.9, 1.6 Hz, 1H) 3.35 (t, J = 7.2 Hz, 2H) 2.43 (t, J = 7.2 Hz, 2H) 
2.26 (tt, J = 8.6, 5.4 Hz, 1H) 2.16 (p, J = 7.2 Hz, 2H) 1.46 (s, 9H) 1.13-1.02 (m, 2H) 0.77-0.66 
(m, 2H); TOF ES+ MS: (M+H) 395.1; HPLC Ret: 9.19 min. 
tert-butyl 4-((5-(2-chloro-5-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method 
E starting from 5-(2-chloro-5-cyclopropylphenyl)-1,3,4-oxadiazole-2-thiol (0.05 g, 0.2 mmol) and 
t-butyl 4-bromobutanoate (0.05 g, 0.24 mmol) gave tert-butyl 4-((5-(2-chloro-5-
cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.07 g, 90%); Column: 
5% EtOAc: 95% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.63 (d, J = 2.3 Hz, 1H) 7.39 (d, J = 
8.4 Hz, 1H) 7.14 (dd, J = 8.3, 2.3 Hz, 1H) 3.35 (t, J = 7.2 Hz, 2H) 2.43 (t, J = 7.2 Hz, 2H) 2.16 
(p, J = 7.2 Hz, 2H) 1.93 (ddd, J = 13.5, 8.6, 5.1 Hz, 1H) 1.45 (s, 9H) 1.07-0.98 (m, 2H) 0.75-0.64 
(m, 2H); TOF ES+ MS: (M+H) 395.1; HPLC Ret: 9.21 min. 
tert-butyl 4-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method 
E starting from 5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazole-2-thiol (0.08 g, 0.30 mmol) 
and t-butyl 4-bromobutanoate (0.05 g, 0.36 mmol) gave tert-butyl 4-((5-(2-chloro-4-
cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.1 g, 85%); Column: 
5% EtOAc: 95% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.82 (d, J = 8.2, 1H) 7.20 (d, J = 1.7 
Hz, 1H) 7.05 (dd, J = 8.2, 1.8 Hz, 1H) 3.34 (t, J = 7.2 Hz, 2H) 2.42 (t, J = 7.2 Hz, 2H) 2.15 (p, J 
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= 7.2 Hz, 2H) 1.92 (tt, J = 8.4, 5.0 Hz, 1H) 1.45 (s, 9H) 1.14-1.03 (m, 2H) 0.79 (dt, J = 6.8, 4.8 
Hz, 2H); TOF ES+ MS: (M+H) 395.1; HPLC Ret: 9.18 min. 
tert-butyl 4-((5-(2-chloro-4-(prop-1-en-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
Method E starting from 5-(2-chloro-4-(prop-1-en-2-yl)phenyl)-1,3,4-oxadiazole-2-thiol (0.06 g, 
0.24 mmol) and t-butyl 4-bromobutanoate (0.06 g, 0.29 mmol) gave tert-butyl 4-((5-(2-chloro-4-
(prop-1-en-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as white solid (0.07 g, 72%); 
Column: 12% EtOAc: 88% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.92 (d, J = 8.3, 1H) 7.61 
(d, J = 1.9 Hz, 1H) 7.47 (dd, J = 8.1, 1.3 Hz, 1H) 5.51 (s, 1H) 5.25 (s, 1H) 3.36 (t, J = 7.3 Hz, 
2H) 2.43 (t, J = 7.2 Hz, 2H) 2.25-2.12 (m, 5H) 1.46 (s, 9H); TOF ES+ MS: (M+H) 395.1; HPLC 
Ret: 9.54 min. 
tert-butyl 4-((5-(2-chloro-4-isopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate & tert-
butyl 4-((5-(4-isopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E starting from 
a mixture of 5-(2-chloro-4-isopropylphenyl)-1,3,4-oxadiazole-2-thiol and 5-(4-isopropylphenyl)-
1,3,4-oxadiazole-2-thiol (0.05 g, 0.24 mmol) and t-butyl 4-bromobutanoate (0.05 g, 0.30 mmol) 
gave a mixture of tert-butyl 4-((5-(2-chloro-4-isopropylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate and tert-butyl 4-((5-(4-isopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as 
colorless oil (0.03 g, 56%); Column: 10% EtOAc: 90% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
7.92 (d, J = 8.3Hz, 2H) 7.86 (d, J = 8.0 Hz, 0.5H) 7.41-7.32 (m, 2.5H) 7.25 (dd, J = 8.0, 1.6 Hz, 
0.5H) 3.34 (t, J = 7.2 Hz, 3H) 3.02-2.90 (m, 1.5H) 2.43 (t, J = 7.2 Hz, 3H) 2.15 (p, J = 7.2 Hz, 
3H) 1.45 (s, 13.5H) 1.30-1.26 (m, 9H); TOF ES+ MS: (M+H) 397.1 & 363.2; HPLC Ret: 9.70 & 
9.40 min. 
tert-butyl 4-((5-(2-chloro-4-vinylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(2-chloro-4-vinylphenyl)-1,3,4-oxadiazole-2-thiol (0.05 g, 0.21 mmol) and t-butyl 
4-bromobutanoate (0.06 g, 0.25 mmol) gave tert-butyl 4-((5-(2-chloro-4-vinylphenyl)-1,3,4-
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oxadiazol-2-yl)thio)butanoate as colorless oil (0.06 g, 75%); Column: 0% EtOAc: 100% Hex to 
15% EtOAc: 85% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.92 (d, J = 8.2 Hz, 1H) 7.55 (d, J = 
1.6 Hz, 1H) 7.41 (dd, J = 8.2, 1.6 Hz, 1H) 6.69 (dd, J = 17.5, 10.9 Hz, 1H) 5.89 (d, J = 17.5 Hz, 
1H) 5.45 (d, 10.9 Hz, 1H) 3.35 (t, J = 7.2 Hz, 2H) 2.43 (t, J = 7.2 Hz, 2H) 2.16 (p, J = 7.3 Hz, 2H) 
1.45 (s, 9H); TOF ES+ MS: (M+Na) 403.1; HPLC Ret: 9.02 min. 
tert-butyl 4-((5-(2-chloro-4-ethylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(2-chloro-4-ethylphenyl)-1,3,4-oxadiazole-2-thiol (0.05 g, 0.21 mmol) and t-butyl 
4-bromobutanoate (0.06 g, 0.25 mmol) gave tert-butyl 4-((5-(2-chloro-4-ethylphenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate as colorless oil (0.07 g, 85%); Column: 0% EtOAc: 100% Hex to 
15% EtOAc: 85% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.85 (dd, J = 8.0, 1.5 Hz, 1H) 7.37 
(d, J = 1.5 Hz, 1H) 7.22 (dd, J = 8.0, 1.6 Hz, 1H) 3.34 (t, J = 7.2 Hz, 2H) 2.70 (q, J = 7.6 Hz, 2H) 
2.43 (t, J = 7.2 Hz, 2H) 2.15 (p, J = 7.2 Hz, 2H) 1.45 (s, 9H) 1.27 (t, J = 7.6 Hz, 3H); TOF ES+ 
MS: (M+Na) 405.1; HPLC Ret: 9.28 min. 
tert-butyl 4-((5-(2-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E 
starting from 5-(2-(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thiol (0.1 g, 0.41 mmol) and t-butyl 
4-bromobutanoate (0.08 g, 0.49 mmol) gave tert-butyl 4-((5-(2-(trifluoromethyl)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate as colorless oil (0.14 g, 88%); Column: 15% EtOAc: 75% Hex; 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.06-8.00 (m, 1H) 7.85 (dd, J = 7.1, 1.9 Hz, 1H) 7.74-7.64 (m, 
2H) 3.34 (t, J = 7.2 Hz, 2H) 2.43 (t, J = 7.2 Hz, 2H) 2.15 (p, J = 7.2 Hz, 2H) 1.45 (s, 9H); TOF 
ES+ MS: (M+H) 389.1; HPLC Ret: 8.46 min. 
tert-butyl 4-((5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method E starting from 
5-(2-fluorophenyl)-1,3,4-oxadiazole-2-thiol (0.1 g, 0.51 mmol) and t-butyl 4-bromobutanoate 
(0.14 g, 0.61 mmol) gave tert-butyl 4-((5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as 
yellow oil (0.16 g, 91%); Column: 15% EtOAc: 75% Hex 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
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8.02 (td, J = 7.5, 1.8 Hz, 1H) 7.56-7.48 (m, 1H) 7.32-7.20 (m, 2H) 3.36 (t, J = 7.2 Hz, 2H) 2.43 
(t, J = 7.2 Hz, 2H) 2.15 (p, J = 7.2 Hz, 2H) 1.46 (s, 9H); TOF ES+ MS: (M+H) 339.1; HPLC Ret: 
8.08 min. 
tert-butyl 4-((5-(2-chloro-4-ethoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method L 
starting from tert-butyl 4-((5-(2-chloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate 
(0.05 g, 0.14 mmol) and ethyl iodide (0.03 g, 0.2 mmol) gave tert-butyl 4-((5-(2-chloro-4-
ethoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.05 g, 97%); 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.86 (d, 8.8 Hz, 1H) 7.03 (d, J = 2.4 Hz, 1H) 6.89 (dd, J = 8.8, 2.5 Hz, 1H) 
4.09 (q, J = 7.0 Hz, 2H) 3.33 (t, J = 7.2 Hz, 2H) 2.42 (t, J = 7.2 Hz, 2H) 2.15 (p, J = 7.2 Hz, 2H) 
1.45 (t, J = 7.0 Hz, 3H) 1.45 (s, 9H); TOF ES+ MS: (M+H) 399.12; HPLC Ret: 7.40 min. 
tert-butyl 4-((5-(2-chloro-4-propoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method L 
starting from tert-butyl 4-((5-(2-chloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate 
(0.05 g, 0.14 mmol) and 1-bromopropane (0.02 g, 0.2 mmol) gave tert-butyl 4-((5-(2-chloro-4-
propoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.05 g, 94%); Column: 18% 
EtOAc: 82% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.86 (d, 8.8 Hz, 1H) 7.04 (d, J = 2.4 Hz, 
1H) 6.90 (dd, J = 8.5, 2.5 Hz, 1H) 3.98 (t, J = 6.5 Hz, 2H) 3.33 (t, J = 7.2 Hz, 2H) 2.42 (t, J = 7.2 
Hz, 2H) 2.15 (p, J = 7.2 Hz, 2H) 1.89-1.78 (m, 2H) 1.45 (s, 9H) 1.05 (t, J = 7.4 Hz, 3H); TOF 
ES+ MS: (M+H) 413.13; HPLC Ret: 9.51 min. 
tert-butyl 4-((5-(4-butoxy-2-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method L 
starting from tert-butyl 4-((5-(2-chloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate 
(0.05 g, 0.14 mmol) and 1-iodobutane (0.03 g, 0.2 mmol) gave tert-butyl 4-((5-(4-butoxy-2-
chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.05 g, 92%); Column: 18% 
EtOAc: 82% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.86 (d, 8.8 Hz, 1H) 7.04 (d, J = 2.5 Hz, 
1H) 6.90 (dd, J = 8.8, 2.5 Hz, 1H) 4.02 (t, J = 6.5 Hz, 2H) 3.33 (t, J = 7.2 Hz, 2H) 2.42 (t, J = 7.2 
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Hz, 2H) 2.15 (p, J = 7.2 Hz, 2H) 1.84-1.74 (m, 2H) 1.55-1.43 (m, 11H) 0.99 (t, J = 7.4 Hz, 3H); 
TOF ES+ MS: (M+H) 427.15; HPLC Ret: 10.13 min. 
tert-butyl 4-((5-(2-chloro-4-(cyclopropylmethoxy)phenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate. Method L starting from tert-butyl 4-((5-(2-chloro-4-hydroxyphenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate (0.05 g, 0.14 mmol) and (bromomethyl)cyclopropane (0.02 g, 0.16 
mmol) gave tert-butyl 4-((5-(2-chloro-4-(cyclopropylmethoxy)phenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate as colorless oil (0.05 g, 93%); Column: 20% EtOAc: 80% Hex; 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.86 (d, 8.8 Hz, 1H) 7.04 (d, J = 2.4 Hz, 1H) 6.90 (dd, J = 8.8, 2.6 Hz, 1H) 
3.86 (d, J = 6.9 Hz, 2H) 3.33 (t, J = 7.2 Hz, 2H) 2.42 (t, J = 7.2 Hz, 2H) 2.15 (p, J = 7.2 Hz, 2H) 
1.45 (s, 9H) 1.33-1.22 (m. 1H) 0.73-0.63 (m, 2H) 0.43-0.34 (m, 2H); TOF ES+ MS: (M+H) 
425.13; HPLC Ret: 9.24 min. 
tert-butyl 4-((5-(2-chloro-4-isopropoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. Method 
L starting from tert-butyl 4-((5-(2-chloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate 
(0.05 g, 0.14 mmol) and 2-bromopropane (0.02 g, 0.16 mmol) gave tert-butyl 4-((5-(2-chloro-4-
isopropoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate as colorless oil (0.05 g, 84%); Column: 
18% EtOAc: 82% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.85 (d, 8.8 Hz, 1H) 7.02 (d, J = 2.5 
Hz, 1H) 6.87 (dd, J = 8.7, 2.5 Hz, 1H) 4.61 (hept, J = 6.0 Hz, 1H) 3.33 (t, J = 7.2 Hz, 2H) 2.42 (t, 
J = 7.2 Hz, 2H) 2.15 (p, J = 7.2 Hz, 2H) 1.45 (s, 9H) 1.40-1.35 (m, 6H); TOF ES+ MS: (M+H) 
413.13; HPLC Ret: 9.29 min. 
methyl 4-((5-(2-chloro-3-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate. 
In a 10 mL round-bottomed flask, methyl 4-((5-(2-chloro-3-hydroxyphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.04 g, 0.12 mmol) was dissolved in 0.75 mL anhydrous DMSO. Cs2CO3 
(0.05 g, 0.15 mmol) and 1, 1, 1-trifluoro-2-iodoethane (0.08 g, 0.37 mmol) were added and the 
reaction was heated at 105 °C for 16 hr. The reaction was cooled, diluted with H2O, and 
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extracted with EtOAc (3 x 20 mL). The organic layers were combined, washed with brine, and 
concentrated in vacuo. The yellow residue was subjected to silica gel chromatography eluting 
with 35% EtOAc: 65% Hex.  The fractions containing product were concentrated in vacuo to 
produce white solid. Yield=28%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.67 (dt, 7.9, 1.2 Hz, 1H) 
7.38 (t, J = 8.1 Hz, 1H) 7.16 (dd, J = 8.3, 1.4 Hz, 1H) 4.51-4.41 (m, 2H) 3.70 (s, 3H) 3.38 (t, J = 
7.2 Hz, 2H) 2.54 (t, J = 7.1 Hz, 2H) 2.22 (p, J = 7.0 Hz, 2H); TOF ES+ MS: (M+H) 411.04; HPLC 
Ret: 7.46 min. 
3-((5-(2-chloro-4-methylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid (CCG-232001). 
Method F starting from tert-butyl 3-((5-(2-chloro-4-methylphenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoate (0.27 g, 0.77 mmol) gave 3-((5-(2-chloro-4-methylphenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoic acid as white solid (0.13 g, 57%); 1H NMR (401 MHz, DMSO-d6) 𝛿 ppm 12.45 
(br. s., 1H) 7.85 (d, J = 8.0 Hz, 1H) 7.55 (s, 1H) 7.37 (d, J = 8.1 Hz, 1H) 3.46 (t, J = 6.8 Hz, 2H) 
2.84 (t, J = 6.8 Hz, 2H) 2.40 (s, 3H); 13C NMR (401 MHz, DMSO-d6) 𝛿 ppm 172.88, 164.42, 
163.75, 144.35, 131.77, 131.26, 128.98, 119.78, 34.26, 27.99, 21.05; TOF ES+ MS: (M+H) 
398.9; HPLC Ret: 6.31 min; 99% pure. 
3-((5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid (CCG-232002). 
Method F starting from tert-butyl 3-((5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoate (0.28 g, 0.78 mmol) gave 3-((5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoic acid as white solid (0.12 g, 50%); 1HNMR (401 MHz, DMSO-d6) 𝛿 ppm 12.53 
(br. s., 1H) 8.09-8.02 (m, 1H) 7.76-7.71 (m, 1H) 7.48 (d, J = 8.1 Hz, 1H) 3.46 (t, J = 6.8 Hz, 2H) 
2.84 (t, J = 6.8 Hz, 2H); 13CNMR (101 MHz, DMSO-d6) 𝛿 ppm 172.89, 165.13, 164.74, 163.02, 
162.60, 133.72, 119.58, 116.08, 115.87, 34.26, 27.99; TOF ES+ MS: (M+H) 302.9; HPLC Ret: 




258021). Method F starting from tert-butyl 3-((5-(2,4-dichloro-5-methylphenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoate (0.09 g, 0.23 mmol) gave 3-((5-(2,4-dichloro-5-methylphenyl)-1,3,4-
oxadiazol-2-yl)thio)propanoic acid as white solid (0.4 g, 65%); 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 7.83 (s, 1H) 7.54 (s, 1H) 3.55 (t, J = 6.8 Hz, 2H) 3.04 (t, J = 6.8 Hz, 2H) 2.41 (s, 3H); 13C 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 175.94, 164.62, 163.72, 138.29, 135.72, 132.36, 131.31, 
130.62, 129.34, 120.94, 33.84, 27.05, 19.46; QTOF ES+ MS: (M+H) 330.97; HPLC Ret: 6.81 
min; 95% pure. 
3-((5-(2-chloro-4,5-dimethylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid. (CCG-
258041). Method F starting from tert-butyl 3-((5-(2-chloro-4,5-dimethylphenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoate (0.13 g, 0.35 mmol) gave 3-((5-(2-chloro-4,5-dimethylphenyl)-1,3,4-
oxadiazol-2-yl)thio)propanoic acid as white solid (0.08 g, 75%); 1H NMR (501 MHz, CDCl3-d) 𝛿 
ppm 11.00 (br. s., 1H) 7.71 (s, 1H) 7.29 (s, 1H) 3.54 (t, J = 6.8 Hz, 2H) 3.32 (s, 3H) 3.04 (t, J = 
6.8 Hz, 2H) 2.28 (s, 3H); 13C NMR (126 MHz, CDCl3-d) 𝛿 ppm 176.49, 164.54, 164.10, 142.24, 
135.99, 131.95, 131.52, 129.77, 119.69, 33.99, 27.00, 19.70, 19.06; QTOF ES+ MS: (M-H) 
311.03; HPLC Ret: 5.91 min; 99% pure. 
3-((5-(2-chloro-3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid. (CCG-
258043). Method F starting from tert-butyl 3-((5-(2-chloro-3,4-dimethylphenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoate (0.17 g, 0.45 mmol) gave 3-((5-(2-chloro-3,4-dimethylphenyl)-1,3,4-
oxadiazol-2-yl)thio)propanoic acid as white solid (0.11 g, 80%); 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 10.59 (br. s., 1H) 7.60 (d, J = 7.9 Hz, 1H) 7.17 (d, J = 7.9 Hz, 1H) 3.53 (t, J = 6.8 Hz, 2H) 
3.32 (s, 3H) 3.04 (t, J = 6.8 Hz, 2H) 2.28 (s, 3H); 13C NMR (126 MHz, CDCl3-d) 𝛿 ppm 176.37, 
165.02, 164.19, 142.27, 136.67, 133.15, 128.14, 120.93, 34.00, 26.99, 21.37, 16.72; QTOF ES+ 
MS: (M-H) 311.03; HPLC Ret: 5.83 min; 95% pure. 
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3-((5-(2,6-difluorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid. (CCG-262527). Method 
F starting from tert-butyl 3-((5-(2,6-difluorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate (0.09 g, 
0.26 mmol) gave 3-((5-(2,6-difluorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid as white 
solid (0.07 g, 94%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.25 (br. s, 1H) 7.53 (tt, J = 8.5, 6.1 
Hz, 1H) 7.13-7.05 (m, 2H) 3.55 (t, J = 6.7 Hz, 2H) 2.73 (t, J = 7.0 Hz, 2H); 13C NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 176.42, 165.20, 161.53, 159.50, 157.96, 133.59, 112.46, 33.89, 26.99; TOF 
ES+ MS: (M+H) 287.0; HPLC Ret: 5.57 min; 95% pure. 
3-((5-(2-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid. (CCG-262528). 
Method F starting from tert-butyl 3-((5-(2-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoate (0.09 g, 0.24 mmol) gave 3-((5-(2-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)propanoic acid as colorless oil (0.07 g, 93%); product required 45% EtOAc: 65% Hex: 
0.01% AcOH column chromotragraphy; 1H NMR (501 MHz, CDCl3-d) 𝛿 ppm 10.22 (br. s, 1H) 
8.06-7.99 (m, 1H) 7.86 (dd, J = 7.3, 1.9 Hz, 1H) 7.78-7.67 (m, 2H) 3.53 (t, J = 6.8 Hz, 2H) 3.03 
(t, J = 6.8 Hz, 2H); 13C NMR (126 MHz, CDCl3-d) 𝛿 ppm 176.64, 165.31, 164.17, 132.19, 
131.66, 128.83, 127.13, 127.04, 124.17, 121.76, 33.97, 26.95; TOF ES+ MS: (M+H) 319.04; 
HPLC Ret: 6.18 min; 99% pure. 
3-((5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid. (CCG-262529). Method F 
starting from tert-butyl 3-((5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate (0.1 g, 0.31 
mmol) gave 3-((5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid as white solid (0.07 
g, 85%); 1H NMR (501 MHz, CDCl3-d) 𝛿 ppm 10.31 (br. s, 1H) 8.00 (td, J = 7.5, 1.7 Hz, 1H) 
7.57-7.49 (m, 1H) 7.36-7.15 (m, 2H) 3.55 (t, J = 6.8 Hz, 2H) 3.03 (t, J = 6.7 Hz, 2H); 13C NMR 
(126 MHz, CDCl3-d) 𝛿 ppm 176.28, 164.49, 162.69, 160.85, 158.79, 133.55, 129.49, 124.65, 
116.89, 33.93, 27.03; TOF ES+ MS: (M+H) 269.0; HPLC Ret: 5.58 min; 95% pure. 
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3-((5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid. (CCG-262530). Method 
F starting from tert-butyl 3-((5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoate (0.09 g, 
0.24 mmol) gave 3-((5-(2,6-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid as colorless 
oil (0.07 g, 90%); product required 45% EtOAc: 65% Hex: 0.01% AcOH column 
chromotragraphy; 1H NMR (501 MHz, CDCl3-d) 𝛿 ppm 10.51 (br. s, 1H) 7.36-7.24 (m, 3H) 3.56 
(t, J = 6.7 Hz, 2H) 3.05 (t, J = 6.7 Hz, 2H); 13C NMR (126 MHz, CDCl3-d) 𝛿 ppm 176.79, 165.49, 
160.91, 136.51, 133.05, 128.30, 123.75, 33.93, 27.01; TOF ES+ MS: (M+H) 318.97; HPLC Ret: 
6.23 min; 99% pure. 
4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)oxy)butanoic acid. (CCG-257223). Method F 
starting from tert-butyl 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)oxy)butanoate (0.06 g, 
0.16 mmol) gave 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)oxy)butanoic acid as white solid 
(0.4 g, 89%); 1H NMR (501 MHz, CDCl3-d) 𝛿 ppm 7.75 (d, J = 8.5 Hz, 1H) 7.59 (br. s., 1H) 7.54 
(d, J = 2.1 Hz, 1H) 7.37 (dd, J = 8.5, 2.1 Hz, 1H) 3.93 (t, J = 6.7 Hz, 2H) 2.53 (t, J = 7.2 Hz, 2H) 
2.17 (p, J = 7.0 Hz, 2H); 13C NMR (126 MHz, CDCl3-d) 𝛿 ppm 177.90, 153.08, 150.84, 137.89, 
133.40, 131.38, 130.53, 127.56, 121.02, 45.15, 30.61, 23.22; TOF ES+ MS: (M+Na) 338.9; 
HPLC Ret: 6.52 min; 98% pure. 
4-((5-(4-bromo-2-chlorophenyl)-1,3, 4-oxadiazole-2-yl)thio)butanoic acid. (CCG-257389). 
Method F starting from tert-butyl 4-((5-(4-bromo-4-chlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.05 g, 0.12 mmol) gave 4-((5-(4-bromo-2-chlorophenyl)-1,3, 4-oxadiazole-2-
yl)thio)butanoic acid as white solid (0.04 g, 94%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.83 (d, J 
= 8.4 Hz, 1H) 7.73 (d, J = 1.9 Hz, 1H) 7.54 (dd, J = 8.5, 1.9 Hz, 2H) 3.39 (t, J = 7.2 Hz, 2H) 2.59 
(t, J = 7.1 Hz, 2H) 2.22 (p, J = 7.1 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 176.35, 164.99, 
163.50, 134.00, 133.78, 131.66, 130.54, 126.15, 121.75, 32.23, 31.60, 24.31; TOF ES+ MS: 




259066) Method F starting from tert-butyl 4-((5-(2-chloro-3-cyclopropylphenyl)-1,3,4-oxadiazol-
2-yl)thio)butanoate (0.06 g, 0.15 mmol) gave 4-((5-(2-chloro-3-cyclopropylphenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoic acid as white oil (0.02 g, 39%); **post evaporation, 0% to 5% 
MeOH DCM column performed; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.68 (dd, J = 7.7, 1.6 Hz, 
1H) 7.29 (t, J = 7.8 Hz, 1H) 7.15 (dd, J = 7.8, 1.6 Hz, 1H) 3.39 (t, J = 7.2 Hz, 2H) 2.59 (t, J = 7.1 
Hz, 2H) 2.31-2.18 (m, 3H) 1.13-0.98 (m, 2H) 0.77-0.66 (m, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 
ppm 175.45, 164.64, 143.05, 134.30, 129.45, 128.56, 126.72, 123.34, 109.99, 32.30, 31.60, 
24.37, 14.02, 8.05; TOF ES+ MS: (M+H) 339.0; HPLC Ret: 6.94 min; 95% pure 
4-((5-(2-chloro-5-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-
259067). Method F starting from tert-butyl 4-((5-(2-chloro-5-cyclopropylphenyl)-1,3,4-oxadiazol-
2-yl)thio)butanoate (0.07 g, 0.18 mmol) gave 4-((5-(2-chloro-5-cyclopropylphenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoic acid as white oil (0.03 g, 55%); **post evaporation, 0% to 5% 
MeOH DCM column performed; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.90 (br. s, 1H) 7.63 (d, J = 
2.2 Hz, 1H) 7.39 (d, J = 8.3 Hz, 1H) 7.14 (dd, J = 8.4, 2.3 Hz, 1H) 3.38 (t, J = 7.1 Hz, 2H) 2.59 
(t, J = 7.1 Hz, 2H) 2.22 (p, J = 7.1 Hz, 2H) 1.93 (tt, J = 8.4, 5.0 Hz, 1H) 1.08-0.98 (m, 2H) 0.73 
(dt, 6.8, 4.9 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.92, 164.64, 164.35, 143.59, 
130.93, 129.86, 129.51, 128.16, 122.37, 32.32, 31.62, 24.35, 14.89, 9.56; TOF ES+ MS: (M+H) 
339.1; HPLC Ret: 6.98 min; 97% pure. 
3-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)propanoic acid. (CCG-
259068). Method F starting from tert-butyl 4-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-
2-yl)thio)butanoate (0.04 g, 0.11 mmol) gave 4-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoic acid as white oil (0.01 g, 41%); **post evaporation, 0% to 5% 
MeOH DCM column performed; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.81 (d, J = 8.2, 1H) 7.20 
(d, J = 1.7 Hz, 1H) 7.05 (dd, J = 8.2, 1.8 Hz, 1H) 3.53 (t, J = 6.8 Hz, 2H) 3.03 (t, J = 6.8 Hz, 2H) 
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1.92 (tt, J = 8.4, 5.0 Hz, 1H) 1.14-1.02 (m, 2H) 0.79 (dt, J = 6.9, 4.8 Hz, 2H); 13C NMR (500 
MHz, CDCl3-d) 𝛿 ppm 176.07, 164.42, 164.12, 150.11, 132.83, 130.66, 128.15, 124.29, 119.45, 
33.97, 27.05, 15.41, 10.39; TOF ES+ MS: (M+H) 325.0; HPLC Ret: 6.79 min; 95% pure. 
4-((5-(2-chloro-4-ethoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-262687). 
Method F starting from tert-butyl 4-((5-(2-chloro-4-ethoxyphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.05 g, 0.13 mmol) gave 4-((5-(2-chloro-4-ethoxyphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as white solid (0.03 g, 70%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.18 (br. 
s, 1H) 7.86 (d, 8.8 Hz, 1H) 7.03 (d, J = 2.5 Hz, 1H) 6.89 (dd, J = 8.8, 2.5 Hz, 1H) 4.09 (q, J = 7.0 
Hz, 2H) 3.37 (t, J = 7.1 Hz, 2H) 2.59 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.1 Hz, 2H) 1.44 (t, J = 7.0 
Hz, 3H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.97, 163.97, 161.63, 134.07, 131.92, 116.78, 
114.90, 113.76, 64.19, 32.29, 31.59, 24.35, 14.54; TOF ES+ MS: (M+H) 343.05; HPLC Ret: 6.78 
min; 97% pure. 
4-((5-(2-chloro-4-propoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-262688). 
Method F starting from tert-butyl 4-((5-(2-chloro-4-propoxyphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.05 g, 0.12 mmol) gave 4-((5-(2-chloro-4-propoxyphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as white solid (0.03 g, 70%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.50 (br. 
s, 1H) 7.86 (d, 8.8 Hz, 1H) 7.04 (d, J = 2.5 Hz, 1H) 6.90 (dd, J = 8.8, 2.5 Hz, 1H) 3.97 (t, J = 6.5 
Hz, 2H) 3.37 (t, J = 7.1 Hz, 2H) 2.59 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.2 Hz, 2H) 1.84 (p, J = 7.2 
Hz, 2H) 1.05 (t, J = 7.4 Hz, 3H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 178.06, 164.26, 163.96, 
161.83, 134.05, 131.91, 116.81, 114.83, 113.76, 70.10, 32.31, 31.59, 24.34, 22.33, 10.39; TOF 
ES+ MS: (M+H) 357.07; HPLC Ret: 7.30 min; 99% pure. 
4-((5-(4-butoxy-2-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-262689). 
Method F starting from tert-butyl 4-((5-(4-butoxy-2-chlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.05 g, 0.12 mmol) gave 4-((5-(4-butoxy-2-chlorophenyl)-1,3,4-oxadiazol-2-
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yl)thio)butanoic acid as white solid (0.04 g, 81%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.34 (br. 
s, 1H) 7.85 (d, 8.8 Hz, 1H) 7.03 (d, J = 2.5 Hz, 1H) 6.90 (dd, J = 8.8, 2.5 Hz, 1H) 4.01 (t, J = 6.5 
Hz, 2H) 3.37 (t, J = 7.1 Hz, 2H) 2.59 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.1 Hz, 2H) 1.84-1.74 (m, 
2H) 1.49 (t, J = 7.5 Hz, 2H) 0.99 (t, J = 7.4 Hz, 3H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 
178.02, 164.26, 163.95, 161.84, 134.05, 131.90, 116.80, 114.82, 113.79, 68.34, 32.30, 31.59, 
30.97, 24.34, 19.11, 13.76; TOF ES+ MS: (M+H) 371.08; HPLC Ret: 7.76 min; 99% pure. 
4-((5-(2-chloro-4-(cyclopropylmethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid 
(CCG-262690). Method F starting from tert-butyl 4-((5-(2-chloro-4-(cyclopropylmethoxy)phenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate (0.05 g, 0.12 mmol) gave 4-((5-(2-chloro-4-
(cyclopropylmethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid (0.03 g, 
76%); column: 45% EtOAc: 55% Hex: 0.1% AcOH; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.24 
(br. s, 1H) 7.85 (d, 8.8 Hz, 1H) 7.04 (d, J = 2.4 Hz, 1H) 6.91 (dd, J = 8.9, 2.5 Hz, 1H) 3.86 (t, J = 
7.0 Hz, 2H) 3.37 (t, J = 7.1 Hz, 2H) 2.58 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.1 Hz, 2H) 1.33-1.22 
(m, 1H) 0.73-0.63 (m, 2H) 0.43-0.32 (m, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.98, 
164.23, 164.02, 161.68, 134.07, 131.92, 116.88, 114.88, 113.86, 73.34, 32.31, 31.59, 24.34, 
9.95, 3.28; TOF ES+ MS: (M+H) 369.07; HPLC Ret: 7.14 min; 97% pure. 
4-((5-(2-chloro-4-isopropoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-262691). 
Method F starting from tert-butyl 4-((5-(2-chloro-4-isopropoxyphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.05 g, 0.11 mmol) gave 4-((5-(2-chloro-4-isopropoxyphenyl)-1,3,4-oxadiazol-
2-yl)thio)butanoic acid as white oil (0.03 g, 82%); column: 45% EtOAc: 55% Hex: 0.1% AcOH; 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.77 (br. s, 1H) 7.85 (d, 8.8 Hz, 1H) 7.02 (d, J = 2.5 Hz, 1H) 
6.88 (dd, J = 8.8, 2.5 Hz, 1H) 4.61 (p, J = 6.1 Hz, 1H) 3.37 (t, J = 7.1 Hz, 2H) 2.59 (t, J = 7.1 Hz, 
2H) 2.21 (p, J = 7.1 Hz, 2H) 1.37 (d, J = 6.1 Hz, 6H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 
178.00, 164.27, 163.92, 160.73, 134.08, 131.96, 117.80, 114.63, 114.53, 70.76, 32.31, 31.59, 
24.35, 21.80; TOF ES+ MS: (M+H) 357.07; HPLC Ret: 7.12 min; 99% pure. 
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4-((5-(2-chloro-4-propylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-259001). 
Method F starting from t-butyl 4-((5-(2-chloro-4-propylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.03 g, 0.06 mmol) gave 4-((5-(2-chloro-4-propylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as white oil (0.01 g, 47%); product required 2% MeOH:98% DCM:0.01% 
AcOH silica gel column chromatography followed by semi-prep; 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 7.84 (d, J = 8.0, 1H) 7.35 (s, 1H) 7.20 (dd, J = 8.1, 1.6 Hz, 1H) 3.38 (t, J = 7.2 Hz, 2H) 
2.64-2.57 (m, 4H) 2.22 (p, J = 7.2 Hz, 2H) 1.68 (h, J = 7.4 Hz, 2H) 0.96 (t, J = 7.5 Hz, 3H); 13C 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.82, 164.39, 164.31, 148.13, 132.68, 131.10, 131.06, 
130.72, 127.35, 120.08, 37.52, 32.27, 31.59, 24.35, 23.95, 13.65; TOF ES+ MS: (M+H) 341.1; 
HPLC Ret: 7.43 min; 97% pure. 
4-((5-(4-butyl-2-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-259002). 
Method F starting from t-butyl 4-((5-(4-butyl-2-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate 
(0.05 g, 0.11 mmol) gave 4-((5-(4-butyl-2-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid 
as white solid (0.02 g, 52%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.84 (d, J = 8.0 Hz, 1H) 7.35 
(d, J = 1.6 Hz, 1H) 7.20 (dd, J = 8.0, 1.6 Hz, 1H) 3.38 (t, J = 7.1 Hz, 2H) 2.65 (t, J = 7.3 Hz, 2H) 
2.59 (t, J = 7.1 Hz, 2H) 2.23 (p, J = 7.1 Hz, 2H) 1.63 (p, J = 7.6 Hz, 2H) 1.37 (h, J = 7.4 Hz, 2H) 
0.93 (t, J = 7.5 Hz, 3H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 178.06, 164.41, 164.30, 148.40, 
132.67, 131.09, 131.04, 130.73, 127.30, 120.00, 35.22, 32.92, 32.32, 31.59, 24.34, 22.22, 
13.84; TOF ES+ MS: (M+H) 355.1; HPLC Ret: 7.90 min; 95% pure. 
4-((5-(2-chloro-4-isobutylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-259003). 
Method F starting from t-butyl 4-((5-(2-chloro-4-isobutylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.03 g, 0.06 mmol) gave 4-((5-(2-chloro-4-isobutylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as colorless oil (0.02 g, 79%); product required 2% MeOH:98% 
DCM:0.01% AcOH silica gel column chromatography followed by semi-prep; 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 7.84 (dd, J = 8.1, 1.3 Hz, 1H) 7.32 (d, J = 1.5 Hz, 1H) 7.17 (dd, J = 8.1, 1.3 Hz, 
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1H) 3.38 (t, J = 7.1 Hz, 2H) 2.59 (t, J = 7.1 Hz, 2H) 2.52 (d, J = 7.2 Hz, 2H) 2.22 (p, J = 7.1 Hz, 
2H) 1.91 (hept, J = 6.7 Hz, 1H) 0.93 (d, J = 6.6 Hz, 6H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 
177.74, 164.41, 164.31, 147.21, 132.58, 131.64, 130.59, 127.94, 120.14, 44.87, 32.30, 31.60, 
29.99, 24.38, 22.22; TOF ES+ MS: (M+H) 355.1; HPLC Ret: 7.79 min; 93% pure. 
4-((5-(2-chloro-4-(prop-1-en-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-
259164). Method F starting from t-butyl 4-((5-(2-chloro-4-(prop-1-en-2-yl)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate (0.02 g, 0.06 mmol) gave 4-((5-(2-chloro-4-(prop-1-en-2-
yl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white oil (0.006 g, 34%); product required 
40% EtOAc:60% DCM:0.01% AcOH silica gel column chromatography followed by semi-prep; 
1H NMR (500 MHz, MeOH-d4) 𝛿 ppm 7.92 (d, J = 8.2 Hz, 1H) 7.71 (d, J = 1.7 Hz, 1H) 7.61 (dd, 
J = 8.3, 1.8 Hz, 1H) 5.58 (d, J = 1.3 Hz, 1H) 5.29 (t, J = 1.5 Hz, 1H) 3.38 (t, J = 7.2 Hz, 2H) 2.51 
(t, J = 7.2 Hz, 2H) 2.17 (m, 5H); 13C NMR (500 MHz, MeOH-d4) 𝛿 ppm 174.78, 165.21, 163.91, 
145.82, 141.17, 132.50, 130.52, 127.70, 124.18, 120.87, 114.90, 47.06, 31.81, 31.34, 24.62, 
20.05; TOF ES+ MS: (M+H) 339.1; HPLC Ret: 7.17 min; 96% pure. 
4-((5-(4-isopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-262458). Method F 
starting from t-butyl 4-((5-(2-chloro-4-isopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate (0.03 
g, 0.08 mmol) gave 4-((5-(4-isopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white oil 
(0.008 g, 32%); product required semi-prep (bonus product); 1H NMR (500 MHz, MeOH-d4) 𝛿 
ppm 7.86 (d, J = 8.1 Hz, 1H) 7.49 (d, J = 1.7 Hz, 1H) 7.38 (dd, J = 8.1, 1.7 Hz, 1H) 3.38 (t, J = 
7.2 Hz, 2H) 2.99 (hept, J = 7.0 Hz, 1H) 2.51 (t, J = 7.2 Hz, 2H) 2.14 (p, J = 7.2 Hz, 2H) 1.29 (d, 
J = 6.9 Hz, 6H); 13C NMR (500 MHz, MeOH-d4) 𝛿 ppm 174.11, 165.07, 164.11, 154.83, 132.45, 
130.74, 128.88, 125.45, 119.83, 33.80, 31.86, 31.34, 24.65, 22.39; TOF ES+ MS: (M+H) 341.1; 
HPLC Ret: 7.32 min; 99% pure. 
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4-((5-(2-chloro-4-isopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-259165). 
Method F starting from t-butyl 4-((5-(2-chloro-4-isopropylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.03 g, 0.08 mmol) gave 4-((5-(2-chloro-4-isopropylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as white oil (0.009 g, 36%); product required semi-prep; 1H NMR (500 
MHz, MeOH-d4) 𝛿 ppm 7.91 (d, J = 8.3 Hz, 2H) 7.42 (d, J = 8.3 Hz, 2H) 3.36 (t, J = 7.2 Hz, 2H) 
2.98 (hept, J = 6.9 Hz, 1H) 2.51 (t, J = 7.2 Hz, 2H) 2.13 (q, J = 7.2 Hz, 2H) 1.28 (d, J = 6.9 Hz, 
6H); 13C NMR (500 MHz, MeOH-d4) 𝛿 ppm 174.79, 165.97, 164.35, 153.44, 127.04, 126.41, 
120.69, 34.07, 31.79, 31.30, 24.60, 22.64; TOF ES+ MS: (M+H) 307.1; HPLC Ret: 7.05 min; 
99% pure. 
4-((5-(2-chloro-4-ethylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-259166). 
Method F starting from t-butyl 4-((2-chloro-4-ethylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate 
(0.07 g, 0.18 mmol) gave 4-((5-(2-chloro-4-ethylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid 
as white solid (0.05 g, 83%); product required 50% EtOAc 50% Hex 0.01% AcOH silica gel 
column chromatography; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.52 (br. s, 1H) 7.85 (d, J = 8.0, 
1H) 7.37 (d, J = 1.6 Hz, 1H) 7.22 (dd, J = 8.1, 1.6 Hz, 1H) 3.38 (t, J = 7.1 Hz, 2H) 2.70 (q, J = 
7.6 Hz, 2H) 2.59 (t, J = 7.1 Hz, 2H) 2.23 (p, J = 7.2 Hz, 2H) 1.27 (t, J = 7.6 Hz, 3H); 13C NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 178.04, 164.39, 164.29, 149.58, 132.76, 130.81, 130.54, 126.78, 
120.06, 32.32, 31.60, 28.51, 24.34, 14.87,; TOF ES+ MS: (M+Na) 349.0; HPLC Ret: 6.96 min; 
98% pure. 
4-((5-(2-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-262525). 
Method F starting from t-butyl 4-((2-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate 
(0.13 g, 0.34 mmol) gave 4-((5-(2-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid 
as colorless oil (0.1 g, 93%); product required 55% EtOAc 45% Hex 0.01% AcOH silica gel 
column chromatography; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.45 (br. s, 1H) 8.07-8.00 (m, 
1H) 7.85 (dd, J = 7.1, 2.0 Hz, 1H) 7.75-7.65 (m, 2H) 3.37 (t, J = 7.2 Hz, 2H) 2.59 (t, J = 7.1 Hz, 
273 
 
2H) 2.21 (p, J = 7.1 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 178.29, 165.45, 164.05, 
132.18, 131.65, 128.78, 127.06, 126.98, 124.19, 122.01, 32.28, 31.55, 24.34; TOF ES+ MS: 
(M+H) 333.1; HPLC Ret: 6.31 min; 97% pure. 
4-((5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-262526). Method F 
starting from t-butyl 4-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate (0.15 g, 0.44 mmol) 
gave 4-((5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid (0.11 g, 89%); 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.76 (br. s, 1H) 8.07-8.00 (td, J = 7.5, 1.7 Hz, 1H) 7.53 
(dd, J = 7.6, 1.7 Hz, 1H) 7.31-7.20 (m, 2H) 3.39 (t, J = 7.1 Hz, 2H) 2.59 (t, J = 7.1 Hz, 2H) 2.21 
(p, J = 7.1 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 178.02, 164.64, 162.49, 158.77, 
133.48, 129.47, 124.64, 116.64, 111.93, 32.32, 31.59, 24.30; TOF ES+ MS: (M+H) 283.1; 
HPLC Ret: 5.75 min; 97% pure. 
4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-232120). Method G 
starting from methyl 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate (0.19 g, 0.54 
mmol) gave 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid 
(0.06 g, 35%); 1H NMR (401 MHz, DMSO-d6) 𝛿 ppm 12.21 (br. s., 1H) 8.00 (d, J = 8.6 Hz, 1H) 
7.93 (d, J = 2.1 Hz, 1H) 7.66 (dd, J = 8.6, 2.1 Hz, 1H) 3.34 (t, J = 7.3 Hz, 2H) 2.40 (t, J = 7.3 Hz, 
2H) 2.11-1.95 (m, 2H); 13C NMR (401 MHz, DMSO-d6) 𝛿 ppm 174.15, 164.95, 162.95, 137.54, 
133.14, 132.75, 131.19, 128.64, 121.70, 32.62, 31.96, 24.96; TOF ES+ MS: (M+H) 332.9; 
HPLC Ret: 6.82 min; 98% pure. 
4-((5-(2-chloro-4-methylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-232922). 
Method G starting from methyl 4-((5-(2-chloro-4-methylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.15 g, 0.46 mmol) gave 4-((5-(2-chloro-4-methylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as white solid (0.1 g, 69%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.67 (br. 
s., 1H) 7.82 (d, J = 8.0 Hz, 1H) 7.35 (s, 1H) 7.19 (d, J = 7.9 Hz, 1H) 3.38 (t, J = 7.1 Hz, 2H) 2.59 
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(t, J = 7.1 Hz, 2H) 2.40 (s, 3H) 2.21 (q, J = 7.1 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 
178.02, 164.39, 164.28, 143.42, 132.64, 131.68, 130.67, 127.96, 119.89, 32.31, 31.60, 24.34, 
21.24; TOF ES+ MS: (M+H) 313.4; HPLC Ret: 6.53 min; 99% pure. 
4-((5-(p-tolyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-232924). Method G starting from 
methyl 4-((5-(p-tolyl)-1,3,4-oxadiazol-2-yl)thio)butanoate (0.13 g, 0.43 mmol) gave 4-((5-(p-
tolyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid (0.1 g, 97%); 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 7.89 (dd, J = 8.2, 1.5 Hz, 2H) 7.29 (dd, J = 7.8, 1.5 Hz, 2H) 3.38 (t, J = 7.2 Hz, 
2H) 2.59 (t, J = 7.2 Hz, 2H) 2.42 (s, 3H) 2.21 (p, J = 7.1 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 
𝛿 ppm 177.89, 166.00, 163.65, 142.29, 129.74, 126.65, 120.69, 32.30, 31.57, 24.30, 21.63,; 
TOF ES+ MS: (M+H) 279.4; HPLC Ret: 6.23 min; 99% pure. 
4-((5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-232943). Method G 
starting from methyl 4-((5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate (0.29 g, 0.93 
mmol) gave 4-((5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid (0.18 g, 
63%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.67 (br. s., 1H) 7.94 (d, J = 10 Hz, 2H) 7.48 (d, J = 
10 Hz, 2H) 3.39 (t, J = 7.2 Hz, 2H) 2.59 (t, J = 7.2 Hz, 2H) 2.22 (p, J = 7.1 Hz, 2H); 13C NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 178.05, 165.01, 164.32, 137.98, 129.45, 127.94, 121.95, 32.27, 
31.58, 24.24; TOF ES+ MS: (M+H) 299.0; HPLC Ret: 6.46 min; 99% pure. 
6-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)hexanoic acid (CCG-232923). Method G 
starting from ethyl 6-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)hexanoate (0.15 g, 0.39 
mmol) gave 6-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)hexanoic acid as white solid 
(0.08 g, 55%); reaction needed 6 hours to complete; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.73 
(br. s., 1H) 7.91(d, J = 8.5 Hz, 1H) 7.57 (d, J = 2.1 Hz, 1H) 7.39 (dd, J = 8.5, 2.1 Hz, 1H) 3.31 (t, 
J = 7.3 Hz, 2H) 2.39 (t, J = 7.3 Hz, 2H) 1.90 (p, J = 7.5 Hz, 2H) 1.70 (q, J = 7.6 Hz, 2H) 1.59-
1.49 (m, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 179.55, 165.47, 163.23, 137.97, 133.70, 
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131.57, 131.15, 127.59, 121.45, 33.84, 32.49, 29.08, 28.41, 28.20, 24.42; TOF ES+ MS: (M+H) 
376.0; HPLC Ret: 7.71 min; 98% pure. 
7-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)heptanoic acid (CCG-232962). Method 
G starting from methyl 7-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)heptanoate (0.27 g, 
0.69 mmol) gave 7-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)heptanoic acid as white 
solid (0.17 g, 65%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.91 (d, J = 8.5, 1H) 7.58-7.54 (m, 1H) 
7.39 (dd, J = 8.5, 1.4 Hz, 1H) 3.30 (t, J = 7.3 Hz, 2H) 2.37 (t, J = 7.4 Hz, 2H) 1.87 (p, J = 7.4 Hz, 
2H) 1.67 (q, J = 7.6 Hz, 2H) 1.50 (p, J = 7.4 Hz, 2H) 1.42 (q, J = 8.0 Hz, 2H); 13C NMR (500 
MHz, CDCl3-d) 𝛿 ppm 179.55, 165.47, 163.23, 137.97, 133.70, 131.57, 131.15, 127.59, 121.45, 
33.84, 32.49, 29.08, 28.41, 28.20, 24.42; TOF ES+ MS: (M+Na) 411.0; HPLC Ret: 8.85 min; 
99% pure. 
8-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)octanoic acid (CCG-232963). Method G 
starting from ethyl 8-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)octanoate (0.33 g, 0.79 
mmol) gave 8-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)octanoic acid as white solid 
(0.19 g, 63%); reaction needed 24 hours to complete; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.91 
(d, J = 8.5, 1H) 7.56 (s, 1H) 7.39 (dd, J = 8.5, 2.0 Hz, 1H) 3.30 (t, J = 7.4 Hz, 2H) 2.36 (t, J = 7.4 
Hz, 2H) 1.86 (p, J= 7.4 Hz, 2H) 1.65 (p, J= 7.5 Hz, 2H) 1.49 (q, J= 7.5 Hz, 2H) 1.43-1.34 (m, 
4H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 179.49, 165.53, 163.22, 137.96, 133.70, 131.56, 
131.15, 127.58, 121.48, 33.89, 32.56, 29.20, 28.80, 28.62, 28.35, 24.52; TOF ES+ MS: (M+H) 
389.0; HPLC Ret: 7.98 min; 99% pure. 
4-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-
232964). Method G starting from methyl 4-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.07 g, 0.21 mmol) gave 4-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-
2-yl)thio)butanoic acid as white oil (0.07 g, 92%); column: 5% MeOH: 95% DCM: 0.01% AcOH; 
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1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.11 (br. s., 1H) 7.81 (d, J = 8.2 Hz, 1H) 7.19 (s, 1H) 7.05 
(dd, J = 8.2, 1.7 Hz, 1H) 2.58 (t, J = 7.1 Hz, 2H) 2.37 (t, J = 7.2 Hz, 2H) 2.20 (p, J = 7.2 Hz, 2H) 
1.96-1.91 (tt, J = 8.4, 5.0 Hz, 1H) 1.08 (dt, J = 6.9, 4.9 Hz, 2H) 0.78 (dt, J = 6.9, 4.9 Hz, 2H); 13C 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.84, 164.36, 164.26, 150.10, 132.77, 130.66, 128.12, 
124.27, 119.43, 32.36, 31.61, 24.37, 15.40, 10.41; TOF ES+ MS: (M+H) 339.0; HPLC Ret: 6.93 
min; 97% pure. 
4-((5-(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-
257390). Method G starting from methyl 4-((5-(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate (0.16 g, 0.42 mmol) gave 4-((5-(2-chloro-4-
(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid (0.12 g, 81%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.12 (d, J = 8.2 Hz, 1H) 7.82 (d, J = 1.6 Hz, 1H) 7.66 (dd, J = 
8.3, 1.8 Hz, 1H) 3.41 (t, J = 7.2 Hz, 2H) 2.60 (t, J = 7.1 Hz, 2H) 2.24 (p, J = 7.1 Hz, 2H);  19F 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 63.24; 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.45, 165.54, 
163.05, 133.60, 131.35, 128.38, 125.99, 123.94, 123.91, 32.16, 31.62, 24.28; TOF ES+ MS: 
(M+H) 367.0; HPLC Ret: 6.99 min; 97% pure. 
4-((5-(3-chloro-[1, 1’-biphenyl]-4-yl)-1, 3, 4-oxadiazol-2-yl)thio)butanoic acid (CCG-
257423). Method G starting from methyl 4-((5-(3-chloro-[1, 1’-biphenyl]-4-yl)-1, 3, 4-oxadiazol-2-
yl)thio)butanoate (0.36 g, 3.9 mmol) gave 4-((5-(3-chloro-[1, 1’-biphenyl]-4-yl)-1, 3, 4-oxadiazol-
2-yl)thio)butanoic acid as white solid (0.28 g, 82%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.03 (d, 
J = 8.1 Hz, 1H) 7.77 (d, J = 1.8 Hz, 1H) 7.63-7.60 (m, 3H) 7.52-7.39 (m, 3H) 3.40 (t, J = 7.2 Hz, 
2H) 2.60 (t, J = 7.1 Hz, 2H) 2.24 (p, J = 7.1 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 
177.29, 164.63, 164.11, 145.45, 138.32, 133.28, 131.16, 129.64, 129.10, 128.75, 127.11, 




4-((5-(2-chloro-4,5-dimethylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-258042). 
Method G starting from methyl 4-((5-(2-chloro-4,5-dimethylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.11 g, 0.33 mmol) gave 4-((5-(2-chloro-4,5-dimethylphenyl)-1,3,4-oxadiazol-
2-yl)thio)butanoic acid as white solid (0.08 g, 71%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.83 
(br. s., 1H) 7.71 (s, 1H) 7.29 (s, 1H) 3.38 (t, J = 7.1 Hz, 2H) 3.32 (s, 3H) 2.59 (t, J = 7.1 Hz, 2H) 
2.28 (s, 3H) 2.22 (p, J = 7.2 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.93, 164.41, 
164.24, 142.14, 135.96, 131.93, 131.52, 129.74, 119.82, 32.27, 31.60, 24.34, 19.69,19.05; 
QTOF ES- MS: (M-H) 325.0; HPLC Ret: 5.93 min; 95% pure. 
4-((5-(2-chloro-3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-258044). 
Method G starting from methyl 4-((5-(2-chloro-3,4-dimethylphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.15 g, 0.45 mmol) gave 4-((5-(2-chloro-3,4-dimethylphenyl)-1,3,4-oxadiazol-
2-yl)thio)butanoic acid as white solid (0.11 g, 73%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.91 
(br. s., 1H) 7.60 (d, J = 7.9 Hz, 1H) 7.17 (d, J = 7.9 Hz, 1H) 3.37 (t, J = 7.2 Hz, 2H) 3.42 (s, 3H) 
2.59 (t, J = 7.1 Hz, 2H) 2.38 (s, 3H) 2.23 (p, J = 7.1 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 
ppm 178.00, 164.88, 164.32, 142.18, 136.63, 133.13, 128.30, 128.13, 121.05, 32.30, 31.58, 
24.34, 21.36, 16.72; QTOF ES+ MS: (M-H) 325.0; HPLC Ret: 5.89 min; 99% pure. 
4-((5-(2-chloro-4-cyclopropoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-
262762). Method G starting from methyl 4-((5-(2-chloro-4-cyclopropoxyphenyl)-1,3,4-oxadiazol-
2-yl)thio)butanoate (0.1 g, 0.27 mmol) gave 4-((5-(2-chloro-4-cyclopropoxyphenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoic acid as white solid (0.07 g, 75%); 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 11.07 (br. s, 1H) 7.86 (d, J = 8.8 Hz, 1H) 7.22 (d, J = 2.4 Hz, 1H) 7.04 (dd, J = 8.8, 2.5 Hz, 
1H) 3.80 (tt, J = 6.2, 3.0 Hz, 1H) 3.37 (t, J = 7.1 Hz, 2H) 2.59 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.1 
Hz, 2H) 0.92-0.77 (m, 4H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.72, 164.22, 164.01, 
133.99, 131.86, 131.78, 117.37, 115.47, 114.41, 51.62, 32.22, 31.60, 24.35, 6.28; TOF ES+ 
MS: (M+H) 369.07; HPLC Ret: 6.90 min; 98% pure. 
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4-((5-(2-chloro-4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. CCG-262827. 
Method G starting from methyl 4-((5-(2-chloro-4-methoxyphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.1 g, 0.29 mmol) gave 4-((5-(2-chloro-4-methoxyphenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as white solid (0.09 g, 94%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.78 (br. 
s, 1H) 7.87 (d, J = 8.8 Hz, 1H) 7.04 (d, J = 2.5 Hz, 1H) 6.91 (dd, J = 8.8, 2.5 Hz, 1H) 3.87 (s, 
3H) 3.37 (t, J = 7.2 Hz, 2H) 2.59 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.1 Hz, 2H); 13C NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 178.05, 164.18, 164.03, 162.21, 134.12, 131.96, 116.34, 115.12, 113.38, 
55.76, 32.32, 31.60, 24.34; TOF ES+ MS: (M+H) 329.0; HPLC Ret: 6.27 min; 99% pure. 
4-((5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-263094). 
Method G starting from methyl 4-((5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.09 g, 0.27 mmol) gave 4-((5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as white solid (0.06 g, 68%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.41 (br. 
s., 1H) 8.14 (d, J = 8.2 Hz, 2H) 7.77 (d, J = 8.2 Hz, 2H) 3.41 (t, J = 7.2 Hz, 2H) 2.60 (t, J = 7.1 
Hz, 2H) 2.22 (p, J = 7.1 Hz, 2H); 19F NMR (500 MHz, CDCl3-d) 𝛿 ppm -63.16 (s, 3H); 13C NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 177.97, 165.00, 164.64, 133.41, 126.97, 126.13, 124.59, 121.90, 
32.22, 31.57, 24.22; TOF ES+ MS: (M+H) 333.04; HPLC Ret: 6.76 min; 99% pure. 
4-((5-(2-chloro-4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid 
(CCG-263095). Method G starting from methyl 4-((5-(2-chloro-4-(2,2,2-trifluoroethoxy)phenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate (0.08 g, 0.19 mmol) gave 4-((5-(2-chloro-4-(2,2,2-
trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid (0.06 g, 77%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.85 (br. s., 1H) 7.93 (d, J = 8.8 Hz, 1H) 7.12 (d, J = 2.5 Hz, 
1H) 6.98 (dd, J = 8.9, 2.6 Hz, 1H) 4.42 (q, J = 7.9 Hz, 2H) 3.38 (t, J = 7.1 Hz, 2H) 2.59 (t, J = 7.1 
Hz, 2H) 2.22 (p, J = 7.1 Hz, 2H); 19F NMR (500 MHz, CDCl3-d) 𝛿 ppm -73.76 (t, 3H); 13C NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 177.80, 164.41, 163.71, 159.47, 134.41, 132.23, 123.89, 117.40, 
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117.14, 113.78, 65.58, 32.22, 31.59, 24.30; TOF ES+ MS: (M+H) 397.01; HPLC Ret: 6.88 min; 
97% pure. 
4-((5-(2-chloro-4-(oxetan-3-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-
263096). Method G starting from methyl 4-((5-(2-chloro-4-(oxetan-3-yloxy)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate (0.07 g, 0.18 mmol) gave 4-((5-(2-chloro-4-(oxetan-3-
yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid (0.05 g, 79%); 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.88 (d, 8.8 Hz, 1H) 6.85 (d, J = 2.5 Hz, 1H) 6.73 (dd, J = 8.8, 2.5 Hz, 1H) 
5.27 (p, 6.0 Hz, 1H) 5.02 (t, J = 7.1 Hz, 2H) 4.78 (dd, J = 7.3, 5.1 Hz, 2H) 3.37 (t, J = 7.1 Hz, 
2H) 2.58 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.1 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 
177.64, 164.26, 163.89, 159.11, 134.38, 132.27, 117.00, 116.16, 113.67, 77.44, 70.69, 32.25, 
31.60, 24.33; TOF ES+ MS: (M+H) 371.03; HPLC Ret: 5.85 min; 98% pure. 
4-((5-(2-chloro-4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-
263097). Method G starting from methyl 4-((5-(2-chloro-4-(trifluoromethoxy)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate (0.03 g, 0.08 mmol) gave 4-((5-(2-chloro-4-
(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid (0.01 g, 33%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.02 (d, J = 8.8 Hz, 1H) 7.42 (d, J = 2.3 Hz, 1H) 7.27 (dd, J = 
8.8, 2.3 Hz, 1H) 3.39 (t, J = 7.1 Hz, 2H) 2.60 (t, J = 7.1 Hz, 2H) 2.24 (p, J = 7.1 Hz, 2H); 19F 
NMR (500 MHz, CDCl3-d) 𝛿 ppm -57.88 (s, 3H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.82, 
165.06, 163.15, 151.14, 134.28, 132.15, 123.89, 123.27, 121.36, 119.17, 32.21, 31.60, 24.27; 
TOF ES+ MS: (M+H) 382.99; HPLC Ret: 7.14 min; 98% pure. 
4-((5-(2-chloro-4-(oxetan-3-ylmethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid 
(CCG-263098). Method G starting from methyl 4-((5-(2-chloro-4-(oxetan-3-ylmethoxy)phenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate (0.07 g, 0.19 mmol) gave 4-((5-(2-chloro-4-(oxetan-3-
ylmethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid (0.06 g, 81%); 1H NMR 
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(500 MHz, CDCl3-d) 𝛿 ppm 7.89 (d, 8.8 Hz, 1H) 7.08 (d, J = 2.5 Hz, 1H) 6.94 (dd, J = 8.8, 2.5 
Hz, 1H) 4.91 (p, 6.0 Hz, 1H) 4.59 (t, J = 6.1 Hz, 2H) 4.26 (d, J = 6.6 Hz, 2H) 3.47 (hept., J = 6.6 
Hz, 1H) 3.37 (t, J = 7.1 Hz, 2H) 2.58 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.1 Hz, 2H); 13C NMR (500 
MHz, CDCl3-d) 𝛿 ppm 177.35, 164.11, 164.07, 161.27, 134.18, 132.02, 116.88, 115.56, 113.70, 
73.99, 69.44, 34.28, 32.23, 31.62, 24.37; TOF ES+ MS: (M+H) 385.05; HPLC Ret: 5.83 min; 
94% pure. 
4-((5-(2-chloro-4-((3-methyloxetan-3-yl)methoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic 
acid (CCG-263099). Method G starting from methyl 4-((5-(2-chloro-4-((3-methyloxetan-3-
yl)methoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoate (0.08 g, 0.2 mmol) gave 4-((5-(2-chloro-
4-((3-methyloxetan-3-yl)methoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid 
(0.06 g, 74%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.89 (d, 8.8 Hz, 1H) 7.10 (d, J = 2.5 Hz, 1H) 
6.96 (dd, J = 8.8, 2.5 Hz, 1H) 4.63 (d, J = 6.1 Hz, 2H) 4.50 (d, J = 6.0 Hz, 2H) 4.10 (s, 2H) 3.38 
(t, J = 7.1 Hz, 2H) 2.59 (t, J = 7.1 Hz, 2H) 2.21 (p, J = 7.1 Hz, 2H) 1.46 (s, 3H); 13C NMR (500 
MHz, CDCl3-d) 𝛿 ppm 177.32, 164.09, 161.50, 134.17, 132.01, 116.94, 115.54, 113.72, 79.54, 
73.17, 39.54, 32.22, 31.61, 24.36, 21.12; TOF ES+ MS: (M+H) 399.06; HPLC Ret: 6.24 min; 
98% pure. 
4-((5-(4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-
263100). Method G starting from methyl 4-((5-(4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazol-
2-yl)thio)butanoate (0.08 g, 0.22 mmol) gave 4-((5-(4-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoic acid as white solid (0.07 g, 87%); 1H NMR (500 MHz, DMSO-d6) 𝛿 
ppm 12.20 (br. s., 1H) 7.96 (d, J = 8.0 Hz, 2H) 7.27 (d, J = 8.0 Hz, 2H) 4.90 (q, J = 7.9 Hz, 2H) 
3.32 (t, J = 7.2 Hz, 2H) 2.40 (t, J = 7.3 Hz, 2H) 2.00 (p, J = 7.2 Hz, 2H); 19F NMR (500 MHz, 
DMSO-d6) 𝛿 ppm -72.55 (t, 3H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 174.15, 165.20, 135.31, 
130.88, 128.77, 117.45, 116.15, 113.69, 64.91, 32.61, 31.95, 24.99; TOF ES+ MS: (M+H) 
363.06; HPLC Ret: 6.59 min; 99% pure. 
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4-((5-(4-(difluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-263101). 
Method G starting from methyl 4-((5-(4-(difluoromethyl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.09 g, 0.27 mmol) gave 4-((5-(4-(difluoromethyl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as white solid (0.07 g, 77%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 11.13 (br. 
s., 1H) 8.10 (d, J = 8.0 Hz, 2H) 7.65 (d, J = 8.0 Hz, 2H) 6.70 (t, J = 56.1 Hz, 1H) 3.40 (t, J = 7.1 
Hz, 2H) 2.60 (t, J = 7.1 Hz, 2H) 2.23 (p, J = 7.1 Hz, 2H); 19F NMR (500 MHz, CDCl3-d) 𝛿 ppm -
112.20 (d, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 178.10, 164.99, 164.69, 137.31, 126.97, 
126.35, 125.64, 113.86, 111.95, 32.27, 31.57, 24.23; TOF ES+ MS: (M+H) 315.06; HPLC Ret: 
6.20 min; 99% pure. 
4-((5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-263103). 
Method G starting from methyl 4-((5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.09 g, 0.27 mmol) gave 4-((5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as white solid (0.05 g, 58%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.88 (br. 
s., 1H) 8.06 (d, J = 8.6 Hz, 2H) 7.34 (d, J = 8.4 Hz, 2H) 3.39 (t, J = 7.2 Hz, 2H) 2.60 (t, J = 7.1 
Hz, 2H) 2.22 (p, J = 7.1 Hz, 2H); 19F NMR (500 MHz, CDCl3-d) 𝛿 ppm -57.72 (s, 3H); 13C NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 178.08, 164.72, 164.47, 151.51, 128.47, 122.01, 121.23, 119.25, 
32.26, 31.57, 24.23; TOF ES+ MS: (M+H) 349.05; HPLC Ret: 6.86 min; 98% pure. 
4-((5-(2-chloro-3-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-
263104). Method G starting from methyl 4-((5-(2-chloro-3-(trifluoromethyl)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoate (0.09 g, 0.23 mmol) gave 4-((5-(2-chloro-3-
(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as white solid (0.05 g, 60%); 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.88 (br. s., 1H) 8.10 (dd, J = 7.9, 1.6 Hz, 1H) 7.89 (dd, J = 
7.9, 1.6 Hz, 1H) 7.54 (t, J = 7.9 Hz, 1H) 3.41 (t, J = 7.2 Hz, 2H) 2.60 (t, J = 7.1 Hz, 2H) 2.24 (p, J 
= 7.2 Hz, 2H); 19F NMR (500 MHz, CDCl3-d) 𝛿 ppm -62.59 (s, 3H); 13C NMR (500 MHz, CDCl3-
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d) 𝛿 ppm 178.11, 165.46, 163.33, 134.44, 130.31, 130.27, 127.03, 125.65, 123.52, 121.34, 
32.26, 31.61, 24.24; TOF ES+ MS: (M+H) 367.01; HPLC Ret: 6.81 min; 98% pure. 
4-((5-(2-chloro-4-(2-fluoropropan-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid 
(CCG-263105). Method G starting from methyl 4-((5-(2-chloro-4-(2-fluoropropan-2-yl)phenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate (0.09 g, 0.24 mmol) gave 4-((5-(2-chloro-4-(2-fluoropropan-
2-yl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as colorless oil (0.06 g, 76%); column: 30% 
EtOAc: 70% Hex to 60% EtOAc: 40% Hex: 0.1% AcOH; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
9.58 (br. s, 1H) 7.94 (d, J = 8.2 Hz, 1H) 7.56 (d, J = 1.7 Hz, 1H) 7.38 (dd, J = 8.3, 1.7 Hz, 1H) 
3.39 (t, J = 7.1 Hz, 2H) 2.60 (t, J = 7.1 Hz, 2H) 2.23 (p, J = 7.1 Hz, 2H) 1.72 (s, 3H) 1.68 (s, 3H); 
19F NMR (500 MHz, CDCl3-d) 𝛿 ppm -139.23 (hept, 1H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 
178.08, 164.73, 163.90, 150.88, 133.03, 130.94, 126.80, 122.72, 121.58, 32.30, 31.60, 29.05, 
28.85, 24.31; TOF ES+ MS: (M+H) 359.06; HPLC Ret: 6.95 min; 98% pure. 
4-((5-(4-(2-fluoropropan-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-
263106). Method G starting from methyl 4-((5-(4-(2-fluoropropan-2-yl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.04 g, 0.10 mmol) gave 4-((5-(4-(2-fluoropropan-2-yl)phenyl)-1,3,4-
oxadiazol-2-yl)thio)butanoic acid as white solid (0.01 g, 33%); 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 7.99 (d, J = 8.4 Hz, 2H) 7.51 (d, J = 8.4 Hz, 2H) 3.39 (t, J = 7.1 Hz, 2H) 2.60 (t, J = 7.1 Hz, 
2H) 2.22 (p, J = 7.1 Hz, 2H) 1.73 (s, 3H) 1.69 (s, 3H); 19F NMR (500 MHz, CDCl3-d) 𝛿 ppm -
138.73 (hept, 1H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.78, 165.57, 164.03, 149.70, 
126.72, 124.48, 122.44, 32.24, 31.57, 29.20, 29.00, 24.28; TOF ES+ MS: (M+H) 325.10; HPLC 
Ret: 6.64 min; 94% pure. 
4-((5-(4-(difluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (CCG-263107). 
Method G starting from methyl 4-((5-(4-(difluoromethoxy)phenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.08 g, 0.22 mmol) gave 4-((5-(4-(difluoromethoxy)phenyl)-1,3,4-oxadiazol-2-
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yl)thio)butanoic acid as white solid (0.06 g, 75%); 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.81 (br. 
s., 1H) 8.02 (d, J = 8.5 Hz, 2H) 7.24 (d, J = 8.5 Hz, 2H) 6.60 (t, J = 73.0 Hz, 1H) 3.39 (t, J = 7.2 
Hz, 2H) 2.59 (t, J = 7.1 Hz, 2H) 2.22 (p, J = 7.1 Hz, 2H); 19F NMR (500 MHz, CDCl3-d) 𝛿 ppm -
81.70 (d, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 178.00, 164.97, 164.18, 153.54, 128.53, 
120.55, 119.70, 117.43, 115.35, 111.26, 32.26, 31.57, 24.25; TOF ES+ MS: (M+H) 331.06; 
HPLC Ret: 6.28 min; 99% pure. 
4-((5-(2-chloro-3-(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. 
CCG-263235. Method G starting from methyl 4-((5-(2-chloro-3-(2,2,2-trifluoroethoxy)phenyl)-
1,3,4-oxadiazol-2-yl)thio)butanoate (0.01 g, 0.03 mmol) gave 4-((5-(2-chloro-3-(2,2,2-
trifluoroethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid as colorless oil (0.01 g, 89%); 
column: 55% EtOAc: 45% Hex to 60% EtOAc: 40% Hex: 0.1% AcOH; 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 7.67 (d, 7.9 Hz, 1H) 7.38 (t, J = 8.1 Hz, 1H) 7.16 (d, J = 8.2 Hz, 1H) 4.47 (q, J = 
8.0 Hz, 2H) 3.39 (t, J = 7.2 Hz, 2H) 2.59 (t, J = 7.2 Hz, 2H) 2.22 (p, J = 7.2 Hz, 2H); 13C NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 177.76, 165.01, 163.76, 154.32, 127.78, 125.13, 124.84, 121.84, 
118.05, 67.37 32.27, 31.60, 29.70, 24.33; 19F NMR (500 MHz, CDCl3-d) 𝛿 ppm -73.84 (t, 3H); 
TOF ES+ MS: (M+H) 397.02; HPLC Ret: 6.56 min; 95% pure. 
4-((5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. CCG-263236. 
Method G starting from methyl 4-((5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoate (0.01 g, 0.04 mmol) gave 4-((5-(2-chloro-4-fluorophenyl)-1,3,4-oxadiazol-2-
yl)thio)butanoic acid as white solid (0.015 g, 100%); column: 45% EtOAc: 55% Hex. White solid. 
Yield = 100%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.96 (dd, J = 8.8, 5.9 Hz, 1H) 7.30 (dd, J = 
8.4, 2.5 Hz, 1H) 7.13 (ddd, J = 8.7, 7.5, 2.6 Hz, 1H) 3.39 (t, J = 7.2 Hz, 2H) 2.59 (t, J = 7.2 Hz, 
2H) 2.23 (p, J = 7.2 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.89, 164.93, 163.42, 
162.89, 134.53, 132.59, 119.35, 118.87, 114.96, 32.25, 31.59, 24.29; 19F NMR (500 MHz, 




262707). Method G starting from methyl 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)-
2,2-dimethylbutanoate (0.05 g, 0.13 mmol) gave 4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)-2,2-dimethylbutanoic acid as white oil (0.02 g, 42%); column: 20% EtOAc: 80% Hex: 
0.01% AcOH; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.81 (br. s, 1H) 7.90 (d, J = 8.5 Hz, 1H) 7.56 
(d, J = 2.1 Hz, 1H) 7.39 (dd, J = 8.5, 2.1 Hz, 1H) 3.35-3.27 (m, 2H) 2.17-2.09 (m, 2H) 1.31 (s, 
6H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 183.13, 165.07, 163.31, 138.02, 133.73, 131.53, 
131.17, 127.60, 121.37, 42.23, 39.68, 28.22, 24.90; TOF ES+ MS: (M+H) 361.02; HPLC Ret: 
7.64 min; 95% pure. 
trans-3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)cyclobutanecarboxylic acid 
(CCG-262587). Method G starting from methyl trans-3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-
2-yl)thio)cyclobutanoate (0.03 g, 0.09 mmol) gave trans-3-((5-(2,4-dichlorophenyl)-1,3,4-
oxadiazol-2-yl)thio)cyclobutanecarboxylic acid as white solid (0.02 g, 57%); column: 40% 
EtOAc: 60% Hex: 0.01% AcOH; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.41 (br. s, 1H) 7.91 (d, J = 
8.5 Hz, 1H) 7.57 (d, J = 2.0 Hz, 1H) 7.39 (dd, J = 8.5, 2.0 Hz, 1H) 4.48 (p, J = 7.5 Hz, 1H) 3.44 
(tt, J = 9.9, 5.5 Hz, 1H) 2.99 (ddd, J = 13.9, 8.3, 5.8 Hz, 2H) 2.61 (dtd, J = 13.3, 6.6, 2.2 Hz, 2H); 
13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 179.91, 164.00, 163.37, 138.15, 133.76, 131.61, 131.20, 
127.63, 121.31, 37.48, 35.22, 32.70, 29.68; **NOSEY attached; TOF ES+ MS: (M+H) 344.99; 
HPLC Ret: 7.03 min; 95% pure. *NOSEY does not show trans protons. 
cis-3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)cyclobutanecarboxylic acid (CCG-
262588). Method G starting from methyl cis-3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)cyclobutanoate (0.09 g, 0.25 mmol) gave cis-3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-
2-yl)thio)cyclobutanecarboxylic acid as white solid (0.05 g, 61%); 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 10.08 (br. s, 1H) 7.90 (d, J = 8.4 Hz, 1H) 7.56 (d, J = 2.1 Hz, 1H) 7.39 (dd, J = 8.3, 2.1 Hz, 
1H) 4.32 (p, J = 8.6 Hz, 1H) 3.23 (p, J = 8.9 Hz, 1H) 2.94 (dtt, J = 10.8, 8.1, 4.6 Hz, 2H) 2.60 
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(qd, J = 9.5, 2.7 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 178.94, 164.09, 163.37, 138.13, 
133.75, 131.60, 131.18, 127.62, 121.30, 35.35, 34.62, 33.56; **NOSEY attached; TOF ES+ MS: 
(M+H) 344.99; HPLC Ret: 6.90 min; 95% pure. *NOSEY shows cis protons. 
cis-3-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)cyclobutanecarboxylic 
acid (CCG-263087). Method G starting from methyl cis-3-((5-(2-chloro-4-cyclopropylphenyl)-
1,3,4-oxadiazol-2-yl)thio)cyclobutanoate (0.08 g, 0.23 mmol) gave cis-3-((5-(2-chloro-4-
cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)cyclobutanecarboxylic acid as white solid (0.05 g, 
64%); column: 30% EtOAc: 70% Hex to 35% EtOAc: 65% Hex: 0.1% AcOH followed by 
trituration with EtOAc/Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.96 (br. s, 1H) 7.81 (d, J = 8.2 
Hz, 1H) 7.20 (d, J = 1.7 Hz, 1H) 7.05 (dd, J = 8.2, 1.7 Hz, 1H) 4.30 (p, J = 8.7 Hz, 1H) 3.22 (p, J 
= 8.9 Hz, 1H) 2.99-2.88 (m, 2H) 2.59 (qd, J = 9.5, 2.8 Hz, 2H) 1.92 (tt, J = 8.7, 5.0 Hz, 1H) 1.08 
(dt, J = 6.9, 4.9 Hz, 2H) 0.78 (dt, J = 6.7, 4.8 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 
178.92, 164.24, 163.46, 150.10, 132.79, 130.68, 128.12, 124.27, 119.46, 35.30, 34.66, 32.71, 
15.40, 10.40; **NOSEY attached; TOF ES+ MS: (M+H) 351.04; HPLC Ret: 7.00 min; 93% pure 
with trans-diastereomer impurity; 97% pure without trans-diastereomer impurity. *NOSEY shows 
cis protons. 
trans-3-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-
yl)thio)cyclobutanecarboxylic acid (CCG-263088). Method G starting from methyl trans-3-((5-
(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)cyclobutanoate (0.05 g, 0.14 mmol) 
gave trans-3-((5-(2-chloro-4-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)thio)cyclobutanecarboxylic 
acid as white solid (0.03 g, 57%); column: 40% EtOAc: 60% Hex: 0.1% AcOH followed by 
trituration with EtOAc/Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.03 (br. s, 1H) 7.82 (d, J = 8.2 
Hz, 1H) 7.20 (d, J = 1.7 Hz, 1H) 7.05 (dd, J = 8.2, 1.7 Hz, 1H) 4.46 (p, J = 8.7 Hz, 1H) 3.43 (p, J 
= 4.8 Hz, 1H) 2.98 (ddd, J = 13.7, 8.1, 5.4 Hz, 2H) 2.60 (ddd, J = 13.4, 9.6, 6.5 Hz, 2H) 1.92 (tt, 
J = 8.5, 5.4 Hz, 1H) 1.09 (dt, J = 6.9, 4.9 Hz, 2H) 0.79 (dt, J = 6.8, 4.9 Hz, 2H); 13C NMR (500 
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MHz, CDCl3-d) 𝛿 ppm 180.08, 164.27, 163.36, 150.12, 132.80, 130.69, 128.14, 124.29, 119.46, 
37.43, 35.23, 32.70, 15.41, 10.40; **NOSEY attached; TOF ES+ MS: (M+H) 351.04; HPLC Ret: 
7.21 min; 92% pure with cis-diastereomer impurity; 94% pure without cis-diastereomer impurity. 
*NOSEY does not show trans protons. 
cis-3-((5-(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)cyclobutanecarboxylic acid (CCG-263089). Method G starting from methyl cis-3-((5-
(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)cyclobutanoate (0.05 g, 0.12 mmol) 
gave cis-3-((5-(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)cyclobutanecarboxylic acid as white solid (0.02 g, 48%); column: 40% EtOAc: 60% Hex: 
0.1% AcOH followed by trituration with EtOAc/Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.69 
(br. s, 1H) 8.12 (d, J = 8.2 Hz, 1H) 7.82 (d, J = 1.7 Hz, 1H) 7.66 (dd, J = 8.3, 1.7 Hz, 1H) 4.34 
(p, J = 8.6 Hz, 1H) 3.24 (p, J = 8.9 Hz, 1H) 3.04-2.91 (m, 2H) 2.61 (qd, J = 9.4, 2.8 Hz, 2H); 13C 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 178.97, 164.68, 162.99, 134.31, 133.60, 131.60, 128.41, 
125.94, 123.95, 121.59, 35.35, 34.63, 33.53; **NOSEY attached; TOF ES+ MS: (M+H) 379.00; 
HPLC Ret: 7.14 min; 95% pure. *NOSEY shows cis protons. 
trans-3-((5-(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)cyclobutanecarboxylic acid (CCG-263090). Method G starting from methyl trans-3-((5-
(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thio)cyclobutanoate (0.03 g, 0.06 mmol) 
gave trans-3-((5-(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-
yl)thio)cyclobutanecarboxylic acid as white solid (0.09 g, 37%); column: 40% EtOAc: 60% Hex: 
0.1% AcOH followed by trituration with EtOAc/Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.43 
(br. s, 1H) 8.12 (d, J = 8.2 Hz, 1H) 7.82 (d, J = 1.7 Hz, 1H) 7.66 (dd, J = 8.3, 1.7 Hz, 1H) 4.51 
(p, J = 7.5 Hz, 1H) 3.45 (p, J = 5.5 Hz, 1H) 3.01 (ddd, J = 13.7, 8.1, 5.3 Hz, 2H) 2.62 (ddd, J = 
13.8, 9.5, 6.5 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 180.10, 164.62, 162.98, 134.33, 
287 
 
133.60, 131.38, 128.39, 125.94, 123.93, 121.70, 37.49, 35.26, 32.68; **NOSEY attached; TOF 
ES+ MS: (M+H) 379.00; HPLC Ret: 7.25 min; 98% pure. *NOSEY does not show trans protons. 
cis-3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)cyclopentanecarboxylic acid (CCG-
263108). Method G starting from methyl cis-3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio) 
cyclopentanoate (0.14 g, 0.36 mmol) gave cis-3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)cyclopentanecarboxylic acid as white solid (0.08 g, 62%); column: 40% EtOAc: 60% Hex: 
0.1% AcOH followed by trituration with EtOAc/Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.61 
(br. s, 1H) 7.92 (d, J = 8.5 Hz, 1H) 7.57 (d, J = 1.7 Hz, 1H) 7.39 (dd, J = 8.5, 1.8 Hz, 1H) 4.28-
4.20 (m, 1H) 3.18-3.08 (m, 1H) 2.67-2.57 (m, 1H) 2.51-2.41 (m, 1H) 2.29-1.99 (m, 3H) 1.92-1.83 
(m, 1H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 181.03, 164.71, 163.29, 138.08, 133.73, 131.60, 
131.18, 127.62, 121.35, 45.04, 42.42, 36.87, 33.18, 28.77; TOF ES+ MS: (M+H) 358.99; HPLC 
Ret: 7.33 min. *HNMR, CNMR, MS, & HPLC indicated that a 20% impurity remained after 
column and crystallization purifications. Based on the NMR and HPLC evidence, this impurity 
was thought to be the thermodynamically stable conformational isomer so it was further 
investigated. A high temperature HNMR in DMSO at 90 °C did not resolve the expected peaks; 
however, the formation of this conformer impurity may require a longer time than the 5 min high 
temp experiment to resolve the isomers. A high-resolution LC/MS showed that the two 
compounds in the mixture had the same mass of 359.00, and therefore it was concluded that 
the impurity was the thermodynamically more stable conformer as no other proposed homolog 
matched the data obtained. Of note, the trans isomer (CCG-263091) did not contain this 
conformer impurity—having used the same starting material to make both analogs this further 
strengthened the hypothesis. 82% pure with conformer impurity; 99% pure without conformer 
impurity. *Comparisons between the experimental CNMR chemical shifts to MestreNova 
predicted CNMR chemical shifts was used to assign cis and trans isomers; the experimental 




(CCG-263091). Method G starting from methyl trans-3-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-
2-yl)thio) cyclopentanoate (0.05 g, 0.14 mmol) gave trans-3-((5-(2,4-dichlorophenyl)-1,3,4-
oxadiazol-2-yl)thio)cyclopentanecarboxylic acid as white solid (0.03 g, 60%); 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 11.54 (br. s, 1H) 7.87 (d, J = 8.5 Hz, 1H) 7.58 (d, J = 1.9 Hz, 1H) 7.42 (dd, J = 
8.5, 1.9 Hz, 1H) 5.32-5.24 (m, 1H) 3.31-3.23 (m, 1H) 2.53-2.45 (m, 1H) 2.38-2.28 (m, 3H) 2.14-
2.00 (m, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 181.40, 175.08, 156.36, 138.64, 133.80, 
131.56, 130.85, 127.73, 119.81, 59.55, 42.40, 34.24, 31.02, 28.56; TOF ES+ MS: (M+H) 
358.99; HPLC Ret: 7.58 min; 95% pure. *Comparisons between the experimental CNMR 
chemical shifts to MestreNova predicted CNMR chemical shifts was used to assign cis and 
trans isomers; the experimental and predicted shifts were extremely close. 
cis-4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)cyclohexanecarboxylic acid (CCG-
263092). Method G starting from ethyl cis-4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-
yl)thio)cyclohexanoate (0.07 g, 0.18 mmol) gave cis-4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-
2-yl)thio)cyclohexanecarboxylic acid as white solid (0.03 g, 52%); reaction required 24 hr; 
column: 40% EtOAc: 60% Hex: 0.1% AcOH followed by trituration with EtOH/H2O; 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 10.66 (br. s, 1H) 7.91 (d, J = 8.5 Hz, 1H) 7.56 (d, J = 1.8 Hz, 1H) 7.39 
(dd, J = 8.5, 1.6 Hz, 1H) 4.15-4.10 (m, 1H) 2.62-2.55 (m, 1H) 2.11-1.98 (m, 6H) 1.93-1.83 (m, 
2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 180.77, 164.93, 163.21, 138.01, 133.71, 131.57, 
131.16, 127.59, 121.40, 45.46, 40.46, 30.08, 25.32; TOF ES+ MS: (M+H) 373.00; HPLC Ret: 
7.40 min; 89% pure with trans-diastereomer impurity; 99% pure without trans-diastereomer 
impurity. *See ethyl ester homolog for explanation of how assignment was made for cis/trans 
isomers. 
trans-4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)cyclohexanecarboxylic acid 
(CCG-263093). Method G starting from ethyl trans-4-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-
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yl)thio)cyclohexanoate (0.04 g, 0.09 mmol) gave trans-4-((5-(2,4-dichlorophenyl)-1,3,4-
oxadiazol-2-yl)thio)cyclohexanecarboxylic acid as white solid (0.02 g, 47%); reaction required 
24 hr; column: 40% EtOAc: 60% Hex: 0.1% AcOH followed by trituration with EtOAc/Hex; 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.67 (br. s, 1H) 7.92 (d, J = 8.5 Hz, 1H) 7.57 (d, J = 2.0 Hz, 
1H) 7.39 (dd, J = 8.5, 2.0 Hz, 1H) 3.75-3.69 (m, 1H) 2.44-2.38 (m, 3H) 2.21-2.09 (m, 2H) 1.73-
1.57 (m, 4H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 180.73, 164.43, 163.27, 138.07, 133.70, 
131.58, 131.18, 127.62, 121.38, 45.43, 41.70, 32.10, 28.45; TOF ES+ MS: (M+H) 373.00; 
HPLC Ret: 7.55 min; 98% pure. *See ethyl ester homolog for explanation of how assignment 
was made for cis/trans isomers. 
2-(1-(((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)thio)methyl)cyclopropyl)acetic acid 
(CCG-262705). 2-(2,4-dichlorophenyl)-5-(methylsulfonyl)-1,3,4-oxadiazole (0.05 g, 0.171 mmol) 
was dissolved in 2 mL acetone. K2CO3 (0.028 g, 0.205 mmol) and 2-(1-
(mercaptomethyl)cyclopropyl)acetic acid (0.03 g, 0.21 mmol) were added and the mixture was 
stirred at 25 °C for 1 hr. The acetone was removed in vacuo and the remaining residue was 
partitioned between water (5 mL) and DCM (5 mL). The product was extracted with DCM (3x 10 
mL), washed with brine (10 mL), dried with MgSO4, and concentrated in vacuo. The residue was 
subjected to silica gel chromatography eluting with 45% EtOAc: 55% Hex: 0.01% AcOH to 
produce white solid. Yield=98%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 10.88 (br. s, 1H) 7.91 (d, J 
= 8.5 Hz, 1H) 7.56 (d, J = 2.0 Hz 1H) 7.39 (dd, J = 8.5, 2.0 Hz, 1H) 3.54 (s, 2H) 2.52 (s, 2H) 
0.82-0.77 (m, 2H) 0.73-0.68 (m, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 177.39, 165.35, 
163.38, 138.08, 133.73, 131.59, 131.16, 127.61, 121.31, 41.36, 39.86, 17.33, 13.48; TOF ES+ 
MS: (M+H) 359.0; HPLC Ret: 7.28 min; 99% pure. 
4-((5-(2-chloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. CCG-263233. 4-
((5-(2-chloro-4-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid (0.04 g, 0.11 
mmol) was dissolved in 2:1 DMF/H2O solution. Bis(triphenylphosphine)palladium(II) chloride 
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(0.01 g, 0.01 mmol) and trimethylamine (0.09 g, 0.91 mmol, 0.13 mL) were added and the 
reaction was stirred under nitrogen at 85 °C for 2 hr. The reaction was quenched with H2O (5 
mL) and acidified to pH ~ 1 with 1N HCl (2 mL). The product was extracted with EtOAc (3 x 15 
mL), and the resulting organic layer was washed with brine (20 mL), dried with MgSO4, and 
evaporated. The oil was subjected to silica gel chromatography eluting with 70% EtOAc: 30% 
Hex: 0.01% AcOH. The fractions containing product were concentrated in vacuo to produce 
white powder. Similar compounds were made in an analogous fashion. Yield=25%. 1H NMR 
(500 MHz, MeOD-d4) 𝛿 ppm 7.76 (dd, J = 8.7, 1.3 Hz, 1H) 6.99 (dd, J = 2.4, 1.3 Hz, 1H) 6.87 
(ddd, J = 8.6, 2.4, 1.3 Hz, 1H) 3.36 (t, J = 7.1 Hz, 2H) 2.50 (t, J = 7.1 Hz, 2H) 2.13 (p, J = 7.1 
Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 174.86, 164.42, 164.38, 161.35, 133.61, 131.97, 
117.35, 114.52, 113.08, 31.84, 31.31, 24.65; TOF ES+ MS: (M+H) 315.02; HPLC Ret: 5.31 min; 
98% pure. 
4-((5-(2-chloro-3-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid. (CCG-263234). 
*note: 4-((5-(2-chloro-3-(prop-2-yn-1-yloxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)butanoic acid used 
as starting material; silica gel chromatography eluting with 70% EtOAc: 30% Hex: 0.01% AcOH. 
White powder. Yield=25%. 1H NMR (500 MHz, MeOD-d4) 𝛿 ppm 7.37 (dt, 7.8, 1.4 Hz, 1H) 7.29 
(dt, J = 8.0, 1.2 Hz, 1H) 7.14 (dt, J = 8.2, 1.4 Hz, 1H) 3.37 (t, J = 7.1 Hz, 2H) 2.51 (d, J = 7.1 Hz, 
2H) 2.14 (p, J = 7.1 Hz, 2H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 174.86, 165.19, 164.34, 
154.45, 127.62, 123.52, 121.38, 119.37, 119.19, 31.86, 31.33, 24.63; TOF ES+ MS: (M+H) 
315.02; HPLC Ret: 5.05 min; 94% pure. 
222740-Series SBDD Procedures: 
cis-6-oxabicyclo[3.2.1]oct-3-en-7-one. At 0 oC in a 250 mL round bottomed flask, a solution of 
cis-cyclohex-3-enecarboxylic acid (5 g, 39.6 mmol), sodium bicarbonate (10 g, 119 mmol), and 
H2O (40 mL) was combined with a solution of potassium iodide (33 g, 198 mmol), iodine (10.6 g, 
41.6 mmol), and H2O (40 mL). The mixture was stirred warmed to 25 oC for 18 hr. The product 
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was extracted with DCM (3 x 50 mL) and the organic layers were combined, washed with 
NaHSO3 (2 x 50 mL), brine, dried with MgSO4, and then concentrated in vacuo. The remaining 
oil was dissolved in THF (80 mL) and DBU (7.8 g, 51.5 mmol, 7.77 mL) was added. The 
reaction took place at 70 oC for 5 hr. The solvent was evaporated in vacuo and the subsequent 
oil was subjected to silica gel plug eluting with with 90% EtOAc: 10% Hex. The fractions 
containing product were concentrated in vacuo to produce pale yellow oil. Yield=93%. 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 6.24 (dddd, J = 9.2, 5.4, 2.9, 1.5 Hz, 1H) 5.86 (dddd, J = 9.4, 3.8, 
2.6, 1.3 Hz, 1H) 4.77 (t, J = 5.7 Hz, 1H) 2.93-2.91 (m, 1H) 2.56-2.43 (m, 4H) 2.10 (d, J = 11.1 
Hz, 1H). 
trans-5-azidocyclohex-3-enecarboxylic acid. In a 100 mL round-bottomed flask, trans-6-
oxabicyclo[3.2.1]oct-3-en-7-one (0.5 g, 4.03 mmol) in H2O (4 mL) was added to a solution of 
NaN3 (0.3 g, 4.43 mmol) in THF (10 mL) and stirred at 50 °C for 48 hr. The volatile organics 
were evaporated in vacuo and 2M NaOH (8 mL) was added. The aqueous was washed with 
Et2O (3 x 10 mL) and then acidified with 6N HCl (5 mL) on ice. The product was extracted with 
DCM (3 x 15 mL), washed with brine (30 mL), dried with MgSO4, and concentrated in vacuo. 
Yield=50%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 6.06 (dddd, J = 10.0, 4.9, 2.7, 1.0 Hz, 1H) 5.82 
(dddt, J = 9.9, 4.4, 2.7, 1.5 Hz, 1H) 4.06 (t, J = 4.3 Hz, 1H) 2.82 (m, 1H) 2.44 (dt, 8.0, 4.5 Hz, 
1H) 2.31-2.23 (m, 1H) 2.17 (dt, 7.5, 2.0 Hz, 1H) 1.91 (ddd, J = 13.8, 11.7, 4.8 z, 1H). 
trans-3-((tert-butoxycarbonyl)amino)cyclohexanecarboxylic acid. trans-5-azidocyclohex-3-
enecarboxylic acid (0.1 g, 0.60 mmol) was dissolved in EtOH (2 mL) and H2O (0.8 mL), and the 
solvents were degassed. 5% Pd/C (0.02 g, 0.01 mmol) was added and the reaction was stirred 
at 25 °C for 24 hr under 1 atm hydrogen. The catalyst was filtered through a pad of Celite and 
the filtrate was concentrated in vacuo. The resulting amino acid was dissolved in 1M NaOH (1.5 
mL) and dioxane (1.5 mL). The solution was cooled to 0 °C and Boc2O (0.16 g, 0.69 mmol) was 
added in one portion. The reaction was warmed to 25 °C and stirred for 16 hr. The reaction was 
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concentrated in vacuo and then acidified with 1M HCl (5 mL). The product was extracted with 
EtOAc (3 x 15 mL), washed with brine (30 mL), dried with MgSO4, and concentrated in vacuo. 
White solid. Yield=50% (2 steps). TOF ES+ MS: (M-H) 242.0. 
cis-3-(methoxycarbonyl)cyclohexanecarboxylic acid. A solution of DCC (0.6 g, 2.9 mmol) in 
DCM (5 mL) was added dropwise to cis-cyclohexane-1,3-dicarboxylic acid (0.5 g, 2.9 mmol) in 
DCM (5 mL). The reaction was stirred for 1.5 hr at 25 °C. The dicyclohexylurea side product 
was filtered and washed with cold DCM (20 mL). The filtrate was concentrated in vacuo to 
provide 3-oxabicyclo[3.3.1]nonane-2,4-dione as a white solid. The resulting intermediate was 
dissolved in MeOH (10 mL). The solution was stirred for 2 days at 25 °C. The reaction was 
concentrated in vacuo to provide a white solid. Yield = 93% (2 steps). 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 3.68 (s, 3H) 2.40-2.22 (m, 1H) 2.05-1.96 (m, 2H) 1.92 (dd, J = 6.0, 3.0 Hz, 1H) 
1.57 (q, J = 12.7 Hz, 1H) 1.44-1.27 (m, 4H); TOF ES+ MS: (M-H) 185.0. 
cis-methyl 3-(((benzyloxy)carbonyl)amino)cyclohexanecarboxylate. In a 100 mL round 
bottomed flask cis-3-(methoxycarbonyl)cyclohexanecarboxylic acid (0.56 g, 3.01 mmol) was 
dissolved in toluene (10 mL). Et3N (0.34 g, 0.46 mL, 3.31 mmol) and diphenyl phosphorazidate 
(0.91 g, 0.71 mL, 3.31 mmol) was added and the reaction was stirred at 110 °C for 1 hr. The 
solution was cooled to 70 °C and benzyl alcohol (0.49 g, 0.47 mL, 4.5 mmol) was added. The 
reaction was stirred at 85 °C for 19 hr. The solution was cooled to 25 °C, poured into EtOAc (20 
mL) and H2O (20 mL). The product was extracted with EtOAc (3 x 20 mL), washed with brine (2 
x 20 mL), dried with MgSO4, and concentrated in vacuo. The subsequent oil was subjected to 
silica gel chromatography eluting with 50% EtOAc: 50% Hex. The fractions containing product 
were concentrated in vacuo to produce yellow oil. Yield=98%. 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 7.40-7.21 (m, 5H) 5.08 (s, 2H) 4.70 (s, 1H) 3.66 (s, 3H) 2.42 (td, J = 12.0, 6.1 Hz, 1H) 
2.29-2.21 (m, 2H) 2.02-1.89 (m, 2H) 1.84 (dt, J = 13.2, 3.4 Hz, 1H) 1.44-1.05 (m, 4H); TOF ES+ 
MS: (M+H) 248.1; HPLC Ret: 7.01 min. 
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cis-3-oxabicyclo[3.2.1]octane-2,4-dione. In a 2 mL microwave flask, cyclopentane-1,3-
dicarboxylic acid (0.12 g, 0.95 mmol) was dissolved in Ac2O (0.81 g, 0.75 mL, 8.40 mmol). The 
reaction was stirred at 150 °C for 30 mins. The solvents were concentrated in vacuo, and the 
product was crystalized from Et2O to produce white solid. Yield=47%. 1H NMR (500 MHz, 
DMSO-d6) 𝛿 ppm 3.18 (q, J = 3.9 Hz, 2H) 2.35 (d, J = 12.4 Hz, 1H) 2.15-2.02 (m, 2H) 1.89 (dq, 
J = 6.8, 2.1 Hz, 2H) 1.68 (dt, J = 12.4, 4.1 Hz, 1H). 
Cis/trans-cyclopentane-1,3-dicarboxylic acid. In a 50 mL round bottomed flask, 
cyclopentane-1,3-dicarboxylic acid (0.25 g, 1.6 mmol) was dissolved in conc. HCl (5 mL). The 
reaction was stirred at 130 °C for 16 mins. The solution was poured into ice, and the products 
were extracted with EtOAc (3 x 20 mL). The organic layers were combined, dried with MgSO4, 
and concentrated in vacuo to produce white solid. Yield=94%. 1H NMR (500 MHz, DMSO-d6) 𝛿 
ppm 12.07 (s, 4H) 2.80-2.66 (m, 5H) 2.10 (dt, J = 12.8, 8.1 Hz, 1H) 2.01-1.64 (m, 11H). 
5-((tert-butoxycarbonyl)amino)nicotinate, Et3NH+. In a 25 mL round bottomed flask 5-
aminonicotinic acid (0.2 g, 1.45 mmol) was dissolved in 1, 4-dioxane (4 mL) and H2O (2 mL). 
Et3N (0.22 g, 0.3 mL, 2.17 mmol) followed by Boc2O (0.47 g, 2.17 mmol) were added and the 
reaction was stirred at 25 °C for 24 hr. The solvents were evaporated in vacuo and the product 
was subjected to high vacuum until completely dry. The product was washed with Et2O (3 x 5 
mL) and concentrated to afford yellow solid. Yield=70%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 
9.58 (s, 1H) 8.61 (s, 1H) 8.21 (s, 1H) 8.00 (s, 1H) 7.39 (t, J = 2.3 Hz, 1H) 2.73 (q, J = 7.2H, 6H) 
1.49 (s, 9H) 1.05 (t, J = 7.2 Hz, 9H); TOF ES+ MS: (M-H) 236.9; HPLC Ret: 4.55 min. 
1-(1-chloroethyl) 3-methyl 5,6-dihydropyridine-1,3(2H)-dicarboxylate. Arecoline HBr (1.0 g, 
4.24 mmol) and K2CO3 (0.88 g, 6.4 mmol) were dissolved in 10 mL H2O were stirred at 25 °C for 
30 min. The product was extracted with Et2O (4 x 20 mL), the organic layers were combined, 
dried with MgSO4, and evaporated in vacuo. The crude oil was dissolved in DCE (15 mL) and 
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cooled to 0 °C. 1-chloroethylchloroformate (0.67 g, 0.5 mL, 4.66 mmol) was added dropwise 
and the reaction took place at 90 °C for 30 min. The reaction was cooled then concentrated in 
vacuo. The oil was subjected to silica gel chromatography eluting with 20% EtOAc: 80% Hex. 
The fractions containing product were concentrated to produce yellow oil. Yield=60% (2 steps). 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.09 (br. s., 1H) 6.64-6.59 (m, 1H) 4.31-4.12 (m, 2H) 3.77 
(s, 3H) 3.63-3.51 (m, 2H) 2.45-2.29 (m, 2H) 1.83 (d, J = 1.7 Hz, 3H). 
1,2,5,6-tetrahydropyridine-3-carboxylic acid, HBr. 1-(1-chloroethyl) 3-methyl 5,6-
dihydropyridine-1,3(2H)-dicarboxylate (0.62 g, 2.5 mmol) was stirred in MeOH (10 mL) at 85 °C 
for 2 hr. The reaction was concentrated in vacuo and then dissolved in 48% HBr (15 mL). The 
reaction was stirred at 85 °C for 2 hr and then concentrated to dryness in vacuo. The product 
was crystalized out of water as the HBr salt to produce colorless crystals. Yield=61%. 1H NMR 
(500 MHz, DMSO-d6) 𝛿 ppm 12.91 (br. s., 1H) 8.95 (br. s., 2H) 7.00 (tt, J = 3.9, 1.8 Hz, 1H) 3.73 
(s, 2H) 3.18 (t, J = 6.1 Hz, 2H) 2.47 (dp, J = 5.7, 2.7 Hz, 2H). 
1-(tert-butoxycarbonyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid. 1,2,5,6-
tetrahydropyridine-3-carboxylic acid, HBr (0.32 g, 1.54 mmol) was dissolved in 4M NaOH (5 mL) 
and tBuOH (5 mL). Boc2O (0.5 g, 2.31 mmol) was added and the reaction was stirred at 50 °C 
for 2 hr. The solution was washed with Hex (2 x 10 mL) and acidified with 6N HCl (10 mL). The 
product was extracted with EtOAc (3 x 20 mL), washed with brine (3 x 15 mL), dried with 
MgSO4, and concentrated in vacuo. The product was crystalized with EtOAc/Hex to afford white 
powder. Yield=36%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 12.91 (br. s., 1H) 8.95 (br. s, 2H) 7.21 
(br. s, 1H) 4.13 (br. s, 2H) 3.50 (t, J = 5.7 Hz, 2H) 2.34 (br. s., 2H) 1.48 (s, 9H). 
1-(tert-butoxycarbonyl)-5,5-difluoro-3-methylpiperidine-3-carboxylic acid. In a flame dried 
50 mL round bottomed flask, 1-tert-butyl 3-methyl 5,5-difluoropiperidine-1,3-dicarboxylate (0.31 
g, 1.11 mmol) was dissolved in 5 mL THF and cooled to -78 °C. 1M LiHMDS in THF (1.22 mL, 
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1.22 mmol) was added dropwise, and the reaction was stirred at -78 °C for 1 hr. MeI (0.17 g, 
0.08 mL, 1.22 mmol) was added, and after 2 hr stirring at -78 °C, the reaction was warmed to 25 
°C and stirred for another 2 hr. The reaction was quenched with NH4Cl, and the product was 
extracted with EtOAc (3 x 20 mL), the organic layers were combined, dried with MgSO4, and 
evaporated in vacuo. The subsequent oil was subjected to silica gel chromatography eluting 
with 10% to 15% EtOAc/Hex. The fractions containing product were concentrated to produce 
colorless oil. 1-tert-butyl 3-methyl 5,5-difluoro-3-methylpiperidine-1,3-dicarboxylate (0.222 g, 
0.76 mmol) was dissolved in 2 mL THF, 2 mL 1M NaOH, and 0.5 mL MeOH. The reaction was 
stirred for 1 hr at 25 °C, the volatile solvents were removed in vacuo, and the aqueous was 
acidified with 1N HCl. The product was extracted with EtOAc (3 x 15 mL), the organic layers 
were combined, washed with brine, dried with MgSO4, and evaporated in vacuo to produce 
white solid Yield=81% (2-steps). 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 3.75-3.37 (m, 3H) 2.48-
2.32 (m, 1H) 2.08-1.96 (m, 1H) 1.40 (s, 9H), 1.15 (s, 3H); 19F NMR (470 MHz, DMSO-d6) 𝛿 ppm 
-95.22—-99.04 (m, 2H); 13C NMR (126 MHz, DMSO-d6) 𝛿 ppm 175.85, 154.13, 120.26, 109.99, 
79.98, 49.47, 42.53, 28.33, 22.23. 
ethyl 3,7-dihydro-2H-[1,4]dioxino[2,3-e]indole-8-carboxylate & ethyl 3,6-dihydro-2H-
[1,4]dioxino[2,3-f]indole-7-carboxylate. In a 100 mL round bottomed flask, a solution of 
sodium nitrite (0.91 g, 13.2 mmol) in H2O (6 mL) was added to a solution of 6-amino-1,4-
benzodioxane (2 g, 13.2 mmol) in 18% HCl (16 mL) at 0 °C. The combined solution was stirred 
at 0 °C for 30 min. A solution of ethyl-2-methyl acetoacetate (1.91 g, 1.93 mL, 13.2 mmol) in 
iPrOH (16 mL) was quickly added, and then the the colution was cooled to -10 °C. A solution of 
AcOK (1.3 g, 13.2 mmol) in H2O (6 mL) was added followed by 10 % NaOH dropwise until pH ~ 
6. The reaction was stirred at 0 °C for 3 hr. Upon completion, DCM (100 mL) was added, and 
the product was extracted with DCM (3 x 100 mL). The organic layers were combined, washed 
with brine (1 x 100 mL), dried with MgSO4, and concentrated in vacuo. The residue was 
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dissolved in EtOH (2 mL) and then heated to boiling. The solution was added to a 10% alcoholic 
HCl solution (10 mL), and then the solution was heated at reflux for 1 hr. The reaction was 
diluted with water, and the product was extracted with EtOAc (3 x 100 mL). The organic layers 
were combined, dried with MgSO4, and concentrated in vacuo. The subsequent oil was 
subjected to silica gel chromatography eluting with 15% to 60% EtOAc: Hex. The fractions 
containing product were concentrated in vacuo producing yellow and orange oil, respectively. 
Analogous compounds were made in a similar fashion. Yield: ethyl 3,7-dihydro-2H-
[1,4]dioxino[2,3-e]indole-8-carboxylate = 13% & ethyl 3,6-dihydro-2H-[1,4]dioxino[2,3-f]indole-7-
carboxylate = 9% (2-steps). ethyl 3,7-dihydro-2H-[1,4]dioxino[2,3-e]indole-8-carboxylate: 1H 
NMR (500 MHz, DMSO-d6) 𝛿 ppm 11.78 (s, 1H) 6.97 (s, 1H) 6.91 (d, J = 8.8 Hz, 1H) 6.84 (d, 
8.8 Hz, 1H) 4.35-4.25 (m, 6H) 1.33 (t, J = 7.1Hz, 3H); TOF ES+ MS: (M+H) 247.0; HPLC Ret: 
6.51 min. ethyl 3,6-dihydro-2H-[1,4]dioxino[2,3-f]indole-7-carboxylate: 1H NMR (500 MHz, 
DMSO-d6) 𝛿 ppm 11.45 (s, 1H) 7.06 (s, 1H) 6.96 (s, 1H) 6.83 (s, 1H) 4.36-4.18 (m, 6H) 1.32 (t, J 
= 7.1Hz, 3H); TOF ES+ MS: (M+H) 248.09; HPLC Ret: 6.57 min. 
ethyl 3,7-dihydro-2H-[1,4]dioxino[2,3-e]indole-8-carboxylate & ethyl 3,6-dihydro-2H-
[1,4]dioxino[2,3-f]indole-7-carboxylate. Yield: 12% (2-steps). 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 8.82 (br. s., 1H) 7.93 (s, 1H) 7.20-7.10 (m, 1H) 6.83 (t, J = 8.1 Hz, 1H) 6.50 (d, 8.2 Hz, 1H) 
4.43-4.26 (m, 8H) 2.11 (d, J = 1.4 Hz, 3H) 1.43-1.33 (m, 4H); TOF ES+ MS: (M+H) 246.07; 
HPLC Ret: 6.94 min. 
Ethyl 6,7-difluoro-1H-indole-2-carboxylate. In a 50 mL round bottomed flask, (2,3-
difluorophenyl)hydrazine (0.25 g, 1.74 mmol) was dissolved in DCM (8 mL). Ethyl pyruvate 
(0.20 g, 1.74 mmol, 0.19 mL) was added, and the reaction was stirred at 25 °C for 1 hr. The 
reaction was diluted with H2O, and then the product was extracted with DCM (3 x 15mL). The 
organics were combined, washed with 1N HCl (2 x 15 mL), washed with brine, MgSO4, and 
concentrated in vacuo (HPLC = 7.23 min). This hydrozone product was dissolved in PhMe (8 
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mL) and pTSA (0.3 g, 1.56 mmol) was added. The reaction was attached to a Dein-Stark trap 
and stirred at reflux for 24 hr. The reaction was cooled and neutralized with sodium bicarbonate. 
The product was extracted with EtOAc (3 x 15 mL), the organics were combined, washed with 
brine, dried with MgSO4, and concentrated in vacuo. The subsequent oil was subjected to silica 
gel chromatography eluting with 10% EtOAc: Hex. The fractions containing product were 
concentrated in vacuo producing yellow solid. Yield: 29% (2-steps). 1H NMR (500 MHz, CDCl3-
d) 𝛿 ppm 9.05 (br. s., 1H) 7.36 (dd, J = 8.9, 4.2 Hz, 1H) 7.21 (t, J = 2.7 Hz, 1H) 7.04-6.98 (m, 
1H) 4.42 (q, J = 7.2 Hz, 2H) 1.40 (t, J = 7.1 Hz, 3H); TOF ES+ MS: (M+H) 226.01. 
3,7-dihydro-2H-[1,4]dioxino[2,3-e]indole-8-carboxylic acid. In a 25 mL round bottomed flask, 
ethyl 3,7-dihydro-2H-[1,4]dioxino[2,3-e]indole-8-carboxylate (0.1 g, 0.40 mmol) was dissolved in 
a solution of KOH (0.05 g, 0.81 mmol) in H2O (2 mL) & EtOH (0.05 mL). The solution was stirred 
at 100 °C for 4 hr, and then cooled to 25 °C. The solution was diluted with H2O (~2 mL), and 
then acidified with 4N HCl until precipitate formation. The product was filtered, washed with 
water, and dried on the high vacuum to produce tan solid. Analogous compounds were made in 
a similar fashion. Yield=56%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 12.85 (br. s, 1H) 11.64 (s, 
1H) 6.92 (s, 1H) 6.88 (d, J = 8.7 Hz, 1H) 6.81 (d, 8.7 Hz, 1H) 4.36-4.31 (m, 2H) 4.28-4.21 (m, 
2H); TOF ES+ MS: (M-H) 218.05; HPLC Ret: 4.99 min. 
3,7-dihydro-2H-[1,4]dioxino[2,3-e]indole-8-carboxylic acid. Pink solid. Yield=74%. 1H NMR 
(500 MHz, DMSO-d6) 𝛿 ppm 12.69 (br. s, 1H) 11.31 (s, 1H) 7.04 (s, 1H) 6.90 (s, 1H) 6.82 (s, 
1H) 4.28-4.18 (m, 4H); TOF ES+ MS: (M-H) 218.05; HPLC Ret: 5.10 min. 
3,9-dihydro-2H-[1,4]dioxino[2,3-g]indole-8-carboxylic acid. Brown solid. Yield=56%. 1H 
NMR (500 MHz, DMSO-d6) 𝛿 ppm 12.14 (br. s, 1H) 8.39 (s, 1H) 7.10 (d, 1H) 6.77 (t, J = 8.2 Hz, 
1H) 6.45 (d, J = 8.1 Hz, 1H) 4.34-4.24 (m, 4H); HPLC Ret: 5.43 min. 
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6,7-difluoro-1H-indole-2-carboxylic acid. White solid. Yield=54%. 1H NMR (500 MHz, DMSO-
d6) 𝛿 ppm 13.15 (br. s, 1H) 12.46 (s, 1H) 7.47 (br.s, 1H) 7.19 (br. s, 1H) 7.12 (br. s, 1H); HPLC 
Ret: 5.76 min. 
methyl 3-(2-(pyrrolidin-1-yl)ethoxy)benzoate. In a 50mL round bottomed flask, methyl 3-
hydroxybenzoate (0.25 g, 1.64 mmol) was dissolved in 5 mL DMF. K2CO3 (0.30 g, 2.14 mmol) 
and 1-(2-chloroethyl)pyrrolidine (0.66 g, 4.93 mmol) were added, and the reaction was stirred at 
100 °C for 4 hr. The reaction was cooled and diluted with H2O, and then the product was 
extracted with EtOAc (3 x 20 mL). The organics were combined, washed with brine, dried with 
MgSO4, and concentrated in vacuo. The oil was subjected to silica gel chromatography eluting 
with 2.5% to 10% MeOH: DCM. The fractions containing product were concentrated in vacuo to 
produce colorless oil. Analogous compounds were made in a similar fashion. Yield=67%. 1H 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.63 (d, J = 8.6 Hz, 2H) 7.58 (s, 1H) 7.33 (t, J = 8.0 Hz, 1H) 
7.12 (d, J = 8.6 Hz, 1H) 4.17 (t, J = 5.9 Hz, 2H) 3.91 (s, 3H) 2.94 (t, J = 5.9 Hz, 2H) 2.66 (d, J = 
5.8 Hz, 4H) 1.83 (t, J = 3.7 Hz, 4H); TOF ES+ MS: (M+H) 250.15; HPLC Ret: 4.38 min. 
methyl 4-(2-(pyrrolidin-1-yl)ethoxy)benzoate. Brown oil. Yield=87%. 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 7.98 (d, J = 8.1 Hz, 2H) 6.93 (d, J = 8.0 Hz, 2H) 4.16 (t, J = 5.9 Hz, 2H) 3.88 (s, 
3H) 2.94 (t, J = 5.9 Hz, 2H) 2.62 (ddt, J = 7.5, 6.0, 2.4 Hz, 4H) 1.81 (q, J = 3.4 Hz, 4H); TOF 
ES+ MS: (M+H) 250.15; HPLC Ret: 4.00 min. 
methyl 3-(3-(pyrrolidin-1-yl)propoxy)benzoate. Yellow oil. Yield=34%. 1H NMR (500 MHz, 
CDCl3-d) 𝛿 ppm 7.62 (d, J = 7.6 Hz, 1H) 7.55 (s, 1H) 7.33 (t, J = 7.9 Hz, 1H) 7.09 (d, J = 8.3 Hz, 
1H) 4.80 (t, J = 6.2 Hz, 2H) 3.91 (s, 3H) 2.74 (s, 2H) 2.66 (br. s, 4H) 2.10 (q, J = 7.1 Hz, 2H) 
1.86 (br. s, 4H); TOF ES+ MS: (M+H) 264.16; HPLC Ret: 5.16 min. 
1-(2-(3-carboxyphenoxy)ethyl)pyrrolidin-1-ium, HCl. In a 25 mL round-bottomed flask methyl 
3-(2-(pyrrolidin-1-yl)ethoxy)benzoate (0.27 g, 1.08 mmol) was dissolved in THF (2.5 mL). 1 M 
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NaOH (2.5 mL) was added to the solution and the reaction was stirred at 25 °C for 3 hr. The 
THF was evaporated in vacuo and then the solution was acidified with 1 N HCl (7 mL). The 
solution was concentrated in vacuo, and then MeOH was added and the inorganic solids were 
filtered. The filtrate was concentrated in vacuo to produce pink solid. Analogous compounds 
were made in a similar fashion. Yield=100%. 1H NMR (500 MHz, DMSO-d6) 𝛿 13.07 (s, 1H) 
11.04 (br. s, 1H) 7.58 (dt, J = 7.7, 1.4 Hz, 1H) 7.51 (dt, J = 2.8, 1.5 Hz, 1H) 7.46 (td, J = 8.0, 1.4 
Hz, 1H) 7.27 (ddt, J = 8.2, 2.6, 1.2 Hz, 1H) 4.49-4.35 (m, 2H) 3.64-3.51 (m, 4H) 3.15-3.02 (m, 
2H) 2.09-1.84 (m, 4H); TOF ES+ MS: (M+H) 236.12; HPLC Ret: 3.75 min. 
4-(2-(pyrrolidin-1-yl)ethoxy)benzoic acid, HCl. White solid. Yield=84%. 1H NMR (500 MHz, 
DMSO-d6) 𝛿 12.71 (br. s, 1H) 11.58 (br. s, 1H) 7.91 (d, J = 8.4 Hz, 2H) 7.09 (d, J = 8.4 Hz, 2H) 
4.47 (t, J = 5.1 Hz, 2H) 3.64-3.50 (m, 4H) 3.09 (br. s, 2H) 2.04-1.86 (m, 4H); TOF ES+ MS: 
(M+H) 236.13; HPLC Ret: 2.99 min. 
3-(3-(pyrrolidin-1-yl)propoxy)benzoic acid, HCl. White solid. Yield=79%. 1H NMR (500 MHz, 
DMSO-d6) 𝛿 ppm 13.02 (br. s, 1H) 10.80 (br. s, 1H) 7.55 (d, J = 7.6 Hz, 1H) 7.50-7.39 (m, 2H) 
7.20 (d, J = 7.9 Hz, 1H) 4.13 (q, J = 5.7 Hz, 2H) 3.54 (h, J = 5.4 Hz, 2H) 3.28 (dt, J = 10.7. 6.2 
Hz, 2H) 3.00 (dq, J = 14.9, 7.5 Hz, 2H) 2.17 (dq, J = 12.3, 6.2 Hz, 2H) 2.00 (q, J = 7.2 Hz, 2H) 
1.89 (dd, J = 7.7, 4.9 Hz, 2H); TOF ES+ MS: (M+H) 250.14. 
(5-amino-2-chlorophenyl)methanol. In a 50-mL round bottomed flask, (2-chloro-5-
nitrophenyl)methanol (0.5 g, 2.67 mmol) was dissolved in a solution of H2O (5.0 mL) and EtOH 
(2.5 mL). Iron fillings (1.5 g, 26.7 mmol) and conc. HCl (0.1 mL) were added. The reaction was 
stirred at 100 °C for 3 hr, and then neutralized to pH ~ 10 with 1M NaOH. EtOH (2.5 mL) was 
added and the iron was filtered, washing with EtOH. The filtrate was concentrated, water was 
added, and the product was filtered, washing with water, producing pink crystals. Yield=55%. 1H 
NMR (500 MHz, DMSO-d6) 𝛿 6.96 (d, J = 8.4 Hz, 1H) 6.77 (d, J = 2.7 Hz, 1H) 6.42 (dd, J = 8.5, 
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2.8 Hz, 1H) 5.19 (d, J = 4.7 Hz, 3H) 4.41 (d, J = 5.6 Hz, 2H); TOF ES+ MS: (M+H) 158.04; 
HPLC Ret: 2.27 min. 
3-(((tert-butyldiphenylsilyl)oxy)methyl)-4-chloroaniline. In a 25-mL round bottomed flask, (5-
amino-2-chlorophenyl)methanol (0.15 g, 0.95 mmol), imidazole (0.1 g, 1.43 mmol), and TBDPS-
Cl (0.29 g, 0.27 mL, 1.05 mmol) was dissolved in DMF (4.0 mL) at 0 °C. The reaction was 
stirred at 25 °C for 24 hr, and then quench with sat. NH4Cl. The product was extracted with 
EtOAc (3 x 30 mL), and the organic layers combined, washed with brine (2 x 15 mL), dried with 
MgSO4, and concentrated in vacuo. The subsequent oil was subjected to silica gel 
chromatography eluting with 10% to 40% EtOAc: Hex. The fractions containing product were 
concentrated in vacuo to produce colorless oil. Analogous compounds were made in a similar 
fashion. Yield=66%. 1H NMR (500 MHz, CDCl3-d) 𝛿 7.70 (d, J = 6.8 Hz, 4H) 7.47-7.32 (m, 7H) 
7.09-7.01 (m, 2H) 6.52 (dd, J = 8.4, 2.9 Hz, 1H) 4.76 (s, 2H) 3.70 (br. s, 2H) 1.12 (s, 9H); TOF 
ES+ MS: (M+H) 396.15; HPLC Ret: 7.79 min. 
3-((tert-butyldiphenylsilyl)oxy)-5-chloroaniline. Colorless oil. Yield=24%. 1H NMR (500 MHz, 
CDCl3-d) 𝛿 7.70 (d, J = 6.8 Hz, 4H) 7.47-7.31 (m, 6H) 7.26 (s, 1H) 6.22 (dd, J = 9.5, 1.7 Hz, 1H) 
5.92 (s, 1H) 3.49 (s, 2H) 1.07 (s, 9H); TOF ES+ MS: (M+H) 382.1; HPLC Ret: 7.97 min. 
3-(((tert-butyldiphenylsilyl)oxy)methyl)-5-chloroaniline. Colorless oil. Yield=73%. 1H NMR 
(500 MHz, CDCl3-d) 𝛿 7.61 (d, J = 6.8 Hz, 4H) 7.40-7.27 (m, 6H) 7.18 (s, 1H) 6.62 (s, 1H) 6.51-
6.45 (m, 2H) 4.56 (s, 2H) 3.63 (s, 2H) 1.02 (s, 9H); TOF ES+ MS: (M+H) 396.2; HPLC Ret: 8.12 
min. 
trans-3-((tert-butoxycarbonyl)amino)cyclopentanecarboxylic acid. Method A starting from 
trans-methyl 3-((tert-butoxycarbonyl)amino)cyclopentanecarboxylate (0.25 g, 1.03 mmol) gave 
trans-3-((tert-butoxycarbonyl)amino)cyclopentanecarboxylic acid as white solid (0.19 g, 81%); 
1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 4.49 (br. s, 1H) 4.08 (br. s, 1H) 2.93 (p, J = 7.9 Hz, 1H) 
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2.23 (dt, J = 14.0, 7.1 Hz, 1H) 2.13-2.01 (m, 2H) 1.94-1.83 (m, 1H) 1.79 (dd, J = 14.0, 5.4 Hz, 
1H) 1.44 (s, 9H); TOF ES+ MS: (M+H) 230.14. 
tert-butyl (trans-3-((4-chlorophenyl)carbamoyl)cyclohexyl)carbamate. Method I starting 
from trans-3-(tert-butoxycarbonyl)cyclohexanecarboxylic acid (0.2 g, 0.82 mmol) and 4-
chloroaniline (0.11 g, 0.82 mmol) gave tert-butyl (trans-3-((4-
chlorophenyl)carbamoyl)cyclohexyl)carbamate as yellow solid (0.3 g, 100%); TOF ES+ MS: 
(M+Na) 375.1; HPLC Ret: 7.50 min. 
tert-butyl (trans-3-((4-chlorophenyl)carbamoyl)cyclopentyl)carbamate. Method I starting 
from trans-3-((tert-butoxycarbonyl)amino)cyclopentanecarboxylic acid (0.19 g, 0.84 mmol) and 
4-chloroaniline (0.11 g, 0.84 mmol) gave tert-butyl (trans-3-((4-
chlorophenyl)carbamoyl)cyclopentyl)carbamate as white solid (0.18 g, 63%); 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.47 (d, J = 8.4 Hz, 2H) 7.28 (d, J = 8.4 Hz, 2H) 4.51 (br. s, 1H) 4.11 (br. 
s, 1H) 2.84 (p, J = 8.0 Hz, 1H) 2.29-2.11 (m, 2H) 2.10-1.86 (m, 2H) 1.55 (dd, J = 16.3, 9.7 Hz, 
1H) 1.45 (s, 9H); TOF ES+ MS: (M+H) 339.14; HPLC Ret: 7.22 min. 
tert-butyl (cis-3-((4-chlorophenyl)carbamoyl)cyclopentyl)carbamate. Method I starting from 
cis-3-((tert-butoxycarbonyl)amino)cyclopentanecarboxylic acid (0.3 g, 1.31 mmol) and 4-
chloroaniline (0.17 g, 1.31 mmol) gave tert-butyl (cis-3-((4-
chlorophenyl)carbamoyl)cyclopentyl)carbamate as yellow solid (0.36 g, 81%); 1H NMR (500 
MHz, CDCl3-d) 𝛿 ppm 7.48 (d, J = 8.5 Hz, 2H) 7.38 (s, 1H) 7.28 (d, J = 8.4 Hz, 2H) 4.08 (s, 1H) 
2.84-2.74 (m, 1H) 2.20 (dt, J = 13.2, 6.5 Hz, 1H) 2.01 (q, J = 8.2 Hz, 2H) 1.88 (dt, J = 14.1, 6.4 
Hz, 2H) 1.78 (dd, J = 12.4, 6.0 Hz, 1H) 1.44 (s, 9H); TOF ES+ MS: (M+H) 339.1; HPLC Ret: 
7.15 min. 
cis-3-((4-chlorophenyl)carbamoyl)cyclopentanecarboxylic acid. In a 25 mL round bottomed 
flask, cis-3-oxabicyclo[3.2.1]octane-2,4-dione (0.05 g, 0.36 mmol) was dissolved in DMF (2 mL). 
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4-chloroaniline (0.046 g, 0.36 mmol) was added and the reaction was stirred at 25 °C for 16 hr. 
The reaction was acidified with 1N HCl, and the product was extracted with EtOAc (3 x 15 mL). 
The layers were combined, washed with brine (2 x 15 mL), dried with MgSO4, and concentrated 
in vacuo to produce white solid. Yield=95%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 12.07 (br. s, 
1H) 10.01 (s, 1H) 7.63 (d, J = 7.8 Hz, 2H) 7.34 (d, J = 7.9 Hz, 2H) 2.85-2.70 (m, 2H) 2.14 (dt, J 
= 12.6, 7.7 Hz, 1H) 1.98-1.75 (m, 5H); TOF ES+ MS: (M+Na) 290.06; HPLC Ret: 5.63 min. 
cis-3-((4-chlorophenyl)carbamoyl)cyclopentanecarboxylic acid, trans-3-((4-
chlorophenyl)carbamoyl)cyclopentanecarboxylic acid, & cis-N1,N3-bis(4-
chlorophenyl)cyclopentane-1,3-dicarboxamide (CCG-263871). Method I starting from 
cyclopentane-1,3-dicarboxylic acid (0.16 g, 1.01 mmol) and 4-chloroaniline (0.12 g, 1.01 mmol) 
gave a seperable mixture of cis-3-((4-chlorophenyl)carbamoyl)cyclopentanecarboxylic acid 
(0.22 g, 82%), trans-3-((4-chlorophenyl)carbamoyl)cyclopentanecarboxylic acid (0.063 g, 95%), 
& cis-N1,N3-bis(4-chlorophenyl)cyclopentane-1,3-dicarboxamide as white solids (0.06 g, 34%), 
respectively); column: 30% EtOAc: 60% Hex: 0.01% AcOH; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 
cis-3-((4-chlorophenyl)carbamoyl)cyclopentanecarboxylic acid: 12.09 (br. s, 1H) 10.01 (s, 1H) 
7.63 (d, J = 8.4 Hz, 2H) 7.34 (d, J = 8.3 Hz, 2H) 2.77 (dtt, J = 30.9, 14.7, 7.7 Hz, 2H) 2.12 (tt, J = 
19.0, 8.2 Hz, 1H) 2.01-1.73 (m, 5H), trans-3-((4-chlorophenyl)carbamoyl)cyclopentanecarboxylic 
acid: 12.08 (br. s, 1H) 10.05 (s, 1H) 7.63 (d, J = 8.8 Hz, 2H) 7.33 (d, J = 8.8 Hz, 2H) 2.88 (dp, J 
= 22.0, 7.4 Hz, 1H) 2.70 (dq, J = 15.3, 7.9, 7.4 Hz, 2H) 2.10 (dt, J = 13.0, 8.2 Hz, 1H) 2.02-1.90 
(m, 2H) 1.83-1.67 (m, 2H), and cis-N1,N3-bis(4-chlorophenyl)cyclopentane-1,3-dicarboxamide: 
10.09 (s, 2H) 7.65 (d, J = 8.6 Hz, 4H) 7.34 (d, J = 8.5 Hz, 4H) 3.00 (p, J = 7.4 Hz, 2H) 2.09-1.97 
(m, 5H) 1.90-1.73 (m, 1H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 174.44, 138.79, 128.98, 
126.92, 121.03, 45.49, 34.38, 30.71; TOF ES+ MS: (M-H) cis-acid: 266.06, trans-acid 266.06 
(M-H), and (M+Na) bis-amide: 399.06; HPLC Ret: cis-acid: 5.72 min, trans-acid: 5.77 min, and 
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bis-amide: 7.58 min; 98% pure. Note: stereochemical assignment based on procedure directly 
above. 
cis-methyl 3-((4-chlorophenyl)carbamoyl)cyclohexanecarboxylate. Method I starting from 
cis-3-(methoxycarbonyl)cyclohexanecarboxylic acid (0.1 g, 0.54 mmol) and 4-chloroaniline (0.07 
g, 0.54 mmol) gave cis-methyl 3-((4-chlorophenyl)carbamoyl)cyclohexanecarboxylate as white 
solid (0.15 g, 94%); column: 30% EtOAc: 70% Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 9.98 
(s, 1H) 7.62 (d, J = 8.5 Hz, 2H) 7.33 (d, J = 8.5 Hz, 2H) 3.60 (s, 3H) 2.39 (tt, J = 12.3, 3.7 Hz, 
2H) 2.01 (d, J = 13.0 Hz, 1H) 1.89 (d, J = 12.5 Hz, 1H) 1.82 (d, J = 8.8 Hz, 1H) 1.82 (d, J = 8.8 
Hz, 2H) 1.48 (q, J = 12.6 Hz, 1H) 1.37-1.20 (m, 3H); TOF ES+ MS: (M+Na) 318.09; HPLC Ret: 
6.94 min. 
trans-3-((4-chlorophenyl)carbamoyl)cyclohexanecarboxylic acid & trans-N1,N3-bis(4-
chlorophenyl)cyclohexane-1,3-dicarboxamide (CCG-263874). Method I starting from trans-
cyclohexane-1,3-carboxylic acid (0.1 g, 0.58 mmol) and 4-chloroaniline (0.07 g, 0.54 mmol) 
gave trans-3-((4-chlorophenyl)carbamoyl)cyclohexanecarboxylic acid (0.09 g, 55%) and trans-
N1,N3-bis(4-chlorophenyl)cyclohexane-1,3-dicarboxamide as white solid (0.05 g, 22%); column: 
40% EtOAc: Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm trans-3-((4-
chlorophenyl)carbamoyl)cyclohexanecarboxylic acid: 12.13 (br. s, 1H) 9.98 (s, 1H) 7.63 (d, J = 
8.8 Hz, 2H) 7.33 (d, J = 8.8 Hz, 2H) 2.73 (p, J = 4.7 Hz, 1H) 2.60 (tt, J = 9.5, 4.1 Hz, 1H) 2.55-
2.49 (m, 1H) 1.90 (dt, J = 13.9, 4.2 Hz, 1H) 1.86-1.70 (m, 2H) 1.61 (q, J = 5.9 Hz, 2H) 1.55-1.39 
(m, 2H), trans-N1,N3-bis(4-chlorophenyl)cyclohexane-1,3-dicarboxamide: 9.99 (s, 2H) 7.66 (d, J 
= 8.8 Hz, 4H) 7.34 (d, J = 8.8 Hz, 4H) 2.86 (q, J = 5.7 Hz, 2H) 1.89 (t, J = 5.9 Hz, 2H) 1.72-
1.1.61 (m, 6H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 174.72, 138.89, 128.90, 126.84, 121.13, 
39.88, 30.08, 28.81, 21.75; TOF ES+ MS: (M+H) trans-acid: 280.07, (M+Na) bis-amide: 413.08; 
HPLC Ret: trans-acid: 6.20 min, bis-amide: 7.84 min; 99% pure. Note: stereochemical 




carboxylate. Method I starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic 
acid (0.05 g, 0.19 mmol) and 2,3-dihydrobenzo[b][1,4]dioxin-6-amine (0.03 g, 0.19 mmol) gave 
tert-butyl 5-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate 
as yellow solid (0.07 g, 99%); column: 10% to 15% EtOAc: Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 7.79 (br.s, 1H) 7.16 (br. s., 1H) 6.91 (d, J = 8.7 Hz, 1H) 6.80 (d, J = 8.7, 1H) 4.24 (s, 4H) 
4.17 (br. s, 2H) 3.30-3.10 (m, 2H) 2.80-2.75 (m, 1H) 2.51-2.30 (m, 2H) 1.48 (s, 9H); TOF ES+ 
MS: (M+Na) 421.2; HPLC Ret: 7.35 min. 
tert-butyl 5-((3,4-dimethoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate. 
Method I starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.05 g, 
0.19 mmol) and 3,4-dimethoxyaniline (0.03 g, 0.19 mmol) gave tert-butyl 5-((3,4-
dimethoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as yellow solid (0.07 g, 96%); 
column: 30% to 50% EtOAc: Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.91 (br.s., 1H) 7.35 
(br.s, 1H) 7.26 (s, 1H) 6.92 (d, J = 8.6 Hz, 1H) 6.81 (d, J = 8.6, 1H) 4.25-4.05 (m, 2H) 3.87 (2d, 
J = 1.3 Hz, 6H) 3.34-3.30 (m, 2H) 2.81-2.72 (m, 1H) 2.48-2.30 (m, 2H) 1.48 (s, 9H); TOF ES+ 
MS: (M+Na) 423.2; HPLC Ret: 6.79 min. 
(S)-tert-butyl 3-((4-chlorophenyl)carbamoyl)piperidine-1-carboxylate. Method I starting from 
(S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (0.08 g, 0.33 mmol) and 4-chloroaniline 
(0.05 g, 0.36 mmol) gave (S)-tert-butyl 3-((4-chlorophenyl)carbamoyl)piperidine-1-carboxylate 
as white solid (0.11 g, 97%); column 20% to 30% EtOAc/Hex. 1H NMR (500 MHz, CDCl3-d) 𝛿 
ppm 8.43 (br. s, 1H) 7.55 (d, J = 8.3 Hz, 2H) 7.29 (d, J = 8.3 Hz, 2H) 3.79-3.59 (m, 2H) 3.58-
3.42 (m, 2H) 3.40-3.32 (m, 1H) 2.56-2.46 (m, 1H) 2.21-2.15 (m, 1H) 1.93-1.85 (m, 1H) 1.62-1.60 
(m, 1H) 1.46 (s, 9H); TOF ES+ MS: (M+Na) 361.13; HPLC Ret: 7.67 min. 
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(R)-tert-butyl 3-((4-chlorophenyl)carbamoyl)piperidine-1-carboxylate. Method I starting 
from (R)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (0.08 g, 0.33 mmol) and 4-
chloroaniline (0.05 g, 0.36 mmol) gave (R)-tert-butyl 3-((4-chlorophenyl)carbamoyl)piperidine-1-
carboxylate as white solid (0.11 g, 96%); column 20% to 30% EtOAc/Hex. 1H NMR (500 MHz, 
CDCl3-d) 𝛿 8.47 (br. s, 1H) 7.55 (d, J = 8.5 Hz, 2H) 7.29 (d, J = 8.3 Hz, 2H) 3.80-3.30 (m, 5H) 
2.51 (s, 1H) 2.14 (s, 1H) 1.88 (s, 1H) 1.66 (s, 1H) 1.47 (s, 9H); TOF ES+ MS: (M+Na) 361.13; 
HPLC Ret: 7.63 min. 
tert-butyl 5-((4-chlorobenzyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate. Method I 
starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.07 g, 0.26 mmol) 
and (4-chlorophenyl)methanamine (0.04 g, 0.26 mmol) gave tert-butyl 5-((4-
chlorobenzyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as white solid (0.06 g, 57%); 
column: 30% to 40% EtOAc/Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 7.30 (d, J = 8.0 Hz, 2H) 7.18 
(d, J = 8.1 Hz, 2H) 6.63 (br. s, 1H) 4.45-4.31 (m, 2H) 4.05 (d, J = 13.8 Hz, 2H) 3.32-3.19 (m, 2H) 
3.13 (dd, J = 13.9, 9.8 Hz, 1H) 2.62 (s, 1H) 2.38 (s, 1H) 2.26 (s, 1H) 1.43 (s, 9H); TOF ES+ MS: 
(M+Na) 411.13; HPLC Ret: 6.36 min. 
tert-butyl 5-((3-chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate. Method I 
starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.07 g, 0.26 mmol) 
and 3-chloroaniline (0.03 g, 0.26 mmol) gave tert-butyl 5-((3-chlorophenyl)carbamoyl)-3,3-
difluoropiperidine-1-carboxylate as white solid (0.06 g, 65%); column: 15% to 30% EtOAc/Hex; 
1H NMR (500 MHz, CDCl3-d) 𝛿 8.15 (br. s, 1H) 7.71 (s, 1H) 7.36 (d, J = 8.0 Hz, 1H) 7.25 (t, J = 
8.1Hz, 1H) 7.10 (d, J = 8.0 Hz, 1H) 4.15-4.01 (m, 2H) 3.38 (br. s, 2H) 2.79 (s, 1H) 2.50 (s, 1H) 
2.31 (s, 1H) 1.48 (s, 9H); TOF ES+ MS: (M+Na) 397.11; HPLC Ret: 8.01 min. 
tert-butyl 5-((3,4-dichlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate. Method I 
starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.07 g, 0.26 mmol) 
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and 3,4-dichloroaniline (0.04 g, 0.26 mmol) gave tert-butyl 5-((3,4-dichlorophenyl)carbamoyl)-
3,3-difluoropiperidine-1-carboxylate as yellow solid (0.06 g, 57%); column: 15% to 30% 
EtOAc/Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 8.39 (br. s, 1H) 7.85 (s, 1H) 7.39-7.34 (m, 1H) 7.28-
7.25 (m, 1H) 4.00-3.94 (m, 2H) 3.51 (br. s, 2H) 2.80 (s, 1H) 2.55 (s, 1H) 2.28 (s, 1H) 1.48 (s, 
9H); TOF ES+ MS: (M+Na) 431.07; HPLC Ret: 8.42 min. 
tert-butyl 5-((3-(((tert-butyldiphenylsilyl)oxy)methyl)-4-chlorophenyl)carbamoyl)-3,3-
difluoropiperidine-1-carboxylate. Method I starting from 1-(tert-butoxycarbonyl)-5,5-
difluoropiperidine-3-carboxylic acid (0.12 g, 0.45 mmol) and 3-(((tert-
butyldiphenylsilyl)oxy)methyl)-4-chloroaniline (0.18 g, 0.45 mmol) gave tert-butyl 5-((3-(((tert-
butyldiphenylsilyl)oxy)methyl)-4-chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as 
white solid (0.19 g, 66%); column: 15% to 20% EtOAc/Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 8.09 
(br. s, 1H) 7.73-7.65 (m, 6H) 7.48-7.36 (m, 6H) 7.28-7.21 (m, 2H) 4.79 (s, 2H) 4.25-4.17 (m, 1H) 
3.21-3.15 (m, 2H) 2.85-2.78 (m, 1H) 2.40-2.30 (m, 2H) 1.48 (s, 9H) 1.14 (s, 9H); TOF ES+ MS: 
(M+H) 643.26; HPLC Ret: >13 min. 
tert-butyl 3-((4-chlorophenyl)carbamoyl)-5,5-difluoro-3-methylpiperidine-1-carboxylate. 
Method I starting from 1-(tert-butoxycarbonyl)-5,5-difluoro-3-methylpiperidine-3-carboxylic acid 
(0.07 g, 0.25 mmol) and 4-chloroaniline (0.03 g, 0.25 mmol) gave tert-butyl 3-((4-
chlorophenyl)carbamoyl)-5,5-difluoro-3-methylpiperidine-1-carboxylate as yellow solid (0.07 g, 
72%); column: 15% to 20% EtOAc/Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 9.10 (br. s, 1H) 7.62 (d, 
J = 8.5 Hz, 2H) 7.25 (d, J = 8.1 Hz, 2H) 4.56 (br. s, 1H) 4.27 (br. s, 1H) 3.12 (br. s, 2H) 1.74-
1.61 (m, 1H) 1.48 (s, 9H) 1.31 (s, 3H); TOF ES+ MS: (M+Na) 395.15; HPLC Ret: 8.17 min. 
tert-butyl 5-((4-chloropyridin-2-yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate. Method 
I starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.06 g, 0.23 
mmol) and 4-chloropyridin-2-amine (0.03 g, 0.23 mmol) gave tert-butyl 5-((4-chloropyridin-2-
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yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as colorless oil (0.04 g, 47%); column: 10% 
to 25% EtOAc/Hex; reaction done at 85 oC; 1H NMR (500 MHz, CDCl3-d) 𝛿 8.47 (br. s, 1H) 8.26 
(s, 1H) 8.18 (d, J = 5.4 Hz, 1H) 7.07 (d, J = 5.3 Hz, 1H) 4.39-4.18 (m, 2H) 3.19-2.95 (m, 2H) 
2.81 (s, 1H) 2.45-2.21 (s, 2H) 1.48 (s, 9H); TOF ES+ MS: (M+Na) 398.11; HPLC Ret: 7.10 min. 
tert-butyl 5-((5-chloropyridin-3-yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate. Method 
I starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.06 g, 0.23 
mmol) and 5-chloropyridin-3-amine (0.03 g, 0.23 mmol) gave tert-butyl 5-((5-chloropyridin-3-
yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as colorless oil (0.04 g, 49%); column: 10% 
to 35% EtOAc/Hex; reaction done at 55 °C; 1H NMR (500 MHz, CDCl3-d) 𝛿 9.05 (br. s, 1H) 8.49 
(s, 1H) 8.33 (d, J = 15.2 Hz, 2H) 3.94 (s, 2H) 3.48 (s, 2H) 2.88 (s, 1H) 2.56 (s, 1H) 2.29 (s, 1H) 
1.48 (s, 9H); TOF ES+ MS: (M+H) 376.12; HPLC Ret: 7.13 min. 
tert-butyl 5-((2-chloropyridin-4-yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate. Method 
I starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.06 g, 0.23 
mmol) and 2-chloropyridin-4-amine (0.03 g, 0.23 mmol) gave tert-butyl 5-((2-chloropyridin-4-
yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as yellow oil (0.01 g, 16%); column: 35% 
EtOAc/Hex; reaction done at 85 oC; 1H NMR (500 MHz, CDCl3-d) 𝛿 9.37 (br. s, 1H) 8.26 (d, J = 
5.6 Hz, 1H) 7.71 (s, 1H) 7.41 (dd, J = 5.7, 1.8 Hz, 1H) 3.98 (s, 2H) 3.41 (s, 2H) 2.88 (s, 1H) 2.52 
(s, 1H) 2.29 (s, 1H) 1.48 (s, 9H); TOF ES+ MS: (M+H) 376.12; HPLC Ret: 7.26 min. 
tert-butyl 5-((6-chloropyridin-2-yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate. Method 
I starting from 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid (0.06 g, 0.23 
mmol) and 6-chloropyridin-2-amine (0.03 g, 0.23 mmol) gave tert-butyl 5-((6-chloropyridin-2-
yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate as colorless oil (0.04 g, 44%); column: 10-
15% EtOAc/Hex; reaction done at 85 °C; 1H NMR (500 MHz, CDCl3-d) 𝛿 8.44 (br. s, 1H) 8.11-
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8.05 (m, 1H) 7.72-7.65 (s, 1H) 7.12-7.06 (m, 1H) 4.45-4.18 (m, 2H) 3.09 (s, 2H) 2.80 (s, 1H) 
2.39 (s, 1H) 2.32-2.22 (m, 1H) 1.48 (s, 9H); TOF ES+ MS: (M+Na) 398.10; HPLC Ret: 7.71 min. 
tert-butyl 5-((4-chloro-3-(prop-2-yn-1-yloxy)phenyl)carbamoyl)-3,3-difluoropiperidine-1-
carboxylate. Method J followed by Method I starting from tert-butyl (4-chloro-3-(prop-2-yn-1-
yloxy)phenyl)carbamate (0.11 g, 0.40 mmol) and 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-
3-carboxylic acid (0.11 g, 0.40 mmol) gave tert-butyl 5-((4-chloro-3-(prop-2-yn-1-
yloxy)phenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.1 g, 58%) as white solid; 
column: 15% to 20% EtOAc/Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.40 (br. s, 1H) 7.65-7.60 
(m, 1H) 7.29 (d, J = 13.8 Hz, 1H) 7.01 (d, J = 8.6 Hz, 1H) 4.78 (d, J = 2.6 Hz, 2H) 4.11-4.05 (m, 
1H) 3.45-3.29 (m, 2H) 2.85-2.79 (m, 1H) 2.57 (d, J = 3.0 Hz, 1H) 2.56-2.30 (m, 2H) 1.49 (s, 9H); 
HPLC Ret: 7.88 min. 
tert-butyl (3-((4-chlorophenyl)carbamoyl)phenyl)carbamate. In a 25 mL round bottomed 
flask, 3-((tert-butoxycarbonyl)amino)benzoic acid (0.2 g, 0.84 mmol) was dissolved in DMF (4 
mL) and HATU (0.39 g, 1.01 mmol), 4-chloroaniline (0.13 g, 1.01 mmol), and DIPEA (0.22 g, 0.3 
mL, 1.69 mmol) were added. The reaction was stirred at 25 °C for 1 hr and then heated at 150 
°C for 30 min. The reaction was cooled to room temperature and then concentrated in vacuo. 
The subsequent oil was subjected to silica gel chromatography eluting with 30% EtOAc: 70% 
Hex. The fractions containing product were concentrated in vacuo to produce white solid. 
Yield=70%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.95 (t, J = 1.9 Hz, 1H) 7.87 (br. s., 1H) 7.60 (d, 
J = 8.0 Hz, 2H) 7.56-7.47 (m, 2H) 7.40 (t, J = 7.9 Hz, 1H) 7.33 (d, J = 8.0 Hz, 2H) 6.62 (s, 1H) 
1.54 (s, 9H); TOF ES+ MS: (M+H) 247.1; HPLC Ret: 7.74 min. 
tert-butyl (5-((4-chlorophenyl)carbamoyl)pyridin-3-yl)carbamate. 5-((tert-
butoxycarbonyl)amino)nicotinate, Et3NH+ (0.34 g, 1.00 mmol) was dissolved in DMF (4 mL) and 
HATU (0.76 g, 2.00 mmol), 4-chloroaniline (0.14 g, 1.10 mmol), and DIPEA (0.32 g, 0.44 mL, 
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2.50 mmol) were added. The reaction was stirred at 25 °C for 1 hr and then at 150 °C for 2 hr. 
Brine (20 mL) was added, the product was extracted with EtOAc (3 x 15 mL), and the organic 
layers combined, washed with dilute HCl (3 x 15 mL) and NaHCO3 (3 x 15 mL), dried with 
MgSO4, and concentrated in vacuo. The subsequent oil was subjected to silica gel 
chromatography eluting with 100% EtOAc. The fractions containing product were concentrated 
in vacuo to produce colorless oil. Yield=20.2%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.55 (s, 
1H) 9.82 (s, 1H) 8.73 (dd, J = 15.6, 2.2 Hz, 1H) 8.39 (t, J = 2.2 Hz, 1H) 7.79 (d, J = 10 Hz, 2H) 
7.43 (d, J = 10 Hz, 2H) 1.50 (s, 9H); TOF ES+ MS: (M+H) 348.1; HPLC Ret: 6.63 min. 
tert-butyl 3-((4-chlorophenyl)carbamoyl)-5,6-dihydropyridine-1(2H)-carboxylate. In a 25 
mL round bottomed flask, 1-(tert-butoxycarbonyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid 
(0.12 g, 0.53 mmol) was dissolved in THF (2 mL) and EDC (0.15 g, 0.8 mmol), DMAP (0.03 g, 
0.26 mmol), 4-chloroaniline (0.08 g, 0.63 mmol), and DIPEA (0.14 g, 0.18 mL, 1.06 mmol) were 
added. The reaction was stirred at 25 °C for 5 hr and the reaction was concentrated in vacuo. 
The product was partitioned between H2O and DCM, extracted with DCM (3 x 20 mL), washed 
with sat. NaHCO3 (2 x 20 mL), 10% citric acid (2 x 20 mL), and brine (3 x 20 mL), dried with 
MgSO4, and concentrated in vacuo. The product was crystalized with EtOAc/Hex to afford white 
powder. Yield=79%. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.49 (d, J = 8.5 Hz, 2H) 7.30 (d, J = 
8.5 Hz, 2H) 6.69 (br. s, 1H) 4.23 (br. s, 2H) 3.53 (t, J = 5.8 Hz, 2H) 2.34 (br. s., 2H) 1.49 (s, 9H); 
QTOF ES+ MS: (M+H) 337.13. 
tert-butyl (cis-3-(4-chlorobenzamido)cyclopentyl)carbamate. Method I starting from cis-(t-
butyl-3-aminocyclopentyl)carbamate, HCl (0.2 g, 0.85 mmol) and 4-chlorobenzoic acid (0.13 g, 
0.85 mmol) gave tert-butyl (cis-3-(4-chlorobenzamido)cyclopentyl)carbamate as white solid 
(0.23 g, 80%); column: 50% to 60% EtOAc:Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.41 (d, J 
= 7.4 Hz, 1H) 7.85 (d, J = 8.5 Hz, 2H) 7.53 (d, J = 8.4 Hz, 2H) 6.92 (d, J = 7.5 Hz, 1H) 4.20 (h, J 
= 7.4 Hz, 1H) 3.78 (q, J = 7.4 Hz, 1H) 2.22 (dt, J = 14.3, 7.6 Hz, 1H) 1.87 (dq, J = 12.6, 7.0, 6.4 
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Hz, 1H) 1.79 (dq, J = 14.3, 7.5, 6.6 Hz, 1H) 1.68-1.50 (m, 2H) 1.43 (dd, J = 13.6, 7.0 Hz, 1H) 
1.38 (s, 9H); TOF ES+ MS: (M+H) 339.15; HPLC Ret: 6.88 min. 
tert-butyl (trans-3-(4-chlorobenzamido)cyclopentyl)carbamate. Method I starting from trans-
t-butyl-(3-aminocyclopentyl)carbamate (0.08 g, 0.37 mmol) and 4-chlorobenzoic acid (0.06 g, 
0.37 mmol) gave tert-butyl (trans-3-(4-chlorobenzamido)cyclopentyl)carbamate as white solid 
(0.12 g, 97%); column: 40% to 80% EtOAc:Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 8.40 (d, J 
= 7.3 Hz, 1H) 7.86 (d, J = 8.2 Hz, 2H) 7.52 (d, J = 8.1 Hz, 2H) 6.91 (d, J = 7.4 Hz, 1H) 4.33 (h, J 
= 7.1 Hz, 1H) 3.96 (q, J = 7.0 Hz, 1H) 2.06-1.92 (m, 2H) 1.78 (tt, J = 12.1, 6.8 Hz, 2H) 1.49 (dd, 
J = 12.1, 7.9 Hz, 1H) 1.43 (dd, J = 17.7, 10.0 Hz, 1H) 1.38 (s, 9H); TOF ES+ MS: (M+Na) 
361.13; HPLC Ret: 6.76 min. 
tert-butyl (trans-3-(4-chlorobenzamido)cyclohexyl)carbamate & tert-butyl (cis-3-(4-
chlorobenzamido)cyclohexyl)carbamate. Method I starting from tert-butyl (3-
aminocyclohexyl)carbamate (0.18 g, 0.82 mmol) and 4-chlorobenzoic acid (0.13 g, 0.82 mmol) 
gave a mixture tert-butyl (trans-3-(4-chlorobenzamido)cyclohexyl)carbamate (0.06 g, 40%) & 
tert-butyl (cis-3-(4-chlorobenzamido)cyclohexyl)carbamate (0.04 g, 29%) as white solid; column: 
25% to 40% EtOAc:Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm trans: 8.20 (d, J = 7.5 Hz, 1H) 
7.86 (d, J = 8.2 Hz, 2H) 7.52 (d, J = 8.2 Hz, 2H) 6.86 (d, J = 7.7 Hz, 1H) 4.19-4.06 (m, 1H) 3.80-
3.74 (m, 1H) 1.69-1.50 (m, 6H) 1.48-1.37 (m, 11H), cis: 8.34 (d, J = 7.9 Hz, 1H) 7.86 (d, J = 8.2 
Hz, 2H) 7.52 (d, J = 8.2 Hz, 2H) 6.84 (d, J = 8.1 Hz, 1H) 3.82-3.73 (m, 1H) 3.35-3.22 (m, 1H) 
1.94 (d, J = 11.9 Hz, 1H) 1.74 (t, J = 16.0, 3H) 1.38 (s, 9H) 1.33-1.15 (m, 3H) 1.11-1.03 (m, 1H); 
TOF ES+ MS: (M+Na) trans: 375.15, (M+Na) cis: 375.15; HPLC Ret: trans: 7.08 min, cis: 6.93 
min. Note: Amide coupling was performed with tert-butyl (cis-3-aminocyclohexyl)carbamate 
purchased from vendor to confirm assignment of the mixture. 
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tert-butyl (3-(4-chlorobenzamido)-4-methylphenyl)carbamate. Method I starting from t-butyl-
(3-amino-4-methylphenyl)carbamate (0.07 g, 0.32 mmol) and 4-chlorobenzoic acid (0.05 g, 0.32 
mmol) gave tert-butyl (3-(4-chlorobenzamido)-4-methylphenyl)carbamate as white solid (0.09 g, 
76%); column: 20% EtOAc: Hex. 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.99 (d, J = 7.8 Hz, 2H) 
7.60 (d, J = 7.8 Hz, 2H) 7.51 (br. s, 1H) 7.21 (dd, J = 8.3, 2.2 Hz, 1H) 7.12 (d, J = 8.4 Hz, 1H) 
2.13 (s, 3H) 1.47 (s, 9H); TOF ES+ MS: (M+Na) 383.1; HPLC Ret: 7.66 min. 
cis-methyl 3-(3-(furan-2-yl)benzamido)cyclohexanecarboxylate. In a dry 25 mL round 
bottomed flask cis-methyl 3-(((benzyloxy)carbonyl)amino)cyclohexanecarboxylate (0.88 g, 3.00 
mmol) was dissolved in MeOH (8 mL) and the solvent was degassed. Pd/C (10%, Degussa) 
(0.16 g, 0.15 mmol) was added and the reaction proceeded at 25 °C for 12 hr under balloon of 
H2. The catalyst was filtered through a pad of Celite and the filtrate was concentrated producing 
yellow oil. 3-(furan-2-yl)benzoic acid (0.24 g, 1.27 mmol) was dissolved in DMF (4 mL) and cis-
methyl 3-aminocyclohexanecarboxylate (0.2 g, 1.27 mmol), HATU (0.58 g, 1.53 mmol), and N-
methylmorpholine (0.52 g, 0.56 mL, 5.09 mmol) were added. The reaction proceeded at 25 °C 
for 16 hr. Brine (20 mL) was added and the product was extracted with EtOAc (3 x 20 mL). The 
combined organic layers were washed with sat. NaHCO3 (2 x 20 mL), dilute HCl (2 x 20 mL), 
dried with MgSO4, and evaporated in vacuo. The subsequent oil was subjected to silica gel 
chromatography eluting with 30% EtOAc: 70% Hex. The fractions containing product were 
concentrated in vacuo to produce colorless oil. Yield=21% (2 steps). 1H NMR (500 MHz, CDCl3-
d) 𝛿 ppm 8.48 (d, J = 8.4 Hz, 1H) 8.15 (s, 1H) 7.93-7.70 (m, 3H) 7.51-7.43 (m, 1H) 7.14 (d, J = 
3.4 Hz, 1H) 6.56-6.44 (m, 1H) 4.12-3.94 (m, 1H) 3.68 (s, 3H) 3.47-3.35 (m, 1H) 2.54 (td, J = 
11.3, 6.1 Hz, 1H) 2.41-2.27 (m, 2H) 1.94-1.85 (m, 1H) 1.55-1.34 (m, 4H); HPLC Ret: 6.42 min. 
cis-3-(3-(furan-2-yl)benzamido)cyclohexanecarboxylic acid. Method G starting from cis-
methyl 3-(3-(furan-2-yl)benzamido)cyclohexanecarboxylate (0.09 g, 0.27 mmol) gave cis-3-(3-
(furan-2-yl)benzamido)cyclohexanecarboxylic acid as white solid (0.04, 48%); 1H NMR (500 
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MHz, DMSO-d6) 𝛿 ppm 11.98 (br. s., 1H) 8.76-8.71 (m, 1H) 8.48 (d, J = 7.9 Hz, 1H) 8.14 (s, 1H) 
7.86-7.70 (m, 2H) 7.54-7.46 (m, 1H) 7.02 (d, J = 3.4 Hz, 1H) 6.63 (d, J = 2.6 Hz, 1H) 2.39-2.31 
(m, 1H) 2.09-2.02 (m, 1H) 1.90-1.76 (m, 4H) 1.47-1.14 (m, 4H); TOF ES+ MS: (M+H) 314.1; 
HPLC Ret: 6.05 min. 
cis tert-butyl (3-(3-(furan-2-yl)benzamido)cyclohexyl)carbamate. Method I starting from cis 
t-butyl-(3-aminocyclohexyl)carbamate (0.1 g, 0.47 mmol) and 3-(furan-2-yl)benzoic acid (0.09 g, 
0.47 mmol) gave cis tert-butyl (3-(3-(furan-2-yl)benzamido)cyclohexyl)carbamate as white solid 
(0.1 g, 53%); column: 2.5% MeOH/DCM then crystalized from DCM/MeOH; 1H NMR (500 MHz, 
DMSO-d6) 𝛿 ppm 8.38 (d, J = 8.0 Hz, 1H) 8.14 (s, 1H) 7.86-7.77 (m, 2H) 7.74 (d , J = 7.8 Hz, 
1H) 7.50 (t, J = 7.8 Hz, 1H) 7.02 (d, J = 3.3 Hz, 1H) 6.86 (d, J = 8.1 Hz, 1H) 6.63 (dt, J = 3.1, 1.4 
Hz, 1H) 3.88-3.73 (m, 1H) 3.34-3.24 (m, 1H) 1.97 (d, J = 11.8 Hz, 1H) 1.76 (dd, J = 24.9, 12.2, 
3H) 1.38 (s, 9H) 1.37-1.20 (m, 3H) 1.08 (q, J = 12.2 Hz, 1H); TOF ES+ MS: (M+Na) 385.21; 
HPLC Ret: 7.21 min. 
cis tert-butyl (3-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)cyclohexyl)carbamate. 
Method I starting from cis t-butyl-(3-aminocyclohexyl)carbamate (0.01 g, 0.47 mmol) and 2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxylic acid (0.08 g, 0.47 mmol) gave c cis tert-butyl (3-(2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxamido)cyclohexyl)carbamate as white solid (0.1 g, 56%); 
column: 2.5% MeOH/DCM then crystalized from DCM/MeOH; 1H NMR (500 MHz, DMSO-d6) 𝛿 
ppm 8.07 (d, J = 7.9 Hz, 1H) 7.40-7.33 (m, 2H) 6.89 (d , J = 8.4 Hz, 1H) 6.82 (d, J = 8.1 Hz, 1H) 
4.27 (q, J = 5.1 Hz, 4H) 3.79-3.71 (m, 1H) 3.32-3.25 (m, 1H) 1.91 (d, J = 11.8 Hz, 1H) 1.71 (d, J 
= 10.7, 3H) 1.38 (s, 9H) 1.37-1.17 (m, 3H) 1.05 (q, J = 12.1 Hz, 1H); TOF ES+ MS: (M+Na) 




methyl 5-(3-(furan-2-yl)benzamido)-2-methylbenzoate. Method I starting from methyl 5-
amino-2-methylbenzoate (0.04 g, 0.27 mmol) and 3-(furan-2-yl)benzoic acid (0.05 g, 0.27 mmol) 
gave methyl 5-(3-(furan-2-yl)benzamido)-2-methylbenzoate as white solid (0.08 g, 84%); 
column: 20% to 30% EtOAc: Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 8.18-8.14 (m, 1H) 8.13-
8.08 (m, 1H) 7.90-7.82 (m, 3H) 7.75 (dp, J = 7.7, 1.0 Hz, 1H) 7.55-7.48 (m, 2H) 7.30 (d, J = 12.1 
Hz, 1H) 6.77 (dt, J = 3.4, 0.9 Hz, 1H) 6.52 (dt, J = 3.1, 1.3 Hz, 1H) 3.91 (s, 3H) 2.60 (s, 3H); 
TOF ES+ MS: (M+H) 336.1; HPLC Ret: 7.79 min. 
methyl 1-(5,6-difluoro-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-carboxylate. Method 
J followed by Method I starting from 1-tert-butyl 3-methyl 5,5-difluoropiperidine-1,3-dicarboxylate 
(0.15 g, 0.65 mmol) and 5,6-difluoro-1H-indole-2-carboxylic acid (0.13 g, 0.65 mmol) gave 
methyl 1-(5,6-difluoro-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-carboxylate (0.14 g, 60% (2 
steps)) as white solid; column: 40% EtOAc: 60% Hex; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 9.41 
(br. s, 1H) 7.40 (dd, J = 10.3, 7.7 Hz, 1H) 7.26 (s, 1H) 7.21 (dd, J = 10.3, 6.6 Hz, 1H) 6.87-6.82 
(m, 1H) 4.79-4.65 (m, 2H) 3.79 (s, 3H) 3.49 (dd, J = 27.0, 13.9 Hz, 1H) 3.40-3.19 (m, 1H) 2.98 
(tt, J = 10.5, 4.4 Hz, 1H) 2.59 (d, J = 11.7 Hz, 1H) 2.30-2.20 (m, 1H); QTOF ES+ MS: (M+H) 
359.20; HPLC Ret: 6.83 min. 
methyl 5,5-difluoro-1-(5-(trifluoromethoxy)-1H-indole-2-carbonyl)piperidine-3-carboxylate. 
Method J followed by Method I starting from 1-tert-butyl 3-methyl 5,5-difluoropiperidine-1,3-
dicarboxylate (0.15 g, 0.65 mmol) and 5-(trifluoromethoxy)-1H-indole-2-carboxylic acid (0.16 g, 
0.65 mmol) gave methyl 5,5-difluoro-1-(5-(trifluoromethoxy)-1H-indole-2-carbonyl)piperidine-3-
carboxylate (0.17 g, 64% (2 steps)) as yellow solid; column: 35% EtOAc: 65% Hex; 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 9.39 (br. s, 1H) 7.54 (s, 1H) 7.42 (d, J = 8.9 Hz, 1H) 7.18 (dd, J = 
8.9, 2.2 Hz, 1H) 6.92-6.87 (m, 1H) 4.80-4.60 (m, 2H) 3.78 (s, 3H) 3.49 (dd, J = 27.0, 13.9 Hz, 
1H) 3.45-3.17 (m, 1H) 2.98 (tt, J = 10.5, 4.5 Hz, 1H) 2.59 (d, J = 11.2 Hz, 1H) 2.30-2.20 (m, 1H); 
QTOF ES+ MS: (M+H) 307.10; HPLC Ret: 7.39 min. 
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methyl 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxylate. Method J 
followed by Method I starting from 1-tert-butyl 3-methyl 5,5-difluoropiperidine-1,3-dicarboxylate 
(0.39 g, 1.79 mmol) and 3-fluoro-5-(pyridin-4-yl)benzoic acid (0.39 g, 1.79 mmol) gave methyl 
5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxylate (0.65 g, 96% (2 steps)) 
as yellow solid; column: 80% EtOAc: 20% Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 8.80-8.66 
(m, 2H) 7.95 (s, 1H) 7.86 (d, J = 9.7 Hz, 1H) 7.84-7.77 (m, 2H) 7.72 (br. s, 1H) 7.45-7.36 (m, 
1H) 4.58 (br. s, 1H) 4.26 (br. s, 1H) 3.70 (br. s, 1H) 3.56 (br. s, 2H) 3.02 (br. s, 1H) 2.89 (s, 3H) 
2.47-2.30 (m, 1H); QTOF ES+ MS: (M+H) 379.13; HPLC Ret: 4.73 min. 
5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxylic acid. Method G 
starting from methyl 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxylate (0.7 
g, 1.72 mmol) gave 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxylic acid 
(0.35 g, 56%); filtered solid that formed after acidification; crystalized with EtOH; 1H NMR (500 
MHz, DMSO-d6) 𝛿 ppm 13.50 (br. s, 1H) 8.80-8.66 (m, 2H) 7.95 (s, 1H) 7.86 (d, J = 9.7 Hz, 1H) 
7.84-7.77 (m, 2H) 7.72 (br. s, 1H) 7.45-7.36 (m, 1H) 4.58 (br. s, 1H) 4.26 (br. s, 1H) 3.70 (br. s, 
1H) 3.56 (br. s, 2H) 3.02 (br. s, 1H) 2.47-2.30 (m, 1H); QTOF ES+ MS: (M+H) 365.1; HPLC Ret: 
2.10 min. 
1-(3-(furan-2-yl)benzoyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid. Method M followed 
by Method N starting from 3-(furan-2-yl)benzoic acid (0.1 g, 0.53 mmol) and 1,2,5,6-
tetrahydropyridine-3-carboxylic acid, HBr (0.12, 0.59 mmol) gave 1-(3-(furan-2-yl)benzoyl)-
1,2,5,6-tetrahydropyridine-3-carboxylic acid as yellow solid (0.08 g, 47% (2 steps)); column: 
2.5% MeOH/DCM; 1H NMR (500 MHz, CDCl3-d) 𝛿 ppm 7.73 (d, J = 6.8 Hz, 1H) 7.49-7.42 (m, 
2H) 7.32-7.19 (m, 2H) 6.69 (d, J = 3.4 Hz, 1H) 6.48 (dd, J = 3.4, 1.8 Hz, 1H) 4.47 (br. s, 1H) 
4.18 (br. s, 1H) 3.85 (br. s, 1H) 3.51 (br. s, H) 2.51-2.35 (m, 2H); QTOF ES- MS: (M-H) 296.09; 
HPLC Ret: 5.66 min. 
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1-(3-fluoro-5-(pyridin-4-yl)benzoyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid. Method M 
followed by Method N starting from 3-fluoro-5-(pyridin-4-yl)benzoic acid (0.1 g, 0.47 mmol) and 
1,2,5,6-tetrahydropyridine-3-carboxylic acid, HBr (0.1, 0.49 mmol) gave 1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid as yellow solid (0.07 g, 45% (2 steps)); 
column: 8% to 10% MeOH: DCM; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 12.65 (br. s, 1H) 8.67 
(d, J = 7.8 Hz, 2H) 7.88-7.78 (m, 2H) 7.72 (s, 1H) 7.41 (d, J = 8.3 Hz, 1H) 7.00 (s, 1H) 5.76 (d, J 
= 1 Hz, 1H) 4.27 (br. s, 1H) 4.05 (br. s, 1H) 3.72 (br. s, 1H) 3.39 (br. s, 1H) 2.42-2.33 (m, 2H); 
QTOF ES+ MS: (M+H) 327.11; HPLC Ret: 3.90 min. 
N-(trans-3-((4-chlorophenyl)carbamoyl)cyclohexyl)-3-(furan-2-yl)benzamide. (CCG-
257863) Method J followed by Method I starting from tert-butyl (trans-3-((4-
chlorophenyl)carbamoyl)cyclohexyl)carbamate (0.14 g, 0.40 mmol) and 3-(furan-2-yl)benzoic 
acid (0.08 g, 0.4 mmol) gave N-(trans-3-((4-chlorophenyl)carbamoyl)cyclohexyl)-3-(furan-2-
yl)benzamide (0.07 g, 44% (2 steps)) as white solid; column: 50% EtOAc: 50% Hex; 1H NMR 
(500 MHz, DMSO-d6) 𝛿 ppm 9.89 (s, 1H) 8.18-8.12 (m, 2H) 7.87-7.74 (m, 3H) 7.64 (d, J = 8.9 
Hz, 2H) 7.51 (t, J = 7.7 Hz, 1H) 7.34 (d, J = 8.8 Hz, 2H) 7.04 (d, J = 3.4 Hz, 1H) 6.64 (dd, J = 
3.4, 1.8 Hz, 1H) 4.25-4.19 (m, 1H) 2.82-2.77 (m, 1H) 1.88 (t, 5.8 Hz, 2H) 1.72-1.59 (m, 6H); 13C 
NMR (500 MHz, DMSO-d6) 𝛿 ppm 174.45, 166.21, 152.95, 143.69, 138.80, 136.16, 130.70, 
129.21, 128.94, 126.90, 126.27, 122.76, 121.22, 112.63, 109.98, 107.00, 45.49, 40.42, 33.06, 
30.57, 28.65, 20.98; TOF ES+ MS: (M+H) 423.1; HPLC Ret: 7.57 min; 98 % pure. 
N-(cis-3-((4-chlorophenyl)carbamoyl)cyclopentyl)-3-(furan-2-yl)benzamide. (CCG-257942). 
Method J followed by Method I starting from tert-butyl (cis-3-((4-
chlorophenyl)carbamoyl)cyclopentyl)carbamate (0.36 g, 1.05 mmol) and 3-(furan-2-yl)benzoic 
acid (0.19 g, 1.02 mmol) gave N-(cis-3-((4-chlorophenyl)carbamoyl)cyclopentyl)-3-(furan-2-
yl)benzamide (0.29 g, 69% (2 steps)) as white solid; the solid was washed with EtOAc; 1H NMR 
(500 MHz, DMSO-d6) 𝛿 ppm 10.13 (s, 1H) 8.63 (d, J = 7.5 Hz, 1H) 8.21-8.18 (m, 1H) 7.87-7.74 
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(m, 3H) 7.68 (d, J = 8.3 Hz, 2H) 7.52 (t, J = 7.6 Hz, 1H) 7.36 (d, J = 8.4 Hz, 2H) 7.03 (d, J = 3.4 
Hz, 1H) 6.64 (dd, J = 3.4, 1.8 Hz, 1H) 4.42-4.32 (m, 1H) 2.95 (p, J = 7.7 Hz, 1H) 2.24 (dt, J = 
14.1, 7.1 Hz, 1H) 2.09-1.85 (m, 3H) 1.79-1.71 (m, 1H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 
174.79, 165.76, 152.95, 143.67, 138.68, 135.67, 130.78, 129.35, 129.01, 127.11, 126.67, 
126.28, 122.53, 121.20, 112.61, 106.94, 51.49, 44.00, 36.51, 32.31, 28.02; TOF ES+ MS: 
(M+H) 409.1; HPLC Ret: 7.75 min; 100 % pure. 
N-(trans-3-((4-chlorophenyl)carbamoyl)cyclopentyl)-3-(furan-2-yl)benzamide (CCG-
258452). Method J followed by Method I starting from tert-butyl (trans-3-((4-
chlorophenyl)carbamoyl)cyclopentyl)carbamate (0.18 g, 0.52 mmol) and 3-(furan-2-yl)benzoic 
acid (0.11 g, 0.52 mmol) gave N-(trans-3-((4-chlorophenyl)carbamoyl)cyclopentyl)-3-(furan-2-
yl)benzamide (0.07 g, 29% (2 steps)) as white solid; column: 2% MeOH: 98% DCM; 1H NMR 
(500 MHz, DMSO-d6) 𝛿 ppm 10.04 (s, 1H) 8.46 (d, J = 6.9 Hz, 1H) 8.15 (t, J = 1.8 Hz, 1H) 7.87-
7.78 (m, 2H) 7.76 (dt, J = 7.8, 1.3 Hz, 1H) 7.65 (d, J = 8.4 Hz, 2H) 7.51 (t, J = 7.8 Hz, 1H) 7.35 
(d, J = 8.5 Hz, 2H) 7.04 (d, J = 3.3 Hz, 1H) 6.64 (dd, J = 3.4, 1.8 Hz, 1H) 4.39 (h, J = 6.7 Hz, 
1H) 3.04 (p, J = 7.8 Hz, 1H) 2.17-2.01 (m, 3H) 1.91 (ddd, J = 13.1, 8.9, 5.8 Hz, 1H) 1.79 (dq, J = 
11.7, 7.1 Hz, 1H) 1.70 (ddt, J = 14.0, 11.9, 4.8 Hz, 1H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 
174.57, 166.13, 152.93, 143.70, 138.79, 135.87, 130.73, 129.28, 128.99, 126.94, 126.77, 
126.30, 122.62, 121.12, 112.64, 107.00, 51.51, 44.01, 36.57, 32.44, 28.88; TOF ES+ MS: 
(M+H) 409.13; HPLC Ret: 7.30 min; 98 % pure. 
N-(cis-3-(4-chlorobenzamido)cyclopentyl)-3-(furan-2-yl)benzamide. (CCG-263875). Method 
J followed by Method I starting from tert-butyl (cis-3-(4-chlorobenzamido)cyclopentyl)carbamate 
(0.04 g, 0.22 mmol) and 3-(furan-2-yl)benzoic acid (0.04 g, 0.22 mmol) gave N-(cis-3-(4-
chlorobenzamido)cyclopentyl)-3-(furan-2-yl)benzamide (0.09 g, 97% (2 steps)) as pink solid; 
column: 80% to 100% EtOAc: Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 8.57 (dd, J = 11.6, 7.0 
Hz, 2H) 8.16 (s, 1H) 7.92-7.86 (m, 2H) 7.84 (dd, J = 7.8, 1.6 Hz, 1H) 7.82-7.73 (m, 2H) 7.58-
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7.48 (m, 3H) 7.02 (d, J = 3.4 Hz, 1H) 6.64 (dt, J = 3.0, 1.3 Hz, 1H) 4.26 (dp, J = 14.1, 6.9 Hz, 
2H) 2.37 (dt, J = 13.0, 7.4 Hz, 1H) 1.97 (dq, J = 13.3, 7.1 Hz, 2H) 1.81 (td, J = 7.1, 6.5, 4.0 Hz, 
2H) 1.69 (dt, J = 13.0, 8.0 Hz, 1H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 166.13, 165.35, 
152.90, 143.68, 136.30, 135.87, 133.86, 130.75, 129.66, 129.32, 128.71, 126.72, 126.30, 
122.57, 112.63, 106.99, 50.03, 49.98, 38.91, 38.68, 30.66, 30.63; TOF ES+ MS: (M+H) 409.13; 
HPLC Ret: 7.13 min; 98 % pure. 
N-(trans-3-(4-chlorobenzamido)cyclopentyl)-3-(furan-2-yl)benzamide. (CCG-263877). 
Method J followed by Method I starting from tert-butyl (trans-3-(4-
chlorobenzamido)cyclopentyl)carbamate (0.04 g, 0.22 mmol) and 3-(furan-2-yl)benzoic acid 
(0.06 g, 0.22 mmol) gave N-(trans-3-(4-chlorobenzamido)cyclopentyl)-3-(furan-2-yl)benzamide 
(0.05 g, 55% (2 steps)) as orange solid; column: 50% to 100% EtOAc: Hex; 1H NMR (500 MHz, 
DMSO-d6) 𝛿 ppm 8.52 (dd, J = 11.7, 7.4 Hz, 2H) 8.16 (s, 1H) 7.93-7.75 (m, 5H) 7.57-7.49 (m, 
3H) 7.03 (d, J = 3.4 Hz, 1H) 6.64 (dd, J = 3.3, 1.8 Hz, 1H) 4.51 (dp, J = 14.1, 6.9 Hz, 2H) 2.14 
(dt, J = 12.9, 7.3 Hz, 2H) 1.97 (t, J = 7.1 Hz, 2H) 1.61 (qd, J = 13.3, 12.9, 7.6 Hz, 2H); 13C NMR 
(500 MHz, DMSO-d6) 𝛿 ppm 166.03, 165.25, 152.92, 143.64, 136.28, 135.81, 133.82, 130.72, 
129.69, 129.28, 128.66, 126.76, 126.29, 122.59, 112.62, 106.96, 50.03, 49.78, 49.71, 39.17, 
38.66, 31.50, 31.48; TOF ES+ MS: (M+Na) 431.11; HPLC Ret: 6.99 min; 95 % pure. 
N-(trans-3-(4-chlorobenzamido)cyclohexyl)-3-(furan-2-yl)benzamide. (CCG-263879). 
Method J followed by Method I starting from tert-butyl (trans-3-(4-
chlorobenzamido)cyclohexyl)carbamate (0.06 g, 0.16 mmol) and 3-(furan-2-yl)benzoic acid 
(0.03 g, 0.16 mmol) gave N-(trans-3-(4-chlorobenzamido)cyclohexyl)-3-(furan-2-yl)benzamide 
(0.05 g, 77% (2 steps)) as yellow solid; column: 50% to 60% EtOAc: Hex; 1H NMR (500 MHz, 
DMSO-d6) 𝛿 ppm 8.33 (dd, J = 15.2, 7.4 Hz, 2H) 8.14 (d, J = 1.6 Hz, 1H) 7.92-7.73 (m, 5H) 
7.57-7.47 (m, 3H) 7.03 (d, J = 3.4 Hz, 1H) 6.64 (dt, J = 3.3, 1.5 Hz, 1H) 4.38-4.27 (m, 2H) 1.85 
(t, J = 5.9 Hz, 2H) 1.79-1.66 (m, 4H) 1.58-1.50 (m, 2H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 
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166.20, 165.43, 152.95, 143.65, 136.18, 136.14, 134.12, 130.64, 129.88, 129.17, 128.59, 
126.92, 126.21, 122.79, 112.60, 106.95, 45.31, 45.19, 36.18, 31.13, 31.01, 20.11; TOF ES+ 
MS: (M+H) 423.15; HPLC Ret: 7.32 min; 96 % pure. 
N-(cis-3-(4-chlorobenzamido)cyclohexyl)-3-(furan-2-yl)benzamide. (CCG-263880). Method 
J followed by Method I starting from tert-butyl (cis-3-(4-chlorobenzamido)cyclohexyl)carbamate 
(0.06 g, 0.16 mmol) and 3-(furan-2-yl)benzoic acid (0.03 g, 0.16 mmol) gave N-(cis-3-(4-
chlorobenzamido)cyclohexyl)-3-(furan-2-yl)benzamide (0.04 g, 53% (2 steps)) as white solid; 
column: 50% EtOAc: Hex to 20% MeOH: DCM; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 8.42 (dd, 
J = 10.0, 7.9 Hz, 2H) 8.14 (t, J = 1.8 Hz, 1H) 7.90-7.72 (m, 5H) 7.57-7.47 (m, 3H) 7.02 (d, J = 
3.4 Hz, 1H) 6.63 (dt, J = 3.4, 1.8 Hz, 1H) 3.90 (dqt, J = 11.7, 7.8, 3.5 Hz, 2H) 2.09 (d, J = 11.9 
Hz, 1H) 1.89-1.78 (m, 3H) 1.51-1.26 (m, 4H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 165.56, 
164.79, 152.92, 143.67, 136.24, 135.96, 133.95, 130.72, 129.68, 129.23, 128.68, 126.74, 
126.25, 122.59, 112.61, 106.96, 48.11, 48.02, 39.65, 39.01, 31.81, 23.49; TOF ES+ MS: (M+H) 
423.15; HPLC Ret: 7.07 min; 98 % pure. 
N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-
carboxamide (CCG-263152). Method J followed by Method I starting from tert-butyl 5-((2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.07 g, 0.19 
mmol) and 3-(furan-2-yl)benzoic acid (0.04 g, 0.22 mmol) gave N-(2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide 
(0.07 g, 72% (2 steps)) as white solid; column: 35% to 50% EtOac: Hex; 1H NMR (500 MHz, 
DMSO-d6) 𝛿 ppm 10.13 (br. s, 1H) 9.93 (br. s, 1H) 7.86-7.76 (m, 2H) 7.71 (s, 1H) 7.54 (t, J = 
7.8, 1H) 7.35-7.20 (m, 2H) 7.17 (br. s, 1H) 7.07 (s, 1H) 6.79 (br. s, 1H) 6.63 (dd, J = 3.4, 1.8 Hz, 
1H) 4.78-4.56 (m, 1H) 4.20 (br. s, 4H) 3.78 (br. s, 2H) 3.49-3.33 (m, 2H) 2.88 (br. s, 1H) 2.44 
(br. s, 1H) 2.36-2.22 (m, 1H); 13C NMR (126 MHz, DMSO-d6) δ 168.81, 158.23, 152.48, 143.89, 
143.32, 139.96, 131.09, 129.77, 126.19, 125.24, 122.21, 117.22, 113.00, 112.68, 108.92, 
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107.34, 64.61, 64.36, 60.20, 39.97, 36.02, 33.54, 21.20, 14.53; QTOF ES+ MS: (M+H) 469.2; 
HPLC Ret: 7.25 min; 98 % pure. 
N-(3,4-dimethoxyphenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide 
(CCG-263232). Method J followed by Method I starting from tert-butyl 5-((3,4-
dimethoxyphenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.07 g, 0.2 mmol) and 3-
(furan-2-yl)benzoic acid (0.04 g, 0.2 mmol) gave N-(3,4-dimethoxyphenyl)-5,5-difluoro-1-(3-
(furan-2-yl)benzoyl)piperidine-3-carboxamide (0.06 g, 62% (2 steps)) as white solid; column: 
50% to 80% EtOac: Hex; precipitate out of EtOAc/Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 
10.19 (br. s, 1H) 10.01 (br. s, 1H) 7.87-7.78 (m, 2H) 7.74 (s, 1H) 7.55 (t, J = 7.8 Hz, 1H) 7.40-
7.30 (m, 2H) 7.16 (br. s, 1H) 7.08 (s, 1H) 6.90 (br. s, 1H) 6.64 (d, J = 3.4 Hz, 1H) 4.80-4.60 (m, 
1H) 3.90-3.63 (m, 8H) 3.48 (br. s, 1H) 3.07 (br. s., 1H) 2.91 (br. s, 1H) 2.47 (br. s, 1H) 2.38-2.21 
(m, 1H); 13C NMR (126 MHz, DMSO-d6) δ 168.80, 160.54, 152.49, 145.48, 143.88, 139.91, 
131.10, 129.72, 126.17, 125.23, 122.22, 118.49, 112.67, 112.41, 111.72, 107.33, 104.9, 59.02, 
56.12, 55.76, 39.96, 36.01, 31.40, 22.50, 14.39; TOF ES+ MS: (M+H) 471.2; HPLC Ret: 6.72 
min; 98 % pure. 
N-(3-(4-chlorobenzamido)-4-methylphenyl)-3-(furan-2-yl)benzamide (CCG-263154). Method 
J followed by Method I starting from tert-butyl (3-(4-chlorobenzamido)-4-
methylphenyl)carbamate(0.09 g, 0.31 mmol) and 3-(furan-2-yl)benzoic acid (0.06 g, 0.31 mmol) 
gave N-(3-(4-chlorobenzamido)-4-methylphenyl)-3-(furan-2-yl)benzamide (0.04 g, 30% (2 
steps)) as white solid; column: 30% to 40% EtOac: Hex; crashed out of fractions; 1H NMR (500 
MHz, DMSO-d6) 𝛿 ppm 10.36 (s, 1H) 10.03 (s, 1H) 8.26 (q, J = 2.0 Hz, 1H) 8.06-7.99 (m, 2H) 7-
94-7.80 (m, 4H) 7.66-7.55 (m, 4H) 7.26 (d, J = 8.3 Hz, 1H) 7.08 (d, 3.4 Hz, 1H) 6.65 (dd, J = 
3.4, 1.8 Hz, 1H) 2.22 (s, 3H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 165.53, 164.72, 152.78, 
143.81, 137.56, 136.84, 136.57, 136.08, 133.67, 130.88, 130.66, 130.03, 129.52, 128.97, 
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127.02, 126.69, 122.90, 119.17, 118.76, 112.68, 107.21, 17.86; QTOF ES+ MS: (M+H) 431.1; 
HPLC Ret: 7.84 min; 99 % pure. 
N-(4-chlorophenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-3-methylpiperidine-3-
carboxamide. (CCG-264061). Method J followed by Method I starting from tert-butyl 3-((4-
chlorophenyl)carbamoyl)5,5-difluoro-3-methylpiperidine-1-carboxylate (0.07 g, 0.18 mmol) and 
3-(furan-2-yl)benzoic acid (0.03 g, 0.18 mmol) gave N-(4-chlorophenyl)-5,5-difluoro-1-(3-(furan-
2-yl)benzoyl)-3-methylpiperidine-3-carboxamide (0.07 g, 80% (2 steps)) as yellow solid; column: 
40% to 50% EtOac: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 9.37 (br.s 1H) 7.77 (d, J 
= 8.0 Hz, 1H) 7.69 (d, J = 8.4 Hz, 2H) 7.59 (d, J = 8.4 Hz, 2H) 7.50 (t, J = 7.9 Hz, 1H) 7.36-7.26 
(m, 3H) 6.92 (d, J = 3.1 Hz, 1H) 6.58 (dt, J = 3.7, 1.6 Hz, 1H) 3.97 (d, J = 13.7 Hz, 1H) 3.92-
3.62 (m, 3H) 2.70 (td, J = 20.0, 17.7, 10.4 Hz, 1H) 2.39-2.24 (m, 1H) 1.30 (s, 3H) 1.28-1.14 (m, 
1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -97.46—-100.35 (m, 2H); QTOF ES+ MS: 
(M+H) 459.13; HPLC Ret: 8.00 min; 96% pure. 
N-(cis-3-(4-chlorobenzamido)cyclohexyl)-3-(2-(pyrrolidin-1-yl)ethoxy)benzamide. (CCG-
264119). Method J followed by Method I starting from tert-butyl (cis-3-(4-
chlorobenzamido)cyclohexyl)carbamate (0.05 g, 0.11 mmol) and 3-(2-(pyrrolidin-1-
yl)ethoxy)benzoic acid, HCl (0.03 g, 0.11 mmol) gave N-(cis-3-(4-chlorobenzamido)cyclohexyl)-
3-(2-(pyrrolidin-1-yl)ethoxy)benzamide (0.03 g, 56% (2 steps)) as white solid; column: 8% to 
10% MeOH: DCM; crystalized from DCM:MeOH; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 8.43 (d, 
J = 7.9 Hz, 1H) 8.33 (d, J = 8.0 Hz, 1H) 7.88 (d, J = 8.4 Hz, 2H) 7.53 (d, J = 8.2 Hz, 2H) 7.47-
7.40 (m, 2H) 7.36 (t, J = 7.9 Hz, 1H) 7.10 (dd, J = 8.2, 2.5 Hz, 1H) 4.21 (br. s, 2H) 3.87 (dtt, J = 
11.8, 7.8, 3.9 Hz, 2H) 3.07 (br. s, 2H) 2.80 (br. s, 4H) 2.04 (d, J = 11.9 Hz, 1H) 1.85-1.76 (m, 
7H) 1.49-1.25 (m, 4H); 13C NMR (126 MHz, DMSO-d6) 𝛿 ppm 165.46, 164.75, 158.45, 136.67, 
136.23, 133.93, 129.77, 129.69, 128.67, 120.26, 117.66, 113.69, 54.33, 54.15, 48.11, 47.97, 




yl)ethoxy)quinoline-6-carboxamide. (CCG-264120). Method J followed by Method I starting 
from N-((1R,3S)-3-aminocyclohexyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide (0.06 g, 
0.15 mmol) and 2-(2-(pyrrolidin-1-yl)ethoxy)quinoline-6-carboxylic acid (0.04 g, 0.15 mmol) gave 
N-(cis-3-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)cyclohexyl)-2-(2-(pyrrolidin-1-
yl)ethoxy)quinoline-6-carboxamide (0.04 g, 50% (2 steps)) as white solid; column: 8% to 10% 
MeOH: DCM; crystalized from DCM:MeOH; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 8.48 (d, J = 
7.8, Hz, 1H) 8.42 (d, J = 2.0 Hz, 1H) 8.33 (d, J = 8.9 Hz, 1H) 8.19-8.09 (m, 2H) 7.80 (d, J = 8.7 
Hz, 1H) 7.42-7.35 (m, 2H) 7.09 (d, J = 8.8 Hz, 1H) 6.90 (d, J = 8.3 Hz, 1H) 4.60 (br. s, 2H) 4.27 
(q, J = 5.1 Hz, 4H) 3.90 (ddt, J = 25.6, 11.8, 3.9 Hz, 2H) 3.08 (br. s, 2H) 2.78 (br. s, 4H) 2.07 (d, 
J = 11.8 Hz, 1H) 1.93-1.71 (m, 7H) 1.51-1.26 (m, 4H); 13C NMR (126 MHz, DMSO-d6) 𝛿 ppm 
165.37, 164.93, 162.34, 147.48, 146.23, 143.24, 140.79, 131.04, 128.88, 128.24, 128.05, 
126.93, 124.57, 121.20, 117.01, 116.76, 114.18, 64.76, 64.44, 54.09, 53.35, 48.16, 47.93, 
45.76, 39.91, 39.24, 31.88, 23.56; TOF ES+ MS: (M+H) 545.28; HPLC Ret: 5.05 min; 97% pure. 
3-(furan-2-yl)-N-(cis-3-(4-(2-(pyrrolidin-1-yl)ethoxy)benzamido)cyclohexyl)benzamide. 
(CCG-264121). Method J followed by Method I starting from tert-butyl (cis-3-(3-furan-2-
yl)cyclohexyl)carbamate (0.05 g, 0.13 mmol) and 4-(2-(pyrrolidin-1-yl)ethoxy)benzoic acid (0.03 
g, 0.13 mmol) gave 3-(furan-2-yl)-N-(cis-3-(4-(2-(pyrrolidin-1-
yl)ethoxy)benzamido)cyclohexyl)benzamide (0.05 g, 72% (2 steps)) as white solid; column: 8% 
to 10% MeOH: DCM; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 8.44 (d, J = 7.9 Hz, 1H) 8.21-8.15 
(m, 2H) 7.86-7.72 (m, 5H) 7.50 (t, J = 7.8 Hz, 1H) 7.01 (dd, J = 15.3, 5.8 Hz, 3H) 6.63 (dd, J = 
3.3, 1.8 Hz, 1H) 4.16 (br. s, 2H) 3.93-3.84 (m, 2H) 2.93 (br. s, 2H) 2.66 (br. s, 4H) 2.07 (d, J = 
11.8 Hz, 1H) 1.89-1.70 (m, 7H) 1.50-1.22 (m, 4H); 13C NMR (126 MHz, DMSO-d6) 𝛿 ppm 
165.54, 165.28, 160.92, 152.92, 143.66, 135.96, 130.71, 129.54, 129.28, 127.52, 126.74, 
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126.24, 122.60, 114.30, 112.61, 109.99, 106.97, 54.41, 48.08, 47.89, 39.90, 39.26, 31.92, 
31.84, 23.55, 23.49; TOF ES+ MS: (M+H) 502.27; HPLC Ret: 5.46 min; 99 % pure. 
N-(4-chlorophenyl)-1-(2,3-dihydrobenzo[b][1,4]dioxine-6-carbonyl)-5,5-difluoropiperidine-
3-carboxamide (CCG-263151). Method J followed by Method I starting from tert-butyl 5-((4-
chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.07 g, 0.20 mmol) and 2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxylic acid (0.04 g, 0.20 mmol) gave N-(4-chlorophenyl)-1-
(2,3-dihydrobenzo[b][1,4]dioxine-6-carbonyl)-5,5-difluoropiperidine-3-carboxamide (0.05 g, 54% 
(2 steps)) as white solid; column: 40% to 45% EtOAc: Hex; triturated with EtOAc: Hex; 1H NMR 
(500 MHz, DMSO-d6) 𝛿 ppm 7.71-7.60 (m, 2H) 7.41-7.34 (m, 2H) 6.97-6.87 (m, 3H) 4.28 (dd, J 
= 7.8, 3.2 Hz, 4H) 4.00-3.89 (m, 2H) 3.18-3.00 (m, 2H) 2.95-2.88 (m, 1H) 2.52-2.41 (m, 1H) 
2.36-2.21 (m, 1H); 13C NMR (126 MHz, DMSO-d6) δ 169.54, 157.88, 153.13, 145.47, 143.61, 
138.11, 130.37, 129.10, 127.58, 125.20, 122.36, 122.25, 121.31, 120.96, 119.72, 118.82, 
117.55, 116.81, 64.66, 64.50, 60.19, 40.40, 34.68, 27.85, 21.20, 14.53; QTOF ES+ MS: (M+H) 
437.1; HPLC Ret: 7.34 min; 94 % pure. 
N-(4-chlorophenyl)-1-(3,4-dimethoxybenzoyl)-5,5-difluoropiperidine-3-carboxamide (CCG-
263231). Method J followed by Method I starting from tert-butyl 5-((4-chlorophenyl)carbamoyl)-
3,3-difluoropiperidine-1-carboxylate (0.07 g, 0.15 mmol) and 3,4-dimethoxybenzoic acid (0.03 g, 
0.15 mmol) gave N-(4-chlorophenyl)-1-(3,4-dimethoxybenzoyl)-5,5-difluoropiperidine-3-
carboxamide (0.02 g, 23% (2 steps)) as white solid; column: 50% to 80% EtOAc: Hex; triturated 
with EtOAc: Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.35 (br. s., 1H) 7.65-7.59 (m, 2H) 
7.40-7.31 (m, 2H) 7.04-6.96 (m, 3H) 4.65-4.32 (m, 1H) 3.90-3.50 (m, 7H) 3.25-3.00 (m, 2H) 
2.97-2.90 (m, 1H) 2.47-2.38 (m, 1H) 2.35-2.25 (m, 1H); TOF ES+ MS: (M+H) 439.1; HPLC Ret: 




difluoropiperidine-3-carboxamide. (CCG-263481). Method J followed by Method I starting 
from tert-butyl 5-((4-chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.09 g, 0.23 
mmol) and 3,9-dihydro-2H-[1,4]dioxino[2,3-g]indole-8-carboxylic acid (0.05 g, 0.23 mmol) gave 
N-(4-chlorophenyl)-1-(3,9-dihydro-2H-[1,4]dioxino[2,3-g]indole-8-carbonyl)-5,5-
difluoropiperidine-3-carboxamide (0.08 g, 77% (2 steps)) as white solid; column: 45% EtOAc: 
Hex; 1H NMR (500 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.06 (br. s, 1H) 7.99 (s, 1H) 7.60 (d, J = 8.7 
Hz, 2H) 7.33 (d, J = 8.7 Hz, 2H) 6.85 (d, J = 8.0 Hz, 1H) 6.65 (t, J = 8.1 Hz, 1H) 6.37 (d, J = 8.1 
Hz, 1H) 4.73-4.56 (m, 2H) 4.30 (dd, J = 5.8, 2.7 Hz, 2H) 4.24 (dd, J = 5.8, 2.7 Hz, 2H) 3.46 (dd, 
J = 31.1, 13.8 Hz, 1H) 3.19 (t, J = 12.5 Hz, 1H) 3.05-2.91 (m, 1H) 2.51-2.45 (m, 1H) 2.27 (dtd, J 
= 12.9, 5.4 Hz, 1H); 19F NMR (500 MHz, DMSO-d6) 𝛿 ppm -98.96 (d, 1H), -101.73 (d, 1H); TOF 
ES+ MS: (M+MeCN) 515.13; HPLC Ret: 7.67 min; 98 % pure. 
N-(4-chlorophenyl)-1-(6,7-difluoro-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-
carboxamide. (CCG-263595). Method J followed by Method I starting from tert-butyl 5-((4-
chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.09 g, 0.23 mmol) and 6,7-
difluoro-1H-indole-2-carboxylic acid (0.05 g, 0.23 mmol) gave N-(4-chlorophenyl)-1-(6,7-difluoro-
1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-carboxamide (0.06 g, 62% (2 steps)) as white 
solid; taken up in hot EtOH and filtered after extraction and evaporation; 1H NMR (400 MHz, 
DMSO-d6, 80 °C) 𝛿 12.07 (s, 1H) 10.08 (s, 1H) 7.60 (d, J = 8.4 Hz, 2H) 7.43 (dd, J = 8.9, 4.3 Hz, 
1H) 7.33 (d, J = 8.4 Hz, 2H) 7.05 (dt, J = 11.1, 7.6 Hz, 1H) 6.93 (d, J = 3.1 Hz, 1H) 4.63-4.56 
(m, 2H) 3.62 (dd, J = 30.4, 13.8 Hz, 1H) 3.34 (t, J = 12.4 Hz, 1H) 3.01 (d, J = 16.5 Hz, 1H) 2.27 
(dd, 30.2, 12.8 Hz, 1H); 19F NMR (376 MHz, DMSO-d6) 𝛿 ppm -99.17 (d, J = 240 Hz, 1H) -
101.49 (d, J = 238.2 Hz, 1H) -147.29 (ddd, J = 20.2, 11.4, 4.4 Hz, 1H) -158.27 (ddd, J = 20.2, 




carboxamide. (CCG-263596). Method J followed by Method I starting from tert-butyl 5-((4-
chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.08 g, 0.18 mmol) and 1-(2-(3-
carboxyphenoxy)ethyl)pyrrolidine-1-ium, HCl (0.05 g, 0.18 mmol) gave N-(4-chlorophenyl)-5,5-
difluoro-1-(3-(2-(pyrrolidin-1-yl)ethoxy)benzoyl)piperidine-3-carboxamide (0.05 g, 52% (2 steps)) 
as white solid; column: 5% to 10% MeOH: DCM; 1H NMR (400 MHz, MeOD-d4, 40 °C) 𝛿 7.66 
(d, J = 7.8 Hz, 2H) 7.43 (t, J = 8.1 Hz, 1H) 7.29 (d, J = 8.5 Hz, 2H) 7.18-7.11 (m, 1H) 7.10-7.03 
(m, 2H) 4.34 (t, J = 5.0 Hz, 2H) 3.40-3.33 (m, 4H) 2.96 (d, J = 14.1 Hz, 1H) 2.52-2.24 (m, 2H) 
2.13-2.01 (m, 4H); 19F NMR (376 MHz, MeOD-d4, 40 °C) 𝛿 ppm -73.54 (s, 1H) -75.43 (s, 1H); 
TOF ES+ MS: (M+H) 492.19; HPLC Ret: 5.83 min; 96 % pure. 
(S)-N-(4-chlorophenyl)-1-(5-(trifluoromethoxy)-1H-indole-2-carbonyl)piperidine-3-
carboxamide. (CCG-263658). Method J followed by Method I starting from (S)-tert-butyl 3-((4-
chlorophenyl)carbamoyl)piperidine-1-carboxylate (0.11 g, 0.32 mmol) and 5-(trifluoromethoxy)-
1H-indole-2-carboxylic acid (0.08 g, 0.32 mmol) gave (S)-N-(4-chlorophenyl)-1-(5-
(trifluoromethoxy)-1H-indole-2-carbonyl)piperidine-3-carboxamide (0.15 g, 99% (2 steps)) as 
white solid; column: 65% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 11.54 (s, 
1H) 9.82 (br. s, 1H) 7.60 (d, J = 7.8 Hz, 2H) 7.53 (d, J = 8.0 Hz, 2H) 7.30 (d, J = 7.9 Hz, 2H) 
7.12 (d, J = 9.0 Hz, 1H) 6.84 (d, J = 2.2 Hz, 1H) 4.44 (dd, J = 13.2, 3.9 Hz, 1H) 4.31-4.20 (m, 
1H) 3.35 (t, J = 11.8 Hz, 1H) 3.20 (t, J = 12.2 Hz, 1H) 2.64 (dt, J = 11.9, 6.5 Hz, 1H) 2.07 (d, J = 
12.5 Hz, 1H) 1.83 (q, J = 11.8 Hz, 2H) 1.56 (d, J = 12.6 Hz, 1H); 19F NMR (376 MHz, DMSO-d6, 
80 °C) 𝛿 ppm -56.85 (d, J = 5.5 Hz, 1H) -69.63 (s, 1H) -71.52 (s, 1H); QTOF ES+ MS: (M+H) 
466.11; HPLC Ret: 7.89 min; Optical rotation: +67.2872 (0.65 g/L); 99% pure. 
(R)-N-(4-chlorophenyl)-1-(5-(trifluoromethoxy)-1H-indole-2-carbonyl)piperidine-3-
carboxamide. (CCG-263687). Method J followed by Method I starting from (R)-tert-butyl 3-((4-
chlorophenyl)carbamoyl)piperidine-1-carboxylate (0.1 g, 0.3 mmol) and 5-(trifluoromethoxy)-1H-
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indole-2-carboxylic acid (0.08 g, 0.31 mmol) gave (R)-N-(4-chlorophenyl)-1-(5-
(trifluoromethoxy)-1H-indole-2-carbonyl)piperidine-3-carboxamide (0.14 g, 100% (2 steps)) as 
white solid; column: 60% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 11.56 (s, 
1H) 9.82 (br. s, 1H) 7.59 (d, J = 7.9 Hz, 2H) 7.56-7.46 (m, 2H) 7.30 (d, J = 7.9 Hz, 2H) 7.12 (d, J 
= 8.9 Hz, 1H) 6.83 (d, J = 2.1 Hz, 1H) 4.43 (dd, J = 13.0, 3.8 Hz, 1H) 4.25 (d, J = 13.3 Hz, 1H) 
3.32 (t, J = 11.8 Hz, 1H) 3.18 (t, J = 12.0 Hz, 1H) 2.62 (p, J = 6.3 Hz, 1H) 2.06 (d, J = 12.3 Hz, 
1H) 1.83 (td, J = 14.7, 14.2, 4.3 Hz, 2H) 1.56 (d, J = 12.8 Hz, 1H); 19F NMR (376 MHz, DMSO-
d6, 80 °C) 𝛿 ppm -56.83 (s, 3H) -69.65 (s, 1H) -71.54 (s, 1H); QTOF ES+ MS: (M+H) 466.11; 
HPLC Ret: 7.81 min; Optical rotation: -76.6770 (0.646 g/L); 98% pure. 
N-(4-chloro-3-(prop-2-yn-1-yloxy)phenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide. Method J followed by Method I starting from tert-butyl 
5-((4-chloro-3-(prop-2-yn-1-yloxy)phenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.1 g, 
0.23 mmol) and 3-fluoro-5-(pyridin-4-yl)benzoic acid (0.05 g, 0.23 mmol) gave N-(4-chloro-3-
(prop-2-yn-1-yloxy)phenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide (0.09 g, 73% (2 steps)) as white solid; column: 75% to 100% EtOAc: Hex; 1H NMR 
(500 MHz, CDCl3-d) 𝛿 ppm 8.70-8.64 (m, 2H) 7.79-7.68 (m, 3H) 7.65-7.60 (m, 1H) 7.55-7.50 (m, 
1H) 7.35-7.28 (m, 2H) 7.22 (d, J = 8.6 Hz, 1H) 4.80 (d, J = 2.6 Hz, 2H) 4.38-4.10 (m, 1H) 3.68-
3.50 (m, 1H) 3.42 (t, J = 3.0 Hz, 1H) 3.30-3.21 (m, 1H) 2.94-2.90 (m, 1H) 2.40-2.21 (m, 1H); 
HPLC Ret: 5.97 min. 
N-(4-chlorobenzyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264058). Method J followed by Method I starting from tert-butyl 5-((4-
chlorobenzyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.06 g, 0.14 mmol) and 3-fluoro-
5-(pyridin-4-yl)benzoic acid (0.03 g, 0.14 mmol) gave N-(4-chlorobenzyl)-5,5-difluoro-1-(3-fluoro-
5-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.06 g, 87% (2 steps)) as colorless oil; 
column: 100% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 8.69-8.62 (m, 2H) 8.40 
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(br. s, 1H) 7.95 (s, 1H) 7.78-7.67 (m, 3H) 7.60 (s, 2H) 7.63-7.58 (m, 5H) 4.26 (d, J = 5.8 Hz, 2H) 
4.21-4.11 (m, 2H) 3.52 (dd, J = 30.2, 13.9 Hz, 1H) 3.20 (t, J = 12.1 Hz, 1H) 3.00 (s, 1H) 2.82 (q, 
J = 9.4 Hz, 1H) 2.39 (br. s, 1H) 2.34-2.13 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm 
-97.46—-104.28 (m, 2H) -111.11 (s, 1H); QTOF ES+ MS: (M+H) 488.13; HPLC Ret: 5.56 min; 
96% pure. 
N-(3-chlorophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264059). Method J followed by Method I starting from tert-butyl 5-((3-
chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.06 g, 0.16 mmol) and 3-fluoro-
5-(pyridin-4-yl)benzoic acid (0.04 g, 0.16 mmol) gave N-(3-chlorophenyl)-5,5-difluoro-1-(3-
fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.05 g, 59% (2 steps)) as white solid; 
column: 90% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.07 (br.s 1H) 8.66 (d, 
J = 5.7 Hz, 2H) 7.78-7.67 (m, 4H) 7.62 (d, J = 1.6 Hz, 1H) 7.43 (d, J = 8.3 Hz, 1H) 7.35-7.26 (m, 
2H) 7.09 (d, J = 8.1 Hz, 1H) 4.44-4.00 (m, 2H) 3.59 (dd, J = 29.6, 14.1 Hz, 1H) 3.27 (t, J = 12.1 
Hz, 1H) 2.96 (br. s, 1H) 2.42-2.24 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -
97.46—-102.51 (m, 2H) -111.09 (s, 1H); QTOF ES+ MS: (M+H) 474.11; HPLC Ret: 5.87 min; 
99% pure. 
N-(3,4-dichlorophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264060). Method J followed by Method I starting from tert-butyl 5-((3,4-
dichlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.06 g, 0.15 mmol) and 3-
fluoro-5-(pyridin-4-yl)benzoic acid (0.03 g, 0.15 mmol) gave N-(3,4-dichlorophenyl)-5,5-difluoro-
1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.04 g, 40% (2 steps)) as white 
solid; column: 90% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.17 (br.s 1H) 
8.66 (d, J = 5.7 Hz, 2H) 7.90 (d, J = 2.3 Hz, 1H) 7.78-7.67 (m, 3H) 7.61 (d, J = 1.7 Hz, 1H) 7.54-
7.42 (m, 2H) 7.30 (d, J = 8.1 Hz, 1H) 4.39-4.02 (m, 2H) 3.59 (dd, J = 29.6, 14.0 Hz, 1H) 3.27 (t, 
J = 12.3 Hz, 1H) 2.96 (br. s, 2H) 2.42-2.21 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 
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ppm -97.46—-103.79 (m, 2H) -111.08 (s, 1H); QTOF ES+ MS: (M+H) 508.08; HPLC Ret: 6.22 
min; 96% pure. 
N-(4-chloropyridin-2-yl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264606). Method J followed by Method I starting from tert-butyl 5-((4-
chloropyridin-2-yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.04 g, 0.11 mmol) and 3-
fluoro-5-(pyridin-4-yl)benzoic acid (0.02 g, 0.11 mmol) gave N-(4-chloropyridin-2-yl)-5,5-difluoro-
1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.04 g, 78% (2 steps)) as white 
solid; column: 65% to 85% EtOAc: Hex; H2O wash post column needed; 1H NMR (400 MHz, 
DMSO-d6, 80 °C) 𝛿 ppm 10.72 (br.s 1H) 8.66 (d, J = 4.5 Hz, 2H) 8.28 (d, J = 5.4 Hz, 1H) 8.08 
(s, 1H) 7.78-7.68 (m, 3H) 7.62 (t, J = 1.5 Hz, 1H) 7.31 (d, J = 8.8 Hz, 1H) 7.19 (d, J = 8.1 Hz, 
1H) 4.35-4.09 (m, 2H) 3.57 (dd, J = 29.2, 13.9 Hz, 1H) 3.30 (t, J = 13.2 Hz, 1H) 2.98 (br. s, 2H) 
2.42-2.21 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -98.83—-101.73 (m, 2H) -
111.15 (t, J = 9.4 Hz, 1H); QTOF ES+ MS: (M+H) 475.11; HPLC Ret: 5.53 min; 98% pure. 
N-(5-chloropyridin-3-yl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264607). Method J followed by Method I starting from tert-butyl 5-((5-
chloropyridin-3-yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.04 g, 0.11 mmol) and 3-
fluoro-5-(pyridin-4-yl)benzoic acid (0.02 g, 0.11 mmol) gave N-(5-chloropyridin-3-yl)-5,5-difluoro-
1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.05 g, 85% (2 steps)) as white 
solid; column: 85% to 100% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.31 
(br.s 1H) 8.69-8.59 (m, 3H) 8.29 (s, 1H) 8.15 (s, 1H) 7.77-7.68 (m, 3H) 7.62 (s, 1H) 7.31 (d, J = 
9.0 Hz, 1H) 4.37-4.10 (m, 2H) 3.60 (dd, J = 29.5, 14.0 Hz, 1H) 3.29 (t, J = 13.2 Hz, 1H) 2.98 (br. 
s, 2H) 2.42-2.25 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -97.70—-103.55 (m, 2H) 




carboxamide. (CCG-264608). Method J followed by Method I starting from tert-butyl 5-((2-
chloropyridin-4-yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.02 g, 0.05 mmol) and 3-
fluoro-5-(pyridin-4-yl)benzoic acid (0.01 g, 0.05 mmol) gave N-(2-chloropyridin-4-yl)-5,5-difluoro-
1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.02 g, 74% (2 steps)) as white 
solid; column: 80% to 100% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.47 
(br.s 1H) 8.68-8.62 (m, 3H) 8.23 (d, J = 5.6 Hz, 1H) 7.78-7.66 (m, 4H) 7.61 (s, 1H) 7.44 (d, J = 
5.7 Hz, 1H) 7.28 (d, J = 8.5 Hz, 1H) 4.38-4.08 (m, 2H) 3.61 (dd, J = 29.1, 13.8 Hz, 1H) 3.28 (t, J 
= 13.2 Hz, 1H) 2.98 (br. s, 2H) 2.42-2.21 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -
98.42—-103.31 (m, 2H) -111.09 (t, J = 9.3 Hz, 1H); QTOF ES+ MS: (M+H) 475.11; HPLC Ret: 
5.20 min; 97% pure. 
N-(6-chloropyridin-2-yl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264609). Method J followed by Method I starting from tert-butyl 5-((6-
chloropyridin-2-yl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.04 g, 0.1 mmol) and 3-
fluoro-5-(pyridin-4-yl)benzoic acid (0.02 g, 0.1 mmol) gave N-(6-chloropyridin-2-yl)-5,5-difluoro-
1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.02 g, 32% (2 steps)) as white 
solid; column: 75% to 100% EtOAc: Hex; H2O wash post column needed; 1H NMR (400 MHz, 
DMSO-d6, 80 °C) 𝛿 ppm 10.75 (br.s 1H) 8.66 (d, J = 5.2 Hz, 2H) 7.96 (d, J = 8.2 Hz, 1H) 7.83-
7.68 (m, 4H) 7.62 (s, 1H) 7.31 (d, J = 5.8 Hz, 1H) 7.15 (d, J = 7.7 Hz, 1H) 4.32-4.10 (m, 2H) 
3.55 (dd, J = 29.2, 13.8 Hz, 1H) 3.29 (t, J = 13.2 Hz, 1H) 2.98 (br. s, 2H) 2.39-2.23 (m, 1H); 19F 
NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -97.46—-104.04 (m, 2H) -111.16 (t, J = 9.5 Hz, 1H); 
QTOF ES+ MS: (M+H) 475.11; HPLC Ret: 5.67 min; 98% pure. 
1-(5-bromo-2-fluorobenzoyl)-N-(3-chlorophenyl)-5,5-difluoropiperidine-3-carboxamide. 
(CCG-264464). Method J followed by Method I starting from tert-butyl 5-((3-
chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.06 g, 0.2 mmol) and 5-bromo-2-
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fluorobenzoic acid (0.04 g, 0.2 mmol) gave 1-(5-bromo-2-fluorobenzoyl)-N-(3-chlorophenyl)-5,5-
difluoropiperidine-3-carboxamide (0.07 g, 88% (2 steps)) as yellow solid; column: 20% EtOAc: 
Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.07 (br. s, 1H) 7.77-7.65 (m, 2H) 7.54 (br. s, 
1H) 7.42 (br. s, 1H) 7.29 (q, J = 9.4, 9.0 Hz, 2H) 7.09 (d, J = 8.0 Hz, 1H) 4.50-4.12 (m, 2H) 3.74-
3.38 (m, 2H) 3.37-3.31 (m, 1H) 2.90 (br. s, 1H) 2.38-2.22 (m, 1H); 19F NMR (376 MHz, DMSO-
d6, 80 °C) 𝛿 ppm -97.59—-102.14 (m, 2H) -117.67 (s, 1H); QTOF ES+ MS: (M+Na) 498.98; 
HPLC Ret: 7.78 min; 99% pure. 
1-(5-bromo-2-fluorobenzoyl)-N-(3,4-dichlorophenyl)-5,5-difluoropiperidine-3-carboxamide. 
(CCG-264467). Method J followed by Method I starting from tert-butyl 5-((3,4-
dichlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.06 g, 0.15 mmol) and 5-
bromo-2-fluorobenzoic acid (0.03 g, 0.15 mmol) gave 1-(5-bromo-2-fluorobenzoyl)-N-(3,4-
dichlorophenyl)-5,5-difluoropiperidine-3-carboxamide (0.06 g, 87% (2 steps)) as yellow solid; 
column: 20% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.18 (br. s, 1H) 7.90 
(br. s, 1H) 7.71-7.67 (m, 1H) 7.56-7.45 (m, 3H) 7.28 (t, J = 9.1 Hz, 1H) 4.65-4.12 (m, 2H) 3.74-
3.30 (m, 3H) 2.89 (br. s, 1H) 2.37-2.21 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -
95.46—-104.76 (m, 2H) -117.69 (s, 1H); QTOF ES+ MS: (M+Na) 532.94; HPLC Ret: 8.16 min; 
99% pure. 
N-(3-chlorophenyl)-5,5-difluoro-1-(3-(2-(pyrrolidin-1-yl)ethoxy)benzoyl)piperidine-3-
carboxamide. (CCG-264465). Method J followed by Method I starting from tert-butyl 5-((3-
chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.06 g, 0.16 mmol) and 3-(2-
(pyrrolidine-1-yl)ethoxy)benzoic acid, HCl (0.05 g, 0.18 mmol) gave N-(3-chlorophenyl)-5,5-
difluoro-1-(3-(2-(pyrrolidin-1-yl)ethoxy)benzoyl)piperidine-3-carboxamide (0.06 g, 75% (2 steps)) 
as white solid; column: 5% to 8% MeOH: DCM; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 
10.07 (br. s, 1H) 7.73 (s, 1H) 7.47-7.35 (m, 2H) 7.31 (t, J = 8.1 Hz, 1H) 7.09 (d, J = 7.4 Hz, 2H) 
7.03-6.95 (m, 2H) 4.47-4.02 (m, 2H) 3.35 (dd, J = 30.4, 14.0 Hz, 1H) 3.52-3.47 (m, 2H) 3.20-
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2.87 (m, 5H) 2.41-2.14 (m, 1H) 1.84 (br. s, 4H) 1.26 (br. s, 4H); 19F NMR (376 MHz, DMSO-d6, 
80 °C) 𝛿 ppm -97.78—-102.24 (m, 2H); QTOF ES+ MS: (M+H) 492.19; HPLC Ret: 5.95 min; 
99% pure. 
N-(3-chlorophenyl)-5,5-difluoro-1-(3-(3-(pyrrolidin-1-yl)propoxy)benzoyl)piperidine-3-
carboxamide. (CCG-264466). Method J followed by Method I starting from tert-butyl 5-((3-
chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.06 g, 0.16 mmol) and 3-(3-
(pyrrolidine-1-yl)propoxy)benzoic acid, HCl (0.05 g, 0.18 mmol) gave N-(3-chlorophenyl)-5,5-
difluoro-1-(3-(3-(pyrrolidin-1-yl)propoxy)benzoyl)piperidine-3-carboxamide (0.05 g, 57% (2 
steps)) as white solid; column: 5% to 8% MeOH: DCM; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 
ppm 10.09 (br. s, 1H) 7.74 (s, 1H) 7.47-7.27 (m, 3H) 7.13-7.02 (m, 2H) 7.02-6.92 (m, 2H) 4.27 
(br. s, 2H) 3.51 (dd , J = 30.3, 14.1 Hz, 1H) 3.20 (br. s, 7H) 3.01-2.91 (m, 1H) 2.42-2.16 (m, 1H) 
2.09 (p, J = 7.3 Hz, 2H) 1.93 (br. s, 4H) 1.25 (br. s, 4H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 
ppm -98.35—-103.24 (m, 2H); QTOF ES+ MS: (M+H) 506.20; HPLC Ret: 6.07 min; 99% pure. 
N-(3,4-dichlorophenyl)-5,5-difluoro-1-(3-(2-(pyrrolidin-1-yl)ethoxy)benzoyl)piperidine-3-
carboxamide. (CCG-264468). Method J followed by Method I starting from tert-butyl 5-((3,4-
dichlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.06 g, 0.16 mmol) and 3-(2-
(pyrrolidine-1-yl)ethoxy)benzoic acid, HCl (0.05 g, 0.15 mmol) gave N-(3,4-dichlorophenyl)-5,5-
difluoro-1-(3-(2-(pyrrolidin-1-yl)ethoxy)benzoyl)piperidine-3-carboxamide (0.06 g, 75% (2 steps)) 
as white solid; column: 4% to 6% MeOH: DCM; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 
10.17 (br. s, 1H) 7.91 (s, 1H) 7.54-7.36 (m, 3H) 7.07 (d, J = 8.4 Hz, 1H) 7.02-6.94 (m, 2H) 4.48-
4.00 (m, 2H) 3.51 (dd, J = 30.2, 13.7 Hz, 1H) 3.52-3.47 (m, 1H) 3.15 (br. s, 2H) 2.98-2.89 (m, 
4H) 2.38-2.19 (m, 1H) 1.81 (br. s, 4H) 1.24 (br. s, 4H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 




carboxamide. (CCG-264469). Method J followed by Method I starting from tert-butyl 5-((3,4-
dichlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-carboxylate (0.06 g, 0.16 mmol) and 3-(3-
(pyrrolidine-1-yl)propoxy)benzoic acid, HCl (0.05 g, 0.16 mmol) gave N-(3,4-dichlorophenyl)-5,5-
difluoro-1-(3-(3-(pyrrolidin-1-yl)propoxy)benzoyl)piperidine-3-carboxamide (0.07 g, 91% (2 
steps)) as white solid; column: 5% to 8% MeOH: DCM; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 
ppm 10.17 (br. s, 1H) 7.91 (s, 1H) 7.55-7.46 (m, 2H) 7.39 (t, J = 8.0 Hz, 1H) 7.05 (d, J = 8.4 Hz, 
1H) 7.01-6.92 (m, 2H) 4.27 (br. s, 2H) 3.51 (dd , J = 30.0, 13.8 Hz, 1H) 3.19 (br. s, 7H) 3.01-
2.91 (m, 1H) 2.39-2.21 (m, 1H) 2.10 (p, J = 7.6 Hz, 2H) 1.93 (br. s, 4H) 1.27 (br. s, 4H); 19F 
NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -97.39—-103.98 (m, 2H); QTOF ES+ MS: (M+H) 
540.16; HPLC Ret: 6.44 min; 99% pure. 
N-(3-(((tert-butyldiphenylsilyl)oxy)methyl)-4-chlorophenyl)-5,5-difluoro-1-(3-fluoro-5-
(pyridin-4-yl)benzoyl)piperidine-3-carboxamide. In a 25 mL round bottomed flask tert-butyl 5-
((3-(((tert-butyldiphenylsilyl)oxy)methyl)-4-chlorophenyl)carbamoyl)-3,3-difluoropiperidine-1-
carboxylate (0.19 g, 0.30 mmol) was dissolved in 4 M HCl/Dioxanes (2.0 mL) and the reaction 
was stirred at 25 °C for 1 hr. The solvents were evaporated in vacuo, and the subsequent solid 
was taken into the next step without further purification (HPLC = 7.74 min). 3-fluoro-5-(pyridin-4-
yl)benzoic acid (0.06 g, 0.29 mmol) was dissolved in DMF (2 mL) and HATU (0.22 g, 0.58 
mmol), N-(3-(((tert-butyldiphenylsilyl)oxy)methyl)-4-chlorophenyl)-5,5-difluoropiperidine-3-
carboxamide, HCl (0.17 g, 0.29 mmol), and NMM (0.09 g, 0.10 mL, 0.88 mmol) were added. 
The reaction was stirred at 25 °C for 16 hr and brine (10 mL) was added. The subsequent solid 
was filtered and dried in vacuo to produce white solid. Yield=84% (2-steps). 1H NMR (500 MHz, 
DMSO-d6) 𝛿 10.49 (br. s, 1H) 10.27 (br. s, 1H) 8.68 (br. s, 2H) 8.06 (br. s, 1H) 7.86 (br. s, 1H) 
7.79 (d, J = 5.3 Hz, 2H) 7.72-7.58 (m, 6H) 7.54-7.28 (m, 8H) 4.80-4.62 (m, 2H) 3.95-3.74 (m, 
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1H) 3.58-3.41 (m, 1H) 3.04-2.94 (m, 1H) 2.45-2.21 (m, 1H) 1.06 (s, 9H); TOF ES+ MS: (M+H) 
742.25; HPLC Ret: 8.40 min. 
N-(4-chlorophenyl)-3-(3-(furan-2-yl)benzamido)benzamide. (CCG-257866). In a 25 mL round 
bottomed flask tert-butyl (3-((4-chlorophenyl)carbamoyl)phenyl)carbamate (0.2 g, 0.58 mmol) 
was dissolved in 4N HCl/dioxane solution (2 mL). The reaction was stirred at 25 °C for 3 hr and 
then concentrated to dryness in vacuo. The remaining white solid was dissolved in DMF (1 mL), 
and then added to a solution of 3-(furan-2-yl)benzoic acid (0.11 g, 0.58 mmol) and HATU (0.44 
g, 1.15 mmol) in DMF (1mL). DIPEA (0.19 g, 0.25 mL, 1.44 mmol) was added and the solution 
was stirred at 25 °C for 1 hr and then heated at 150 °C for 2 hr. Once cooled to 25 °C the 
reaction was diluted with brine (30 mL). The product was extracted with EtOAc (3 x 20 mL), 
washed with dilute HCl (3 x 15 mL) and sat. NaHCO3 (3 x 15 mL), and then concentrated in 
vacuo. The subsequent oil was subjected to silica gel chromatography eluting with 100% 
EtOAc. The fractions containing product were concentrated in vacuo to produce colorless oil. 
The product was crystalized as white powder from the oil using EtOAc/Hex. Similar analogs 
were made in an analogous fashion. Yield=11%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.57 (s, 
1H) 10.43 (s, 1H) 8.32 (d, J = 13.0 Hz, 2H) 8.07 (d, J = 8.1 Hz, 1H) 7.92 (dd, J = 13.9, 7.7 Hz, 
2H) 7.84 (d, J = 8.3 Hz, 2H) 7.71 (d, J = 7.6 Hz, 1H) 7.61 (t, J = 7.7 Hz, 1H) 7.54 (t, J = 8.0 Hz, 
1H) 7.43 (d, J = 8.2 Hz, 2H) 7.12-7.07 (m, 1H) 6.66 (s, 1H); 13C NMR (500 MHz, DMSO-d6) 𝛿 
ppm 166.08, 165.82, 152.75, 143.85, 139.76, 138.60, 135.84, 135.80, 130.96, 129.60, 129.17, 
129.00, 127.73, 127.09, 126.92, 123.96, 123.19, 122.96, 122.28, 120.45, 112.71, 107.27; TOF 
ES+ MS: (M+H) 417.1; HPLC Ret: 7.89 min; 99.5 % pure. 
N-(4-chlorophenyl)-5-(3-(furan-2-yl)benzamido)nicotinamide. (CCG-257922). Starting from 
5-amino-N-(4-chlorophenyl)nicotinamide, HCl. Column: 50% EtOAc: Hex. Crystalized from 
EtOAc: Hex. White powder. Yield=12.5%. 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.76 (s, 1H) 
10.62 (s, 1H) 9.17 (d, J = 2.5 Hz, 1H) 8.89 (s, 1H) 8.70 (s, 1H) 8.32 (s, 1H) 7.94 (dd, J = 20.4, 
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7.8 Hz, 2H) 7.89-7.80 (m, 3H) 7.63 (t, J = 7.8 Hz, 1H) 7.45 (d, J = 8.4 Hz, 2H) 7.10 (d, J = 3.4 
Hz, 1H) 6.66 (s, 1H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 166.21, 164.45, 152.65, 144.84, 
143.92, 143.78, 138.25, 136.17, 135.25, 131.05, 130.89, 129.71, 129.09, 128.09, 127.15, 
127.06, 123.00, 122.38, 112.74, 107.38; TOF ES+ MS: (M+H) 418.1; HPLC Ret: 6.88 min; 98% 
pure. 
cis-N1-(4-chlorophenyl)-N3-(3-(furan-2-yl)phenyl)cyclopentane-1,3-dicarboxamide (CCG-
263872). Method I starting from cis-3-((4-chlorophenyl)carbamoyl)cyclopentanecarboxylic acid 
(0.07 g, 0.27 mmol) and 3-(furan-2-yl)aniline, HCl (0.05 g, 0.27 mmol) gave cis-N1-(4-
chlorophenyl)-N3-(3-(furan-2-yl)phenyl)cyclopentane-1,3-dicarboxamide (0.11 g, 98%) as white 
solid; column: 60% to 80% EtOAc: Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.05 (s, 1H) 
10.00 (s, 1H) 8.03 (d, J = 1.9 Hz, 1H) 7.75 (d, J = 1.7 Hz, 1H) 7.66 (d, J = 8.5 Hz, 2H) 7.52 (d, J 
= 7.9 Hz, 1H) 7.41-7.32 (m, 4H) 6.87 (d, J = 3.4 Hz, 1H) 6.60 (dd, J = 3.2, 1.8 Hz, 1H) 2.89 (q, J 
= 9.3 Hz, 2H) 2.19 (dt, J = 12.5, 7.4 Hz, 1H) 2.04 (dt, J = 12.5, 10.3 Hz, 1H) 1.92 (dt, J = 8.1, 5.4 
Hz, 4H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 173.93, 173.90, 153.37, 143.34, 140.29, 138.73, 
131.12, 129.70, 128.99, 126.98, 121.12, 118.80, 118.66, 114.43, 112.50, 106.27, 46.15, 46.12, 
34.58, 30.05; TOF ES+ MS: (M+Na) 431.11; HPLC Ret: 7.71 min; 98 % pure. 
trans-N1-(4-chlorophenyl)-N3-(3-(furan-2-yl)phenyl)cyclopentane-1,3-dicarboxamide. 
Method I starting from trans-3-((4-chlorophenyl)carbamoyl)cyclopentanecarboxylic acid (0.04 g, 
0.15 mmol) and 3-(furan-2-yl)aniline, HCl (0.03 g, 0.15 mmol) gave trans-N1-(4-chlorophenyl)-
N3-(3-(furan-2-yl)phenyl)cyclopentane-1,3-dicarboxamide (0.02 g, 38%) as white solid; column: 
30% to 80% EtOAc: Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.10 (s, 1H) 10.05 (s, 1H) 8.03 
(d, J = 1.5 Hz, 1H) 7.75 (d, J = 1.5 Hz, 1H) 7.66 (d, J = 8.6 Hz, 2H) 7.50 (d, J = 7.7 Hz, 1H) 
7.41-7.30 (m, 4H) 6.86 (d, J = 2.7 Hz, 1H) 6.62-6.57 (m, 1H) 3.03 (dt, J = 14.3, 7.5 Hz, 2H) 
2.13-1.98 (m, 4H) 1.86-1.76 (m, 2H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 174.49, 153.39, 
143.36, 140.36, 138.42, 131.10, 129.68, 128.99, 126.56, 121.03, 118.75, 118.58, 114.39, 
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112.50, 109.99 106.24, 45.54, 45.50, 34.45, 30.73, 30.70; TOF ES+ MS: (M+H) 409.13; HPLC 
Ret: 7.62 min; >95 % pure (80% trans: 20% cis). 
N-(cis-3-((4-chlorophenyl)carbamoyl)cyclohexyl)-3-(furan-2-yl)benzamide. (CCG-257865) 
Method I starting from cis-3-(3-(furan-2-yl)benzamido)cyclohexanecarboxylic acid (0.04 g, 0.13 
mmol) and 4-chloroaniline (0.016 g, 0.13 mmol) gave N-(cis-3-((4-
chlorophenyl)carbamoyl)cyclohexyl)-3-(furan-2-yl)benzamide (0.02 g, 30%) as brown solid; the 
product was crystalized from EtOAc/Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.05 (br. s, 1H) 
8.42 (d, J = 8.0 Hz, 1H) 8.15 (br. s, 1H) 7.83 (d, J = 7.9 Hz, 1H) 7.79 (s, 1H) 7.75 (d, J = 7.8 Hz, 
1H) 7.64 (d, J = 8.9 Hz, 2H) 7.50 (t, J = 7.7 Hz, 1H) 7.34 (d, J = 8.8 Hz, 2H) 7.02 (d, J = 3.4 Hz, 
1H) 6.63 (dd, J = 3.4, 1.8 Hz, 1H) 3.99-3.85 (m, 1H) 3.32 (br. s., 1H) 2.15-1.79 (m, 6H) 1.57 (q, 
J = 12.2 Hz, 1H) 1.42-1.29 (m, 2H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 173.94, 165.48, 
152.93, 143.67, 138.80, 135.85, 130.74, 129.31, 128.98, 126.93, 126.73, 126.28, 122.56, 
121.06, 112.62, 106.97, 48.12, 44.48, 35.45, 32.17, 28.74, 24.50; TOF ES+ MS: (M+H) 423.1; 
HPLC Ret: 7.61 min; 98 % pure. 
N-(4-chlorophenyl)-1-(3-(furan-2-yl)benzoyl)-1,2,5,6-tetrahydropyridine-3-carboxamide 
(CCG-258161). Method I starting from 1-(3-(furan-2-yl)benzoyl)-1,2,5,6-tetrahydropyridine-3-
carboxylic acid (0.08 g, 0.25 mmol) and 4-chloroaniline (0.03 g, 0.24 mmol) gave N-(4-
chlorophenyl)-1-(3-(furan-2-yl)benzoyl)-1,2,5,6-tetrahydropyridine-3-carboxamide (0.03 g, 27%) 
as white solid; column: 60% EtOAc: 40% Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.02 (br. 
s, 1H) 7.92-7.51 (m, 6H) 7.45-7.29 (m, 3H) 7.08 (br. s, 1H) 6.92 (br. s, 1H) 6.63 (br.s, 1H) 4.40 
(br. s, 1H) 4.18 (br. s, 1H) 3.77 (br. s, 1H) 3.45 (br. s, 1H) 2.38 (br. s, 2H); 13C NMR (500 MHz, 
DMSO-d6) 𝛿 ppm 169.28, 165.12, 152.65, 143.80, 137.20, 131.82, 131.00, 129.64, 128.90, 
127.52, 124.733, 122.11, 112.66, 107.24, 84.55, 68.83, 46.65, 43.65, 25.85; QTOF ES+ MS: 




carboxamide (CCG-264643). Method I starting from 1-(3-(furan-2-yl)benzoyl)-1,2,5,6-
tetrahydropyridine-3-carboxylic acid (0.04 g, 0.12 mmol) and 3-chloroaniline (0.02 g, 0.12 mmol) 
gave N-(3-chlorophenyl)-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)-1,2,5,6-tetrahydropyridine-3-
carboxamide (0.03 g, 62%) as white solid; column: 100% EtOAc; 1H NMR (400 MHz, DMSO-d6) 
𝛿 ppm 9.75 (br. s, 1H) 8.65 (d, J = 8.0 Hz, 2H) 7.80-7.60 (m, 3H) 7.56 (d, J = 8.3 Hz, 1H) 7.38-
7.22 (m, 2H) 7.08 (d, J = 8.0 Hz, 1H) 6.91 (br. s, 1H) 5.93 (s, 1H) 4.31 (br. s, 2H) 3.60 (br. s, 2H) 
2.38 (br. s, 2H); 19F NMR (376 MHz, DMSO-d6) 𝛿 ppm -111.36 (t, J = 9.4 Hz, 1H); TOF ES+ MS: 
(M+H) 436.12; HPLC Ret: 5.51 min; 85 % pure. 15% impurity is conformational isomer; verified 
via HPLC/MS & hi-temp HNMR/FNMR. 
5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)-N-(m-tolyl)piperidine-3-carboxamide. 
(CCG-264321). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-
3-carboxylic acid (0.05 g, 0.12 mmol) and m-toluidine (0.02 g, 0.15 mmol) gave 5,5-difluoro-1-
(3-fluoro-5-(pyridin-4-yl)benzoyl)-N-(m-tolyl)piperidine-3-carboxamide (0.05 g, 96%) as white 
solid; column: 70% to 80% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 9.78 (s, 
1H) 8.66 (d, J = 5.0 Hz, 2H) 7.77-7.67 (m, 3H) 7.61 (q, 1.4 Hz, 1H) 7.39-7.28 (m, 3H) 7.15 (t, J = 
7.8 Hz, 1H) 6.87 (d, J = 7.5 Hz, 1H) 4.26 (br. s, 2H) 3.56 (dd, J = 30.0, 13.7 Hz, 1H) 3.27 (t, J = 
9.9 Hz, 1H) 2.96 (s, 2H) 2.26 (s, 3H) 2.46-2.34 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 
ppm -98.42—-102.51 (m, 2H) -111.09 (t, J = 9.3 Hz, 1H); QTOF ES+ MS: (M+H) 454.17; HPLC 
Ret: 5.70 min; 98% pure. 
N-(3-ethylphenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264322). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.05 g, 0.12 mmol) and 3-ethylaniline (0.02 g, 0.15 
mmol) gave N-(3-ethylphenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide (0.05 g, 88%) as white solid; column: 65% to 80% EtOAc: Hex; 1H NMR (400 
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MHz, DMSO-d6, 80 °C) 𝛿 ppm 9.83 (s, 1H) 8.66 (d, J = 4.9 Hz, 2H) 7.78-7.67 (m, 3H) 7.62 (s, 
1H) 7.42-7.27 (m, 3H) 7.18 (t, J = 7.8 Hz, 1H) 6.90 (d, J = 7.5 Hz, 1H) 4.20 (br. s, 2H) 3.56 (dd, 
J = 29.9, 14.0 Hz, 1H) 3.26 (t, J = 9.9 Hz, 1H) 2.98 (br. s, 2H) 2.54 (q, J = 7.6 Hz, 2H) 2.30 (dd, 
J = 19.2, 13.2 Hz, 1H) 1.17 (t, J = 7.6 Hz, 3H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -
97.30—-102.57 (m, 2H) -111.09 (t, J = 9.3 Hz, 1H); QTOF ES+ MS: (M+H) 468.19; HPLC Ret: 
5.99 min; 98% pure. 
5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)-N-(3-isopropylphenyl)piperidine-3-
carboxamide. (CCG-264323). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.05 g, 0.12 mmol) and 3-isopropylaniline (0.02 g, 0.15 
mmol) gave 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)-N-(3-isopropylphenyl)piperidine-3-
carboxamide (0.05 g, 86%) as white solid; column: 65% to 80% EtOAc: Hex; 1H NMR (400 
MHz, DMSO-d6, 80 °C) 𝛿 ppm 9.82 (s, 1H) 8.66 (d, J = 4.9 Hz, 2H) 7.77-7.67 (m, 3H) 7.62 (s, 
1H) 7.45-7.28 (m, 3H) 7.18 (t, J = 7.9 Hz, 1H) 6.93 (d, J = 7.7 Hz, 1H) 4.20 (br. s, 2H) 3.56 (dd, 
J = 30.0, 13.9 Hz, 1H) 3.26 (t, J = 12.1 Hz, 1H) 2.98 (br. s, 2H) 2.84 (p, J = 6.9 Hz, 1H) 2.37-
2.19 (m, 1H) 1.22-1.13 (m, 6H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -96.90—-104.28 
(m, 2H) -111.09 (t, J = 9.4 Hz, 1H); QTOF ES+ MS: (M+H) 482.21; HPLC Ret: 6.23 min; 99% 
pure. 
N-(3-cyclopropylphenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264324). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.05 g, 0.12 mmol) and 3-cyclopropylaniline (0.02 g, 
0.15 mmol) gave N-(3-cyclopropylphenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide (0.06 g, 100%) as purple solid; column: 70% to 80% 
EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 9.78 (s, 1H) 8.66 (d, J = 4.9 Hz, 2H) 
7.77-7.67 (m, 3H) 7.61 (s, 1H) 7.37-7.23 (m, 3H) 7.14 (t, J = 7.9 Hz, 1H) 6.79 (d, J = 7.6 Hz, 1H) 
4.20 (br. s, 2H) 3.56 (dd, J = 30.0, 14.0 Hz, 1H) 3.25 (t, J = 12.5 Hz, 1H) 2.98 (br. s, 2H) 2.39-
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2.20 (m, 1H) 1.92-1.81 (m, 1H) 0.96-0.82 (m, 2H) 0.61-0.58 (m, 2H); 19F NMR (376 MHz, 
DMSO-d6, 80 °C) 𝛿 ppm -96.90—-101.35 (m, 2H) -111.09 (t, J = 9.4 Hz, 1H); QTOF ES+ MS: 
(M+H) 480.19; HPLC Ret: 5.98 min; 99% pure. 
5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)-N-(3-(trifluoromethyl)phenyl)piperidine-3-
carboxamide. (CCG-264325). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.05 g, 0.12 mmol) and 3-(trifluoromethyl)aniline (0.02 g, 
0.15 mmol) gave 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)-N-(3-
(trifluoromethyl)phenyl)piperidine-3-carboxamide (0.05 g, 78%) as white solid; column: 70% 
EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.22 (br. s, 1H) 8.66 (d, J = 4.9 Hz, 
2H) 8.01 (s, 1H) 7.80-7.67 (m, 4H) 7.62 (s, 1H) 7.52 (t, J = 8.0 Hz, 1H) 7.40-7.28 (m, 2H) 4.40-
4.12 (m, 2H) 3.59 (dd, J = 29.6, 14.0 Hz, 1H) 3.28 (t, J = 12.5 Hz, 1H) 2.98 (br. s, 2H) 2.42-2.22 
(m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -61.54 (s, 3H) -96.90—-101.35 (m, 2H) -
111.10 (t, J = 9.4 Hz, 1H); QTOF ES+ MS: (M+H) 508.15; HPLC Ret: 6.12 min; 97% pure. 
5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)-N-(3-(trifluoromethoxy)phenyl)piperidine-
3-carboxamide. (CCG-264326). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.05 g, 0.12 mmol) and 3-(trifluoromethoxy)aniline (0.03 
g, 0.15 mmol) gave 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)-N-(3-
(trifluoromethoxy)phenyl)piperidine-3-carboxamide (0.06 g, 85%) as white solid; column: 65% 
EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.17 (br. s, 1H) 8.66 (d, J = 4.9 Hz, 
2H) 7.78-7.59 (m, 5H) 7.48 (d, J = 8.1 Hz, 1H) 7.40 (t, J = 8.1 Hz, 1H) 7.28 (d, J = 8.4 Hz, 1H) 
7.00 (d, J = 8.2 Hz, 1H) 4.38-4.08 (m, 2H) 3.58 (dd, J = 29.8, 13.9 Hz, 1H) 3.27 (t, J = 12.5 Hz, 
1H) 2.98 (br. s, 2H) 2.42-2.25 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -56.61 (s, 
3H) -96.90—-101.35 (m, 2H) -111.10 (t, J = 9.4 Hz, 1H); QTOF ES+ MS: (M+H) 524.14; HPLC 




carboxamide. (CCG-264327). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.05 g, 0.12 mmol) and 2-chloroaniline (0.02 g, 0.15 
mmol) gave N-(2-chlorophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide (0.03 g, 43%) as white solid; column: 70% EtOAc: Hex; 1H NMR (400 MHz, 
DMSO-d6, 80 °C) 𝛿 ppm 9.54 (br. s, 1H) 8.66 (d, J = 4.9 Hz, 2H) 7.79-7.68 (m, 3H) 7.66-7.57 
(m, 2H) 7.45 (d, J = 8.1 Hz, 1H) 7.36-7.25 (m, 2H) 7.19 (t, J = 8.5 Hz, 1H) 4.24 (m, 2H) 3.56 (dd, 
J = 30.0, 14.0 Hz, 1H) 3.27 (t, J = 12.5 Hz, 1H) 3.13 (br. s, 1H) 3.00 (s, 1H) 2.42-2.26 (m, 1H); 
19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -95.94—-104.76 (m, 2H) -111.10 (t, J = 9.5 Hz, 
1H); QTOF ES+ MS: (M+H) 474.12; HPLC Ret: 5.55 min; 95% pure. 
N-(3-cyanophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264604). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.05 g, 0.14 mmol) and 3-aminobenzonitrile (0.02 g, 
0.14 mmol) gave N-(3-cyanophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide (0.01 g, 19%) as white solid; column: 80% EtOAc: Hex; 1H NMR (400 MHz, 
DMSO-d6, 80 °C) 𝛿 ppm 10.21 (br. s, 1H) 8.67 (t, J = 5.8 Hz, 2H) 8.01 (d, J = 6.3 Hz, 1H) 7.83-
7.67 (m, 4H) 7.63 (d, J = 8.0 Hz, 1H) 7.49 (dq, J = 13.7, 7.4 Hz, 2H) 7.30 (t, J = 7.9 Hz, 1H) 
4.37-4.08 (m, 2H) 3.60 (dd, J = 31.2, 14.2 Hz, 1H) 3.35-3.21 (m, 1H) 2.98 (br. s, 2H) 2.42-2.19 
(m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -97.94—-103.31 (m, 2H) -111.08 (t, J = 
9.4 Hz, 1H); QTOF ES+ MS: (M+H) 465.15; HPLC Ret: 5.45 min; 100% pure. 
N-(3-ethynylphenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264605). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.05 g, 0.14 mmol) and 3-ethynylaniline (0.02 g, 0.14 
mmol) gave N-(3-ethynylphenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide (0.03 g, 52%) as white solid; column: 80% EtOAc: Hex; 1H NMR (400 MHz, 
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DMSO-d6, 80 °C) 𝛿 ppm 9.97 (br. s, 1H) 8.70-8.62 (m, 2H) 7.77-7.67 (m, 4H) 7.62 (d, J = 1.7 
Hz, 1H) 7.53 (d, J = 8.3 Hz, 1H) 7.29 (td, J = 8.0, 2.0 Hz, 2H) 7.16 (d, J = 8.2 Hz, 1H) 4.38-4.10 
(m, 2H) 3.92 (s, 1H) 3.58 (dd, J = 29.6, 13.9 Hz, 1H) 3.27 (t, J = 12.2 Hz, 1H) 2.98 (br. s, 2H) 
2.42-2.22 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -98.91—-101.74 (m, 2H) -
111.08 (t, J = 9.4 Hz, 1H); QTOF ES+ MS: (M+H) 464.16; HPLC Ret: 5.74 min; 99% pure. 
(4-chloro-1H-indazol-1-yl)(5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidin-3-
yl)methanone. (CCG-264641). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.05 g, 0.14 mmol) and 4-chloro-1H-indazole (0.02 g, 
0.14 mmol) gave (4-chloro-1H-indazol-1-yl)(5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidin-3-yl)methanone (0.03 g, 45%) as white solid; column: 65% EtOAc: Hex; 1H 
NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 8.70-8.58 (m, 2H) 8.23 (d, J = 8.3 Hz, 1H) 7.79-7.70 
(m, 3H) 7.70-7.51 (m, 3H) 7.47 (d, J = 7.7 Hz, 1H) 7.37 (td, J = 8.7, 2.5 Hz, 1H) 4.55-4.21 (m, 
2H) 3.65 (dd, J = 28.3, 14.0 Hz, 1H) 3.46 (t, J = 12.0 Hz, 1H) 2.98 (br. s, 2H) 2.63-2.48 (m, 1H); 
19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -97.94—-102.03 (m, 2H) -111.26 (t, J = 9.4 Hz, 
1H); QTOF ES+ MS: (M+H) 499.12; HPLC Ret: 6.27 min; 90% pure (10% impurity is fluoro 
elimination product). 
N-(3-chlorobenzyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264642). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.05 g, 0.14 mmol) and (3-chlorophenyl)methanamine 
(0.02 g, 0.14 mmol) gave N-(3-chlorobenzyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide (0.03 g, 49%) as tan solid; column: 80% to 100% EtOAc: 
Hex; washed with water post-column to remove remaining PF6 salt; 1H NMR (400 MHz, DMSO-
d6, 80 °C) 𝛿 ppm 8.65 (d, J = 8 Hz, 2H) 8.42 (s, 1H) 7.82-7.67 (m, 3H) 7.60 (s, 1H) 7.34-7.25 (m, 
4H) 7.17 (d, J = 7.5 Hz, 1H) 4.27 (d, J = 5.8 Hz, 2H) 4.25-4.13 (m, 2H) 3.52 (dd, J = 30.0, 13.9 
Hz, 1H) 3.22 (t, J = 12.1 Hz, 1H) 2.98 (br. s, 2H) 2.34-2.16 (m, 1H); 19F NMR (376 MHz, DMSO-
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d6, 80 °C) 𝛿 ppm -96.66—-102.51 (m, 2H) -111.11 (t, J = 9.3 Hz, 1H); QTOF ES+ MS: (M+H) 
488.14; HPLC Ret: 5.53 min; 98% pure. 
N-(3,5-dichlorophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-265067). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.08 mmol) and 3,5-dichloroaniline (0.01 g, 0.08 
mmol) gave N-(3,5-dichlorophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide (0.01 g, 19%) as white solid; reaction done at 85 °C; column: 65% to 80% EtOAc: 
Hex; washed with water post-column to remove remaining PF6 salt; 1H NMR (400 MHz, DMSO-
d6, 80 °C) 𝛿 ppm 10.22 (br. s, 1H) 8.66 (d, J = 8.0 Hz, 2H) 7.78-7.67 (m, 3H) 7.67-7.60 (m, 3H) 
7.30 (d, J = 8.5Hz, 1H) 7.20 (s, 1H) 4.38-4.10 (m, 2H) 3.60 (dd, J = 29.3, 14.0 Hz, 1H) 3.26 (s, 
1H) 2.93 (br. s, 2H) 2.46-2.20 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -97.22—-
106.44 (m, 2H) -111.08 (t, J = 9.5 Hz, 1H); QTOF ES+ MS: (M+H) 508.1; HPLC Ret: 6.49 min; 
95% pure. 
N-(3-bromo-5-chlorophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-265068). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.08 mmol) and 3-bromo-5-chloroaniline (0.02 g, 
0.08 mmol) gave N-(3-bromo-5-chlorophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide (0.01 g, 22%) as white solid; reaction done at 85 °C; 
column: 65% to 75% EtOAc: Hex; washed with water post-column to remove remaining PF6 
salt; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.27 (br. s, 1H) 8.74 (d, J = 8.0 Hz, 2H) 7.86-
7.67 (m, 6H) 7.43-7.34 (m, 2H) 4.40-4.11 (m, 2H) 3.68 (dd, J = 29.5, 14.0 Hz, 1H) 3.25 (s, 1H) 
3.00 (br. s, 2H) 2.51-2.29 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -97.56—-





carboxamide. (CCG-265069). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.08 mmol) and 3-chloro-5-methylaniline (0.01 g, 
0.08 mmol) gave N-(3-chloro-5-methylphenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide (0.02 g, 50%) as white solid; reaction done at 80 °C; 
column: 65% to 75% EtOAc: Hex; washed with water post-column to remove remaining PF6 
salt; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 9.97 (br. s, 1H) 8.66 (d, J = 8.0 Hz, 2H) 7.77-
7.67 (m, 3H) 7.62 (s, 1H) 7.52 (s, 1H) 7.30 (ddt, J = 8.7, 2.4, 1.1 Hz, 1H) 7.26 (s, 1H) 6.93 (s, 
1H) 4.35-4.09 (m, 2H) 3.58 (dd, J = 29.7, 14.0 Hz, 1H) 3.26 (t, J = 12.2 Hz, 1H) 2.97 (br. s, 2H) 
2.41-2.29 (m, 1H) 2.27 (s, 3H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -96.90—-102.27 
(m, 2H) -111.09 (t, J = 9.3 Hz, 1H); QTOF ES+ MS: (M+H) 488.1; HPLC Ret: 6.20 min; 99% 
pure. 
N-(3-chloro-5-methoxyphenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-
3-carboxamide. (CCG-265070). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.08 mmol) and 3-chloro-5-methoxyaniline (0.01 
g, 0.08 mmol) gave N-(3-chloro-5-methoxyphenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide (0.01 g, 24%) as white solid; reaction done at 80 °C; 
column: 65% to 75% EtOAc: Hex; washed with water post-column to remove remaining PF6 
salt; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.01 (br. s, 1H) 8.66 (d, J = 8.0 Hz, 2H) 7.78-
7.67 (m, 3H) 7.61 (s, 1H) 7.34-7.25 (m, 2H) 7.12 (s, 1H) 6.69 (s, 1H) 4.35-4.08 (m, 2H) 3.75 (s, 
3H) 3.58 (dd, J = 29.6, 14.0 Hz, 1H) 3.28 (t, J = 12.2 Hz, 1H) 2.96 (br. s, 2H) 2.43-2.19 (m, 1H); 
19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -99.07—-101.76 (m, 2H) -111.09 (t, J = 9.4 Hz, 
1H); QTOF ES+ MS: (M+H) 504.1; HPLC Ret: 6.06 min; 98% pure. 
N-(3-chloro-5-hydroxyphenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-265071). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
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yl)benzoyl)piperidine-3-carboxylic acid (0.04 g, 0.11 mmol) and 3-((tert-butyldiphenylsilyl)oxy)-5-
chloroaniline (0.04 g, 0.11 mmol) gave N-(3-chloro-5-hydroxyphenyl)-5,5-difluoro-1-(3-fluoro-5-
(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.02 g, 41% (2 steps)) as white solid; reaction 
done at 75 °C; column: 75% to 90% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 
9.90 (br. s, 1H) 9.55 (br. s, 1H) 8.66 (d, J = 5.2 Hz, 2H) 7.77-7.67 (m, 3H) 7.61 (s, 1H) 7.30 (d, J 
= 8.7 Hz, 1H) 7.12 (s, 1H) 6.99 (s, 1H) 6.50 (s, 1H) 4.37-4.09 (m, 2H) 3.57 (dd, J = 29.7, 13.8 
Hz, 1H) 3.24 (t, J = 14.6 Hz, 1H) 2.97 (br. s, 2H) 2.41-2.17 (m, 1H); 19F NMR (376 MHz, DMSO-
d6, 80 °C) 𝛿 ppm -97.22—-103.07 (m, 2H) -111.09 (t, J = 9.3 Hz, 1H); QTOF ES+ MS: (M+H) 
490.1; HPLC Ret: 5.37 min; 95% pure. 
N-(3-(((tert-butyldiphenylsilyl)oxy)methyl)-5-chlorophenyl)-5,5-difluoro-1-(3-fluoro-5-
(pyridin-4-yl)benzoyl)piperidine-3-carboxamide. Method I starting from 5,5-difluoro-1-(3-
fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxylic acid (0.04 g, 0.11 mmol) and 3-(((tert-
butyldiphenylsilyl)oxy)methyl)-5-chloroaniline (0.04 g, 0.11 mmol) gave N-(3-(((tert-
butyldiphenylsilyl)oxy)methyl)-5-chlorophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide (0.02 g, 49%) as white solid; reaction done at 75 °C; 
column: 55% to 65% EtOAc: Hex; 1H NMR (500 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.51 (br. s, 1H) 
8.68 (br. s, 2H) 7.86 (br. s, 1H) 7.79 (d, J = 5.1 Hz, 2H) 7.64 (br. s, 7H) 7.45 (br. s, 7H) 7.06 (s, 
1H) 4.79-4.68 (m, 2H) 4.03 (qd, J = 7.0 Hz, 1H) 3.81 (br. s, 2H) 3.48 (br. s, 1H) 3.25-2.92 (m, 
2H) 2.42-2.27 (m, 1H) 1.05 (br. s, 9H); QTOF ES+ MS: (M+H) 742.2; HPLC Ret: 8.62 min. 
N-(3-chloro-5-cyanophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-265171). Method I starting from 5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.08 mmol) and 3-amino-5-chlorobenzonitrile 
(0.01 g, 0.09 mmol) gave N-(3-chloro-5-cyanophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide (0.01 g, 32%) as yellow solid; reaction done at 75 °C; 
column: 65% to 75% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.37 (br. s, 1H) 
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8.66 (d, J = 5.3 Hz, 2H) 7.94 (s, 1H) 7.88 (s, 1H) 7.78-7.67 (m, 3H) 7.61 (d, J = 7.0 Hz, 2H) 7.30 
(d, J = 8.8 Hz, 1H) 4.36-4.09 (m, 2H) 3.61 (dd, J = 29.5, 13.9 Hz, 1H) 3.27 (s, 1H) 2.96 (br. s, 
2H) 2.47-2.21 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -97.22—-101.90 (m, 2H) -
111.08 (t, J = 9.3 Hz, 1H); QTOF ES+ MS: (M+H) 499.1; HPLC Ret: 5.83 min; 96% pure. 
N-(3-chloro-5-(trifluoromethyl)phenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide. (CCG-265173). Method I starting from 5,5-difluoro-1-(3-
fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.08 mmol) and 3-chloro-5-
(trifluoromethyl)aniline (0.02 g, 0.12 mmol) gave N-(3-chloro-5-(trifluoromethyl)phenyl)-5,5-
difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.02 g, 38%) as yellow 
solid; reaction done at 85 °C; column: 60% EtOAc: Hex; washed with water post-column to 
remove remaining PF6 salt; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.35 (br. s, 1H) 8.65 
(d, J = 5.5 Hz, 2H) 7.90 (d, J = 19.9 Hz, 2H) 7.77-7.66 (m, 3H) 7.61 (s, 1H) 7.43 (s, 1H) 7.30 (d, 
J = 8.6 Hz, 1H) 4.38-4.09 (m, 2H) 3.60 (dd, J = 29.2, 13.8 Hz, 1H) 3.27 (s, 1H) 2.96 (br. s, 2H) 
2.45-2.22 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -61.83 (s, 3H) -99.16—-101.82 
(m, 2H) -111.10 (t, J = 9.0 Hz, 1H); QTOF ES+ MS: (M+H) 542.1; HPLC Ret: 6.48 min; 99% 
pure. 
N-(3-chloro-5-(trifluoromethoxy)phenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide. (CCG-265174). Method I starting from 5,5-difluoro-1-(3-
fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.08 mmol) and 3-chloro-5-
(trifluoromethoxy)aniline (0.03 g, 0.12 mmol) gave N-(3-chloro-5-(trifluoromethoxy)phenyl)-5,5-
difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.02 g, 33%) as yellow 
solid; reaction done at 85 °C; column: 60% EtOAc: Hex; washed with water post-column to 
remove remaining PF6 salt; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.31 (br. s, 1H) 8.65 
(d, J = 5.6 Hz, 2H) 7.78-7.67 (m, 3H) 7.69-7.55 (m, 3H) 7.30 (d, J = 8.5 Hz, 1H) 7.12 (s, 1H) 
4.40-4.10 (m, 2H) 3.60 (dd, J = 29.4, 13.9 Hz, 1H) 3.29 (s, 1H) 2.97 (br. s, 2H) 2.45-2.14 (m, 
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1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -56.82 (s, 3H) -99.08—-101.85 (m, 2H) -
111.10 (t, J = 9.3 Hz, 1H); QTOF ES+ MS: (M+H) 558.1; HPLC Ret: 6.58 min; 99% pure. 
5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-phenethylpiperidine-3-carboxamide. (CCG-
265187). Method I starting from 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxylic acid 
(0.03 g, 0.09 mmol) and 2-phenylethanamine (0.01 g, 0.1 mmol) gave 5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)-N-phenethylpiperidine-3-carboxamide (0.01 g, 31%) as white solid; column: 30% 
EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 7.90-7.81 (br. s, 1H) 7.78 (d, J = 8.0 
Hz, 1H) 7.71 (s, 1H) 7.65 (s, 1H) 7.58-7.46 (m, 1H) 7.30-7.17 (m, 3H) 7.18-7.12 (m, 3H) 6.95 (d, 
J = 3.4 Hz, 1H) 6.58 (dt, J = 3.0, 1.2 Hz, 1H) 4.33-4.05 (m, 2H) 3.43 (dd, J = 30.8, 13.8 Hz, 1H) 
3.35-3.25 (m, 2H) 3.07 (t, J = 12.4 Hz, 1H) 2.74-2.64 (m, 2H) 2.27-2.05 (m, 3H); 19F NMR (376 
MHz, DMSO-d6, 80 °C) 𝛿 ppm -97.36—-103.39 (m, 2H); QTOF ES+ MS: (M+H) 439.2; HPLC 
Ret: 7.21 min; 99% pure. 
N-(2-chlorophenethyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide. 
(CCG-265188). Method I starting from 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-
carboxylic acid (0.03 g, 0.09 mmol) and 2-(2-chlorophenyl)ethanamine (0.02 g, 0.1 mmol) gave 
N-(2-chlorophenethyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide (0.01 g, 
28%) as white solid; column: 25% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 
7.95-7.85 (br. s, 1H) 7.79 (d, J = 8.0 Hz, 1H) 7.71 (s, 1H) 7.65 (s, 1H) 7.57-7.46 (m, 1H) 7.38-
7.30 (m, 1H) 7.31-7.14 (m, 5H) 6.96 (d, J = 2.7 Hz, 1H) 6.58 (dt, J = 3.8, 1.8 Hz, 1H) 4.28-4.05 
(m, 2H) 3.50-3.27 (m, 3H) 3.07 (t, J = 12.4 Hz, 1H) 2.85 (br. s, 1H) 2.71-2.61 (m, 1H) 2.29-2.07 
(m, 3H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -98.77—-102.18 (m, 2H); QTOF ES+ MS: 
(M+H) 473.1; HPLC Ret: 7.50 min; 99% pure. 
5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-3-carboxamide. 
(CCG-265189). Method I starting from 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-
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carboxylic acid (0.03 g, 0.09 mmol) and 2-(pyridin-4-yl)ethanamine (0.01 g, 0.1 mmol) gave 5,5-
difluoro-1-(3-(furan-2-yl)benzoyl)-N-(2-(pyridin-4-yl)ethyl)piperidine-3-carboxamide (0.01 g, 
31%) as white solid; column: 95% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 
8.39 (d, J = 5.4 Hz, 2H) 7.93 (br. s, 1H) 7.79 (d, J = 7.9 Hz, 1H) 7.71 (s, 1H) 7.65 (s, 1H) 7.50 (t, 
J = 7.8 Hz, 1H) 7.27 (d, J = 7.7 Hz, 1H) 7.14 (d, J = 4.9 Hz, 2H) 6.95 (d, J = 3.4 Hz, 1H) 6.58 (d, 
J = 2.9 Hz, 1H) 4.27-4.05 (m, 2H) 3.50-3.30 (m, 3H) 3.05 (t, J = 12.2 Hz, 1H) 2.77-2.60 (m, 3H) 
2.40-2.00 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -98.83—-102.13 (m, 2H); QTOF 
ES+ MS: (M+H) 440.2; HPLC Ret: 5.14 min; 96% pure. 
N-(3-(1H-imidazol-1-yl)propyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-
carboxamide. (CCG-265190). Method I starting from 5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.09 mmol) and 3-(1H-imidazol-1-yl)propan-1-
amine (0.01 g, 0.1 mmol) gave N-(3-(1H-imidazol-1-yl)propyl)-5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxamide (0.01 g, 35%) as white solid; column: 5% MeOH: DCM; 
washed with water post-column to remove remaining PF6 salt; 1H NMR (400 MHz, DMSO-d6, 80 
°C) 𝛿 ppm 7.89 (br. s, 1H) 7.77 (d, J = 8.1 Hz, 1H) 7.73-7.63 (m, 2H) 7.56-7.46 (m, 2H) 7.28 (d, 
J = 7.5 Hz, 1H) 7.07 (s, 1H) 6.95 (d, J = 3.4 Hz, 1H) 6.86 (s, 1H) 6.58 (dd, J = 3.4, 2.0 Hz, 1H) 
4.28-4.05 (m, 2H) 3.94 (t, J = 7.1 Hz, 2H) 3.47 (dd, J = 30.7, 14.1 Hz, 1H) 3.14 (t, J = 12.1 Hz, 
1H) 3.04 (br. s, 2H) 2.37-2.07 (m, 1H) 1.85 (t, J = 7.6 Hz, 2H); 19F NMR (376 MHz, DMSO-d6, 
80 °C) 𝛿 ppm -98.89—-102.13 (m, 2H); QTOF ES+ MS: (M+H) 443.2; HPLC Ret: 5.19 min; 95% 
pure. 
N-(2-(1H-imidazol-4-yl)ethyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-
carboxamide. (CCG-265191). Method I starting from 5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.09 mmol) and 2-(1H-imidazol-4-yl)ethanamine 
(0.01 g, 0.1 mmol) gave N-(2-(1H-imidazol-4-yl)ethyl)-5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxamide (0.02 g, 57%) as white solid; column: 2.5% MeOH: DCM; 
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1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 11.52 (br. s, 1H) 7.87 (br. s, 1H) 7.78 (d, J = 8.0 
Hz, 1H) 7.71 (s, 1H) 7.66 (s, 1H) 7.50 (t, J = 7.7 Hz, 1H) 7.42 (s, 1H) 7.27 (d, J = 7.6 Hz, 1H) 
6.95 (d, J = 3.4 Hz, 1H) 6.71 (s, 1H) 6.58 (dd, J = 3.4, 2.0 Hz, 1H) 4.27-4.07 (m, 2H) 3.45 (dd, J 
= 30.1, 14.0 Hz, 1H) 3.34-3.25 (m, 2H) 3.09 (t, J = 12.1 Hz, 1H) 2.71-2.60 (m, 2H) 2.36-2.02 (m, 
1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -98.82—-102.17 (m, 2H); QTOF ES+ MS: 
(M+H) 429.2; HPLC Ret: 5.11 min; 93% pure. 
5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-((R)-2-hydroxy-2-phenylethyl)piperidine-3-
carboxamide. (CCG-265192). Method I starting from 5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.09 mmol) and (R)-2-amino-1-phenylethanol 
(0.01 g, 0.1 mmol) gave 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-((R)-2-hydroxy-2-
phenylethyl)piperidine-3-carboxamide (0.01 g, 30%) as white solid; column: 50% to 65% EtOAc: 
Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 7.86 (br. s, 1H) 7.79 (d, J = 7.7 Hz, 1H) 7.71 
(s, 1H) 7.65 (s, 1H) 7.51 (t, J = 7.8 Hz, 1H) 7.35-7.21 (m, 6H) 6.96 (d, J = 3.4 Hz, 1H) 6.58 (dd, 
J = 3.4, 2.0 Hz, 1H) 5.10 (br. s, 1H) 4.61 (br. s, 1H) 4.33-4.00 (m, 2H) 3.43 (dd, J = 30.1, 14.0 
Hz, 1H) 3.30-3.20 (m, 2H) 3.00 (t, J = 12.1 Hz, 1H) 2.75-2.68 (m, 2H) 2.30-2.07 (m, 1H); 19F 
NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -98.57—-102.17 (m, 2H); QTOF ES+ MS: (M+H) 
455.2; HPLC Ret: 6.47 min; 97% pure. 
5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-((S)-2-hydroxy-2-phenylethyl)piperidine-3-
carboxamide. (CCG-265193). Method I starting from 5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.09 mmol) and (S)-2-amino-1-phenylethanol 
(0.01 g, 0.1 mmol) gave 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-((S)-2-hydroxy-2-
phenylethyl)piperidine-3-carboxamide (0.02 g, 54%) as white solid; column: 50% to 60% EtOAc: 
Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 7.87 (br. s, 1H) 7.79 (d, J = 7.9 Hz, 1H) 7.72 
(s, 1H) 7.65 (s, 1H) 7.51 (t, J = 7.7 Hz, 1H) 7.35-7.16 (m, 6H) 6.96 (d, J = 3.4 Hz, 1H) 6.59 (dd, 
J = 3.4, 2.0 Hz, 1H) 5.11 (br. s, 1H) 4.61 (br. s, 1H) 4.29-4.00 (m, 2H) 3.49-3.19 (m, 3H) 3.06 (t, 
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J = 12.1 Hz, 1H) 2.78-2.69 (m, 2H) 2.31-2.07 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 
ppm -98.72—-102.57 (m, 2H); QTOF ES+ MS: (M+H) 455.2; HPLC Ret: 6.48 min; 96% pure. 
5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-(1-methyl-1H-pyrazol-4-yl)piperidine-3-
carboxamide. (CCG-265194). Method I starting from 5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.09 mmol) and 1-methyl-1H-pyrazol-4-amine 
(0.01 g, 0.1 mmol) gave 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-(1-methyl-1H-pyrazol-4-
yl)piperidine-3-carboxamide (0.02 g, 62%) as white solid; column: 70% to 80% EtOAc: Hex; 1H 
NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 9.86 (br. s, 1H) 7.81-7.64 (m, 4H) 7.50 (t, J = 7.7 Hz, 
1H) 7.37 (s, 1H) 7.29 (d, J = 7.8 Hz, 1H) 6.95 (d, J = 3.5 Hz, 1H) 6.58 (dt, J = 3.6, 1.8 Hz, 1H) 
4.31-4.10 (m, 2H) 3.75 (s, 3H) 3.51 (dd, J = 30.4, 13.8 Hz, 1H) 3.18 (t, J = 12.3 Hz, 1H) 2.88-
2.80 (m, 2H) 2.30-2.19 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -98.14—-102.75 
(m, 2H); QTOF ES+ MS: (M+H) 415.2; HPLC Ret: 6.06 min; 99% pure. 
N-(3-ethyl-1H-pyrazol-5-yl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide. 
(CCG-265195). Method I starting from 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-
carboxylic acid (0.03 g, 0.09 mmol) and 3-ethyl-1H-pyrazol-5-amine (0.01 g, 0.1 mmol) gave N-
(3-ethyl-1H-pyrazol-5-yl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide (0.01 g, 
26%) as white solid; column: 20% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 
7.78 (d, J = 7.9 Hz, 1H) 7.75-7.69 (m, 2H) 7.51 (t, J = 7.7 Hz, 1H) 7.32 (d, J = 7.8 Hz, 1H) 6.96 
(d, J = 3.4 Hz, 1H) 6.58 (dt, J = 3.6, 1.8 Hz, 1H) 6.31 (br. s, 2H) 4.40-4.00 (m, 2H) 4.05-3.77 (m, 
2H) 3.52 (dd, J = 30.4, 13.8 Hz, 1H) 3.31 (t, J = 12.2 Hz, 1H) 2.90-2.80 (m, 2H) 2.32-2.22 (m, 
1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -99.54—-104.37 (m, 2H); QTOF ES+ MS: 
(M+H) 429.2; HPLC Ret: 7.41 min; 90% pure. 
5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-(quinolin-3-yl)piperidine-3-carboxamide. (CCG-
265196). Method I starting from 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxylic acid 
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(0.03 g, 0.09 mmol) and quinolin-3-amine (0.01 g, 0.1 mmol) gave 5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)-N-(quinolin-3-yl)piperidine-3-carboxamide (0.01 g, 32%) as white solid; column: 50% 
to 60% EtOAc: Hex; washed with water post-column to remove remaining PF6 salt; 1H NMR 
(400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 8.92 (s, 1H) 8.56 (s, 1H) 7.94 (d, J = 8.6 Hz, 1H) 7.86 (d, J 
= 8.1 Hz, 1H) 7.78 (d, J = 8.0 Hz, 1H) 7.72-7.68 (m, 2H) 7.67-7.47 (m, 4H) 7.32 (d, J = 7.7 Hz, 
1H) 6.95 (d, J = 3.4 Hz, 1H) 6.58 (dt, J = 3.6, 1.8 Hz, 1H) 4.41-4.05 (m, 2H) 3.57 (dd, J = 30.4, 
13.8 Hz, 1H) 3.27 (t, J = 12.0 Hz, 1H) 3.09-3.00 (m, 2H) 2.42-2.24 (m, 1H); 19F NMR (376 MHz, 
DMSO-d6, 80 °C) 𝛿 ppm -99.04—-102.05 (m, 2H); QTOF ES+ MS: (M+H) 462.2; HPLC Ret: 
6.19 min; 94% pure. 
5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-(1H-pyrazolo[3,4-b]pyridin-3-yl)piperidine-3-
carboxamide. (CCG-265197). Method I starting from 5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.09 mmol) and 1H-pyrazolo[3,4-b]pyridin-3-
amine (0.01 g, 0.1 mmol) gave 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-(1H-pyrazolo[3,4-
b]pyridin-3-yl)piperidine-3-carboxamide (0.01 g, 27%) as white solid; column: 75% to 80% 
EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 8.55 (d, J = 4.8 Hz, 1H) 8.28 (d, J = 
7.8 Hz, 1H) 7.74 (d, J = 7.8 Hz, 1H) 7.72-7.59 (m, 3H) 7.48 (t, J = 7.7 Hz, 1H) 7.38-7.27 (m, 2H) 
6.93 (d, J = 3.4 Hz, 1H) 6.57 (dt, J = 3.2, 1.6 Hz, 1H) 6.26 (br. s, 2 Hz) 4.43-4.20 (m, 2H) 3.56 
(dd, J = 29.9, 13.7 Hz, 1H) 3.35 (t, J = 12.0 Hz, 1H) 3.00-2.97 (m, 2H) 2.41-2.26 (m, 1H); 19F 
NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -98.75—-101.91 (m, 2H); QTOF ES+ MS: (M+H) 
452.2; HPLC Ret: 6.16 min; 90% pure. 
N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-
carboxamide. (CCG-265198). Method I starting from 5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.09 mmol) and [1,2,4]triazolo[4,3-a]pyridin-3-
amine (0.01 g, 0.1 mmol) gave N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxamide (0.01 g, 22%) as white solid; column: 100% EtOAc to 5% 
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MeOH: DCM; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 7.97 (d, J = 7.1 Hz, 1H) 7.78 (d, J = 
8.1 Hz, 1H) 7.72-7.65 (m, 4H) 7.51 (t, J = 7.9 Hz, 1H) 7.38-7.28 (m, 3H) 6.98-6.89 (m, 3H) 6.58 
(dt, J = 3.5, 1.9 Hz, 1H) 4.48-4.15 (m, 2H) 3.57 (dd, J = 30.0, 13.9 Hz, 1H) 3.33 (t, J = 12.0 Hz, 
1H) 3.14 (br. s, 2H) 2.41-2.23 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -99.09—-
103.32 (m, 2H); QTOF ES+ MS: (M+H) 452.2; HPLC Ret: 5.67 min; 93% pure. 
5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-(imidazo[1,2-a]pyridin-3-yl)piperidine-3-
carboxamide. (CCG-265199). Method I starting from 5,5-difluoro-1-(3-(furan-2-
yl)benzoyl)piperidine-3-carboxylic acid (0.03 g, 0.09 mmol) and imidazo[1,2-a]pyridin-3-amine 
(0.01 g, 0.1 mmol) gave 5,5-difluoro-1-(3-(furan-2-yl)benzoyl)-N-(imidazo[1,2-a]pyridin-3-
yl)piperidine-3-carboxamide (0.02 g, 40%) as white solid; column: 2.5% MeOH: DCM; 1H NMR 
(400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.05 (br. s, 1H) 8.03 (d, J = 7.0 Hz, 1H) 7.79 (d, J = 7.9 Hz, 
1H) 7.73-7.69 (m, 2H) 7.55-7.42 (m, 3H) 7.32 (d, J = 7.4 Hz, 1H) 7.21 (t, J = 7.9 Hz, 1H) 6.96 (d, 
J = 3.0 Hz, 1H) 6.89 (t, J = 6.8 Hz, 1H) 6.58 (dt, J = 3.6, 1.8 Hz, 1H) 4.45-4.17 (m, 2H) 3.57 (dd, 
J = 29.3, 14.4 Hz, 1H) 3.30 (t, J = 12.3 Hz, 1H) 3.09 (br. s, 2H) 2.42-2.29 (m, 1H); 19F NMR (376 
MHz, DMSO-d6, 80 °C) 𝛿 ppm -99.72—-103.48 (m, 2H); QTOF ES+ MS: (M+H) 451.2; HPLC 
Ret: 5.46 min; 99% pure. 
cis-N1-(4-chlorophenyl)-N3-(3-(furan-2-yl)phenyl)cyclohexane-1,3-dicarboxamide. (CCG-
263876). Method G followed by Method I starting from cis-methyl 3-((4-
chlorophenyl)carbamoyl)cyclohexanecarboxylate (0.10 g, 0.34 mmol) and 3-(furan-2-yl)aniline, 
HCl (0.06 g, 0.22 mmol) gave cis-N1-(4-chlorophenyl)-N3-(3-(furan-2-yl)phenyl)cyclohexane-
1,3-dicarboxamide (0.04 g, 50% (2 steps)) as white solid; column: 50% to 80% EtOAc: Hex; 1H 
NMR (500 MHz, DMSO-d6) 𝛿 ppm 9.99 (s, 1H) 9.93 (s, 1H) 8.01 (s, 1H) 7.75 (s, 1H) 7.64 (d, J = 
8.5 Hz, 2H) 7.51 (d, J = 8.0 Hz, 1H) 7.37-7.31 (m, 4H) 6.86 (d, J = 3.4 Hz, 1H) 6.62-6.57 (m, 
1H) 2.49-2.35 (m, 2H) 2.06-1.87 (m, 4H) 1.68 (q, J = 12.5 Hz, 1H) 1.42-1.36 (m, 3H); 13C NMR 
(500 MHz, DMSO-d6) 𝛿 ppm 174.28, 153.37, 143.35, 140.33, 138.76, 131.10, 129.69, 128.98, 
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126.95, 121.10, 118.78, 118.65, 114.40, 112.50, 106.26, 44.60, 44.57, 31.67, 29.15, 25.17; 
TOF ES+ MS: (M+Na) 445.13; HPLC Ret: 7.53 min; 95% pure. 
trans-N1-(4-chlorophenyl)-N3-(3-(furan-2-yl)phenyl)cyclohexane-1,3-dicarboxamide. CCG-
263878. Method G followed by Method I starting from trans-methyl 3-((4-
chlorophenyl)carbamoyl)cyclohexanecarboxylate (0.05 g, 0.18 mmol) and 3-(furan-2-yl)aniline, 
HCl (0.04 g, 0.18 mmol) gave trans-N1-(4-chlorophenyl)-N3-(3-(furan-2-yl)phenyl)cyclohexane-
1,3-dicarboxamide (0.06 g, 73% (2 steps)) as white solid; column: 30% to 60% EtOAc: Hex; 1H 
NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.04-9.93 (m, 2H) 8.10 (d, J = 2.7 Hz, 1H) 7.75 (d, J = 1.7 
Hz, 1H) 7.67 (d, J = 8.6 Hz, 1H) 7.54-7.47 (m, 1H) 7.39-7.30 (m, 3H) 6.85 (d, J = 3.3 Hz, 1H) 
6.59 (dd, J = 3.4, 1.7 Hz, 1H) 2.91 (dt, J = 13.5, 6.0 Hz, 2H) 1.92 (dt, J = 12.6, 6.3 Hz, 2H) 1.75-
1.66 (m, 6H); 13C NMR (500 MHz, DMSO-d6) 𝛿 ppm 174.81, 174.79, 174.75, 153.45, 143.32, 
140.50, 140.48, 138.91, 131.05, 129.60, 128.91, 126.83, 121.13, 118.67, 114.46, 112.49, 
106.19, 40.09, 40.05, 30.22, 30.16, 28.91, 28.80, 21.79; HPLC/TOF ES+ MS: (M+H) Peak 1: 
423.15, HPLC/TOF ES+ MS: (M+MeOH+H) Peak 2: 455.20; HPLC Ret Peak 1: 7.94 min, HPLC 
Ret Peak 2: 8.05 min; 98 % pure. Note: HNMR, CNMR, & MS all looked good, but HPLC had 
two neighboring peaks. High temp HNMR on 400 caused amide N-H’s to coallese to two broad 
peaks and HPLC/MS showed both peaks had desirable masses for desired product. I think this 
compound can cross energy barrier between the two trans chair conformations. 
N-(4-chlorophenyl)-5-(3-(furan-2-yl)benzamido)-2-methylbenzamide. (CCG-263153) (DJK-
7-42). Method G followed by Method I starting from methyl 5-(3-(furan-2-yl)benzamido)-2-
methylbenzoate (0.08 g, 0.22 mmol) and 4-chloroaniline (0.03 g, 0.22 mmol) gave N-(4-
chlorophenyl)-5-(3-(furan-2-yl)benzamido)-2-methylbenzamide (0.04 g, 41% (2 steps)); column: 
30% to 40% EtOAc: Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.51 (s, 1H) 10.45 (s, 1H) 8.28 
(s, 1H) 7.92 (dt, J = 4.5, 1.7 Hz, 2H) 7.89-7.77 (m, 5H) 7.60 (t, J = 7.8, 1H) 7.45-7.38 (m, 2H) 
7.32 (d, J = 8.3 Hz, 1H) 7.08 (d, 3.3 Hz, 1H) 6.65 (dd, J = 3.4, 1.8 Hz, 1H) 2.36 (s, 3H); 13C NMR 
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(500 MHz, DMSO-d6) 𝛿 ppm 166.17, 165.62, 152.74, 143.85, 138.61, 137.27, 135.86, 131.29, 
130.94, 130.75, 129.59, 129.10, 127.60, 127.01, 126.85, 122.85, 121.93, 121.55, 119.49, 
112.70, 109.99, 107.25, 19.15; QTOF ES+ MS: (M+H) 431.1; HPLC Ret: 8.10 min; 98 % pure. 
1-(5,6-difluoro-1H-indole-2-carbonyl)-5,5-difluoro-N-(4-(2-(pyrrolidin-1-
yl)ethoxy)phenyl)piperidine-3-carboxamide. (CCG-263678). Method G followed by Method I 
starting from methyl 1-(5,6-difluoro-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-carboxylate 
(0.14 g, 0.39 mmol) and 4-(2-(pyrrolidin-1-yl)ethoxy)aniline (0.03 g, 0.13 mmol) gave 1-(5,6-
difluoro-1H-indole-2-carbonyl)-5,5-difluoro-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)piperidine-3-
carboxamide (0.06 g, 84% (2 steps)) as yellow solid; column: 10% MeOH: DCM; crystalized at 0 
°C and washed with hexanes post column; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 11.58 
(s, 1H) 9.84 (br. s, 1H) 7.62-7.47 (m, 2H) 7.39-7.32 (m, 1H) 6.96 (d, J = 8.8 Hz, 2H) 6.90-6.87 
(m, 1H) 6.74 (d, J = 8.3 Hz, 2H) 6.56 (d, J = 8.3 Hz, 2H) 4.72-4.55 (m, 2H) 4.26 (t, J = 5.3 Hz, 
2H) 4.14 (t, J = 5.1 Hz, 2H) 3.50 (dt, J = 16.2, 5.1 Hz, 2H) 3.42-3.25 (m, 3H) 3.09-2.84 (m, 4H) 
2.05-1.90 (m, 4H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -69.66 (s, 1H) -71.55 (s, 1H) -
141.58 (ddd, 20.2, 7.1, 2.9 Hz, 1H) -147.10 (ddd, 20.2, 11.4, 4.4 Hz, 1H); QTOF ES+ MS: (M+H) 
533.22; HPLC Ret: 5.61 min; 95% pure. 
N-(6-chloropyridin-3-yl)-1-(5,6-difluoro-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-
carboxamide. (CCG-263679). Method G followed by Method I starting from methyl 1-(5,6-
difluoro-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-carboxylate (0.02 g, 0.23 mmol) and 6-
chloropyridine-3-amine (0.04 g, 0.13 mmol) gave N-(6-chloropyridin-3-yl)-1-(5,6-difluoro-1H-
indole-2-carbonyl)-5,5-difluoropiperidine-3-carboxamide (0.03 g, 49% (2 steps)) as white solid; 
crystallized from EtOH; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 11.58 (s, 1H) 10.29 (br. s, 
1H) 8.58 (d, J = 2.7 Hz, 1H) 8.03 (dd, J = 8.6, 2.7 Hz, 1H) 7.57 (dd, J = 11.1, 8.1 Hz, 1H) 7.42 
(d, J = 8.7 Hz, 1H) 7.35 (dd, J = 11.0, 7.1 Hz, 1H) 6.92-6.88 (m, 1H) 4.68-4.55 (m, 2H) 3.63 (dd, 
J = 30.4, 13.8 Hz, 1H) 3.34 (t, J = 12.3 Hz, 1H) 2.46-2.25 (m, 1H); 19F NMR (376 MHz, DMSO-
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d6, 80 °C) 𝛿 ppm -99.22 (s, 1H) -101.23 (s, 1H) -141.57 (ddd, 20.2, 7.1, 2.9 Hz, 1H) -147.10 
(ddd, 20.2, 11.4, 4.4 Hz, 1H); QTOF ES+ MS: (M+H) 455.09; HPLC Ret: 7.09 min; 95% pure. 
N-(5-chloropyridin-2-yl)-1-(5,6-difluoro-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-
carboxamide. (CCG-263739). Method G followed by Method I starting from methyl 1-(5,6-
difluoro-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-carboxylate (0.04 g, 0.13 mmol) and 5-
chloropyridine-2-amine (0.02 g, 0.13 mmol) gave N-(5-chloropyridin-2-yl)-1-(5,6-difluoro-1H-
indole-2-carbonyl)-5,5-difluoropiperidine-3-carboxamide (0.02 g, 35% (2 steps)) as white solid; 
reaction performed at 55 °C; column: 35% to 60% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 
80 °C) 𝛿 ppm 11.59 (s, 1H) 10.70 (s, 1H) 8.32 (d, J = 2.6 Hz, 1H) 8.05 (d, J = 8.9 Hz, 1H) 7.85 
(dd, J = 8.9, 2.6 Hz, 1H) 7.56 (dd, J = 11.1, 8.0 Hz, 1H) 7.34 (dd, J = 11.0, 7.1 Hz, 1H) 6.90 (d, J 
= 2.0 Hz, 1H) 4.60 (d, J = 12.6 Hz, 2H) 3.59 (dd, J = 30.0, 14.0 Hz, 1H) 3.35 (t, J = 12.1 Hz, 1H) 
3.19-3.05 (m, 1H) 2.40-2.28 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -97.30—-
103.15 (m, 2H) -141.66 (ddd, 21.2, 11.1, 8.0 Hz, 1H) -147.15 (ddd, 21.0, 11.1, 7.1 Hz, 1H); 
QTOF ES+ MS: (M+H) 455.09; HPLC Ret: 7.41 min; 96% pure. 
5,5-difluoro-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1-(5-(trifluoromethoxy)-1H-indole-2-
carbonyl)piperidine-3-carboxamide. (CCG-263680). Method G followed by Method I starting 
from methyl 1-(5-(trifluoromethoxy)-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-carboxylate 
(0.05 g, 0.13 mmol) and 4-(2-(pyrrolidin-1-yl)ethoxy)aniline (0.03 g, 0.13 mmol) gave 5,5-
difluoro-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-1-(5-(trifluoromethoxy)-1H-indole-2-
carbonyl)piperidine-3-carboxamide (0.02 g, 30% (2 steps)) as yellow solid; crystallized from 
EtOH; 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 11.68 (s, 1H) 9.77 (br. s, 1H) 7.61-7.48 (m, 
2H) 7.45 (d, J = 8.5 Hz, 2H) 7.14 (d, J = 9.1 Hz, 1H) 6.93 (br. s, 1H) 6.86 (d, J = 8.6 Hz, 2H) 
4.65-4.55 (m, 2H) 4.03 (t, J = 6.0 Hz, 2H) 3.61 (dd, J = 30.6, 14.0 Hz, 1H) 3.32 (t, J = 12.1 Hz, 
2H) 2.78 (t, J = 6.0 Hz, 2H) 2.59-2.50 (m, 4H) 2.50-2.45 (m, 2H) 1.74-1.63 (m, 4H); 19F NMR 
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(376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -56.81 (s, 3H) -98.37—-102.40 (m, 1H); QTOF ES+ MS: 
(M+H) 581.22; HPLC Ret: 6.24 min; 95% pure. 
N-(6-chloropyridin-3-yl)-5,5-difluoro-1-(5-(trifluoromethoxy)-1H-indole-2-
carbonyl)piperidine-3-carboxamide. (CCG-263681). Method G followed by Method I starting 
from methyl 1-(5-(trifluoromethoxy)-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-carboxylate 
(0.05 g, 0.13 mmol) and 6-chloropyridine-3-amine (0.02 g, 0.13 mmol) gave N-(6-chloropyridin-
3-yl)-5,5-difluoro-1-(5-(trifluoromethoxy)-1H-indole-2-carbonyl)piperidine-3-carboxamide (0.05 g, 
53% (2 steps)) as whtie solid; column: 40% to 60% EtOAc: Hex; 1H NMR (400 MHz, DMSO-d6, 
80 °C) 𝛿 ppm 11.66 (s, 1H) 10.26 (br. s, 1H) 8.58 (d, J = 2.7 Hz, 1H) 8.03 (dd, J = 8.7, 2.7 Hz, 
1H) 7.60-7.49 (m, 2H) 7.41 (d, J = 8.7 Hz, 1H) 7.14 (d, J = 9.0 Hz, 1H) 6.94-6.90 (m, 1H) 4.66-
4.58 (m, 2H) 3.64 (dd, J = 30.2, 13.8 Hz, 1H) 3.36 (t, J = 12.3 Hz, 1H) 3.08-2.99 (m, 1H) 2.45-
2.26 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -56.81 (s, 3H) -98.33—-102.06 (m, 
2H); QTOF ES+ MS: (M+H) 503.09; HPLC Ret: 7.35 min; 96% pure. 
N-(5-chloropyridin-2-yl)-5,5-difluoro-1-(5-(trifluoromethoxy)-1H-indole-2-
carbonyl)piperidine-3-carboxamide. (CCG-263740). Method G followed by Method I starting 
from methyl 1-(5-(trifluoromethoxy)-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-carboxylate 
(0.05 g, 0.13 mmol) and 5-chloropyridine-2-amine (0.02 g, 0.13 mmol) gave N-(5-chloropyridin-
2-yl)-5,5-difluoro-1-(5-(trifluoromethoxy)-1H-indole-2-carbonyl)piperidine-3-carboxamide (0.03 g, 
47% (2 steps)) as whtie solid; column: 30% to 60% EtOAc: Hex; reaction performed at 55 °C; 1H 
NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 11.67 (s, 1H) 10.68 (s, 1H) 8.31 (d, J = 2.5 Hz, 1H) 
8.04 (d, J = 8.9 Hz, 1H) 7.84 (dd, J = 8.9, 2.6 Hz, 1H) 7.59-7.48 (m, 2H) 7.14 (d, J = 8.9 Hz, 1H) 
6.94 (d, J = 2.1 Hz, 1H) 4.61 (d, J = 10.2 Hz, 2H) 3.60 (dd, J = 30.2, 14.1 Hz, 1H) 3.37 (t, J = 
12.2 Hz, 1H) 3.20-3.15 (m, 1H) 2.44-2.22 (m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm 
-56.81 (s, 3H) -98.96 (d, J = 239.4 Hz, 1H) -101.34 (d, J = 236.5 Hz, 1H); QTOF ES+ MS: (M+H) 





carboxylic acid (0.03 g, 0.08 mmol) was dissolved in DMF (1.0 mL), and EDC (0.02, 0.1 mmol) 
DMAP (0.01 g, 0.08 mmol), 3-chloro-5-fluoroaniline (0.02 g, 0.12 mmol), and DIPEA (0.03 g, 
0.04 mL, 0.25 mmol) were added. The reaction was stirred at 25 °C for 16 hr and brine (10 mL) 
was added. The product was extracted with EtOAc (3 x 15 mL), dried with MgSO4, and 
concentrated in vacuo. The subsequent oil was subjected to silica gel chromatography eluting 
with 70% to 80% EtOAc: Hex to produce white solid. Yield=30% (2-steps). 1H NMR (400 MHz, 
DMSO-d6, 80 °C) 𝛿 ppm 10.24 (br. s, 1H) 8.66 (d, J = 5.7 Hz, 2H) 7.77-7.67 (m, 3H) 7.62 (s, 1H) 
7.48 (s, 1H) 7.40 (d, J = 11.1 Hz, 1H) 7.30 (d, J = 8.2 Hz, 1H) 7.01 (d, J = 8.7 Hz, 1H) 4.37-4.10 
(m, 2H) 3.60 (dd, J = 29.2, 14.0 Hz, 1H) 3.25 (s, 1H) 2.98 (br. s, 2H) 2.41-2.23 (m, 1H); 19F 
NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -98.93—-101.84 (m, 2H) -109.91— -110.56 (m, 1H) -
111.09 (t, J = 9.4 Hz, 1H); QTOF ES+ MS: (M+H) 492.1; HPLC Ret: 6.02 min; 97% pure. 
N-(4-chlorophenyl)-1-(4,5-difluoro-1H-indole-2-carbonyl)-5,5-difluoropiperidine-3-
carboxamide. (CCG-263412). Method M followed by Method N starting from 4,5-difluoro-1H-
indole-2-carboxylic acid (0.03 g, 0.13 mmol) and N-(4-chlorophenyl)-5,5-difluoropiperidine-3-
carboxamide (0.03 g, 0.13 mmol) gave N-(4-chlorophenyl)-1-(4,5-difluoro-1H-indole-2-carbonyl)-
5,5-difluoropiperidine-3-carboxamide as white solid (0.02 g, 37% (2 steps)); column: 35% to 
65% EtOAc:Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 12.13 (br. s., 1H) 10.36 (br. s., 1H) 7.63 
(d, J = 8.4 Hz, 2H) 7.38 (d, J = 8.3 Hz, 2H) 7.25 (d, J = 5.8 Hz, 2H) 7.06-7.02 (m, 1H) 4.65-4.60 
(m, 1H) 3.35-3.15 (m, 2H) 2.99-2.92 (m, 1H) 2.44-2.31 (m, 2H); 19F NMR (470 MHz, DMSO-d6) 
𝛿 ppm -99.39 (d, 1H), -101.78 (d, 1H), -148.03 (s, 1H), -151.95 (s, 1H); TOF ES+ MS: (M-H) 
452.08; HPLC Ret: 7.70 min; 98 % pure. 
N-(4-chlorophenyl)-1-(3,7-dihydro-2H-[1,4]dioxino[2,3-e]indole-8-carbonyl)-5,5-
difluoropiperidine-3-carboxamide. (CCG-263413). Method M followed by Method N starting 
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from 3,7-dihydro-2H-[1,4]dioxino[2,3-e]indole-8-carboxylic acid (0.03 g, 0.11 mmol) and N-(4-
chlorophenyl)-5,5-difluoropiperidine-3-carboxamide (0.03 g, 0.11 mmol) gave N-(4-
chlorophenyl)-1-(3,7-dihydro-2H-[1,4]dioxino[2,3-e]indole-8-carbonyl)-5,5-difluoropiperidine-3-
carboxamide as tan solid (0.02 g, 35% (2 steps)); column: 40% EtOAc:Hex; 1H NMR (500 MHz, 
DMSO-d6) 𝛿 ppm 11.37 (br. s., 1H) 10.34 (br. s., 1H) 10.07 (s, 1H) 7.63 (d, J = 8.4 Hz, 2H) 7.49 
(d, J = 1.7 Hz, 1H) 7.37 (d, J = 8.3 Hz, 2H) 6.91 (br. s., 1H) 4.68-4.30 (m, 5H) 3.80-3.45 (m, 2H) 
2.97-2.91 (m, 1H) 2.44-2.29 (m, 2H); 19F NMR (500 MHz, DMSO-d6) 𝛿 ppm -99.56 (d, 1H), -
101.88 (d, 1H); TOF ES+ MS: (M-H) 474.10; HPLC Ret: 7.39 min; 97 % pure. 
N-(4-chlorophenyl)-1-(3,6-dihydro-2H-[1,4]dioxino[2,3-f]indole-7-carbonyl)-5,5-
difluoropiperidine-3-carboxamide. (CCG-263414). Method M followed by Method N starting 
from 3,6-dihydro-2H-[1,4]dioxino[2,3-f]indole-7-carboxylic acid (0.03 g, 0.11 mmol) and N-(4-
chlorophenyl)-5,5-difluoropiperidine-3-carboxamide (0.03 g, 0.11 mmol) gave N-(4-
chlorophenyl)-1-(3,6-dihydro-2H-[1,4]dioxino[2,3-f]indole-7-carbonyl)-5,5-difluoropiperidine-3-
carboxamide as yellow solid (0.02 g, 39% (2 steps)); column: 40% to 80% EtOAc:Hex; 1H NMR 
(500 MHz, DMSO-d6) 𝛿 ppm 11.26 (br. s., 1H) 10.37 (s, 1H) 7.63 (d, J = 8.5 Hz, 2H) 7.38 (d, J = 
8.8 Hz, 2H) 7.04 (s, 1H) 6.84 (s, 1H) 6.75 (br. s., 1H) 4.73-4.60 (m, 2H) 4.27-4.17 (m, 4H) 3.61-
3.30 (m, 2H) 2.94 (t, J = 12.2 Hz, 1H) 2.42-2.23 (m, 2H); 19F NMR (500 MHz, DMSO-d6) 𝛿 ppm -
99.56 (d, 1H), -101.79 (d, 1H); TOF ES+ MS: (M+H) 476.12; HPLC Ret: 7.31 min; 98 % pure. 
N-(4-chlorophenyl)-5,5-difluoro-1-(6-fluoro-1-methyl-1H-indole-2-carbonyl)piperidine-3-
carboxamide. (CCG-263415). Method M followed by Method N starting from 6-fluoro-1-methyl-
1H-indole-2-carboxylic acid (0.03 g, 0.11 mmol) and N-(4-chlorophenyl)-5,5-difluoropiperidine-3-
carboxamide (0.03 g, 0.11 mmol) gave N-(4-chlorophenyl)-5,5-difluoro-1-(6-fluoro-1-methyl-1H-
indole-2-carbonyl)piperidine-3-carboxamide as white solid (0.06 g, 96% (2 steps)); column: 25% 
EtOAc:Hex; 1H NMR (500 MHz, DMSO-d6) 𝛿 ppm 10.36 (br. s., 1H) 7.68-7.60 (m, 3H) 7.46-7.40 
(m, 1H) 7.37 (d, J = 8.4 Hz, 2H) 6.98 (td, J = 9.2, 2.3 Hz, 1H) 6.79 (br. s., 1H) 4.82-4.19 (m, 3H) 
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3.74 (s, 3H) 3.00-2.91 (m, 1H) 2.42-2.26 (m, 2H); 19F NMR (500 MHz, DMSO-d6) 𝛿 ppm -99.69 
(d, 1H), -102.32 (d, 1H) -118.18 (s, 1H); TOF ES+ MS: (M+H) 450.12; HPLC Ret: 7.91 min; 99% 
pure. 
N-(3-(((tert-butyldiphenylsilyl)oxy)methyl)-4-chlorophenyl)-5,5-difluoro-1-(3-fluoro-5-
(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (CCG-263741). In a 25 mL round-bottomed 
flask methyl N-(3-(((tert-butyldiphenylsilyl)oxy)methyl)-4-chlorophenyl)-5,5-difluoro-1-(3-fluoro-5-
(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.075 g, 0.10 mmol) was dissolved in THF (1.0 
mL). 1M TBAF (in THF) (0.20 mL, 0.20 mmol) was added and the mixture was stirred under 
nitrogen at 25 °C for 1 hr. The reaction was quenched with water (20 mL) and the product was 
extracted with EtOAc (3x 15 mL). The organic layer was washed with NH4Cl (3 x 15 mL), brine 
(2 x 15 mL), dried with magnesium sulfate, and evaporated. The residue was subjected to silica 
gel chromatography eluting with 5% MeOH: 95% DCM. The fractions containing product were 
concentrated in vacuo to produce white solid. Yield=55% (2-steps). 1H NMR (400 MHz, DMSO-
d6, 80 °C) 𝛿 10.02 (br. s, 1H) 8.69-8.62 (m, 2H) 7.78-7.67 (m, 4H) 7.61 (d, J = 1.7 Hz, 1H) 7.51 
(dd, J = 8.4, 2.6 Hz, 1H) 7.35-7.25 (m, 2H) 5.06 (br. s, 1H) 4.53 (d, J = 5.4 Hz, 2H) 4.38-4.10 
(m, 2H) 3.57 (dd, J = 29.8, 13.8 Hz, 1H) 3.28 (t, J = 13.0 Hz, 1H) 3.03-2.93 (m, 2H) 2.40-2.20 
(m, 1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -99.52—-102.20 (m, 2H) -111.08 (s, 1H); 
QTOF ES+ MS: (M+H) 504.13; HPLC Ret: 5.51 min; 97% pure. 
N-(4-chloro-3-hydroxyphenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-263482). N-(4-chloro-3-(prop-2-yn-1-yloxy)phenyl)-5,5-difluoro-1-(3-fluoro-
5-(pyridin-4-yl)benzoyl)piperidine-3-carboxamide (0.09 g, 0.17 mmol) was dissolved in 2:1 
DMF/H2O solution (1.5 mL). Bis(triphenylphosphine)palladium(II) chloride (0.01 g, 0.02 mmol) 
and triethylamine (0.14 g, 0.40 mmol, 0.19 mL) were added and the reaction was stirred under 
nitrogen at 85 °C for 1 hr. The reaction was quenched with H2O (5 mL) and acidified to pH ~ 1 
with 1N HCl (2 mL). The product was extracted with EtOAc (3 x 20 mL), and the resulting 
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organic layer was washed with brine (20 mL), dried with MgSO4, and evaporated. The oil was 
subjected to silica gel chromatography eluting with 80% EtOAc: 100% Hex. The fractions 
containing product were concentrated in vacuo to produce white solid. Yield=62%. 1H NMR (400 
MHz, DMSO-d6, 80 °C) 𝛿 ppm 9.93 (s, 1H) 9.81 (br. s, 1H) 7.79-7.48 (m, 7H) 7.38 (d, J = 2.4 
Hz, 1H) 7.31 (d, J = 8.6 Hz, 1H) 7.19 (d, J = 8.7 Hz, 1H) 6.97 (d, J = 8.7 Hz, 1H) 4.39-4.15 (m, 
2H) 3.58 (dd, J = 30.0, 14.0 Hz, 1H) 3.26 (t, J = 12.5 Hz, 1H) 3.10-2.90 (m, 2H) 2.41-2.20 (m, 
1H); 19F NMR (400 MHz, DMSO-d6) 𝛿 ppm -100.37 (dd, 2H), -111.05 (s, 1H); TOF ES+ MS: 
(M+H) 490.11; HPLC Ret: 5.30 min; 94% pure. 
N-(3-chlorophenyl)-5,5-difluoro-1-(2-fluoro-5-(pyridin-4-yl)benzoyl)piperidine-3-
carboxamide. (CCG-264470). In a 10 mL round-bottomed flask, 1-(5-bromo-2-fluorobenzoyl)-
N-(3-chlorophenyl)-5,5-difluoropiperidine-3-carboxamide (0.034 g, 0.071 mmol) and pyridin-4-
ylboronic acid (0.01 g, 0.075 mmol) were dissolved in a solution of toluene:EtOH (0.5 mL:0.5 
mL). The solution was degassed and sodium carbonate (0.02 g, 0.21 mmol) and Tetrakis (0.003 
g, 0.05 mmol) were added. The reaction was stirred under N2 at 90 °C for 16 hr. The reaction 
was cooled to RT, and the solution was diluted with water (10 mL). The product was extracted 
with EtOAc (3 x 15 mL), washed with brine (20 mL), dried with MgSO4, and concentrated in 
vacuo. The yellow residue was subjected to silica gel chromatography eluting with 3% MeOH: 
97% DCM. The fractions containing product were concentrated in vacuo to produce faint yellow 
solid. Similar compounds were made in an analogous fashion. Yield=83%. 1H NMR (400 MHz, 
DMSO-d6, 80 °C) 𝛿 ppm 10.05 (br. s, 1H) 8.68-8.60 (m, 2H) 7.91 (br. s, 1H) 7.79-7.69 (m, 2H) 
7.70-7.50 (m, 4H) 7.43 (t, J = 8.8 Hz, 2H) 7.30 (t, J = 8.2 Hz, 1H) 7.08 (d, J = 7.5 Hz, 1H) 4.66-
4.13 (m, 2H) 3.71-3.19 (m, 3H) 2.89 (br. s, 1H) 2.41-2.25 (m, 1H); 19F NMR (376 MHz, DMSO-
d6, 80 °C) 𝛿 ppm -96.18—-104.76 (m, 2H) -115.80 (s, 1H); QTOF ES+ MS: (M+Na) 496.10; 




carboxamide. (CCG-264471). Yellow solid. Yield=94%. 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 
ppm 10.19 (br. s, 1H) 8.63 (dt, J = 4.9, 1.6 Hz, 2H) 7.91 (br. s, 1H) 7.79-7.71 (m, 1H) 7.69-7.55 
(m, 3H) 7.56-7.39 (m, 3H) 4.70-4.15 (m, 2H) 3.75-3.18 (m, 3H) 2.96-2.90 (m, 1H) 2.42-2.21 (m, 
1H); 19F NMR (376 MHz, DMSO-d6, 80 °C) 𝛿 ppm -96.90—-104.52 (m, 2H) -115.85 (s, 1H); 
QTOF ES+ MS: (M+Na) 579.16; HPLC Ret: 6.22 min; 99% pure. 
1-(3-bromobenzyl)piperidin-2-one. In a 25-mL round bottomed flask, NaH (0.067 g, 2.77 
mmol) was dissolved in THF (2.0 mL) and cooled to 0 °C. piperidin-2-one (0.25 g, 2.52 mmol) 
dissolved in THF (8 mL) was added, and the reaction was warmed to 25 °C for 2 hr. 1-bromo-3-
(bromomethyl)benzene (0.67 g, 2.70 mmol) was added, and the reaction was stirred at 25 °C for 
4 hr. The reaction was quenched with H2O, and the product was extracted with EtOAc (3 x 15 
mL), washed with brine, dried with MgSO4, and concentrated in vacuo. The subsequent oil was 
subjected to silica gel chromatography eluting with 50% to 60% EtOAc/Hex. The fractions 
containing product were concentrated in vacuo to produce colorless oil. Yield=89%. 1H NMR 
(500 MHz, CDCl3-d) 𝛿 7.41-7.37 (m, 2H) 7.23-7.17 (m, 2H) 4.56 (s, 2H) 3.20 (t, J = 5.6 Hz, 2H) 
2.47 (t, J = 6.2 Hz, 2H) 1.85-1.76 (m, 4H); TOF ES+ MS: (M+H) 268.03; HPLC Ret: 6.26 min. 
benzyl 1-(3-bromobenzyl)-2-oxopiperidine-3-carboxylate. In a 50-mL round bottomed flask, 
1-(3-bromobenzyl)piperidin-2-one (0.3 g, 1.12 mmol) was dissolved in THF (3.0 mL) and cooled 
to -78 °C. 1M LiHMDS in THF (2.3 mL, 2.35 mmol) was added dropwise, and the reaction was 
stirred at -78 °C for 10 mins. Benzyl chloroformate (0.19 g, 0.16 mL, 1.12 mmol) was added, 
and the reaction was stirred at -78 °C for 1 hr. The reaction was quenched with NH4Cl, and the 
product was extracted with EtOAc (3 x 15 mL), washed with brine, dried with MgSO4, and 
concentrated in vacuo. The subsequent oil was subjected to silica gel chromatography eluting 
with 30% to 40% EtOAc/Hex. The fractions containing product were concentrated in vacuo to 
produce colorless oil. Yield=78%. 1H NMR (500 MHz, CDCl3-d) 𝛿 7.44-7.28 (m, 7H) 7.19 (d, J = 
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7.6 Hz, 1H) 7.13 (t, J = 7.7 Hz, 1H) 5.23 (s, 2H) 4.71 (d, J = 14.8 Hz, 1H) 4.45 (d, J = 14.9 Hz, 
1H) 3.56 (t, J = 6.9 Hz, 1H) 3.23 (ddq, J = 24.0, 12.1, 6.5, 5.9 Hz, 2H) 2.21-2.02 (m, 2H) 1.90 
(dddd, J = 13.5, 11.6, 5.7, 3.8 Hz, 1H) 1.80-1.68 (m, 1H); TOF ES+ MS: (M+Na) 326.05; HPLC 
Ret: 7.69 min. 
1-(3-(furan-2-yl)benzyl)-2-oxopiperidine-3-carboxylic acid. In a 25 mL round bottomed flask, 
benzyl 1-(3-bromobenzyl)-2-oxopiperidine-3-carboxylate (0.2 g, 0.5 mmol), furan-2-ylboronic 
acid (0.07 g, 0.6 mmol), Tetrakis® (0.03 g, 0.03 mmol), and Na2CO3 (0.13 g, 1.24 mmol) were 
dissolved in DME (3 mL) and H2O (3 mL). The solution was degassed and heated at 100 °C for 
16 hr under Ar2. The solution was filtered through a pad of Celite® to remove particulates. The 
filtrate was acidified with 1N HCl (15 mL) and the product was extracted with EtOAc (3 x 15 mL), 
washed with brine, dried with MgSO4, and concentrated in vacuo to produce yellow solid. 
Yield=94%. 1H NMR (500 MHz, DMSO-d6) 𝛿 12.63 (br. s, 1H) 7.75 (d, J = 1.7 Hz, 1H) 7.61-7.59 
(m, 2H) 7.39 (t, J = 8.1 Hz, 1H) 7.16 (d, J = 7.7 Hz, 1H) 6.94 (d, J = 3.3 Hz, 1H) 6.59 (dd, J = 
3.4, 1.8 Hz, 1H) 4.68 (d, J = 15.0 Hz, 1H) 4.44 (d, J = 15.0 Hz, 1H) 3.38 (t, J = 6.4 Hz, 1H) 3.24 
(t, J = 6.1 Hz, 2H) 2.09-1.91 (m, 2H) 1.86-1.70 (m, 2H); HPLC Ret: 6.12 min. 
N-(4-chlorophenyl)-1-(3-(furan-2-yl)benzyl)-2-oxopiperidine-3-carboxamide. (CCG-
264644). Method I starting from 1-(3-(furan-2-yl)benzyl)-2-oxopiperidine-3-carboxylic acid (0.05 
g, 0.17 mmol) and 4-chloroaniline (0.02 g, 0.17 mmol) gave N-(4-chlorophenyl)-1-(3-(furan-2-
yl)benzyl)-2-oxopiperidine-3-carboxamide (0.06 g, 85%); column: 40% EtOAc/Hex; 1H NMR 
(500 MHz, DMSO-d6) 𝛿 10.34 (br. s, 1H) 7.76 (d, J = 1.9 Hz, 1H) 7.67 (d, J = 8.7 Hz, 2H) 7.64-
7.58 (m, 2H) 7.44-7.36 (m, 3H) 7.19 (d, J = 7.6 Hz, 1H) 6.97 (d, J = 3.4 Hz, 1H) 6.61 (dd, J = 
3.4, 1.8 Hz, 1H) 4.64 (d, J = 15.0 Hz, 1H) 4.53 (d, J = 15.0 Hz, 1H) 3.51 (t, J = 7.4 Hz, 1H) 3.29 
(h, J = 6.6 Hz, 2H) 2.10-2.01 (m, 2H) 2.02-1.92 (m, 1H) 1.72 (tdd, J = 13.1, 8.5, 5.2 Hz, 1H); 13C 
NMR (500 MHz, CDCl3-d) 𝛿 ppm 169.80, 166.85, 153.34, 143.41, 138.43, 130.97, 129.56, 
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129.10, 127.29, 126.86, 122.80, 122.63, 121.07, 112.52, 106.45, 50.36, 49.82, 47.68, 25.44, 
21.18; QTOF ES+ MS: (M+H) 409.13; HPLC Ret: 7.84 min; 99% pure. 
N-(3-chlorophenyl)-1-(3-(furan-2-yl)benzyl)-2-oxopiperidine-3-carboxamide. (CCG-
264645). Method I starting from 1-(3-(furan-2-yl)benzyl)-2-oxopiperidine-3-carboxylic acid (0.05 
g, 0.17 mmol) and 3-chloroaniline (0.02 g, 0.17 mmol) gave N-(3-chlorophenyl)-1-(3-(furan-2-
yl)benzyl)-2-oxopiperidine-3-carboxamide (0.06 g, 82%); column: 40% EtOAc/Hex; 1H NMR 
(500 MHz, DMSO-d6) 𝛿 10.40 (br. s, 1H) 7.90 (d, J = 2.1 Hz, 1H) 7.76 (t, J = 2.1 Hz, 1H) 7.68-
7.58 (m, 2H) 7.50-7.32 (m, 3H) 7.19 (d, J = 7.6 Hz, 1H) 7.13 (d, J = 7.6 Hz, 1H) 6.99 (d, J = 3.0 
Hz, 1H) 6.61 (dd, J = 3.4, 2.1 Hz, 1H) 4.67 (d, J = 15.0 Hz, 1H) 4.51 (d, J = 15.1 Hz, 1H) 3.52 (t, 
J = 7.4 Hz, 1H) 3.30 (h, J = 4.3 Hz, 2H) 2.11-2.02 (m, 2H) 2.02-1.92 (m, 1H) 1.73 (dt, J = 14.3, 
6.2 Hz, 1H); 13C NMR (500 MHz, CDCl3-d) 𝛿 ppm 170.11, 166.76, 153.36, 143.40, 140.89, 
138.42, 133.54, 130.98, 130.91, 129.56, 126.86, 123.49, 122.78, 122.61, 119.01, 117.93, 
112.49, 106.45, 50.39, 49.82, 47.68, 25.42, 21.12; QTOF ES+ MS: (M+H) 409.13; HPLC Ret: 
7.90 min; 97% pure. 
N-(3-chloro-5-(hydroxymethyl)phenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide (CCG-265072). In a 10 mL round-bottomed flask, N-(3-
(((tert-butyldiphenylsilyl)oxy)methyl)-5-chlorophenyl)-5,5-difluoro-1-(3-fluoro-5-(pyridin-4-
yl)benzoyl)piperidine-3-carboxamide (0.04 g, 0.05 mmol) was dissolved in THF (0.5 mL). 1 M 
TBAF in THF (0.11 mL, 0.11 mmol) was added and the mixture was stirred under nitrogen at 25 
°C for 1 hr. The reaction was quenched with water (20 mL) and the product was extracted with 
EtOAc (3x 15 mL). The organic layer was washed with brine, dried with magnesium sulfate, and 
evaporated, providing yellow oil. The residue was subjected to silica gel chromatography eluting 
with 85% EtOAc: 100% Hex. The fractions containing product were concentrated in vacuo to 
produce white solid. Yield=70%. 1H NMR (400 MHz, DMSO-d6, 80 °C) 𝛿 ppm 10.04 (br. s, 1H) 
8.66 (d, J = 5.3 Hz, 2H) 7.77-7.67 (m, 3H) 7.61 (d, J = 7.0 Hz, 2H) 7.40 (s, 1H) 7.31 (d, J = 8.6 
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Hz, 1H) 7.04 (s, 1H) 5.00 (t, J = 5.5 Hz, 1H) 4.46 (d, J = 5.5 Hz, 2H) 4.34-4.09 (m, 2H) 3.58 (dd, 
J = 29.5, 13.7 Hz, 1H) 3.25 (t, J = 8.0 Hz, 1H) 2.96 (br. s, 2H) 2.45-2.20 (m, 1H); 19F NMR (376 
MHz, DMSO-d6, 80 °C) 𝛿 ppm -99.00—-101.91 (m, 2H) -111.09 (t, J = 9.4 Hz, 1H); QTOF ES+ 
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